Final Program

XXV Congress of the International Society on Thrombosis and Haemostasis and 61st Annual SSC Meeting

June 20 – 25, 2015
Toronto, Canada

www.isth2015.org
ISTH Membership Benefits

- International network that spans more than 85 countries
- Priority registration and meeting discounts
- Complimentary print subscription to JTH
- E-learning opportunities
- Access to the ISTH members-only online resources
- Eligibility to hold elected and/or appointed offices
- Vote on Society matters and serve on subcommittees and working groups
- Career center

www.isth.org
Visit the ISTH at Booth 1036!

The ISTH is a global not-for-profit organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.
Thank You to Everyone Who Supported the 2014 World Thrombosis Day Campaign!

Together, we’ve elevated the global conversation about potentially deadly blood clots.

Visit us at Booth 1036

Venue and Contacts

Venue
Metro Toronto Convention Center (MTCC)
MTCC South Building
222 Bremner Boulevard
Toronto, Ontario M5V 2W6
Canada

T: +1 (416) 585-8000
E: info@mtccc.com
W: http://www.mtccc.com

Contacts
ISTH Headquarters:
610 Jones Ferry Road, Suite 205
Carrboro, NC 27510
USA
T: +1 919 929-3807
F: +1 919 929-3935
headquarters@isth.org
www.isth.org

Executive Meeting Matters:
Lisa Astorga
ISTH Director of Meetings
lisa_astorga@isth.org

Membership Questions or any General Inquiries about the ISTH:
ISTH Membership Staff
T: +1 919 929-3807
membership@isth.org

ISTH 2015 Organizing Secretariat:
(Registration, Logistics, Exhibition, Hotel Accommodations)
c/o MCI Suisse SA
MCI Suisse SA
Rue de Lyon 75
1211 Geneva 13
Switzerland
T: +41 22 33 99 728
isth.reg@mci-group.com

Abstract Questions:
isth2015abs@mci-group.com

Sponsorship and Exhibition:
Thomas Reiser
Executive Director
T: +1 919 929-3807
tom_reiser@isth.org

Marketing and Media:
Louise M. Bannon
Director of Marketing and Membership
T: +1 919 929-3807
louise_bannon@isth.org
Invitation and Welcome Message

Dear ISTH Congress attendees,

We are happy to welcome you to Toronto, which in the Iroquois language means “place where trees stand in the water,” and this was likely the initial native local name. From 1795 to 1834 it was the town of York, then becoming the City of Toronto with a population of 9,000. The population of the Toronto metropolitan area has grown to just over six million in 2015. Toronto is known for its multi-ethnicity and diverse neighbourhoods, where culture and food from many parts of the world can be enjoyed. Similarly, delegates from a large number of countries will convene at this congress to exchange new research data, ideas, opinions and suggestions for future collaboration.

The ISTH Congress, now counting as the 25th since the first congress in Montreux, Switzerland, in 1970, is the largest and most important event every two years for all scientists and clinicians with an interest in thrombosis and hemostasis. The ISTH Congress has expanded - from the previous one in Toronto in 1981 of about 2,000 attendees to more than 8,000 today. Different from many other large meetings, the ISTH Congress takes much of its features from the Local Organizing Committee, which – with logistic support from ISTH Headquarters and the professional congress organizer – has substantial liberty to decide on the format of the sessions as well as the social components. For those established in the field of thrombosis and hemostasis, attending consecutive congresses in different countries and continents generates fond memories and stimulates comparisons. Those joining the ISTH Congress for the first time will hopefully get a very positive impression, encouraging further contributions to science and a return to future meetings.

Saturday and the first half of Sunday are, in keeping with tradition, devoted to the annual meeting (the 61st) of the Scientific and Standardization Committee (SSC) of the ISTH. Work in progress, preliminary or final reports from the multitude of projects of the SSC will be mixed with a wide variety of educational lectures. The latter have been carefully chosen not to duplicate presentations of invited speakers during the following congress. At the end of the SSC meeting, on Sunday at lunch, we extend a warm welcome to the recipients of the Young Investigator and the Reach-The-World awards and invite them to a special reception. Last year was the exciting premier for World Thrombosis Day (WTD), in which more than 175 organizations were involved and spread important educational messages to millions of people. On Sunday afternoon, you can enjoy a special presentation of the experiences and highlights from this inaugural WTD.

The actual ISTH Congress kicks off with the Opening Ceremony on Sunday evening and we are excited to give you a taste of Canadian music and culture from coast to coast. It will be followed by a networking reception in the Exhibition Hall.

The scientific congress is composed of a variety of sessions – five plenary lectures by front-line scientists, 53 state-of-the-art lectures by leaders in the respective fields and accompanied by corresponding articles in the educational book, 52 abstract symposia with an introductory review lecture followed by oral presentations of top-scoring abstracts on the topic, two late-breaking-sessions on Monday and Wednesday, respectively, with piping hot results from 10 clinical trials, 89 oral communication sessions, and from Monday to Wednesday poster sessions as well. For those that have reserved tickets, there are Master Classes covering 40 different topics in the early morning of Sunday to Wednesday. As a new feature we also have Career Mentorship sessions for small groups at lunch time.
We are grateful to the industry for their generous support to the congress and we hope you will take time to visit the exhibition and exchange ideas with the representatives from the diagnostic and pharmaceutical industry. And don’t forget the ISTH booth! During the lunch break, after grabbing a complimentary lunch box, you may attend a satellite symposium, stroll through the poster area or just sit and network with colleagues.

The All Congress Party on Wednesday evening will be a social highlight for you and your friends. You will taste the food of the ethnic neighbourhoods of Toronto while listening to different music bands, culminating with a performance by the rock band the Barenaked Ladies. Make sure you have tickets!

The congress ends on Thursday at noon with a novelty – the Highlights of ISTH session. Here you will get a recap of selected, top-scoring presentations both from basic and from clinical science. Since there are many simultaneous sessions during the congress and you therefore cannot possibly attend everything in your interest, this is the perfect chance to catch up on the important presentations you may have missed.

The congress app, available for download on your mobile device, will help you stay organized, select your sessions and find your way. It will also provide you with the daily news from the congress. In this Program Book the trainees can follow special tracks, identified by symbols, if they have specific interest in Platelets-basic science, Coagulation-basic science, Bleeding-clinical, Thrombosis-clinical, Pediatric thrombosis and hemostasis, or Cardiovascular-basic and clinical science.

Sam Schulman, M.D., Ph.D.
ISTH XXV Congress 2015 President

Sabine Eichinger, M.D.
ISTH SSC Chair

Nigel Key, M.D., Ch.B.
ISTH Council Chair

JOIN US! WEDNESDAY, JUNE 24, 2015
| 12:15 hrs – 13:45 hrs |
CONFERENCE ROOM: Room 717, Level 700

Emerging Trends and Strategies - Thrombosis Medicine

Practical Dimensions of NOAC-Based Management

Acute and Extended Treatment of VENOUS THROMBOEMBOLISM

Focus on the Role of Factor Xa Inhibition for Acute and Extended Duration Treatment of PE and DVT

Principles of Practice at the Front Lines of Thrombosis Care

Professor Samuel Z. Goldhaber, MD
Program Chairman
Professor of Medicine | Harvard Medical School | Director, Thrombosis Research Group | Cardiovascular Division | Brigham and Women’s Hospital | President, North American Thrombosis Forum (NATF) | Boston, Massachusetts

Professor The Lord Ajay Kakkar, MD
Program Chairman
Professor of Surgery | University College London | Director, Thrombosis Research Institute | London, UK

Professor Stavros V. Kastritis, MD, PhD, FESC
Distinguished Faculty
Professor, Clinical Trials, and Medical Director | Center for Thrombosis and Hemostasis (CTH) | Johannes Gutenberg University Mainz | Mainz, Germany

PROGRAM CO-CHAIRS and DISTINGUISHED FACULTY

Save the Date: Wednesday, June 24, 2015 — CME Lunch Symposium
City: Toronto, Ontario | Location: Metro Toronto Convention Centre | Conference Room: Room 717, Level 700

NO PRE-REGISTRATION REQUIRED TO ATTEND!

Funded by an independent educational grant from Bayer Healthcare
Jointly Sponsored by the University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC
This Satellite Program is not part of the official scientific program of the ISTH 2015 Congress
I am pleased to extend my warmest greetings to everyone attending the 25th Congress of the International Society on Thrombosis and Haemostasis (ISTH) and 61st Annual Meeting of ISTH's Scientific and Standardization Committee (SSC).

These events will provide an excellent opportunity for clinicians and researchers to exchange ideas, best practices, and information about the latest developments in thrombosis, haemostasis, and vascular biology, as well as their application to patient care.

Over the years, ISTH has worked diligently to improve global health. I commend your efforts to provide the best outcomes for patients through your commitment to the highest standards of excellence in the prevention, diagnosis, and treatment of thrombotic and bleeding disorders.

On behalf of the Government of Canada, I offer my best wishes for a memorable and productive gathering in Toronto.


OTTAWA
2015

On behalf of the Government of Ontario, I am delighted to extend warm greetings to everyone attending The International Society on Thrombosis and Haemostasis (ISTH) XXV Congress and 61st Annual Scientific and Standardization Committee (SSC) Meeting. I would like to take this opportunity to commend the ISTH for its commitment to supporting members in the ongoing advancement of the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

As Premier, I am proud that Ontario has the opportunity to host an event that facilitates fruitful discourse between clinicians, researchers, educators and practitioners with the noble aim to improve patients’ lives. With an impressive array of lectures, educational sessions and workshops, this conference is sure to both enlighten and inform.

I would like to thank the ISTH for choosing our province to host this wonderful event. I am confident that all the delegates and guests will enjoy their time in Toronto, our vibrant and diverse capital city.

Please accept my best wishes for an informative and memorable congress.

Kathleen Wynne
Premier
Mayor John Tory
City of Toronto

It is my esteemed pleasure to extend greetings and a warm welcome to everyone attending the International Society on Thrombosis & Haemostasis’ (ISTH) XXV Congress and 61st Annual Scientific and Standardization Committee Meeting.

A global non-profit organization, the International Society on Thrombosis & Haemostasis is dedicated to advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

This convention will host thousands of delegates consisting of leading experts on thrombosis, haemostasis and vascular biology from around the world. They will gather together for a productive exchange on the latest in science and clinical applications and to present the most recent advances, in a setting designed for professional development.

I wish to welcome everyone to our city and encourage you to enjoy Toronto at this time of the year as well as learn about vibrant neighborhoods.

On behalf of Toronto City Council, please accept my best wishes for an informative and enjoyable event.

Yours truly,

Mayor John Tory
City of Toronto

---

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td></td>
<td>Chair: Alfonso Iorio (Canada)</td>
</tr>
<tr>
<td>12:20</td>
<td>Review of new Phase III data for BeneF™: once-weekly prophylactic dosing in hemophilia B</td>
</tr>
<tr>
<td></td>
<td>Michael Tarantino (USA)</td>
</tr>
<tr>
<td>12:40</td>
<td>Review of new Phase III data for BeneF™: additional analysis</td>
</tr>
<tr>
<td></td>
<td>Bartholomeo Tortella (Pfizer)</td>
</tr>
<tr>
<td>12:50</td>
<td>Investigating the science behind FIX in the extravascular space</td>
</tr>
<tr>
<td></td>
<td>Darrel Stafford (USA)</td>
</tr>
<tr>
<td>13:10</td>
<td>Patient-centered approaches to dosing; treatment individualization with PK modeling</td>
</tr>
<tr>
<td></td>
<td>Alfonso Iorio (Canada)</td>
</tr>
<tr>
<td>13:30</td>
<td>Panel discussion</td>
</tr>
<tr>
<td></td>
<td>Moderated by Chair</td>
</tr>
<tr>
<td>13:40</td>
<td>Meeting summary and close</td>
</tr>
</tbody>
</table>

---

Managing Hemophilia for Life
Optimizing responses to therapy in hemophilia B: treatment individualization in an era of expanding options

Monday 22nd June 2015, 12:15–13:45
Room 716, Level 700, Metro Toronto Convention Centre, Toronto, Canada
Chair: Alfonso Iorio (Canada)

---

Managing Hemophilia for Life
The role of ultrasound in hemophilia joint health: progress and perspectives from clinical practice

Tuesday 23rd June 2015, 12:15–13:45
Room 716, Level 700, Metro Toronto Convention Centre, Toronto, Canada
Chair: Giovanni DiMinno (Italy)

---

Information based on approved Canadian product information for BeneF™
Date of preparation: April 2015
ISTH 2015 Committees

ISTH Organizing Committee

Local Organizing Committee
Sam Schulman  President
Philip Wells  Vice President
Victor Blanchette  Treasurer
Jeffrey Weitz  Scientific Chair

State-of-the-Art Book Editors
David Lillicrap  Editor
James Douketis  Co-Editor

Scientific Program Subcommittee Chairs
Laurie Sardo  Allied Health Professionals Program
Geoff Werstuck  Atherothrombosis
John Eikelboom  Clinical Cardiovascular
Paula James  Coagulation Factors and Inhibitors
Jeffrey Weitz  Fibrinolysis and Proteolysis
Jerry Teitel  Hemorrhagic Disorders
John Semple  Inflammation and Immunology
Mark Crowther  Innovation and Technology
Patti Massicotte  Pediatric Hemostasis and Thrombosis
Margaret Rand  Platelets - Basic
Peter Gross  Platelets - Clinical
Donald M. Arnold  Transfusion
Ed Conway  Vascular Biology
Marc Rodger  Venous Thrombotic Disorders

Scientific and Standardization Committee Liaison
Sabine Eichinger, Austria, SSC Chair
Lori Linkins, Canada, SSC Liaison

Educational Program
Shannon Bates, Canada, Co-chair
Agnes Lee, Canada, Co-chair

Social Events Committee
Rita Selby, Canada, Chair

Trainee Program Committee
Carol Gonsalves, Canada, Chair
Mandy Lauw, The Netherlands

ISTH 2015 Senior Advisory Board
Morris Blajchman, Canada
Cedric Carter, Canada
Bernadette Garvey, Canada
Jeff Ginsberg, Canada
Jack Hirsh, Canada
John Kelton, Canada
Raelene Kinlough-Rathbone, Canada
Michael Mant, Canada
Marian Packham, Canada
Graham Pineo, Canada
Georges Rivard, Canada
Alexander G. Turpie, Canada

Scientific Program Subcommittees

Platelets – Basic
Margaret Rand, Canada, Chair
Patrick Provost, Canada
Lawrence (Skip) Brass, United States
Sara Israels, Canada
Archie McNicol, Canada
Heyu Ni, Canada

Platelets – Clinical
Peter Gross, Canada, Chair
Walter Kahr, Canada
John Freedman, Canada
Ted Warkentin, Canada
Alan Michelson, United States
Jean-Francois Tanguay, Canada

Coagulation Factors and Inhibitors
Paula James, Canada, Chair
Ed Pryzdial, Canada
Patricia Liaw, Canada
Rodney Camire, United States
Alfonso Iorio, Canada

Fibrinolysis and Proteolysis
Jeffrey Weitz, Canada, Chair
Jim Fredenburgh, Canada
Paul Kim, Canada
Katherine Hajjar, United States
ISTH 2015 Committees

Vascular Biology
- Ed Conway, Canada, Chair
- Mark Blostein, Canada
- William Aird, United States
- Nigel Mackman, United States

Hemorrhagic Disorders
- Jerry Teitel, Canada, Chair
- Leonard Valentino, United States
- Craig Kessler, United States
- Man-Chiu Poon, Canada
- Steven Pipe, United States

Venous Thrombotic Disorders
- Marc Rodger, Canada, Chair
- Susan Kahn, Canada
- Clive Kearon, Canada
- Bill Geerts, Canada
- Mary Cushman, United States
- David Garcia, United States

Atherothrombosis
- Geoff Westuck, Canada, Chair
- Dino Trigatti, Canada
- Murray Hutf, Canada
- Myron Cybulsky, Canada
- Avrum Gottlieb, Canada

Inflammation and Immunology
- John Semple, Canada, Chair
- Andy Weyrich, United States
- Dave Kuter, United States
- Jane Freedman, United States
- Eric Boilard, Canada

Innovation and Technology
- Mark Crowther, Canada, Chair
- Cathy Hayward, Canada
- Adam Cuker, United States
- Karen Moffatt, Canada
- Scott Diamond, United States
- James Zehnder, United States

Transfusion
- Donnie Arnold, Canada, Chair
- Sunny Dzik, United States
- Richard Kaufman, United States
- Yulia Lin, Canada
- Charles Quinn, United States

Pediatric Hemostasis and Thrombosis
- Patti Massicotte, Canada, Chair
- Michele David, Canada
- Manuel Carcao, Canada
- Lynette Bowes, United States
- Neil Goldenberg, Canada
- Leslie Raffini, United States

COMMITTED TO PATIENTS

HOPE IS WHAT SANOFI BRINGS EACH DAY. OVERCOMING NEW CHALLENGES TO PROTECT LIFE FOR SEVEN BILLION PEOPLE.

One of the world’s leading health care companies, Sanofi researches, develops, manufactures and markets innovative therapeutic solutions that prevent disease, heal and improve quality of life for patients and their families.

www.sanofi.com
International Advisory Board

Walter Ageno
Italy
Pantep Angchaisuksiri
Thailand
Yujiro Asada
Japan
Patricia Casais
Argentina
Barry Coller
United States
Javier Corral
Spain
Shaun Coughlin
United States
Björn Dahlbäck
Sweden
Hans Deckmyn
Belgium
Cécile Denis
France
Donna DiMicile
United States
Sabine Eichinger
Austria
Anna Falanga
Italy
Bruce Furie
United States
Christian Gachet
France
Shinya Goto
Japan
Andreas Greinacher
Germany
John-Bjarne Hansen
Norway
Beverley Hunt
United Kingdom
James Huntingdon
United Kingdom
Raul Izaguirre
Mexico
Barry Jacobson
South Africa
Sriram Krishnaswamy
South Africa
Barry Coller
Argentina
Patricia Casais
Japan
Yujiro Asada
Japan
Tetsumei Urano
Japan
Yoshiyuki Tomiyama
Japan
Ahmed Kaino, United States
Abdel Rezq, United States

ISTH 2015 Abstract Reviewers

Leonardo Brandao,
Canada
Lynette Bowes,
Switzerland
Henri Bounameaux,
Argentina
Nuala Booth,
United Kingdom
Mark Blostein,
Canada
Alicia Blanco,
Argentina
David Bergqvist,
Sweden
Saulius Butenas,
United States
Kathleen Brummel-Ziedins,
United States
Harry Büller,
The Netherlands
Saulius Butenas,
United States
Suzanne Cangas,
The Netherlands
Manuel Carcao,
Canada
Anders Carlsson,
Sweden
Marc Carrier,
Canada
Cedric Carter,
Canada
Patricia Casais,
Argentina
Elisabetta Castoldi,
The Netherlands
Spero Cataland,
United States
Marco Cattaneo,
Italy
Elizabeth Chalmers,
United Kingdom
Howard Chan,
Canada
Douglas Cines,
United States
Kenneth Clemenson,
Switzerland
Christine Cockhill,
Canada
Barry Coller,
United States
Ed Conway,
Canada
Michiel Coppens,
The Netherlands
Ramón Corbalan,
Chile
Javier Corral,
Spain
Judith Cosemans,
The Netherlands
Benilde Cosmi,
Italy
Jonathan Coutinho,
The Netherlands
Jim Crawley,
United Kingdom
Adam Cuker,
United States
Armando D’Angelo,
Italy
Björn Dahlbäck,
Sweden
Martina Daly,
United Kingdom
Simon Davidson,
United Kingdom
Raimondo De Cristofaro,
Italy
Philippe De Groot,
The Netherlands
Moniek de Maat,
The Netherlands
Philippe de Moerloose,
Switzerland
Valerio De Stefano,
Italy
Najat Debbi,
France
Han Deckmyn,
Belgium
Paul Delecker,
Belgium
Herve Decousus,
France
Cécile Denis,
France
Francesco Dentali,
Italy
Scott Diamond,
United States
Ludovic Drouet,
France
Sabine Eichinger,
Austria
Jeroen Eikenboom,
The Netherlands
Petra Elfvingson,
Sweden
Jessica Emed,
Canada
Joseph Emmerich,
France
Miguel Escobar,
Spain
Koji Eto,
Japan
Anna Falanga,
Italy
Emmanuel Favaloro,
Australia
Augusto Federici,
Italy
Karim Fijnvandran,
The Netherlands
Kathelijn Fischer,
The Netherlands
ISTH 2015 Abstract Reviewers

Garret Fitzgerald, United States
Robert Fluenenhauf, United States
Veronica FLOOD, United States
Georgina Flores, Canada
Jonathan Foley, United Kingdom
Charles Francis, United States
Jim Freedenburgh, United States
Jane Friedman, United States
John Friedman, Canada
Mi Freieringer III, United States
Satoshi Fuji, Japan
Christian Gachel, France
David Galiani, United States
Monica Galli, Italy
Alex Gallas, Australia
Sophie Gandrille, France
David Garcia, United States
Chris Gardiner, United Kingdom
Bernadette Garvey, Canada
Pascale Gaussem, France
William Geerts, Canada
Jonathan Gibbins, United Kingdom
Hollie Gilmore, Australia
David Ginsburg, United States
Neil Goldenberg, United States
Samuel Goldhaber, United States
Rebecca Goldsmith, Canada
Anne Goodie, United Kingdom
Shinya Goto, Japan
Jenny Goudemand, France
Chris Granger, United States
Andreas Greinacher, Germany
Paolo Gresele, Germany
John Griffin, United States
Jean-Cristophe Gris, France
Peter Gross, Canada
Yves Gruel, France
Chris Guechter, United States
Sylvia Haas, Germany
Tilman Hackeng, the Netherlands
Margaret Hall, United States
John-Bjarne Hansen, Norway
Paul Harrison, United Kingdom
Robert Hart, Canada
Tatsuya Hayashi, Japan
Cathy Hayward, Canada
Mary Heeb, United States
Johan Heemskerk, the Netherlands
John Hee, United States
Stefan Heptinstall, United Kingdom
William Hiatt, United States
Karin Hoffmeister, United States
Philip Hogg, Australia
Keith Hoots, United States
Marie Horellou, France
Menno Huisman, The Netherlands

Beverley Hunt, United Kingdom
Jim Huntington, United Kingdom
Atkaida Ichnose, Italy
Aida Inbal, Israel
Alfonso Iorio, Canada
Sara Israels, Canada
Raul Izaguirre, Mexico
Marc Jacquemin, Belgium
Joseph Jakobowski, United States
Andra James, United States
Paula James, Canada
Martine Jandrot-Perrus, France
Bern Jilma, Austria
Gerhard Johnson, United States
Scott Kaats, United States
Susan Kahn, Canada
Michael Kalafatis, United States
Farhad Kamali, United Kingdom
Pieter Willem Kamphuisen, The Netherlands
Carol Kasper, United States
Newine Kassim, Egypt
Clive Kearon, Canada
David Keeling, United Kingdom
Christine Kempston, United States
Dermot Kenny, Ireland
Steven Kerrigan, Ireland
Nigel Key, United States
Kate Khal, United Kingdom
Paul Kim, China
Mananjualana Kini, Singapore
Steve Kitchen, United Kingdom
Erik Klok, The Netherlands
Tetsuhiro Kojima, Japan
Koichi Kokame, Japan
Krasmus Kolev, Hungary
Barbara Konkle, Australia
Tim Korhonen, Finland
Johanna Kremer, Switzerland
Steven Krilis, Australia
Marieke Kruij, The Netherlands
Thomas Kuehne, Switzerland
Saya Kunapuli, United States
Shinichiro Kurosawa, United States
Paul Kyrie, Australia
David Lane, United Kingdom
Francois Lanzi, France
Sarah Lapner, Canada
Riitta Lasil, Finland
Daniel Lawrence, United States
Alan Lazarus, Canada
Alejandro Lazo-Langner, Canada
Bernard Le Bonniec, France
Grégoire Le Gal, Canada
Ramón Lecumberri, Spain
Agnes Lee, Canada
Peter Lenting, France
Marcel Levi, The Netherlands
Willem Lijfering, The Netherlands
Roger Lijnen, Belgium

Wendy Lim, Canada
Shu-Wha Lin, Taiwan
Yulia Lin, Canada
Ton Liman, The Netherlands
Rolf Ljung, Sweden
Colin Longstaff, United Kingdom
Marc Lordkipanidze, United Kingdom
Gordon Lowe, United Kingdom
Aharon Lubetsky, Israel
Christopher Ludlam, United Kingdom
Brenda Lukun, United Kingdom
Flora Lupu, United States
Jeanne Lusher, United States
Ian Mackie, United Kingdom
Nigel Mackman, United States
Maria Magnusson, Sweden
Mike Makris, United Kingdom
Asrar Malik, United States
Maurine Malone, United States
Naveen Manchanda, United States
Maria Mancuso, Italy
Marina Marchetti, Italy
Ida Martimelli, Italy
Steffen Massberg, Germany
Patti Massicotte, Canada
Alan Mast, United States
Osamu Matsuo, Japan
Tadashi Matsushita, Japan
Owen McCarthy, United States
Keith McCrae, United States
Brian McCrindle, Canada
Archie Mcnicol, Canada
Simon McRae, Australia
John McCaig, United Kingdom
Robert McCaff, Australia
Leonid Medved, United States
Shannon Meeks, United States
Karina Meijer, The Netherlands
Joost Meijers, The Netherlands
Kelcey Mentens, The Netherlands
Guy Meyer, France
Saskia Middeldorp, The Netherlands
Lindsey Miles, United States
Jonathan Miller, United States
Toshiyuki Miyata, Japan
Jun Mizuguchi, Japan
Karen Moffat, Canada
Sebastian Moll, United States
Paul Monahan, United States
Manuel Monreal, Spain
Dougal Monroe, United States
Robert Montgomery, United States
Pierre-Emmanuel Morange, France
Massimo Morfini, Italy
James Morrissey, United States
John Morser, United States
Per Morten Sandset, Norway
Laurent Mooser, United States
David Motto, United States

Jim Munn, United States
László Muszbek, Hungary
Nicola Mutch, United Kingdom
Khalid Naseem, United Kingdom
Marguerite Neerman-Arbez, Switzerland
Claude Negrier, France
Fiona Newall, Australia
Heyu Ni, China
Timothy Nichols, United States
Rien Nieuwland, United States
Marina Nos, Italy
Agata Nowak, United Kingdom
Alan Norden, France
Paquita Norden, France
Doyeon Oh, South Korea
Tetsuhiko Oomori, Japan
Johannes Oldenburg, Germany
Pål Ørlandsson, Iceland
Bjarte Østerud, Norway
Hans-Martin Otten, The Netherlands
Yukio Ozaki, Japan
Bunis Packham, United Kingdom
Joseph Palumbo, United States
Guillaume Paré, Canada
Paola Patrignani, Italy
Carlo Patrono, Italy
Rafai Pawliński, France
Bernard Payrastre, France
Ian Peake, United Kingdom
Kathelijne Peerlinck, Belgium
Vanessa Pellegrinelli, United Kingdom
Vittorio Pergo, Italy
Jaime Peto, Italy
Egon Persson, Sweden
Marjolein Peters, The Netherlands
Flora Pesotski, France
Helen Philippou, United Kingdom
Gregory Piazza, United States
Graham Pines, United States
Steven Pipe, United States
Ed Pow, United States
Mortimer Poncz, United States
Man-Chiu Poon, Canada
Paolo Prandoni, Italy
Kathleen Pratt, United States
Patrick Provost, Canada
Charles Rabb, United States
Leslie Rafini, United States
Margaret Ragni, United States
Janusz Raki, United States
Jacob Rand, United States
Margaret Rand, Canada
Anna Randi, Canada
Jacob Rand, United States
A. Koneti Rao, United States
Gary Raskob, United States
Peter Reitsma, The Netherlands
Thomas Renné, Sweden
Alireza Rezaei, United States
Suely Rezende, Brazil
Frederick Rickles, United States

ISTH 2015 Abstract Reviewers

ISTH 2015 Abstract Reviewers
Dick Rijken, The Netherlands
Georges Rivard, Canada
Francesco Rodeghiero, Italy
Marc Rodger, Canada
Mark Roest, The Netherlands
Frits Rosendaal, The Netherlands
Jan Rosing, The Netherlands
Changgeng Ruan, China
Wolfram Ruf, United States
Evan Sadler, United States
Jean-Marie Saint-Remy, Belgium
Per Morten Sandset, Norway
Elena Santagostino, Italy
Sentot Santoso, Germany
Laurie Sardo, Canada
Ravi Sarode, United States
Anna Savoia, Italy
Rüdiger Scharf, Germany
Inge Scharrer, Germany
Alvin Schmaier, United States
Simone Schoenwaelder, Australia
Sam Schulman, Canada
Jean-François Schwed, France
Marie Scully, France
Dick Rijken,

Arina ten Cate-Hook, The Netherlands
Andreas Tiede, Germany
Cheng-Hock Toh, United Kingdom
Yoshiyuki Tomiyama, Japan
Mauro Torti, Italy
Alberto Tosetto, Italy
Paula Tracy, United States
David Trégouët, France
Bernardo Trigatti, Canada
Hiroko Tsuda, Japan
Alexander G. Turpie, Canada
Shirley Uite de Willighe, The Netherlands
Anetta Undas, Poland
Tetsumei Urao, Japan
Rolf Urbanus, The Netherlands
Elizabeth Van Cott, United States
Ton van den Besselaar, The Netherlands
Anske van der Bom, The Netherlands
Felix van der Meer, The Netherlands
Chris van Greet, Belgium
Maarten van Heerde, The Netherlands
Victor van Hinsbergh, The Netherlands
Astrid van Hylckama Vlieg, The Netherlands
Heleen van Ommen, The Netherlands
Suresh Vedantham, United States
Peter Verhamme, Belgium
Henri Versteeg, The Netherlands
Sara Vesely, United States
Vicente Vicente, Spain
Shoshana Vilk, Israel
Jan Voorberg, The Netherlands
Hideo Wada, Japan
Theodore Warkentin, Canada
Henry Watson, United Kingdom
Steve Watson, United Kingdom
Hartmut Weiler, United States
Jeffrey Weitz, Canada
Yukio Ozaki, Japan
Paula Tracy, United States

Class of 2016
Marco Cattaneo, Italy
Björn Dahlbäck, Sweden
Andreas Greinacher, Germany
Yukio Ozaki, Japan
Paula Tracy, United States

Class of 2018
Peter Lenting, France
Claire Mcintosh, New Zealand
James Morrisey, United States
Ingrid Pabinger, Austria
Jeffrey Weitz, Canada

Class of 2020
Anna Falanga, Italy
David Lillicrap, Canada
Jose Lopez, United States
Suey Rezende, Brazil
Steve Watson, United Kingdom

Ex-Officio Council Members
J. Evan Sadler, United States
Secretary General

Michael Berndt, Australia
Immediate Past Chair, ISTH Council

Sam Schulman, Canada
President, XXV ISTH Congress, Toronto, 2015

Philip Wells, Canada
Vice-President, XXV ISTH Congress Toronto, 2015

Pieter Reitsma, The Netherlands
Editor-in-Chief, Journal of Thrombosis and Haemostasis

Frits Rosendaal, The Netherlands
Past President, XXV ISTH Congress Amsterdam, 2013 and Editor-in-Chief, Journal of Thrombosis and Haemostasis

Sabine Eichinger, Austria
Chair, Scientific and Standardization Committee
ISTH Scientific and Standardization Committee

**SSC Executive Committee 2014-2016**

Sabine Eichinger, Austria
Chair

Walter Ageno, Italy
Secretary/Chair-elect

David Lillicrap, Canada
Immediate Past Chair

Jean-François Schved, France
Ex-Officio: President, SSC 2016

**Standing Committees**

**Bleeding Assessment Tool**
Francesco Rodeghiero, Italy

**Coagulation Standards**
Anthony Hubbard, United Kingdom

**WHO-ISTH Standards Liaison Group**
Peter Lenting, France

**Subcommittees**

**Animal, Cellular and Molecular Models**
Susan Smyth, United States

**Biorheology**
Keith Neeves, United States

**Control of Anticoagulation**
Walter Ageno, Italy

**Disseminated Intravascular Coagulation**
Jecko Thachil, United Kingdom

**Exogenous Hemostatic Factors**
Ivo Francischetti, United States

**Factor VIII, Factor IX and Rare Coagulation Disorders**
Guy Young, United States

**Factor XI and the Contact System**
Jonas Emsley, United Kingdom

**Factor XIII and Fibrinogen**
Helen Philippou, United Kingdom

**Fibrinolysis**
Nicola Mutch, United Kingdom

**Hemostasis and Malignancy**
Alok Khorana, United States

**Lupus Anticoagulant/Phospholipid-Dependent Antibodies**
Bas de Laat, The Netherlands

**Pediatric and Neonatal Hemostasis and Thrombosis**
Anthony Chan, Canada

**Plasma Coagulation Inhibitors**
Richard Marlar, United States

**Platelet Immunology**
Yves Gruel, France

**Platelet Physiology**
Paolo Gresele, Italy

**Predictive Hemostatic Variables**
Paul Kyrie, Austria

**Vascular Biology**
Rienk Nieuwland, The Netherlands

**von Willebrand Factor**
Jorge DiPaola, United States

**Women’s Health Issues in Thrombosis and Hemostasis**
Rezan Abdul-Kadir, United Kingdom

**SAVE THE DATES**

**Addressing complex issues in VWD & haemophilia care**

**Wednesday, June 24, 2015**

12:15 - 13:45

Symposium Room 801

This symposium aims to provide a platform for sharing experiences on critical questions in the management of von Willebrand disease (VWD) and haemophilia A.

**Symposium chaired by Jerry Teitel**

**Should prophylaxis be the standard of care for severe VWD?**
Ulrike Nowak Göttl, Germany

**How to manage labour & delivery in VWD**
Paula James, Canada

**Management of surgeries in VWD: final results of a clinical study**
Alok Srivastava, India

**Canadian experience with 1:1 VWF/FVIII concentrate**
Mark Belletrutti, Canada

**Lunch will be served**

**Symposium**

**Haemophilia A: Individualised solutions to global challenges**

**Tuesday, June 23, 2015**

12:15 - 13:45

Symposium Room 801

This symposium will focus on the future of haemophilia A treatment including major challenges - the development of inhibitors and the need for frequent venous access for FVIII injections. Importance of individually tailored prophylaxis and the final results of personalised prophylaxis study, NuPreviq, will be presented.

**Symposium chaired by Craig Kessler**

**New generation rFVIII concentrates: where do we stand?**
Craig Kessler, USA

**NuProtect: update on human cell-line derived rFVIII in PUPs**
Anthony Chan, Canada

**Every patient is unique: the need for a personalised approach to treatment**
Massimo Morfini, Italy

**NuPreviq: update on human cell-line derived rFVIII in personalised prophylaxis**
John Pasi, UK

**Lunch will be served**
**Congress Support**

ISTH wishes to recognize the following companies and organizations for their support of ISTH 2015

### PLATINUM SPONSORS

- Baxalta
- Bayer HealthCare
- Biogen and Sobi
- Novo Nordisk Health Care AG
- Octapharma AG

### GOLD SPONSORS

- Boehringer Ingelheim GmbH
- CSL Behring GmbH
- Pfizer
- Pfizer Canada Inc./Bristol-Myers Squibb Canada

### SILVER SPONSORS

- Daiichi Sankyo, Inc.
- Kedrion Biopharma
- Siemens Healthcare and Sysmex Corporation
- STAGO

### BRONZE SPONSORS

- Alexion Pharmaceuticals, Inc.
- GRIFOLS
- HYPHEN BioMed
- Instrumentation Laboratory
- LED Pharma
- Portola Pharmaceuticals, Inc.
- Roche Diagnostics International Ltd.

---

**Sponsors and Exhibitors**

<table>
<thead>
<tr>
<th>Platinum Sponsors</th>
<th>Bronze Sponsors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baxalta</td>
<td>Alexion Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Bayer HealthCare</td>
<td>GRIFOLS</td>
</tr>
<tr>
<td>Biogen and Sobi</td>
<td>HYPHEN BioMed</td>
</tr>
<tr>
<td>Novo Nordisk Health Care AG</td>
<td>Immucor</td>
</tr>
<tr>
<td>Octapharma AG</td>
<td>Instrumentation Laboratory</td>
</tr>
</tbody>
</table>

### GOLD SPONSORS

- Boehringer Ingelheim GmbH
- CSL Behring GmbH
- Pfizer
- Pfizer Canada Inc./Bristol-Myers Squibb Canada

### SILVER SPONSORS

- Daiichi Sankyo, Inc.
- Kedrion Biopharma
- Siemens Healthcare and Sysmex Corporation
- STAGO

### BRONZE SPONSORS

- Alexion Pharmaceuticals, Inc.
- GRIFOLS
- HYPHEN BioMed
- Instrumentation Laboratory
- LED Pharma
- Portola Pharmaceuticals, Inc.
- Roche Diagnostics International Ltd.

Please see the ISTH 2015 Show Guide for more detailed information about our corporate supporters, exhibitors and sponsored programs.
**ISTH Awards**

**Robert P. Grant Medal**

The Robert P. Grant Medal is the ISTH’s highest award. It is presented during the biennial ISTH Congress in honor of research achievements, organizational activities, support of research activities, facilitation of institutional cooperation and communication, unusual teaching or educational initiatives and/or the development of concepts that result in a clearer understanding of research data.

The medal is named after Robert P. Grant, a renowned cardiologist who spent many years as a representative of the National Institutes of Health in Europe, traveling extensively and facilitating American-European collaboration in medical research and education.

The ISTH Grant Medal will be presented at the Opening Ceremony on Sunday, June 21.

**Harold R. Roberts Award**

The ISTH Harold R. Roberts Award honors meritorious service to the Scientific and Standardisation Committee of the ISTH, beyond expectations and over a significant period of time.

The Roberts Award will be presented at the President’s Dinner on Monday, June 22.

**Biennial Awards for Contributions to Hemostasis**

The ISTH’s Biennial Awards for Contributions to Hemostasis (BACH) are presented during the ISTH Congress to individuals who, in the opinion of their peers, have made significant contributions to research and education in blood coagulation.

The Investigator Recognition Awards recognize ISTH members whose accomplishments are internationally regarded as exemplary models of excellence in research and teaching.

The Distinguished Career Awards recognize ISTH members whose career contributions have significantly advanced the scientific community’s understanding of the diseases and disorders affecting hemostasis.

The ISTH BACH Awards will be presented at the President’s Dinner on Monday, June 22.

**2015 Recipients of the Biennial Awards for Contributions to Hemostasis (BACH) Award**

- **Distinguished Career**
  - Harry Büller, The Netherlands
  - Nigel Mackman, United States
  - Wolfram Ruf, United States, Germany
  - Ulla Hedner, Sweden
  - Gilbert White, United States

- **Investigator Recognition**
  - Steffen Massberg, Germany
  - Tim Springer, United States
  - Srim Krishnaswamy, United States
  - Willem Ouwehand, United Kingdom
  - Alisa Wolberg, United States

**Call for Applications!**

Visit us at Booth 1036!
Congress Travel Stipends

Young Investigator Travel Stipends

The Young Investigators Travel Stipends were provided in the form of travel grants to medical trainees and young scientists (under 35 years of age as of June 21, 2015) who submitted highly rated abstracts.

We hope that you will find attendance at ISTH 2015 fruitful in your continued research, clinical and educational activities.

Recipients of an ISTH 2015 Young Investigator Travel Stipend

Gregory Adams, United States
Sonja Aguila, Spain
Huda Omar Ali, Norway
Ashley Ambrose, United Kingdom
Ana Belén Arroyo Rodríguez, Spain
Dario Baralesta, Italy
Elena Barbon, Italy
Anthony Batttram, United Kingdom
Paul Batty, United Kingdom
Roeifel Bekendam, United States
Suzanne Bleeker, The Netherlands
Johan Boender, The Netherlands
Luca Bologna, Switzerland
Oliver Borst, Germany
Yacine Boulafati, France
Tara Bracken, United States
Sigríð Bræðsberg, Iceland
Alessio Brancolini, Italy
Katherine Bridge, United Kingdom
Tomasz Brzoska, Poland
Loredana Burri, Italy
James Byrnes, The Netherlands
Michelle Alida Helena Sonneveld, United States
Norway
Birgit Småbrekke, Canada
Maaike Schillemans, The Netherlands
Sarah Schießl, Italy
Daniela Scalet, Norway
Ina Rye-Holmboe, The Netherlands
Rachel Roach, United Kingdom
Rachel Roach, United Kingdom
José Antonio Alvarado-Moreno, Mexico
Hebe Agustina Mena, Argentina
Mukul Aggarwal, India
Yolanda Adamczuk, Philippines
Salma Abdel Ghany Shawkat, Egypt
Oscar A Marcos-Contreras, United States
Simone Merlin, Italy
Kahia Messaoudi, France
Sonaya Mezouar, France
Kristina Modjeski, United States
J.E. Molhoek, The Netherlands
Samantha Moore, United Kingdom
Vincent Muczynski, France
Ahmad Mufti, United Kingdom
Patrick Münder, Germany
Moe Murata, Japan
Giang Nguyen, United States
Agata Anna Nowak, United Kingdom
Kaisa Otteby, Sweden
Marta Palomo De Udáeta, Spain
Leonie Peltmans, The Netherlands
Behnaz Pezeshkipoor, Germany
Raymond Platt, United States
Tom Plug, The Netherlands
Irina Portier, Belgium
Cristina Puy, United States
Julia Riedl, Austria
Ludwig Balteskard Rinde, Norway
Rachel Roach, The Netherlands
Ina Rye-Holmboe, Norway
Daniela Scalet, Italy
Sarah Schießl, Germany
Maaike Schillemans, The Netherlands
Shana Audi Shaya, Canada
Birgit Småbrekke, Norway
Bryn Smith, United States
Michelle Alida Helena Sonneveld, The Netherlands
Erin Soule, United States
Erica Sparkenbaugh, United States
Lucia Stefani, United Kingdom
David Stegner, Germany
Saravanan Subramaniam, Germany
Pierre Suchon, France
Laura Swytun, Canada
Maria Talmon, Italy
Chaojun Tang, China
Claudia Tersteeg, Belgium
Cheng-Hock Toh, United Kingdom
Nagaharu Tsukiji, Japan
Robert Turnbull, United Kingdom
Kristin Ulle, Norway
Bart van den Ehof, The Netherlands
Tom van der Hulle, The Netherlands
Judith Van Eeuwijk, Germany
Nick van Es, The Netherlands
Nienke Van Rein, The Netherlands
Christophe Vandenbriele, Belgium
Imre Varjú, Hungary
Sebastien Verhellen, Belgium
Daniël Verhoeft, The Netherlands
Britta Walker, Germany
Simon James Webster, United Kingdom
John Welsh, United States
Anouk Wijgaerts, Belgium
Christopher Williams, United Kingdom
Gary Woods, United States
Binggang Xiang, United States
Alchen Yang, China
Jonathan Wai-hon Yau, Canada
Patricia Young, United States
Diego Zanolin, Italy
Xiaohua Zhou, Belgium

Reach-the-World Travel Stipends

In recognition of the expanding educational format of the ISTH meetings and congresses, the Society is extending its Reach-the-World initiative by providing travel stipends to enable participation by scientists from all areas of the world in ISTH 2015.

We hope that you will find attendance at ISTH 2015 fruitful in your continued research, clinical and educational activities.

Recipients of an ISTH 2015 Reach-the-World Travel Stipend

Salma Abdel Ghanzy Shawkat, Egypt
Al-Zamam Abubakar, Philippines
Yolanda Adamczuk, Argentina
Mukul Aggarwal, India
Hebe Agustina Mena, Argentina
José Antonio Alvarado-Moreno, Mexico
Nadia Arshad, Pakistan
Yanyan Bai, China
Xia Bai, China
Ergul Berber, Turkey
Luis Bittar, Brazil
Jelena Bodrozić, Serbia
Munira Borhany, Pakistan
Daniela Calderaro, Brazil
Jose Manuel Ceresetto, Argentina
Kao-Wen Chang, Taiwan, China
Zhenping Chen, China
Yingyong Chinthammit, Thailand
Jose Manuel Ceresetto, Argentina
Yao-Wen Chang, Taiwan, China
Zhenping Chen, China
Yingyong Chinthammit, Thailand
Dorothy Chioma Okpokam, Nigeria
Andrew Costache, Romania
Lv Cuicui, China
Jing Dai, China
Maria das Garças Carvalho, Brazil
Zelda De Lange, South Africa
Marie De Lourdes Herrera, Argentina
Ernesto de Meis, Brazil
Lais De Paula, Brazil
Chang-Qing Deng, China
Vrushali Deshpande, India
Pratibha Dhiman, India
Zhongren Ding, China
Valentina Djordjevic, Serbia
Luci Dusse, Brazil
Fernanda Dutra Santiago Bassora, Brazil
Yi Fang, China
Miguel Farfan, Colombia
Marine Flores-Nascimento, Brazil
Juan Pablo Frentoth, Argentina
Rongfeng Fu, China
Taina Gomes, Brazil
Marcelo Luide Goncalves, Brazil
Lailidona Gooneratne, Sri Lanka
Hugo Guglielmone, Argentina
Yang He, China
Mirta Hepsner, Argentina
Diego Higuera, Venezuela, Bolivarian Republic Of
Hu Hu, China
Kho Nhyn, Vietnam
Obinna Iheanacho, Nigeria
Leticia Jardim, Brazil
Anjali Jaydeep Kelkar, India
Marta Martinuzzo, Argentina
Muriel Meiring, South Africa
Lyu Mingen, China
Pravas Mishra, India
Daniella Mizurini, Brazil
Bushra Moiz, Pakistan
Robson Monteiro, Brazil
Katia Moraes, Brazil
Lakshmi Mundkur, India
Béla Nagy, Hungary
Nida Najmi, Pakistan
Hannah Omuwakki, Nigeria
Fernanda Orsi, Brazil
Juvenal Paiva, Argentina
Krisztina Pérez-Daku, Hungary
Benedetto Prezoto, Brazil
Alessandra Prezotti, Brazil
Lucia Remotti, Argentina
Daniel Ribeiro, Brazil
Theera Ruchutra, Thailand
Emelyn Salazar, Venezuela, Bolivarian Republic Of
Ana Sanchez-Luceros, Argentina
Priyanka Saxena, India
Mirta Schattner, Argentina
Tanusree Sengupta, India
Yanyan Shao, China
Ankit Sharma, India
Weihong Shen, China
Shrini Shetty, India
Namchu Sirachainan, Thailand
Samuel Souza Medina, Brazil
Tiantian Sun, China
Vikas Suri, India
Bundarika Suwanawiboon, Thailand
Anna Tanka-Salamon, Hungary
Noemi Klara Toth, Hungary
Fernando Vazquez, Argentina
Biljana Vuckovic, Serbia
Anyou Wang, China
Yao Wang, China
Luciana Wermelinger Serrao, Brazil
Adriana Ines Woods, Argentina
Jianbo Wu, China
Xiaolin Wu, China
Xiaodong Xi, China
Zhang Xian, China
Shilong Xiong, China
Jingyi Yang, China
Hao Yating, China
Ziqiang Yu, China
Yanyan Shao, China
Donglei Zhang, China
Zeping Zhou, China
Hu Zhou, China
Jingyi Zhou, China
Jinbo Wu, China
Xiaolin Wu, China
Xiaodong Xi, China
Zhang Xian, China
Shilong Xiong, China
Jingyi Yang, China
Hao Yating, China
Ziqiang Yu, China
Han Yue, China
Donglei Zhang, China
Bo Zhang, China
Zeping Zhou, China
Jingyi Zhou, China
Hu Zhou, China
Jingyi Zhou, China
Hu Zhou, China
The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

As a professional membership organization, the ISTH is dedicated to transformative scientific discoveries and clinical practices as well as the development of next generation and the education of physicians, scientists and allied health professionals wherever they may live.

With over 3,700 members in more than 90 countries, the ISTH supports a community of specialists in bleeding and clotting disorders through the creation and promotion of education and outreach initiatives, scientific meetings, research activities, peer reviewed publications, expert committees and the development of standards allowing a common language and approach to basic and clinical science all over the world.

A highly regarded Society poised on the leading edge of science, the ISTH offers a comprehensive membership offering that includes the following benefits:

**ISTH membership benefits:**

- An international professional network of 3,700 members spanning more than 90 countries.
- Priority registration and discounted fees for ISTH meetings and congresses.
- Complimentary print (for regular members only) and online subscriptions to ISTH’s *Journal of Thrombosis and Haemostasis* (JTH) as well as subscription to the ISTH monthly e-newsletter.
- Full access to the ISTH Academy, featuring webinars, webcasts, online courses and more. The ISTH also offers a free ISTH Academy membership, with limited access to online educational resources at academy.isth.org.
- Access to ISTH member-only resources, including an increasing array of educational materials, communication and membership directory.
- Exclusive access and reduced fees for other educational activities, programs and publications.
- Engagement opportunities, such as World Thrombosis Day each year on 13 October. Learn more at www.worldthrombosisday.org.
- ISTH Career Center.
- The right to nominate, elect, vote and serve on ISTH committees and working groups.

**ISTH membership categories include:**

- **Regular:** for active researchers, educators and clinicians in the field
- **Associate:** for students, trainees, research staff, post-doctoral fellows as well as allied health professionals
- **Reach-the-World:** for researchers, educators and clinicians in non-industrialized countries
- **Nurse:** registered nurses
- **Allied Health:** laboratory and radiological technicians, occupational and physical therapists, pharmacists, and other health professions distinct from medicine and nursing

For more information, or to join the Society, please contact:

**ISTH Headquarters Office**
610 Jones Ferry Road, Suite 205
Carrboro, NC 27510
United States
T: +1 919 929-3807
F: +1 919 929-3935
headquarters@isth.org
www.isth.org

Join the Conversation Online!

- www.facebook.com/internationalsocietythrombosisandhaemostasis
- www.twitter.com/isth
- www.linkedin.com/company/international-society-on-thrombosis-and-haemostasis-isth
- www.instagram.com/isthofficeteam

Learn more about World Thrombosis Day, an ISTH-lead yearly campaign at www.worldthrombosisday.org.
Visit us at our booth (# 1036) in the Exhibition Area on Level 800.
A GLOBAL FIRST
Join us and our eminent faculty at two symposia to hear exclusive real-world experience with prolonged half-life Fc Fusion Factors in the clinic

AFTERNOON SYMPOSIUM
Monday 22 June
12:15 – 13:45
Chaired by
Dr Manuel Carcao
Room 801, Level 800
Real-world experiences with prolonged half-life rFVIIIFc in hemophilia A: New data and future prospects

EVENING TECHNICAL SESSION
Monday 22 June
18:30 – 19:30
Chaired by
Dr Shannon Jackson
Room 717, Level 700
Sharing real-world experience with Fc Fusion Factors in hemophilia B: New data for rFIXFc

Come and visit us at Booth 922 to hear more about the work we are doing to move hemophilia treatment forward

Use the QR Code with your smartphone, or visit http://medical-congress.info/isth for more information and to add these exciting symposia to your calendar

Date of preparation April 2015
02EOL-INT-2015
From Baxter’s BioScience to Baxalta...

Baxter’s BioScience is expected to become Baxalta in mid-2015.

At Baxter’s BioScience, we see a world of endless possibilities for our patients. And although our name may be changing to Baxalta, our commitment to you is as strong as ever. At our foundation is an enduring heritage of innovation and advocacy. Your life is our inspiration to make a meaningful difference, so you can dream big, and experience life. We are excited about the future and hope you are too!

Visit the Baxalta booth #1602 to learn more,
Program at a Glance

From Saturday, June 20 – Thursday, June 25, 2015

Friday, Jun 19

Saturday, June 20

Master Classes (ticket needed)
07:00 - 07:50

Subcommittee Meetings and Educational Programme
08:00 - 12:20

WHO/Bayer

World Thrombosis Day

Nurse Forum 08:00 - 18:00

Opening Session
18:15 - 19:15

Welcome Reception
19:30 - 22:00

Registration
06:30 – 20:00

Sunday, June 21

Master Classes (ticket needed)
07:00 - 07:50

Oral Communications
08:00 - 09:15

Plenary Session
09:45 - 10:30

Lunch Symposium
12:15 - 13:45

Oral Communications
14:00 - 15:15

Abstract Symposia
15:45 - 17:15

Posters with Refreshments
17:15 - 18:30

Technical Sessions
18:30 - 20:00

Exhibition
09:00 - 18:30

Monday, June 22

Plenary Session
08:00 - 09:15

State of the Art
10:45 - 11:45

Break:
11:00 – 11:30 (Coffee)

Break:
12:15 – 13:00 (Lunch)

Break:
15:00 - 15:30 (Coffee)

Coffee and lunches will be served in the Foyers of the session rooms on Levels 700 and 800.

Registration
6:30 - 19:30

Tuesday, June 23

Master Classes (ticket needed)
07:00 - 07:50

Oral Communications
08:00 - 09:15

Plenary Session
09:45 - 10:30

State of the Art
10:45 - 11:45

Lunch Symposium
12:15 - 13:45

Oral Communications
14:00 - 15:15

Abstract Symposia
15:45 - 17:15

Technical Sessions
18:30 - 20:00

Plenary Session
09:45 - 10:30

State of the Art
10:45 - 11:45

Lunch Symposium
12:15 - 13:45

Oral Communications
14:00 - 15:15

Abstract Symposia
15:45 - 17:15

Posters with Refreshments
18:00 - 19:30

Exhibition
09:00 - 18:30

Wednesday, June 24

Break:
09:15 – 09:45 (Coffee)

Break:
10:30 – 10:45

Break:
11:15 – 12:15 (Lunch)

Break:
15:15 - 15:45 (Coffee)

Coffee will be served in the Foyers of the session rooms on Levels 700 and 800.

Exhibition
09:00 - 18:30

Thursday, June 25

Break:
09:15 – 09:30 (Coffee)

Coffee will be served in the Foyers of the session rooms on Levels 700 and 800.

Master Classes (ticket needed)
07:00 - 07:50

Oral Communications
08:00 - 09:15

Plenary Session
09:45 - 10:30

Posters with Refreshments
17:15 - 18:30

All Congress Party (ticket needed)

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 701</th>
<th>Room 713</th>
<th>Room 714</th>
<th>Room 715</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 11:00</td>
<td>Women’s Issues in Thrombosis and Haemostasis</td>
<td>Fibrinolysis</td>
<td>Vascular Biology</td>
<td>Predictive and diagnostic variables in thrombotic disease</td>
</tr>
<tr>
<td>11:20 - 12:20</td>
<td>Women’s Issues in Thrombosis and Haemostasis (cont’d)</td>
<td>Fibrinolysis</td>
<td>Vascular Biology</td>
<td>Predictive Variables Education Session</td>
</tr>
<tr>
<td>12:20 - 13:20</td>
<td>Exogenous Factors</td>
<td>Vascular Biology</td>
<td>Predictive Variables</td>
<td>Predictive and diagnostic variables in thrombotic disease (cont’d)</td>
</tr>
</tbody>
</table>

**Coffee Break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 716</th>
<th>Room 717</th>
<th>Room 718</th>
<th>Room 801</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:20 - 12:20</td>
<td>Lupus Anticoagulants</td>
<td>Factor VIII, IX and Rare Coagulation Disorders, Part I</td>
<td>Platelet Immunology</td>
<td></td>
</tr>
<tr>
<td>12:20 - 13:20</td>
<td>Lupus Anticoagulants (cont’d)</td>
<td>Factor VIII, IX and Rare Coagulation Disorders, Part I (cont’d)</td>
<td>Platelet Immunology (cont’d)</td>
<td></td>
</tr>
</tbody>
</table>

**Coffee Break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 716</th>
<th>Room 717</th>
<th>Room 718</th>
<th>Room 801</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 15:30</td>
<td>Biorheology Education Sessions</td>
<td>Pediatric/Neonatal T&amp;H Education Session</td>
<td>VWF Education Sessions</td>
<td>Hemostasis &amp; Malignancy Education Sessions</td>
</tr>
<tr>
<td>15:30 - 16:30</td>
<td>Biorheology Session</td>
<td>Pediatric/Neonatal T&amp;H Session</td>
<td>VWF Session</td>
<td>Hemostasis &amp; Malignancy Session</td>
</tr>
</tbody>
</table>

**Coffee Break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 716</th>
<th>Room 717</th>
<th>Room 718</th>
<th>Room 801</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:50 - 18:50</td>
<td>Biorheology Session (cont’d)</td>
<td>Pediatric/Neonatal T&amp;H Session (cont’d)</td>
<td>VWF Session (cont’d)</td>
<td>Hemostasis &amp; Malignancy Session (cont’d)</td>
</tr>
<tr>
<td>Time</td>
<td>Session 1</td>
<td>Session 2</td>
<td>Session 3</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>OC Anti-platelets</td>
<td>OC Reproductive Issues</td>
<td>OC VWD - classification, subtypes - I</td>
<td></td>
</tr>
<tr>
<td>09:15</td>
<td>Coffee Break</td>
<td>OC VWF-1</td>
<td>OC Animal models</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>SOA Hemophilia gene therapy; A Joint ISTH-WFH Symposium</td>
<td>SOA Controversies in VTE management</td>
<td>SOA Extracorporeal circulation in children</td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td>Lunch Symposia</td>
<td>Lunch</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td>SOA Mechanisms of thrombosis</td>
<td>SOA Hijacking of proteolytic mechanisms by pathogens</td>
<td>SOA Platelet function and dysfuntion</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td>AS Coagulation, hemostasis, immunity and inflammation</td>
<td>AS Fibrinogen</td>
<td>AS Microparticles</td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>Technical Sessions</td>
<td>Technical Sessions</td>
<td>Technical Sessions</td>
<td></td>
</tr>
</tbody>
</table>

**Monday, June 22, 2015**

<table>
<thead>
<tr>
<th>Room 714</th>
<th>Room 715</th>
<th>Room 716</th>
<th>Room 717</th>
<th>Room 718</th>
<th>Room 801</th>
<th>Room 803 A</th>
<th>Room 803 B</th>
<th>Intercontinental</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 714</td>
<td>Room 715</td>
<td>Room 716</td>
<td>Room 717</td>
<td>Room 718</td>
<td>Room 801</td>
<td>Room 803 A</td>
<td>Room 803 B</td>
<td>Intercontinental</td>
</tr>
</tbody>
</table>

**Nurse Forum**

08:00 - 16:30

**Career Mentorship Sessions**

12:00-13:00

**Master Class**

7:00-7:50
## Tuesday, June 23, 2015

### Plenary Hall D & E
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### Hall G & F

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plenary</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>Coffee Break</td>
<td>09:15 - 09:45</td>
</tr>
<tr>
<td>Lunch</td>
<td>11:45 - 12:15</td>
</tr>
<tr>
<td>Lunch Symposia</td>
<td>12:15-13:45</td>
</tr>
<tr>
<td>Coffee Break</td>
<td>15:15-15:45</td>
</tr>
</tbody>
</table>

### OC Cancer and Thrombosis – clinical – I
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Immune thrombocytopenia – Basic
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Microparticles - I
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Rare bleeding disorders
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Platelets – Signal Transduction II
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Antiphospholipid antibodies - II
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Pediatrisk thrombosis – I
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Risk factors for venous thrombosis – I
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Factor VIII – II
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC TTP and PNH
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Inflammation
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC VTE epidemiology – II
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Hemophilia inhibitors
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC VTE diagnosis
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC VWD clinical
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Tissue factor – factor VII – II
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Platelets – signal transduction II
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Coagulation factors, V, X, XIII
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Arterial vascular disease
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Pediatric hemostasis
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Hemophilia – novel treatments
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Cancer and thrombosis – clinical – II
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Acquired Disorders – clinical – II
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Megakaryocytes and thrombopoiesis II
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC NOAC – bleeding risk factors and management
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### OC Platelets – I
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### AS Cancer and thrombosis - basic
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### AS Inhibitors - basic
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### AS Mechanisms of ITP
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### AS Vascular progenitor cells and vascular disease
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### AS Developmental hemostasis
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### AS Endothelial cell wall - signaling
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### AS Hemostasis and infection
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### AS Vessel wall in health and disease
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### AS Thrombosis and inflammation
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### AS Platelet signalling
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### AS Non-antigen K antigens in antiplatelet therapy
- Room 701
- Room 705
- Room 707
- Room 709
- Room 711

### Career Mentorship Sessions
- Room 713
- Room 714
- Room 715
- Room 716
- Room 717
- Room 718
- Room 801

---

### Exhibition
- Hall D & E
- Hall G & F
- Room 713
- Room 714
- Room 715
- Room 716
- Room 717
- Room 718
- Room 801

### Master Class
- 07:00-07:50

---

### Career Mentoring Sessions
- 12:00-13:00

### Lunch Symposia
- 12:15-13:45

### Coffee Break
- 09:15-09:45

### Lunch
- 11:45 - 12:15

### Coffee Break
- 15:15-15:45

---

### Posters with refreshments
- 18:00 - 19:30
### Wednesday, June 24, 2015

#### Plenary

- **Hall D & E Room 701**
- **Room 705**
- **Room 707**
- **Room 709**
- **Room 711**
- **Room 713**

**Plenary**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>OC Late-breaking abstract session - Bleeding disorders</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>OC ITP - Clinical</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>OC Factor VIII and IX</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>OC Blood coagulation tests - I</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>OC Heparin and heparinoids</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>OC Microparticles - I</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>OC Platelets - II</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>OC Non-vitamin K oral anticoagulants and surgery</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>OC Contact system</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>OC Platelets</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>OC Factor V and VII</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>OC VWF</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>OC VTE treatment - I</td>
<td>08:00-09:15</td>
</tr>
<tr>
<td>OC Risk Factors for venous thrombosis - I</td>
<td>08:00-09:15</td>
</tr>
</tbody>
</table>

**Coffee Break**

- **09:15 - 09:45**

#### Posters with refreshments

- **17:15 - 18:30**

#### Master Class

- **7:00-7:50**

#### Career Mentorship Sessions

- **12:00-13:00**

---

**Lunch Symposia**

- **12:15-13:45**

**Coffee Break**

- **15:15 - 15:45**

---

**Room 714**

**Room 715**

**Room 716**

**Room 717**

**Room 718**

**Room 801**

**Room 803A**

**Room 803B**

---

**Plenary**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOA Treatment of anticoagulant-associated bleeding</td>
<td>09:00-10:15</td>
</tr>
<tr>
<td>SOA Break (Food and beverages)</td>
<td>10:15-10:45</td>
</tr>
<tr>
<td>Lunch</td>
<td>11:45 - 12:15</td>
</tr>
</tbody>
</table>

**Lunch Symposia**

- **12:15-13:45**

**Coffee Break**

- **09:15 - 09:45**

---

**Plenary**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOA Pathobiology and Immunology</td>
<td>10:45 - 11:45</td>
</tr>
<tr>
<td>SOA Innovations and Technology</td>
<td>10:45 - 11:45</td>
</tr>
<tr>
<td>SOA Trauma-induced coagulopathy</td>
<td>10:45 - 11:45</td>
</tr>
<tr>
<td>SOA Controversies in antiplatelet therapy for coronary artery disease</td>
<td>10:45 - 11:45</td>
</tr>
</tbody>
</table>

**Coffee Break**

- **09:15 - 09:45**

---

**Lunch Symposia**

- **12:15-13:45**

**Lunch**

- **11:45 - 12:15**

---

**AS**

- **Therapeutic management of venous thrombosis**

- **Factor VIII**

- **Modulators of fibrinolytic activity**

- **Membrane scrambling**

- **Platelet activation**

**AS**

- **Structure and function**

- **Factor V and VII**

- **Vascular remodeling**

- **Prevention of thrombosis in children**

- **Function testing assays**

---

**AS**

- **Therapeutic management of venous thrombosis**

- **Factor VIII**

- **Modulators of fibrinolytic activity**

- **Membrane scrambling**

- **Platelet activation**

---

**AS**

- **Therapeutic management of venous thrombosis**

- **Factor VIII**

- **Modulators of fibrinolytic activity**

- **Membrane scrambling**

- **Platelet activation**

---

**AS**

- **Therapeutic management of venous thrombosis**

- **Factor VIII**

- **Modulators of fibrinolytic activity**

- **Membrane scrambling**

- **Platelet activation**
### Thursday, June 25, 2015

#### Plenary Hall G&F

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30-10:15</td>
<td>Plenary</td>
</tr>
</tbody>
</table>

### Coffee Break 09:15 - 09:30

#### OC

- Venous thromboembolism – therapy II 08:00-09:15
- Risk factors for venous thrombosis – III 08:00-09:15
- Blood coagulation factor – II 08:00-09:15
- Fibrinogen and fibrin II 08:00-09:15
- Cancer and thrombosis – basic – II 08:00-09:15
- Fibrinolytic system – II 08:00-09:15

#### AS

- Novo anti-platelet agents 10:30-11:45
- Atherosclerosis, inflammation and cancer 10:30-11:45
- Chronic kidney disease and coagulation 10:30-11:45
- Fibrinolysis in health and disease 10:30-11:45
- Atherosclerosis: progression and development 10:30-11:45
- Glycobiology 10:30-11:45

#### Coffee Break 11:45 - 12:00

#### Highlights of ISTH

11:45 - 12:00

### OC

- Factor VIII – III 08:00-09:15
- Megakaryocytes and thrombopoiesis III 08:00-09:15
- Platelets – III 08:00-09:15
- VWF – II 08:00-09:15
- Regulation of coagulation and fibrinolysis 08:00-09:15
- Hemophilia – joint disease and clinical 08:00-09:15
- Anti-platelet agents – clinical 08:00-09:15

### Coffee Break 09:15 - 09:30

### AS

- Stroke 10:30-11:45
- Protein C and sepsis 10:30-11:45
- Endothelial cell-VTE models 10:30-11:45
- Cancer and thrombosis clinical 10:30-11:45
- ADAMTS13 10:30-11:45
- Unusual site venous thrombosis 10:30-11:45
- Inhibitors – clinical 10:30-11:45
SSC PROGRAM

Saturday, June 20, 2015     9:00-13:20

Factor VIII and IX, part 1     Room 718
Chairman: Guy Young (United States)
Co-chairs: Manuel Carcao (Canada), Danijela Mikovic (Serbia), Flora Peyvandi (Italy), Steve Pipe (United States), Elena Santagostino (Italy), Mike Makris (United Kingdom)
09:00 - 09:15 Welcome and introduction
Guy Young (United States)

PROJECT UPDATES

Moderators: Flora Peyvandi (Italy), Mike Makris (United Kingdom)
09:15 - 09:30 Standardization of post-registration surveillance
Flora Peyvandi (Italy)
09:30 - 09:40 Prophylaxis in patients without inhibitors
Victor Blanchette (Canada), Kathelijn Fischer (The Netherlands)
09:40 - 09:50 Prophylaxis in patients with inhibitors
Carmen Escuriola (Germany)
09:50 - 10:00 Bleeding score in hemophilia
Maria Elisa Mancuso (Italy)
10:00 - 10:10 ITI definitions
Elena Santagostino (Italy)
10:10 - 10:20 Mild hemophilia definitions
Mike Makris (United Kingdom)
10:20 - 10:30 Inhibitor reporting standardization in previously treated patients
Alfonso Iorio (Canada)
10:30 - 10:40 Standardization of genetic assays for diagnosis of hemophilia
Vince Jenkins (Ireland)
10:40 - 11:00 Discussion

COFFEE BREAK

EDUCATION SESSION

Moderators: Guy Young (United States), Manuel Carcao (Canada)
11:20 - 11:50 From Alexie Romanov to Stephen Christmas to 2015: What is different about factor IX deficiency?
Elena Santagostino (Italy)
11:50 - 12:20 What is the “true” incidence of inhibitors in haemophilia?
Michael Soucie (United States)

SSC PROGRAM

RARE BLEEDING DISORDERS
Moderator: Elena Santagostino (Italy)
12:20 - 12:40 Update on afibrinogenemia and dysfibrinogenemia
Philippe de Moerloose (Switzerland), Alessandro Casini (Switzerland)
12:40 - 13:00 PRO-RBDD project: Prospective evaluation of the intensity of bleeding episodes in patients with fibrinogen and FXIII deficiency
Flora Peyvandi (Italy)
13:00 - 13:20 Discussion

Lupus anticoagulant/Phospholipid-dependent antibodies     Room 716
Chairman: Bas de Laat (The Netherlands)
Co-chairs: Tatsuya Atsumi (Japan), Maria Laura Bertolaccini (United Kingdom), Katrien M. Devreese (Belgium), Rolf T. Urbanus (The Netherlands), Denis G. Wahl (France)
09:00 - 09:01 Opening
09:00 - 09:10 The effect of different types of reagents on LAC detection
Osamu Kumano (Japan)
09:10 - 09:25 Multicenter study on cut-off values for solid phase assays
Katrien M. Devreese (Belgium)
09:25 - 09:35 Conformation of beta2GPI
Leonie Peikman (The Netherlands)
09:35 - 09:55 Anti-beta2GPI IgA antibodies & anti-PT/PS antibodies
Maria Laura Bertolaccini (United Kingdom)
09:55 - 10:10 Thrombin generation in APS
Denis G. Wahl (France)
10:10 - 10:25 Unravelling the mechanism behind LAC
Rolf T. Urbanus (The Netherlands)
10:25 - 10:45 Resistance to Annexin A5 anticoagulant activity is a biomarker for adverse clinical outcomes
Jacob H. Rand (United States), Lucia R. Wolgast (United States)
10:45 - 11:00 Domain I and risk stratification
Vittorio Pengo (Italy)

COFFEE BREAK

EDUCATION SESSION

11:20 - 11:50 The activity of antiphospholipid antibodies in vitro and in vivo
Philip G. de Groot (The Netherlands)
SSC PROGRAM

11:50 - 12:20  The antiphospholipid syndrome (APS), a clinician’s perspective  
Vittorio Pengo (Italy)

SUBCOMMITTEE CONTINUES

12:20 - 12:35  Global anti-phospholipid syndrome score (GAPSS)  
Denis G. Wahl (France)

12:35 - 12:50  APS scoring  
Tatsuya Atsumi (Japan)

12:50 - 13:05  LAC in APS patients on rivaroxaban  
Deepa Arachchilage (United Kingdom)

13:05 - 13:19  Rivaroxaban in antiphospholipid syndrome  
Hannah Cohen (United Kingdom)

13:19 - 13:20  Closing remarks  
Bas de Laat (The Netherlands)

Platelet immunology  Room 801

Chairman:  Yves Gruel (France)
Co-chairs:  Donald Arnold (Canada), Tamam Bakchoul (Germany), Francois Mullier (Belgium)
           Sentot Santoso (Germany), Yoshiaki Tomiyama (Japan), Chris Ward (Australia)

09:00 - 09:10  Welcome  
Donald Arnold (Canada)

AUTOIMMUNE AND DRUG-INDUCED ITP  
Moderators: Donald Arnold (Canada), Yoshiaki Tomiyama (Japan)

09:10 - 09:25  Recommendations for platelet autoantibody testing in ITP  
Donald Arnold (Canada)

09:25 - 09:40  Immature platelet fraction measurement for the diagnosis of ITP  
Yoshiaki Tomiyama (Japan)

09:40 - 09:55  Recommendations for cutoff values for positive results of DITP testing and sample materials  
Tamam Bakchoul (Germany), Brian Curtis (United States)

HEPARIN-INDUCED THROMBOCYTOPENIA  
Moderators: Chris Ward (Australia), Yves Gruel (France)

09:55 - 10:15  Standardized protocol of Multiplate assay for HIT diagnosis; and results of a national survey of functional testing  
Chris Ward (Australia), Tamam Bakchoul (Germany)

10:15 - 10:30  5B9, a potential standard for HIT laboratory assays?  
Yves Gruel (France)

COFFEE BREAK

EDUCATION SESSION

11:20 - 11:50  Platelet alloantigens in other tissues, and implications in immunohematology  
Sentot Santoso (Germany)

11:50 - 12:20  New insights explaining the variability in platelet response to HIT antibodies  
Yves Gruel (France)

ALLEMMUNE THROMBOCYTOPENIA  
Moderators: Tamam Bakchoul (Germany), Sentot Santoso (Germany)

12:20 - 12:35  NAIT- Should surface plasmon resonance (SPR) and antibody titre be part of routine investigations and reporting?  
Gerald Bertrand (France)

12:35 - 12:50  A new alloantigen (Cab 4) carried by GPIbIX in a context of severe neonatal alloimmune thrombocytopenia  
Rachel Petermann (France)

12:50 - 13:20  Re-cap of ongoing and new proposals  
Donald Arnold (Canada)

Vascular biology  Room 714

Chairman:  Rienk Nieuwland (The Netherlands)
Co-Chairs:  Alexander Brill (United Kingdom), Elizabeth E. Gardiner (Australia)
            Chris Gardiner (United Kingdom), Anna Randi (United Kingdom)
            Florance Sabatier (France), Pia Siljander (Finland)

CIRCULATING ENDOTHELIAL PROGENITOR CELLS  
Moderators: Anna Randi (United Kingdom), Florence Sabatier (France)

09:00 - 09:20  From VSELs to endothelial progenitor cells: What is the “perfect” vasculogenic cell?  
David Smedja (France)

09:20 - 09:40  Blood outgrowth endothelial cells offer novel insights into von Willebrand disease  
Richard Starke (United Kingdom)

09:40 - 10:00  Derivation of endothelial colony forming cells from pluripotent stem cells  
Nuttan Prasain (United States)
SSC PROGRAM

RECEPTOR SHEDDING FROM PLATELETS IN THE INFLAMED VASCULATURE
Moderators: Elizabeth E. Gardiner (Australia), Alexander Brill (United Kingdom)

10:00 - 10:20 Platelets and the inflamed vasculature
Paul Kubes (Canada)

10:20 - 10:40 Mechanistic insights into platelet receptor shedding
Yotis Senis (United Kingdom)

10:40 - 11:00 Glycoprotein Ib-alpha shedding and platelet clearance
Renhao Li (United States)

COFFEE BREAK

EDUCATION SESSION
Moderators: Rienk Nieuwland (The Netherlands)

11:20 - 11:50 Multiple applications of endothelial colony forming cells
Juan Melero-Martin (United States)

11:50 - 12:20 Measurement of tissue factor in clinical samples
Nigel Mackman (United States)

MICROPARTICLES AND STANDARDIZATION
Moderators: Pia Siljander (Finland), Chris Gardiner (United Kingdom)

12:20 - 12:40 Vesicle size approximation enables interlaboratory comparison of vesicle measurements by flow cytometry
Rienk Nieuwland (The Netherlands)

12:40 - 13:00 Studies of the microparticle cargo and its functional components
Eric Boilard (Canada)

13:00 - 13:20 Progress of endothelial microparticle detection and characterization by flow cytometry
Romaric Lacroix (France)

Predictive and diagnostic variables in thrombotic disease Room 715

Chairman: Paul A. Kyrle (Austria)
Co-chairs: Suzanne Cannegieter (The Netherlands), Shinya Goto (Japan), Karel Moons (The Netherlands), Marc C. Samama (France), Alexander C. Spyropoulos (United States)

09:00 - 09:05 Welcome, information on the new scope of the subcommittee

SSC PROGRAM

PREDICTIVE AND DIAGNOSTIC VARIABLES IN THROMBOTIC DISEASE
Moderators: Paul A. Kyrle (Austria), Gregoire Le Gal (Canada)

09:05 - 09:20 Decision rules in suspected DVT and PE; towards personalized strategies
Geert-Jan Geersing (The Netherlands)

09:20 - 09:35 Diagnosis of recurrent VTE
Frederikus A. Klok (The Netherlands)

09:35- 09:50 Diagnosing small clots: Subsegmental pulmonary embolism
Marc Carrier (Canada)

09:50- 10:15 Diagnosing small clots: Distal deep vein thrombosis
Marc Righini (Switzerland)

10:15- 11:00 On-going studies (ADJUST-DVT, THEIA, CLOT 3, “D-dimer and pre-test clinical probability score in cancer patients with suspected deep vein thrombosis of the legs”, 4D, PEGED)
Marc Righini (Switzerland), Frederikus A. Klok (The Netherlands), Scott Stevens (United States), Marcello Di Nisio (Italy), Clive Kearon (Canada)

COFFEE BREAK

EDUCATION SESSION
Moderators: Marc C. Samama (France), Alexander C. Spyropoulos (United States)

11:20- 11:50 Etiology in clinical research: Possibilities and limitations
Suzanne Cannegieter (The Netherlands)

11:50 - 12:20 Clinical prediction modelling: Do’s and don’ts
Karel Moons (The Netherlands)

PREDICTIVE VARIABLES IN THROMBOTIC DISEASE
Moderators: Suzanne Cannegieter (The Netherlands), Shinya Goto (Japan)

12:20 - 12:40 Extracellular nucleic acids as potential biomarkers of thrombosis and cardiovascular disease
Hector Cabrera-Fuentes (Germany)

12:40 - 13:00 The use of a bivariate model of thrombosis and bleeding in antithrombotic trials
Alexander C. Spyropoulos (United States)

13:00 - 13:20 Should we shorten or even skip VTE prophylaxis after day case surgery and/or surgery with enhanced recovery?
Marc C. Samama (France)

13:20 - 13:30 Closing remarks
**WELCOME AND INTRODUCTION**

**Moderator:** Rezan Abdul-Kadir (United Kingdom)

- **09:00 - 09:05** Outline of the SSC and overview of activities
  Rezan Abdul-Kadir (United Kingdom)

- **09:05 - 09:10** Report on the Women’s Health Issues in Thrombosis and Hemostasis Symposium 2015
  Benjamin Brenner (Israel)

**UPDATES ON REGISTRIES AND PROJECTS**

**Moderators:** Saskia Middeldorp (The Netherlands), Maha Othman (Canada)

- **09:10 - 09:15** NOAC and pregnancy: Registry
  Saskia Middeldorp (The Netherlands)

- **09:15 - 09:20** Thrombophilia screening after recurrent failures in assisted reproductive techniques: Registry
  Elvira Grandone (Italy)

- **09:20 - 09:25** Thrombophilia and outcomes of assisted reproduction technologies: Summary of systematic review and meta-analysis
  Marcello Di Nisio (Italy)

- **09:25 - 09:35** YEARS diagnostic study in PE
  Menno Huisman (The Netherlands)

- **09:35 - 09:45** The use of thrombo-elastography in pregnancy: Registry
  Maha Othman (Canada)

- **09:45 - 09:55** Obstetric issues in mothers of children with severe protein C deficiency
  Adrian Minford (United Kingdom)

- **09:55 - 10:00** Discussion

**THROMBOSIS ISSUES**

**Moderators:** Hannah Cohen (United Kingdom), Ida Martinelli (Italy)

- **10:00 - 10:20** Management of non-vitamin K oral anticoagulants (NOAC) in women of childbearing age
  Deepa Arachchilage (United Kingdom)

- **10:20 - 10:40** Management of obstetric antiphospholipid syndrome: New developments
  Beverley Hunt (United Kingdom)

**HEMOSTATIS ISSUES**

**Moderators:** Rochelle Winikoff (Canada), Peter Kouides (United States)

- **12:20 - 12:30** Women and platelet function defects
  Sarah O’Brien (United States)

- **12:30 - 12:45** Can carriers of hemophilia with normal factor levels bleed?
  Robert Sidonio (United States)

- **12:45 - 13:00** Postpartum hemorrhage in carriers of hemophilia and women with VWD
  Jeroen Eikenboom (The Netherlands)

- **13:00 - 13:15** Abnormal uterine bleeding in adolescents: Patterns, diagnoses and clinical outcomes
  Ayesha Zia (United States)

- **13:15 - 13:20** Foundation for women and girls with blood disorders (FWGBD)
  Ann-Marie Nazzaro (United States)
SSC PROGRAM

09:15 - 09:25  Development of standards for plasmin, streptokinase, anacrod and batroxoban
Craig Thelwell (United Kingdom)

09:25 - 09:40  Standardization of TAFI (CPU)
Craig Thelwell (United Kingdom)

DIVERSE ROLES OF PLASMIN

09:40 - 10:00  Plasmin and von Willebrand factor in thrombotic thrombocytopenic purpura
Claudia Tersteeg (The Netherlands)

10:00 - 10:20  Plasmin generation by staphylokinase during skin infections with Staphylococcus aureus
Marijke Peetermans (Belgium)

IMPACT OF CELLS ON FIBRINOLYSIS

10:20 - 10:40  Effect of hematocrit on clot structure and resistance to lysis
Paraskevi Untiveros (United Kingdom)

10:40 - 11:00  Neutrophils as key modulators of fibrin structure and lysis in thrombi
Imre Varjú (Hungary)

COFFEE BREAK

EDUCATION SESSION

11:20 - 11:50  Influence of alpha-2AP on the pathogenesis of stroke
Guy Reed (United States)

11:50 - 12:20  Plasminogen activation in the brain
Manuel Yepes (United States)

INHIBITORS OF FIBRINOLYSIS IN DISEASE

12:20 - 12:40  Thrombolysis induced by a diabody against PAI-1 and TAFI
Paul Declerck (Belgium)

12:40 - 13:00  Cell-free DNA modulates clot structure and impairs fibrinolysis in sepsis
Travis Gould (Canada)

13:00 - 13:20  Measurement of active CPU (TAFIa) in samples from patients with acute coronary syndrome
Dorien Leenaerts (Belgium)

SSC PROGRAM

Pediatric and neonatal thrombosis and hemostasis
Room 717

Chairman:  Anthony K. Chan (Canada)
Co-Chairs:  Mariana Bonduel (Argentina), Leonardo R. Brandao (Canada)
Elizabeth A. Chalmers (United Kingdom), Neil Goldenberg (United States)
Shoshana Revel-Vilk (Israel), Heleen van Ommen (The Netherlands)

EDUCATION SESSION

Moderators: Anthony Chan (Canada), Elizabeth Chalmers (United Kingdom)

14:30-15:00  Direct oral anticoagulants: Current status in pediatric trials
Heleen van Ommen (The Netherlands)

15:00-15:30  Antithrombin concentrate: What is the evidence on its use?
Paul Monagle (Australia)

SUBCOMMITTEE SESSION 1

Moderators: Anthony Chan (Canada), Heleen van Ommen (The Netherlands)

15:30-15:50  Report from catheter-related arterial thrombosis working group
Manuela Albisetti (Switzerland)

15:50-16:10  Report from radiological diagnosis working group
Leonardo Brandao (Canada)

16:10-16:30  Report from pulmonary embolism working group
Neil Goldenberg (United States)

SUBCOMMITTEE SESSION 2

Moderators: Leonardo Brandao (Canada), Neil Goldenberg (United States)

16:50-17:05  Report from VTE prevention working group
Brian Branchford (United States), Julie Jaffray (United States)

17:05-17:20  RCT: Do we need anti-Xa monitoring for use of enoxaparin?
Mihir Bhatt (Canada)

17:20-17:35  Management of coagulopathy in children with liver disease
Maria Magnusson (Sweden)

17:35-17:50  Purpura fulminans registry
Victoria Price (Canada)

17:50-18:00  DIC registry
Jecko Thachil (United Kingdom)

18:00-18:10  Management guide: CVL related thrombosis
Ketan Kulkarni (Canada)

18:10-18:20  Antithrombin registry
Riten Kumar (United States)
SSC PROGRAM

18:20-18:25  Menorrhagia in adolescence
Ayesha Zia (United States)

18:25-18:30  Conclusion
Anthony Chan (Canada)

Biorheology  Room 716

Chairman:  Keith Neeves (United States)
Co-chairs:  Judith Cosemans (The Netherlands), David N. Ku (United States)
Pierre Mangin (France), Owen J. McCarty (United States)
Mitsuhiko Sugimoto (Japan), Erik Westein (Australia)

JOINT BIORHEOLOGY AND PLATELET PHYSIOLOGY EDUCATION SESSION

14:30 - 15:00  Bioreactors for the study of the biophysical mechanisms that regulate platelet function?
José Lopez (United States)

15:00 - 15:30  Bioreactors for the study of the biophysical mechanisms that regulate platelet function?
Shaun Jackson (Australia)

15:30 - 16:30  Joint Biorheology & VWF session on acquired von Willebrand syndrome in room 718
Jorge A. Di Paola (United States), Keith Neeves (United States)

COFFEE BREAK

VWF-MEDIATED MECHANISMS IN COMPLEX AND PATHOLOGICAL FLOWS
Moderators: Mitsuhiko Sugimoto (Japan), Pierre Mangin (France)

16:50 - 17:05  Biomechanical regulation of VWF and thrombus formation under complex flow conditions
Erik Westein (Australia)

17:05 - 17:20  From single VWF molecules to collective aggregates: Towards an understanding of thrombus formation
Matthias Schneider (United States)

17:20 - 17:35  Relative roles of VWF and platelets in formation of occlusive arterial thrombosis
David N. Ku (United States)

NOVEL FLOW-DEPENDENT MECHANISMS OF PLATELET FUNCTION, COAGULATION AND FIBRINOLYSIS
Moderators: Erik Westein (Australia), Judith Cosemans (The Netherlands)

17:45 - 18:00  Shear effects on platelet surface receptor shedding
Elizabeth E. Gardiner (Australia)

SSC PROGRAM

18:00 - 18:15  Assessment of platelet-dependent coagulation and fibrinolysis under flow
Paola van der Meijden (The Netherlands)

18:15-18:30  Platelet adhesion and aggregation under disturbed blood flow: A focus on the role of pulsatility
Pierre Mangin (France)

18:30 - 18:50  Discussion: Challenges and needs for standardization of flow assays

Exogenous hemostatic factors  Room 713

Chairman:  Ivo Francishetti (United States)
Co-Chairs:  Tur-Fu Huang (Taiwan), Manjunatha R. Kini (Singapore)
Francis Markland Jr. (United States), Robson Monteiro (Brazil)
Kenneth J. Clemetson (Switzerland)

EDUCATION SESSION

14:30 - 15:00  Exogenous factor XIa inhibitors from snake venoms
Manjunatha R. Kini (Singapore)

15:00 - 15:30  Hematophagy, neutrophils and contact pathway
Ivo Francischetti (United States)

SUBCOMMITTEE SESSION

15:30 - 15:50  Structure of Pseutarin-C, a snake venom prothrombin activator
Jim Huntington (United Kingdom)

15:50 - 16:10  Rational strategy applied to a tick salivary FXa inhibitor in order to develop a potential antitumor drug candidate
Ana Marisa Chudzinski-Tavassi (Brazil)

16:10 - 16:30  Exogenous inhibitors as tools for the study of new players in haemostasis and thrombosis
Robson D. Monteiro (Brazil)

COFFEE BREAK

16:50 - 17:10  Exogenous hemostatic factors as tools in platelet research
Kenneth J. Clemetson (Switzerland)

17:10 - 17:30  Anfibatide and other exogenous platelet GPIb antagonists
Heyu Ni (Canada)

17:30 - 17:50  The second generation of platelet GPIIb/IIIa antagonists derived from snake venom disintegrins
Tur-Fu Huang (Taiwan)

17:50 - 18:10  Towards an understanding of the cellular and molecular events that underlie quick wound healing in salamanders
Ren Lai (China)
SSC PROGRAM

18:10 - 18:15  Closing remarks
Ivo Francischetti (United States)

Hemostasis and malignancy
Room 801

Chairman:  Alok A. Khorana (United States)
Co-Chairs:  Marc Carrier (Canada), Howard Liebman (United States)
           Nigel Mackman (United States), Simon I. Noble (United Kingdom)
           Ingrid Pabinger (Austria) Joseph S. Palumbo (United States)

EDUCATION SESSION
Moderators: Marc Carrier (Canada), Alok A. Khorana (United States)

14:30 - 15:00  Occult VTE: Do new trial results change practice?
Marc Carrier (Canada)

15:00 - 15:30 Qualitative research into cancer associated thrombosis: Who needs it?
Simon I. Noble (United Kingdom)

SUBCOMMITTEE SESSION 1
Moderators: Nigel Mackman (United States), Ingrid Pabinger (Austria)

15:30 - 16:10 Platelets, hemostatic factors and malignancy
Ingrid Pabinger (Austria), Nigel Mackman (United States), Joseph S. Palumbo (United States)

16:10 - 16:30 Predicting recurrent VTE: New biomarkers and risk factor analyses from CATCH
Alok A. Khorana (United States)

COFFEE BREAK

SUBCOMMITTEE SESSION 2
Moderators: Jeffrey Zwicker (United States), Cihan Ay (Austria)

16:50 - 17:10 Hypercoagulation screening as a marker of thrombosis and poor disease prognosis in cancer patients: The HYPERCAN prospective study
Marina Marchetti (Italy), Anna Falanga (Italy)

17:10 - 17:25 Incidental VTE: Emerging data
Casey O'Connell (United States)

17:25 - 17:40 Incidental VTE: SSC guidance statement
Marcello Di Nisio (Italy)

17:40 - 18:00 Treating CAT: Indirect comparison of anticoagulants
Cihan Ay (Austria), Florian Posch (Australia)

18:00 - 18:10 Coagulopathy and prostate cancer
Maha Othman (Canada)

18:10 - 18:30 New guidance proposals: Pediatric VTE and intracranial hemorrhage
Joseph S. Palumbo (United States), Jeffrey Zwicker (United States)

18:30 - 18:50 Update on new studies: Longheva registry; Prophylaxis
Pieter W. Kamphuisen (The Netherlands), Marc Carrier (Canada)

Plasma coagulation inhibitors
Room 715

Chairman: Richard Marlar (United States)
Co-chairs: Ian Jennings (United Kingdom), Jun Teruya (United States)
           Hiroko Tsuda (Japan)

PLASMA COAGULATION INHIBITORS: RELATIONSHIP OF PHENOTYPE, PLASMA LEVELS AND CLINICAL PHENOTYPE (THROMBOSIS)
Moderator: Richard Marlar (United States)

14:30 - 15:00 Molecular defects in protein S
Pieter H. Reitsma (The Netherlands)

15:00 - 15:30 Comparison of phenotype and genotype for AT, PC and PS
Anna Pavlova (Germany)

SUBCOMMITTEE SESSION 1
Moderators: Jun Teruya (United States), Richard Marlar (United States)

15:30 - 15:45 Current project: Mutation repository
Richard Marlar (United States)

15:45 - 16:00 Current project: Protein S testing
Ian Jennings (United Kingdom)

16:00 - 16:10 Current project: Racial differences
Hiroko Tsuda (Japan)

16:10 - 16:15 Manuscript progress for clinical testing for AT, PC, PS and APC-R: Protein C
Steve Kitchen (United Kingdom)

16:15 - 16:20 Manuscript progress for clinical testing for AT, PC, PS and APC-R: Protein S
Richard Marlar (United States)

16:20 - 16:25 Manuscript progress for clinical testing for AT, PC, PS and APC-R: Antithrombin
TBD

16:25 - 16:30 Manuscript progress for clinical testing for AT, PC, PS and APC-R: APC resistance
Richard Marlar (United States)
SSC PROGRAM

COFFEE BREAK

16:50 - 17:10 Other plasma Inhibitors: Review of other inhibitors
Jun Teruya (United States)

17:10 - 17:25 Other plasma Inhibitors: Clinical work on heparin cofactor II
Jun Teruya (United States)

17:25 - 17:40 Other plasma Inhibitors: Clinical work on TFPI

17:40 - 17:50 Comparative schemes for thrombophilia testing by region-country: UK
Steve Kitchen (United Kingdom)

17:50 - 18:00 Comparative schemes for thrombophilia testing by region-country: Europe
Piet Meijer (The Netherlands)

18:00 - 18:10 Comparative schemes for thrombophilia testing by region-country: Japan
Hiroko Tsuda (Japan)

18:10 - 18:20 Comparative schemes for thrombophilia testing by region-country: India
TBD

18:20 - 18:30 Comparative schemes for thrombophilia testing by region-country: Australia
TBD

18:30 - 18:40 Comparative schemes for thrombophilia testing by region-country: United States
Dorothy Adcock (United States)

18:40 - 18:45 Summary of schemes
Richard Marlar (United States)

18:45 - 18:50 Conclusions

Von Willebrand factor  Room 718

Chairman: Jorge A. Di Paola (United States)

Co-chairs: Sandra Haberichter (United States), Daniel J. Hampshire (United Kingdom), Koichi Kokame (Japan), Johanna A. Kremer Hovinga (Switzerland), Frank W. Leebeek (The Netherlands), Alberto Tosetto (Italy)

EDUCATION SESSION

Moderators: Jorge A. Di Paola (United States)

14:30 - 15:00 Factor VIII and VWF, rekindling a longstanding relationship
Peter Lenting (France)

15:00 - 15:30 ADAMTS13 deficiency, TTP and beyond
Johanna A. Kremer Hovinga (Switzerland)

SSC PROGRAM

JOINT BIORHEOLOGY & VWF SESSION ON ACQUIRED VON WILLEBRAND SYNDROME

Moderators: Jorge A. Di Paola (United States), Keith Neeves (United States)

15:30 - 15:45 Flow mediated interactions of VWF and ADAMTS13: Shear ecstasy
David Lillicrap (Canada)

15:45 - 16:00 Acquired von Willebrand syndrome in patients with VAD or ECMO
Barbara Zieger (Germany)

16:00 - 16:15 Effects of high shear millisecond exposure on platelets
David Schmidtke (United States)

16:15 - 16:30 Discussion for speakers and proposed AWS working group

COFFEE BREAK

LABORATORY AND CLINICAL UPDATES

Moderators: Frank W. Leebeek (The Netherlands), Alberto Tosetto (Italy)

16:50 - 17:05 Update of VWF functional assays
Sandra Haberichter (United States)

17:05 - 17:20 ADAMTS13 assays, the need for multicenter studies
Johanna A. Kremer Hovinga (Switzerland), Koichi Kokame (Japan)

17:20 - 17:35 Development and validation of assessment tools for clinical trials in VWD
Paula James (Canada), Alberto Tosetto (Italy)

STUDYING VWF AND VWD UNDER FLOW

Moderators: Johanna A. Kremer Hovinga (Switzerland), Daniel J. Hampshire (United Kingdom)

17:35 - 17:50 Studying VWF mutations under flow
Maria Brehm (Germany)

17:50 - 18:05 Studying VWD with microfluidic devices
Chris Ng (United States)

VISUALIZING VWF

Moderators: Koichi Kokame (Japan), Sandra Haberichter (United States)

18:05 - 18:20 VWF in megakaryocytes
Walter Kahr (Canada)

18:20 - 18:35 Optimization of immunocytochemical staining and high resolution imaging of VWF in HEK293 cells
Simon Webster (United Kingdom)

18:35 - 18:50 Visualizing VWF exocytosis
Jeroen C. Eikenboom (The Netherlands)
SSC PROGRAM

Factor XIII and fibrinogen

Room 714

Chairman: Helen Philippou (United Kingdom)

Co-Chairs: Zsuzsa Bagoly (Hungary), Matthew J. Flick (United States), Vytautas Ivaskevicius (Germany), Marlien Pieters (South Africa), Verena Schroeder (Switzerland), Alisa S. Wolberg (United States)

EDUCATION SESSION

14:30 - 15:00 Roles of the alpha chains of fibrinogen
Leonid Medved (United States)

15:00 - 15:30 A historic recollection of factor XIII research
Aki Ichinose (Japan)

SUBCOMMITTEE SESSION

15:30 - 15:50 Standardisation of turbidity and fibrinolysis measurements
Marlien Pieters (South Africa)

15:50 - 16:10 FXIII-B standardisation update
Éva Katona (Hungary), Verena Schroeder (Switzerland)

16:10 - 16:30 New insights into automated fibrinogen Clauss assays
Sanj Raut (United Kingdom)

COFFEE BREAK

16:50 - 17:15 Fibrinogen and factor XIII in chronic inflammation
Matthew J. Flick (United States)

17:15 - 17:40 Fibrinogen density decreases slightly and fiber stiffness decreases strongly with increasing fibrin fiber diameter
Martin Guthold (United States)

17:40 - 18:05 Novel functions of fibrin(ogen) in liver repair and fibrosis
James P. Luyendyk (United States)

18:05 - 18:30 The role of crosslinking in fibrin structure and function
Robert Ariëns (United Kingdom)

18:30 - 18:50 A ten year genotype-clinical phenotype assessment of fibrinogen disorders from Bonn
Vytautas Ivaskevicius (Germany)

SSC PROGRAM

Sunday, June 21, 2015

Disseminated Intravascular Coagulation (DIC)

Room 715

Chairman: Jecko Thachil (United Kingdom)

Co-Chairs: Marcello Di Nisio (Italy), Satoshi Gando (Japan), Takashi Ito (Japan), Bernd Jilma (Austria), Shinichiro Kurosawa (United States), Sacha Zeerleder (The Netherlands)

SUBCOMMITTEE SESSION 1

08:00 - 08:20 DIC in obstetrical disorders
Offer Erez (Israel)

08:20 - 08:40 DAMPS and DIC in sepsis
Patricia Liaw (Canada)

08:40 - 09:00 Sepsis, thrombosis and organ injury
Hala Chabaan (United States)

09:00 - 09:20 Hyperfibrinolytic afibrinogenemia in overt DIC
Bernd Jilma (Austria)

09:20 - 09:40 Where to use thrombomodulin and antithrombin in DIC?
Toshiaki Iba (Japan)

09:40 - 10:00 Discussion

EDUCATION SESSION

10:20 - 10:50 Zebrafish modelling in DIC
Jordan Shavit (United States)

10:50 - 11:20 Management of DIC in a critical care unit
Jerrold Levy (United States)

SUBCOMMITTEE SESSION 2

11:20 - 11:40 DIC in trauma
Satoshi Gando (Japan)

11:40 - 12:00 Fibrin-related markers - current status and further prospects in the detection of in vivo fibrin formation and dissolution
Carl-Eric E. Dempflle (Germany)

12:00 - 12:20 International DIC survey and call for DIC registry
Marcello Di Nisio (Italy)
SSC PROGRAM

Factor VIII and IX, part 2 Room 718

Chairman: Guy Young (United States)
Co-chairs: Manuel Carcao (Canada), Danijela Mikovic (Serbia), Flora Peyvandi (Italy)
Steven Pipe (United States), Elena Santagostino (Italy)
Mike Makris (United Kingdom)

LABORATORY ISSUES 1

Moderators: Steven Pipe (United States), Elena Santagostino (Italy)

08:00 - 08:15 Update on Nijmegen group's high sensitivity inhibitor assay
Bert Verbruggen (The Netherlands)

08:15 - 08:30 Inhibitor measurement using SMIA: A new approach in inhibitor measurement
Sanj Raut (United Kingdom)

08:30 - 08:40 Discussion

08:40 - 08:55 Establishment of the 5th International Standard for FIX
Elaine Gray (United Kingdom)

08:55 - 09:10 Update on EAHA coagulation factor variant genotype database
Keith Gomez (United Kingdom)

09:10 - 09:20 Discussion

09:20 - 09:40 IU vs %: Clearing up the confusion and a proposal for a position paper
Steve Kitchen (United Kingdom)

09:40 - 10:00 WAPPS Project (Web-accessible population pharmacokinetics service)
Alfonso Iorio (Canada)

COFFEE BREAK

CLINICAL ISSUES

Moderators: Manuel Carcao (Canada), Mike Makris (United Kingdom)

10:20 - 10:45 Moderate hemophilia update
Kathelijn Fischer (The Netherlands)

10:45 - 11:10 Clinical use of extended half-life factor products
Guy Young (United States)

LABORATORY ISSUES 2

Moderators: Steven Pipe (United States), Guy Young (United States)

11:10 - 11:30 Extended half-life factors and laboratory assays--overview of the problem
Steven Pipe (United States)

SSC PROGRAM

11:30 - 11:45 Overview of chromogenic assay basics
Kenneth Friedman (United States)

11:45 - 12:00 Implementation of the chromogenic assay into the clinical lab
Richard Ko (United States)

12:00 - 12:20 Discussion

Factor XI and the contact system Room 716

Chairman: Jonas Emsley (United Kingdom)
Co-Chairs: Jose W. Govers-Riemslag (The Netherlands), Christine Mannhalter (Austria)
Joost Meijers (The Netherlands), James Morrissey (United States)
Ophira Salomon (Israel), Evi X. Stavrou (United States)

ACTIVATORS AND BASIC SCIENCE OF FXI AND THE CONTACT SYSTEM

08:00 - 08:30 Propagation of blood coagulation by extracellular nucleosomes/neutrophil extracellular traps
Bernd Engelmann (Germany)

08:30 - 08:50 Structure of contact factors
Jonas Emsley (United Kingdom)

08:50 - 09:00 The factor XII registry database
Ammar Majeed (Sweden)

09:00 - 09:30 Driving plasminogen activation by factor XIIa
Nicola J. Mutch (United Kingdom)

09:30 - 10:00 Kininogen, overlooked but not forgotten
Keith McCrae (United States)

COFFEE BREAK

EDUCATION SESSEON

10:20 - 10:50 Autoantibodies to factor XII and kininogens in patients with recurrent pregnancy loss
Toshitaka Sugi (Japan)

10:50 - 11:20 Effect of plant inhibitors of the contact system on a mouse thrombosis model
Maria Luiza Vilela Oliva (Brazil)

INHIBITORS OF FXI AND THE CONTACT SYSTEM: SAFER ANTICOAGULATION

11:20 - 11:40 An update on factor XI structure function relationships
David Gailani (United States)
SSC PROGRAM

11:40 - 12:00  Antisense reduction of FXI for thromboprophylaxis: A novel therapeutic approach
Sanjay Bhanot (United States)

12:00 - 12:20  Open discussion on topics of factor XI and the contact system that are now very current and relevant
Joost Meijers (The Netherlands)

Working Group on Perioperative Thrombosis and Hemostasis  Room 707

Chairman:  James Douketis (Canada)
Moderators:  Jim Douketis (Canada), Jerrold Levy (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:10</td>
<td>Working group on perioperative thrombosis and hemostasis</td>
<td>James Douketis (Canada)</td>
</tr>
<tr>
<td>08:10 - 08:30</td>
<td>Management of patients on DAPT who need urgent or elective surgery</td>
<td>Pierre Albaladejo (France)</td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td>Management of patients on NOACs who need urgent reversal for surgery</td>
<td>Jerrold Levy (United States)</td>
</tr>
<tr>
<td>08:50 - 09:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:00 - 09:20</td>
<td>Management of perioperative bleeding</td>
<td>Marc C. Samama (France)</td>
</tr>
<tr>
<td>09:20 - 09:40</td>
<td>What are the landmark studies (completed and planned) in perioperative anticoagulant management?</td>
<td>Alexander C. Syropoulos (United States)</td>
</tr>
<tr>
<td>09:40 - 10:00</td>
<td>Panel discussion</td>
<td></td>
</tr>
</tbody>
</table>

SSC PROGRAM

08:00 - 08:10  Working group on perioperative thrombosis and hemostasis
James Douketis (Canada)

08:10 - 08:30  Management of patients on DAPT who need urgent or elective surgery
Pierre Albaladejo (France)

08:30 - 08:50  Management of patients on NOACs who need urgent reversal for surgery
Jerrold Levy (United States)

08:50 - 09:00  Discussion

09:00 - 09:20  Management of perioperative bleeding
Marc C. Samama (France)

09:20 - 09:40  What are the landmark studies (completed and planned) in perioperative anticoagulant management?
Alexander C. Syropoulos (United States)

09:40 - 10:00  Panel discussion

COFFEE BREAK

JOINT PLATELET PHYSIOLOGY AND BIORHEOLOGY EDUCATIONAL SESSION

Moderators:  Paolo Gresele (Italy), Owen McCarty (United States)

10:20 - 10:50  Bioreactors for megakaryocyte studies and platelet formation: Where do we stand?
Jonathan Thon (United States)

10:50 - 11:20  Bioreactors for megakaryocyte studies and platelet formation: Where do we stand?
Alessandra Balduini (Italy)

SUBCOMMITTEE CONTINUED

Moderators:  Paul Harrison (United States), Diego Mezzano (Chile)

11:20 - 11:50  The use of platelets in regenerative medicine: Contribution of platelets to vascular and tissue remodelling
Harald Langer (Germany)

11:50 - 12:20  The use of platelets in regenerative medicine: Use of PRP for Achilles tendon rupture and burn injuries
Paul Harrison (United Kingdom)

Animal, cellular and molecular models of thrombosis  Room 714

Chairman:  Susan Smyth (United States)
Co-Chairs:  Cecile V. Denis (France), Jose A. Diaz (United States)
Tom Knudsen (Denmark), Leslie Parise (United States)
Denise Sabatino (United States), David Motto (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:20</td>
<td>Session introduction</td>
<td>Susan Smyth (United States), Jose A. Diaz (United States)</td>
</tr>
<tr>
<td>08:20 - 08:40</td>
<td>Animal Model of VT: Where we are</td>
<td>Jose A. Diaz (United States)</td>
</tr>
</tbody>
</table>

SSC PROGRAM

08:20 - 08:40  Position statement on the methods for the study of platelet secretion
Diego Mezzano (Chile)

08:40 - 09:00  Position statement on the laboratory monitoring of P2Y12 inhibitors
Andrew L. Frelinger III (United States)

09:00 - 09:10  Prospective evaluation of the bleeding phenotype in PT-VWD to support evidence-based diagnosis and management
Maha Othman (Canada)

09:10 - 09:30  The measurement of platelet dimensions: Methods and clinical use
Patrizia Noris (Italy)

09:30 - 10:00  RNA signatures in platelets from cancer patients
Thomas Wurdinger (The Netherlands)
SSC PROGRAM

08:40 - 09:00 The use of IVC stenosis model in VT
Steve Grover (United States)

09:00 - 09:20 The use of femoral vein electrolytic model in VT
Brian Cooley (United States)

09:20 - 09:40 The use of IVC models in VT (Ligation - EIM - RVT)
Jose A. Diaz (United States)

09:40 - 10:00 Open Discussion

COFFEE BREAK

EDUCATION SESSION

10:20 - 11:00 VWF and NETs in venous thrombosis
Denisa Wagner (United States)

11:00 - 11:30 Role of P-selectin in venous thrombosis
Tom Wakefield (United States)

11:30 - 11:50 Insight into the role of fibrin in VT animal models
Alisa Wolberg (United States)

11:50 - 12:20 Insight into the role of tissue factor in VT animal models
Nigel Mackman (United States)

Genomics in thrombosis and hemostasis Room 701

Chairman: Willem H. Ouwehand (United Kingdom)
Co-Chairs: Paul Bray (United States), Kathleen Freson (Belgium), Anne Goodeve (United Kingdom), Michele P. Lambert (United States), Pieter H. Reitsma (The Netherlands)

PART 1: NGS IN DIAGNOSTICS

Moderators: Willem H. Ouwehand (United Kingdom), Michele Lambert (United States)

08:00 - 08:15 Welcome
Willem H. Ouwehand (United Kingdom)

08:15 - 08:45 Inherited bleeding/ clotting disorder
Char Witmer (United States)

08:45 - 09:00 ThromboGenomics platform
Ilenia Simeoni (United Kingdom)

PART 2: NGS IN DIAGNOSTICS

Moderators: Anne Goodove (United Kingdom), Walter Kahr (Canada)

09:15 - 09:30 Coagulation factor variant database - an update
Daniel J. Hampshire (United Kingdom)

09:30 - 09:45 Challenges in the interpretation of variants from next generation sequencing
Andrew Paterson (Canada)

09:45 - 10:00 Discussion: Sharing sequencing data – All

COFFEE BREAK

EDUCATION SESSION

Moderators: Pieter H. Reitsma (The Netherlands), Paul Bray (United States)

10:20 - 10:50 Statistical and methodological challenges for gene discovery by NGS
Ernest Turro (United Kingdom)

10:50 - 11:20 Inherited platelet disorders
Walter Kahr (Canada)

REPORTING OF CLINICAL VARIANTS

Moderators: Kathleen Freson (Belgium), Daniel Bellissimo (United States)

11:40 - 12:00 International guidelines to annotate pathogenic variants
Kathleen Freson (Belgium), Daniel Bellissimo (United States)

12:00 - 12:20 New large control data: Opportunities & pitfalls
Karyn Megy (United Kingdom), Daniel J. Hampshire (United Kingdom)

Control of anticoagulation Room 717

Chairman: Walter Ageno (Italy)
Co-Chairs: Rebecca Beyth (United States), Benilde Cosmi (Italy), Mark Crowther (Canada), Ismail Elalamy (France), Elanie Hylek (United States), Peter Verhamme (Belgium), Henry G. Watson (United Kingdom), Pieter W. Kamphuisen (The Netherlands)

08:00 - 08:05 Introduction
Walter Ageno (Italy)

UPDATE ON CURRENT SSC PROJECTS: REGISTRIES

Moderators: Benilde Cosmi (Italy), Rebecca Beyth (United States)

08:05 - 08:25 Perioperative management of NOACs
Alexander C. Spyropoulos (United States)
SSC PROGRAM

08:25 - 08:45  START-EVENTS SSC register
Walter Ageno (Italy)

08:45 - 09:05  Pregnancy outcomes in patients who become pregnant while on NOACs
Saskia Middeldorp (The Netherlands)

UPDATE ON CURRENT SSC PROJECTS: STANDARDIZATION
Moderators: Henry G. Watson (United Kingdom), Pieter W. Kamphuisen (The Netherlands)

09:05 - 09:25  Non-major bleeding
Scott Kaatz (United States)

09:25 - 09:45  Clinical outcome for patients treated for a major oral anticoagulant-related bleed
Nakisa Khorsand (The Netherlands)

09:45 - 10:05  Nomenclature of the novel oral anticoagulants
Geoffrey Barnes (United States)

10:05 – 10:15  Progress report on replacement of international standards for thromboplastin
Anton van den Besselar (The Netherlands), Veena Chantarangkul (Italy), Armando Tripodi (Italy)

COFFEE BREAK

EDUCATION SESSION: THE CONTRIBUTION OF PROF. MM SAMAMA TO CONTROL OF ANTICOAGULATION
Moderators: Marc C. Samama (France), Jacqueline Conard (France)

10:30 - 11:00  Clinical: Risk assessment models, VTE prophylaxis, thrombophilia
Jacqueline Conard (France)

11:00 - 11:30  Biological: Pharmacology analysis, mechanisms of action of antithrombotics, global assays
Grigoris Gerotziafas (France)

A LOOK INTO FUTURE INITIATIVES OF THE SSC ON CONTROL OF ANTICOAGULATION
Moderators: Mark Crowther (Canada), Elaine Hylek (United States)

11:30 - 11:55  Update on the clinical experience of the direct oral anticoagulants in real life. What have we learned and what can we learn from registries?
Jan Beyer (Germany)

11:55 - 12:20  The “white book”: Proposal for a position paper on the role of the laboratory with the direct oral anticoagulants
Ismail Elalamy (France)

SSC PROGRAM

Bleeding Assessment Tool (BAT) Standing Committee  Room 707

Chairman: Francesco Rodeghiero (Italy)
Secretary: Alberto Tosetto (Italy)

10:30 - 10:35  Introduction
Francesco Rodeghiero (Italy)

REPORT OF NEW AND ONGOING STUDIES
Moderator: Barry Coller (United States)

10:35 - 10:45  Bleeding phenotype in children with moderate/severe VWD
Yvonne Sanders (The Netherlands), Frank Leebeek (The Netherlands)

10:45 - 10:55  The Vienna Bleeding Biobank
Johanna Gebhart (Austria)

10:55 - 11:05  The REBEL Study
Alberto Tosetto (Italy)

FUTURE DEVELOPMENTS IN BLEEDING ASSESSMENT TOOLS
Moderator: Francesco Rodeghiero (Italy)

11:05 - 11:20  Integrating genotypic and phenotypic data: the perspective of the Subcommittee on Genomics in Thrombosis and Hemostasis
Willem H. Ouwehand (United Kingdom)

11:20 - 11:30  Update on BAT and beyond
Francesco Rodeghiero (Italy)

RTW and Young Investigator Networking Reception
This will take place on Sunday, June 21, from 12:00 – 13:00 in room 713 at the Metro Toronto Convention Center.

If you have been awarded a RTW or Young Investigator Grant from the 2015 ISTH congress we cordially invite you to attend RTW and Young Investigator Networking Reception.

WFH/RTW symposia:
This will take place on Sunday, June 21 from 13:00 – 15:00 in room 715 of the Metro Toronto Convention Center.

Building Capacity and Empowering Future Leaders: Lessons from the ISTH and WFH Fellowship Programs
This session will focus on the ISTH Reach the World (RTW) fellowship program and the World Federation of Hemophilia (WFH) International Hemophilia Training Center (IHTC) fellowship program. The event will discuss the need for capacity building programs in hemophilia, hematology and thrombosis. Past fellows and mentors will share experiences and stories from both programs. Future applicants will be able to ask questions and connect with leaders in both programs.
World Thrombosis Day: From Global Conversation to Global Catalyst
Sunday, June 21
13:00 – 15:00

Now in its second year, World Thrombosis Day (WTD) launched on October 13, 2014, with an important message of awareness and action on a major contributor to the global burden of disease – thrombosis. With one in four people worldwide dying from causes related to thrombosis, the International Society on Thrombosis and Haemostasis (ISTH) launched WTD to help reduce death and disability due to venous thromboembolism (VTE). Highlighting the campaign’s traction in its first year and focused on hospital-associated VTE in year two, this session will include members of the WTD Steering Committee, including Chairman Dr. Gary Raskob, representatives from some of the more than 200 partner organizations and comments and support from the WTD Sponsors. In addition to stories from the first day, attendees will be invited to participate going forward as we continue our work to build awareness of potentially deadly blood clots through educational activities, media outreach and communication with the public and health care professionals around the world.

Special Industry Symposia
15:30 - 17:30
Special Industry Symposia Programs are available in the Show Guide. Please consult the different options to attend the symposium of your choice.

Opening Ceremony

Welcome Reception
The Master Class sessions are a recently introduced educational feature for the ISTH Congress. Young Investigators and Reach-the-World participants are specifically invited for one-hour sessions with a senior, well-known and established investigator. In small groups (20-25 per class), the session leader will give a short introduction (5-10 minutes), after which there will be an interactive exchange of questions and a discussion, which will last for 50 minutes in total. Attendance had to be pre-booked. Master Classes are held daily between 7:00 and 07:50 am from Sunday, June 21 to Wednesday, June 24. Continental breakfast will be provided during these early morning sessions.

Rooms for the Master Classes are located at the Intercontinental Hotel, which is connected to the Metro Toronto Convention Centre. You can find the room names on the vouchers you will receive as part of your registration pack.

The following Master Classes have been organized:

**Sunday, June 21, 2015 07:00-07:50**

- **Room Grenadier: Cathy Hayward (Canada)**  
  Platelet function testing and diagnosis of platelet function disorders
- **Room High Park: Susan Kahn (Canada)**  
  Post-thrombotic syndrome
- **Room Haliburton: Agnes Lee (Canada)**  
  Cancer and thrombosis: Prevention and treatment – where do the new direct acting anticoagulants fit in?
- **Room Oakville: Jeff Weitz (Canada)**  
  Mechanisms of clotting on blood-contacting medical devices
- **Room Wentworth: Margaret Rand (Canada)**  
  The procoagulant platelet
- **Room Halton: Steve Watson (United Kingdom)**  
  Platelet signaling
- **Room Humber: Manuel Carcao (Canada)**  
  Hemophilia (adults, pediatric): prophylaxis, treatment (including use and monitoring of long-acting formulations), and inhibitors
- **Room Caledon: Barbara Konkle (United States)**  
  Laboratory investigations for bleeding disorders
- **Room Kingsway: Phil Wells (Canada)**  
  How to get your paper published

**Monday, June 22, 2015 07:00-07:50**

- **Room Haliburton: Walter Ageno (Italy)**  
  Treatment of thrombosis in unusual sites
- **Room High Park: James Douketis (Canada)**  
  Practical issues of antithrombotic therapy: bleeding and reversal, perioperative management and drug interactions
- **Room Oakville: Alex Syropoulos (United States)**  
  Perioperative anticoagulant management
- **Room Oakville: Paul Cubes (Canada)**  
  NETs
- **Room Wentworth: Shirley Utte de Willige (The Netherlands)**  
  Maintaining vascular flow: from liquid to solid to liquid again: the dynamics of clot formation and lysis
- **Room Grenadier: Sara Israels (Canada)**  
  Platelet disorders in children and newborns
- **Room Kingsway: Bernhard Nieswandt (Germany)**  
  Targeting platelet receptors by antibodies
- **Room Halton: Flora Peyvandi (Italy)**  
  Rare bleeding disorders
- **Room Caledon: Thomas Ortel (United States)**  
  Tests of global hemostasis: What do they mean and why would we use them?
- **Room Humber: Harry Büller (The Netherlands)**  
  Tips for preparing successful grant applications

**Tuesday, June 23, 2015 07:00-07:50**

- **Room Haliburton: Shannon Bates (Canada)**  
  Assisted reproduction, pregnancy, and thrombosis
- **Room Wellington: John Elkelboom (Canada)**  
  Atrial fibrillation: anticoagulant choice and monitoring
- **Room Halton: Ed Prydzial (Canada)**  
  Management issues in pediatric thrombosis
- **Room Kingway: Sara Vesely (United States)**  
  TTP with an emphasis on registries
- **Room Caledon: Patrick Provost (Canada)**  
  Platelet microRNAs
- **Room Oakville: David Lilliecrap (Canada)**  
  VWD - biology, diagnosis, therapy
- **Room Humber: Ken Bauer (United States)**  
  Coagulation system: mechanisms and big unanswered questions
- **Room Grenadier: Mitchell Cohen (United States)**  
  Trauma-induced coagulopathy
- **Room Wentworth: Fred Spencer (Canada)**  
  Understanding and using guidelines to care for your patients

**Wednesday, June 24, 2015 07:00-07:50**

- **Room Oakville: Mark Crowther (Canada)**  
  Antiphospholipid antibodies: testing, treatment, prognosis
- **Room High Park: Martin O’Donnell (Ireland)**  
  Antithrombotic and antiplatelet therapy in the elderly
- **Room Caledon: Rita Selby (Canada)**  
  Laboratory measurements and the direct oral anticoagulants
- **Room Wellington: Charles “Chuck” Esmon (United States)**  
  The ups and downs of thrombin generation
- **Room Halton: Ted Warkentin (Canada)**  
  HIT: clinical and laboratory testing pitfalls
- **Room Haliburton: Eric Boilard (Canada)**  
  Platelet microparticles
- **Room Wentworth: Heyu Ni (Canada)**  
  Platelet integrins and their ligands in thrombosis and hemostasis
- **Room Kingsway: Lawrence Brass (United States)**  
  Platelet thrombus formation
- **Room Humber: Paula James (Canada)**  
  Bleeding scores
- **Room Grenadier: Ed Conway (Canada)**  
  Coagulation and the complement system
CAREER MENTORSHIP SESSIONS

These sessions are a novelty for the ISTH congress. The intention is to provide mentorship in a truly interactive session, which therefore will be limited to 10 participants. The Career Mentorship Sessions are dedicated to the young investigators and recipients of the Reach The World awards. There are a total of 16 sessions and thus maximum 160 attendees, which is less than the total number of eligible attendees at the congress. Therefore, participation is strictly limited to one session per attendee. There are different themes aiming at 3 target groups – basic scientists, clinical investigators, and clinician educators. We have also endeavoured to provide female and male mentors within each subset.

Attendance had to be pre-booked. Career Mentorship Sessions are held daily between 12:00 and 13:00 from Sunday, June 21 to Wednesday, June 24. A lunch will be provided during these sessions.

Rooms for the Career Mentorship Sessions are located at the Intercontinental Hotel, main floor, which is connected to the Metro Toronto Convention Centre. You can find the room names on the vouchers you will receive as part of your registration pack.

The following Career Mentorship Sessions have been organized:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Room Humber</th>
<th>Room Halton</th>
<th>Room Wellington</th>
<th>Room Haliburton</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sunday, June 21, 2015</strong></td>
<td><strong>12:00-13:00</strong></td>
<td>Room Humber: Agnes Lee (Canada)</td>
<td>Clinical Investigators</td>
<td>Room Halton: Nigel Mackman (United States)</td>
<td>Basic Scientists</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Room Wellington: Paula James (Canada)</td>
<td>Clinical Investigators</td>
<td>Room Haliburton: Walter Kahr (Canada)</td>
<td>Basic Scientists</td>
</tr>
<tr>
<td><strong>Monday, June 22, 2015</strong></td>
<td><strong>12:00-13:00</strong></td>
<td>Room Humber: Elaine Hylek (United States)</td>
<td>Clinical Investigators</td>
<td>Room Halton: Marcel Levi (The Netherlands)</td>
<td>Clinician Educators</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Room Wellington: Donnie Arnold (Canada)</td>
<td>Clinical Investigators</td>
<td>Room Haliburton: Charles “Chuck” Esmon (United States)</td>
<td>Basic Scientists</td>
</tr>
<tr>
<td><strong>Tuesday, June 23, 2015</strong></td>
<td><strong>12:00-13:00</strong></td>
<td>Room Humber: Phil Wells (Canada)</td>
<td>Clinical Investigators</td>
<td>Room Halton: Saskia Middeldorp (The Netherlands)</td>
<td>Clinical Investigators</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Room Wellington: Cathy Hayward (Canada)</td>
<td>Basic Scientists</td>
<td>Room Haliburton: Shannon Bates (Canada)</td>
<td>Clinician Educators</td>
</tr>
<tr>
<td><strong>Wednesday, June 24, 2015</strong></td>
<td><strong>12:00-13:00</strong></td>
<td>Room Humber: Susan Kahn (Canada)</td>
<td>Clinical Investigators</td>
<td>Room Halton: Margaret Rand (Canada)</td>
<td>Basic Scientists</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Room Wellington: Jeff Weitz (Canada)</td>
<td>Basic Scientists</td>
<td>Room Haliburton:</td>
<td>Basic Scientists</td>
</tr>
</tbody>
</table>
The Nurses’ Forum takes place Sunday and Monday, June 21-22, 2015, during the Congress. On the morning of Monday, June 22, a scientific session with oral presentation of peer-reviewed abstracts will be held. Nurses and allied health professionals that have ongoing projects, or who can perform and complete a study by the end of 2014, have been encouraged to strongly consider submitting their results as an abstract to the ISTH Congress.

**Moderator:** Maura Malone (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:15</td>
<td>Welcome and overview of Nursing Forum</td>
</tr>
<tr>
<td></td>
<td>Maura Malone (United States)</td>
</tr>
<tr>
<td>09:15-09:30</td>
<td>Host nurses’ perspective on managing patient populations with thrombotic and haemostatic disorders</td>
</tr>
<tr>
<td></td>
<td>Maura Malone (United States)</td>
</tr>
<tr>
<td>09:30-09:45</td>
<td>Thrombosis management in Canada</td>
</tr>
<tr>
<td></td>
<td>Laurie Sardo (Canada)</td>
</tr>
<tr>
<td>09:45-11:00</td>
<td>The Structure of Hemophilia Care and HTC in Canada</td>
</tr>
<tr>
<td></td>
<td>Rebecca Goldsmith (Canada)</td>
</tr>
<tr>
<td>09:45-11:00</td>
<td>Selected oral communications and posters</td>
</tr>
<tr>
<td></td>
<td>Ann O’Sullivan (Ireland)</td>
</tr>
<tr>
<td>09:45 - 10:00</td>
<td>How participating in a clinical trial has had a far reaching</td>
</tr>
<tr>
<td></td>
<td>effect-A case study</td>
</tr>
<tr>
<td></td>
<td>Claire McGregor (Australia)</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>Barriers to inform hemophilic carriers of the possibility in Japan</td>
</tr>
<tr>
<td></td>
<td>Tomie Fuji (Japan)</td>
</tr>
<tr>
<td>10:15 - 10:30</td>
<td>Review of HTC needs assessment</td>
</tr>
<tr>
<td></td>
<td>Ann Forsberg (United States)</td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>Hemophilia and aging: Promoting healthy aging through proactive</td>
</tr>
<tr>
<td></td>
<td>engagement with general practitioners</td>
</tr>
<tr>
<td></td>
<td>Olivia Hollingdrake (Australia)</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Review of research on hematuria disorders</td>
</tr>
<tr>
<td></td>
<td>Greta Mulders (The Netherlands)</td>
</tr>
<tr>
<td>11:00 - 11:20</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:20 - 12:30</td>
<td>Innovation in nursing practice</td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td>Cardiology thrombosis project collaboration between 2 services and nurse practitioners</td>
</tr>
<tr>
<td></td>
<td>Marilyn Blumenstein (United States)</td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>Questions and Answers</td>
</tr>
<tr>
<td>12:30 - 13:30</td>
<td>LUNCH</td>
</tr>
<tr>
<td>13:30 - 15:15</td>
<td>Concurrent Sessions</td>
</tr>
<tr>
<td>13:30-13:45</td>
<td>Thrombosis and anticoagulation program; Home INR monitoring and neona-</td>
</tr>
<tr>
<td></td>
<td>tal prophylactic enoxaparin dosing</td>
</tr>
<tr>
<td></td>
<td>Kathy Harney (United States)</td>
</tr>
<tr>
<td>13:45-14:00</td>
<td>Adherence with DOACs - Application to clinical practice</td>
</tr>
<tr>
<td></td>
<td>Bunis Packham (United Kingdom)</td>
</tr>
<tr>
<td>14:00-14:15</td>
<td>Thrombosis and Cancer ; Education and QOL considerations</td>
</tr>
<tr>
<td></td>
<td>Annie Young (United Kingdom)</td>
</tr>
<tr>
<td>14:15-14:35</td>
<td>Carrier Testing, genetics, education, ethics, age, etc</td>
</tr>
<tr>
<td></td>
<td>Robyn Shoemark, (Australia)</td>
</tr>
<tr>
<td>14:35-14:50</td>
<td>National Patient Needs Assessment</td>
</tr>
<tr>
<td></td>
<td>Regina Butler (United States)</td>
</tr>
<tr>
<td>14:50-15:05</td>
<td>Mild hemophilia A: a manageable condition?</td>
</tr>
<tr>
<td></td>
<td>Daryl Pollock (New Zealand)</td>
</tr>
<tr>
<td>15:05-15:15</td>
<td>Questions and Answer Period</td>
</tr>
<tr>
<td>15:30 – 15:45</td>
<td>Literature Review Workshop – preregistration required (Room 709)</td>
</tr>
<tr>
<td></td>
<td>Facilitator: Fiona Newall (Australia)</td>
</tr>
<tr>
<td>13:30 – 15:15</td>
<td>This interactive workshop aims to confirm the processes supporting</td>
</tr>
<tr>
<td></td>
<td>development of a collaborative literature review suitable for publication</td>
</tr>
<tr>
<td></td>
<td>on behalf of the ISTH Nursing Forum.</td>
</tr>
<tr>
<td></td>
<td>The specific objectives or this session are:</td>
</tr>
<tr>
<td></td>
<td>- Workshop attendees will be provided with a brief education session</td>
</tr>
<tr>
<td></td>
<td>regarding the process of preparing a Literature Review for publication</td>
</tr>
<tr>
<td></td>
<td>in a peer reviewed journal</td>
</tr>
<tr>
<td></td>
<td>- Identification of topics for literature review (1 Hemophilia and 1</td>
</tr>
<tr>
<td></td>
<td>Thrombosis)</td>
</tr>
<tr>
<td></td>
<td>- Authorship panel will be decided and confirmed during the workshop</td>
</tr>
<tr>
<td></td>
<td>- Each working group will brainstorm key words, appropriate limits of</td>
</tr>
<tr>
<td></td>
<td>the literature search, and a possible structure</td>
</tr>
<tr>
<td>15:15 – 15:30</td>
<td>Break</td>
</tr>
<tr>
<td>15:30 – 15:45</td>
<td>Literature Review Workshop – preregistration required (Room 709)</td>
</tr>
<tr>
<td></td>
<td>Facilitator: Fiona Newall (Australia)</td>
</tr>
<tr>
<td>13:30 – 15:15</td>
<td>This interactive workshop aims to confirm the processes supporting</td>
</tr>
<tr>
<td></td>
<td>development of a collaborative literature review suitable for publication</td>
</tr>
<tr>
<td></td>
<td>on behalf of the ISTH Nursing Forum.</td>
</tr>
<tr>
<td></td>
<td>The specific objectives or this session are:</td>
</tr>
<tr>
<td></td>
<td>- Workshop attendees will be provided with a brief education session</td>
</tr>
<tr>
<td></td>
<td>regarding the process of preparing a Literature Review for publication</td>
</tr>
<tr>
<td></td>
<td>in a peer reviewed journal</td>
</tr>
<tr>
<td></td>
<td>- Identification of topics for literature review (1 Hemophilia and 1</td>
</tr>
<tr>
<td></td>
<td>Thrombosis)</td>
</tr>
<tr>
<td></td>
<td>- Authorship panel will be decided and confirmed during the workshop</td>
</tr>
<tr>
<td></td>
<td>- Each working group will brainstorm key words, appropriate limits of</td>
</tr>
<tr>
<td></td>
<td>the literature search, and a possible structure</td>
</tr>
<tr>
<td>15:15 – 15:30</td>
<td>Break</td>
</tr>
</tbody>
</table>
NURSES FORUM

Challenges in delivering care in resource-limited countries 15:30 – 16:00

Moderators: Caroline Baglin (United Kingdom), Regina Butler (United States)

15:30 – 15:45  Serbia:  Inhibitors and CVL - lessons learned
Ljiljana Rakic (Serbia)

15:45 – 16:00  Thrombosis - barriers to care
Elizabeth Dotse (Ghana)

16:00 – 18:00  Nurses’ Network Reception Location TBD

Monday, June 22, 2015  08:00-16:30

Nursing and Allied Health Professionals’ Research Session 09:00 – 12:00  Room 803 A&B

Peer-reviewed abstracts from Nurses and Allied Health Professionals

Nurses and Allied Health Session - Bleeding 08:00 – 09:15

Moderators: Laurie Sardo (Canada), Jim Munn (United States)

NUR001  WHEN 2N VWD SHOULD BE CONSIDERED A DIFFERENTIAL DIAGNOSIS
Claire Mcgregor, Natalie Gamble-Williams (Australia)

NUR002  THE DDAVP CHALLENGE – AN AUDIT TO ASSESS PRACTICE IN A UK HAEMOPHILIA CENTRE
D W George, James Uprichard, Anne Wareing (United Kingdom)

NUR003  CLOSING THE GAP: A MULTIDISCIPLINARY APPROACH DEVELOPING LOCAL SERVICES FOR RURAL AND REMOTE PATIENTS WITH BLEEDING DISORDERS.
James Slade (Australia)

NUR004  NON-ADHERENCE TO PROPHYLAXIS IN HAEMOPHILIA: EXTENT AND UNDERLYING REASON
Marlies Schrijvers, Marlene Beijleveld - van der Zande, Marjolein Peters, Janseke Lock, Marjon Croonen, Marieke Schuurmans, Kathelijn Fischer (The Netherlands)

NUR005  EXPANDING THE KNOWLEDGE BASE: OPPORTUNITIES AND CHALLENGES FOR ALLIED PROFESSIONALS IN BLEEDING DISORDER RESEARCH IN CANADA
Neale Smith, Claude Bartholomew (Canada)

Coffee Break

NURSES FORUM

Nurses and Allied Health Session – Thrombosis and Anticoagulation 09:45 – 12:00

Moderators: Jennifer Lowerison (Canada), Michelle Zondag (Canada)

NUR006  DEVELOPING A NURSE LED ULTRASOUND SCANNING SERVICE TO CONFIRM OR EXCLUDE THE DIAGNOSIS OF LOWER LIMB DEEP VEIN THROMBOSIS - IMPROVING PATIENT CARE AND REDUCING THE RISK OF UNNECESSARY ANTICOAGULANTS IN A UNITED KINGDOM PRIMARY CARE SETTING.
Jo Boyd (United Kingdom)

NUR007  OVERWEIGHT IS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE ARTHROPLASTY DESPITE RIVAROXABAN THROMBOPROPHYLAXIS
Christine Cockhill, Owais Mian, MaryAnne Rizzo, Deborah Siegel, Howard Chan, Ellen McDonald (Canada)

NUR008  MANAGING ANTICOAGULATION THERAPY RISK THROUGH THE MULTIDISCIPLINARY TEAM (MDT) WARD ROUND AT KING’S COLLEGE HOSPITAL
Jignesh Patel, Lara Roberts, Emma Gee, Rosalind Byrne, Julia Czyprynska, Kwsil Kttob, Alison Brown, Raj Patel, Lynda Bonner, Roopen Arya (United Kingdom)

NUR009  SAFE DISCHARGE PLANNING FOR PATIENTS ON ANTICOAGULANTS: LAUNCH OF A NEW QUALITY IMPROVEMENT TOOL FOR NURSES
Suzette Chung, Carla Strulovitch, Jessica Emed, Hetal Patel (Canada)

NUR010  DIRECT-ACTING ORAL ANTICOAGULANTS IN THE REAL WORLD: INSIGHTS INTO APPROPRIATE PRESCRIBING AND MEDICATION USE
Jennifer Delaney, Sam Schulman, Mary Salib, Mohamed Panju, Menaka Pai (Canada)

NUR011  NOVEL ORAL ANTICOAGULANT CHECKLISTS FOR FRONT LINE CLINICIANS
Jennifer Lowerison, Jennifer Bolt, Tammy Bungard, Darcy Lamb (Canada)

NUR012  A CROSS-SECTIONAL REGISTRY ON THE INCIDENCE OF GASTROINTESTINAL ASSOCIATED SYMPTOMS WITH PRADAXA USE (GASP REGISTRY)
Michelle M. Zondag, Laurie Sardo, Sam Schulman (Canada)

NUR013  ASSESSING ORAL ANTICOAGULANT USE IN LONG-TERM CARE RESIDENTS: EVIDENCE FOR ONGOING SUBOPTIMAL USE IN 2014
Carlos Rojas-Fernandez, Aein Zarrin, Melissa Warkentin, Jennifer Bonnie, Jennifer Hartwick, Susan Brown (Canada)

NUR014  "POST-THROMBOTIC PANIC": PANIC, POSITIVE OUTCOMES AND THE PARADOXICAL IMPACT OF VENOUS THROMBOEMBOLISM (VTE)
Rachaell Hunter, Paul Bennett, Sarah Lewis, Jaynie Rance, Simon Noble (United Kingdom)

Lunch and Poster viewing

Satellite symposia
NURSES FORUM

Practice guidelines for optimal health: Section 1 14:00 – 14:45

Moderators: Caroline Baglin (United Kingdom), Maura Malone (United States)

14:00– 14:15  Review of VWD guidelines/compare/contrast/diagnostic
Vanessa Bouskill (Canada)

14:15-14:30  Anticoagulation management for ventricular assist devices: A review
Hollie Gilmore (Australia)

14:30-14:45  Cochrane Report and UKHCDO Guidelines
Kate Khair (United Kingdom)

14:45 – 15:00  BREAK

Practice guidelines for optimal health: Section 2 15:00 -16:30

Moderators: Kim Schafer (United States), Bunis Packham (United Kingdom)

15:00 - 15:15  Impact of footwear on ankle arthropathy in patients with hemophilia
Karen Strike (Canada)

15:15 - 15:30  Innovative treatment for managing PTS
Charlene Gates, PT (United States)

15:30 - 15:45  Prophylaxis and impact on pain
Anne O’Sullivan (Ireland)

15:45 - 16:00  Compression hosiery and PTS
Grace Hughes (United Kingdom)

16:00 - 16:15  First experience with the hemoassist: An electronic substitution diary that
works on the basis of a personal digital assistant
Manuela Siebert (Germany)

16:15 - 16:30  Questions and Answers. Wrap-up

Scientific Program

Monday, June 22

Trainee Tracks (oral sessions only):

- Platelets track
- Basic thrombosis and hemostasis track
- Clinical bleeding track
- Clinical thrombosis track
- Pediatric thrombosis and hemostasis track
- Cardiovascular and arterial diseases track

An asterisk (*) after a name denotes the presenting author
**SCIENTIFIC PROGRAM**

**Monday, June 22, 2015**

**ORAL COMMUNICATIONS 1  08:00-09:15**

**Platelet Disorders**

Moderators: David Wilcox (United States), Paquita Nurden (France)

08:00 – 08:15
**OR001**

**JAK2 V617F MUTATION AND CARDIOVASCULAR RISK FACTORS DISCRIMINATE YOUNG PATIENTS WITH HIGH RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTHESIA**

Rongfeng Fu*, Lei Zhang, Huiyuan Li, Liyan Zhang, Mingen Lv, Yating Hao, Renchi Yang (China)

08:15 – 08:30
**OR002**

**FIRST REPORT OF A NEW HOMOZYGOUS FLI1 MUTATION UNRAVELED BY INCREASED MYH10 EXPRESSIN IN AN INHERITED PLATELET DISORDER**

Marie-Christine Morel-Kopp*, David Rabbolini, Sara Gabrielli, Qiang Chen, William Stevenson, Christopher Ward (Australia)

08:30 – 08:45
**OR003**

**A GAIN-OF-FUNCTION MUTATION IN FILAMIN-A POTENTIATES PLATELET INTEGRIN ALPHA-IIIB/BETA-3 ACTIVATION**

Eliane Berrou, Frédéric Adam, Virginie Planche, Marilyne Lebret, Patricia Fergelot, Isabelle Coupny, Paquita Nurden, Dominique Bonneau, Estelle Colin, Cyril Goizet, Jean-Philippe Rosa, Marijke Bryckaert* (France)

08:45 – 09:00
**OR004**

**HISTONE-ASSOCIATED THROMBOCYTOPENIA: A NEW CAUSE OF THROMBOCYTOPENIA IN CRITICALLY ILL PATIENTS**

Yasir Alhamdi, Simon Abrams, Ingeborg Welters, Guozheng Wang, Cheng-Hock Toh* (United Kingdom)

09:00 – 09:15
**OR005**

**PLATELET MITOCHONDRIAL DYSFUNCTION IN PATIENTS WITH SEPSIS OR CARDIOGENIC SHOCK**

Andrea Artoni*, Alessandro Protti, Silvia La Marca, Anna Lecchi, Francesco Fortunato, Giacomo Comi, Flora Peyvandi (Italy)

**Atherosclerosis**

Moderators: Lina Badimon (Spain), Vi Dong (Canada)

08:00 – 08:15
**OR006**

**SWAPPING OVER TWO PEPTIDE EPITOPES DERIVED FROM APOB AND CSAR LOCATED AT TERMINUSES OF RECOMBINANT PROTEINS MAINTAINS THE SIMILAR EFFECTIVE REDUCTION ON ATHEROSCLEROTIC LESION IN B6;129S-LDLR(1HER)APOB(TM2SGY/J) MICE**

Min Xia, Valeria Endresz, Idikko Lantos, Andrea Szabo, Lakshmi Mundkur, Vijay Kakkar, Xinjie Lu* (United Kingdom)

08:15 – 08:30
**OR007**

**EXAMINING THE HEXOSAMINE BIOSYNTHESIS PATHWAY IN HYPERGLYCEMIA-INDUCED ACCELERATED ATHEROSCLEROSIS.**

Vi T. Dang*, Christina Pettura, Daniel Bersaillt, Yuanyuan Shi, Geoff Werstuck (Canada)

**Hemophilia – clinical**

Moderators: Manuel Carcao (Canada), Peter Collins (United Kingdom)

08:00 – 08:15
**OR011**

**LEOPOLD TRIAL RESULTS: CORRELATION OF VON WILLEBRAND FACTOR ANTIGEN LEVEL WITH BAY 81-8973 PHARMACOKINETIC PARAMETERS OF PATIENTS WITH SEVERE HEMOPHILIA A**

Shadan Lalezari, Teruhisa Fujii, YL Kwong, Heinz Delesen, Anita Shah, Claudia Tückmantel, Waander van Heerde*, Monika Maas Enriquez (Germany)

08:15 – 08:30
**OR012**

**IN HAEMOPHILIC PATIENTS TFPI LEVELS INFLUENCE THROMBIN GENERATION PROFILE AND TFPI NEUTRALIZATION NORMALIZES THROMBIN GENERATION POTENTIAL**

Brigitte Tardy*, Fabienne Volot, Michèle Piot, Céline Chapelpe, Hervé Chambost, Anne Lienhart, Fabienne Dutrillaux, Yesim Dargaou, Pierre Moreange, Patrick Mismetti, Bernard Tardy (France)

08:30 – 08:45
**OR013**

**DDAVP IN MODERATE HEMOPHILIA A PATIENTS: A TREATMENT STRATEGY WORTH CONSIDERING**

Janneke I. Loomans*, Alice Van Velzen, Marjoelen Peters, Marieke Kruijip, Simon McRae, Manuel Carcao, Kathelijne Peerlinck, Shannon Jackson, Robert Klamroth, Marten Nijziel, Russell Keenan, Maria Mancuso, Johanna Van der Bom, Karin Fijnvandraat (The Netherlands)

08:45 – 09:00
**OR014**

**THE IMPACT OF PATIENT ADHERENCE ON FVIII LEVELS: A COMPARISON OF RFVIII AND RFVIII-FC REGIMENS**

Josh Epstein, Elizabeth Schwartz*, Yan Xiong, Armin Reininger, Alessandro Gringeri (United States)

09:00 – 09:15
**OR015**

**FUNCTIONAL EFFECTS OF F8 MISSENSE MUTATIONS ON DDAVP RESPONSE IN NONSEVERE HEMOPHILIA A BROTHERS**

Janneke I. Loomans*, Alice Van Velzen, Michael Tans, Marjoelen Peters, Elena Santagostino, Cristina Santoro, Karina Meijer, Erik Beckers, Savita Rangarajan, Thynn Yee, Pia Petruini, Giancarlo Castaman, Johanna Van der Bom, Karin Fijnvandraat (The Netherlands)
SCIENTIFIC PROGRAM

**Anti-platelet agents – basic**

**Room 714**

**Moderators:** Joseph Jakubowski (United States), Reheman Adili (Canada)

08:00 – 08:15

**OR016**

TICAGRELOR AND CLOPIDOGREL ATTENUATE THE PROTHROMBOTIC STATE INDUCED BY BACTERIAL ENDOTOXEMIA

Mark R. Thomas*, Ramzi Ajjian, Fladia Phoenix, Samuel Outeridge, Heather Judge, David Dockrell, Ian Sabroe, Robert Storey (United Kingdom)

08:15 – 08:30

**OR017**

PLATELET SIGNALING AND ENDOTHELIAL FC GAMMA RECEPTOR IIB ARE BOTH REQUIRED FOR ANTIBODY-INDUCED GLYCOPROTEIN VI ECTODOMAIN SHEDDING IN VIVO

David Stegner*, Michael Popp, Viola Lorenz, Sebastian Dütting, J. Engelbert Gessner, Bernhard Nieswandt (Germany)

08:30 – 08:45

**OR018**

SMALL MOLECULE DCDBS84 REGULATES PLATELET THROMBUS FORMATION BY TARGETING C-SRC SH3 DOMAIN

Zhangbiao Long, Kongkai Zhu, Jiangsong Huang, Xiaofeng Shi, Jingqiu Liu, Jichun Yang, Bing Xiao, Lianchun Li, Hong Ding, Yi Wen, Naixia Zhang, Huiliang Jiang, Zhen Ruan, Cheng Luo, Xiaodong Xi* (China)

08:45 – 09:00

**OR019**

CONGENITAL SEVERE DEFICIENCY OR PHARMACOLOGICAL INHIBITION OF THE PLATELET P2Y12 RECEPTOR FOR ADENOSINE DIPHOSPHATE DOES NOT IMPAIR THE CAPACITY OF PLATELET TO SYNTHESIZE THROMBOXANE A2

Mariangela Scavone*, Eli A. Femia, Vera Caroppi, Marco Cattaneo (Italy)

08:00 – 08:15

**OR020**

GENOTYPING OF VWD PATIENTS IN THE NETHERLANDS: PHENOTYPE-GENOTYPE DISCREPANCIES AND 27 NOVEL VWF GENE MUTATIONS

Johan Boender*, Yvonne Sanders, Waander van Heerde, Marjon Cnossen, Britta Laarman, Karin Fijnvandraat, Selene Schoormans, Natalja Dors, Johanna van der Bom, Karina Meijer, Evelien Mauser-Bunschoten, Jeroen Eikenboom, Frank Leebeek (The Netherlands)

08:15 – 08:30

**OR021**

CASE STUDY OF TWO CONSANGUINEOUS BROTHERS WITH TYPE 3 VON WILLEBRAND DISEASE (VWD), INHIBITORS AND ANAPHYLACTOID REACTION TO VWF

Loren Dangelo*, Craig Platt, A Dioun Broyles, Ellis Neufeld, Stacy Croteau (United States)

08:30 – 08:45

**OR022**

ABNORMAL ANGIOGENESIS IN TYPE 2A AND 2B VON WILLEBRAND DISEASE (VWD): COMPARATIVE STUDIES OF QUANTITATIVE AND QUALITATIVE VWD USING BLOOD OUTGROWTH ENDOTHELIAL CELLS

Lara Casey*, Mackenzie Bowman, Soundarya Selvam, Paula James (Canada)

08:45 – 09:00

**OR023**

TYPE 2N VON WILLEBRAND DISEASE: ONE VARIANT BUT MORE THAN ONE DISEASE

Jenny Goudemand, Christophe Zawadzki, Pierre Boisseau, Catherine Ternisien, Claudine Caron, Fabienne Volot, Katia Pouymayou, Brigitte Pan-Petesch, Sabine Castet, Agnès Veyradier, Edith Fressinaud, Sophie Susen* (France)

09:00 – 09:15

**OR024**

HETEROGENEITY OF VON WILLEBRAND DISEASE TYPE 3 IN A FRENCH COHORT OF 75 PATIENTS

Pierre Boisseau, Edith Fressinaud, Catherine Ternisien, Claudine Caron, Annie Borel-Dorion, Marc Trossaert, Cecile Lavenu-Blombed, Chantal Rothschild, Stephane Beziau, Sophie Susen, Agnès Veyradier, Jenny Goudemand* (France)

**Acquired disorders – treatment – I**

**Room 713**

**Moderators:** Jean St Louis (Canada), Meera Chitlur (United States)

08:00 – 08:15

**OR025**

ACQUIRED VON WILLEBRAND SYNDROME AND RESPONSE TO DESMOPRESSIN

Eugenia Biguzzi*, Franca Franchi, Simona Siboni, Flora Peyvandi (Italy)

08:15 – 08:30

**OR026**

ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE IN ACQUIRED HEMOPHILIA A: AN ITALIAN REGISTRY-THE F.A.I.R. STUDY

Ezio Zanon*, Marta Milan, Gabriella Gamba, Gaetano Giuffrida, Anna Falanga, Augusto Federici, Isabella Cantori, Sergio Siragusa, Maria Mazzucconi (Italy)

08:30 – 08:45

**OR027**

PERIOPERATIVE MANAGEMENT OF BLEEDS WITH RECOMBINANT PORCINE FVIII IN PATIENTS WITH ACQUIRED HEMOPHILIA A

Aaron Novack, Jean St-Louis*, Anne Greist, Amy Shapiro, Hedy Smith, Pratima Chowdary, Anja Drebos, Jay Lozier, Christelle Bourgeois, Min Mo, Heinrich Farin (United States)

09:00 – 09:15

**OR028**

REAL WORLD DATA ON TREATMENT WITH FEIBA IN PATIENTS WITH CLOTTING FACTOR INHIBITORS

Claude Negrier*, Sophie Voisin, Fariba Baghaei, Aaron Novack, Jennifer Doralt, Rober to Crea, Alessandro Gringeri (France)

09:15 – 09:30

**OR029**

“SHORT-TERM PROPHYLAXIS” REGIMEN WITH ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE IN THE PREVENTION OF BLEEDING RELAPSE IN ACQUIRED HEMOPHILIA

Ezio Zanon*, Marta Milan, Chiara Ambaglio, Graziella Saggiorato, Nadia Montani, Gabriella Gamba (Italy)
SCIENTIFIC PROGRAM

Reproductive Issues Room 715

Moderators: Margaret Ragni (Canada), Anna Ågren (Sweden)

08:00 – 08:15
OR031
PATHOLOGY OF PLACENTA IN FETAL AND NEONATAL IMMUNE THROMBOCYTOPENIA: ROLES OF TH17 IMMUNE RESPONSES, ANTI-PLATELET ANTIBODIES AND ANGIogenic FACTORS.
Issaka Yougbare*, Wei-She Tai, Darko Zdravic, Brian Vadasz, Alexandra Marshall, Pingguo Chen, Guangheng Zhu, Howard x Howard Leong-Poi, Dawei Qu, Lisa X. Yu, Lee Adamson, John Sled, John Freedman, Heyu Ni (Canada)

08:15 – 08:30
OR032
CHARACTERISTICS OF VENOUS THROMBOEMBOLISM IN 3072 FRENCH WOMEN USING COMBINED OR PROGESTIN-ONLY CONTRACEPTION.
Justine Hugon-Rodin*, Marie-Hélène Horellou, Jacqueline Conard, Claire Flaujac, Pierre-Yves Scarabin, Geneviève Plu-Bureau (France)

08:30 – 08:45
OR033
CHARACTERISING FIBRIN MONOMER COMPLEX AND D-DIMER PROFILES IN PREGNANCY
Karin Lautmann*, Ranjit Akolekar, Roopen Arya (United Kingdom)

08:45 – 09:00
OR034
PRE-PREGNANCY BMI AND DELIVERY BMI AS RISK FACTORS FOR POSTPARTUM VTE: A POPULATION-BASED, CASE-CONTROL STUDY
Marc Blondon*, Laura Harrington, Françoise Boehlen, Helia Robert-Ebadi, Marc Righini, Nicholas Smith (Switzerland, United States)

Animal models Room 717

Moderators: Hartmut Weiler (United States), John Welsh (United States)

08:00 – 08:15
OR036
ADVANCED IMAGING TECHNIQUES SHOW PROGRESSIVE ARTHROPATHY FOLLOWING EXPERIMENTALLY INDUCED KNEE BLEEDING IN A FACTOR VIII-/- RAT MODEL
Kristine Rothers Sørensen*, Kirstine Roepstorff, Maj Petersen, Bo Winberg, Axel Hansen, Søren Skov, Lise Nielsen (Denmark)

08:15 – 08:30
OR037
DEVELOPMENT OF A MOUSE CAROTID ARTERY THROMBOSIS MODEL FOR THE EVALUATION OF THERAPEUTIC APPROACHES FOR STROKE
Simone M. Schoenwaelder*, Andre Samson, Sharelle Sturgeon, Jessica Lee, Arnold Ju, Shaun Jackson (Australia)

08:30 – 08:45
OR038
REAL TIME INTRAVITAL IMAGING OF THROMBUS FORMATION IN THE MOUSE FEMORAL ARTERY REVEALS CRITICAL DIFFERENCES FROM EVENTS IN THE MICROVASCULARITY
John Welsh*, Timothy Stalker, Scott Diamond, Lawrence Brass (United States)

08:45 – 09:00
OR039
GENOME EDITING OF FACTOR X IN ZEBRAFISH REVEALS UNEXPECTED EARLY SURVIVAL AND LATE ONSET HEMORRHAGE
Zhillian Hu, Michael Huang, Marzia Menegatti, Deepak Reyon, Yang Liu, Catherine Richter, J. Keith Shavit* (United States)

Endothelium and vessel wall Room 705

Moderators: Cormack McDonnell (Ireland), David Lane (United Kingdom)

08:00 – 08:15
OR041
AUTOPHAGY REGULATES THROMBUS FORMATION IN MICE
Jonathan W.-H. Yau*, Yan Hou, Xi Lei, Krishna Singh, Subodh Verma (Canada)

08:15 – 08:30
OR042
PLATELET ACTIVATION AND PLATELET-ENDOTHELIAL INTERACTIONS IN THE SIV-INFECTED PIGTAIL MACAQUE MODEL OF HIV-ASSOCIATED CNS DISEASE
Claire Lyons, Hannah Schneider, Elizabeth Engle, Kevin Najarro, Suzanne Queen, Craig Morrell, Joseph Mankowski, Kelly Metcalf Pate* (United States)

08:30 – 08:45
OR043
VASCULAR ENDOTHELIUM DYSREGULATION FOLLOWING STAPHYLOCOCCUS AUREUS INFECTION: NEW INSIGHTS FOR SEPSIS
Cormac McDonnell*, Elena Bojenov, Alisha McLaughlin, Phil Cummins, Steve Kerrigan (Ireland)

08:45 – 09:00
OR044
ENDOTHELIAL BAMBI (BMP AND ACTIVIN MEMBRANE BOUND INHIBITOR) IS IMPORTANT FOR FIBRIN GENERATION AND THROMBUS STABILITY
Isabelle Sales-Crawley*, James Monkman, David Lane, James Crawley (United Kingdom)

09:00 – 09:15
OR045
VALIDATING A 3D TISSUE-ENGINEERED HUMAN BLOOD VESSEL MODEL FOR USE AS A NOVEL MODEL SYSTEM FOR THE ASSESSMENT OF THROMBUS FORMATION
F I. Musa*, Alan Harper, Ying Yang (United Kingdom)

Tissue factor – factor VII – I Room 707

Moderators: Tara Bracken (United States), Wolfram Ruf (United States)

08:00 – 08:15
OR046
CROSS-TALK BETWEEN TISSUE FACTOR AND EPHA2 IN CANCER: POTENTIATION OF LIGAND-DEPENDENT EPHA2-SIGNALING IN VITRO AND CO-EXPRESSION IN HUMAN COLORECTAL CANCER SPECIMENS
Oskar Eriksson*, Åsa Thulin*, Anna Asplund, Geeta Hedge, Sanjay Navani, Agneta Siegbahn (Sweden)

08:15 – 08:30
OR047
ANTIBODY-BASED TARGETING OF ALTERNATIVELY SPliced TISSUE FACTOR IMPedes THE GROWTH AND AGGRESSIVENESS OF Pancreatic Ductal adenocarcinoma
Dusten Unruh, Xiaoyang Qi, Zhengtao Chu, Robert Sturm, Ryan Keil, Syed Ahmad, Timofey Sovershaev, Mailleet Adam, Patrick Van Dreden, Barry Woodhams, Janusz Rak, Nigel Mackman, Henri Versteeg, Vladimir Bogdanov* (United States)

08:30 – 08:45
OR048
TISSUE FACTOR INHIBITION ATTenuates NEUROnal DAMAGE AND BEHAVIORAL DEFICIT IN A MOUSE MODEL OF ISCHEMIC STROKE
Shaobin Wang, Brandi Reeves, Daniel Kirchoffer, Rafal Pawlinski* (United States)
SCIENTIFIC PROGRAM

08:45 – 09:00
OR049
LOW FACTOR VII LEVELS FAIL TO REDUCE VASCULAR GRAFT THROMBUS PROPAGATION IN A BABOON MODEL
Michael Wallisch*, Jeffrey Crosby, Jennifer Greisel, Sue Murray, Erik Tucker, Owen McCarty, Monica Hinds, Brett Monia, András Gruber (United States)

09:00 – 09:15
OR050
GENETIC DETERMINANTS OF ACTIVATED FACTOR VII-ANTITHROMBIN COMPLEX PLASMA CONCENTRATION INCLUDE TISSUE FACTOR, FACTOR VII AND ENDOTHelial PROTEIN C RECEPTOR GENE VARIANTS.
Filippo Sarnon*, Barbara Lunghi, Federica Tosi, Patrizia Guaranini, Daniela Scalfi, Marcello Baroni, Giovanna Marchetti, Barry Woodhams, Domenico Girelli, Oliviero Olivieri, Francesco Bernardi, Nicola Martinelli (Italy)

Heparin-induced thrombocytopenia

08:00 – 08:15
Moderators: Lori Linkins (Canada), Yves Gruel (France)

08:00 – 09:15
DYNAMIC MECHANICAL THROMBOPROPHYLAXIS IS A MAJOR HEPARIN-INDEPENDENT RISK FACTOR FOR THE FORMATION OF ANTI-PLATELET FACTOR 4/HEPARIN ANTIBODIES IN PATIENTS UNDERGOING TOTAL KNEE OR HIP ARTHROPLASTY
Shigeki Miyata*, Seiji Bito, Kiyoshi Migma, Maschio Nakamara, Kazuhiro Shinozaka, Tomotaro Sato, Takehara Tonai, Motoyuki Shimizu, Yasuhiro Shiba, Kazuhiko Kishi, Chikara Kubota, Shinnosuke Nakahara, Toshihito Mori, Kazuo Ikeda, Shusuke Ota, Takeshi Ninamizaki, Shigeru Yamada, Naofumi Shiota, Masataka Kamei, Satoru Motozawa, Takeshi Miyata* (Japan)

08:15 – 08:30
Moderators: Charles Francis (United States), Frits Rosendaal (The Netherlands)

08:15 – 09:00
MECHANICAL HEART VALVE-INDUCED THROMBIN GENERATION
Shi-Ki R. Hui*, Gregory Pelcey, Vadim Kostosov, Trung Nguyen, Laura Loftis, James Thomas, Jun Teruya (United States)

08:30 – 09:00
COMPARISON OF THE EFFECT OF DABIGATRAN AND WARFARIN ON MECHANICAL HEART VALVE-INDUCED THROMBIN GENERATION
Iqbal Jaffer*, Alan Stafford, Jim Fredenburgh, Richard Whitlock, Jeffrey Weitz (Canada)

09:00 – 09:15
APPLICATION OF A MICROFLUIDIC FLOW-BASED THROMBOSIS ASSAY FOR POST-OPERATIVE PEDIATRIC CARDIOPULMONARY BYPASS PATIENTS
Nabil Othman*, Xufeng Gao, Henry Walters, Patrick Hines (United States)

08:00 – 09:00
SCORE CLINICAL RELEVANCE OF THE ZYMUTEST HIA IGG (HYPHEN BIOMED) IN A ROUTINE LABORATORY SETTING
Andreas Czwalinna, Bärbel Steggewentz, Burghard Arndt, Arndt Gröning, Frauke Bergmann* (Germany)

09:00 – 09:15
EVALUATION OF FLOW CYTOMETRIC ASSAY IN THE DIAGNOSIS OF HIT
Brigitte Tardy*, Aurélie Montmartin, Michele Piot, Céline Chapelle, Madjid Akrour, Francoise Greinacher, Marie-Hélène Horellou, Dominique Lasne, Thomas Lecompte, Gregoire Legal, Agnes Lillo-LeLoutet, Francois Mullier, Philippe Nguyen, Claire Pouplard, Marie Toussaint-Hacquard, Aaron Toner, Bernard Tardy (France)

SCIENTIFIC PROGRAM

08:00 – 08:15
ACQUIRED VON WILLEBRAND SYNDROME IS A COMMON AND PROGRESSIVE CONDITION AMONG PEDIATRIC ECMO PATIENTS
Shi-Ki R. Hui*, Gregory Pelcey, Vadim Kostosov, Trung Nguyen, Laura Loftis, James Thomas, Jun Teruya (United States)

08:15 – 09:00
MECHANICAL HEART VALVE-INDUCED THROMBIN GENERATION
Iqbal Jaffer*, Alan Stafford, Jim Fredenburgh, Richard Whitlock, Jeffrey Weitz (Canada)

08:30 – 09:45
USE OF FIBINOLYTIC THERAPY IN TREATMENT OF VENTRICULAR ASSESSMENT OF PLATELET FUNCTION AND HEMOSTASIS IN ASSIST DEVICE THROMBOSIS
Paul Dobesh*, Brian Trewarow, Sara Varano, Ashley Schenk, Eric Rome (United States)

09:00 – 09:15
APPLICATION OF A MICROFLUIDIC FLOW-BASED THROMBOSIS ASSAY FOR POST-OPERATIVE PEDIATRIC CARDIOPULMONARY BYPASS PATIENTS
Nabil Othman*, Xufeng Gao, Henry Walters, Patrick Hines (United States)

PROGRAMME

08:00 – 08:15
SCIENTIFIC PROGRAM

Moderators: Michelle K. Brenner (United States), Paul Dobesh (United States)

08:00 – 08:15
ACQUIRED VON WILLEBRAND SYNDROME IS A COMMON AND PROGRESSIVE CONDITION AMONG PEDIATRIC ECMO PATIENTS
Shi-Ki R. Hui*, Gregory Pelcey, Vadim Kostosov, Trung Nguyen, Laura Loftis, James Thomas, Jun Teruya (United States)

08:15 – 09:00
MECHANICAL HEART VALVE-INDUCED THROMBIN GENERATION
Iqbal Jaffer*, Alan Stafford, Jim Fredenburgh, Richard Whitlock, Jeffrey Weitz (Canada)

08:30 – 09:45
USE OF FIBINOLYTIC THERAPY IN TREATMENT OF VENTRICULAR ASSESSMENT OF PLATELET FUNCTION AND HEMOSTASIS IN ASSIST DEVICE THROMBOSIS
Paul Dobesh*, Brian Trewarow, Sara Varano, Ashley Schenk, Eric Rome (United States)

09:00 – 09:15
APPLICATION OF A MICROFLUIDIC FLOW-BASED THROMBOSIS ASSAY FOR POST-OPERATIVE PEDIATRIC CARDIOPULMONARY BYPASS PATIENTS
Nabil Othman*, Xufeng Gao, Henry Walters, Patrick Hines (United States)
SCIENTIFIC PROGRAM

08:30 – 08:45
LB003
RAPS (RIVAROXABAN IN ANTIPHOSPHOLIPID SYNDROME): A PROSPECTIVE RANDOMISED CONTROLLED PHASE II/III CLINICAL TRIAL OF RIVAROXABAN VERSUS WARFARIN IN PATIENTS WITH THROMBOTIC ANTIPHOSPHOLIPID SYNDROME, WITH OR WITHOUT SLE
Hannah Cohen*, Beverley Hunt, Maria Efythymiou, Deepa Arachchillage, Maria Ruiz, Simon Clawson, Nicola Muirhead, Yvonne Sylvestre, Samuel Machin, Maria Bertolaccini, Caroline Dore, Ian Mackie, David Isenberg, Munther Khamashta (United Kingdom)

08:45 – 09:00
LB004
ANNEXA™-A PART 2: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL DEMONSTRATING SUSTAINED REVERSAL OF APIXABAN-INDUCED ANTICOAGULATION IN OLDER SUBJECTS BY ANDEXANET ALFA (PRT064445), A UNIVERSAL ANTIDOTE FOR FACTOR XA (FXA) INHIBITORS
Mark Crowther*, Alex Gold, Genmin Lu, Janet Leeds, Brian Wiens, Vandana Mathur, Janice Castillo, Pamela Conley, Stuart Connolly, John Curnutte (Canada)

09:00 – 09:15
LB005
INITIAL RESULTS OF THE RE-VERSE AD TRIAL: IDARUCIZUMAB REVERSES THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY, OR INTERVENTIONS
Charles Pollack*, Paul Reilly, Peter Verhamme, Richard Bernstein, Robert Dubiel, John Eikelboom, Menno Huisman, Elaine Hylek, Chak-Wah Kam, Pieter Kamphuisen, Joerg Kreuzer, Jemold Levy, Frank Sellke, Thorsten Steiner, Bushi Wang, Jeffrey Weitz (United States)

Coffee break time in the exhibition (Level 800)
From 09:15 to 09:45

Monday, June 22, 2015
PLENARY SESSION 09:45-10:30
Frank Schofield Plenary Lecture
Hall F&G
Moderator: Jeffrey Weitz (Canada)
09:45 - 10:30
75 years of progress in antithrombotic therapy for cardiovascular disease
Eugene Braunwald (United States)

STATE-OF-THE-ART LECTURES 10:45-11:45

J. Fraser Mustard SoA: Platelet function and dysfunction
Room 718
Moderator: Peter Gross (Canada)
10:45 - 11:05
Inherited disorders of platelet function
Alan Norden (France)
11:05 - 11:25
The P2Y12 ADP receptor: Structure and function
Marco Cattaneo (Italy)
11:25 - 11:45
αIIbβ3: structure and function
Barry Coller (United States)

Hijacking of proteolytic mechanisms by pathogens
Room 716
Moderator: Jim Fredenburg (Canada)
10:45 - 11:15
Fibrinolytic and procoagulant activities of Yersinia pestis and Salmonella enterica
Timo K. Korhonen (Finland)
11:15 - 11:45
Pathogen activators of plasminogen
Paul Bock (United States)

Mechanisms of thrombosis
Room 714
Moderator: Uri Seligsohn (Israel)
10:45 - 11:05
Thrombosis as a key regulator of innate immunity
Steffen Massberg (Germany)
11:05 - 11:25
Fibrinogen, factor XIII, and red blood cells: novel mechanisms in thrombosis
Alisa Wolberg (United States)
11:25 - 11:45
New insights into the biology of tissue factor pathway inhibitor
Alan Mast (United States)

Hemophilia gene therapy; A Joint ISTH-WFH Symposium
Plenary Hall F&G
Moderators: Marijke van den Berg (The Netherlands); Alok Srivastava (India)
10:45 - 11:05
New approaches to gene and cell therapy for hemophilia
Tsukasa Ohmori (Japan)
11:05 - 11:25
Platelet directed gene therapy
Mortimer Poncz (United States)
SCIENTIFIC PROGRAM

11:25 - 11:45  Gene therapy for hemophilia B
Paul Monahan (United States)

▲ Controversies in VTE management  Room 701
Moderators: Henri Bounaumeaux (Switzerland); Alexander S. Gallus (Australia)

10:45 - 11:15  Pulmonary embolism – Whom to thrombolyse? Whom to discharge?
Guy Meyer (France)

11:15 - 11:45  Controversies in VTE diagnosis
Gregoire Le Gal (Canada)

❤ Burden, prevention and management of periop cardiovascular complications  Room 801
Moderators: Giancarlo Agnelli (Italy); James Douketis (Canada)

10:45 - 11:05  Perioperative myocardial injury
Dan Sessler (United States)

11:05 - 11:25  What is the role of aspirin for prevention and treatment of perioperative cardiovascular events?
Philip J. Devereaux (Canada)

11:25 - 11:45  New paroxysmal perioperative atrial fibrillation: how important is it for patients and what should I do about it?
Pablo Alonso Coello (Spain)

★ Extracorporeal circulation in children: can we restore normal hemostasis?  Room 713
Moderators: Leonardo Brandao (Canada); Ulrike Nowak-Göttl (Germany)

10:45 - 11:15  ECMO: The precarious balance of hemostasis
Gail Annich (United States)

11:15 - 11:45  Ventricular assist devices and antithrombotic therapy: Do we really know what to do?
Patti Massicotte (Canada)

Lunch in the exhibition (Level 800)
From 11:45 to 12:15

Lunch Symposia
From 12:15 to 13:45
Lunch Symposia Programs are available in the Show Guide.
Please consult the different options to attend the symposium of your choice.

SCIENTIFIC PROGRAM

ORAL COMMUNICATIONS 2  14:00-15:15

▲ NOACs in clinical practice  Plenary Hall F&G
Moderators: Deepa Suryanarayan (Canada), Pantep Angchaisukisri (Thailand)

14:00 – 14:15  ADHERENCE TO ANTICOAGULANT TREATMENT WITH DABIGATRAN AND RIVAROXABAN IN A REAL-WORLD SETTING
Faris Al Khalili*, Deepa Suryanarayan, Catrine Lindström, Sam Schulman, Ammar Majed (Sweden)

14:15 – 14:30  THE IMPACT OF THE INTRODUCTION OF DABIGATRAN ON ANTICOAGULANT MANAGEMENT IN NEW ZEALAND
Paul L. Harper*, Daryl Pollock, Laura Chen, Su Chen Fong (New Zealand)

14:30 – 14:45  REAL-WORLD RIVAROXABAN LEVELS FROM KING’S COLLEGE HOSPITAL
Kathryn Lan*, Jignesh Patel, Paradzai Chitongo, Julia Czuprysnska, Lara Roberts, Raj Patel, Roopen Arya (United Kingdom)

14:45 – 15:00  PROSPECTIVE SURVEY OF ADVERSE EFFECTS OF NON-VITAMIN K ORAL ANTICOAGULANTS IN TWO UK HOSPITAL TRUSTS
Owain Myers, Sue Pavord, Marissa Hagan, Bethan Myers* (United Kingdom)

15:00 – 15:15  DABIGATRAN BUT NOT RIVAROXABAN OR APIXABAN REDUCES FIBRINOlytic RESISTANCE IN PATIENTS WITH ATRIAL FIBRILLATION
Concetta T. Ammollo*, Fabrizio Semeraro, Francesca Incampo, Claudia Delleoane, Oriana Paoletti, Sophie Testa, Mario Colucci (Italy)

▲ Management of bleeding?  Room 718
Moderators: Ravindra Sarode (United States), Peter Kouides (United States)

14:00 – 14:15  ROLE OF TRANEXAMIC ACID IN REDUCING BLEEDING EPISODES AND REQUIREMENT OF PLATELET SUPPORT IN PATIENTS WITH APLASTIC ANEMIA
Pravas Mishra*, Sudhir Kumar, Manoranjan Mahapatra, Tulika Seth (India)

14:15 – 14:30  EFFECTS OF IDARUCIZUMAB, GIVEN AS A SPLIT DOSE, IN A BLUNT LIVER DOUBLE TRAUMA MODEL IN PIGS RECEIVING DABIGATRAN
Markus Honickel, Joanne van Ryn, Rolf Rossaint, Hugo ten Cate, Henri Spronk, Oliver Grottke* (Germany)

14:30 – 14:45  HEMODIALYSIS FOR THE TREATMENT OF DABIGATRAN-ASSOCIATED BLEEDING: A SYSTEMATIC REVIEW OF THE LITERATURE
Chatree Chai-Adisaksopha*, Christopher Hills, Wendy Lim, Kochawan Boonyawat, Mark Crowther (Canada)

14:45 – 15:00  OPTIMAL TIMING OF WARFARIN RESUMPTION AFTER WARFARIN RELATED UPPER GASTROINTESTINAL BLEEDING
Ammar Majed*, Joakim Eriksson, Niklas Wallvik, Sam Schulman (Sweden)

MONDAY
SCIENTIFIC PROGRAM

15:00 – 15:15
FIBRINOGEN CONCENTRATE IMPROVES FIBRIN NETWORK STRUCTURE DURING ORTHOTOPIC LIVER TRANSPLANTATION.
Dafna Groeneveld*, Jelle Adelmeijer, Greg Hugenholtz, Robert Porte, Ton Lisman (The Netherlands)

14:00 – 14:15
IMPACT OF INCIDENT MYOCARDIAL INFARCTION ON FUTURE RISK OF VENOUS THROMBOEMBOLISM
Ludvig B. Rinde*, Birgit Småbrekke, Caroline Lind, Inger Njølstad, Ellisiv Mathiesen, Eim Hald, Sigrid Brækkan, John-Bjarne Hansen (Norway)

14:15 – 14:30
DEVELOPMENT AND VALIDATION OF A PATIENT SELF-ADMINISTERED VILLALTA SCALE FOR PATIENT SELF-ASSESSMENT OF THE POST-TROMBOTHROMBOTIC SYNDROME
Kristin Utne*, Waleed Ghana, Per Sandset, Susan Kain, Hilde Wik (Norway)

14:30 – 14:45
OUTCOMES FROM THE NATIONAL VENOUS THROMBOEMBOLISM PREVENTION PROGRAMME IN ENGLAND
Lara Roberts, Helen Morrison, Tim Abbott, Frances Healey, Mike Durkin, Roopen Arya* (United Kingdom)

14:45 – 15:00
RISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM BASED ON PRESENCE OR ABSENCE OF DEEP VEIN THROMBOSIS: SYSTEMATIC REVIEW AND META-ANALYSIS

15:00 – 15:15
REGULAR PHYSICAL ACTIVITY AND FUTURE RISK OF MYOCARDIAL INFARCTION AND VENOUS THROMBOSIS – THE TROMSØ STUDY
Sigrid Brækkan*, Ellen Brodin, Anders Vik, Tom Wilsangaard, Inger Njølstad, Ellisiv Mathiesen, John-Bjarne Hansen (Norway)

Antithrombin

14:00 – 14:15
ANTITHROMBIN DUBLIN (P.VAL30GLU): A POLYMORPHISM WITH MODERATE RISK OF THROMBOSIS THAT CAUSES A TRANSIENT ANTITHROMBIN DEFICIENCY BY INTRACELLULAR FOLDING INTO THE LATENT CONFORMATION
José Navarro-Fernández*, María de la Morena-Barrio, José Padilla, Antonio Miñano, Nataliya Bohdan, Sonia Águila, Irene Martínez-Martínez, Teresa Sevivas, Carmen de Cos, Nuria Fernández-Mosteirín, Pilar Llamas, Susana Atenso, Pilar Medina, Juan Souto, Kim Oeverd, Sören Kristensen, Vicente Vicente, Javier Corral (Spain)

14:15 – 14:30
AGE-DEPENDENT FACTOR IX ACTIVITY IN ASSOCIATION WITH THE A/A-GENOTYPE OF F9 G32023A -POLYMORPHISM (RS440051) AND CONSEQUENTIAL RISK OF VENOUS THROMBOEMBOLISM (VTE)
Rainer B. Zotz*, Daniel Szafarczyk, Ruediger Scharf, Andrea Gerhardt (Germany)

14:45 – 15:00
ANTITHROMBIN HEPARIN BINDING SITE DEFICIENCY: A CHALLENGING DIAGNOSIS OF A NOT SO BENIGN THROMBOPHILIA
Christelle Orlando*, Olivier Heylen, Willy Lissens, Kristin Jochems (Belgium)

15:00 – 15:15
HIGH NEUTROPHIL AND BASOPHIL BLOOD COUNTS ARE ASSOCIATED WITH INCREASED FACTOR II PLASMA COAGULANT ACTIVITY AND MAY BE PREDICTORS OF MORTALITY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE.
Nicola Martinelli*, Domenico Girelli, Federica Tosi, Filippo Sartori, Giovanna Marchetti, Roberto Corrocher, Francesco Bernardi, Oliviero Olivieri (Italy)

Venous thromboembolism – epidemiology – I

14:00 – 14:15
Moderators: Cynthia Wu (Canada), Ken Bauer (United States)

14:15 – 14:30
AGE-DEPENDENT FACTOR IX ACTIVITY IN ASSOCIATION WITH THE A/A-GENOTYPE OF F9 G32023A -POLYMORPHISM (RS440051) AND CONSEQUENTIAL RISK OF VENOUS THROMBOEMBOLISM (VTE)
Rainer B. Zotz*, Daniel Szafarczyk, Ruediger Scharf, Andrea Gerhardt (Germany)

14:00 – 14:15
THE INCIDENCE OF VTE IN ASYMPTOMATIC CARRIERS OF A DEFICIENCY OF AT, PC OR PS: A PROSPECTIVE COHORT STUDY
Dania Tormene*, Laura Guerra, Sabrina Gavasso, Cristina Bulato, Francesca Sartorello, Elena Campello, Fabio Dall’Alba, Luca Spiezia, Paolo Simioni (Italy)

14:45 – 15:00
ANTITHROMBIN HEPARIN BINDING SITE DEFICIENCY: A CHALLENGING DIAGNOSIS OF A NOT SO BENIGN THROMBOPHILIA
Christelle Orlando*, Olivier Heylen, Willy Lissens, Kristin Jochems (Belgium)

15:00 – 15:15
HIGH NEUTROPHIL AND BASOPHIL BLOOD COUNTS ARE ASSOCIATED WITH INCREASED FACTOR II PLASMA COAGULANT ACTIVITY AND MAY BE PREDICTORS OF MORTALITY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE.
Nicola Martinelli*, Domenico Girelli, Federica Tosi, Filippo Sartori, Giovanna Marchetti, Roberto Corrocher, Francesco Bernardi, Oliviero Olivieri (Italy)

14:00 – 14:15
GENETIC ABLATION OF TRPM7 ALTERS MAGNESIUM HOMEOSTASIS AND INDUCES MACROTHROMBOCYTOPENIA IN MICE
Simon Stritt, Sanjeev Goru, Vladimir Chubanov, Thomas Gudermann, Harald Schulze, Paquita Norden, Bernhard Nieswandt, Attila Braun* (Germany)

14:15 – 14:30
OF MEN AND MICE: DIVERGENCE EFFECT OF HDAC6 ON PROPLATELET FORMATION
Kahia Messaoudi*, Ali Ashfaq, Alberta Palazzo, Olivier Bluteau, Philippe Rameau, Hana Raslova, Isabelle Plo, William Vainchenker, Najet Debili (France)

14:30 – 14:45
GLYCOPROTEIN VI INTERACTIONS WITH COLLAGEN TYPE I SELECTIVELY INHIBIT PROPLATELET FORMATION
Harald Schulze*, David Stegner, Daniela Semeniak, Beate Ecks, Bernhard Nieswandt, Rebecca Kulagw (Germany)

14:45 – 15:00
RAPID ‘RUPTURE’-TYPE THROMBOPOIESIS PROCESSES FROM BONE MARROW MEGAKARYOCYTE IN RESPONSE TO ACUTE PLATELET NEEDS IS REGULATED BY IL-1ALPHA
Satoshi Nishimura*, Asuka Sakata, Kinya Seo, Tsukasa Ohmori, Koji Eto (Japan)

15:00 – 15:15
SYNTHESIS OF MARKS IN THE LATE STAGES OF MEGAKARYOCYTE MATURATION DRIVES PROPLATELET FORMATION
Kellie Macclus*, Stephen Wu, Debbie Stumpo, Robert Campbell, Andrew Weyrich, Perry Blackshear, Joseph Italiano (United States)

Von Willebrand Disease

14:00 – 14:15
DETECTION OF LARGE EXONIC AND INTERGENIC DELETIONS IN THE VWF LOCUS OF VWD PATIENTS USING ARRAY COMPARATIVE GENOMIC HYBRIDISATION (ACGH)
Simon J. Webster*, Daniel Hampshire, Reinhard Schneggenheim, Daniel Bellissimo, Paula James, Bimal Theophilus, Ian Peake, Anne Goodeve (United Kingdom)

14:45 – 15:00
ANTITHROMBIN HEPARIN BINDING SITE DEFICIENCY: A CHALLENGING DIAGNOSIS OF A NOT SO BENIGN THROMBOPHILIA
Christelle Orlando*, Olivier Heylen, Willy Lissens, Kristin Jochems (Belgium)

15:00 – 15:15
HIGH NEUTROPHIL AND BASOPHIL BLOOD COUNTS ARE ASSOCIATED WITH INCREASED FACTOR II PLASMA COAGULANT ACTIVITY AND MAY BE PREDICTORS OF MORTALITY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE.
Nicola Martinelli*, Domenico Girelli, Federica Tosi, Filippo Sartori, Giovanna Marchetti, Roberto Corrocher, Francesco Bernardi, Oliviero Olivieri (Italy)
SCIENTIFIC PROGRAM

14:15 – 14:30
LONG-TERM EXPRESSION OF VON WILLEBRAND FACTOR VIA SLEEPING BEAUTY SANDWICH TRANSPONSON-MEDIATED GENE THERAPY
Irina Portier*, Karen Vanhoorelbeke, Sebastien Verhenne, Inge Pareyn, Hans Deckmyn, Zsuzsanna Izsák, Simon De Meyer (Belgium)

14:30 – 14:45
SAFETY, EFFICACY AND PHARMACOKINETICS OF A RECOMBINANT VON WILLEBRAND FACTOR IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE: A PROSPECTIVE CLINICAL TRIAL
Joan Gill, Giancarlo Castaman, Jerzy Windyga, Peter Koudies, Margaret Ragni*, Frank Leebeek, Obrun Obermann-Slupetzky, Miranda Chapman, Sandor Fritsch, Borislava Pavlova, Isabella Presch, Bruce Ewenstein (Austria)

14:45 – 15:00
NO DIFFERENCE IN WVF LEVELS NOR WVF SURVIVAL IN INDEX CASES AND FAMILY MEMBERS WITH AND WITHOUT P.Y1584C ENROLLED IN ZIMMERMAN PROGRAM FOR THE MOLECULAR AND CLINICAL BIOLOGY OF VWD (ZPMCB-VWD)
Pamela A. Christopherson, Daniel Bellissimo, Veronica Flood, Kenneth Friedman, Joan Gill, Robert Montgomery, Sandra Haberichter* (United States)

15:00 – 15:15
PREVALENCE AND RISK FACTORS ASSOCIATED WITH HYPERTENSION IN VON WILLEBRAND DISEASE
Mariya Apostolova*, Craig Seaman, Diane Comer, Jonathan Yabes, Margaret Ragni (United States)

14:00 – 14:15
EFFECTS OF ANTIPHOSPHOLIPID ANTIBODIES ON VASCULAR SMOOTH MUSCLE CELLS
Camille Rouillon*, Stéphanie Makhoul, Patrick Lacolley, Véronique Regnault, Denis Wahl (France)

14:15 – 14:30
IMPACT OF HYDROXYCHLOROQUINE TREATMENT ON PREGNANCY OUTCOME IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES
Savino Sciascia*, Beverley Hunt, Eva Talavera, Margaret Friedman, Joan Gill, Robert Montgomery, Sandra Haberichter* (United States)

14:30 – 14:45
Bleeding Risks Are High in Elderly Persons Who Use Vitamin K Antagonists Combined with Platelet Aggregation Inhibitors
Nieke Van Rein*, Ulle Heide-Jørgensen, Willem Liljering, Lars Pedersen, Olaf Dekkers, Henrik Sørensen, Suzanne Canninghe (Denmark, The Netherlands)

14:45 – 15:00
THE EFFECT OF CYP2C9 POLYMORPHISM ON INR DECLINE IN PATIENTS STOPPING WARFARIN BEFORE SURGERY
Salah Atouhelaika*, Hilary Wynne, Peter Avery, Farhad Kamali (United Kingdom)

15:00 – 15:15
IMPACT OF VITAMIN K ANTAGONISTS (VKA) ON QUALITY OF LIFE (QOL) IN A PROSPECTIVE COHORT OF 807 ATRIAL FIBRILLATION (AF) PATIENTS
Hilde A. Kooistra*, Margriet Piersma-Wichers, Hanneke Kluin-Nelemans, Nic Veeger, Karina Meijer (The Netherlands)

14:00 – 14:15
QUALITY OF VITAMIN K ANTAGONIST CONTROL AND 1-YEAR OUTCOMES: A GLOBAL PERSPECTIVE FROM THE GARFIELD-AF REGISTRY
Hugo ten Cate*, Sylvia Haas, Gabriele Accetta, Pantep Angchaisukjar, John Camp, Raman Corbalan, John Eikelboom, David Fitzmaurice, Samuel Goldhaber, Shinya Goto, Barry Jacobson, Gloria Kayani, Alexander Turpie, Ajay Kakkar (The Netherlands)

14:15 – 14:30
INDEPENDENT PREDICTORS OF POOR VITAMIN K ANTAGONIST CONTROL IN VENOUS THROMBOEMBOLISM PATIENTS: DATA FROM THE EINSTEIN-DVT AND PE STUDIES.
Hilde A. Kooistra*, Martin Gebel, Kurtulus Sahin, Anthonie Lensing, Karina Meijer (The Netherlands)

14:30 – 14:45
BLEEDING RISKS ARE HIGH IN ELDERLY PERSONS WHO USE VITAMIN K ANTAGONISTS TO PREVENT STROKE IN PATIENTS WITH ATRIAL FIBRILLATION
Salah Atouhelaika*, Hilary Wynne, Peter Avery, Farhad Kamali (United Kingdom)

14:45 – 15:00
THE EFFECT OF CYP2C9 POLYMORPHISM ON INR DECLINE IN PATIENTS STOPPING WARFARIN BEFORE SURGERY
Salah Atouhelaika*, Hilary Wynne, Peter Avery, Farhad Kamali (United Kingdom)

15:00 – 15:15
IMPACT OF VITAMIN K ANTAGONISTS (VKA) ON QUALITY OF LIFE (QOL) IN A PROSPECTIVE COHORT OF 807 ATRIAL FIBRILLATION (AF) PATIENTS
Hilde A. Kooistra*, Margriet Piersma-Wichers, Hanneke Kluin-Nelemans, Nic Veeger, Karina Meijer (The Netherlands)

14:00 – 14:15
SPINART TRIAL 3-YEAR RESULTS WITH BAYER’S SUCROSE-FORMULATED RECOMBINANT FACTOR VIII: RELATIONSHIP BETWEEN BLEEDING FREQUENCY AND JOINT HEALTH IN ADULTS WITH SEVERE HEMOPHILIA A USING PROPHYLAXIS
Mark T. Reding*, Christine Kempston, Sharon Funk, Sylvia Engelen, Dale Walker, Walter Hong (United States)

14:15 – 14:30
DISCONTINUING EARLY PROPHYLAXIS IN YOUNG ADULTS WITH SEVERE HEMOPHILIA A: DETERIORATION OF JOINT STATUS AFTER 10 YEARS DESPITE LOW BLEEDING RATES
Annelies Niijdam, Wouter Foppen, Piet de Kleijn, Evelien Mauser-Bunschoten, Boris Roosenendaal, Karin van Galen, Roger Schutgens, Kathelijn Fischer* (The Netherlands)

14:30 – 14:45
RETROSPECTIVE 28-YEAR LONG-TERM FOLLOW-UP OF PROPHYLAXIS IN A COHORT OF 49 PATIENTS WITH SEVERE HEMOPHILIA A
Johannes Oldenburg*, Lemonia Krämer, Georg Goldmann, Natascha Marquardt, Hans-Hermann Brackmann (Germany)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45 – 15:00</td>
<td>Prophylaxis in Children with Severe and Moderate Haemophilia: A Survey of UK Practice</td>
<td>OR104</td>
<td>Ryan Rodgers*, Jay Alamelu, Peter Collins, Mary Mathias, Jeanette Payne, Mike Richards, Oliver Tunstall, Mike Williams, David Young, Tina Biss, Angela Thomas, Elizabeth Chalmers (United Kingdom)</td>
</tr>
<tr>
<td>15:00 – 15:15</td>
<td>Prophylaxis in Adult Patients with Severe Hemophilia A or B Without Inhibitors</td>
<td>OR105</td>
<td>Louis Aledort*, Laura Avila, Victor Blanchette, Thierry Lambert (United States)</td>
</tr>
<tr>
<td>14:00 – 14:15</td>
<td>Transgene Expression under the Control of FVIII Promoter for Hemophilia A Targeted Therapy</td>
<td>OR106</td>
<td>Diego Zanolini*, Simone Merlin, Valentina Bruscaggin, Antonia Follenzi (Italy)</td>
</tr>
<tr>
<td>14:15 – 14:30</td>
<td>Role of the IgG Backbone in B Cell Depletion and Inhibitor Reversal in Hemophilia A with Anti-Cd20 Antibodies</td>
<td>OR107</td>
<td>Geoffrey L. Rogers*, Alexandra Sherman, David Markusic, Haiyan Jiang, Roland Herzog (United States)</td>
</tr>
<tr>
<td>14:30 – 14:45</td>
<td>High Throughput Amino Acid Sequence Epitope Mapping of Inhibitory Antibodies in Severe Hemophilia A</td>
<td>OR108</td>
<td>Paul Batty*, Stuart Skelton, Adrian Shepherd, Maria Mancuso, Elena Santagostino, Flora Peyvandi, Daniel Hart (United Kingdom)</td>
</tr>
<tr>
<td>14:45 – 15:00</td>
<td>Adoptive Transfer of In Vitro Expanded FVIII-Specific Regulatory T Cells to Mediate Tolerance in Hemophilia A Mice</td>
<td>OR109</td>
<td>Bryn Smith*, Meghan Lyle, Carol Miao (United States)</td>
</tr>
<tr>
<td>14:00 – 14:15</td>
<td>Hepatocellular Distribution of FVIII in Ex Vivo Perfused Rat Liver: Liver Sinusoidal Endothelial Cells are the Cells Primarily Responsible for Uptake of FVIII</td>
<td>OR110</td>
<td>Kirstine Roepstorff*, Mette Loftager, Jes Clausen, Marianne Kjalke, Frederik Rode, Jesper Haaning, Rupa Appa (Denmark)</td>
</tr>
<tr>
<td>14:30 – 14:45</td>
<td>Casein Kinase 2β is Critical Player in Platelet Activation, Arterial Thrombosis and Ischemic Stroke</td>
<td>OR114</td>
<td>Oliver Borst*, Patrick Münder, Britta Walker, Friederike Langhauser, Mita Chatterjee, Anna Fotinos, Christoph Kleinschnitz, Florian Lang, Meinrad Gawaz (Germany)</td>
</tr>
<tr>
<td>14:00 – 14:15</td>
<td>Different Pathways Regulate Syk Activation Downstream of Itam and Hemi-Itam Receptors in Platelets</td>
<td>OR111</td>
<td>Bhanukanth Manne*, Rachit Badolia, Carol Dangelmaier, Wilfried Ellmeier, Mark Kahn, Satua P Kunapuli (United States)</td>
</tr>
<tr>
<td>14:15 – 14:30</td>
<td>Glycogen Synthase Kinase 3 Phosphorylation Prevents Pathological Gpvi-Mediated Platelet Activation and Thrombosis</td>
<td>OR112</td>
<td>Samantha F. Moore*, Thomas Blair, Ingeborg Hers (United Kingdom)</td>
</tr>
<tr>
<td>14:00 – 14:15</td>
<td>Distinct Pathways Regulate Syk Activation Downstream of Itam and Hemi-Itam Receptors in Platelets</td>
<td>OR111</td>
<td>Bhanukanth Manne*, Rachit Badolia, Carol Dangelmaier, Wilfried Ellmeier, Mark Kahn, Satua P Kunapuli (United States)</td>
</tr>
<tr>
<td>14:15 – 14:30</td>
<td>Glycogen Synthase Kinase 3 Phosphorylation Prevents Pathological Gpvi-Mediated Platelet Activation and Thrombosis</td>
<td>OR112</td>
<td>Samantha F. Moore*, Thomas Blair, Ingeborg Hers (United Kingdom)</td>
</tr>
</tbody>
</table>
**SCIENTIFIC PROGRAM**

**Innate and acquired Immunity**

*Room 711*

**Moderators:** Anne Zufferey Bakos (Canada), Craig Morell (United States)

14:00 – 14:15

**NEUTROPHIL EXTRACELLULAR TRAP (NET) FORMATION IN PATIENTS WITH POST-BURN SEPSIS**

Robert J. Dinsdale*, Peter Hampson, Chris Wearn, Jon Hazeldine, Alexander Brill, Janet Lord, Naiem Moiemen, Paul Harrison (United Kingdom)

14:15 – 14:30

**COMPAARED TO B220/CD45R+ B LYMPHOCYTES, SPLENIC DENDRITIC CELLS AND MACROPHAGES HAVE LIMITED PROPENSITY TO BIND FACTOR VIII AND DEMONSTRATE DOWN-REGULATION OF CO-STIMULATORY MOLECULES.**

Jesse Lal*, Dominique Cartier, Alice van Velzen, Christine Hough, David Lillicrap (Canada)

14:30 – 14:45

**MITOCHONDRIAL DNA AND TOLL-LIKE RECEPTOR 9 ARE ASSOCIATED WITH MORTALITY IN CRITICALLY ILL PATIENTS**

Sarah Ruhittel, Konstantin Krychiuk*, Philipp Hohensinner, Lorenz Koller, Christoph Kaun, Max Lenz, Benedikt Bauer, Lisa Wutzelhofer, Dominik Draxler, Gerald Maurer, Kurt Huber, Johann Wojta, Gottfried Heinz, Alexander Niessner, Walter Speidl (Austria)

14:45 – 15:00

**AKI DEVELOPMENT UPON SIRS IS ASSOCIATED WITH PLATELET ACTIVATION, POSSIBLY TRIGGERED BY MITOCHONDRIAL DNA DERIVED FROM DAMAGED CELLS**

Marcel P. B. Jansen*, Wilco Pulsens, Loes Butter, Nike Claessen, Diba Emal, Sandrine Florquin, Nicole Juffermans, Joris Roelofs, Jaklien Leemans (The Netherlands)

15:00 – 15:15

**DIPHOSPHORYLATED LIPID A TRIGGERS TISSUE FACTOR MRNA SPlicing IN HUMAN PLATELETS**

Krystin Krauel*, Ulrike Thorack, Anne Schumacher, Hansjörg Schwertz (Germany)

**Coffee break time in the exhibition (Level 800)**

From 15:15 to 15:45

**Platelets and bacteria**

*Room 711*

**Moderators:** John Semple (Canada), Archie McNichol (Canada)

15:45 - 16:15

**THROMBUS FORMATION CAUSED BY INVADING PATHOGENS: THE ROLE OF PLATELETS**

Steven Kerrigan (Ireland)

16:15 – 16:30

**CLEC-2 IS REQUIRED FOR THE ACTIVATION OF MOUSE PLATELETS BY BACTERIAL DNA MICROMITICS**

Celine Deienerneux*, Alexandre Hego, Christelle Lecut, Maud Vandereyken, Lucia Musumeci, Sauud Rahmouni, Vincent Bours, Patrizio Lanciloti, Cécile Oury (Belgium)

16:30 – 16:45

**PLATELET MYD88 ENHANCES CYTOKINE PRODUCTION INDUCED BY TLR AGONISTS AND KLEBSIELLA PNEUMONIAE**

Theodora A. Clauwsuis*, Sacha de Stoppelaar, Cornelis van ‘t Veer, Tom van der Poll (The Netherlands)

16:45 – 17:00

**POLYPHOSPHATE CHAIN LENGTH DETERMINES ANTIGENICITY OF COMPLEXES FORMED WITH PLATELET FACTOR 4 (PF4) AND PF4-BINDING TO BACTERIA**

Mihaela Delcea*, Sven Brandt, Krystin Krauel, Miriam Jaax, Thomas Renné, Christiane Helm, Sven Hammerschmidt, Andreas Greinacher (Germany)

17:00 – 17:15

**SHEAR-RESISTANT BINDING TO VON WILLEBRAND FACTOR ALLOWS STAPHYLOCOCCUS LUGDUNENSIS TO ADHERE TO THE CARDIAC VALVES AND INITIATE ENDOCARDITIS**

Laurens Liesenborghs*, Marjike Peetemans, Jorien Claes, Marleen Lox, Christophe Vandebriele, Maarten Criel, Thomas Vanasse, Marc Hoylaerts, Peter Verhamme (Belgium)

**Genetic basis of platelet disorders**

*Room 715*

**Moderators:** Kathleen Freson (Belgium), Matthew Rondina (United States)

15:45 - 16:15

**PLATELET GRANULE BIOGENESIS**

Walter Kahr (Canada)
16:15 – 16:30
AS011

CONSECUTIVE SLFN14 MUTATIONS IN 3 UNRELATED FAMILIES WITH AN INHERITED BLEEDING DISORDER, THROMBOCTYPENIA AND SECRETION DEFECTS
Sarah Fletcher, Ben Johnson, Gill Lowe, Danai Bern, Sian Drake, Marie Lordkipanidze, Isabel Sánchez Guiú, Ban Dawood, José Rivera, Michael Simpson, Martina Daly, Jayasheee Motwani, Peter Collins, Steve Watson, Neil V. Morgan* (United Kingdom)

16:30 – 16:45
AS012

UNRAVELLING RARE BLEEDING AND PLATELET DISORDERS (BPD) USING COMPREHENSIVE PHENOTYPING AND GENOME SEQUENCING
Claire Lentaigne* (United Kingdom)

16:45 – 17:00
AS013

A DOMINANT GAIN-OF-FUNCTION MUTATION IN A TYROSINE KINASE GENE CAUSES A NEW GRAY PLATELET-LIKE SYNDROME WITH BONE PATHOLOGIES
Anouck Wijsaerts* (Belgium)

17:00 – 17:15
AS014

MUTATION IN ETS VARIANT GENE 6 ASSOCIATES WITH AUTOSOMAL DOMINANT THROMBOCTYPENIA AND RAISED LEVELS OF CIRCULATING CD34+ CELLS
Marjorie Poggi, Véronique Baccini, Marie Favier, Matthias Canault*, Anna Mezzapesa, Dorsaf Ghalloussi, Nadjim Chelghoum, Badreddine Mohand-Oumoussa, Céline Falaise, Franck Guider, Denis Bernot, Paquita Norden, Hans Raslova, David-Alexandre Tregouet, Marie-Christine Alessi (France)

17:00 – 17:15
AS019

THROMBIN GENERATION IS INCREASED IN PLASMA FROM HEALTHY MALES WHO HAVE RECEIVED CONCIZUMAB, AN ANTIBODY AGAINST TISSUE FACTOR PATHWAY INHIBITOR (EXPLORERTM2)
Emily K. Waters*, Jens Sigh, Mirella Ezban, Ida Hilden (Denmark)

Women’s issues in venous thrombosis Room 801

15:45 - 16:15
AS020

ANTITHROMBOTIC THERAPY TO PREVENT PLACENTA MEDIATED COMPLICATIONS
Robert M. Silver (United States)

16:15 – 16:35
AS021

TIME TO LIVE BIRTH IN WOMEN WITH RECURRENT MISCARRIAGE AND INHERITED THROMBOPHILIA
Paulien G. de Jong*, Stef Kaandorp, Remi Kool, Barbara Hutten, Saskia Middeldorp, Mariëtte Goddijn (The Netherlands)

16:35 – 16:55
AS022

HORMONAL THERAPY AND THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN WOMEN RECEIVING ANTICOAGULANT TREATMENT
Ida Martinelli*, Anthonie Lensing, Jan Beyer-Westendorf, Mila Trajanovic, Martin Gebel, Phuong Lam, Martin Prins (Italy)

16:55 – 17:15
AS023

THE PROPORTION OF NONDIAGNOSTIC COMPUTED TOMOGRAPHIC PULMONARY ANGIOGRAPHY AND VENTILATION/PERFUSION LUNG SCANS IN PREGNANT WOMEN WITH SUSPECTED PULMONARY EMBOLISM: A SYSTEMATIC REVIEW.
Arabesque Parker*, Ghazi Alotaibi, Cynthia Wu, Sarah Takach Lapner (Canada)

Modulation of atherothrombosis Room 705

15:45 - 16:15
AS024

THE HEMOSTATIC SYSTEM AS A MODULATOR OF ATHEROSCLEROSIS
Hugo Ten Cate (The Netherlands)

16:15 – 16:30
AS025

ADOPTIVE TRANSFER OF ANTIGEN-INDUCED SPECIFIC REGULATORY T CELLS (TREG) PROTECTS AGAINST ATHEROSCLEROTIC LESION FORMATION IN B6;129S-LDLR(TM1HER)APOB(TM2SGY)/J MICE
Min Xia, Valeria Endresz, Ildiko Lantos, Andrea Szabo, Lakshmi Mundkur, Vijay Kakkar, Xinjie Lu* (United Kingdom)

16:30 – 16:45
AS026

DISRUPTION OF SEMAPHORIN 7A DECREASES PLAQUE SIZE INDUCED BY DISTURBED FLOW AND CONFERS PROTECTION AGAINST THE DEVELOPMENT OF ATHEROSCLEROSIS
Chaoqiu Tang*, Shuhong Hu, Fei Yang, Li Zhu (China)

16:45 – 17:00
AS027

CHANGES IN PERIPHERAL IMMUNE MARKERS IN RESPONSE TO IMMUNE TOLERANCE AND ITS CORRELATION WITH PROGRESSION OF ATHEROSCLEROSIS IN APOB1TG25LDL1HER MICE
Thota Lakshmi narasimha Rao, Sheena Philip, Thiruvelselvan Ponnumasy, Xinjie Lu, Vijay Kakkar, Lakshmi Mundkur* (India)
**SCIENTIFIC PROGRAM**

17:00 – 17:15

**AS028**

**BONE MORPHOGENETIC PROTEIN (BMP)-7 UPREGULATES ADHESIVE AND MIGRATORY PROPERTIES OF HUMAN MONOCYTIC CELLS VIA BETα2 INTEGRIN-BMP RECEPTOR TYPE II (BMPRII) CROSSTALK**

Timofey Sovershaev*, Dusten Unruh, John-Bjarne Hansen, Vladimir Bogdanov, Mikhail Sovershaev (Norway, United States)

**Moderators: Paul Kim (Canada), Lawrence Leung (United States)**

| 15:45 - 16:15 | **CROSS-TALK BETWEEN COAGULATION AND FIBRINOLYSIS**
| AS029 | John Morser (United States) |

| 16:15 – 16:35 | **IMAGING ANALYSES OF COAGULATION-DEPENDENT INITIATION OF FIBRINOLYSIS ON ACTIVATED PLATELETS AND ITS MODIFICATION BY TAFI**
| AS030 | Tomasz Brzoska*, Yuko Suzuki, Hitode Sano, Martyna Tomczyk, Tetsumei Urano (Japan) |

| 16:35 – 16:55 | **ACTIVATION OF PROCHEREMIN BY FACTOR XIA REPRESENTS A NEW MOLECULAR LINK BETWEEN INNATE IMMUNITY AND BLOOD COAGULATION**
| AS031 | Xiaomei Ge*, Yasuto Yamaguchi, Lei Zhao, Shwu Shin Chang, John Morser, Lawrence Leung (United States) |

| 16:55 – 17:15 | **INTRAVENOUS THROMBOLYSIS GENERATES LARGE AMOUNTS OF BRADYKININ IN STROKE PATIENTS: NEUROTOXIC IMPACT.**
| AS032 | Maxime Gauberti*, Sara Martinez de Lizarrondo, Oscar Marcos-Contreras, Denis Vivien (France) |

| **Antiphospholipid antibodies** | Room 701 |

| 15:45 - 16:15 | **UNRAVELLING THE ANTIPHOSPHOLIPID SYNDROME: FROM EMPIRIC DESCRIPTION TO PATHOGENIC MECHANISMS**
| AS033 | Jacob Rand (United States) |

| 16:15 – 16:30 | **INCREASED MORTALITY IN PATIENTS WITH THE LUPUS ANTICOAGULANT: THE VIENNA LUPUS ANTICOAGULANT AND THROMBOSIS STUDY (LATS)**
| AS034 | Johanna Gebhart*, Florian Posch, Silvia Koder, Thomas Perkmann, Peter Quehenberger, Claudia Zoghlami, Cihan Ay, Ingrid Pabinger (Austria) |

| 16:30 – 16:45 | **LUPUS ANTICOAGULANT ACTIVITY CAN BE EXPLAINED BY INTERFERENCE OF ANTI-B2GPI ANTIBODIES WITH THE PROTHROMBINASE COMPLEX**
| AS035 | J.E. Molhoek*, Ph.G. de Groot, J.C.M. Meijers, R.T. Urbanus (The Netherlands) |

| 16:45 – 17:00 | **CIRCULATING ENDOTHELIAL CELLS IDENTIFY PATIENTS WITH ANTIPHOSPHOLIPID-ANTIBODIES AND ASSOCIATED AUTO-IMMUNE DISEASES AT RISK FOR THROMBOSIS.**
| AS036 | Stéphane Zuly*, Marie Heymonet, Qian Tu, Marcelo De Carvalho Bittencourt, Gilbert Faure, Denis Wahl (France) |

---

**MICROPARTICLES IN HEALTH AND DISEASE**

| 15:45 - 16:15 | **MICROPARTICLES IN HEALTH AND DISEASE**
| AS038 | Rienk Nieuwland (The Netherlands) |

| 16:15 – 16:30 | **MICROPARTICLES FROM PATIENTS WITH ACUTE CORONARY SYNDROME AND HEART TRANSPLANTED PATIENTS INDUCE PREMATURITY ENDOTHELIAL SENECEENCE AND THROMBOGENICITY: ROLE OF OXIDATIVE STRESS AND OF THE LOCAL ANGIOTENSIN SYSTEM**
| AS039 | Malak Abbas*, Laurence Jesel, Thuong Nga Nguyen, Cyril Auger, Nathan Messas, Thais Ribeiro, Graziele C Silva, Patrick Ohlman, Olivier Morel, Valerie Schini-Kerth, Florence Toli (France) |

| 16:30 – 16:45 | **THE GAS6-AXL INTERACTION MEDIATES ENDOTHELIAL UPTAKE OF PLATELET MICROPARTICLES**
| AS040 | Kaisa Otteby*, Sinh Tran, Matthias Mögelin, Björn Dahlbäck (Sweden) |

| 16:45 – 17:00 | **PLATELETS RELEASE EXTRACELLULAR VELOCITIES IN AN AGONIST DEPENDENT MANNER BUT RELEASE A CONSISTENT PROFILE OF MICRORNA**
| AS041 | Ashley R. Ambrose*, J Pringle, Alison Goodall (United Kingdom) |

| 17:00 – 17:15 | **A PROSPECTIVE EVALUATION OF THE PROTHROMBOTIC AND PROGNOSTIC POTENTIAL OF CIRCULATING MICROPARTICLES IN GLOBLASTOMA MULTIFORME (GBM), PANCREATIC ADENOCARCINMA (PAC) AND ESOPHAGEAL-GASTRIC CANCER (EGC).**
| AS042 | Elena Campello*, Claudia Radu, Luca Spiezia, Sabrina Gavasso, Barry Woodhams, Paolo Simioni (Italy) |

---

**Obesity – bench to bedside**

| 15:45 - 16:15 | **ROLE OF ENDOTHELIAL CELLS IN ADIPOSE TISSUE INFLAMMATION AND ADIPOCYTE ALTERATIONS DURING OBESITY**
| AS043 | Vanessa Pellegrinielli (United Kingdom) |

| 16:15 – 16:30 | **SILENCING OF SEC23A AND FLOTILIN PROTECTS ENDOTHELIAL CELLS FROM DEVELOPING A PROINFLAMMATORY / PROTHROMBOTIC PHENOTYPE IN OBESITY**
| AS044 | Marta Palomo De Udaeta*, Rebeca Fernandez-Ruiz, Sergi Torramadé, Ginés Escolar, Ramón Gomis, Felicia Hanzu, Maribel Diaz-Ricart (Spain) |
SCIENTIFIC PROGRAM

16:30 – 16:45
AS045
DNA METHYLATION PROFILING IDENTIFIES A LOCUS NEAR A HMG-COA SYNTHASE GENE ASSOCIATED WITH TRIGLYCERIDE LEVELS AND MODIFIED BY BMI
Vinh Truong*, Nora Zwingerman, Irfahan Kassam, Dylan Alissi, Jessica Dennis, Michael Wilson, Philip Wells, Pierre-Emmanuel Morange, David-Alexandre Trégouët, France Gagnon (Canada)

16:45 – 17:00
AS046
OBESITY MEASURES, CRP AND RISK OF VENOUS THROMBOEMBOLISM AND MYOCARDIAL INFARCTION
Lars Daæe Horreli*, Signis Brekke, Ellisiv Mathiesen, Inger Njølstad, Tom Wilsgaard, Jan Brox, John-Bjarne Hansen (Norway)

17:00 – 17:15
AS047
VISCERAL ADIPOSEITY INDEPENDENTLY DETERMINES THROMBIN GENERATION LAG TIME AND PEAK THROMBIN IN MORBID OBESITY
Paradzai Chitongo*, Lara Roberts, Lyall Rebecca, Raj Patel, Simon Aylwin, Roopen Arya (United Kingdom)

Sickle cell disease Room 707

Moderators: Michael DeBaun (United States), Madeleine Verhovsek (Canada)

15:45 - 16:15
AS048
THE OPPORTUNITIES FOR PRIMARY AND SECONDARY STROKE PREVENTION IN SICKLE CELL DISEASE
Michael DeBaun (United States)

16:15 – 16:30
AS049
KININOGEN DEFICIENCY ATTENUATES THROMBIN GENERATION IN A MOUSE MODEL OF SICKLE CELL DISEASE
Erica Sparkenbaugh*, Niley Key, Kasemsiri Chandrajeti, Andras Gruber, Nigel Mackman, Keith McCrae, Rafał Pawlinski (United States)

16:30 – 16:45
AS050
MICROPARTICLES GENERATED DURING STORAGE OF PACKED RED BLOOD CELL UNITS SUPPORT THROMBIN GENERATION
Beth A. Bouchard*, Hollis Keith, Elizabeth Lavoie, Thomas Orfeo, Kenneth Mann (United States)

16:45 – 17:00
AS051
SPECIFIC INHIBITION OF GPIbα SHEDDING IMPROVES POST-TRANSFUSION RECOVERY AND ADHESIVE FUNCTION OF OUTDATED HUMAN APHERESIS PLATELETS
Xi Liang, Yue Tao, Anum Syed, Paula Jessup, William Church, Cassandra Josephson, Xi Mo, Renhao Li* (United States)

17:00 – 17:15
AS052
THE GLOBAL IMPACT OF PATHOGEN REDUCTION SYSTEMS ON THE PLATELET MRNA TRANSCRIPTOME, ANALYSED BY DIFFERENTIAL EXPRESSION OF RNA-SEQ DATA
Abdimalijid Osman*, Walter Hitzler, Patrick Provost (Sweden)

Innovation and Technology Room 709

Moderators: Deborah Siegal (Canada), Benjamin Brenner (Israel)

15:45 - 16:15
AS053
HIGH THROUGHPUT MICROFLUIDICS
Shaun Jackson (Australia)

16:15 – 16:35
AS054
WHOLE EXOME SEQUENCING IN PATIENTS WITH INHERITED THROMBOCYTOPENIA AND EXCESSIVE BLEEDING IS AN EFFICIENT WAY TO IDENTIFY GENETIC VARIANTS IN KNOWN AND NOVEL GENES
Ben Johnson*, Gillian Lowe, Michael Simpson, Isabel Sánchez Guiú, Sian Drake, David MacDonald, Danai Bem, Sarah Fletcher, Jane Füttner, Vincenzo Leo, Marie Lordkipanidze, Ban Dawood, Tina Biss, Paula Bolton-Maggs, Peter Collins, Nicola Curry, Mike Makris, Jayashree Motwani, Sue Pavord, Katherine Talks, Jecko Thacil, Jonathan Wilde, Mike Williams, Paul Harrison, Paul Gissen, Stuart Mundell, Andrew Mumford, Martina Daly, Steve Watson, Neil Morgan (United Kingdom)

16:35 – 16:55
AS055
A NOVEL PLATFORM TO STUDY THE MECHANO-SENSING MECHANISM ON A SINGLE ASPIRED PLATELET
Lining Ju*, Yunfeng Chen, Shaun Jackson, Cheng Zhu (United States, Australia)

16:55 – 17:15
AS056
FACTOR XA OVERCOMES INHIBITION BY THE DIRECT FACTOR XA-INHIBITORS FOLLOWING INSERTION OF A STRUCTURAL ELEMENT FROM THE SERINE PROTEASE DOMAIN OF SNAKE VENOM FACTOR XA
Daniel Verhoef*, Mark Schreuder, Carlijn van der Sluijs, Ka Lei Cheung, Xiaoxun Yang, Pieter Reitsma, Mettine Bos (The Netherlands)

Poster with refreshments 17:15 - 18:30 in the Exhibition on Level 800

Technical Sessions
The Technical Session Programs are in the Show Guide. Please consult the different options to attend the session of your choice.
SCIENTIFIC PROGRAM

Monday, June 22, 2015
POSTER SESSION 17:15-18:30

Posters will be presented on different days during the Congress and are accessible at the same times as the exhibition opening hours. The official poster sessions with refreshments will take place as follows:

Monday, June 22, 2015, from 17.15-18.30
Tuesday, June 23, 2015, from 18.00-19.30
Wednesday, June 24, 2015, from 17.15-18.30

The Poster Area is located inside the Exhibition on Level 800.

Poster setup times are as follows:

Monday, June 22, 2015, from 07.30 - 09.15
Tuesday, June 23, 2015, from 07.30 - 09.15
Wednesday, June 24, 2015, from 07.30 - 09.15

Poster dismantling times are as follows:

Monday, June 22, 2015, from 18.30 - 19.00
Tuesday, June 23, 2015, from 19.30 - 20.00
Wednesday, June 24, 2015, from 18.30 - 19.00

Posters not taken down after the dismantling time will be discarded.

If you have sent your poster to the poster printing service, kindly note that you will be able to pick it up at the Poster Booth located in the Swing Space on Level 800.

Poster Booth opening times are:

Monday, June 22, 2015, from 07.30 - 19.00
Tuesday, June 23, 2015, from 19.30 - 20.00
Wednesday, June 24, 2015, from 18.30 - 19.00

Pins are provided on the poster boards directly.

ANGIOGENESIS/VASCULOGENESIS

ADAMTS13

PO001-MON  PROTECTIVE EFFECT OF ADAMTS13 HAPLOTYPE ON CORONARY ARTERY DISEASE
Surakanya Lasom*, Nantarat Komanasin, Nongnuch Settasatian, Chatri Settasatian, Upa Kukongviriyapan, Vichai Senthong, Pongsak Intharapetch (Thailand)

PO002-MON  AN UNBALANCE BETWEEN VON WILLEBRAND FACTOR AND ADAMTS13 FOLLOWING A MAJOR PARTIAL HEPATECTOMY
Dafna Groeneveld*, Edris Alkozai, Jelle Adelmeijer, Robert Porte, Ton Lisman (The Netherlands)

PO003-MON  THE NOVEL C.774_775 INS CCGCGCC MUTATION COMBINED WITH C.4085 T>A IN THE ADAMTS13 GENE CONTRIBUTES TO THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
Juvenal Paiva*, Ana Kempfer, Adriana Woods, Maria Casinelli, Ana Maria Sanchez-Luceros, Maria Lazzari (Argentina)

PO004-MON  THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN A MEMBER OF A FAMILY WITH ADAMTS13 GENE ABNORMALITIES
Juvenal Paiva*, Ana Kempfer, Adriana Woods, Maria Casinelli, Fabiana Alberto, Alicia Blanco, Maria Lazzari, Ana Maria Sanchez-Luceros (Argentina)

CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) CAUSED BY COMPOUND HETEROZYGOSITY OF C.1225C>T AND A NOVEL C.2321DELG ADAMTS13 GENE MUTATIONS
Ana Kempfer, Juvenal Paiva*, Adriana Woods, Ana Maria Sanchez-Luceros, Maria Lazzari (Argentina)

QUALITY ASSESSMENT FOR ADAMTS-13 TESTING: A CANADIAN EXPERIENCE
Arnaud Bonnefoy*, Michael Keeney (Canada)

PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS: THE ROLE OF ADAMTS13
Raimondo De Cristofaro*, Maria Basso, Vito Veca, Stefano Lancellotti, Laura Riccardi, Maurizio Pompili (Italy)

IMPORTANCE OF MONITORING ACTIVITY AND ANTI-ADAMTS-13 ANTIBODIES LEVELS IN PREGNANCY WITH SEVERE PREECLAMPSIA HISTORY
Victoria Bitsadze*, Svetlana Akinshina, Ekaterina Zhuravleva, Alexander Makatsaria (Russian Federation)

PAR1-STIMULATED PLATELETS ENHANCE ANGIOGENIC ACTIVITIES OF ENDOTHELIAL PROGENITOR CELLS MORE POTENTLY THAN PAR4-STIMULATED PLATELETS
Zhangsen Huang, Xinyan Miao, Yun Luan, Feng Kong, Nainli Li* (Sweden)

DEVELOPMENT OF AN EX OVO CHICKEN EMBRYO MODEL FOR MEASURING TRACTION FORCES DURING IN VIVO ANGIOGENESIS
Sandra Baker-Groberg*, Dobryna Zalvidea, Arlyng Gonzalez, Xavier Trepat, Owen McCarthy (United States)

MICRORNA-126 REDUCES BLOOD-RETINAL BARRIER BREAKDOWN IN OXYGEN-INDUCED RETINOPATHY MOUSE MODEL
Yanay Bai*, Xia Bai, Zhao Yue Wang (China)

STIMULATION OF PAR-1 OR PAR-4 PROMOTES A SIMILAR PATTERN OF PLATELET-MEDIATED ANGIOGENESIS
Julia Etulain, Agustina Mena, Soledad Negrotto, Mirta Schattner* (Argentina)

PLATELET MEMBRANE GLYCOPROTEIN CD151 PROMOTES ENDOTHELIAL PROGENITOR CELL ANGIOGENESIS
Zhangsen Huang*, Gunnar Nilsson, John Pernow, Nainli Li (Sweden)

PROANGIOGENIC PROPERTIES OF FUCOIDAN IS ASSOCIATED WITH RECRUITMENT AND MODULATION OF MACROPHAGE POLARIZATION
Elene Sapharikas*, Amel Mohamadi, Blandine Düzer, Anna Okajczyk, Isabelle Gay-luy-fauvoux, Dominique Helley, Anne-Marie Fischer, Catherine Boisson-Vidal (France)

UNALTERED ANGIOGENESIS-REGULATORY ACTIVITIES OF PLATELETS FROM MILD TYPE 2 DM PATIENTS DESPITE A MARKED PLATELET HYPERREACTIVITY
Xinyan Miao, Wei Zhang, Zhangsen Huang, Nainli Li* (Sweden)
SCIENTIFIC PROGRAM

PO016-MON  HUMAN PLATELET LYSATE GEL (HPLG) SUPPORTS AND STIMULATES ENDOTHELIAL PROGENITOR CELL-DRIVEN VASCULOGENESIS
Giordano Pula*, Tiago Fortunato, Paul DeBank (United Kingdom)

PO017-MON  TF-MEDIATED POSITIVE FEEDBACK CROSS-TALK BETWEEN ENDOTHELIAL CELLS AND PATROLLING CD14+/CD16+ MONOCYTES STIMULATES ANGIOGENESIS
Sonia Espinosa, Gemma Arderiu, Esther Pena, Vladimir Bogdanov, Javier Crespo, Lina Badimon* (Spain)

PO019-MON  PAR2-DEPENDENT SIGNALING VIA SMA3 IN TF-INDUCED ANGIOGENESIS
Gemma Arderiu, Esther Pena, Sonia Espinosa, Lina Badimon* (Spain)

PO020-MON  INCREASE OF REACTIVE OXYGEN SPECIES AND SENESCENCE DOWN THE PROLIFERATIVE RATE OF ENDOTHELIAL PROGENITOR CELLS FROM PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE
José Antonio Alvarado-Moreno*, José Rubicel Hernandez-López, María Antonieta Chávez-González, Mervin C. Yoder, Irma Isordia-Salas, Jesús Hernández-Juárez, Abraham Majluf-Cruz (Mexico)

Animal models I

PO021-MON  PLASMIN, NOT THROMBIN, ACTIVATES COMPLEMENT IN ARTERIAL AND VENOUS THROMBOSIS
Jonathan H. Foley*, Bethany Walton, Alice O’Byrne, Victor Lei, Kimberly Foley, Jay Degen, Alisa Wobberg, Edward Conway (Canada, United Kingdom)

PO022-MON  ESTABLISHMENT OF A VASCULAR INJURY MODEL DEMONSTRATING DIFFERENT EFFICACIES OF ANTITHROMBOTIC AGENTS ON THROMBUS FORMATION IN MICE
Chaojun Tang*, Daoxi Lei, Lu Huang, Guixue Wang, Li Zhu (China)

PO023-MON  FERRIC CHLORIDE-INDUCED VENOUS THROMBOSIS MODEL IN RATS: FINDING THE OPTIMAL CONCENTRATION OF FERRIC CHLORIDE
Polina Alekseeva*, Natalia Pilukhina (Russian Federation)

PO025-MON  CLOTH CONTRACTION AND POLYHEDROCYTES IN CLOTS FORMED AFTER SAPHENOUS VEIN PUNCTURE IN THE MOUSE
John W. Weisel*, Chandrasekaran Nagaswami, Iyun Xu, Irina Chernysh, Zelda de Lange, Sofia Kosolapova, Lilley Leong, Katalin Kaiser, Derek Sim (United States)

PO027-MON  BENEFICIAL THERAPEUTIC PROPERTIES OF DIETARY ALPHA-LINOLENIC ACID (ALA) IN A MOUSE MODEL OF SICKLE CELL DISEASE
Simona Stivala*, Sara Gobbato, Martin Reiner, Thomas Lüscher, Jürg Beer (Switzerland)

PO028-MON  RABBIT MODEL OF FERRIC CHLORIDE-INDUCED CAROTID ARTERIAL THROMBOSIS OPTIMIZED FOR TRANSLATIONAL DRUG DISCOVERY
Xinkang Wang*, Stan Kurowski, Xueping Zhou, Weizhen Wu, Michael Wismer, Lin Chu, Dietmar Seiffert (United States)

PO029-MON  DISSECTION OF THE THERAPEUTIC EFFICACY OF FIX-TRIPLE FOR REDUCING HAEMOPHILIC ARTHROPATHY IN HEMOPHILIA B USING A BLOOD-INDUCED JOINT INJURY MURINE MODEL
Guan-Ying Zheng*, Shu-Jhu Yang, Chun-Yu Chen, Mi-Hua Tao, Yu-Chen Hsu, I-Shing Yu, Sh-Feng Yang, Shu-Wha Lin (Taiwan)

Antiphospholipid syndrome I

PO030-MON  STANDARDIZING ENOXAPARIN DOsing IN MOUSE MODELS OF DEEP VEIN THROMBOSIS
Joshua Rainey, Kelsey Kus, Daniel Myers, Shirley Wobleski, Diana Farris, Angela Hawley, Thomas Wakefield, José A. A. Dia* (United States)

PO031-MON  GENERATION OF HEMOPHILIA B MICE IN NSG BACKGROUND USING CRISPR/CAS9 TECHNOLOGY
Meng-Ni Fan*, Shu-Wha Lin (China)

PO032-MON  ACUTE BONE LOSS IN FVIII AND FIX BUT NOT VWF DEFICIENT MICE FROM JOINT INJURY
Ted Bateman*, William Hanna, Anthony Lau, Eric Livingston, Junjiang Sun, Dominique Heymann, Paul Monahan (United States)

PO033-MON  ENOXAPARIN ACUTELY WORSENS HEMODYNAMIC MEASUREMENTS COMPARED WITH TPA IN A LARGE ANIMAL MODEL OF SUBMASSIVE PULMONARY EMBOLISM
Daren M. Beam*, Jeffrey Kline, Evandro Neto-Neves (United States)

PO034-MON  GENOME-WIDE KNOCKDOWNS IN ZEBRAFISH TO STUDY THROMBOCYTE FUNCTION
Pudur Jagadeeswaran, Hemalatha Sundaramoorthi*, Gauri Khandekar (United States)

POSTERS

MONDAY

SCIENTIFIC PROGRAM

PO029-MON  DISSECTION OF THE THERAPEUTIC EFFICACY OF FIX-TRIPLE FOR REDUCING HAEMOPHILIC ARTHROPATHY IN HEMOPHILIA B USING A BLOOD-INDUCED JOINT INJURY MURINE MODEL
Guan-Ying Zheng*, Shu-Jhu Yang, Chun-Yu Chen, Mi-Hua Tao, Yu-Chen Hsu, I-Shing Yu, Sh-Feng Yang, Shu-Wha Lin (Taiwan)

PO030-MON  STANDARDIZING ENOXAPARIN DOSING IN MOUSE MODELS OF DEEP VEIN THROMBOSIS
Joshua Rainey, Kelsey Kus, Daniel Myers, Shirley Wobleski, Diana Farris, Angela Hawley, Thomas Wakefield, José A. A. Dia* (United States)

PO031-MON  GENERATION OF HEMOPHILIA B MICE IN NSG BACKGROUND USING CRISPR/CAS9 TECHNOLOGY
Meng-Ni Fan*, Shu-Wha Lin (China)

PO032-MON  ACUTE BONE LOSS IN FVIII AND FIX BUT NOT VWF DEFICIENT MICE FROM JOINT INJURY
Ted Bateman*, William Hanna, Anthony Lau, Eric Livingston, Junjiang Sun, Dominique Heymann, Paul Monahan (United States)

PO033-MON  ENOXAPARIN ACUTELY WORSENS HEMODYNAMIC MEASUREMENTS COMPARED WITH TPA IN A LARGE ANIMAL MODEL OF SUBMASSIVE PULMONARY EMBOLISM
Daren M. Beam*, Jeffrey Kline, Evandro Neto-Neves (United States)

PO034-MON  GENOME-WIDE KNOCKDOWNS IN ZEBRAFISH TO STUDY THROMBOCYTE FUNCTION
Pudur Jagadeeswaran, Hemalatha Sundaramoorthi*, Gauri Khandekar (United States)
SCIENTIFIC PROGRAM

PO038-MON
A MULTICONTROL KIT FOR ANTIPHOSPHOLIPID AND ANTI-PLATELET FACTOR 4-HEPARIN ANTIBODIES: NINE DIFFERENT ANALYSES IN A SINGLE VIAL
Josep Puig*, Fernando Cavalcanti, Raquel Torres, Sandra Matilla, Josep Serra (Spain)

PO039-MON
PERSISTENT LUPUS ANTICOAGULANT IN CLINICAL SETTINGS OTHER THAN ANTIPHOSPHOLIPID SYNDROME
Lucia Remotti*, Silvia Grosso, Marcelo Ingratti, Maria Vera Morandini, Emilese Bermejo, Analía Sanchez Luceros, Susana Meschengieser, Maria Lazzari, Alicia Blanco (Argentina)

PO040-MON
HOW APPROPRIATE IS THE ANTIPHOSPHOLIPID ANTIBODIES TESTING AT SIRIRAJ HOSPITAL?
Yingyong Chinthammitr*, Thanitsak Thaweekhot, Panutsaya Tientadakul, Chaicharoen Tantanate (Thailand)

PO041-MON
THROMBOMODULIN DOWN-REGULATION IS RELATED TO THE THROMBOSIS RISK IN ANTIPHOSPHOLIPID SYNDROME PATIENTS
Osamu Kumano*, Masahiro Ieko, Sumiyoshi Naito, Mika Yoshida, Nobuhiko Takahashi, Takeshi Suzuki, Takashi Aoki (Japan)

PO042-MON
USE OF D DIMER IN BIOLOGICAL CONTROL OF PREGNANCY
Ana Otero, Ana M. Lena*, Elena De Lisa, Datevig Attarian, Enrique Pons, Ricardo Pou, Nora Mota, Gabriela Dominguez, Sebastián De Los Santos, Cecilia Carrizo (Uruguay)

PO043-MON
ANTI-ANNEXIN V ANTIBODIES IN PATIENTS WITH OBSTETRIC MORBIDITY
Alberto Maneyro*, Susana Ouviña, Laila Noya, Luis Palmer (Argentina)

PO044-MON
INTERACTIONS BETWEEN RIVAROXABAN AND ANTIPHOSPHOLIPID ANTIBODIES IN THROMBOTIC ANTIPHOSPHOLIPID SYNDROME
Deepa Jayakody Arachchilage*, Ian Mackie, Maria Ethhymiou, David Isenberg, Samuel Machin, Hannah Cohen (United Kingdom)

PO045-MON
PROPOSED TRIAL: HYPATIA - A PROSPECTIVE RANDOMISED CONTROLLED TRIAL OF HYDROXYCHOROQUINE VERSUS PLACEBO DURING PREGNANCY IN WOMEN WITH ANTIPHOSPHOLIPID ANTIBODIES
Karen Schreiber*, Savino Sciascia, Karen Breen, Soren Jacobsen, Roy Farquharson, Saskia Middeleandro, Lesley Regan, Beverley Hunt (United Kingdom, Denmark)

PO046-MON
RIVAROXABAN LIMITS COMPLEMENT ACTIVATION IN PATIENTS WITH THROMBOTIC ANTIPHOSPHOLIPID SYNDROME
Deepa Jayakody Arachchilage*, Ian Mackie, Maria Ethhymiou, Andrew Chitolie, Beverly Hunt, David Isenberg, Munther Khamasha, Samuel Machin, Hannah Cohen (United Kingdom)

PO047-MON
ANALYTICAL AND CLINICAL PERFORMANCE OF A NEW AUTOMATED CHEMILUMINESCENT ASSAY (CIA)
Teresa Iwaniec*, Marcin Kaczor, Magdalena Celinska-Lowenhoff, Stanislaw Polanski, Jacek Musial (Poland)

PO048-MON
FALSE POSITIVE RESULTS OF PLATELET NEUTRALIZATION PROCEDURE (PNP) IN LUPUS ANTICOAGULANT (LA) TESTING OF PATIENTS WITH COAGULATION FACTOR DEFICIENCIES
Geoffrey D. Wool*, Krzysztof Mikrut, Jonathan Miller (United States)

POSTERS

PO050-MON
FREQUENCY OF CLINICALLY SIGNIFICANT ANTIPHOSPHOLIPID ANTIBODIES PROFILE IN PATIENTS WITH VENOUS THROMBOEMBOLISM, STROKE, MYOCARDIAL INFARCTION, PERIPHERAL ARTERIAL DISEASE AND PREGNANCY MORBIDITY
Benilde Cosmi*, Cristina Legnani, Michela Cini, Guilio Palaireli (Italy)

PO051-MON
CLINICAL ASSESSMENT OF ANTIPHOSPHOLIPID ANTIBODIES AGAINST β2-GLYCOPEPTIDE DOMAIN I IN ANTIPHOSPHOLIPID SYNDROME.
Pascual Marco*, Ana Marco, Virgilio Cabrera, Vanessa González (Spain)

PO052-MON
MULTIPLE POSITIVITY AND APA PROFILE IN WOMEN WITH FETAL LOSS SYNDROME
Natalya Makatsariya, Nadezhda Stuleva, Jamila Khizoeva* (Russian Federation)

Antiplatelet agents I

PO054-MON
IMPACT OF PREANALYTICAL DELAY ON RESULTS OF LIGHT TRANSMISSION AGGREGOMETRY IN STEMI PATIENTS
Anna Vybitantsvea*, Olga Demkova, Natalia Seraeva, Larisa Koryakina, Elena Andreeva, Galina Lifshits, Konstantin Apatsrin (Russian Federation)

PO055-MON
ASSOCIATION OF PLATELET RESPONSE TO CILOSTAZOL WITH CLINICAL OUTCOME AND CYP GENOTYPES IN PATIENTS WITH CEREBRAL INFARCTION
Jun Yamamouchi*, Takaaki Hato, Masaki Yasukawa (Japan)

PO056-MON
PLATELET REACTIVITY BASED RISK ASSESSMENT FOR PATIENTS WITH CORONARY ARTERY DISEASE ON P2Y12 INHIBITORS IS NOT CONSISTENT BETWEEN DIFFERENT PLATELET FUNCTION TESTS

PO057-MON
PLATELET FUNCTION TESTING IN ACS PATIENTS USING MEASUREMENT OF PLATELET P-SELECTIN: COMPARISON WITH OTHER COMMERICAL TESTS
Jane May*, Natalia Dovlatova, Ashwin Radhakrishnan, Stan Heptinstall, Sue Fox (United Kingdom)

PO058-MON
EFFECTICITY OF PRASUGREL ADMINISTRATION IMMEDIATELY AFTER PERCUTANEOUS CORONARY INTERVENTION IN ACUTE MYOCARDIAL INFARCTION
Andreas Schäfer*, Ulrike Flierl, Johanna Bauersachs (Germany)

PO059-MON
THE ANTITHROMBOTIC EFFECTS OF SYNTHETIC POLYPEPTIDES DERIVED FROM SNACLECS: INVOLVEMENT OF PLATELET GLYCOPROTEIN VI ANTAGONISM
Chien-Hsin Chang*, Ching-Hu Chung, Chun-Chieh Hsu, Tur-Fu Huang (Taiwan)

PO060-MON
CORRELATION BETWEEN PLATELET MRP4 EXPRESSION AND PLATELET FUNCTION IN PATIENTS UNDER CHRONIC ASPHRIN TREATMENT
Isabella Massimi*, Flavia Temperillli, Maria Luisa Guarino, Teresa Maltese, Lavinia Vittoria Lotti, Luigi Frati, Fabio Maria Pulcinelli (Italy)
SCIENTIFIC PROGRAM

PO061-MON PLATELET FUNCTION MONITORING IN PATIENTS ON DUAL ANTIPLATELET THERAPY UNDERGOING URGENT HIP SURGERY: PRELIMINARY RESULTS.
Luca Spiezia*, Francesco Vasques, Astrid Behr, Elena Campello, Sara Maggiolo, Paolo Simioni (Italy)

PO062-MON PLATELET REACTIVITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION CHRONICALLY TREATED WITH BETA-BLOCKERS BEFORE THE ONSET OF THE ACUTE EVENT.
Maria T. Santos*, Antonio Moscardó, Ana Latorre, Isabel Madrid, Maria Paz Fuset, Juana Valles (Spain)

PO063-MON PROTEOMIC PROFILING OF PLATELET RESPONSE TO ANTIPLATELET AGENTS REVEALS A WIDE INTER-INDIVIDUAL VARIABILITY AND DISTINCT SIGNATURES OF DRUGS ALONE AND IN COMBINATION
Simone Marcone*, Desmond Fitzgerald (Ireland)

PO064-MON DUAL ANTIPLATELET THERAPY COMBINING ASPIRIN AND TICAGRELOR IN INTRACRANIAL ANEURYSMAL EMBOLIZATION. A 13-MONTH FRENCH EXPERIENCE.
Ana Paula Narata, Yves Gruel*, Denis Angoulvant, Denis Herbreteau (France)

PO065-MON INHIBITION OF THIOREDOXIN INHIBITS GPVI-MEDIATED PLATELET ACTIVATION
Clive Metcalfe, Anjana Ramasubramoni, Giordana Pula, Matthew Harper, Stuart Mundell, Carmen Coxon* (United Kingdom)

PO066-MON PREDICTION OF HIGH ON-TREATMENT PLATELET REACTIVITY IN CLOPIDOGREL-TREATED PATIENTS WITH ACUTE CORONARY SYNDROMES, USING ADVANCED ARTIFICIAL NEURAL NETWORKS
Gian Marco Podda*, Enzo Grossi, Tullio Palmerini, Massimo Buscema, Eti A. Femia, Andrea Mariani, Diego Della Riva, Marco Cattaneo (Italy)

PO069-MON ADAMTS13 AND THE RISK OF MYOCARDIAL INFARCTION: AN INDIVIDUAL PATIENT DATA META-ANALYSIS
Alberto Maino*, Bob Siegerink, Luca Lotta, James Crawley, Saskia Le Cessie, Frank Leebeek, David Lane, Gordon Lowe, Flora Peyvandi, Frits Rosendaal (United Kingdom)

Arterial vascular disorders - clinical I

SCIENTIFIC PROGRAM

PO070-MON DIVERSE EFFECTS OF PAI-1 ON VASCULAR SMOOTH MUSCLE CELLS PHENOTYPE SWITCH
Xin Deng*, Mao Luo, Rong Li, Meiping Ren, Ni Chen, Kai Yan, Min Zeng, Jianbo Wu (China)

PO071-MON RETINAL VESSEL CALIBERS AND HAEMOSTASIS IN BLACK AND WHITE SOUTH AFRICANS: THE SABPA STUDY
Leandi Lammertyn*, Aletta Schutte, Wayne Smith, Marlien Pieters, Rudolph Schutte (South Africa)

PO072-MON PROGNOSTIC VALUE OF THE CHA2DS2VASC SCORE IN PATIENTS EXPERIENCING A MYOCARDIAL INFARCTION
Serenella Conti*, Maria Cristina Vedovati, Roberta Molle, Giorgio Maragioni (Italy)

PO073-MON GENETIC RISK FACTORS ONATHEROTHROMBOTIC DISEASE: COMPARISON BETWEEN TWO TERRITORIES.
Irina Isordia-Salas*, Lorena Mendoza-Valéz, José Antonio Alvarado-Moreno, David Santiago-Germán, María Guadalupe Valades-Mejía, Jesús Hernández-Juárez, Rosa Maria Jiménez-Alvarado, Abraham Majul-Cruz (Mexico)

PO074-MON CARDIOLOGICAL AND THROMBOPHILIC RISK PROFILE IN PATIENTS WITH OCULAR ARTERIAL OCCLUSION
Jerzy Dropinski*, Agnieszka Kubicka-Trzaska, Teresa Domagala, Marek Sanak, Teresa Iwaniec, Jakeck Musial (Poland)

PO075-MON A NOVEL ASSAY DEMONSTRATES PROCOAGULANT PLATELETS ARE INCREASED IN PATIENT UNDERGOING CORONARY ANGIOGRAPHY WITH DIFFERENTIAL EFFECTS BY ANTI-PLATELET AND ANTI-COAGULANT THERAPY
Leonardo Pasalic*, Heather Campbell, Edwina Wing-Lun, Philip Hogg, David Connor, David Muller, Vivien Chen (Australia)

PO076-MON RELATION BETWEEN INVASIVE CENTRAL PULSE PRESSURE AND THROMBOGENICITY
Gailing Chen, Kevin Blinken, Fang Liu, Udaya Tantry, Paul Gurbel* (United States)

PO077-MON DRUG-ELUTING CORONARY STENTS GENERATE LOWER LEVEL OF CELLULAR ACTIVATION COMPARED TO BARE METAL STENTS IN STABLE ANGINA PATIENTS
Béla Nagy Jr*, Tibor Szik, Ildikó Debreceni, Zsolt Fejes, Adrienne Kerényi, István Édes, János Kappelmayer (Hungary)

PO078-MON NEUTROPHIL EXTRACELLULAR TRAPS IN CORONARY ARTERY THROMBI IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Anouchska Autar*, Mie Kurata, Danielle Mensink, Evelyn Regar, Marco Valgimigli, Frank Leebeek, Felix Zijlstra, Moniek De Maat, Heleen Van Beusekom (The Netherlands)

PO079-MON ASSOCIATION BETWEEN GLUCOMETABOLIC CONTROL AND DEGREE OF HYPERCOAGULABILITY IN PATIENTS WITH COMBINED TYPE 2 DIABETES MELLITUS AND CORONARY HEART DISEASE.
Vibeke Bratset*, Rune Byrkjeland, Svein Solheim, Harald Arnesen, Ingebjørg Seljefflot (Norway)
PO079-MON

THE COBALT-CHROMIUM ALLOY COMPOSING STENT IS THROMBOGENIC
Veronique Ollivier*, Caroline Roques, Elmina Mammadova-Bach, Matthias Gratz, Christopher Gachet, Didier Letourneur, Pierre Mangin, Martine Jandrot-Perrus (France)

PO080-MON

ASSOCIATION OF ABCB1 C3435T POLYMORPHISM WITH BLOOD GLUCOSE LEVELS AND RISK OF CORONARY ARTERY DISEASE IN THAIS
Sornsith Jurinuda*, Nantarut Komasanin, Nongnuch Settasatian, Chatri Settasatian, Upa Kukongwiriyapan, Pongsak Inharapetch, Vichai Senthong (Thailand)

PO081-MON

UNDERSTANDING GENE EXPRESSION IN CORONARY ARTERY DISEASE THROUGH GLOBAL PROFILING, NETWORK ANALYSIS AND INDEPENDENT VALIDATION OF KEY CANDIDATE GENES
Prathima Arvind* (India)

PO082-MON

INSIGHTS INTO THE GENETIC ARCHITECTURE OF CORONARY ARTERY DISEASE IN ASIAN INDIANS
Jiny Nair*, Prathima Arvind, Jayashree Shanker, Vijay Kakkar (India)

PO083-MON

CIRCULATING LYMPHOCYTES AND MONOCYTES AS RISK FACTORS FOR CORONARY ARTERY DISEASE IN INDIAN POPULATION
Thiruvelselvan Ponnusamy, Srikanth Venkatachala, Manjunatha Ramanjappa, Vijay Kakkar, Lakshmi Mundkur* (India)

PO084-MON

TRANSLATIONAL INFORMATICS APPROACH LINKING RISK OF CORONARY ARTERY DISEASE, INFECTION AND INFLAMMATION
Rajani Kanth Vangala, Ankith Sharma*, Madanakumar Ghatge (India)

PO085-MON

IDENTIFICATION OF NOVEL GENETIC MUTATIONS IN LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR) GENE CAUSING FAMILIAL HYPERCHOLESTEROLEMIA IN SAUDI ARAB HOMOZYGOUS CHILDREN
Faisal A. Al-Allaf*, Mohammad Athar, Zainularifeen Abduljaleel, Mohiuddin Taher, Abdellatif Bouazzaoui, Halah Abalkhail, Rakan Own, Ahmad Al-Allaf, Iman AboMansoor, Zoher Azhar, Faisal Ba-hammam, Abdullah Alashwal (Saudi Arabia)

PO086-MON

ROLE OF R5498300 AND R53781590 LRPS GENE AND RS1466535 LRPI GENE POLYMORPHISMS IN THE COHORT OF THE PROSPECTIVE MONTIGNOSO STUDY
Alice Serrini*, Bettì Giusti, Francesco Sofì, Claudia Saracini, Silvia Galora, Rosina De Cari, Daniele Della Latta, Dante Chiappino, Gian Franco Gensini (Italy)

PO087-MON

ACTIVE THROMBIN ASSAY FOR IMPROVED TREATMENT OF THROMBOSIS
Vera Ignjatovic, Leslie Berry, Anthony Chan, Paul Monagle* (Australia)

PO088-MON

ACCURATE RECOVERY OF PEGYLATED AND NON-PEGYLATED THERAPEUTIC FVIII, USING A SPECIFIC APTT REAGENT, AND APPLICATION ON AN AUTOMATED COAGULATION ANALYZER
Mary J. Doyle*, Anuja Khan, Karen DiStasio, Alexandra Sullivan, Mark Triscott (United States)

PO089-MON

THROMBIN GENERATION CAPACITY AND PHENOTYPIC ASSOCIATION IN ABO BLOOD GROUPS
Romy Kremers*, Abdulrahman Mohamed, Leonie Pelmans, Salwa Hindawi, Coenraad Hemker, Bas de Laat, Dana Huskens, Raed Al Dien (The Netherlands)

PO090-MON

HAEMOSTASIS IN CARDIAC ARREST PATIENTS TREATED WITH THERAPEUTIC HYPOTHERMIA
Anne Katrine Wulff Nielsen*, Anni Jeppesen, Hans Kirkegaard, Anne-Mette Hvas (Denmark)

PO091-MON

IS TGA ABLE TO DISCRIMINATE A DIFFERENT COAGULATION PROFILE IN INHIBITOR PATIENTS WITH SEVERE HEMOPHILIA A AS COMPARED TO NON-INHIBITOR PATIENTS?
Maria Elisa Mancuso*, Veena Chantarangkul, Marigrazia Clerici, Maria Fasulo, Lidia Padovan, Erica Scalambro, Fma Fleravandi, Armando Tripodi, Elena Santagostino (Italy)

PO092-MON

IMPACT OF EDOXABAN ON A LARGE PANEL OF ROUTINE OR MORE SPECIFIC COAGULATION ASSAYS
Jonathan Douxfils*, Tania Del Bianco, Justine Baudar, Sarah Lessire, Bernard Chatelain, Jean-Michel Dogné, François Mullier (Belgium)

PO093-MON

MODIFICATION OF A THROMBIN GENERATION TEST TO IDENTIFY NEW COFACTORS OF THE PROTEIN C PATHWAY IN PLASMA
Laura Martos, Hiroshi Deguchi, Elena Bonet, Pilar Medina, Luis A Ramon, Saturnino Haya, Ana R Cid, Santiago Bonanad, John H Griffin, Francisco España, Silvia Navarro* (Spain)

PO094-MON

PRELIMINARY PERFORMANCE DATA OF A NEW ASSAY FOR THE QUANTITATIVE DETERMINATION OF THE ACTIVITY OF UNFRACTIONATED HEPARIN (UHF) AND LOW MOLECULAR WEIGHT HEPARIN (LMWH) USING A SINGLE CALIBRATION CURVE FOR BOTH TYPES OF HEPARIN*
Matthias Wilkens*, Beate Becker-Scheidemann, Anja Borchert, Sabine Halliövic, Anja Hecker, Regina Hoffmann, Irene Jennennann-Watzka, Markus Muth, Ruth Neunziger, Juergen Patzke, André Scheidler, Stephanie Schmidt, Bettina Wecht, Andrea Lichte (Germany)

PO095-MON

PROVISION OF EXTERNAL QUALITY ASSURANCE FOR THROMBOELASTOGRAPHY (TEG) AND THROMBOELASTOMETRY (ROTEM)
Dianne P. Kitchen*, Shelene Munroe-Peart, Ian Jennings, Steve Kitchen, Tim Woods, Isabel Walker (United Kingdom)

PO096-MON

ANTICOAGULATION ASSESSMENT WITH PROTHROMBIN TIME AND ANTI-XA ASSAYS IN REAL-WORLD PATIENTS ON TREATMENT WITH RIVAROXABAN
Oliver Königsbrügge*, Peter Qwenenberger, Sabine Belik, Günter Weigel, Christoph Seger, Andrea Griesmacher, Ingrid Pabinger, Cihan Ay (Austria)
SCIENTIFIC PROGRAM

PO097-MON
GLOBAL HEMOSTASIS ASSAYS THROMBOELASTOGRAPHY AND THROMBODYNAMICS EVALUATE HYPERCOAGULATION IN CHILDREN WITH HEMOLYTIC ANEMIA
Elena A. Seregina*, Janna Kuzminova, Alexander Poletaev, Asmik Sepoyan, Fazool Ataullakhanov, Natalya Smetanina, Anna Balandina (Russian Federation)

PO098-MON
CLINICALLY IMPORTANT DIFFERENCES IN PHARMACODYNAMIC EFFECTS OF RIVAROXABAN AND APIXABAN
Ross I. Baker*, Roza Szollosi, Scott McGregor (Australia)

PO099-MON
MONITORING NEW ORAL ANTICOAGULANTS (NOACS) USING NEW-GENERATION THROMBOELASTOGRAPHY TEG®6S SYSTEM
Kevin Bidden, Adina Muresan, Gabriel Raviv, Eli Cohen, Fowzia Zaman, Katayoon Saadin, Nafees Mohammed, Rahul Chaudhary, Rahil Rafeedheen, Udaya Tantry, Paul Gurbel* (United States)

PO100-MON
IN VITRO MODELS OF THROMBOSIS USING HUMAN WHOLE BLOOD UNDER FLOW CONDITIONS
Lewis Hardy*, Emma Hethershaw, Helen Philippou (United Kingdom)

PO101-MON
FXI11618, A NEW FACTOR XII INHIBITOR: VALIDATION FOR THROMBIN GENERATION ASSAY
Sara Calzavarini*, Vanessa Baeriswyl, Claudia Quarroz, Christian Heinis, Anne Angelillo-Scherrer (Switzerland)

PO102-MON
PF4-R, A NOVEL HEPARIN NEUTRALIZING REAGENT SUITABLE FOR AUTOMATED COAGULOMETERS: COMPARISON WITH HEPARINASE IN ROUTINE COAGULATION TESTS
Steven Raynard*, Ali Sadeghi-Khomami, Zhou Hui (Canada)

PO103-MON
GLOBAL ASSAYS DO NOT PREDICT BLEEDING PHENOTYPE IN HEMOPHILIA A.
Marilyn J. Manco-Johnson*, Taylor Blades, John Kittelson, Elizabeth Vil-lalobos-Menuet, Linda Jacobson (United States)

PO104-MON
TESTING AN IN VITRO MODEL OF LAMINAR FLOW FOR USE IN LARGE-SCALE APTAMER SCREENING
Laura Sommerville*, George Pitoc, Bruce Sullenger, Maureane Hoffman (United States)

SCIENTIFIC PROGRAM

PO108-MON
MODELISATION OF THE PROCOAGULANT PROPERTIES OF ADENOCARCINOMA PANCREATIC CELLS (BXPC3) AND BREAST CANCER CELLS (MCF7) AND ANALYSIS OF THEIR SPECIFIC INTERACTIONS WITH THE COAGULATION SYSTEM
Aurélie Rousseau, Patrick Van Dreden*, Grigoris Gerotziafas (France)

PO109-MON
EFFECT OF HYPOXIA ON TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION IN BREAST CANCER CELLS
Cui Xue Yan, Benedicte Stavik, Grethe Skretting, Anders Erik Astrup Dahm, Nina Iversen, Sebastian Seidl, Sandip Kanse, Per Morten Sandset (Norway)

PO110-MON
THE THROMBOTIC POTENTIAL OF CIRCULATING TUMOR MICROEMBOLI
Anichanira Mitrugno*, Kevin Phillips, Michael King, Siddhardh Chandrasekaran, Paul Newton, Peter Kuhn, Craig Williams, Owen McCarty (United States)

PO111-MON
FIBRIN DEGRADATION BY RTPA IMPROVES NANO- PARTICLE DRUG DELIVERY FOR TUMORS
Bo Zhang*, Yu Hu (China)

PO112-MON
HUMAN ANGIOSARCOMA CELLS EXPRESS TISSUE FACTOR AND GENERATE THROMBIN IN A TISSUE FACTOR-DEPENDENT MANNER
Marianne Andresen, Huda Ali, Nina Iversen, Benedicte Stavik, Christiane Myklebust, Per Morten Sandset, Grete Skretting* (Norway)

PO113-MON
ROLE OF AUTOANTIBODIES TO PLASMINOGEN AT ONCOLOGIC DISEASES
Roza Asina*, E. Goufman, V Yakovlev V.N., L Mukhametova, N Tikhonova, K Gershkovich K.B., O Gulin (Russian Federation)

PO115-MON
PROTHROMBOTIC RISK ASSOCIATED WITH INTRAVENOUSLY GIVEN HIGH DOSE VITAMIN C: ANOTHER EVIDENCE WARNING AGAINST THE BLIND FAITH IN VITAMINS?
Keunyoung Kim*, Ok-Nam Bae, Sung-Hee Koh, Seojin Kang, Kyung-Min Lim, Ji-Yoon Noh, Sue Shin, Inho Kim, Jin-Hee Chung (Korea, Republic Of)

PO116-MON
DOXORUBICIN-INDUCED MDR1/P-GP IN MCF-7 BREAST CANCER CELLS WAS ASSOCIATED WITH TISSUE FACTOR OVEREXPRESSION AND THROMBIN GENERATION
Amir Khaterchi*, asmae Karroum, Elisabeth Mbemba, Aurelie Rousseau, Patrick van Dreden, Vasiliki Gkalea, Ismail Elalamy, Mohamed Hatmi, Grigoris Gerotziafas (France)

PO117-MON
ACTIVATED PROTEIN C UP-REGULATES THE OVARIAN CANCER CELL MIGRATION AND PROMOTES UNCLOTTABILITY OF CANCER PERITONEAL FLUID
Hamda Althawadi*, Halema Alfarsi, Shahsoltan Mirshahi, Jean Chidiac, Samaher Besbes, Amu Therwath, Marc Pocard, Jeannette Soria, Massoud Mirshahi (France, Qatar)

PO118-MON
ESTROGENS UPREGULATE TFPI-2 EXPRESSION IN MCF-7 CELLS PROBABLY BY PROMOTER DEMETHYLATION
Marianne Andresen, Huda Alfi, Nina Iversen, Benedicte Stavik, Christiane Myklebust, Per Morten Sandset, Grethe Skretting* (Norway)

PO119-MON
ENDOTHELIAL PROTEIN C RECEPTOR IN BREAST CANCER CELLS, CO-EXPRESSED WITH MULTIDRUG RESISTANCE PROTEIN, INHIBITS FIBRIN FORMATION IN TUMOR MICRO ENVIRONMENT
Halema Alfarsi*, Hamda Althawadi, Shahsoltan Mirshahi, Eiodic Ducros, Amu Therwath, Marc Pocard, Jeannette Soria, Massoud Mirshahi (France, Qatar)
SCIENTIFIC PROGRAM

PO120-MON  CHANGES IN COAGULATION IN ACUTE PROMYELOCYTIC LEUKAEMIA  
Richard Dillon, Kiran Parmar, David Grimwade, Beverley Hunt* (United Kingdom)

PO121-MON  FIBRINOlytic ACTIVATION IN ACUTE PROMYELOCYTIC LEUKAEMIA  
Richard Dillon, Kiran Parmar, David Grimwade, Beverley Hunt* (United Kingdom)

PO122-MON  CONDITIONAL INACTIVATION OF INTEGRIN AV SUBUNIT IN VASCULAR SMOOTH MUSCLE CELLS DECREASES THROMBIN GENERATION IN VESSELS AND BLOOD.  
Amel Mohamadi*, Zhenli Li, Huguette Louis, Mustapha Bouhrim, Patrick Lalcolley*, Véronique Regnault (France)

PO123-MON  OESTROGENS REGULATE TFPI EXPRESSION THROUGH OESTROGEN RESPONSE ELEMENTS IN TFPI 5' FLANKING REGION  
Huda O. Ali*, Benedicte Stavik, Christiane Myklebust, Elisabeth Dørum, Nina Iversen, Per Morten Sandset, Grethe Skretting (Norway)

PO124-MON  MONOCYTIC LEUKEMIA CELL LINES POSSESS ENHANCED PROCOAGULANT ACTIVITY, THE ROLE OF FLT3-ITD MUTATION  
Renáta Hudák*, Erika Debreceni, Gabriella Gál, Péter Antal-Szalmás, János Kappelmayer (Hungary)

PO125-MON  THROUGHIN DRIVES PANCREATIC DUCTAL ADENOCARCINOMA GROWTH AND DISSEMINATION THROUGH MECHANISMS LINKED TO FIBRINOGEN AND PROTEASE-ACTIVATED RECEPTOR-1  
Cheryl Rewerts, Carolina Cruz, Joseph Palumbo, James Luyendyk, Yi Yang, Stephen Konieczny, Matthew Flack* (United States)

PO126-MON  MICROCIRCULATION THROMBOSIS IN BONE: A POSSIBLE MECHANISM FOR BONE PAIN  
Eli Peled*, Mai Assalia, Elena Axelman, Doron Norman, Benjamin Brenner, Yona Nadir (Israel)

PO127-MON  PROCOAGULANT EFFECTS OF LUNG CANCER CHEMOTHERAPY THROUGH RELEASE OF MICROPARTICLES AND CELL-FREE DNA.  
Zakhar Lysov*, Dhruva Dwivedi, Patricia Liaw (Canada)

PO128-MON  THE REED STERNBERG CELL COAGULOMA  
Gabriela N. Cesarman-Maus*, Jonathan Reichel, Mikhail Roshal, Esteban Braggio, Rafael Fonseca, Ethel Cesarman (Mexico)

PO129-MON  FACTOR VII DERIVED PROTEIN EGF-EGF1 MEDIATE DRUG DELIVERY SYSTEM FOR HUMAN TUMOR  
Shi Wei*, Zhang Bo, Hu Yu (China)

PO130-MON  THE ROLE OF M-COMPONENTS AND IMMUNOGLOBULINS IN PATIENTS WITH MULTIPLE MYELOMA - PROCOAGULANT AND PROGNOSTIC?  
Thoger Nielsen*, Henrik Gregersen, Anna-Marie Bloch Münster, Ann Katharina Stausholm-Mellér, Saren Risom Kristensen Risom Kristensen, Shona Pedersen (Denmark)

PO131-MON  HYPOXIA-INDEPENDENT TUMOR PROGRESSION: ACTIVATION OF TRANSCRIPTION FACTOR HIF 1 VIA PAR1 AND PAR2 RECEPTORS IN BREAST CANCER.  
Tainá Gomes*, Robson de Queiroz Monteiro, Sandra Konig (Brazil)

SCIENTIFIC PROGRAM

PO132-MON  THE PHOTODYNAMIC THROMBI-SPECIFIC NANOPARTICLES STARVE SOLID LYMPHOMA TO DEATH  
Yao Wang*, Wei Shi, Bo Zhang, Yu Hu (China)

PO133-MON  NEUTROPHIL EXTRACELLULAR TRAPS MEDIATE ARTERIAL AND VEINOUS THROMBUS FORMATION IN A MURINE BREAST CANCER MODEL  
Robson Q. Monteiro*, Ana Carolina Leal, Natalia Rochael, Susana Ortiz-Costa, Claudio Wernek, Elvira Cristina, Daniella Mizurini (Brazil)

PO134-MON  OESTROGENS REGULATE TFPI EXPRESSION THROUGH OESTROGEN RESPONSE ELEMENTS IN TFPI 5' FLANKING REGION  
Huda O. Ali*, Benedicte Stavik, Christiane Myklebust, Elisabeth Dørum, Nina Iversen, Per Morten Sandset, Grethe Skretting (Norway)

PO135-MON  PROTEOLYTIC INACTIVATION OF COAGULATION FACTOR V BY OMPT FROM ENTEROHEMORRHAGIC ESCHERICHA COLI.  
John A. Samis*, Derek Tilley, Veena Premjani, Samantha Gruenheid, Herve Le Moual, Jeffrey Weitz (Canada)

PO136-MON  COMBINED FV AND FVIII DEFICIENCY (F5F8D) IN A CHINESE FAMILY WITH A NOVEL MISSENSE MUTATION IN MCF2 GENE  
Anyou Wang*, Xin Liu, Jingsheng Wu (China)

PO137-MON  SUCCESSFUL ABDOMINAL OPERATION WITHOUT REPLACEMENT THERAPY IN A PATIENT WITH COMBINED FV AND FVIII DEFICIENCY DUE TO NOVEL HOMOZYGOUS MUTATION IN LM1  
Anyou Wang*, Qiaoqiao Duan, Xin Liu, Jingsheng Wu (China)

PO138-MON  ENGAGEMENT OF THE ACTIVE SITE OF THROMBIN BY DABIGATRAN OR ARGATROBAN MODULATES ITS EXOSIDE-MEDIATED INTERACTIONS WITH FIBRIN AND FACTOR VA  
Calvin Yeh*, Alan Stafford, Beverly Leslie, James Fenidburgh, Jeffrey Weitz (Canada)

PO139-MON  FACTOR VA IN SYNERGY WITH PROTEIN S ENHANCES ACTIVATED PROTEIN C BINDING TO PHOSPHOLIPIDS  
Magdalena Gierula*, Isabelle I. Salles-Crawley, James T.B. Crawley, David A. Lane*, Josef Ahnström (United Kingdom)

PO140-MON  MEMBRANE CHOLESTEROL IS A CRITICAL REGULATOR OF PLATELET-ASSOCIATED PROTHROMBINASE COMPLEX ASSEMBLY  
Laura M. Haynes*, Paula Tracy (United States)

PO141-MON  REFERENCE VALUE AND STABILITY OF FACTOR V  
Rahajuninglish Dharma*, Rudianto Rudianto (Indonesia)

PO142-MON  ACTIVATED FACTOR V INHIBITS THE ACTIVATION OF FACTOR IX BY TISSUE FACTOR/FACtOR VIA COMPLEX  
Dana Huskens*, Minka Vries, Joke Konings, Rob Wagenvoord, Saartje Bloemen, Raed Al Dieri, Mark Roest, H. Hemker, Marcus Lance, Henri Spronk, Hugo Ten Cate, Yvonne Henkens, Bas de Laat (The Netherlands)

PO143-MON  THE C-DOMAINS OF PSEUDONAJA TEXTILIS VENOM FACTOR V CONTRIBUTE TO COFACTOR STABILITY BUT ARE DISPENSABLE FOR LIPOID-INDEPENDENT PROTHROMBINASE FUNCTION  
Daniël Verhoef*, Rodney Camire, Pieter Reitsma, Metline Bos (The Netherlands)
PO145-MON

ASSESSING THE ROLE OF COMPLEX N-LINKED GLYCANS ON THE FACTOR V LIGHT CHAIN IN ENDOCYTOSIS BY MEGAKARYOCYTES
Jacqueline M. Gertz*, Mark Jennings, Cody Couperus, Jay Silveira, Paula Tracy, Beth Bouchard (United States)

PO146-MON

N9-GP OVERESTIMATION IN ONE-STAGE CLOT METHOD DUE TO SILICA-MEDIATED CONVERSION TO FIXA DURING CONTACT ACTIVATION
Per Rosén*, Steffen Rosén, Mirella Ebzan, Egon Persson (Denmark)

PO147-MON

IN VIVO EFFECT OF RECOMBINANT FVIA (NOVOSEVEN®) AND RFIX IN A REFINED TAIL VEIN TRANSECTION BLEEDING MODEL IN MICE WITH HAEMOPHILIA A AND B
Peter B. Johansen, Mikael Tranholm, Carsten Ley*, Torben Elm, Jesper Haaning, Mirella Ebzan, Tom Knudsen (Denmark)

PO148-MON

EARLY IMMUNOLOGICAL EVENTS IN AAV-F9 MEDIATED ITI FOR HEMOPHILIA B MICE WITH PATHOGENIC FIX INHIBITORS
David Markusic*, Geoffrey Rogers (United States)

PO149-MON

RECOMBINANT LONG-ACTING GLYCOPEGULATED FACTOR IX (NONACOG BETA PEGOL) IN HEMOPHILIA B: ASSESSMENT OF TARGET JOINTS IN THE MULTINATIONAL RANDOMIZED PHASE 3 CLINICAL TRIAL
Claude Negrier*, Farazia Abdul Karim, Hideji Hanabusa, Peter Collins, Torben Colberg, Bryan Goldman, Christopher Walsh (France)

PO150-MON

ASSESSMENT OF RECOMBINANT FACTOR IX-FC FUSION PROTEIN (RFIX-FC) CLOTTING ACTIVITY IN PLASMA SAMPLES AT CANADIAN HAEMOPHILIA TREATMENT CENTRES
F. Jon Geske*, Ali Sadeghi-Khomami, Hina Chaudhry, Michelle Sholzberg, Jerry Teitel (Canada)

PO151-MON

A CASE OF SEVERE HEMOPHILIA B ASSOCIATED WITH A LARGE INSERTION OF SVA RETROTRANSPOSON IN THE COAGULATION FACTOR IX GENE
Naoki Mizutani*, Yuki Nakamura, Moe Murata, Yuki Takagi, Ryo Hasebe, Toshihiro Kozuka, Yukiko Nakata, Akira Takagi, Jun-Ichi Kitazawa, Midori Shima, Tetsuhito Kojima (Japan)

PO152-MON

TISSUE DISTRIBUTION OF RIX-FP AFTER INTRAVENOUS APPLICATION TO RODENTS
Sabrina Schenk, Bärbel Doerr, Frauke May, Eva Herzog, Gerhard Dickneite, Marc W. Nolte* (Germany)

PO153-MON

THE EFFECTS OF A NOVEL LONG-ACTING FACTOR IX PRODUCT (N9-GP) ON WOUND HEALING
Elizabeth Chappell*, Mirella Ebzan, Maureane Hoffman, Dougald Monroe (United States)

PO154-MON

INHERITED FACTOR VIII AND IX DEFICIENCY IN PATIENTS REPORTED TO A TERTIARY CARE UNIVERSITY HOSPITAL IN INDIA: A RETROSPECTIVE COHORT ANALYSIS
Benson Babu* (India)

PO155-MON

PROTEIN S, A NEW AGENT IN ADJUNCT THERAPY OF HEMOPHILIA B
Rinku Majumder*, Howard Fried, Valder Arruda (United States)

PO156-MON

IN VIVO EFFICACY OF HUMAN RECOMBINANT FACTOR IX PRODUCED BY THE HUMAN HEPATOMA CELL LINE HUH-7
Nathalie Enjolras*, Eloise Perot, Sandra Le Quellec, Alice Indalecio, Jonathan Girard, Claude Negrier, Yosim Dargaud (France)

PO157-MON

INCORPORATION OF MUTATIONS AT E410 OF FACTOR IX IMPROVES CLOTTING ACTIVITY IN VITRO AND IN VIVO
Eloise Perot, Nathalie Enjolras*, Sandra Le Quellec, Jonathan Girard, Alice Indalecio, Claude Negrier, Yosim Dargaud (France)

PO158-MON

THE SLEEPING-BEAUTY TRANSPORTON TECHNOLOGY FOR THE GENERATION OF CELLULAR AND ANIMAL MODELS OF HAEMOPHILIA B AND THE ASSESSMENT OF RNA-BASED THERAPEUTIC APPROACH
Elena Barbon*, Mattia Ferrarese, Giuseppe Ronzitti, Mirko Pinotti, Federico Mingozzi (Italy)

PO159-MON

COMPARISON OF FACTOR IX GLYCOSYLATION IN DIFFERENT AGE GROUPS
Helen M. Atkinson*, Leslie Berry, Anthony Chan (Canada)

PO160-MON

INVESTIGATIONS INTO ANTICOAGULANT RESISTANCE AND ENHANCED ACTIVATION AS PUTATIVE MOLECULAR MECHANISMS OF THE HYPER-ACTIVITY OF FACTOR IX PADUA
Ben Samelson-Jones*, Jonathan Finn, Rodney Camire, Valder Arruda (United States)

PO161-MON

VARIETY OF F9 MUTATION IDENTIFIED IN 43 JAPANESE HEMOPHILIA B PATIENTS
Keiko Shinozawa*, Hiroshi Inaba, Takashi Suzuki, Masato Bango, Ikuo Seita, Takeshi Hagiwara, Kagehiro Amano, Katsuyuki Fukutake (Japan)

PO162-MON

LOCATION OF TWO NOVEL LARGE GENE DELETIONS IN CHINESE HEMOPHILIA B PATIENTS
Qingyun Wang*, Hui Liu, Liang Tang, Bei Hu, Yu Hu (China)

PO163-MON

QUANTITATION AND VISUALISATION OF NANOSIZE PROTEIN AGGREGATES IN RFIX AND PDFIX CONCENTRATES
Martin Brodde*, Martin Wiemann, Anja Müller, Beate Kehrel (Germany)

PO164-MON

INHIBITOR DEVELOPMENT IN RELATION TO TREATMENT DURATION IN SEVERE HEMOPHILIA A IN PREVIOUSLY UNTREATED PATIENTS: RESULTS FROM THE SIPPET TRIAL
PO165-MON

USING HPSEC TO QUANTIFY THE EFFECT OF GAMMA-CARBOXYLATION ON DIVALENT METAL-INDUCED COMPACTION OF VKD-PROTEINS AND BIOLOGICAL FUNCTION
Nicholas Vanderslice*, Amanda Messer, Kanagasabai Vadivel, S. Paul Bajaj, Martin Phillips, Mostafa Fatemi, Weijie Xu, William Velander (United States)

PO166-MON

INCREASED IMMUNOGENICITY OF FACTOR IX ADMINISTERED SUBCUTANEOUSLY VERSUS INTRAVENOUSLY DEMONSTRATED IN HEMOPHILIA B MICE EXPRESSING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX II HAPLOTYPE
Yasmina Abajas*, Junjiang Sun, Genlin Hu, Paul Monahan (United States)

PO167-MON

PHARMACOKINETIC (PK) AND CLINICAL DATA SUPPORT FOR EFFECTIVENESS OF ONCE-WEEKLY RECOMBINANT COAGULATION FACTOR IX (RFIX) DOSING FOR PROPHYLAXIS IN PATIENTS WITH MODERATELY SEVERE OR SEVERE HEMOPHILIA B
Joan Korth-Bradley, Lynne Smith, Joanne Fuiman, Pablo Rendo* (United States)

PO168-MON

EVALUATION OF HOST CELL PROTEIN IMMUNOGENICITY OF A POLISHED RECOMBINANT FACTOR IX INVESTIGATIONAL PRODUCT, IB1001 IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA B
Bojan Drobic*, Yi Hua, Tim Babinchak, Edward Gomperts, Christine Hall (Canada)

PO169-MON

FACTOR IX IMMUNOGENICITY IN HEMOPHILIA B PATIENTS ON REPLACEMENT THERAPY WITH A RECOMBINANT FACTOR IX INVESTIGATIONAL PRODUCT (IB1001)
Bojan Drobic, Yi Hua, Tim Babinchak*, Edward Gomperts, Christine Hall (United States)

PO170-MON

INDIRECT COMPARISONS OF FACTOR CONSUMPTION, BLEEDING RATES, AND INFUSION FREQUENCIES DURING ROUTINE PROPHYLAXIS WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN AND OTHER RECOMBINANT FACTOR VIII PRODUCTS
Alfonso Iorio*, Sangeeta Krishnan, Karl-Johan Myrên, Stefan Lethagen, Nora McCormick, Paul Kammer (Canada)

PO171-MON

INDIRECT COMPARISONS OF FACTOR CONSUMPTION, BLEEDING RATES, AND INFUSION FREQUENCIES DURING ROUTINE PROPHYLAXIS WITH RECOMBINANT FACTOR IX FC FUSION PROTEIN AND OTHER RECOMBINANT FACTOR IX PRODUCTS
Alfonso Iorio*, Sangeeta Krishnan, Karl-Johan Myrên, Stefan Lethagen, Nora McCormick, Paul Kammer (Canada)

PO172-MON

SAFETY AND EFFICACY OF A NOVEL AAV VECTOR FOR TREATMENT OF HEMOPHILIA B
Xavier Anguela*, Raffaela Tos, Linda Couto, Yifeng Chen, Daniel Hui, Marta DiPietro, Benjamin Lee, Guang Qu, Bernd Hauck, Romu Corbau, Fraser Wright, Katherine High (United States)

PO173-MON

COMPARISON OF FIX ACTIVITY OF SELECT NOVEL RECOMBINANT FIX REPLACEMENT PRODUCTS IN COMMONLY USED FDA APPROVED ONE-STAGE CLOT ASSAY SYSTEMS
Mary M. Robinson*, Stefán Tiefenbacher, Erika Ross, Patrick Williams, Caroline Cogswell, Tyrelle Wham, Dorothy Adcock (United States)

PO174-MON

MOYAMOYA SYNDROME IN A HEMOPHILIA A PATIENT WITH A HIGH-TITRE FVIII INHIBITOR
Wolf A. Hassenpflug*, Johanna Schrum, Manuela Albisetti, Nadia Khan, Reinhard Schneppenheim (Germany)

PO175-MON

OPTIMIZING PROCOAGULANT ACTIVITY FOR MUTANT RECOMBINANT FACTOR IX WITH RESISTANCE TO HEPARIN- AND ANTITHROMBIN
John P. Sheehan*, Pamela Westmark (United States)

Disseminated intravascular coagulation

PO176-MON

TO EVALUATE THE UTILITY OF ISTH SCORING SYSTEM, APTT AND SCHISTOCYTES AS MARKERS OF SEVERITY IN CASES OF DISSEMINATED INTRAVASCULAR COAGULATION.
Anjali J. Kelkar*, Amit Nisal, Parineeta Shelke, Ravindra Nimargi (India)

PO177-MON

ROLE OF PLASMA HIGH MOBILITY GROUP BOX 1 IN DISSEMINATED INTRAVASCULAR COAGULATION WITH LEUKEMIA.
Manzhi Wang, Heng Mei*, Haiming Kou, Jun Deng, Yu Hu (China)

PO178-MON

ROLE OF ACTIVATED PROTEIN C AND SOLUBLE FIBRIN IN THE EARLY PHASE OF TRAUMA WITH DISSEMINATED INTRAVASCULAR COAGULATION: COMPARISON WITH ACUTE COAGULOPATHY OF TRAUMA-SHOCK
Satoshi Gando*, Atsushi Sawamura, Mineji Hayakawa, Takeshi Wada, Yuichiro Yanagida, Daishi Myamoto, Kunihiko Maekawa, Yuichi Ono, Asumi Mizugaki, Subrina Jesmin (Japan)

PO179-MON

EVALUATION OF NEW CHINESE DIAGNOSTIC SCORING SYSTEM FOR DISSEMINATED INTRAVASCULAR COAGULATION.
Manzhi Wang, Heng Mei*, Haiming Kou, Jun Deng, Huafang Wang, Yu Hu (China)

PO180-MON

A NOVEL MURINE MODEL OF DISSEMINATED INTRAVASCULAR COAGULATION (DIC) TO AID THE DEVELOPMENT OF NOVEL THERAPEUTICS TO TREAT DIC
Majid Ali*, Keith Norman, Helen Philippou (United Kingdom)

PO181-MON

THE PRESENCE OF OVERT DISSEMINATED INTRAVASCULAR COAGULATION AT DIAGNOSIS OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
Tadej Pajic*, Irena Zupan, Helena Podgornik, Uroš Miklar, Peter Cemelc (Slovenia)

PO182-MON

BIOMARKER PROFILE OF SEPSIS-ASSOCIATED COAGULOPATHY USING BIOCHIP ASSAYS FOR INFLAMMATORY CYTOKINES
Amanda Wallerm*, Debra Hoppensteadt, Daneyal Syed, Schuharazad Abro, Michael Mosier, Jawed Fareed (United States)

Endothelium/vessel wall I

PO183-MON

HYPOXIA INDUCES DYSREGULATION OF MIR-126 AND AFFECTS VEGF AND MMP-9 EXPRESSION IN ENDOTHELIAL CELLS
Satoshi Fujii*, Misa Ogasawara, Soichiro Iwaki (Japan)
PO184-MON
ANTIOXIDANT PHARMACOLOGICAL STRATEGIES FOR THE PREVENTION OF ENDOTHELIAL DYSFUNCTION IN UREMIA
Susana Martín-Rodríguez*, Manel Vera, Enrique Mir, Jose Rivera, Josep Cruzado, Aleix Cases, Ginés Escolar, Maribel Díaz-Ricart (Spain)

PO185-MON
ANTI-THROMBOTIC AND PRO-FIBRINOLYTIC EFFECTS OF LEVOSIMENDAN IN HUMAN ENDOTHELIAL CELLS IN VITRO
Konstantin Krychtíuk*, Christoph Kaun, Stefan Stojkovic, Stefan Kastl, Andreas Zuckermann, Wolfgang Eppel, Gerald Maurer, Kurt Huber, Johann Wojta, Walter Speidl (Austria)

PO186-MON
RNA-SEQ ANALYSIS OF HUMAN MAJOR LIVER CELL TYPES REVEALS DIFFERENTIAL EXPRESSION PROFILE OF SINUSOIDAL VERSUS OTHER HEPATIC VASCULAR ENDOTHELIAL CELLS
Tina Shahan*, Peyman Zarrineh, Kris Covens, Majid Ashtiani, Renaud Lavend’Homme, Hassan Rokni Zadeh, Kathelijne Peerlinck, Marc Jacquemin (Iran, Islamic Republic Of)

PO187-MON
ENDOTHELIAL FIBRINOLYTIC RESPONSE ONTO AN EVOLVING MATRIX OF FIBRIN
Rita Marchi*, Oscar Castillón, Héctor Rojas, Zury Dominguez, Eduardo Anglés-Cano (Venezuela, Bolivarian Republic Of)

PO188-MON
A MICROFLUIDIC VASCULAR INJURY MODEL USING HEAT-ACTIVATED ENDOTHELIAL CELLS
Joanna L. Sylman*, Dylan Artzer, Keith Neeves (United States)

PO189-MON
EVIDENCE OF DEFIBROTIDE INTERNALIZATION AND ITS ENDOTHELIAL PROTECTIVE EFFECT IN HEPATIC ENDOTHELIAL IN VITRO MODEL
Marta Palomo De Udaeta*, Enrique Mir, Montse Rovira, Ginés Escolar, Enric Carreras, Maribel Díaz-Ricart (Spain)

PO190-MON
CIRCULATING ENDOTHELIAL CELLS ARE INCREASED IN POST-THROMBOTIC SYNDROME PATIENTS
Mariane Flores-Nascimento*, Bruna Mazetto, Fernanda Orsi, Joyce Annichino-Bizzacchi (Brazil)

PO191-MON
ENDOTHELIAL DYSFUNCTION AFTER HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IS ENHANCED IN ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD)
Enrique Mir*, Marta Palomo, Montse Rovira, Ginés Escolar, Enric Carreras, Maribel Díaz-Ricart (Spain)

PO192-MON
ENDOTHELIAL DYSFUNCTIONS IN CIRRHOSIS PATIENTS
Claudia Maria Radu*, Cristina Bulato, Kryssia Rodriguez-Castro, Patrizia Zerbinati, Grazziella Saggiorato, Marco Senzolo, Paolo Simioni (Italy)

PO193-MON
KINDLINS ARE ACTIN BINDING PROTEINS
Katarzyna Blaikowska*, Kamila Biedzka, Elżbieta Pluskota, Jun Qin, Edward Plow (United States)

PO194-MON
KINDLINS ARE ACTIN BINDING PROTEINS
Katarzyna Blaikowska*, Kamila Biedzka, Elżbieta Pluskota, Jun Qin, Edward Plow (United States)
PO205-MON  MIR-30C REGULATES THROMBUS FORMATION IN TYPE 2 DIABETIC MELLITUS
Mao Luo*, Fei Liu, Rong Li, Ni Chen, Ming Zeng, Xin Deng, Yan Yang, Qin Wan, Jianbo Wu (China)

Tatiana Shubina*, Tomara Obergan, Ludmila Lyapina (Russian Federation)

PO207-MON  EXPERIMENTAL VALIDATION OF A STOCHASTIC MULTISCALE MODEL OF FIBRINOLYSIS
Brittany Bannish*, Krasimir Kolev, Colin Longstaff (United States)

PO208-MON  THROMBOLYTIC PREPARATION LONGLYTIN FROM LOW FUNGUS RESOLVES SUPERFICIAL HAEMATOMAS
Podorolskaya Lidya*, Sharoka Tamara (Russian Federation)

PO209-MON  THE ANTIFIBRINOLYTIC EFFECT OF FACTOR XIII STRONGLY DEPENDS ON CLOT COMPACITION/RETRACTION
Dick C. Rijken*, Joyce Malfliet, Shiraaz Abdul, Frank Leebeek, Shirley Uitte de Willige (The Netherlands)

PO210-MON  THE ASSOCIATION OF PAI-1 AND CLOT LYSIS TIME WITH BODY COMPOSITION IN AFRICANS IS SEX DEPENDENT
Zelda De Lange*, Philina Eksteen, Marlien Pieters, H. Salome Kruger (South Africa)

PO211-MON  FIBRINOLYTIC DYSREGULATION IN ARTHROPLASTY PATIENTS MAY CONTRIBUTE TO POSTOPERATIVE HEMOSTATIC COMPLICATIONS.
Drew Burleson*, Nil Guler, Jennifer Saluk, Andrew Banos, Debra Hoppensteadt, Harold Rees, Jawed Fareed, William Hopkinson (United States)

PO212-MON  THE EFFECT OF ALPHA-2 PLASMIN INHIBITOR ARG6TRP POLYMORPHISM ON THE RISK OF CORONARY ARTERY DISEASE
Éva Katona*, Adrienn Orosz, Zoltán Mezei, László Balogh, István Czuriga, István Édes, László Muszbek (Hungary)

PO213-MON  THROMBI FORMED AT LOW HAEMATOCRIT ARE RESISTANT TO FIBRINOLYSIS VIA A FACTOR XIIIA-MEDIATED MECHANISM
Paraskevi Untiveros*, Ausra Lionikiene, Michael Greaves, Henry Watson, Nicola Mutch (United Kingdom)

PO214-MON  IMPAIRED FIBRINOLYSIS IN BEHÇET SYNDROME
Elena Silvestri, Giacomo Emmi, Anna Cellai, Emilia Antonucci, Danilo Squatrito, Lucia Ciucciarelli, Caterina Cenci, Rosanna Abbate, Lorenzo Embrini, Domenico Prisco* (Italy)

PO215-MON  VARIABLE RESISTANCE TO PLASMINOGEN ACTIVATOR INITIATED FIBRINOLYSIS FOR INTERMEDIATE-RISK PULMONARY EMBOLISM
William Stubblefield*, Jeff Kline, Matt Rondina (United States)

PO216-MON  THE INFLUENCE OF RESIDUAL PLATELETS ON PLASMA PAI-1 ASSAYS
Sunelle Barnard*, Marlien Pieters, Du Toit Loots, Dingeman Rijken (South Africa)

PO217-MON  GLOBAL FIBRINOLYTIC PROFILE IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Aurélien Lebreton*, Alessandro Casini, Frédéric Lador, Philippe de Moerloose, Marguerite Neerman-Arbez (France)

PO218-MON  MEASUREMENT OF IN VIVO GENERATED CARBOXYPEPTIDASE U (CPU, CPB2, TAFIA) IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Dorien Leenaerts*, Johan Bosmans, Pieter Van Der Veken, Yan Sim, Anne-Marie Lambeir, Dirk Hendriks (Belgium)

PO219-MON  CHARACTERISTICS OF CARBOXYPEPTIDASE U (CPU, CPB2 OR TAFIA) GENERATION DURING IN VITRO CLOT LYSIS
Dorien Leenaerts*, Jef Aernouts, Yan Sim, Anne-Marie Lambeir, Dirk Hendriks (Belgium)

PO220-MON  CELL-FREE DNA MODULATES CLOT STRUCTURE AND IMPAIRS FIBRINOLYSIS IN SEPSIS.
Travis J. Gould*, Trang Vu, Dhruva Dwivedi, Jeffrey Weltz, Patricia Liaw (Canada)

PO221-MON  IDENTIFICATION OF FUNCTIONAL PROCARBOXYPEPTIDASE U (PROCPU, TAFI) IN CEREBROSPINAL FLUID AND ITS ENHANCEMENT IN THE ACUTE PHASE OF BRAIN INJURY
Dorien Leenaerts*, Bart Feyen, Suleyman Sener, Andrey Maas, Yan Sim, Margareta Ieven, Anne-Marie Lambeir, Dirk Hendriks (Belgium)

PO222-MON  IN-VITRO IMAGING OF PLATELET/FIBRIN CLOT FORMATION AND LYSIS IN FLOW CONDITION
Stéphane Loyau*, Yacine Boulafati, Benoît Ho Tin Noe, Martine Jandrot-Perrus (France)

PO223-MON  PAI-1 REGULATES FIBRIN CLOT STABILITY AND LYSIS
Carhel Dassi*, Sylviane Fontaine, Olivier Mathieu, Landry Seye, Raphaël Marlu, Benoit Polack, François Caton, Geneviève Contant (France)

PO224-MON  THE EFFECT OF ALPHA-2 PLASMIN INHIBITOR ARG6TRP POLYMORPHISM ON THE RISK OF CORONARY ARTERY DISEASE
Éva Katona*, Adrienn Orosz, Zoltán Mezei, László Balogh, István Czuriga, István Édes, László Muszbek (Hungary)

PO225-MON  THROMBI FORMED AT LOW HAEMATOCRIT ARE RESISTANT TO FIBRINOLYSIS VIA A FACTOR XIIIA-MEDIATED MECHANISM
Paraskevi Untiveros*, Ausras Lionikiene, Michael Geaves, Henry Watson, Nicola Mutch (United Kingdom)

PO226-MON  IMPAIRED FIBRINOLYSIS IN BEHÇET SYNDROME
Elena Silvestri, Giacomo Emmi, Anna Cellai, Emilia Antonucci, Danilo Squatrito, Lucia Ciucciarelli, Caterina Cenci, Rosanna Abbate, Lorenzo Embrini, Domenico Prisco* (Italy)

PO227-MON  VARIABLE RESISTANCE TO PLASMINOGEN ACTIVATOR INITIATED FIBRINOLYSIS FOR INTERMEDIATE-RISK PULMONARY EMBOLISM
William Stubblefield*, Jeff Kline, Matt Rondina (United States)
**SCIENTIFIC PROGRAM**

**Hemophilia – clinical I**

**PO228-MON** CARRIER AND PREGNATAL DIAGNOSIS OF CHINESE HEMOPHILIA A FAMILIES IN ONE CENTER FROM 2007 TO 2014
Yeling Lu*, Jin Dai, Guilian Ding, Xuefeng Wang (China)

**PO229-MON** GENETIC ALTERATIONS IN HEMOPHILIC PATIENTS WITH INHIBITOR IN THE REGION OF MURCIA, SPAIN
Faustino García-Candel*, Antonia Melero-Amor, Noemi Marin-Atucha, Paola Romecin (Spain)

**PO230-MON** A RETROSPECTIVE EVALUATION OF BLEEDING EPISODES IN PATIENTS WITH HAEMOPHILIA A, B AND VON WILLEBRAND’S DISEASE
Aylin Canbolat Ayhan*, Cetin Timur, Enise Avcı, Ayse Ulusoy, Asım Yoruk (Turkey)

**PO231-MON** ANTIBODIES OF HIGH AVIDITY IS THE HALLMARK OF SEVERE HEMOPHILIA A PATIENTS WITH FVIII INHIBITORS
Daniel Chaves*, Amanda Silveira, Hayama Araújo, Mariana Ruckert, Olindo Martins-Filho (Brazil)

**PO232-MON** THE ROLE OF LARGE POPULATION-BASED DATABASES IN THE EVALUATION OF SAFETY OF BYPASSING AGENTS IN HEMOPHILIA PATIENTS WITH INHIBITORS
Katsiaryna Bykov*, Rhonda Bohn, Bruce Ewenstein, Jerry Avorn, John Seeger (United States)

**PO233-MON** EFFICACY OF SECONDARY PROPHYLAXIS ON ANNUAL BLEEDING RATIO (ABR) IN ADULT PATIENTS WITH HEMOPHILIA: A SINGLE CENTER OBSERVATION STUDY IN JAPAN.
Teruhisa Fujii*, Seiji Salto, Naoya Yamasaki, Tomie Fujii (Japan)

**PO234-MON** IMPACT OF THE INTRINSIC PATHWAY IN INDIVIDUAL THROMBIN GENERATION AMONG HEMOPHILIA B PATIENTS
Vuokko H. Jokela*, Annukka Jouppila, Riitta Lassila (Finland)

**PO235-MON** SAFETY AND EFFICACY OF RECOMBINANT FACTOR VIII ESSENTIAL FUSION PROTEIN (RFVIIIEFC) FOR THE PREVENTION AND TREATMENT OF BLEEDING IN PREVIOUSLY-TREATED ADULT AND ADOLESCENT SUBJECTS WITH HEMOPHILIA A: INTERIM ANALYSIS OF THE ASPIRE STUDY
Shannon Jackson*, David Perry, Doris Quon, Pratima Chowdary, Amy Shapiro, Ingrid Pabinger, Elena Santagostino, Xiaoji Li, Desilu Glazebrook, Geoffrey Allen (Canada)

**PO236-MON** NEW ANTIVIRAL TREATMENT OF HCV INFECTED YOUNG HAEMOPHILIA-ACS – EXPECTATIONS TO CURE HEPATITIS C
Katalin Koehler-Vajta*, Gerald Denk, Matthias Wettstein (Germany)

**PO237-MON** ANALYSIS OF BLEEDING RATES IN PEDIATRIC SUBJECTS WITH TARGET JOINTS AND SEVERE HEMOPHILIA A RECEIVING PROPHYLAXIS WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) IN KIDS A-LONG
Beatrice Nolan*, Guy Young, Savita Rangarajan, Michael Wang, Bryce Kerlin, Alex Leung, Elisa Tsao, Desilu Glazebrook, Glenn Pierce, Geoffrey Allen (Ireland)

**SCIENTIFIC PROGRAM**

**PO238-MON** BURDEN OF ILLNESS AMONG PERSONS WITH HEMOPHILIA B: DIRECT AND INDIRECT COSTS
Christina X. Chen*, Judith Baker, Barbara Konkle, Megan Ullman, Rosnih Kulkarni, Jeffrey Hord, Mimi Lou, Michael Nichol (United States)

**PO239-MON** TREATMENT OF BLEEDING WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN PREVIOUSLY-TREATED PEDIATRIC SUBJECTS WITH HEMOPHILIA A IN THE PHASE 3 KIDS A-LONG STUDY
Elizabeth Chalmers*, Guy Young, Johnny Mahlangu, Michael Recht, Amy Geddis, Janythi Alamelu, Giulia Gambino, Glenn Pierce, Geoffrey Allen (United Kingdom)

**PO240-MON** ACUTE EFFECTS OF EXERCISE ON SPECIFIC AND GLOBAL COAGULATION PARAMETERS IN SEVERE HEMOPHILIA A
Eva Zetterberg, Henric Ex Olsson*, Lövdahl Susanna, Ola Thorsson, Erik Berntorp (Sweden)

**PO241-MON** FIRST PROSPECTIVE RESULTS OF JOINT DISTRACTION IN HAEMOPHILIC ANKLE ARTHROPATHY

**PO242-MON** INITIAL RESULTS OF A CLINICAL TRIAL EVALUATING A FULL-LENGTH PEGYLATED RECOMBINANT FACTOR VIII WITH EXTENDED HALF-LIFE FOR THE PERIOPERATIVE CONTROL OF HEMOSTASIS IN HEMOPHILIA A
Brigitte Brand, Ralph Gruppo, Tung Wynn, Laimonas Griskevicius, Maria Fernanda Lopez Fernandez, Ferianadas Greblikas*, Thomas Dvorak, Lisa Patrone, Monika Fuenderling, Brigit Abuehl (United States)

**PO243-MON** EVALUATION OF JOINT DAMAGE IN BOYS WITH HEMOPHILIC ARTHROPATHY BY ULTRASONOGRAPHY AND BIOMARKER OF CARTILAGE TURNOVER URINARY C TERMINAL TEOLEPTIDE OF TYPE II COLLAGEN (U-CTX-II)
Hoda Hasaab*, Wessam El-Gendy, Khaled EL-Noueam, Hayam Abd EL Ghani, Nimeen Abdallah (Egypt)

**PO244-MON** SYSTEMATIC MONITORING OF HEMOSTATIC MANAGEMENT IN HEMOPHILIA A PATIENTS WITH INHIBITOR IN THE PERIOPERATIVE PERIOD USING ROTATIONAL THROMBOELASTOMETRY
Shoko Furukawa*, Keiji Nogami, Kenichi Ogawa, Hiroaki Minami, Midori Shima (Japan)

**PO245-MON** SYMPTOMATIC FEMALE HEMOPHILIA SEEN IN TAIWAN
Ming-Ching Shen*, Ming Chen, Shun-Ping Chang, Woei Tsai, Ching-Yeh Lin, Shyuann-Yuh Lin (Taiwan)

**PO246-MON** NO RELATION BETWEEN PLATELET ACTIVITY AND HEMOPHILIA B PHENOTYPE
Roger EG Schutgens*, Esther R van Bladel, Kathelijn Fischer, Mark Roest, Rolf T Urbanus (The Netherlands)

**PO247-MON** OUTCOME OF LONG TERM PLASMA DERIVED FVIII CONCENTRATE FANHID® USE IN THE MATURE HAEMOPHILIA POPULATION.
Pu-Lin Luo*, Savita Rangarajan, Ruth Pink, Steve Austin (United Kingdom)
PO248-MON
RACE AND THE IMMUNE RESPONSE TO FACTOR VIII REPLACEMENT THERAPY
Kenneth G. Mann*, Saulius Butenas, Glenn Pierce, Robert Peters, Siyuan Tan, Jeanne Lusher, David Lillincap, Christine Kempton, Johnny Mahlangu, Afshin Ameri, Nigel Key, Raymond Watts, Alexis Thompson, Cindy Leissinger, Kevin McRedmond, Christopher Walsh, Craig Kessler, Neil Josephson, Dana Matthews, Kathleen Pratt (United States)

PO249-MON
ANTIBODIES AGAINST POLYETHYLENE GLYCOL (PEG) IN HEALTHY SUBJECTS – MYTH OR REALITY?
Christian Lubich, Peter Allacher, Alexander Bauer, Thomas Prenninger, Frank Horling, Jürgen Siekmann, Friedrich Scheiffinger, Birgit Reipert* (Austria)

PO250-MON
CORRELATION BETWEEN ABR AND PK PARAMETERS IN PATIENTS WITH SEVERE HAEMOPHILIA A RECEIVING TÚROTOCOCG ALFA (NOVO-EIGHT®) FOR PROPHYLAXIS
Víctor Jiménez-Yuste*, Sandra Leijniece, Anders Rosholm, Nikola Tripkovic, Elena Santagostino (Spain)

PO251-MON
EXPRESSION OF PLATELET PROTEIN DISULFIDE ISOMERASE (PDI) IS INCREASED IN PATIENTS WITH HEMOPHILIA OR VON WILLEBRAND DISEASE
Minna Voigtlander*, Katharina Holstein, Christina Dicke, Brigitte Spath, Carsten Boke-meyer, Florian Langer (Germany)

PO252-MON
ALTERNATIONS OF OXIDATIVE STRESS MARKERS IN PATIENTS WITH SEVERE HAEMOPHILIA TREATED BY DIFFERENT PROPHYLAXIS REGIMENS
Irena Djunic*, Violeta Dopsaj, Predrag Miljic, Aleksandra Novkovic, Nada Suvađiz-Vukovic, Dragica Tomin, Ivo Elezovic (Serbia)

PO253-MON
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOFILIA A AND B IN BRAZIL
Tassila Salomon, Daniel Chaves*, Stella Brener, Sérgio Peixoto (Brazil)

PO254-MON
COMPARISON OF PROPHYLAXIS AND EPISODIC TREATMENT IN CHILDREN WITH MODERATE TO SEVERE HEMOPHILIA A
Darirn Sosothikul*, Rachaneekom Songnuay, Panya Seksam (Thailand)

PO255-MON
USING MINUTE DOSES OF APTT REAGENT AND TISSUE FACTOR AS THE COAGULATION TRIGGER TO QUANTIFY THE COAGULATION PROFILE IN HEMOPHILIA A
Shu He*, Anna Eelde, Anna Petrini, Margareta Blombäck (Sweden)

PO256-MON
USER EXPERIENCE ASSESSMENT OF THE THERAPY MANAGEMENT SYSTEM HAEMOASSIST® 2
Charlotte Böttger, Jörg Grimm, Susan Hallimeh, Michael Sigl-Kraetzig, Johannes Oldenburg, Andreas Tiede, Jan Winburn*, Martin Schulz (Germany)

PO257-MON
ONCE WEEKLY NONACOG ALFA IN HEMOPHILIA B (HEMB): A TIME COURSE PROFILE OF SPONTANEOUS BLEEDS IN PATIENTS FROM A PIVOTAL TRIAL
Bartholomew J. Tortella*, Marcus Carr, Pablo Rendo, Lynne Smith, Kaa Kavakli (United States)

PO258-MON
RESULTS FROM THE PUP-GCP CLINICAL TRIAL: LOW INHIBITOR RATE IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HAEMOPHILIA A TREATED WITH A PLASMA DERIVED FVIII CONCENTRATE
Anna Kłukowska, Sigurd Knaub, Vladimir Komrská, Paweł Laguna, Vladimir Vdovin, Martina Jansen* (Austria)

PO259-MON
DESIGNING A STUDY FOR REAL-WORLD DATA ON SAFETY AND EFFECTIVENESS OF RIXUBIS (NONACOG GAMMA) IN PEOPLE WITH HEMOPHILIA B
Andreas Tiede*, Robert Klamroth, Carmen Escurriola-Eittinghausens, Karin Kunik, Florian Langer, Cornelia Wermes, Niharja Chatterjee, Ingrid Rauter, Alessandro Gringeri (Germany)

PO260-MON
BLEEDING PATTERNS EVALUATED DURING PROPHYLAXIS WITH A FULL-LENGTH PEGYLATED RECOMBINANT FACTOR VIII (BAX 855) WITH EXTENDED HALF-LIFE IN HEMOPHILIA A
Barbara Konkle, Oleksandra Stasyszyn, Tung Wynn, Marilyn Manno-Johnson, Ralph Gruppo, Pratima Chowdary, Vladimir Komrská, Laimonas Griskevicius, M. Eyster, Krysztof Chojnowski, Werner Engl, Lisa Patrone, Birgit E. Abbeuhl* (Austria)

PO261-MON
BAYESIAN APPROACH TO THE ASSESSMENT OF THE POPULATION SPECIFIC RISK OF INHIBITORS
Alfonso Iorio*, Ji Cheng, Maura Marucci, Vadim Romanov, Lehana Thabane (Canada)

PO262-MON
PHARMACOKINETIC CHARACTERISTICS OF FACTOR VIII AND IX CONCENTRATES – A SYSTEMATIC REVIEW
Mengchen Xi, Victor Blanchette, Jan Blatny, Peter Collins, Amy Dunn, Kathleen Fischer, Cedric Hermans, Tamara Navarro-Ruan, Kaa Kavakli, Shannon Jackson, Paula James, Sunil Mammn, Massimo Morfini, Ellis Neufeld, Margarete Ozelo, Paolo Radossi, Savita Rangarajan, Arlette Ruiz-Sáez, Jerry Teitel, Lehana Thabane, Guy Young, Alfonso Iorio* (Canada)

PO263-MON
IMMUNE TOLERANCE INDUCTION WITH HAEMATE® P IN HEMOPHILIA A: EXPERIENCE FROM A SINGLE CENTER.
Ralf Knöfler*, Gabriele Siegert, Julia Stächele, Judith Lohse (Germany)

PO264-MON
2003-2014 TWELVE YEAR RESULTS OF INHERITED BLEEDING DISORDERS REGISTRY OF THE EMILIA ROMAGNA REGION IN ITALY
Gianna Franca Rivolta, Caterina Di Perna, Federica Riccardi, Gabriele Quintavalle, Giuseppina Rodorigo, Lelia Valdrè, Chiara Biasalli, Attilia Pizzi, Maria Luisa Serino, Mariacriscina Arbasì, Silvia Macchi, Paola Pedrazzi, Annarita Tagliaferri* (Italy)

PO265-MON
CONGENITAL FACTOR DEFICIENCIES: TWENTY-FIVE-YEAR FOLLOW-UP
Zafar Salicioglu*, Hulya Sayilan Sen, Deniz Tugcu, Tugce Kalyaci, Gonul Aydogan, Ferhan Akici, Zayer Baslar (Turkey)

PO266-MON
THERE IS A DIRECT RELATIONSHIP BETWEEN THE PHYSICAL ACTIVITY SCORE AND HDL CHOLESTEROL LEVEL IN HEMOPHILIA PATIENTS
Fahri Sahin*, Miray Bozgul Kilincer, Ugur Turk, Gunes Basol, Burcu Barutcuoğlu, Kaa Kavakli, Guray Saydam (Turkey)

PO267-MON
MEASUREMENT OF GAIT VARIABILITY IN PATIENTS WITH AND WITHOUT HEMOPHILIC ARTHROPATHY: MOVE-STUDY (NTR 4561)
Sara C. Stood*, Diana Hodgins, Frank Leebeek, Marjon Cnossen, Herwin Horemans, Stephan Praet, Marieke Krup (The Netherlands)
PO268-MON  THE EFFECTIVENESS OF EXERCISE PROGRAMME AND RADIOISOTOPE SYNOVECTOMY IN HEMOPHILIC PATIENTS  Melike Sezgin Evim, Ufuk Sekir, Birol Baytan, Adale Meral Günes* (Turkey)

PO269-MON  ADHERENCE TO TREATMENT IN PATIENTS WITH HAEMOPHILLIA IN GERMANY  Wolfgang Miesbach*, Werner Kainnis (Germany)

PO270-MON  PROPHYLAXIS PRACTICES IN CHILDREN AND ADULTS WITH HEMOPHILIA A OR B AND INHIBITORS  Manuel Carcaro*, Laura Avila, Louis Aledort, Cindy Leissinger (Canada)

PO271-MON  CURRENT STATUS OF OLDER PATIENTS WITH HEMOPHILIA: INSIGHTS FROM A CROSS-SECTIONAL PAN-EUROPEAN STUDY  Pål Andre Holme*, Robert Tait, Christophe Combescure, Erik Berntorp, Stephan Rauchensteiner, Philippe de Moerloose (Norway)

PO272-MON  COMPARING THROMBIN GENERATION IN PATIENTS WITH HAEMOPHILIA A AND PATIENTS ON VITAMIN K ANTAGONISTS  Marie-Sophie L. Y. De Koning, Kathelijn Fischer, Bas De Laat, Albert Huisman, Marisa Ninivaggi, Roger Schutgens* (The Netherlands)

PO273-MON  COATED PLATELET LEVELS IN SEVERE HEMOPHILIA DO NOT CORRELATE TO BLEEDING PHENOTYPE  Kelly L. Lastrapes*, Bassem Mohammed, Erika Martin, Dougald Monroe, Maureane Hoffman, Melinda Nolte, Janice Kuhn, John Barrett, Donald Brophy (United States)

PO274-MON  SUCCESSFUL IMMUNE TOLERANCE INDUCTION IN AN ADULT WITH HEMOPHILIA A AND CHRONIC INHIBITOR – A CASE STUDY  Michelle Sholzberg*, Georgina Floros, Jerry Teitel (Canada)

PO275-MON  PROPHYLACTIC APPROACH TO RECURRENT BLEEDING IN HEMOPHILIA A WITH INHIBITORS  Bulent Zulfikar*, Basak Koc, Nihal Ozdemir (Turkey)

PO276-MON  UTILIZATION OF ANTI-INHIBITORS PRODUCTS AND INHIBITORS STATUS OF SEVERE HEMOPHILIA PATIENTS: 5 YEARS NATIONAL DATA FROM THE CANADIAN HEMOPHILIA ASSESSMENT AND RESOURCE MANAGEMENT SYSTEM  Aicha N. Traore*, Anthony Chan, Alfonso Iorio, Nancy Heddle, Irwin Walker (Canada)

PO277-MON  RELIABILITY OF PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS IN US ADULT PEOPLE WITH HEMOPHILIA (PWH): THE PAIN FUNCTIONAL IMPAIRMENT AND QUALITY OF LIFE (P-FIQ) STUDY  Michael Wang*, Anne Neff, Amy Shapiro, Roshni Kulkarni, Mark Reding, Philip Kuriakose, Craig Kessler, Michelle Witkop, Christine Kempton, David Cooper (United States)

PO278-MON  ACQUIRED HEMOPHILIA IN PATIENT WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CML1)-A CASE REPORT.  Bernadeta Ceglarek, Robert Wasilewski, Ksenia Bykowski, Anna Sikorska, Beata Baran, Edyta Odnoczko, Adam Wiszniewski*, Jerzy Windyga (Poland)

PO279-MON  RESULTS OF RADIOSYNOVECTOMY IN CHILDREN WITH SEVERE HEMOPHILIA AND FACTOR VIII OR IX INHIBITOR  Pawel Laguna*, Jaroslaw Cwikla, Piotr Zbikowski, Anna Klukowska, Michal Matsiak (Poland)

PO280-MON  F8 MUTATION AND INHIBITOR DEVELOPMENT IN SEVERE FACTOR VIII DEFICIENCY: RESULTS FROM THE IRISH NATIONAL DATABASE  Vince Jenkins*, Catriona Keenan, Gary White, James O’Donnell, Kevin Ryan, Beatrice Nolan, Niamh O’Connell (Ireland)

PO281-MON  PATIENT PREFERENCES FOR FVIII AND BAX 855: RESULTS FROM THE BAX 855 PIVOTAL TRIAL  Josh Epstein, Elizabeth Schwartz*, Brigit Abuebuehi, Bruce Ewenstein (United States)

PO282-MON  RECURRENT HEMATURIA IN HEMOPHILIA PATIENTS IS NOT INDICATIVE OF THE PRESENCE OF AN UNDERLYING CAUSE  Greta Mulders*, Sara Stoof, Frank Leeeb, Martijn Buastra, Marieke Kruip (The Netherlands)

PO283-MON  SPONTANEOUS INTRACRANIAL BLEEDING IS A MAJOR CAUSE OF DEATH IN NONSEVERE HEMOPHILIA A PATIENTS  Janneke I. Loomans*, Corien Eckhardt, Alice Van Velzen, Marjolein Peters, Evelien Mauzen-Bunschoten, Rainer Schwaab, Maria Mazzucconi, Annarita Tagliaferri, Bethold Siegmund, Sylvia Reitter-Pförtner, Johanna Van der Bom, Karin Fijnvandraat (The Netherlands)

PO284-MON  RELIABLE RNA RETRIEVAL FROM LOW-VOLUME PAXGENE TUBES IN SIMULATED “REAL WORLD” NEXT GENERATION SEQUENCING (RNA-SEQ): GENA-05 SUBSTUDY PILOT  Paul Baty*, Charles Mein, Eva Wozniak, Daniel Hart (United Kingdom)

PO285-MON  U.S. SURVEILLANCE OF PROPHYLAXIS USE AMONG PERSONS WITH HEMOPHILIA A RECEIVING CARE AT HEMOPHILIA TREATMENT CENTERS (HTCs)  Marilyn J. Manco-Johnson*, Vanessa Byams, Brandi Cooke, Michael Recht, Diane Aschman, Becky Dudley, Mariam Voutsis, Meredith Oakley (United States)

PO286-MON  ASSESSMENT OF INHIBITOR RISK AFTER SWITCHING FROM PLASMA-DERIVED FACTOR VIII TO RECOMBINANT FACTOR VIII (BRASIL-RFVIII: BRAZILIAN STUDY OF INHIBITOR LINKED TO RECOMBINANT FACTOR VIII)  Alessandra Prezottii*, Silvana Aparecida Montalvão, Ana Paula Marques, Clarissa Ferreira, Luciana Oliveira, Paula Vilaça, Luiz Ivando Ferreira Filho, Cláudia Lorenzato, Samuel Medina, Fatima Araujo, Margareth Ozelo (Brazil)

PO287-MON  PHENOTYPIC PROFILE OF A CHILD WITH SEVERE HEMOPHILIA B AND INHIBITORS WITH NOVEL MUTATION IN THE FIX (F9) GENE  Zorica Trajkova Antevska*, Sofijanka Giamocanin, Biljana Copen, Violeta Dejanova Ilievskaja, Emilia Sukarovstara Stefanovska (Macedonia, The Former Yugoslav Republic Of)

PO288-MON  MILD HEMOPHILIA A COMPLICATED BY INHIBITOR AFTER SURGERY AND FACTOR REPLACEMENT THERAPY  Miguel Escobar*, Shivika Chandra, Eric Wilson, Keneth Chong (United States)
PO290-MON  
DISTURBANCE OF THE HEMOSTATIC BALANCE BY CARDIOPULMONARY BYPASS SURGERY  
Romy Kremers*, Yvonne Bosch, Edwin Mannens, Saartje Bloemen, Rob Wagenvoord, Raed Al Dieri, Coenraad Hemker (The Netherlands)

PO291-MON  
BOVINE AND PORCINE MUCOSAL HEPARINS EXHIBIT SIMILAR BIOLOGIC PROFILES  
Jawed Fareed*, Helena Nader, Marcelo Lima, Debra Hoppensteadt, Jeanine Walenga, Walter Jeske, Mary Lewis, Emmanuelle Kumar, Wolfram Raake, Mamdough Bakhos (United States)

PO292-MON  
CHARACTERIZATION OF THE ANTITHROMBOTIC FINGERPRINT OF THE BRANDED AND COPIES OF THE LOW MOLECULAR WEIGHT ENOXAPARIN USING THROMBIN GENERATION ASSAY.  
Grigoris Gerotziafas*, Patrick Van Dreden, Elisabeth Mbemba, Amir Khartechi, Jeanine Walenga, Jawed Fareed, Ismail Elalamy (France)

PO293-MON  
COMPARATIVE STUDIES ON THE MOLECULAR AND FUNCTIONAL PROFILE OF SHEEP MUCOSAL DERIVED ENOXAPARIN WITH VARYING ANHYDRO-MANNO GROUPS  
Schuharazad Abro*, Emmanuel Kumar, Omer Iqbal, Daniel Kahn, Daneyal Syed, Debra Hoppensteadt, Jawed Fareed (United States)

PO294-MON  
SEVUPARIN; EFFECTS ON HEMOSTASIS OF A NOVEL POLYSACCHARIDE DRUG DERIVED FROM HEPARIN  
Maria Lindgren*, Joost Meijers, Bart Biemond, Sofia Ramström, Tomas Lindahl, Per-Olov Eriksson, Anna Leitgeb, Mats Wahlgren, Per-Olov Eriksson, Jeanine Walenga, Jawed Fareed (Sweden)

PO295-MON  
REVERSAL OF THE HEPARINOID EFFECT WITH PROTHROMBIN COMPLEX CONCENTRATE – AN IN VITRO STUDY USING THE THROMBIN GENERATION ASSAY  
Emma L. Fosbury*, Colleen Hamid, Anne Riddell, Pratima Chowdary (United Kingdom)

PO296-MON  
PERFORMANCE EVALUATION OF A NEW ASSAY FOR THE QUANTITATIVE DETERMINATION OF BOTH UNFRAGMENTED HEPARIN (UFH) AND LOW MOLECULAR WEIGHT HEPARIN (LMWH) USING A HYBRID CALIBRATION CURVE.  
Mechthild Merz, Sascha Lange*, Katharina Madlener (Germany)

PO297-MON  
STRATEGIES AND OUTCOMES OF PERIPROCEDURAL BRIDGING THERAPY WITH LOW-MOLECULAR-WEIGHT HEPARIN IN PATIENTS WITH MECHANICAL HEART VALVES  
Jacqueline Schulman*, Ammar Majeed, Eva Mattsson, Sam Schulman, Margareta Holmström, Anna Ågren (Sweden)

PO298-MON  
BIOPHYSICAL CHARACTERIZATION OF THE INTERACTION BETWEEN PLATELET FACTOR 4 AND SYNTHETIC LOW MOLECULAR WEIGHT HEPARINS  
Mihaela Delcea*, Thi-Huong Nguyen, Sven Brandt, Martin Kreimann, Wen Zhou, Jian Liu, Andreas Greinacher (Germany)

PO299-MON  
MEASUREMENT OF HEPARANASE ACTIVITY IN PLASMA REQUIRES THE USE OF SAMPLE ANTITHROMBIN-DEPLETION  
Shahsoltan Mirshahi*, Marc Pocard, Massoud Mirshahi, Soria Jeannette (France)

PO300-MON  
NOVEL SYNTHETIC COPOLYMERS ABLE TO BIND UNFRAGMENTED AND LOW MOLECULAR WEIGHT HEPARINS.  
Bartlomiej Kalaska, Kamil Kaminski, Emilia Sokolowska, Joanna Miklos, Shin-ichi Yusa, Krzysztof Szczubialka, Dariusz Pawlak, Maria Nowakowska, Andrzej Mogiełnicki* (Poland)

PO301-MON  
DIFFERENCES BETWEEN NORMAL AND CANCER CELLS IN THE BIO-RESPONSE TO HEPARIN  
Yunliang Chen*, Michael Scully, Christopher Goodwin, Ajay Kakkar (United Kingdom)

PO302-MON  
MONITORING UNFRAGMENTED HEPARIN IN CHILDREN – APTT, ANTI-XA AND ACT IN A RANDOMIZED CONTROLLED TRIAL OF COMPARING TWO DOSE PROTOCOLS  
Katharina Ellen Thom*, Andreas Hanslik (Austria)

PO303-MON  
OVINE MUCOSAL HEPARIN AND ENOXAPARIN ARE BIOSIMILAR TO THEIR PORCINE COUNTERPARTS  
Emmanuel Kumar*, Yiming Yao, Daniel Kahn, Debra Hoppensteadt, Omer Iqbal, Walter Jeske, Jawed Fareed (United States)

PO304-MON  
THE EFFICACY AND SAFETY OF LOW-MOLECULAR-WEIGHT HEPARIN THROMBOPROPHYLAXIS IN CRITICALLY ILL ADULT PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS  
Annukka Tönen*, Anne Kuitunen, Suvi Vaara, Ville Pettilä, Heini Huhtala (Finland)

PO305-MON  
COMPARATIVE ANTICOAGULANT AND ANTI-INFLAMMATORY EFFECTS OF SULODEXIDE AND ENOXAPARIN IN CITRATED WHOLE BLOOD  
Schuharazad Abro*, Cafer Adiguzel, Daneyal Syed, Debra Hoppensteadt, Walter Jeske, Jeanine Walenga, Jawed Fareed (United States)

PO306-MON  
IN VITRO EVALUATION OF NOVEL SYNTHETIC HEPARIN SULFATES MIMETICS TO PREVENT XENOGENIC RELATED-THROMBOSIS  
Prabhjot Benipal, Hayato Iwase, Rami Al-Horani, Akul Mehta, Rajesh Karuturi, Lars Burdorf, Xiangfei Cheng, Donald Harris, Richard Pierson, Simon Robson, David Cooper, Umesh Desai, Agnes M. Azimzadeh* (United States)

PO307-MON  
ARAGATOBAN VS FONDAPARINUX IN HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS: A RESPONSE COMPARATIVE STUDY  
Fahad Aleidan*, Saud Alrokan (Saudi Arabia)

PO308-MON  
ANTICOAGULANT AND FIBRINOLYTIC EFFECTS OF COMPLEXES OF DIPEPTIDE PRO-GLY WITH LOW-MOLECULAR-WEIGHT HEPARINS ANIMAL AND PLANT ORIGIN  
Tamara Obergang*, Tatiana Shubina (Russian Federation)
PO309-MON  USAGE OF ELTHROMBOPAG IN A 9 YEAR OLD SYRIAN PATIENT WITH IMMUNE THROMBOCYTOPENIC PURPURA AND FAMILIAL DEAFNESS-FIRST PEDIATRIC EXPERIENCE IN TURKEY
Fatma Burcu Belen*, Meltem Polat, Ulker Kocak, Shinnji Kunishima (Turkey)

PO310-MON  ACUTE IMMUNE THROMBOCYTOPENIC PURPURA FOLLOWING COMBINED VACCINE
Sinan Abdurrahman*, Kamuran Karaman, Hatice Abayram, Mesut Gariardic, Ahmet Oner (Turkey)

PO311-MON  THROMBOPOIETIN RECEPTOR AGONISTS DO NOT CAUSE COAGULATION ACTIVATION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
Lamya Garabet*, Waleed Ghanima, Soo Lee, Marie-Christine Mowinckel, Howard Liebman, Christine Jonassen, James Bussel, Per Morten Sandset (Norway)

PO312-MON  TREATMENT-RELATED ADVERSE EVENT BURDEN IN IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Prina Donga*, S. Pinar Billir, Julie Munakata, Gregg Little, Tim Babincak (United States)

PO313-MON  HASHIMOTO’S THYROIDITIS IN CHILDREN WITH CHRONIC IODOPATHIC THROMBOCYTOPENIA
Muge Gokce*, Tubanur Tahtakesen, Cengiz Bayram, Deniz Tugcu, Zafer Salcioglu, Gonul Aydogan, Gonca Keskindemirci, Ferhan Akcay (Turkey)

PO314-MON  SERIAL MEAN PLATELET VOLUMES IN IMMUNE THROMBOCYTOPENIA
Mala Varma* (United States)

PO315-MON  RITUXIMAB EXPERIENCE IN CHILDHOOD IMMUNE THROMBOCYTOPENIC PURPURA FROM A TERTIARY CENTER IN TURKEY
Gonca Keskindemirci, Muge Gokce*, Deniz Tugcu, Seviç Genç, Arzu Akcay, Gonul Aydogan (Turkey)

PO320-MON  AN INCREASED MAJOR LIPID RAFT PROTEIN RAFTLIN ASSOCIATED WITH B CELLS SIGNALING IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
Zhang Xian*, Yang Li, Zhang Donglei, Li Huiyuan, Fu Rongfeng, Yang Renchi (China)

PO321-MON  NEUTROPHIL ELASTASE IS NOT REQUIRED FOR NEUTROPHIL EXTRACELLULAR TRAP OR DEEP VEIN THROMBOSIS FORMATION IN MICE
Kimberly Martinod*, Maureen Gallant, Denis Wagner (United States)

PO322-MON  TISSUE FACTOR-DEPENDENT PLATELET ACTIVATION SUPPORTS NEUTROPHIL RECRUITMENT, ROLLING AND TRANSmigration DURING INFLAMMATION
Soraya Mezouar*, Roxane Darbouset, Peter Lenting, Cécile Denis, Jean-louis Mege, Nigel Mackman, Francoise Dignat-George, Laurence Panici-Dubois, Christophe Dubois (France)

PO323-MON  EFFECT OF GLUCOSE LEVELS IN INCREASED NEUTROPHIL EXTRACELLULAR TRAP FORMATION (NETS) IN TYPE 2 DIABETES PATIENTS AT DIAGNOSIS AND AFTER 6 AND 12 MONTHS OF METABOLIC CONTROL.
Mirta A. Schattner*, Agostina Carestia, Gustavo Frechtel, Gloria Cerrone, Claudio Gonzalez, Maria Linari, Patricia Casais (Argentina)

PO324-MON  IMPACT OF PCSK9 IN A MURINE MOUSE MODEL OF SEPSIS.
Dhruva J. Dwivedi*, Momina Khan, Zakhra Lysoy, Anrik Prat, Alison Fox-Robichaud, Nabil Seidah, Patricia Liaw (Canada)

PO325-MON  PLASMA CELL-FREE DNA LEVELS ARE ELEVATED IN PATIENTS WITH ACUTE ISCHEMIC HEART FAILURE PARTIALLY DUE TO NEUTROPHIL EXTRACELLULAR TRAP FORMATION
Alexander Brill*, Eduard Shantsila, Tatyana Ponomaryov, Robert Dinsdale, Paul Harrison, Gregory Lip (United Kingdom)

PO326-MON  THE HISTONE-CLEAVING FACTOR SEVEN ACTIVATING PROTEASE DOES NOT PROMOTE DEGRADATION OF NEUTROPHIL EXTRACELLULAR TRAPS
Brenda M. Luken*, Ingrid Bulder, Melissa Stunnenberg, Gerben Marsman, Marein Schimmel, Sacha Zeerleder (The Netherlands)

PO327-MON  MECHANISM OF E- VINIFERIN INHIBITS SUPEROXIDE GENERATION IN HUMAN NEUTROPHIL
Chin-Hsuan Lin, Hsien-Feng Chen, Tean-Wei Liao, Hsin-Chih Chen, Jih-Jung Chen (Taiwan)

PO328-MON  INHIBITORY EFFECT OF NK-SE-5A ON SUPEROXIDE ANION GENERATION IN HUMAN NEUTROPHILS
Tzu-Chi Tseng*, Ih-Sheng Chen, Hsien-Ruei Liao (Taiwan)

PO329-MON  DIABETES PRIMES NEUTROPHILS TO UNDERGO NETOSIS WHICH SEVERELY IMPAIRS WOUND HEALING
Siu Ling Wong*, Melanie Demers, Kimberly Martinod, Maureen Gallant, Yanming Wang, Allison Goldfine, C. Ronald Kahn, Denis Wagner (United States)
**SCIENTIFIC PROGRAM**

**PO330-MON**
**DETERMINANTS OF THE REGULATORY ACTION OF PLATELETS TOWARDS NEUTROPHIL ACTIVITIES**
Angèle Gros*, Véronique Ollivier, Varouna Syvannarath, Martine Jandrot-Perrus, Benoît Ho-Tin-Noè (France)

**PO331-MON**
**THE LEUKOCYTE INTEGRIN α2 PRIMES NEUTROPHILS FOR NETOSIS IN SICKLE CELL DISEASE**
Laila Elsherif**, Jessica Shen, Delli Strayhorn, Kenneth Ataga, Claire Doerschuk, Leslie Parise (United States)

**PO332-MON**
**NEUTROPHIL INCORPORATION OF MEMBRANE FRAGMENTS FROM DYING PLATELETS**
Shaun Jackson, Yaping Yuan*, David Bark Jr (Australia)

**Non-vitamin K antagonist oral anticoagulants I**

**PO333-MON**
**GENERAL DECREASE OF CIRCULATING MICROPARTICLES IS RELATED TO THE PRESENCE OF FVIII INHIBITORS IN HEMOPHILIA A PATIENTS**
Daniel Chaves*, Amanda Silveira, Marcela Moreira, Samantha Béia, Hayama Araújo, Andrea Teixeira-Carvalho, Fernando Campos-Nunes, Olibio Martins-Filho (Brazil)

**PO334-MON**
**PRO-COAGULANT ACTIONS OF CIRCULATING MICROPARTICLES IN SICKLE CELL ANEMIA AND SEPSIS ASSOCIATED COAGULOPATHY AND THEIR MODULATION BY A TRIBLOCK POLYMER MST 1-88**
Jawed Fareed**, Debra Hoppensteadt, Marty Emanuel, Danyel Syed, Schuhrarazad Abro, Walter Jeske, Rakesh Wahl (United States)

**PO335-MON**
**THE ROLE OF MICROSVELCES DERIVED FROM MYELOMA CELLS IN THROMBOGENICITY AND ANGIOGENESIS**
Moran Zarfat, Tami Katz, Irit Avivi, Anat Aharon* (Israel)

**PO336-MON**
**ANTITHROMBIN IS INCORPORATED INTO EXOSOMES AND ITS PRESENCE IN THESE VESICLES IS MODULATED BY LOW MOLECULAR WEIGHT HEPARIN**
Irene Martínez-Martínez*, Patricia Carrasco, Ester Martín-Villar, Antonio García-Andreo, Nataliya Bohdan, Salvador Espín, Javier Corral, Vicente Vicente, Miguel Quintanilla (Spain)

**PO337-MON**
**SINGLE CASE REPORT: MONITORING THE BALANCE OF MICROPARTICLE-ASSOCIATED PROCOAGULANT AND FIBRINOLYTIC POTENTIALS AFTER ORTHOPEDIC SURGERY.**
Philippe Poncelet*, Coralie Judicone, Jérémie Bez, Tarik Bouriche, Benjamin François, Etienne Forestier, Olivier Béréziat, José Sampol, Romaric Lacroix, Françoise George (France)

**PO338-MON**
**PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM HAVE HIGHER CONCENTRATION OF LARGE EXTRACELLULAR VESICLES WITH AUGMENTED POTENTIAL TO INITIATE COAGULATION ACTIVATION**
Simin Jamaly*, Irina Starikova, Vladimir Tichelaar, Cathrine Ramberg, Nadezhda Latsheva, John-Bjarne Hansen (Norway)

**PO339-MON**
**INFLUENCE OF CALR AND JAK2 MUTATIONS ON PROCOAGULANT POTENTIAL OF PLATELET-DERIVED MICROPARTICLES IN ESSENTIAL THROMBOCYTHEMIA (ET)**
Marina Marchetti*, Sara Gamba, Alfonso Vignoli, Laura Russo, Carmen Tartari, Guido Finazzi, Anna Falanga (Italy)

**SCIENTIFIC PROGRAM**

**PO340-MON**
**TF- AND UPA-BEARING MICROPARTICLES MODULATE FIBRIN NANOSTRUCTURE**
Geneviève Contant, Olivier Mathieu, Sylvie Cointe, Tarik Bouriche, Jeremie Bez, Carhel Dassi, Benoît Polack, François Caton, Romaric Lacroix, Philippe Poncelet* (France)

**PO341-MON**
**MODULATING THROMBOTIC DIATHESIS IN HEREDITARY THROMBOPHILIA: A ROLE FOR CIRCULATING MICROPARTICLES?**
Elena Campello*, Luca Spiezia, Claudia Radu, Cristina Bulato, Sabrina Gavasso, Daniela Tormene, Barry Woodhams, Paolo Simioni (Italy)

**PO342-MON**
**CIRCULATING EXTRACELLULAR VESICLE (EV) AFTER ACUTE HINDLIMB ISCHEMIA**
Violeta Gomez-Rodriguez, Anita Böing, Josune Orbe, Rienk Nieuwland, José A. Parra, Carmen Roncal* (Spain)

**PO343-MON**
**COMPARISON OF INTRACARDIAC AND VENOUS BLOOD LEVELS OF MICROTURVEICLES, TISSUE FACTOR AND PROCOAGULANT PHOSPHOLIPIDS IN PATIENTS WITH AND WITHOUT ATRIAL FIBRILLATION**
Morton Mark*, Shona Pedersen, Lars Rasmussen, Jan Andreasen, Søren Risom (Denmark)

**PO344-MON**
**ANTICOAGULATION IN PATIENTS UNDERGOING CARDIOVERSION**
Sufyan Benamer*, Kandiah Chandrakumar, Debbie Lusty, Tamara Everington (United Kingdom)

**PO345-MON**
**EVALUATION OF DABIGATRAN, RIVAROXABAN AND APIXABAN TARGET-SPECIFIC ASSAYS IN A MULTICENTER FRENCH STUDY.**
Isabelle Guinou-Thibault*, Emmanuel de Maistre, Sophie Susen, Geneviève Freyburger, Jean-Louis Golmard, Yves Grue, Pierre Sié (France)

**PO346-MON**
**VALIDATION STUDIES ON COAGULATION LABORATORY ASSAYS USEFUL FOR ASSESSING THE PLASMA LEVELS OF APIXABAN**
Debra Hoppensteadt*, Danyel Syed, Marc Goldford, Anne Bisset, Leon Zuckerman, Walter Jeske, Job Harenberg, Jawed Fareed (United States)

**PO347-MON**
**HOW DO REAL-WORLD APIXABAN CONCENTRATIONS COMPARE TO EXPECTED CONCENTRATIONS?**
Hawre Yones, Jignesh Patel*, Paradzai Chitongo, Rosalind Byrne, Alison Brown, Margaret Watras, Kathryn Lang, Julia Czuprynska, Lara Roberts, Raj Patel, Roopen Arya (United Kingdom)

**PO348-MON**
**THE DAILY PRACTICE OF NOACS; AN OBSERVATIONAL COHORT STUDY**
Arina Ten Cate-Hoek*, Yvonne Henskens, René van Oerle, Rick Wetzel, Henri Spronk, Simon Schalla, Harry Crijns, Hugo ten Cate (The Netherlands)

**PO349-MON**
**POTENT ANTITHROMBOTIC EFFECT OF A NOVEL, SMALL-MOLECULE AND DIRECT INHIBITOR OF FACTOR XIA IN PREVENTION AND TREATMENT OF THROMBOSIS IN RABBIT MODEL OF ARTERIAL THROMBOSIS AT DOSES THAT PRESERVE HEMOSTASIS**
Pancras C. Wong*, Mimi Quan, Carol Watson, Earl Crain, Simon Schalla, Harry Crijns, Hugo ten Cate (The Netherlands)
PO350-MON
COMPARING FEIBA WITH RECOMBINANT FVIIa FOR REVERSAL OF RIVAROXABAN WITH A MODIFIED ANTI-XA ASSAY IN UNDILUTED PLASMA
Jorell Gantioqui*, Ivan Stevic, Frank Lee, Anthony Chan, Howard Chan (Canada)

PO351-MON
DISCOVERY OFONO-7750512, AN ORALLY BIOAVAILABLE SMALL MOLECULE FACTOR XA INHIBITOR: THE PHARMACOKINETIC AND PHARMACOLOGICAL PROFILES
Sho Koyama*, Takehiro Ono, Kazutsune Harada, Aiko Fujioka, Keiko Tsukamoto, Shinya Sakimoto, Masashi Gohda, Tetsuya Hagio, Tomoyuki Koda, Naoya Matsumura, Yoshiyuki Yamamura, At Hashimoto, Motoyuki Tanaka, Takashi Kondo, Masaru Sakai, Kenji Tanaka, Hidekazu Matsuura, Akira Imagawa, Yasushi Hirota, Kazuhito Kawabata (Japan)

PO352-MON
MONITORING NOVEL ANTICOAGULANTS DABIGATRAN, RIVAROXABAN AND APIXABAN USING THE NEW FULLY AUTOMATED THROMBELASTOGRAPHY TECHNIQUE TEG®6S
Ramin Artang*, Gregg Galloway, Jean Amiral, Jorn Dalsgaard Nielsen (United States)

PO353-MON
ENHANCEMENT OF FIBRINOLYSIS BY A FACTOR XA INHIBITOR EDOXABAN AND COMBINATION WITH AN INHIBITOR OF ACTIVATED THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR IN VITRO
Yoshiyuki Morishima*, Chikako Kamisato, Taketoshi Furugohri (Japan)

PO354-MON
NOVEL ORAL ANTICOAGULANTS: INCIDENCE AND MANAGEMENT OF MAJOR BLEEDING. RETROSPECTIVE REVIEW AT A SINGLE CENTER.
Juan Peris*, Gueralt Salas, Miren Gabilondo, Elena Pina, Elena Rosselló, Pere Dome nech (Spain)

PO355-MON
INITIATING THROMBOPROPHYLAXIS WITH RIVAROXABAN UP TO 26 HOURS AFTER ELECTIVE KNEE ARTHROPLASTY DOES NOT INCREASE THE INCIDENCE OF VENOUS THROMBOEMBOLISM
Ovais Mian*, Christine Cockhill, Mary Ann Rizzo, Deborah Siegal, Howard Chan, Ellen McDonald (Canada)

PO356-MON
EVALUATION OF THE SAFETY AND TOLERABILITY OF TARGET SPECIFIC ORAL ANTICOAGULANTS AT A LARGE UNIVERSITY SETTING
Gina Woodhouse, Patrick Klem*, Renjbar Zebari, Kathyrn Hassell, Toby Trujillo (United States)

PO357-MON
EVALUATION OF ANTICOAGULANT THERAPY WITH DABIGATRAN BASED ON ECARIN CLOTTING TIME
Takeshi Suzuki*, Masahiro Ikeda, Ichiro Sakuma, Sumiyoshi Naito, Mika Yoshida, Osamu Kuminou, Nobuhiko Takahashi (Japan)

PO358-MON
SWITCH FROM VITAMIN K ANTAGONISTS (VKAS) TO DIRECT ORAL ANTI COAGULANTS (DOACS): A PRATICAL APPROACH
Samantha Pasca, Ugo Venturelli, Antonella Bertoni, Giovanni Barillari* (Italy)

PO359-MON
WARFARIN AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE “REAL WORLD” OF PATIENTS WITH ATRIAL FIBRILLATION
Pasquale Pignatelli, Daniele Pastori*, Gregory Lip, Francesco Violi (Italy)

PO360-MON
GLOBAL ANTICOAGULANT SCREENING USING A DILUTE RVV REAGENT
Zhenghua Cao*, Ralph Bottenus, Mark Triscott (United States)
SCIENTIFIC PROGRAM

PO370-MON
REAL-LIFE USE OF NON-VITAMIN K ANTAGONIST ORAL ANTIICOAGULANTS IN COMPARISON WITH VITAMIN K ANTAGONISTS FOR NON-VALVULAR ATRIAL FIBRILLATION: DATA FROM A PROSPECTIVE COHORT
Michela Giustozzi*, Maria Cristina Vedovati, Federica Cianella, Paolo Verdeccchia, Melina Verso, Serenella Conti, Esmeralda Filippucci, Emanuela Marchesini, Giancarlo Agnelli, Cecilia Becallitini (Italy)

PO371-MON
THE MODULATION OF PROTHROMBINASE LIFETIME BY RIVAROXABAN
Maria Cristina Bravo*, Tom Ofreo, Matthew Gissel, Elizabeth Lavoie, Laura Haynes, Kenneth Mann (United States)

PO372-MON
PHARMACOKINETICS AND -DYNAMICS OF DABIGATRAN ETIXILATE AND RIVAROXABAN IN PATIENTS REQUIRING PARENTERAL NUTRITION FOR SHORT BOWEL SYNDROME (THE PDER PAN STUDY)
Stefano L. Barco*, Yuk Cheung, Michel Coppens, Mireille Serlie, Ron Mathot, Saskia Middeldorp (The Netherlands)

PO373-MON
IS IT POSSIBLE TO ASSESS RIVAROXABAN ACTIVITY WITHOUT SPECIFIC CALIBRATORS?
Maria De Lourdes Herrera*, Alicia Grinspon, Silvina Pons, Carolina Mahuad, Alejandra Scazzotta (Argentina)

PO374-MON
A NEW ASSAY FOR THE MEASUREMENT OF RIVAROXABAN CONCENTRATIONS IN HUMAN PLASMA
Valeri Krougliak*, Zhenghua Cao, Hency Patel, Jessy Mathew, Asley Belanger, Chun Kung, Ralph Bottenus (United States)

PO375-MON
MONITORING VITAMIN K ANTAGONIST TREATMENT: INTERESTS OF GOOD THERAPEUTIC EDUCATION
Dalila Aïtchafa Tadlaoui*, Amina Taboukouyout, Z’hor Guechi (Algeria)

Nursing and Allied Health

PO376-MON
HOW PARTICIPATING IN A CLINICAL TRIAL HAS HAD A FAR REACHING EFFECT – A CASE STUDY.
Claire Mcgregor*, Marina Goruppi (Australia)

PO377-MON
BARRIERS TO INFORM HEMOPHILIC CARRIERS OF THAT POSSIBILITY IN JAPAN
Tomie Fuji*, Ayana Murakami, Teruhisa Fujii, Yukiko Miyakoshi (Japan)

PO378-MON
MECHANICAL THROMBOPROPHYLAXIS – SOLVING DILEMMAS
Cara Doyle*, Emma Gee (United Kingdom)

PO379-MON
THE NURSES ROLE IN IDIOPATHIC THROMBOCYTOPENIA
Vashti Ragoonanan* (United Kingdom)

PO380-MON
THE IMPACT OF FOOTWEAR ON ANKLE ARTHROPATHY IN PATIENTS WITH HEMOPHILIA.
Karen Strike*, Jherica Irwin (Canada)

PO381-MON
DEVELOPMENT OF INPATIENT PEDIATRIC ANTICOAGULATION MANAGEMENT SERVICE: THE ADVANCED PRACTICE NURSE PRACTITIONER SERVICE MODEL
Jennifer Meldau*, Christine Guelcher, Carole Hennessey, Deepika Darbari, Michael Guerrera, Yaser Diab (United States)

PO382-MON
FIRST EXPERIENCE WITH THE HAEMOASSIST, AN ELECTRONIC SUBSTITUTION DIARY THAT WORKS ON THE BASIS OF A PERSONAL DIGITAL ASSISTANT (PDA)
Manuela Siebert*, Michaela Bicker, Britta Lachmann (Germany)

PO383-MON
AN EVALUATION OF A MYELOPROLIFERATIVE NEOPLASM SPECIALIST NURSE LED CLINIC
Vashti Ragoonanan* (United Kingdom)

PO384-MON
PHARMACIST SUPPORTED ANTICOAGULATION MANAGEMENT CLINIC - IMPROVING PATIENT CARE IN AN EMERGING COUNTRY
Nida Najmi*, Bushra Moiz, Sumaira Khan (Pakistan)

PO385-MON
NURSING MANAGEMENT OF VENOUS THROMBOEMBOLISM (VTE) TREATMENT WITH RIVAROXABAN AT THE UNIVERSITY HOSPITAL OF PADUA: A 6-MONTH EXPERIENCE
Chiara Tonello*, Elisabetta Baracco, Marianna Bettella, Lorenza Cocco, Nicola Griggio, Stefano Morandini, Fabiana Nalin, Alessandra Noventa, Ornella Scarpazza, Paolo Zulian, Giampiero Avuscio (Italy)

PO386-MON
RESPONSE OF LEUCOCYTE COUNT, LEUCOCYTE DIFFERENTIAL COUNT AND THROMBOCYTE COUNT ON FREQUENT BLOOD DONATIONS AMONG MALE SUBJECTS IN UNIVERSITY OF CALABAR TEACHING HOSPITAL DONOR CLINIC, CALABAR, NIGERIA
Dorothy C. Okpokam*, Ifeyinwa Okafor, Josephine Akpotuzor, Eme Osien, Esien Usang, Ogha Okpokam (Nigeria)

PO387-MON
PARTICIPATION OF NURSES IN PREPARATION OF PATIENTS WITH HEMOPHILIA FOR SURGERY OF COLON CANCER
Lijilana Rakic* (Serbia)

PO388-MON
MILD HAEMOPHILIA A: A MANAGEABLE CONDITION?
Daryl Pollock* (New Zealand)

PO389-MON
SOURCE DATA VERIFICATION PILOT: USING CENTRAL MONITORING IN AN OBSERVATIONAL CRITICAL CARE BIOMARKER STUDY
Ellen McDonald*, Davinder Jain, Roxanne Ward, Patricia Liaw, Alison Fox-Robichaud (Canada)

PO390-MON
RAISING AWARENESS OF VENOUS THROMBOEMBOLISM PREVENTION: HOW THE JEWISH GENERAL HOSPITAL IS MEETING THE REQUIREMENTS FOR HOSPITAL ACCREDITATION
Jessica Emes*, Carla Strulovitch, Suzette Chung, Hetal Patel (Canada)

PO391-MON
HAEMOPHILIA AND AGEING. PROMOTING HEALTHY AGEING THROUGH PROACTIVE ENGAGEMENT WITH GENERAL PRACTITIONERS – LITERATURE REVIEW AND PILOT SURVEY.
Olivia Hollingdrake*, Beryl Zeissink (Australia)
PO392-MON
A SURVEY OF CLINICAL RESEARCH COORDINATORS TO MANAGE THE CLINICAL RESEARCH PAPERWORK MOUNTAIN
Terri Schnurr*, Susan Cooke, Dori Kazimer, Mary Jane Sayles, Ellen McDonald (Canada)

PO393-MON
THE JEWISH EXPERIENCE IN DEVELOPING PATIENT-TEACHING MATERIALS ON WARFARIN AND VENOUS THROMBOEMBOLISM
Carla Strulovitch*, Jessica Emed, Suzette Chung, Helal Patel (Canada)

PO394-MON
THE IMPACT OF I3 CYTOPLASMIC TAIL MIMETIC PEPTIDES ON PLATELET AGGREGATION AND αIIbβ3 ACTIVATION
Huong T. T. Nguyen*, Khon Huynh, Rudiger Scharf, Volker Stoldt (Germany)

PO395-MON
BILE SALT CHENODEOXYCHOLATE SUPPRESSES NORMAL PLATELET FUNCTIONS THROUGH CYCLIC AMP ACTIVATION PATHWAY
Pat Metharom*, Fergal O’Gara, Michael Bendi (Australia)

SCIENTIFIC PROGRAM

PO396-MON
THE ROLE OF HETEROTRIMERIC G PROTEINS IN REGULATION OF GPIIb-IIIa ACTIVATION AND PLATELET CONTRACTILITY
Ivan Budnik, Boris Shenkman, Naphali Savion* (Israel)

PO397-MON
THE GUT MICROBIOTA REGULATES VON WILLEBRAND FACTOR EXPRESSION AND PLATELET PROTHROMBOTIC FUNCTION VIA TOLL-LIKE RECEPTOR-2
Sven Jäckel*, Mare Lüll, Klytaijinnia Kioupatty, Nives Hörmann, Katharina Alber, Kerstin Jurk, Wolfram Ruf, Christoph Reinhardt (Germany)

PO398-MON
NUCLEAR RECEPTOR DEPENDENT FORMATION OF COATED PLATELETS INHIBITS PLATELET RESPONSES TO STIMULI.
Amanda J. Unsworth*, Tanya Sage, Neline Kriek, Michael Schenk, Christopher Jones, Leonardo Moraes, Jonathan Gibbins (United Kingdom)

PO399-MON
CONSIDERABLE VARIABILITY OF PLATELET RESPONSE TO TISSUE FACTOR IN HEALTHY INDIVIDUALS AND POTENTIAL ROLE OF FXA INHIBITOR AS AN ANTI-PLATELET AGENT
Kagari M. Murasaki*, Kaori Ishigaki, Nobuhisa Hagiwara (Japan)

PO400-MON
PHYSIOLOGICAL REGULATION OF PLATELET AGGREGATION BY THE GASOTRANSFER HYDROGEN SULFIDE
Michael Emerson*, Oumid Ahmad, Francesca Rauzi, Erica Smyth, Mark Wood, Matthew Whiteman (United Kingdom)

PO401-MON
PLATELET-SPECIFIC GARP DEFICIENCY DOES NOT AFFECT THROMBOSIS AND HEMOSTASIS IN MICE
Ellen Vermeersch*, Karen Vanhoorebeke, Simon De Meyer, Hans Deckmyn, Claudia Tersteeg (Belgium)

PO402-MON
CONSTRUCTION OF EXPRESSION SYSTEM FOR BIOLOGICALLY FUNCTIONAL RECOMBINANT RHODOCYTI
Tomoyuki Sasaki*, Shogo Tamura, Toshiaki Shirai, Nagaharu Tsukiji, Kaneo Satoh, Katsue Suzuki-Inoue, Yukio Ozaki (Japan)

PO403-MON
LOCALIZATION OF ZN2+ IN DENSE GRANULES OF HUMAN PLATELETS AND THE EXTENT OF ITS RELEASE UPON PLATELET ACTIVATION
Sara J. Henderson*, Fred Pluthero, Alan Stafford, Ji Zhou, Nima Vaeezadeh, Ran Ni, James Fredenburgh, Walter Kahr, Jeffrey Weitz (Canada)

PO404-MON
NEUTROPHILS CONTRIBUTE TO THE GENERATION OF PROCOAGULANT PLATELETS BY A MYELOPEROXIDASE INDEPENDENT MECHANISM
Leonardo Pasalic*, Latasha Abeynaite, Elias Glaros, Shane Thomas, Philip Hogg, Vivien Chen (Australia)

PO405-MON
IMPAIRED RESPONSE TO COLLAGEN OF PLATELETS FROM HYPERLIPIDEMIC MICE
Marco van der Steep*, Inge Snoeren, Menno Hoekstra, Philip de Groot, Miranda Van Eck, Suzanne Korporaal (The Netherlands)

PO406-MON
IMPROVING THE QUANTIFICATION OF IN VITRO THROMBUS FORMATION
Kjersti Claesson*, Lars Fävälä, Tomas Lindahl (Sweden)

PO407-MON
RS6929846-DEPENDENT REGULATION OF BTTNAI EXPRESSION IN INNATE AND ADAPTIVE IMMUNE CELLS AFFECTS PLATELET REACTIVITY TO THROMBIN
Ann-Stephan Gori, Christelle Lecut, Julia Dmitrieva, Céline Delierneux, Emilie Théâtre, Patrizio Lancellotti, Michel Georges, Cécile Oury* (Belgium)

PO408-MON
MOUSE CLEC-2 CAN SUPPORT PLATELET ADHESION TO MOUSE PODOPHILLIN UNDER ARTERIAL FLOW
Stephanie Lombard*, Matthew Harrison, Marie Lordkipanidze, Alice Pollitt, G Rainger, Steve Watson (United Kingdom)

PO409-MON
AKT TRANSLOCATION AND PHOSPHORYLATION REGULATES PLATELET AGGREGATION DOWNSCALING OF G12/13 AND GI PATHWAYS
Zhongren Ding*, Yan Zhang, Leilei Chen, Shuang Zheng, Liang Huang, Si Zhang (China)

PO410-MON
EFFECTS OF CYCLIC NUCLEOTIDES ON PLATELET AGGREGATION AND BIOLOGICAL RESPONSE MODIFIER RELEASE INDUCED BY STREPTOCOCCUS SANGUINIS STRAIN 2017-78
Archie McNicol*, Ahmed Abdulrehman, Elke Jackson, Sara Israels, Hind Hamzeh-Cognasse, Fabrice Cognasse (Canada)

PO411-MON
COMBINED ROLES OF FACTOR XIIIA AND GLYCOPROTEIN IIB/IIIa IN PLATELET-DRIVEN FIBRIN FORMATION
Nadine Mattheij*, Frauke Swieringa, Michelle Berny-Lang, Frauke May, Paola van der Meijden, Dennis Nuijens, Marc Nolte, Tim Hackeng, Owen McCarty, Johan Heemskerk, Judith M. Cosemans (The Netherlands)

PO412-MON
PIVOTAL ROLE OF SGK1 IN THE REGULATION OF PLATELET SECRETORY PROTEOME, DENSE GRANULE BIOGENESIS AND SECRETION
Britta Walker*, Evri Schmid, Antonella Russo, Patrick Münzer, Eva-Maria Schmidt, Olli Ver Burk, Ana Velic, Boris Macek, Martin Schaller, Matthias Schwab, Miguel C. Seabra, Meinrad Gawaz, Florian Lang, Oliver Borst (Germany)

PO413-MON
IMPACT OF ELEVATED SHEAR STRESS ON INTEGRIN ALPHAIIBETA3 – LIGAND INTERACTION
Marianna Gyenes*, Volker R. Stoldt, Rudiger E. Scharf (Germany)
SCIENTIFIC PROGRAM

PO414-MON

PLATELET FUNCTION IS REGULATED BY ACETYLATION AND DEACETYLATION MECHANISMS CONTROLLED BY SIRTUINS.
Ana M. Latorre*, Maria Santos, Juana Valles, Maria Angeles Dasi, Antonio Moscardo (Spain)

PO415-MON

FIBRIN STIMULATES SPREADING AND ACTIVATION OF PLATELETS THROUGH GPGVI
Osama M. Alshehri*, Craig Hughes, Samantha Montague, Jon Frampton, Steve Watson (United Kingdom)

PO416-MON

KINDLIN-2 IN MEGAKARYOCYTE AND PLATELET FUNCTIONS
Dorsaf Ghallousi, Pierre Dillard, Gaëtan Chicanne, Bernard Payrastre, Alan Nurden, Véronique Baccini, Laurent Limozin, Marie-Christine Alessi, Matthias Canault* (France)

PO417-MON

THE PRO33 (HPA-1B) ISOFORM OF INTEGRIN ALPHAIIBETA3 IS INDEED A PROTHROMBOTIC RECEPTOR VARIANT
Rudiger. E Scharf*, Marianna Gyenes, Volker R. Stoldt (Germany)

PO418-MON

THE PRO33 VARIANT OF PLATELET ALPHAIIBETA3: ALLOSTERIC CHANGES RESULTING FROM A POINT MUTATION IN THE INTEGRIN ECTODomain ARE ASSOCIATED WITH A PROTHROMBOTIC RECEPTOR PHENOTYPE
Giulia Pagani*, Joana Ventura Pereira, Nadine Homeyer, Volker R. Stoldt, Holger Gohlke, Rüdiger E. Scharf (Germany)

SCIENTIFIC PROGRAM

PO419-MON

VASCULAR SMOOTH MUSCLE CELLS STIMULATE PLATELETS VIA CLEC-2: INVOLVEMENT OF INTRACELLULAR AND EXTRACELLULAR LIGANDS OF CLEC-2
Katsue Suzuki-Inoue*, Osamu Inoue, Nagaharu Tsukiji, Yukio Ozaki (Japan)

PO420-MON

PLATELET-FIBRIN THROMBI CAN KILL STENOTROPHOMONAS MALTOPHILI
Volker R. Stoldt*, Rudiger E. Scharf (Germany)

PO421-MON

ENGINEERING PLATELETS FOR THE DELIVERY OF RNA
Stefanie Novakowski*, Vivienne Chan, Simon Law, Christian Kastrup (Canada)

PO422-MON

INHIBITION OF SORBITOL DEHYDROGENASE INCREASES PLATELETS ADHESION IN MICE TREATED WITH FIDARESTAT
Mariane Flores-Nascimento*, Kiara Zapponi, Regiane Ferreira, Lúcia Helena Siqueira, Thais Fornari, Bruna Mazetto, Fernanda Orsi, Erich De Paula, Joyce Annicchio-Bizzacchi (Brazil)

SCIENTIFIC PROGRAM

PO423-MON

THE RAP1-GAP RASA3 PREVENTS CLEARANCE OF CIRCULATING PLATELETS
Caterina Casari*, David Paul, Lucia Stefanini, Yacine Boulaftali, Robert Campbell, Daniel Kechele, Kathleen Caron, Andrew Weyrich, Dale Cowley, Matthew Parrott, Luanne Peters, Wolfgang Bergmeier (United States)

PO424-MON

BIOMECHANICS OF BLOOD CLOT CONTRACTION
Valerie Tutwiler*, Hailong Wang, Rustem Litvinov, John Weisel, Vivek Shenoy (United States)

PO425-MON

REVERSAL OF THE ANTITHROMBOTIC PROPERTIES OF QUERCETIN-3-RUTINOSIDE WITH THE B' DOMAIN OF PDI IN A MOUSE THROMBOSIS MODEL
Lin Lin*, Srilal Gopal, Anish Sharda, Freda Passam, Shereyl Bowley, Jack Stopa, Robert Flaumenhaft, Mingdong Huang, Bruce Furie (United States)

PO426-MON

PLATELET IN RATS WITH ACUTE RENAL FAILURE PRESENT HYPERREACTIVITY IN VITRO
Zhang-Yin Ming*, Guang-qiang Yao, Ming-lu Liang, Ao-di He, Xin-Wen Da, Wen Xie (China)

PO427-MON

FACTOR XI-DEPENDENT PLATELET THROMBIN GENERATION INDUCED BY THROMBIN IS REGULATED BY CD36
Mareike Dörhrmann*, Kathrin Schwierczek, Ivo Volf, Ulrich Walter, Kerstin Jurk (Germany)

PO428-MON

DELETION OF PI3K P110A RESULTS IN ENHANCED PRIMER-MEDIATED REGULATION OF PLATELET FUNCTION AND THROMBOSIS.
Thomas Blair*, Samantha Moore, Ingeborg Hers (United Kingdom)

PO429-MON

PROFILING OXYLIPINS RELEASED BY GPVI-ACTIVATED PLATELETS AND THE EFFECT OF INHIBITORS OF CYCLOOXYGENASE-1 AND 12-LIPOXYGENASE
Robert E. Turnbull*, Katrin Sander, David Barrett, Alison Goodall (United Kingdom)

PO430-MON

ROLE OF HYDRODYNAMIC SHEAR MEDIATED PLATELET DEFORMATION ON CELL TETHERING, TRANSLATION AND ACTIVATION
Changjie Zhang*, Srizam Neelamegham (United States)

PO431-MON

THE ACTIVATING EFFECTS OF SHEAR STRESS GRADIENTS ON THROMBUS FORMATION
Thomas Hoenfer*, Elizabeth Gardiner, Robert Andrews, Karlheinz Peter, Erik Westein (Australia)

PO432-MON

MEMBRANE ESTROGEN RECEPTOR (MER) – PROTEASE ACTIVATED RECEPTOR (PAR) CROSS TALK MODULATES PLATELET FUNCTION
Joseph E. Aslan*, Ishan Patel, Peizhong Mao, Fuchun Xie, Xiangshu Xiao, Oline Rønkleiv, Martin Kelly, Owen McCarty (United States)

PO433-MON

PLATELET CD34 EXPRESSION IS INCREASED IN FAMILIES WITH DISTINCT GFI1B MUTATIONS: UTILITY AS A SCREENING TEST
Marie-Christine Morel-Kopp*, David Rabbolini, Sara Gabrielli, Qiang Chen, Christopher Ward*, William Stevenson (Australia)

PO434-MON

A CASE OF MYH9 DISORDERS CAUSED BY A NOVEL Mutation (P.K74E)
Takeshi Kanematsu*, Nobuaki Suzuki, Mayuko Kishimoto, Tomohiro Aoki, Mika Ogawa, Yoshiyoyo Kagami, Shinji Kunishima, Hitoshi Kiyoi, Tadashi Matsushita (Japan)

Platelet disorders I
### SCIENTIFIC PROGRAM

| PO435-MON | ACTN1-RELATED THROMBOCYTOPENIAS (ACTN1-RT): PHENOTYPE/GENOTYPE OF A SERIES OF 13 NEW CASES | Tom Noga, Susan Nahirniak, Jennifer Conway, Holger Buchholz, Mary Bauman, Patti Massicotte, Aisha Bruce* (Canada) |
| PO436-MON | DIFFERENT MICROTUBULE ABNORMALITIES IN TWO CASES OF MACROTHROMBOCYTOPENIA ASSOCIATED WITH TUBB1 VARIANTS | Simon Stritt, Ernest Turro, Noémie Saut, Marie-Christine Alessi, Nicole Schlegel, Alan Norden, Willem Ouwehand, Bernhard Nieswandt, Paquita Nurden* (Germany) |
| PO437-MON | SOLUBLE GLYCOPROTEIN VI: A POTENTIAL BIOMARKER FOR DISEASE ACTIVITY AND PLATELET REACTIVITY IN ACUTE GOUT. | Geraldine McCarthy*, Claire Louise Murphy, Anne Madigan, Paul MacMullan, Laura Duncan, Eimear Dunne (Ireland) |
| PO438-MON | PERSONALIZED REFERENCE INTERVALS FOR PLATELET COUNT REDUCE THE PREVALENCE OF UNEXPLAINED THROMBOCYTOPENIA AND INCREASE THAT OF REACTIVE THROMBOCYTOSIS IN ELDERLY PEOPLE | Patrizia Noris*, Carlo Zaninetti, Ginevra Biino, Elisa Clavaschi, Federica Melazolini, Carlo Baldolini (Italy) |
| PO439-MON | MYH9 DISEASE: IDENTIFICATION OF TWO MUTATIONS ASSOCIATED WITH UNCOMMON CLINICAL PHENOTYPE | Maria Isabel Sánchez Guiu*, Begoña Muñía, Adela Periago, Daniel Jaimes Albornoz, María Luisa Lozano, José Rivera (Spain) |
| PO440-MON | ACTN1-RELATED THROMBOCYTOPENIAS (ACTN1-RT): PHENOTYPE/GENOTYPE OF A SERIES OF 13 NEW CASES | Anne Vincenot*, Olivier Rene, Sylvie Binard, Marie-Christine Alessi, Eric Durot, Paul Gueguen, Felipe Guerrero, Veronique Le Cam-Duchez, Elisabeth Mazoyer, Stephane Muller, Benedecic Neven, Catherine Pousymayou, Bruno Royer, Pierre Sie, Catherine Trchet, Nathalie Trillot, Nicole Schlegel (France) |
| PO441-MON | ROCK1 OR FLI1 MUTATIONS IN PATIENTS WITH MILD THROMBOCYTOPENIA | Maripiel Poggia, Matthias Canault*, Pauline Lucca, Catherine Pousymayou, Dorasf Ghaloussi, Noémie Saut, Pierre Morange, Davd-Alexandre Tregouet, Marie-Christine Alessi (France) |
| PO442-MON | CONGENITAL THROMBOCYTOPENIAS AND IMMUNE THROMBOCYTOPENIC PURPURA: A MISLEADING DIAGNOSIS | Maria Coutinho, Maria Isabel Sánchez Guiu*, Begoña Muñia, Adela Periago, Daniel Jaimes Albornoz, María Luisa Lozano, José Rivera (Spain) |
| PO443-MON | FIVE NEW HETEROZYGOUS MUTATIONS IN THE GPIB AND GPIX ARE ASSOCIATED WITH THE BOLZANO PHENOTYPE | Veronique Baccini*, Noémie Saut, Catherine Pousymayou, Matthias Canault, Dorasf Ghaloussi, Céline Falaise, Xavier Pillois, François Lanza, Pierre Morange, Marie-Christine Alessi (France) |
| PO444-MON | INCREASE THE NUMBER OF GP IIB-IIIa AND P2Y12 RECEPTORS IN ACTIVATED PLATELETS – POSSIBLE EVIDENCE FOR PROTEINS’ SYNTHESIS DE NOVO | Olga Sirotkina*, Pavel Andoskin, Anton Emelyanov, Tatiana Vavilova (Russian Federation) |

### Pediatric thrombosis and hemostasis

| PO445-MON | RISK FACTORS AND CO-MORBIDITIES IN ADOLESCENT THROMBOEMBOLISM ARE DIFFERENT THAN THOSE IN YOUNGER CHILDREN | Susan Kirk, Tíllope Ishola*, Katherine Voigt, Mona Shah, Lakshmi Sirwah (United States) |
| PO446-MON | DO PRETERM INFANTS WITH PATENT DUCTUS ARTERIOSUS (PDA) WHO FAIL INDOMETHACIN TREATMENT HAVE LOWER PLATELET COUNTS?: A SYSTEMATIC REVIEW AND META-ANALYSIS | Souvik Mitra*, Bosco Paes, Anthony Chan (Canada) |
| PO447-MON | CATHETER-DIRECTED THROMBOLYSIS AS SAFE AND EFFECTIVE THERAPY FOR PROXIMAL LOWER LIMB DEEP VEIN THROMBOSIS IN ADOLESCENTS | Kathryn Musgrave*, Adriano Tanna, Tina Biss (United Kingdom) |
| PO448-MON | AGE-DEPENDENCY OF COAGULATION PARAMETERS DURING CHILDHOOD. RESULTS OF A MULTICENTER STUDY. | Pierre Toulon*, Micheline Berrouer, François Grand, Marie Brionne-François, Dominique Lasne, Neila DePooter (France) |
| PO449-MON | CLINICAL FEATURES IN CHILDREN PRESENTING FROM THE COMMUNITY WITH PULMONARY EMBOLISM | Charlie Y. Wang*, Peter Francis, Timothy Cain, Vera Ignjatovic, Fiona Newall, Ed Oakley, Paul Monagle (Australia) |
| PO450-MON | EFFECTS OF MATERNAL HYPERTENSION ON NEONATAL HEMORRHAGE IN SOUTH-SOUTH NIGERIA | Helen Okoye*, Lisa Ewenpulanna, Kaladada Korubo, Oseikhuemen Ejele (Nigeria) |
| PO451-MON | TREATMENT WITH ROMIPLOSTIM IN CHILDREN. INCIDENCE AND QUALITY OF THE RESPONSE. | Maria Del Carmen Gómez Del Castillo* (Spain) |
| PO452-MON | OFF-LABEL USE OF RECOMBINANT FACTOR VIIA FOR DIFFUSE PULMONARY HEMORRHAGE IN CHILDREN | Te-Fu Weng*, Kang-Hsi Wu Wu, Ching-Tien Peng (Taiwan) |
| PO453-MON | INVESTIGATING THE ROLE OF POLYPHOSPHATES IN NEONATAL HEMOSTASIS | Axel Schlagenhauf*, Andrea Ehammer-Rosenkranz, Harald Haidl, Bettina Leschnik, Siegfried Gallistl, Wolfgang Muntean (Austria) |
| PO454-MON | RATIONALE AND DESIGN OF AESOP: APIXABAN FOR PREVENTION OF DEEP VEIN THROMBOSIS IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR LYMPHOMA TREATED WITH L-ASPARAGINASE | Vílmarie Rodríguez*, Sarah O’Brien, Lillian Sung, Luz Ramirez, Danshi Li, Lesley Mitchell (United States) |
| PO455-MON | USE OF PROTHROMBIN COMPLEX CONCENTRATES (PCC) IN PAEDIATRIC EXTRACORPOREAL LIFE SUPPORT PATIENTS | Tom Noga, Susan Nahimik, Jennifer Conway, Holger Büchholz, Mary Bauman, Patti Massicotte, Aisha Bruce* (Canada) |
SCIENTIFIC PROGRAM

PO456-MON  ANTITHROMBIN PLASMA LEVELS AND FIBTEM DETERMINATION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ASPARAGINASE TREATMENT  Luca Spiezia*, Maria Putti, Elena Campello, Sara Maggiolo, Maria Sartori, Alessandra Todesco, Maria Petriss, Laura Sainati, Giuseppe Basso, Paolo Simioni (Italy)

PO457-MON  WARFARIN THERAPY IN CHILDREN: CAN FAMILIES SAFELY AND EFFICIENTLY MONITOR INR'S AT HOME?  Kathy Harney*, Juliann Duzan, Jenna Murray, Peter Forbes, Kathleen O'Neil, Karen Mittler, Rosemary Galvin, Ellis Neufeld, Alan Michelson, Christopher Almond (United States)

PO458-MON  PROPHYLACTIC Enoxaparin in Young Infants – are the Currently Recommended Doses Too Low?  Kathy M. Harney*, Juliann Duzan, Stacy Croteau, Rachael Grace, Kathleen Houlahan*, Ellis Neufeld, Alan Michelson, Cameron Trenor (United States)

PO459-MON  THROMBOEMBOLIC EVENTS IN CHILDREN  Zafer Salcioglu*, Hulya Sayilan Sen, Deniz Tugcu, Gonul Aydogan, Muge Gokce, Cengiz Bayram, Ali Ayicek, Ferhan Akici (Turkey)

PO460-MON  BIVALIRUDIN USE IN CHILDREN ON ECMO FOLLOWING HEPARIN FAILURE  Mary Bauman, Patti Massicotte, Aisha Bruce*, Don Granoski, Laurance Lequier, Lindsay Ryerson (Canada)

PO461-MON  THROMBOEMBOLIC EVENTS IN PEDIATRIC PATIENTS WITH CYANOTIC CONGENITAL HEART DISEASES IN SRINAGARIND HOSPITAL  Patcharee Komvilaisak*, Yuttapong Wongswadiwat, Arnkisa Chaikitpinyo (Thailand)

PO462-MON  PHENOMENON OF HYPERCOAGULABILITY IN CHILDREN WITH DEEP VEIN THROMBOSIS  Marina Gracheva*, Pavel Zharkov, Elena Seregina, Hasmik Sepoyan, Alexandr Poletaev, Fazoil Ataullakhanov (Russian Federation)

PO463-MON  IMPACT OF INHERITED AND ACQUIRED PROTHROMBOTIC DEFECTS (PD) ON THE DEVELOPMENT OF SYMPTOMATIC THROMBOEMBOLISM (STE) IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) TREATED ACCORDING TO THE DANAFARBER CANCER INSTITUTE (DFCI) 05-01 ALL-THERAPY PROTOCOL  Uma Athale*, Caroline Laverdiere, Trishana Nayiager, Yves-Line Delva, Gary Foster, Lehana Thabane, Anthony Chan (Canada)

PO464-MON  EXAMINING THE FEASIBILITY OF RECOMBINANT FACTOR VIIA TO COMPENSATE FOR PHYSIOLOGICAL OR DRUG-INDUCED IMPAIRMENT OF PLATELET FUNCTION: AN IN-VITRO STUDY  Harold Haidt*, Axel Schlagenhauf, Gernot Grangl, Gerhard Cvrin, Siegfried Gallistl, Wolfgang Muntean (Austria)

PO465-MON  ASSESSING THE ASSOCIATION OF FVIII and ABO BLOOD GROUP WITH DEEP VEIN THROMBOSIS IN PEDIATRIC ONCOLOGY PATIENTS  Jackie Halton, Maria Spavor, Kevin Dietrich, Sarah Israels, Leonardo Brandao, Qi Liu, Yutaka Yasui, Lesley G. Mitchell* (Canada)

PO466-MON  DENSER CLOTS PREDISPOSE TO POST THROMBOTIC SYNDROME  Annemieke C. Bouman*, Helen McPherson, Yue Cheung, Marie ten Wolde, Hugo ten Cate, Robert Ariens, Arina ten Cate-Hoek (The Netherlands)


PO468-MON  TWO WEEKS OF LOW MOLECULAR WEIGHT HEPARIN FOR ISOLATED SYMPTOMATIC DISTAL VEIN THROMBOSIS (TWISTER STUDY): INTERIM ANALYSIS OF FIRST 100 PATIENTS – POST THROMBOTIC SYNDROME SUB-STUDY  Eileen Merriman*, Sanjeev Chunilal, Simon McRae, Tim Brightton, Huyen Tran (New Zealand)

PO469-MON  TITLE: FREQUENCY OF PERSISTENTLY ABNORMAL ECHOCARDIOGRAPHY AFTER ACUTE PULMONARY EMBOLISM  Emily Gundert*, Jeffrey Kline, David Jimenez, Llorenç Font, Manuel Lorente, Barbara Pagan, Radovan Maly, Peter Vehamme, Manuel Monreal (United States)

PO470-MON  TOLL-LIKE 9 GENE EXPRESSION IN THE POST THROMBOTIC SYNDROME, RESIDUAL THROMBOSIS AND RECURRENT DEEP VENOUS THROMBOSIS: A CASE-CONTROL STUDY  Whitney Cheung*, Annemieke Bouman, Elisabetta Castoldi, Simone Wielders, Henri Spronk, Hugo ten Cate, Arina ten Cate-Hoek, Marie ten Wolde (The Netherlands)

PO471-MON  PATIENTS’ PREFERENCES REGARDING ELASTIC COMPRESSION STOCKING THERAPY FOR THE PREVENTION OF POST THROMBOTIC SYNDROME  Annemieke C. Bouman*, Arina ten Cate-Hoek, Carmen Dirksen, Manuela Joore (The Netherlands)


PO473-MON  IS POST THROMBOTIC SYNDROME PERCEIVED TO BE A CLINICALLY RELEVANT OUTCOME?: A SURVEY OF PHYSICIAN PRIORITIES  Rick T. Ikesaka*, Susan Kahn, Jean-Philippe Galanau, Fernando Vazquez, Graham Roche-Nagle, Marc Carrier, Gregoire Le Gai, Marc Rodger, Esteban Gandara (Canada)

PO474-MON  EXERCISE LIMITATION IN CHRONIC POST-THROMBOTIC ILEOFEMORAL VEIN OBSTRUCTION  Jacob Luboshitz*, Michael Segal, Ronen Reuveny, Issachar Ben Dov (Israel)
**SCIENTIFIC PROGRAM**

**PO475-MON**  
ADVANCING THE DIAGNOSIS OF PEDIATRIC POST-THROMBOTIC SYNDROME: A FOUNDATION FOR THE IMPROVEMENT AND STANDARDIZATION OF ITS MEASUREMENT TOOLS  
Laura Avila*, Leonardo Brandao, Suzan Williams, Madeline Montoya, Jennifer Stinson, Alex Kiss, Leigh Ward, Irene Lara Corrales, Brian Feldman (Canada)

**PO476-MON**  
FIBRINOGEN CHARACTERISTICS HELP PREDICT CHRONIC THROMBOTIC VENOUS DISEASE AFTER ACUTE DEEP VEIN THROMBOSIS  
Timothy Fernandes, James Marsh, Peter Chiles, Anthony Gamst, Tanya Wolfson, Roger Moore, Gabriel Gugiu, Terry Lee, Timothy A. Morris* (United States)

**PO477-MON**  
RESIDUAL THROMBUS MASS AND INCIDENCE OF POST THROMBOTIC SYNDROME IN PATIENTS TREATED WITH VKA OR NON-VKA ORAL ANTICOAGULANTS IN PHASE-III DVT TREATMENT TRIALS  
Sebastian Werth*, Ines Paternoga, Luise Tittl, Norbert Weiss, Jan Beyer-Westendorf (Germany)

**PO478-MON**  
THE ROLE OF INFLAMMATION IN POST-THROMBOTIC SYNDROME AFTER PREGNANCY-RELATED VENOUS THROMBOSIS  
Hilde Skuterud Wik*, Anne Jacobsen, Per Sandset (Norway)

**PO479-MON**  
MOM, WHY SHOULD I WEAR THESE SOCKS? TAKING THE FIRST STEP IN THE JOURNEY TO UNDERSTANDING THE ROLE OF COMPRESSION GARMENTS IN THE TREATMENT OF PEDIATRIC POST-THROMBOTIC SYNDROME  
Madeline I. Montoya*, Maria Laura Avila, Jennifer Vincelli, Leonardo Brandão (Canada)

**PO480-MON**  
INADEQUATE ANTICOAGULATION IS THE ONLY RISK FACTOR FOR DEVELOPMENT OF POST THROMBOTIC SYNDROME IN UNPROVOKED DEEP VEIN THROMBOSIS  
Pravas Mishra*, Kamal Kishor, Tulika Seth, Manoranjan Mahapatra, Renu Saxena (India)

**PO481-MON**  
PATIENT COMPRESSION HOUSIERY CONCORDANCE  
Gary Benson*, Rosemary Lavery, Hilary Speers (United Kingdom)

**PO482-MON**  
THE UTILITY OF THROMBELASTOGRAPHY AND MULTIPLATE AS SCREENING TOOLS FOR RARE INHERITED BLEEDING DISORDERS NOT ASSOCIATED WITH A COAGULATION FACTOR DEFICIENCY  
Eva B. Leine*, Jakob Stensballe, Peter Kampmann, Jens P Goetze (Denmark)

**PO483-MON**  
BLEEDING SCORE AND CLOTTING SCREENING TEST PERFORMED BEFORE ELECTIVE SURGERY TO DIAGNOSE UNKNOWN HEMORRHAGIC DISEASES.  
Federica Zane, Catherine Klersy, Luigia Scudeller, Chiara Ambaglio, Mariaconcetta Russo, Nicola Ghiiddi, Nicolò Allorto, Gabriella Gamba* (Italy)

**PO484-MON**  
EFFECTIVENESS OF FGTW FIBRINOGEN CONCENTRATE IN THE TREATMENT OF BLEEDING EPISODES AND PREVENTION OF EXCESSIVE BLEEDING DURING SURGERY IN PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY  
Claudia Djambas Khayat*, Mohamed El Khorassani, Valérie Gay, Malika Barthez-Toulec, Céline Henriet, Françoise Bidey, Luis Carreras, Claude Négrier, Philippe de Moerloose (Lebanon)

**PO485-MON**  
A NEW SWISS FAMILY WITH CONSTITUTIONAL HYPOFIBRINOGENEMIA AND LIVER DISEASE  
Alessandro Casini*, Christiane Sokollik, Samuel Lukowski, Eberhard Luz, Claudine Rieubland, Philippe de Moerloose, Marguerite Neerman-Arbez (Switzerland)

**PO486-MON**  
SAFE USE OF FXI CONCENTRATE IN A SINGLE CENTRE EXPERIENCE OVER 19 YEARS  
Gavin Ling*, Museini Kagdi, Pratima Chowdary, Keith Gomez (United Kingdom)

**PO487-MON**  
THE EPIDEMIOLOGY OF INHERITED BLEEDING DISORDERS IN NEWFOUNDLAND AND LABRADOR, CANADA  
Aaron Wiseman*, Sarah Boyd, Mary-Frances Scully (Canada)

**PO488-MON**  
PHARMACOKINETIC AND PHARMACODYNAMIC RESULTS OF A MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY WITH A FIBRINOGEN CONCENTRATE (FGTW) IN SUBJECTS WITH AFBIRINOGENEMIA  
Claudia Djambas Khayat*, Mohamed El Khorassani, Thierry Lambert, Anne Bellon, Malika Barthez-Toulec, Françoise Bidey, Luis Carreras, Claude Négrier, Philippe de Moerloose (Lebanon)

**PO489-MON**  
ALTERNATIVE STRATEGY TO TREAT HEMOPHILIA TROUGH PROTEIN S INACTIVATION: INSIGHT FROM A MOUSE MODEL  
Luca Bologna*, Sara Calzavarrini, Raja Prince, Natacha Demaillet, Francois Saller, Anne Angelillo-Scherrer (Switzerland)

**PO490-MON**  
GENOTYPE AND PHENOTYPE REPORT ON PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY IN SOUTH OF IRAN  
Mehran Karimi*, Mohammad Mostafa Safarpour, Sezaneh Hagphanah, Aidin Meshk-sar*, Abdolreza Afrasiabi, Javad Gerdab, Rezvan Ardehili (Iran, Islamic Republic Of)

**PO491-MON**  
FVIIIA MIMICKING BISPECIFIC ANTIBODY, ACE910 IMPROVES IN VITRO COAGULATION FUNCTION OF FXI DEFICIENCY PATIENT’S PLASMA  
Hiroaki Minami*, Keiji Nogami, Takehisa Kitazawa, Kunihiro Hattori, Midori Shimura (Japan)

**PO492-MON**  
SPECTRUM OF FACTOR XI MUTATIONS IN THE CHINESE POPULATION  
Yanyan Shao*, Qiulan Ding, Yelin Lu, Jing Dai, Xiaodong Xi, Xuefeng Wang, Hongli Wang (China)

**PO493-MON**  
CHARACTERIZING MECHANISMS OF FACTOR VIII BINDING TO THE LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1  
Patricia Young*, Molly Migliorini, Joni Prasad, Andrey Sarafanov, Dudley Strickland (United States)
SCIENTIFIC PROGRAM

Karima W. Chennoukh*, Meriem Bensadok, Mylade Aribi, Nadia Zidani, Mohamed Ramaoun, Meriem Belhani, Salim Nekkal (Algeria)

PO495-MON THE THROMBIN GENERATION ASSAY IS SUPERIOR TO THROMBOELASTOGRAPHY AT DETERMINING BLEEDING PHENOTYPE IN CONGENITAL FXI DEFICIENCY.
Gillian N. Pike*, Anthony Cumming, Charles Hay, John Burthem, Paula Bolton-Maggs (United Kingdom)

PO496-MON A NEW MUTATION IN THE SVIL GENE IS ASSOCIATED WITH AUTOSOMAL DOMINANT FAMILIAL GRAY PLATELET SYNDROME
Irina Demina*, Maria Kumskova, Artem Artemov, Sofya Lushchekina, Alyona Ivanova, Maria Suntsova, Sergey Vasilyev, Anton Buzdin, Alexey Maschan, Galina Novichkova, Mikhail Panteleev (Russian Federation)

PO497-MON ACQUIRED GPVI DEFICIENCY IN TWO UNRELATED PATIENTS WITH MILD THROMBOCYTOPENIA
Marta Romera*, Eva Caparrós-Pérez, José Vicente Sánchez-Méndez, Maria Isabel Sánchez Guin, Irene Martínez Martínez, José Padilla, Francisca Ferrer-Marin, Raúl Tenero-Montoya, Vicente Vicente, Steve P Watson, Robert Andrews, Elizabeth Gardiner, Maria Luisa Lozano, José Rivera (Spain)

PO498-MON IDENTIFICATION OF THE PATHOPHYSIOLOGICAL MECHANISM OF THE VKCF2D CAUSING MUTATION P.ARG98TRP IN HUMAN VKORC1 GENE
Katrin Czogalla*, Arijit Biswas, Matthias Watzka, Johannes Oldenburg (Germany)

PO499-MON SCOTT SYNDROME PLATELETS SHOW ALTERATIONS IN PROTEIN EXPRESSION LEVELS, CALCULUM-DEPENDENT PHOSPHORYLATION AND CLEAVAGE AS REVEALED BY PROTEOMICS
Nadine Mattheij, Fiorella Solari, Julia Burkhart, Frauke Swieringa, Peter Collins, Judith Cosemans, Albert Sickmann, René Zahedi, Johan W. Heemskerk* (The Netherlands)

PO500-MON A FAILURE TO DIAGNOSE DYSFIBRINOGENAEIA: DATA FROM MULTICENTRE STUDIES AMONGST UK NEQAS AND PRO-RBDD PROJECT LABORATORIES.
Ian Jennings*, Flora Peyvandi, Steve Kitchin, Marzia Menegatti, Roberta Palla, Isobel Walker, Mike Makris (United Kingdom)

PO501-MON POST AUTHORIZATION SAFETY STUDY OF A TRIPLY SECURED FIBRINOGEN CONCENTRATE IN CONGENITAL AFIBRINOGENEMIA: A PROSPECTIVE OBSERVATIONAL STUDY.
Zéra Tellier*, Claude Négrier, Chantal Rothschild, Jeanne-Yvonne Borg, Thierry Lambert, Natalie Stelljes, Stéphane Claeyssens, Laurence Sanhes, Arnaud Bertrand, Marie-Hélène André, Pierre Sié, Yves Gruel (France)

PO502-MON FIBRINOGEN DEFICIENCY: PRELIMINARY RESULTS OF THE PRO-RBDD PROJECT
Flora Peyvandi*, Marzia Menegatti, Roberta Palla, Simona Siboni, Marco Boscarino, Helen Pergantou, Helen Platokouki, Britta Lachmann, Susan Halimeh, Marlies van Lent, Paul Bruns, Britta Laros-van Gorkom, Naveena Fatima, Munira Borhany, Ay Yilmaz, Adrianna Williamson, Amy Shapiro, Alessandro Casini, Nihal Ozdemir, Ordej Zapletal, Jan Blanty, Fraustina Hsu, John Chapin, Muriel Gruel-de Blaitz, Jean François Schved, Andrew Harvey, Andrew Mumford, Pearl Quartey, Steve Austin, Marko Saracevic, Danijela Miljkovic, Philippe de Moerloose (Italy)

PO503-MON DECREASED FIBRINOLYTIC RESISTANCE IN FXI-DEFICIENCY IS INDEPENDENT OF CLOTTING IMPAIRMENT
Francesca Incampo*, Antonio Cannavo, Marzia Menegatti, Eugenia Biguzzi, Nicola Semeraro, Mario Colucci, Flora Peyvandi (Italy)

PO504-MON IMPACT OF ASSAY METHOD ON CLINICAL DOSING OF A PURIFIED FACTOR X CONCENTRATE
Joanne Lloyd*, Miranda Norton (United Kingdom)

PO505-MON SCOTT SYNDROME PLATELETS SHOW ALTERATIONS IN PROTEIN EXPRESSION LEVELS, CALCIUM-DEPENDENT PHOSPHORYLATION AND CLEAVAGE AS REVEALED BY PROTEOMICS
Nadine Mattheij, Fiorella Solari, Julia Burkhart, Frauke Swieringa, Peter Collins, Judith Cosemans, Albert Sickmann, René Zahedi, Johan W. Heemskerk* (The Netherlands)

PO506-MON BIOGENESIS, SUBCELLULAR LOCALIZATION AND MOBILIZATION OF TWO ABUNDANT PLATELET THIOL ISOMERASES

PO507-MON RISK FACTORS FOR OBSTETRIC BLEEDING IN VON WILLEBRAND DISEASE (VWD)
Gavin D. Roach*, David Elashoff, Judith Baker (United States)

PO508-MON PLACENTAL INSUFFICIENCY RESOLUTION WITH FULL ANTICOAGULATION IN PATIENTS WITH PRIOR BAD OBSTETRIC OUTCOME AND DYSLIPIDEMIA DURING PREGNANCY.
Roberta Santos*, Venina Barros, Ana Igai, Rossana Pulcinelli, Marcelo Zugaib (Brazil)

PO509-MON D-DIMER MEASUREMENT HAS NO DIAGNOSTIC VALUE DURING PREGNANCY – A LONGITUDINAL STUDY OF 4314 SAMPLES FROM 791 HEALTHY WOMEN
Katrine Hedengran*, Malene Andersen, Steen Stender, Pal Szecsi (Denmark)

PO510-MON MEN WITH FACTOR V LEIDEN HAVE INCREASED SPERM COUNTS
Thijs E. Van Mens*, Cindy Kotter, Danny Cohn, Joost Meijers, Saskia Middeldorp, Sjerp Reppin (The Netherlands)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO511-MON</td>
<td>INCIDENCE OF VENOUS THROMBOSIS IN PREGNANCIES AFTER SPONTANEOUS AND ART CONCEPTION - AN ITALIAN COHORT STUDY -</td>
<td>Michela Villani*, Francesco Dentali, Donatella Calaizzo, Giovanni Tiscia, Patrizia Vegura, Tiziana Petruzzelli, Francesco Petruzzelli, Walter Ageno, Maurizio Margaglione, Elvira Grandone (Italy)</td>
</tr>
<tr>
<td>PO512-MON</td>
<td>POST-PARTUM PROPHYLAXIS IN PRACTICE.</td>
<td>Emmanuelle Le Moigne*, Pascal Nicolas, Aurelien Delluc, Karine Lacut, Michel Collet, Dominique Mottier, Brigitte Pan-Petesch (France)</td>
</tr>
<tr>
<td>PO513-MON</td>
<td>THE M2 HAPLOTYPE WITHIN THE ANNEXIN A5 GENE AND ANTIPHOSPHOLIPID ANTIBODIES IN UNSELECTED PREGNANT WOMEN- A PROSPECTIVE HOSPITAL- BASED STUDY-</td>
<td>Michela Villani*, Elena Chinini, Filomena Cappucci, Pasquale Martinelli, Giuseppe Manduelli, Giovanni Tiscia, Donatella Calaizzo, Lucia Fischetti, Maurizio Margaglione, Elvira Grandone (Italy)</td>
</tr>
<tr>
<td>PO514-MON</td>
<td>AGE OF MENARCHE AND RISK OF VENOUS THROMBOEMBOLISM</td>
<td>Luuk Scheres*, Saskia Middeldorp, Frits Rosendaal, Suzanne Canningieler (The Netherlands)</td>
</tr>
<tr>
<td>PO515-MON</td>
<td>EFFECT OF PROPHYLAXIS WITH LMWH ON IMPLANTATION IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE PROCEDURES (IVF OR ICSI): A PROSPECTIVE RANDOMIZED STUDY</td>
<td>Daniela Tormene*, Federica Esposito, Libera Falcone, Francesca Viganò, Michele Gangemi, Giovanni Battista Nardelli, Paolo Simioni (Italy)</td>
</tr>
<tr>
<td>PO516-MON</td>
<td>PREDICTION OF VENOUS THROMBOEMBOLIC RELATED FETAL LOSSES BY A NEW GENETIC RISK SCORE</td>
<td>Eduardo Salas, Jose A. Paramo*, Ramon Lecumberri, Ana Alfonso, Kevin Guilin, Sara Pich, Oriol Casagran, Ana Ferro, Jose Soria (Spain)</td>
</tr>
<tr>
<td>PO517-MON</td>
<td>MONITORING OF COAGULATION ACTIVATION MARKER AND APPLICATION OF LMWH IN PREGNANCY</td>
<td>Annelies Siegemund*, Ute Scholz, Thomas Siegemund (Germany)</td>
</tr>
<tr>
<td>PO518-MON</td>
<td>MECHANISM OF THE INCREASED THROMBOSIS RISK INDUCED BY BLOOD LOSS DURING CAESARIAN SECTION</td>
<td>Victoria Kuhnt*, Maria Thomassen, Tilman Hackeng, Ana Zencuslens, Serban-Dan Costa, Svetlana Tchaikovski (Germany)</td>
</tr>
<tr>
<td>PO519-MON</td>
<td>IDENTIFYING COMMON AND RARE GENETIC VARIANTS ASSOCIATED WITH SERUM LEVELS OF ATHEROSCLEROTIC BIOMARKER PROTEINS</td>
<td>Terry Solomon*, Erin Smith, Sigrid Braekkan, Tom Wilskaard, John-Bjarne Hansen, Kelly Frazer (United States)</td>
</tr>
<tr>
<td>PO520-MON</td>
<td>COMPARISON OF THROMBIN GENERATION TEST AND MARKERS OF COAGULATION ACTIVATION IN UNCOMPLICATED PREGNANCY AND PREGNANCY-RELATED VENOUS THROMBOEMBOLISM</td>
<td>Berangere Joly, Virginie Barbay, Jeanne-Yvonne Borg, Veronique Le Cam-Duchez* (France)</td>
</tr>
</tbody>
</table>

**Risk factors in thrombosis**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO521-MON</td>
<td>ALL CAUSE MORTALITY AND USE OF ANTIITHROMBOTICS WITHIN 90 DAYS OF DISCHARGE IN ACUTELY ILL MEDICAL PATIENTS</td>
<td>Charles E. Mahan*, Larry Fields, Roger Mills, Judith Stephenson, An-Chen Fu, Maxine Fisher, Alex Spyropoulos (United States)</td>
</tr>
<tr>
<td>PO522-MON</td>
<td>RISK OF VENOUS THROMBOSIS AND COAGULATION PROFILE IN DUTCH NATIVES AND IMMIGRANTS IN THE NETHERLANDS: RESULTS FROM THE MEGA STUDY</td>
<td>Suley Rezende*, Willem Lijfering, Mettine Bos, Joost Meijers, Frits Rosendaal, Suzanne Canningieler (Brazil)</td>
</tr>
<tr>
<td>PO523-MON</td>
<td>IMPACT OF TORNADOES ON HOSPITAL ADMISSIONS FOR VENOUS THROMBOEMBOLISM AND CARDIOVASCULAR EVENTS</td>
<td>Ana I. Casanegra*, Federico Silva, Alan Shapiro, Minh Phan, Beau Hawkins, Ji Li, Julie Stoner, Alfonso Tafur (United States)</td>
</tr>
<tr>
<td>PO524-MON</td>
<td>JOINT EFFECTS OF F5 GENE VARIANTS AND TALL STATURE ON VTE RISK</td>
<td>Tine S. Lanneberg*, Erin Smith, Sigrid Braekkan, Lars Horvei, Terry Solomon, Tom Wilskaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)</td>
</tr>
<tr>
<td>PO525-MON</td>
<td>JOINT EFFECT OF OBESITY AND RISK ALLELES IN THE KNG1 GENE ON RISK OF VENOUS THROMBOEMBOLISM.</td>
<td>Tine Lanneberg*, Erin Smith, Sigrid Braekkan, Lars Horvei, Terry Solomon, Tom Wilskaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)</td>
</tr>
<tr>
<td>PO526-MON</td>
<td>JOINT EFFECT OF CANCER AND THE GP6 RS1613662 SINGLE NUCLEOTIDE POLYMORPHISM ON VTE RISK</td>
<td>Olga Dziewiecka*, Erin Smith, Sigrid Braekkan, Hilde Jensvoll, Kristine Blix, Terry Solomon, Tom Wilskaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)</td>
</tr>
<tr>
<td>PO528-MON</td>
<td>INVOLVEMENT OF HEREDITARY THROMBOPHILIA IN CEREBRAL VENOUS THROMBOSIS OCCURRING IN YOUNG PATIENTS</td>
<td>Héla Baccouche*, Eya Chakroun, Sonia Mahjoub, Montaha Ben Jemaa, Samia Ben Sassi, Zeineb Manai, Nella Ben Romdhane (Tunisia)</td>
</tr>
<tr>
<td>PO529-MON</td>
<td>CHRONIC LIVER DISEASE IS A SIGNIFICANT RISK FACTOR FOR VENOUS THROMBOEMBOLISM AMONG MEDICAL PATIENTS IN SINGAPORE GENERAL HOSPITAL</td>
<td>Lai Heng Lee*, Xiao Zhu Zhang, Han Seong Ng, Jeffrey Hui, Yong Yang (Singapore)</td>
</tr>
<tr>
<td>PO530-MON</td>
<td>THE EFFECT OF HEMODIALYSIS AND HEMODIALYSIS ON COAGULATION PARAMETERS IN PATIENTS WITH END-STAGE RENAL DISEASE</td>
<td>Kristzina Pénzes-Daku*, Gergely Becs, Boglárka Hurjak, Eva Molnár, Judit Csapó, Éva Katona, József Balla, László Muszbek (Hungary)</td>
</tr>
</tbody>
</table>
# Scientific Program

<table>
<thead>
<tr>
<th>Posters</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PO531-MON</strong></td>
<td>MIR-15A, MIR-96, MIR-144, MIR-150, MIR-155, MI210, MIR-212, MIR-223, MIR-424 AND MIR-451 ARE DIFFERENTIALLY EXPRESSED IN PLATELETS FROM DVT PATIENTS</td>
</tr>
<tr>
<td><strong>PO532-MON</strong></td>
<td>PREVENTION OF VENOUS THROMBOSIS AFTER AN ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION: COMPRESSION STOCKINGS ALONE VERSUS ITS COMBINATION WITH LOW MOLECULAR WEIGHT HEPARIN.</td>
</tr>
<tr>
<td><strong>PO533-MON</strong></td>
<td>EFFECT OF N-HOMOCYTEINYLATION PROCESS ON TISSUE PLASMINOGEN ACTIVATOR.</td>
</tr>
<tr>
<td><strong>PO534-MON</strong></td>
<td>INCREASED CIRCULATING DNA, CALPROTECTIN AND MIELOPEROXIDASE, AS NEUTROPHIL EXTRACELLULAR TRAP MARKERS, ARE RISK FACTORS FOR DEEP VEIN THROMBOSIS</td>
</tr>
<tr>
<td><strong>PO535-MON</strong></td>
<td>IN-HOSPITAL COSTS AND CLINICAL DETERMINANTS OF COSTS OF ACUTE PULMONARY EMBOLISM: A PROSPECTIVE STUDY</td>
</tr>
<tr>
<td><strong>PO536-MON</strong></td>
<td>IDENTIFICATION AND VALIDATION OF PLASMA MICRORNAS INVOLVED IN VENOUS AND ARTERIAL THROMBOSIS</td>
</tr>
<tr>
<td><strong>PO537-MON</strong></td>
<td>THE INCIDENCE OF CATHETER-RELATED THROMBOSIS IN PATIENTS ON LONG-TERM PARENTERAL NUTRITION: A SYSTEMATIC REVIEW AND META-ANALYSIS.</td>
</tr>
<tr>
<td><strong>PO538-MON</strong></td>
<td>VENA CAVA THROMBOSIS IN ADULTHOOD VS PEDIATRICS PATIENTS: DIFFERENT PHENOTYPES AND RISK FACTORS FOR THE SAME ENTITY.</td>
</tr>
<tr>
<td><strong>PO539-MON</strong></td>
<td>A CLINICAL AUDIT OF HERITABLE THROMBOPHILIA TEST PROFILE IN A TERTIARY HEALTH CARE FACILITY, PAKISTAN.</td>
</tr>
</tbody>
</table>

---

### Thrombophilia I

<table>
<thead>
<tr>
<th>Posters</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PO540-MON</strong></td>
<td>THROMBOPHILIC PROFILE IN EXTRAHEPATIC PORTAL VEIN OBSTRUCTION - EXPERIENCE FROM A TERTIARY CENTRE IN INDIA</td>
</tr>
<tr>
<td><strong>PO541-MON</strong></td>
<td>ISTH'S CLARION CALL: &quot;TO RAISE THE AWARENESS OF THROMBOSIS WORLDWIDE - A GLOBAL DISEASE BURDEN&quot;</td>
</tr>
<tr>
<td><strong>PO542-MON</strong></td>
<td>RISK FACTORS OF THROMBOSIS AND SICKLE CELL ANEMIA</td>
</tr>
<tr>
<td><strong>PO543-MON</strong></td>
<td>GENETIC VARIABILITY OF NGF1 AND F11 GENES USING NEXT GENERATION SEQUENCING</td>
</tr>
<tr>
<td><strong>PO544-MON</strong></td>
<td>LABORATORY MARKERS OF THROMBOPHILIA</td>
</tr>
<tr>
<td><strong>PO545-MON</strong></td>
<td>EVALUATION OF PROTEIN S SPECIFIC ACTIVITY PERMITS ACCURATE DIAGNOSIS OF PROTEIN S TOKUSHIMA, A MISSENSE MUTATION WITH TYPE II PROTEIN S DEFICIENCY</td>
</tr>
<tr>
<td><strong>PO546-MON</strong></td>
<td>HYPOXIA INDUCES A PROTHROMBOTIC STATE INDEPENDENTLY OF THE PHYSICAL ACTIVITY</td>
</tr>
<tr>
<td><strong>PO547-MON</strong></td>
<td>THE POSSIBLE ROLE OF C.1824C&gt;T PROTHROMBIN GENE VARIANT IN PATHOGENESIS OF THROMBOPHILIA</td>
</tr>
<tr>
<td><strong>PO548-MON</strong></td>
<td>PATHOGENETIC PROPHYLAXIS PRE-ECCLAMPSIA IN PATIENTS WITH THROMBOPHILIA AND THE HISTORY OF PRE-ECCLAMPSIA</td>
</tr>
<tr>
<td><strong>PO549-MON</strong></td>
<td>THE CLINICAL AND LABORATORY ANALYSIS OF HOMOZYGOUS CARRIERS FACTOR V LEIDEN MUTATION</td>
</tr>
<tr>
<td><strong>PO550-MON</strong></td>
<td>MOLECULAR CHARACTERIZATION OF NEW ANTIITHROMBIN MUTATIONS</td>
</tr>
<tr>
<td><strong>PO551-MON</strong></td>
<td>A REASON TO INCLUDE HOMOCYTEINE IN THE HYPERCOAGULABLE WORKUP</td>
</tr>
</tbody>
</table>

---

**Scientific Program**

**PO531-MON**


Mariane Flores-Nascimento*, Regiane Ferreira, Thais Fornari, Lúcia Helena Siqueira, Bruna Mazzetto, Fernanda Orsi, Erich De Paula, Marina Colletta, Joyce Annichino-Bizzacchi (Brazil)

**PO532-MON**

**PREVENTION OF VENOUS THROMBOSIS AFTER AN ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION: COMPRESSION STOCKINGS ALONE VERSUS ITS COMBINATION WITH LOW MOLECULAR WEIGHT HEPARIN.**

Raymond A. Van Adrichem*, Nicole Tolen, Lucas Goldman, Anna Boef, Nienke van Rein, Marcel Driessen, Manfred Vischjager, Ing Schipper, Rob Nelissen, Frits Rosendaal, Suzanne Canneugieter (The Netherlands)

**PO533-MON**

**EFFECT OF N-HOMOCYTEINYLATION PROCESS ON TISSUE PLASMINOGEN ACTIVATOR.**

Heliana Hernández Herrera, Lucía Kordich, Irene Quintana*, Ana María Lauricella (Argentina)

**PO534-MON**

**INCREASED CIRCULATING DNA, CALPROTECTIN AND MIELOPEROXIDASE, AS NEUTROPHIL EXTRACELLULAR TRAP MARKERS, ARE RISK FACTORS FOR DEEP VEIN THROMBOSIS**

Laura Martos, Silvia Navarro, Luis Ramón, Fernando Ferrando, Ana Cid, Santiago Bonanad, Francisco España, Pilar Medina* (Spain)

**PO535-MON**

**IN-HOSPITAL COSTS AND CLINICAL DETERMINANTS OF COSTS OF ACUTE PULMONARY EMBOLISM: A PROSPECTIVE STUDY**

Jean-Philippe Galanoud*, Aurelie Ternissien, Vera Georgescu, Daniel Pontal, Isabelle Quere, Pierre Aubas, Gregoire Mercier (France)

**PO536-MON**

**IDENTIFICATION AND VALIDATION OF PLASMA MICRORNAS INVOLVED IN VENOUS AND ARTERIAL THROMBOSIS**

Luis A Ramon, Laura Martos, Joaquín Rueda, Miguel A Arnau, Esther Zorio, Fernando Ferrando, Yolanda Mira, Santiago Bonanad, Pilar Medina, Francisco España, Silvia Navarro* (Spain)

**PO537-MON**

**THE INCIDENCE OF CATHETER-RELATED THROMBOSIS IN PATIENTS ON LONG-TERM PARENTERAL NUTRITION: A SYSTEMATIC REVIEW AND META-ANALYSIS.**

Stefano L. Barco*, Bram Salman, Mireille Serlie, Saskia Middeldorp, Michiel Coppens (The Netherlands)

**PO538-MON**

**VENA CAVA THROMBOSIS IN ADULTHOOD VS PEDIATRICS PATIENTS: DIFFERENT PHENOTYPES AND RISK FACTORS FOR THE SAME ENTITY.**

Georgina Daher*, Verónica Pons, Inés Valcarce, Gonzalo Artaza, Pavel Olivera, Laura López, Amparo Santamaría, Francesc Bosch (Spain)

**PO539-MON**

**A CLINICAL AUDIT OF HERITABLE THROMBOPHILIA TEST PROFILE IN A TERTIARY HEALTH CARE FACILITY, PAKISTAN.**

Anila Rashid, Bushra Molz*, Humaira Perveen, Bushra Rizvi (Pakistan)
SCIENTIFIC PROGRAM

PO552-MON

PATHOLOGICAL DETERMINANTS OF HUMAN CORONARY THROMBUS FORMATION: DISTINCT PROCOAGULANT ACTIVITY AND LAC TATE PRODUCTION OF M1/M2 POLARIZED MACROPHAGES.

Shuntaro Matsuda, Atsushi Yamashita*, Sayaka Moriguchi-Goto, Naoki Sameshima, Takashi Ikawiri, Yunosuke Matsuura, Yuichiro Sato, Yuijro Asada (Japan)

PO553-MON

SINGLE PHOSPHORYLATION OF THE CYTOPLASMIC DOMAIN OF TISSUE FACTOR AT SERINE 253 IS SUFFICIENT FOR THE BINDING OF TISSUE FACTOR TO FILAMIN-A

Mary E. W. Collier*, Ben Goulit, Anthony Maraveyas, Camille Ettelaie, Alison Goodall (United Kingdom)

PO554-MON

THE INTERPLAY BETWEEN TISSUE FACTOR AND ALTERNATIVELY SPICLED TISSUE FACTOR AND ITS EFFECT ON THROMBOSIS AND HEMOSTASIS.

Betul Unlu*, Henri Versteeg (The Netherlands)

PO555-MON

K63-LINKED POLYUBIQUITINATION OF LYSINE 255 WITHIN TF PROMOTES SELECTIVE TF-DENPHOSPHORYLATION, TRIGGERS TF-ENDOCYTOSIS AND TERMINATES TF ACTIVITY

Camille Ettelaie*, Anthony Maraveyas, Mary Collier (United Kingdom)

PO556-MON

CHARACTERISATION OF TF UBQUITINATION: INVOLVEMENT OF MDM2 AND THE UBE2D FAMILY OF E2 ENZYMES

Camille Ettelaie*, Mary Collier, Sohpie Featherby, Anthony Maraveyas (United Kingdom)

PO557-MON

HIGH LEVEL OF TISSUE FACTOR INDUCES CELL APOPTOSIS IN ENDO THELIAL CELLS, MEDIATED THROUGH ACTIVATION OF P38 AND P53

Azza EIKeeb, Mary Collier, Anthony Maraveyas (United Kingdom)

PO558-MON

THE POTENTIAL OF CANCER CELL LINES TO RELEASE TISSUE FACTOR-CONTAINING MICROSICLES CORRELATES WITH TISSUE FACTOR AND PAR2 MRNA LEVELS BUT NOT TISSUE FACTOR PROTEIN OR SURFACE ACTIVITY

Camille Ettelaie*, Mary Collier, Sophie Featherby, John Greenman, Anthony Maraveyas (United Kingdom)

PO559-MON

TISSUE FACTOR IS INDUCED BY INTERLEUKIN-33 IN HUMAN ENDO THELIAL CELLS: A NEW LINK BETWEEN COAGULATION AND INFLAMMATION

Stefan Stojkovic*, Christoph Kaun, José Basilio, Sabine Rauscher, Lena Hell, Konstan tin Krychtiuk, Wolfgang Holnthoner, Christoph Neumayer, Cihan Ay, Wolfgang Eppel, Ihor Huk, Rainer De Martin, Kurt Huber, Svitlana Demyanets, Johann Wojta (Austria)

PO560-MON

SOLUBLE TISSUE FACTOR IMPROVES DETECTION OF THROMBIN GENERATION RESPONSES TO WIDE RANGE OF FACTOR Vlla DOSES

Alexey Shibeko, AliReza Rezaie, Timothy Lee, Mikhail V. Ovanesov* (United States)

PO561-MON

NATURALLY OCCURRING NEISSERIA MENINGITIDIS WITH MUTATED LIPID A MOIETY IS A WEAKER INDUCER OF TISSUE FACTOR EXPRESSION AND ACTIVITY IN HUMAN MONOCYTES AND MONOCYTE-DERIVED MICROSICLES THAN THE WILDTYPE MENINGOCCCI

Marit Hellum, Anne Marie Siebeke Troseid, Jens Putter Berg, Petter Brandtzæg, Reidun Ovstebo, Carolina Henrisson* (Norway)

PO562-MON

DO ELEVATED COAGULATION FACTOR LEVELS AFFECT THE TISSUE FACTOR-THRESHOLD IN THROMBIN GENERATION?

Inge M. Rietveld*, Pieter Reitsma, Mettine Bos (The Netherlands)

PO563-MON

TISSUE FACTOR/FACTOR VIIA SIGNALING PROMOTES CYTOKINE-INDUCED BETA CELL DEATH AND IMPAIRS GLUCOSE STIMULATED INSULIN SECRETION FROM HUMAN PANCREATIC ISLETS.

Desirée Edén*, Agnete Siegbahn, John Schwabe, Alison Goodall (United Kingdom)

PO564-MON

TISSUE FACTOR ACTIVATION IN PREGNANCY COMPLICATIONS

Martin Prochazka*, Lukáš Procházková, Jana Ullehová, Martin Novák, Eliska Hostinska, Petr Polák (Czech Republic)

PO565-MON

ACTIVATED PLATELETS REGULATE MONOCYTE TFPi GENE EXPRESSION THROUGH THE NUCLEAR TRANSCRIPTION FACTOR PPARγ

Robert E. Turnbull*, Katrin Sander, Peter Watson, David Barrett, John Schwabe, Alison Goodall (United Kingdom)

PO566-MON

TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR ASSESSMENT IN EARLY AND LATE SEVERE PREECLAMPASIA

Lara C. Godoi*, Patricia Silva, Karina Borges, Maria das Graças Carvalho, Melina Pinheiro, Luci Duarte (Brazil)

PO567-MON

LEVONORGESTREL-RELEASING INTRA-UTERINE DEVICE USE IN ADOLESCENT FEMALES WITH HEAVY MENSTRUAL BLEEDING AND BLEEDING DISORDERS: SINGLE INSTITUTION REVIEW

Olyemsi A. Aseyemi, Xiaomara Santos, Jennifer Dietrich, Lakshmi Srivaths* (United States)

PO568-MON

A NEW ALLOANTIGEN (CAB4) CARRIED BY GPIX IDENTIFIED IN A CONTEXT OF SEVERE NEONATAL ALLOIMMUNE THROMBOCYTOPENIA

Vincent Jallu, Thomas Beranger, Frederic Bianchi, Cecile Casale, Christophe Chenet, Nicolas Ferre, Sebastien Philippe, Jeanneine Quesne, Corinne Martageix, Rachel Petermann* (France)

PO569-MON

ASSESSMENT OF QUALITY AND CLINICAL EFFECTIVENESS OF Apher EIS PLATELET CONCENTRATES TREATED WITH MIRASOL PATHOGEN REDUCTION SYSTEM IN PLASMA OR IN PLATELET ADDITIVE SOLUTION SSP+

Anastasia Ignatova*, Oksana Karpova, Pavel Trahtman, Sergey Rumyantsev, Mikhail Pantaleev (Russian Federation)
PO570-MON
QUANTIFICATION OF CELL FREE DNA IN RED BLOOD CELL CONCENTRATES PRODUCED VIA BUFFY COAT (B1) OR WHOLE BLOOD (B2) METHODS
Andrew Shih*, Vinai Bhagirath, Patricia Liaw, Jason Acker, John Eikelboom, Nancy Heddle (Canada)

PO571-MON
RESPONSIVENESS OF PLATELETS DURING STORAGE STUDIED WITH FLOW CYTOMETRY – FORMATION OF PLATELET SUBPOPULATIONS AND LAMP-1 AS NEW MARKERS FOR THE PLATELET STORAGE LESION
Anna L. Södergren*, Nahreen Tynngård, Gösta Berlin, Sofia Ramström (Sweden)

PO572-MON
PRESERVED ULTRASTRUCTURE AND BIOCHEMICAL CHARACTERISTICS OF PLATELET COMPONENTS PREPARED WITH AMOTOSALEN AND UVA FOR PATHOGEN INACTIVATION
Beatrice Hechler*, Catherine Ravanat, Philippe Ohlmann, Anita Eckly, Marjorie Leduc, François Guillonneau, Hervé Isola, Christian Gachet (France)

PO573-MON
PLATELET TRANSFUSIONS AT THE CLINIC OF CHEMOTHERAPY: A HOSPITAL-BASED COHORT STUDY

PO574-MON
RELATIVE EFFECTS OF FRESH FROZEN PLASMA, FIBRINOGEN CONCENTRATE, AND FACTOR XIII IN MASSIVE TRANSFUSION REGIMENS: A LABORATORY STUDY
David Schmidt**, Agneta Wikman, Anna Ågren, Anders Östlund (Sweden, Netherlands)

PO575-MON
HPA BEADCHIP GENOTYPING STUDY: COMPARISON BETWEEN DNA EXTRACTED FROM BLOOD SAMPLES AND BUCCAL SWABS
Rachel Petermann*, Christophe Chenet, Thomas Beranger, Frederic Bianchi, Cecile Castale, Nicolas Ferre, Sebastien Philippe, Corinne Martageix, Vincent Jallu, Olivier Garraud (France)

PO576-MON
DEFECTIVE DEGRADATION OF NEUTROPHIL EXTRACELLULAR TRAPS IS ASSOCIATED WITH ACUTE THROMBOTIC MICROANGIOPATHIES
Miguel Jiménez-Alcázar*, Markus Napirei, Rachita Panda, Elodie Köhler, Johanna Kremer Hovinga, Hans Mannherz, Sven Peine, Thomas Renné, Bernhard Lämmer, Tobias Fuchs (Germany)

PO577-MON
PLATELET INHIBITION IN TTP: A MECHANISM TO ESCAPE THROMBOSIS
Mark Roest*, Rob Fijnheer, Loes Cornelissen, Judith Zandstra, Silvie Sebastian, Rolf Urbanus (The Netherlands)

PO578-MON
TREATMENT OF A JEHOVAH’S WITNESS WITH RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA WITH RITUXIMAB
Mari Thomas*, Rens De Groot, James Crawley, Marie Scully (United Kingdom)

PO579-MON
PHASE II STUDY OF DANAZOL WITH PLASMA EXCHANGE AND CORTICOSTEROIDS FOR THE TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA
Vamsee Torri*, Mark Friedman, Ivan Shapira, Amit Patel, Joseph Yoe, Vijay Shah, Tahir Mirzoyev*, Maria Machuca, Malva Varma (United States)

PO580-MON
DENSE GENOTYPING OF IMMUNE-RELATED DISEASE REGIONS FOR THE IDENTIFICATION OF GENETIC RISK FACTORS IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA.
Ilaria Mancini*, Emanuela Pappalardo, Andrea Cairo, Marcin Gorski, Barbara Ferrari, Isis Ricoa-Ponce, Coscin Wijmenga, Flora Peyrandi (Italy)

PO581-MON
CHARACTERIZATION OF SINGLE SORTED ANTI-ADAMTS13 SPECIFIC B CELLS FROM THE SPLEEN OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) PATIENTS
Magdalena Skowronska*, Monica Schaller, Johanna Kremer Hovinga (Switzerland)

PO582-MON
Stefano Lancellotti*, Flora Peyrandi, Maria Teresa Pagliari, Andrea Cairo, Kafwat Abdel-Azeim, Edrisse Cherma, Ilaria Lazzareschi, Stefano Mastrangelo, Luigi Cavallio, Rominia Oliva, Raimondo De Cristofaro (Italy)

PO583-MON
PLATELET TRANSFUSIONS AT THE CLINIC OF CHEMOTHERAPY: A HOSPITAL-BASED COHORT STUDY

PO584-MON
Stefano Lancellotti*, Flora Peyrandi, Maria Teresa Pagliari, Andrea Cairo, Kafwat Abdel-Azeim, Edrisse Cherma, Ilaria Lazzareschi, Stefano Mastrangelo, Luigi Cavallio, Rominia Oliva, Raimondo De Cristofaro (Italy)

PO585-MON
TREATMENT OF A JEHOVAH’S WITNESS WITH RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA WITH RITUXIMAB
Mari Thomas*, Rens De Groot, James Crawley, Marie Scully (United Kingdom)

PO586-MON
MAJOR CLINICAL OUTCOMES ARE SIMILAR BETWEEN INITIAL AND RE-LAPSED EPISODES OF THROMBOTIC THROMBOCYTOPENIC PURPURA
Shangbin Yang*, Susan Geyer, Elizabeth Biller, Haiwa Wu, Spero Cataland, Haifeng Wu (United States)

PO587-MON
ACTIVATION OF THE COMPLEMENT SYSTEM AND REDUCTION OF ADAMTS13 ACTIVITY BOTH PRECEDE CLINICAL EVENTS OF TTP RE-LAPSE
Shangbin Yang*, Susan Geyer, Elizabeth Biller, Haiwa Wu, Spero Cataland, Haifeng Wu (United States)

TTP/thrombotic microangiopathies I

PO578-MON
NEURO-IMAGING DOES NOT CORRELATE WITH DISEASE SEVERITY IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP), BUT MAY PREDICT LONG TERM SEQUELAE.
Indrani Karpha*, Clare Kay-Jones, Jennifer Burgess, Vanessa Martlew, Cheng Toh, Paul Fitzsimmons*, Tina Dutt (United Kingdom)
SCIENTIFIC PROGRAM

PO589-MON
BASELINE DEMOGRAPHICS AND CHARACTERISTICS OF 570 PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME IN THE GLOBAL AHUS REGISTRY
Christoph Licht*, Gianluigi Ardissino, Gema Ariceta, David Cohen, Christoph Gasteiger, Larry Greenbaum, Sally Johnson, Masayo Ogawa, Varant Kupilian, Franz Schaefer, Johan Vande Walle, Veronique Freneaux-Bacchi (Canada)

PO590-MON
A CASE OF THROMBOTIC MICROANGIOPATHY WITH CFH GENE ALTERATIONS THAT ARE NOT ASSOCIATED WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME
Yesim Oymak*, Tuba Karapinar, Yilmaz Ay, Erkin Serdaroglu, Neryal Muminoglu, Canan Vurgin (Turkey)

PO591-MON
SEVERE FIRST MANIFESTATION OF TTP IN A 96-YEAR-OLD FEMALE
Markus Munder, Lothar van den Abeelen, Roland Hardt, Charis von Auer, Ina Pretzell, Annette Shresthna, Inge Scharrer* (Germany)

PO592-MON
GENOTYPE AND PHENOTYPE FEATURES OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS (MILAN TTP REGISTRY).
Andrea Cairo, Ilaria Mancini*, Gloria Casoli, Andrea Antoni, Barbara Ferrari, Haifeng Wu, Flora Peyvandi (Italy)

PO593-MON
NEUROLOGICAL AND PSYCHOLOGICAL CONSEQUENCES AFTER RECOVERY FROM THROMBOTIC THROMBOCYTOPENIC PURPURA (TPP)
Veronique Schmitt, Stephanie Herold, Veronika Weyer, Charis Von Auer, Heidi Rossmann, Karl Lackner, Inge Scharrer, Bernhard Lämmlle, Tanja Falter* (Germany)

PO594-MON
THE NEW CLINICAL PREDICTION SCORE FOR DIAGNOSIS OF LOWER LIMB DEEP VEIN THROMBOSIS IN UNSELECTED POPULATION OF OUTPATIENTS AND INPATIENTS
Nuttawut Sermchantanasawadi* (Thailand)

PO595-MON
OVER REPRESENTATION OF SEVERE SUBCLAVIAN VEIN OCCLUSION IN THE AFFECTED ARM, COMPARED WITH THE CONTRALATERAL ARM, IN PATIENTS WITH UNPROVOKED UNILATERAL UPPER EXTREMITY DEEP VEIN THROMBOSIS
Shouyan Ning*, Ryan Rebello, Anthony Chan, Howard Chan (Canada)

PO596-MON
THE PERFORMANCE OF THE AGE-ADJUSTED D-DIMER THRESHOLD FOR SUSPECTED PULMONARY EMBOLISM IN RELEVANT SUBGROUPS: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF 7,000 PATIENTS
Nick van Es*, Tom van der Hulst, Josien Van Es, Paul den Exter, Renee Douma, Robbert Goekoop, Inge Mos, Pieter Kamphuisen, Patrick Bossuyt, Menno Huisman, Frederikus Klok, Harry Büller (The Netherlands)

PO597-MON
A SIMPLE DECISION RULE INCLUDING THE D-DIMER TEST TO REDUCE THE NEED FOR CT-SCANNING IN PATIENTS WITH SUSPECTED PULMONARY EMBOLISM
Josien Van Es*, Ludo Beenen, Renee Douma, Paul den Exter, Inge Mos, Karin Kaasjager, Menno Huisman, Pieter Kamphuisen, Patrick Bossuyt (The Netherlands)

PO598-MON
ACCURACY OF X-RAY WITH PERFUSION SCAN IN YOUNG PATIENTS WITH SUSPECTED PULMONARY EMBOLISM
Josien Van Es*, Renee Douma, Rachel Hezemans, Andrea Penaloza, Serge Motte, Petra Erkens, Marc Durian, Berthe van Eck-Smit, Pieter Kamphuisen (The Netherlands)

PO599-MON
DEVELOPMENT OF ELISA SYSTEM FOR DETECTION OF PROTEIN S K196E MUTATION, A GENETIC RISK FACTOR FOR VENOUS THROMBOEMBOLISM
Keiko Maruyama*, Masashi Akiyama, Koichi Kokame, Akiko Sekiya, Eriko Morishita, Toshiyuki Miyata (Japan)

PO600-MON
MODIFIED COMPUTER-ASSISTED STRAIN GAUGE PLETHYSMOGRAPHY AS A SIMPLE SCREENING TEST FOR PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS: A COHORT STUDY.
Andrew S. Hughes*, Benjamin Hall, Kate Jennings, Victoria Webb, Georgia Page, Christine Smith, Florence Charova (United Kingdom)

PO601-MON
MODIFIED STRAIN GAUGE PLETHYSMOGRAPHY CAN DECREASE THE NEED FOR COMPRESSION ULTRASONOGRAPHY IN PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS: A RETROSPECTIVE MULTICENTRE COHORT STUDY.
Andrew S. Hughes*, Benjamin Hall, Jane Strong, Rachel Clarke-Drury, Mark Bennett, Lyn Hooton, Nimal Muttucumaru, Tracy Muttucumaru (United Kingdom)

PO602-MON
ULTRASOUND DIAGNOSTIC CRITERIA AND CLOT DIAMETERS OF ISOLATED DISTAL DEEP VENOUS THROMBOSIS
Michelangelo Sartori*, Gianfranco Lessiani, Elisabetta Favaretto, Ludovica Migliaccio, Matteo Iotti, Angelo Ghirarduzzi, Benilde Cosmi (Italy)

PO603-MON
OUTCOME OF SCREENING FOR OCCULT MALIGNANCY IN PATIENTS PRESENTING WITH UNPROVOKED VENOUS THROMBOEMBOLISM AT A LARGE TERTIARY HOSPITAL IN CENTRAL LONDON
Anne Mwirigi*, Vickie McDonald, Richard Glaves, Johanna Young, Susie Shapiro, Beverley Hunt, Karen Breen (United Kingdom)

PO604-MON
A PROSPECTIVE STUDY OF VENOUS THROMBOEMBOLISM INCIDENCE AND RISK FACTORS IN SEVERE SEPSIS AND SEPTIC SHOCK
David Kaplan*, Charles Casper, Larry Kraiss, Andrew Weyrich, Colin Grissom, Shaohua Men, Robert Pendleton, Guy Zimmerman, Matthew Rondina (United States)

PO605-MON
VENOUS THROMBOEMBOLISM IN NORTHEAST MELBOURNE, AUSTRALIA: EVALUATION OF EPIDEMIOLOGY, RISK FACTORS AND TREATMENT STRATEGIES IN THE WARFARIN ERA.
Prahlad Ho*, Hui Yin Lim, Chyn Chua, Matthew Sleeman, Lachlan Hayes (Australia)

PO606-MON
LOW INCIDENCE OF DEEP VEIN THROMBOSIS AFTER TOTAL KNEE ARTHROPLASTY IN AN ASIAN POPULATION
Stephrene S. W. Chan*, Jing Loong Moses Loh, Sanjay De Mel, Deborah Chew, Keng Lin Wong, Eng Soo Yap (Singapore)

Venous thromboembolism - diagnosis I

Venous thromboembolism - epidemiology I
SCIENTIFIC PROGRAM

**PO607-MON**  
ASYMPTOMATIC THROMBOSIS FOLLOWING THE USE OF CENTRAL VENOUS LINES IN CHILDREN  
Sophie E. Jones*, Fiona Newall, Warwick Butt, Paul Monagle (Australia)

**PO608-MON**  
DOES DIABETES INFLUENCE OUTCOME WITHIN THREE MONTHS AFTER VENOUS THROMBOEMBOLISM? FINDINGS FROM 4,011 CASES ENROLLED IN THE WORLDWIDE RIETE REGISTRY  
Stefania Frasson, Gualberto Gussoni, Pierpaolo Di Micco, Laurent Bertoletti, Alicia Lorenzo, Olga Madridano, Javier Trujillo-Santos, Antonio Ceriello, Paolo Prandoni, Manuel Monreal* (Italy)

**PO609-MON**  
TIME TRENDS IN INCIDENCE RATES OF VENOUS THROMBOEMBOLISM IN A LARGE COHORT RECRUITED FROM THE GENERAL POPULATION  
Nadia Arshad*, Trond Isaksen, John-Bjarne Hansen, Sigrid Braekkan (Norway)

**PO610-MON**  
POOR SELF-RATED HEALTH IS ASSOCIATED WITH FUTURE RISK OF VENOUS THROMBOEMBOLISM IN WOMEN. THE TROMSO STUDY  
Sigrid Braekkan*, Trond Isaksen, John-Bjarne Hansen (Norway)

**PO611-MON**  
ORAL AND INHALED CORTICOSTEROID USE HAS A TIME-DEPENDENT ASSOCIATION WITH RECURRENT PULMONARY EMBOLISM  
Marlous Sneeboer, Barbara Hutten, Christof Majoor, Pieter-Willem Kamphuisen*, Elisabeth Bel (The Netherlands)

**PO612-MON**  
CASE FATALITY AND RECURRENT RATES AFTER FIRST VENOUS THROMBOEMBOLISM IN A LARGE POPULATION-BASED COHORT  
Nadia Arshad*, Trond Isaksen, John-Bjarne Hansen, Sigrid Braekkan (Norway)

**PO613-MON**  
TIME TRENDS AND CASE FATALITY RATE OF PULMONARY EMBOLISM DURING 11 YEARS OF OBSERVATION IN NORTHWESTERN ITALY  
Francesco Dentali*, Walter Ageno, Fulvio Pomero, Luigi Fenoglio, Alessandro Squizzato, Matteo Bonzini (Italy)

**PO614-MON**  
NATURAL HISTORY AND ANTITHROMBOTIC TREATMENT OF INCIDENTALLY DETECTED SPLANCHNIC VEIN THROMBOSIS: FINDINGS FROM THE ISTH REGISTRY  
Nicoletta Riva*, Walter Ageno, Sam Schulman, Jan Beyer-Westendorf, Soo-Mee Bang, Samantha Pasca, Daniela Poli, Peter Verhamme, Adriano Alatri, Donatella Colaizzo, Elena Rancan, Suely Meireles Rezende, Antonietta Piana, Mario Bazzan, Maria T. De Sancho, Etienne Ciantar, Elena Elii, Kristyna Zawilska, Francesco Dentali, ISTM study investigators (Italy)

**PO615-MON**  
DEEP VEIN THROMBOSIS IN SEPTIC PATIENTS IN THE INTENSIVE CARE UNIT  
Vaia Florou*, Gregoris Komodikis, Damodor Penigalapati, Paris Charilaou, Haris Rana (United States)

**PO616-MON**  
FACTOR V IS ASSOCIATED WITH A MODERATELY INCREASED RISK OF VENOUS THROMBOSIS  
Inge M. Rietveld*, Metline Bos, Frits Rosendaal, Pieter Reitsma, Suzanne Cannegieter (The Netherlands)

---

**VENOUS THROMBOEMBOLISM - THERAPY I**

**PO617-MON**  
THROMBIN GENERATION AND THE RISK OF VENOUS THROMBOSIS: RESULTS FROM A LARGE POPULATION-BASED CASE-CONTROL STUDY  
Kristien Winckers*, Astrid van Hylckama Vlieg, Stella Thomassen, Tilman Hackeng, Frits Rosendaal (The Netherlands)

**PO618-MON**  
TWO WEEKS OF LOW MOLECULAR WEIGHT HEPARIN FOR ISOLATED SYMPTOMATIC DISTAL VENOUS THROMBOSIS (TWISTER STUDY): INTERIM ANALYSIS OF FIRST 100 PATIENTS  
Eileen Merriman*, Sanjeev Chunnilal, Simon McRae, Tim Brighton, Huyen Tran (New Zealand)

**PO619-MON**  
A CANADIAN CONSENSUS ON VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS PREVENTION IN THORACIC SURGERY, A NATIONAL DELPHI CONSENSUS SURVEY  
Yaron Shargall*, Lori-Ann Linkins, Laura Schneider, Mark Crowther, Marc De Perrot, Christian Finley, Wael Hanna, Coli Schieman (Canada)

**PO620-MON**  
ADHERENCE TO INTERNATIONAL GUIDELINES IN TREATMENT OF VENOUS THROMBOEMBOLIC EVENTS IN CANCER PATIENTS: A HOSPITAL-BASED COHORT STUDY IN PARIS, FRANCE  
Isabelle Mahé*, Hortense Puget, Jean Chidiac, Andrey Strukov, Jean-Claude Buzzi, Helene Hefter, Michele Lamurglia, Anne Peroziello (France)

**PO621-MON**  
A FIRST-IN-HUMAN, SINGLE ASCENDING DOSE STUDY OF DS-1040, AN INHIBITOR OF THE ACTIVATED FORM OF THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR (TAFIA), IN HEALTHY SUBJECTS  
Jin Zhou*, Cynthia Zamora, George Attee, Vance Warren, Ophelia Tin, Jarema Kochan, Joseph Pay, Yasushi Orihashi, Vijay Kumar Vashi, Victor Dichy (United States)

**PO622-MON**  
A RETROSPECTIVE MEDICATION USE EVALUATION OF ANTITHROMBOTIC THERAPY AFTER TOTAL HIP ARTHROPLASTY OR TOTAL KNEE ARTHROPLASTY AT UNIVERSITY OF COLORADO HEALTH.  
Patrick Klem*, Toby Trujillo, Larry Golightly, Megan Wong, Craig Hogan (United States)

**PO623-MON**  
PLATELET REACTIVITY IN PATIENTS WITH A HISTORY OF VENOUS THROMBOSIS WHO USE ROSUVASTATIN: RANDOMIZED CLINICAL TRIAL  
Joseph Biedermann*, Suzanne Cannegieter, Felix van der Meer, Marjorie Kruij, Pieter Reitsma, Willem Lijfering (The Netherlands)

**PO624-MON**  
LONG-TERM USE OF LOW-MOLECULAR-WEIGHT HEPARINS (LMWH) FOR THE TREATMENT OF CANCER-ASSOCIATED THROMBOSIS (CAT): FACTORS ASSOCIATED WITH NON-COMPLIANCE WITH TREATMENT RECOMMENDATIONS (NCTR) IN CLINICAL PRACTICE.  
Francis Caffin*, Philippe Debarbouleau, Anne Lamblin, Dominique Farge-Bancel (France)

**PO625-MON**  
HOSPITAL LENGTH OF STAY FOR DEEP VEIN THROMBOSIS OR PULMONARY EMBOLISM AMONG PATIENTS RECEIVING RIVAROXABAN OR WARFARIN  
Steven Deitelzweig*, Monika Raut, Jay Margolis, Oth Tran, David Smith, Brahim Bookhart, Jeff Schein, William Olson (United States)
SCIENTIFIC PROGRAM

PO626-MON  ACUTE PULMONARY EMBOLISM: EXTERNAL VALIDATION OF THE 2014 RISK STRATIFICATION MODEL OF THE EUROPEAN SOCIETY OF CARDIOLOGY
Cecilia Becattini*, Giancarlo Agnelli, Mareike Lankeit, Luca Masotti, Piotr Pruszczyk, Franco Casazza, Simone Vanni, Cinzia Nitti, Pieter Kamphuisen, Maria Vedovati, Maria De Natale, Stavros Konstantinides (Italy)

PO627-MON  RISK FACTORS FOR RECURRENCE AND THROMBOEMBOLIC EVENTS AFTER ISOLATED SUPERFICIAL VEIN THROMBOSIS OF LOWER LIMBS
Michelangelo Sartori*, Elisabetta Favaretto, Ludovica Migliaccio, Giuseppina Rodorigo, Guatliero Palareti, Benilde Cosmi (Italy)

PO628-MON  EFFICACY AND SAFETY OF TREATMENT WITH ANTICOAGULANTS IN PATIENTS WITH VENOUS THROMBOEMBOLISM IN KOREA
Hun Gyu Hwang*, Myung Shin Kim, Gune-Il Lim, Eunju Sim, Won-Il Choi (Korea, Republic Of)

SCIENTIFIC PROGRAM

PO629-MON  PREVALENCE OF VKORC1 POLYMORPHISMS ACROSS CAUCASIANS AND AMERINDIANS
Maria Paula Vera Morandini, Lucia Remotti, Silvia Grosso, Marcelo Ingratti, Fabiana Alberto, Vanessa Caruso, Analia Sanchez Luceros, Susana Sara Meschengieser, Maria Lazzari, Alicia Blanco* (Argentina)

PO630-MON  INFLUENCE VITAMIN K ANTAGONISTS ON THE THROMBINEMIA AND HOMOCYSTEINE LEVELS
Nadezda Vorobyeva*, Alexandra Rogozina (Russian Federation)

PO631-MON  SUSCEPTIBILITY OF VKORC1 AND ITS PARALOG VKORC1L1 TOWARDS DIFFERENT 4-HYDROXYCOUMARINS
Kerstin Liphardt*, Katrin Czogalla, Klara Höning, Veit Hornung, Matthias Watzka, Johannes Oldenburg (Germany)

PO632-MON  ZYMOCENG-LIKE FXA VARIANT AS NOVEL WARFARIN REVERSAL STRATEGY: PRE-CLINICAL EVALUATION AND MECHANISM OF ACTION
Lindsey A. Greene*, Nabil Thalji, Rodney Camire (United States)

PO633-MON  CLINICAL AUDIT OF ANTICOAGULATION REVERSAL AND OUTCOME IN WARFARIN-ASSOCIATED INTRACRANIAL HAEAMORRHAGE (WAICH)
Danielle Blunt*, Safoorah Sagheer, Simon McRae (Australia)

PO634-MON  EFFECT OF INR PRECISION AND ACCURACY ON THERAPEUTIC QUALITY CONTROL IN PATIENTS RECEIVING VITAMIN K-ANTAGONISTS
Anton Van Den Besselaar*, Felix van der Meer (The Netherlands)

PO635-MON  HEMIZYGOUS DELETION OF 7Q11.21-Q11.23 ELIMINATING VKORC1L1 DOES NOT IMPAIR BLOOD COAGULATION BUT REVEALS ACCUMULATION OF MENAQUINONE-4
Sol Schulman*, Xueyan Fu, Sarah Booth, Benno Rothlisberger, Barbara Furie, Bruce Furie (United States)

Vitamin K antagonists I

PO636-MON  SELECTION, MANAGEMENT AND OUTCOME OF VKA PATIENTS WITH ATRIAL FIBRILLATION NOT SWITCHED TO NOVEL ORAL ANTICOAGULANTS – RESULTS FROM THE DRESDEN NOAC REGISTRY (NCT01588119)
Franziska Michalski, Sebastian Werth, Luise Tittl, Sandra Marten, Norbert Weiss, Jan Beyer-Westendorf* (Germany)

PO637-MON  ANTAGONIZATION OF WARFARIN IN CELLS: WARFARIN BINDING ON HUMAN VKORC1 IS REVERSIBLE
Katrin Czogalla*, Arijit Biswas, Matthias Watzka, Klara Höning, Veit Hornung, Johannes Oldenburg (Germany)

PO638-MON  RELATIONSHIP BETWEEN VITAMIN K ANTAGONISTS AND RECURRENT BLEEDING EVENTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: REAL-WORLD FINDINGS FROM ENGLAND
Raza Ali Khan*, Cinira Lefevre, Ian Menown, Steven Lister, Laure Lacoin, Alex Bird, Min You, Essra Ridha, David Evans (United Kingdom)

PO639-MON  RISK FACTORS FOR GASTRO-INTESTINAL BLEEDING IN ATRIAL FIBRILLATION PATIENTS ON VKA TREATMENT: PROSPECTIVE ANALYSIS OF TWO COHORTS OF PATIENTS
Daniela Poli*, Emilia Antonucci, Sophie Testa, Alberto Tosetto, Walter Ageno, Gautiliero Palareti (Italy)

PO640-MON  PREDICTORS OF ICH RECURRENT ON VKA: SEVERITY OF THE FIRST EPISODE AND HASBLED SCORE FAIL TO IDENTIFY HIGH RISK PATIENTS FROM THE CHIRONE STUDY
Daniela Poli*, Emilia Antonucci, Francesco Dentali, Sophie Testa, Gautiliero Palareti (Italy)

PO641-MON  PERIOPERATIVE INTERRUPTION OF WARFARIN ANTICOAGULATION
Joseph Shaw*, Dimitri Scarvelis, Lana Castellucci, Esteban Gandara, Wendy Riches, Kerstin Hogg, Philip Wells (Canada)

Von Willebrand disease I

PO642-MON  COST OF TREATING THROMBOTIC EVENTS IN A US POPULATION OF VON WILLEBRAND DISEASE PATIENTS
Alexandra Khachatryan*, Yan Xiong (United States)

PO643-MON  AN OPEN-LABEL, MULTI-CENTER EXTENSION STUDY TO ASSESS THE EFFICACY AND SAFETY OF A PLASMA-DERIVED VON WILLEBRAND FACTOR/FACTOR VIII (VWF/FVIII)CONCENTRATE IN PEDIATRIC, ADOLESCENT, AND ADULT SUBJECTS WITH VON WILLEBRAND DISEASE
Toshiko Lisitschkov, Anna Klukowska, Kazimierz Kuliczkowski, Evgeny Buevich, Guenter Auerwald, Olexandra Stasyshyn, Wilfried Seifert* (Germany)

PO644-MON  THROMBOCYTOPENIA DURING DDAVP TEST IN TWO CHILDREN WITH TYPE 2A VON WILLEBRAND DISEASE
Juan P. Frontroth*, Carolina Pepe, Mirta Hepner, Gabriela Sciuatti, Graciela Pieroni, Silvina Annetta, Carolina Cervio, Aurora Feliu-Torres, Marianda Bonduel (Argentina)
SCIENTIFIC PROGRAM

PO645-MON  RULING OUT VON WILLEBRAND DISEASE IN PREOPERATIVE PATIENTS WITH BLEEDING SYMPTOMS

PO646-MON  HEALTH-RELATED QUALITY OF LIFE AMONG VON WILLEBRAND DISEASE PATIENTS IS NOT RELATED TO DISEASE SEVERITY.
Yan Xu*, Meghan Deforest, Julie Grabell, Wilma Hopman, Paula James (Canada)

PO647-MON  PLASMA-DERIVED, PURIFIED, PASTEURISED VON WILLEBRAND FACTOR/FACTOR VIII CONCENTRATE IN THE TREATMENT OF PATIENTS WITH VON WILLEBRAND DISEASE AND HAEMOPHILIA A: UPDATE OF A LONG-TERM OBSERVATIONAL STUDY
Cornelia Wermes*, Susanne Holzhauer, Susan Halimeh, Bettina Kemkes-Matthes, Patrick Sommerer, Ivonne Wieland, Manuela Krause (Germany)

PO648-MON  EVALUATION OF AN ELISA BASED ASSAY FOR DETECTION OF TYPE 2N VON WILLEBRAND DISEASE
Rachel R. Leger*, Adam Tricker, Julie Tange, Dong Chen, Rajiv Pruthi (United States)

PO649-MON  NEW INSIGHTS INTO TYPE 3 VON WILLEBRAND DISEASE: THE TYPE 3 VON WILLEBRAND DISEASE INTERNATIONAL REGISTRIES AND INHIBITOR PROSPECTIVE STUDY (3WINTERS-IPS) PROJECT UPDATE
Augusto B Federici*, Flora Peyvandi, Ulrich Budde, Giancarlo Castaman, Jeroen Eikenboom, Peyman Eshghi, Anne Goodeve, Jenny Goodeman, Hamid Hoorfar, Mehran Karimi, Ian Peake, Reinhard Schneppenheim, Alberto Tosetto, Pier M Mannucci (Italy)

PO650-MON  EFFICACY AND SAFETY OF VON WILLEBRAND FACTOR CONCENTRATE WITH A LOW VIII CONTENT IN SEVERE VWD CHILDREN LESS THAN 6 YEARS OF AGE
Emna Gouider*, Anna Klukowska, Philippe Maes, Helen Platokouki, Wanda Badowska, Nathalie Knuchel, Céline Henriet, Françoise Bridey, Claudine Caron, Annie Borel-Derian, Balíkis Meddeeb, Christel Van Geet (Tunisia)

PO651-MON  OVERDOSING OF REPLACEMENT THERAPY IN PERIOPERATIVE VON WILLEBRAND PATIENTS: A LOT “TO WIN”
Hilde C. Veerman*, Hendrika C.A.M. Hazendonk, Yvonne V. Sanders, Karina Meijer, Frank W.G. Leebeek, Marjon H. Cnossen (The Netherlands)

PO652-MON  A MICROCHIP FLOW-CHAMBER SYSTEM (T-TAS®) REFLECTS THE CLINICAL PHENOTYPES IN PATIENTS WITH TYPE 1 VON WILLEBRAND DISEASE
Keiji Nogami*, Koji Yada, Yasuaki Shida, Kenichi Gigiwa, Shoko Furukawa, Hiroaki Minami, Hiroaki Yaoi, Tomoko Matsumoto, Midori Shima (Japan)

PO653-MON  THE USE OF NEXT-GENERATION SEQUENCING TO SCREEN FOR DISORDERS OF COAGULATION USING A 24 GENE PANEL
Patricia Bignell*, Nicola Currie, Joanne Mason, Pamela Wright, David Keeling, Paul Giangrande, Shirley Henderson, Anna Schuh (United Kingdom)

PO654-MON  COURSE OF VON WILLEBRAND FACTOR (VWF) DURING PREGNANCY IN WOMEN WITH VON WILLEBRAND DISEASE (VWD)
Mario von Depka*, Carsten Detering, Anja Henkel-Klene, Stefanie Döpke, Emilie von Depka, Mahnzah Ekhlasi-Hundrieser (Germany)

SCIENTIFIC PROGRAM

PO655-MON  IDENTIFICATION OF LARGE VWF GENE DELETIONS AND DUPLICATIONS BY MLPA IN THE SOUTH MORAVIAN (CZECH REPUBLIC) VWD COHORT IN THE BRNO-VWD STUDY
Inge Vangenechten*, Petr Smejkal, O Zapletal, J Zavrelova, J Blatny, M Penka, Jan Jacques Michiels, Alain Gadisseur (Belgium)

PO656-MON  BASELINE FACTOR VIII PLASMA LEVELS AND AGE AT FIRST BLEEDING IN PATIENTS WITH SEVERE FORMS OF VON WILLEBRAND DISEASE
Simona Maria Siboni, Eugenia Biguzzi*, Valeria Caiani, Claudia Mistrretta, Paolo Bucciarelli, Flora Peyvandi (Italy)

PO657-MON  TYPE 1 VWD DOES NOT LEAD TO INCREASED GINGIVAL BLEEDING
Lisa Weickert, Peter Eckholz, Katrin Nickles, Stefanie Krekeler, Wolfgang Miesbach* (Germany)

PO658-MON  JOINT SURGERY IN MODERATE AND SEVERE VON WILLEBRAND DISEASE: A CROSS-SECTIONAL STUDY.
Karina van Galen, Frank Leebeek, Roger Schutgens*, Marjon Cnossen, Jeroen Eikenboom, Charles Vogely, Karin Fijnvandraat, Karina Meijer, Evelien Mauser-Bunschoten (The Netherlands)

PO659-MON  ETHNIC AND Racial VARIATION OF PLASMA VWF IN HEALTHY CONTROLS
Robert R. Montgomery*, Joan Gill, Pamela Christopherson, Veronica Flood, Sandra Haberichter, Thomas Abshire (United States)

PO660-MON  A COMPARATIVE STUDY OF MICROFLUIDIC FLOW ASSAYS AND CLINICAL ASSAYS IN TYPE I VON WILLEBRAND’S DISEASE
Marcus Lehmann*, Christopher Ng, Jorge Di Paola, Keith Neeves (United States)

PO661-MON  TOTAL THROMBUS-FORMATION ANALYSIS SYSTEM (T-TAS) FOR THE MONITORING OF VON WILLEBRAND FACTOR-FVIII CONCENTRATE TREATMENT IN PATIENTS WITH VON WILLEBRAND DISEASE TYPE 3. Anna Ąger*, Paul Hjemdahl, Margareta Blombåck, Kaziya Hosokawa, Margareta Holmström (Sweden)

PO662-MON  SURVEILLANCE STUDY OF SAFETY AND EFFICACY OF A WVF/FVIII CONCENTRATE IN PATIENTS WITH VON WILLEBRAND DISEASE (WIL-20) – A PLANNED INTERIM ANALYSIS
Kate Khair, Maria Sol Cruz*, Sylvia Werner, Sigurd Knaub, Alfonso Iorio (United Kingdom)

PO663-MON  PREDICTORS OF COMPLETE RESPONSE TO DDAVP IN PATIENTS WITH VON WILLEBRAND DISEASE
Eugenia Biguzzi*, Paolo Bucciarelli, Franca Franchi, Francesca Stufano, Simona Siboni, Luciano Baronciani, Flora Peyvandi (Italy)

PO664-MON  MAJOR SURGERIES IN CHILDREN AND ADULTS WITH VON WILLEBRAND DISEASE MANAGED WITH A HIGH-PURITY HUMAN VWF/FVIII CONCENTRATE IN A PHYSIOLOGICAL 1:1 RATIO
Alrik Srivastava, Sylvia Werner, Margit Serban, Bruce Schwartz, Sigurd Knaub, Craig Kessler* (United States)
Von Willebrand Factor I

PO670-MON | IDENTIFICATION AND CHARACTERIZATION OF ABERRANT SPlicing FROM A NOVEL BRANCH SITE MUTATION IN VON WILLEBRAND FACTOR
Lindsey Hawke*, Georges Rivard, Paula James (Canada)

PO671-MON | FUNCTIONAL LINK BETWEEN VON WILLEBRAND FACTOR (VWF) AND TISSUE FACTOR (TF) IN FLOW-DEPENDENT THROMBUS FORMATION: AUGMENTATION OF INTRA-THROMBUS FIBRIN GENERATION BY CATHEPSIN G ON VWF-TF COMPLEX
Yasunori Matsunari*, Hideto Matsui, Masahiko Kagauchi, Mitsuhiro Sugimoto (Japan)

PO672-MON | THROMBIN-DEPENDENT INCORPORATION OF VON WILLEBRAND FACTOR INTO A FIBRIN NETWORK
Adam Miszta, Leonie Peikmans*, Theo Lindhout, Philip de Groot, Coenraad Hemker, Johan Heemskerk, Hilde Keilteermans, Bas de Laat (The Netherlands)

PO673-MON | MIR-24 REGULATES VON WILLEBRAND FACTOR IN DIABETES
Yaozu Xiang*, Jijun Cheng, Jun Lu, Kathleen Martin, John Hwa (United States)

PO674-MON | THE FIRST CASE OF AN INTRON RETENTION RESULTING FROM A SILENT MUTATION IN THE VWF WHICH EXERTS A STRUCTURAL IMPACT ON THE 5’ SPlice SITE
Hamideh Yadegari Baharanchi*, Arijit Biswas, Julia Diesen, Vytautas Ivasevicius, Natascha Marquardt, Johannes Oldenburg (Germany)
Scientific Program

Tuesday, June 23

Trainee Tracks (oral sessions only):

- Platelets track
- Basic thrombosis and hemostasis track
- Clinical bleeding track
- Clinical thrombosis track
- Pediatric thrombosis and hemostasis track
- Cardiovascular and arterial diseases track

An asterisk (*) after a name denotes the presenting author.
**Cancer and thrombosis – clinical – I**

**Moderators:** Simon Noble (United Kingdom), Howard Liebman (United States)

08:00 – 08:15
**OR126**
RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH BCR-ABL TKIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Jonathan Douxfils*, Hélène Haguet, François Mullier, Christian Chatelain, Carlos Graux, Jean-Michel Degné (Belgium)

08:15 – 08:30
**OR127**
DIFFERENCES IN VENOUS THROMBOEMBOLIC EVENTS IN SUBJECTS ENROLLED IN STANDARD PHASE I CLINICAL TRIALS AND THOSE ON PHASE I HEPATIC DYSFUNCTION CLINICAL TRIALS
Aaron Mansfield*, Alfonso Tafur, Diana Vulih, Gary Smith, Pamela Jo Harris, S. Percy Ivy (United States)

08:30 – 08:45
**OR128**
RISK FACTORS FOR INCIDENT VENOUS THROMBOEMBOLISM IN ACTIVE CANCER PATIENTS: A POPULATION BASED CASE-CONTROL STUDY
Aneel A. Ashrani*, Rachel Gullerud, Tanya Petterson, Randolph Marks, Kent Bailey, John Heit (United States)

08:45 – 09:00
**OR129**
COHORT PROFILE: THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) STUDY
Hilde Jensvoll*, Marianne Severinsen, Jens Hammerstrøm, Sigrid Brækkan, Søren Kristensen, Suzanne Cannegieter, Kristine Blix, Anne Tjønneland, Frits Rosendaal, Anne Tjønneland, Frits Rosendaal, Olga Dziewiecka, John-Bjarne Hansen (Norway)

09:00 – 09:15
**OR130**
PREDICTION OF VENOUS THROMBOEMBOLISM IN LUNG CANCER PATIENTS RECEIVING CHEMOTHERAPY
Simon Noble*, Andrew Robbins, Raza Alikhan, Kerenza Hood, Fergus Macbeth (United Kingdom)

**Venous thromboembolism – epidemiology – II**

**Moderators:** Sarah Lapner (Canada), Daniel Witt (United States)

08:00 – 08:15
**OR131**
RISK OF VENOUS THROMBOSIS IN INDIVIDUALS USING VITAMIN SUPPLEMENTS: A CASE-CONTROL STUDY
Biljana Vuckovic*, Nienke van Rein, Suzanne Cannegieter, Frits Rosendaal, Willem Lijfering (Serbia)

08:15 – 08:30
**OR132**
RISK FACTORS FOR INCIDENT VENOUS THROMBOEMBOLISM IN ACTIVE CANCER PATIENTS: A POPULATION BASED CASE-CONTROL STUDY
Nienke van Rein*, Suzanne Cannegieter, Frits Rosendaal, Willem Lijfering (Serbia)

08:30 – 08:45
**OR133**
HIGH-DOSE DEXAMETHASONE CORRECTS IMPAIRED MYELOID-DERIVED SUPPRESSOR CELL FUNCTIONS VIA POSITIVE CROSSTALK BETWEEN GLUCOCORTICOID RECEPTOR AND ETS1 IN IMMUNE THROMBOCYTOPENIA
Yu Hou*, Miao Xu, Qi Feng, Yingyi Yu, Xuena Liu, Ming Hou, Jun Peng (China)

08:45 – 09:00
**OR134**
SUPPRESSION OF CELL-MEDIATED IMMUNE THROMBOCYTOPENIA (ITP) BY B CELL DEPLETION THERAPY IN A MURINE MODEL.
Li Guo*, Edwin Speck, Ruhksana Aslam, Rick Kapur, Heyu Ni, John Semple (Canada)

09:00 – 09:15
**OR135**
STAT1 SINGLE NUCLEOTIDE POLYMORPHISMS AND SUSCEPTIBILITY TO IMMUNE THROMBOCYTOPENIA
Zhenping Chen*, Zhenxing Guo, Jingyao Ma, Chao Gao, Runhui Wu (China)

**Hemophilia inhibitors**

**Moderators:** Georges Rivard (Canada), Pål Andre Holme (Norway)

08:00 – 08:15
**OR136**
DO VACCINATIONS INFLUENCE THE RISK OF INHIBITOR DEVELOPMENT IN PATIENTS WITH SEVERE HEMOPHILIA A?
SM Hashemi*, K Fischer, SC Gouw, A Rafowicz, M Carcao, H Platokouki, G Kenet, R Liesner, K Kurnik, G Rivard, HM van den Berg (The Netherlands)
SCIENTIFIC PROGRAM

08:30 – 08:45
OR143
PLASMA-DERIVED FACTOR VIII PRODUCTS AND INHIBITOR DEVELOPMENT IN PREVIOUSLY UNTREATED BOYS WITH SEVERE HEMOPHILIA A: REPORT OF THE FRANCECOAG NETWORK
Jenny Goudemand*, Chantal Rothschild, Roseline d’Oron, Virginie Demugel, Vincent Dalibard, Marguerite Micheau, Patrick Lutz, Iyes Guel, Christine Vinciguerra, Hervé Chambost, Thierry Calvez (France)

08:45 – 09:00
OR144
DETERMINANTS OF INHIBITOR DEVELOPMENT IN PREVIOUSLY TREATED HEMOPHILIA A PATIENTS

09:00 – 09:15
OR145
ITI FOR INHIBITORY ANTIBODIES IN BOYS WITH SEVERE HAEMOPHILIA A AT EIGHT UK CHILDREN’S CENTRES 2003-2013
Mary Mathias*, Jayanthi Alamelu, Peter Collins, Mike Richards, Oliver Tunstall, Mike Williams, Tina Biss, Elizabeth Chalmers (United Kingdom)

08:00 – 08:15
OR146
RISK FACTORS OF RESIDUAL PERFUSION DEFECTS AFTER A FIRST EPISODE OF UNPROVOKED PE: RESULTS FROM THE PADIS PE MULTICENTER, DOUBLE-BLIND, RANDOMIZED TRIAL
Olivier Sanchez*, Cécile Tromeur, Pierre Yves Salaun, Michel Nonent, Philippe Girard, Karine Lacut, Solen Mélac, Marie Guégan, Gisèle Marhic, Silvy Laporte, Christophe Leroyer, Hervé Décosus, Dominique Mottier, Guy Meyer, Francis Couturaud (France)

08:15 – 08:30
OR147
EVOLUTIONARY CONSERVATION OF AUTOINHIBITORY B-DOMAIN REGIONS IN BLOOD COAGULATION FACTOR V OF THE SUBORDER SERPENTES
Daniel Verhoef*, Ka Lei Cheung, Hans Vos, Ryan McCleary, Manjunatha Kini, Pieter Reitsma, Martine Bos (The Netherlands)

08:30 – 08:45
OR148
IDENTIFICATION OF NEW GENETIC RISK FACTORS FOR RECURRENT VENOUS THROMBOSIS
Hugoline G. de Haan*, Marine Germain, Trevor Baglin, Jean-François Deleuze, David-Alexandre Tréguot, Frits Rosendaal, Astrid van Hyckama Vlieg (The Netherlands)

08:45 – 09:00
OR149
RISK FACTORS OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH A FIRST EPISODE OF UNPROVOKED PULMONARY EMBOLISM: RESULTS FROM THE PADIS PE MULTICENTER, DOUBLE-BLIND, RANDOMIZED TRIAL
Francis Couturaud*, Olivier Sanchez, Emilie Presles, Pierre Yves Salaun, Gilles Pernod, Patrick Mismetti, Patrick Jego, Elisabeth Duhamel, Karine Provost, Claire Bai Dit Solier, Philippe Castellant, Florence Parent, Luc Bressollette, Philippe Girard, Karine Lacut, Solen Mélac, Marie Guégan, Silvy Laporte, Christophe Leroyer, Hervé Décosus, Guy Meyer, Dominique Mottier (France)

08:00 – 08:15
OR150
LIPID LEVELS AND RISK OF VENOUS THROMBOSIS: RESULTS FROM THE MEGA STUDY
Vânia M. Morelli*, Willem Lijfering, Frits Rosendaal, Suzanne Cannegieter (Brazil, Netherlands)

08:00 – 08:15
OR151
RECOMBINANT ADAMTS13 AS AN EFFECTIVE THERAPY FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA IN RATS
Claudia Tersteeg*, Alexandra Schinv, Barbara Plaimauer, Simon De Meyer, Friedrich Scheifflinger, Karen Vanhoorelbeke, Hanspeter Rottensteiner (Belgium)

08:15 – 08:30
OR152
HEREDITARY TTP – A YOUNG PATIENT POPULATION WITH HIGH PREVALENCE OF ARTERIAL THROMBOEMBOLIC EVENTS. FIRST RESULTS FROM THE HEREDITARY TTP REGISTRY
Magnus Mansouri, Masanori Matsumoto, Zuzana Cermakova, Kenneth Friedman, James George, Ingrid Hrachovinova, Paul Knöbl, Koichi Kokame, Anne Sophie von Krogh, Reinhard Schnepfenheim, Sara Vesley, Yoshihiro Fujimura, Bernhard Lammle, Johanna A. Kremer Hubinger* (Switzerland)

08:30 – 08:45
OR153
ENDOGENOUS PLASMIN LEVELS CONTROL THE DEVELOPMENT OF ACUTE EPISODES OF THROMBOTIC THROMBOCYTOPENIC PURPURA IN MICE

08:45 – 09:00
OR154
COVERSIN, A NOVEL COMPLEMENT C5 INHIBITOR AND POTENTIAL THERAPEUTIC AGENT, PREVENTS C5 ACTIVATION IN PATIENTS WITH C5 POLYMORPHISMS
Ian J. Mackie*, Andrew Chitolie, Miles Nunn, Wynne Weston-Davies, Samuel Machin (United Kingdom)

09:00 – 09:15
OR155
LONG-TERM GENE THERAPY FOR THROMBOTIC THROMBOCYTOPENIC PURPURA USING THE ‘SLEEPING BEAUTY’ TRANSPOSON SYSTEM
Sebastien Verhenne*, Nele Vandeputte, Inge Pareyn, Zsuzsanna Izsvak, Hanspeter Rottensteiner, Hans Decker, Simon F De Meyer, Karen Vanhoorelbeke (Belgium)

08:00 – 08:15
OR156
IDENTIFICATION OF INDEPENDENT RISK FACTORS FOR ACQUIRED TTP: A MULTI-INSTITUTIONAL DATABASE FOR PROSPECTIVE STUDIES
Claudia Tersteeg*, Alexandra Schinv, Barbara Plaimauer, Simon De Meyer, Friedrich Scheifflinger, Karen Vanhoorelbeke, Hanspeter Rottensteiner (Belgium)

08:15 – 08:30
OR157
CORRELLATION BETWEEN ACTIVATED PARTIAL THROMBOPLASSTIN TIME (APTT) AND ANTI-FXA ASSAY IN CHILDREN ON UNFRACTIONATED HEPARIN (UFH) THERAPY: AN INSTITUTIONAL EXPERIENCE
Gary Woods*, Sheilah Harrison, Karen Texter, Joseph Stanek, Amy Dunn, Bryce Kerlin, Riten Kumar (United States)

08:00 – 09:15
TTP and PNH – from basic science to clinical practice
Room 716
Moderators: Ian J. Mackie (United Kingdom), Karen Vanhoorelbeke (Belgium)
SCIENTIFIC PROGRAM

08:30 – 08:45
OR158
AGE IS MAIN CLINICAL RISK FACTOR FOR VENOUS THROMBOEMBOLISM WITHIN A LARGE COHORT OF CHILDREN WITH ACUTE LYMPHOBlastic LEUKEMIA
Mandy N. Lauw*, Irene Klaassen, Marianne Van de Wetering, Inge Van der Sluis, Rob Pieters, C. Heleen Van Ommen (The Netherlands)

08:45 – 09:00
OR159
OUTCOMES OF LOWER LIMB DEEP VEIN THROMBOSIS AND PREDICTORS OF LOWER LIMB POST-THROMBOTIC SYNDROME IN PEDIATRIC PATIENTS

09:00 – 09:15
OR160
DIAGNOSIS AND MANAGEMENT OF VENOUS THROMBOEMBOLISM (VTE) IN CHILDREN: A PROSPECTIVE 22-YEAR REGISTRY FROM A SINGLE TERTIARY CENTER IN ARGENTINA
Gabriela Sciuccati, Mirta Hepner, Carolina Cervio*, Graciela Pieroni, Eliana Annetta, Aurora Felìu Torres, Nicolás Fernández Ponce, Juan Frontroth, Mariana Bonduel (Argentina)

Factor VIII – II

08:00 – 08:15
OR161
HEMATOPOIETIC CELLS A NOVEL TARGET FOR HEMOPHILIA A CELL THERAPY
Diego Zanolini*, Simone Merlin, Alessio Stevano, Mauro Zaffaroni, Guido Valente, Maria Prat, Antonia Follenzi (Italy)

08:15 – 08:30
OR162
RELATIONS BETWEEN FACTOR ACTIVITY LEVEL AND JOINT BLEEDING IN A LARGE COHORT OF MALES WITH MILD AND MODERATE HEMOPHILIA IN THE UNITED STATES
Mike Soucie*, Paul Monahan, Marshall Mazeppa, Roshni Kulkarni, Barbara Konkle (United States)

08:30 – 08:45
OR163
CHARACTERIZATION OF INTERACTIVE SITES OF ACTIVATED COAGULATION FACTOR VIII AND LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1
James Kurasawa, Svetlana Shestopal, Timothy Lee, Andrey G. Sarafanov* (United States)

08:45 – 09:00
OR164
ACCUCOPY QUANTIFICATION COMBINED WITH PRE-AMPLIFICATION OF LONG-DISTANCE PCR FOR FAST GENOTYPING OF INT22H-RELATED INVERSIONS IN HEMOPHILIA A
Qiyan Ding*, Guoqiang Sheng, Xi Wu, Zhengwen Jiang, Xuefeng Wang (China)

Inflammation

08:00 – 08:15
OR166
PLATELET FACTOR 4 REGULATES B CELL DIFFERENTIATION
Catherine A. Lemarie*, Manraj Sidhu, Le Angola, Sandrine Laurance, Francois-Rene Berlin, Mark Blystone (Canada)

08:15 – 08:30
OR167
CIRCULATING HISTONES DISTURB INTRACELLULAR CALCIUM HOMEOSTASIS AND CAUSE CALCIUM OVERLOAD TO INDUCE CARDIOVASCULAR ABNORMALITIES IN SEPSIS
Yasir Alhamdi, Simon Abrams, Min Z, Ingeborg Welters, Elizabeth Cartwright, Guozheng Wang, Cheng-Hock Toh* (United Kingdom)

08:30 – 08:45
OR168
PLATELET GRANULE RELEASE IS CRUCIAL FOR VASCULAR INTEGRITY IN THE ISCHEMIC BRAIN BUT NOT IN THE INFLAMED SKIN OR LUNG
Carsten Deppermann*, Peter Kraft, Karen Wolf, Paquita Nurden, Guido Stoll, David Stegner, Bernhard Nieswandt (Germany)

09:00 – 09:15
OR169
DUAL ACTION OF PLATELETS AND GLYCOPROTEIN-VI IN IMMUNE COMPLEX-MEDIATED INFLAMMATION
Angèle Gros*, Lamia Lamrani, Véronique Ollivier, Varouna Suyanarath, Stéphane Loyau, Tobias Goerge, Bernhard Nieswandt, Martine Jandrot-Perrus, Benoît Ho-Tin-Noé (France)

Microparticles – I

08:00 – 08:15
OR171
THE ROLE OF BREAST CANCER CELL MICROVESICLES IN THROMBOGENICITY, ANGIOGENESIS AND APOPTOSIS FOLLOWING CHEMOTHERAPY
Anat Aharon*, Gil Barsela, David Loven, Benjamin Brenner (Israel)

08:15 – 08:30
OR172
CIRCULATING MICROPARTICLES IN DEFICIENCY OF THE NATURAL ANTICOAGULANTS
Elena Campello*, Luca Spiezia, Claudia Radu, Cristina Bulato, Sabrina Gavasso, Daniela Tormene, Barry Woodhams, Paolo Simioni (Italy)

08:30 – 08:45
OR173
CELLULAR MICROPARTICLES AS PREDICTIVE MARKERS FOR THROMBOSIS AND OTHER CLINICAL EVENTS IN PATIENTS WITH IMPLANTED LVADS
Jeanine M. Walenga*, Bryan Menapace, Walter Jeske, Erin Cogliane, Vicki Escalante, Emmanuel Kumar, Jeffrey Schwartz, Alain Heroux, Mamdouh Bakhos (United States)

08:45 – 09:00
OR174
ANALYSIS OF EXOSOME-LIKE MEMBRANE MICROPARTICLES RELEASED FROM TRAP-ACTIVATED PLATELETS
Silvia De Paoli, Tseday Tegegn, Michael Strader, Ivan Tarandovskiy, Martina Orecna, Oumsalam Elhefi, Mikhail Ovanesov, Abdu Ayalash, Jan Simak* (United States)
SCIENTIFIC PROGRAM

09:00 – 09:15
OR175
PEPTIDYL-PROLYL ISOMERASE 1 (PIN1) PRESERVES THE PHOSPHORYLATION STATE OF TISSUE FACTOR AND PROLONGS THE RELEASE OF TF WITHIN MICROVESICLES
Camille Ettelaie*, Anthony Maraveyas, Mary Collier (United Kingdom)

Rare bleeding disorders

08:00 – 08:15
OR176
DIAGNOSIS OF INHERITED BLEEDING, THROMBOTIC AND PLATELET DISEASES BY NEXT GENERATION SEQUENCING
Ilene Simeoni* (United Kingdom)

08:15 – 08:30
OR177
ANTITHROMBIN REDUCTION IMPROVES COAGULATION IN RARE BLEEDING DISORDER PLASMA
Alfica Sehgal*, Kun Qian, Julia Hettinger, Benny Sorensen, Akin Akinc (United States)

08:30 – 08:45
OR178
LONG-TERM CORRECTION OF CANINE FVII DEFICIENCY USING AAV-MEDIATED EXPRESSION OF ZYMOSEREN FVII
Oscar A Marcos-Contreras*, Shannon Smith, Dwight A Bellinger, Elizabeth Merricks, Armida Faella, Giulia Pavani, Shangzhen Zhou, Timothy Nichols, Katherine High, Paris Margaritis (United States)

08:45 – 09:00
OR179
ENGINEERED TRANSCRIPTION FACTORS (TALE-TF) AS POTENTIAL THERAPEUTIC STRATEGY FOR COAGULATION FACTOR DEFICIENCIES CAUSED BY PROMOTER MUTATIONS
Elena Barbon*, Silvia Pignani, Alessio Branchini, Francesco Bernardi, Mirko Pinotti, Matteo Bovolenta (Italy)

09:00 – 09:15
OR180
STUDIES OF MCFD2 KNOCKOUT MICE SUGGEST ALTERNATIVE PATHWAYS FOR FV, FVIII AND ALPHA-1-ANTITRYPSIN SECRETION
Bin Zhang*, Chunlei Zheng, Min Zhu, Lesley Everret, David Ginsburg (United States)

Antiphospholipid antibodies – II

08:00 – 08:15
OR181
ACTIVATED PROTEIN C RESISTANCE DETERMINED BY THROMBIN GENERATION IS PREDICTIVE OF THROMBOSIS IN ANTIPHOSPHOLIPID-POSITIVE PATIENTS AND ASSOCIATED AUTO-IMMUNE DISEASES. A MULTICENTER PROSPECTIVE COHORT STUDY
Stéphane Zuily*, Veronique Regnault, Shirine Mohamed, Claire Lamboux-Mathieu, Anne-Christine Rat, Jacques Ninet, Nadine Magy-Bertrand, Jean-Louis Pasquali, Marc Lambert, Bernard Lorcerie, Pierre Kaminsky, Francis Guillemot, Denis Wahl (France)

08:15 – 08:30
OR182
EFFECTS OF NEW (DIRECT) ORAL ANTICOAGULANTS ON LUPUS ANTICOAGULANT ASSAYS
Jovan Antovic*, Aleksandra Antovic, Eva-Marie Norberg, Maria Berndtsson, Mika Skeppholm (Sweden)

08:30 – 08:45
OR183
OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: EARLY LMWH-INDUCED VARIATIONS OF ANGIOGENIC FACTORS PREDICT PLACENTA-MEDIATED PREGNANCY COMPLICATIONS.
Jean-Christophe R. Gris*, Sylvie Bouvier, Géraldine Lavigne, Eva Nouvellon, Erick Mercier, Jean-Philippe Galanaud, Isabelle Quéré, Céline Chauleur, Pierre Marès (France)

08:45 – 09:00
OR184
INCREASED RISK FOR PULMONARY HYPERTENSION ASSOCIATED WITH ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. A META-ANALYSIS OF ECHOCARDIOGRAPHIC STUDIES
Stéphane Zuily*, Vinicius Domingues, Denis Wahl (France)

09:00 – 09:15
OR185
OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: EARLY LMWH-INDUCED VARIATIONS OF ANGIOGENIC FACTORS PREDICT PREGNANCY LOSS.
Jean-Christophe R. Gris*, Sylvie Bouvier, Géraldine Lavigne, Eva Nouvellon, Erick Mercier, Jean-Philippe Galanaud, Isabelle Quéré, Pierre Marès (France)

Coffee break time in the exhibition (Level 800)
From 09:15 to 09:45
Tuesday, June 23, 2015

PLENARY SESSION  09:45-10:30

J. Fraser Mustard Plenary Lecture  Hall F&G
Moderator: Margaret Rand (Canada)

09:45 - 10:30 Platelets, NETs and Immunity
Paul Kubes (Canada)

Tuesday, June 23, 2015

STATE-OF-THE-ART LECTURES  10:45-11:45

Genetics of megakaryocytes and platelets  Room 801
Moderator: Jane Freedman (United States)

10:45 - 11:15 Genetic regulation of megakaryocyte and platelet function
Andy Weyrich (United States)

11:15 - 11:45 The formation of platelets: Lessons learned from population and rare disease cases genomics
Willem Ouwehand (United Kingdom)

Making Platelets for Transfusion  Room 701
Moderator: Erik Yeo (Canada)

10:45 - 11:15 Towards a self-renewing megakaryocyte
Koji Eto (Japan)

11:15 - 11:45 Road blocks in making platelets for transfusion
Jonathan Thon (United States)
### SCIENTIFIC PROGRAM

#### Thrombotic Thrombocytopenic Purpura  
**Room 713**  
**Moderator:** Kenneth Clemetson (Switzerland)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:45 - 11:15 | Long-term outcomes and pregnancy outcomes in TTP  
Sara Vesely (United States) |
| 11:15 - 11:45 | ADAMTS13, thrombotic microangiopathies, and eculizumab  
Spero Catalan (United States) |

**Lunch in the exhibition (Level 800)**  
From 11:45 to 12:15

**Lunch Symposia**  
From 12:15 to 13:45

Lunch Symposia Programs are available in the Show Guide. Please consult the different options to attend the symposium of your choice.

#### ORALS

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:00 – 14:15 | WITHHOLDING ANTICOAGULATION AFTER NORMAL CTPA IS SAFE IN PATIENTS WITH A HIGH CLINICAL PROBABILITY OF PE IN THE ABSENCE OF A PRIOR EPISODE OF VTE  
Tom van der Hulle*, Nick van Es, Paul den Exter, Josien van Es, Inge Mos, Renée Douma, Pieter Kamphuisen, Harry Bülter, Menno Huisman, Frederikus Klok (The Netherlands) |
| 14:15 – 14:30 | REPRODUCIBILITY OF CLINICAL EVENTS ADJUDICATIONS IN A TRIAL OF VENOUS THROMBOEMBOLISM PREVENTION  
Philippe Girard*, Florence Parent, Beatrice Gable, Olivier Sanchez, Pierre Durieux, Pierre Haussafet, Andrea Penaloza, Sophie Dambrine, Aurore Armand-Perroux, Marie Bezlau, Jean-Pierre Nguyen, Guy Meyer, Pierre-Marie Roy (France) |
| 14:30 – 14:45 | DNA IN PLASMA INDICATES DISEASE EXTENT AND PREDICTS MORTALITY IN PATIENTS WITH VENOUS THROMBOEMBOLISM  
Tobias A. Fuchs*, Miguel Jiménez-Alcázar, Andreas Limacher, Marie Ménan, Thomas Renné, Drahamir Ajouksy, Bernhard Lammle (Sweden, Germany) |
| 14:45 – 15:00 | LOW END-TIDAL CO2 SIGNIFICANTLY INCREASES PRETEST PROBABILITY OF PULMONARY EMBOLISM  
Jeffrey Kline*, Franck Venschuren, Kerstin Hogg, Pierre-Marie Roy, Andrea Penaloza, Donna Prentice (United States) |

**Venous thromboembolism – diagnosis**  
**Plenary Hall F&G**  
**Moderators:** Clive Kearon (Canada), Nakisa Khorsand (The Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:00 – 14:15 | VON WILLEBRAND DISEASE: DOES VON WILLEBRAND FACTOR DEFICIENCY DECREASE THE RISK OF CARDIOVASCULAR DISEASE?  
Craig Seaman*, Margaret Ragni, Jonathan Yabes, Diane Comer (United States) |
| 14:15 – 14:30 | QUALITATIVE AND QUANTITATIVE MODIFICATIONS OF VON WILLEBRAND FACTOR IN ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PLATELETS AND NON-ADAMTS13-DEPENDENT PROTEOLYTIC ROCESSING  
Stefano Lancellotti*, Alfredo Dragani, Paola Ranalli, Giovanna Petrucci, Maria Basso, Raffaele Tartaglione, Bianca Rocca, Raimondo De Cristofaro (Italy) |

**NOAC – bleeding risk factors and management**  
**Room 718**  
**Moderators:** Steen Husted (Denmark), Kerstin de Wit (Canada)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:00 – 14:15 | INFLUENCE OF ABCB1 GENOTYPE AND OF A P-GP DRUG INHIBITOR, CLARITHROMYCIN, ON DABIGATRAN AND RIVAROXABAN PHARMACOKINETIC PROFILES IN HEALTHY VOLUNTEERS  
Isabelle Gouin-Thibault*, Xavier Delavenne, Anne Blanchard, Virginie Sigaret, Pascale Gaussem, Christian Funck-Brentano, Michel Azizi, Patrick Mismetti, Marie-Anne Loriot (France) |
| 14:15 – 14:30 | NEW ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY HIGH RISK ATRIAL FIBRILLATION WITH HISTORY OF INTRACRANIAL HEMORRHAGE  
Dimitry Arioli*, Elisa Romagnoli, Valentina Cocchi, Monica Casella, Angela Muoio, Maria Del Mar, Jordana Sanchez, Attilia Pizzini, Annamaria Casali, Ido Iori (Italy) |
| 14:30 – 14:45 | INTRACRANIAL BLEEDING WITH THE NEW ORAL ANTICOAGULANT DRUGS  
Kerstin Hogg*, Bharat Bahl, Lana Castellucci, Ian Stiell (Canada) |
| 14:45 – 15:00 | CLINICAL IMPACT AND COURSE OF MAJOR BLEEDING WITH EDOXABAN VERSUS VITAMIN K ANTAGONISTS  
Marjolein P. Brekelmans*, Suzanne Bleker, Rupert Bayersdor, Zoltán Boda, Harry Bülter, Youngsook Choi, Alex Gallus, Michael Grosso, Michele Mercuri, Saskia Middeldorp, Doyeon Oh, Gary Raskob, Lee Schwocho, Ander Cohen (The Netherlands) |

**SCIENTIFIC PROGRAM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15:00 – 15:15 | A PROSPECTIVE ALGORITHM INCORPORATING LIMITED AND WHOLE-LEG ASSESSMENT OF THE DEEP VENOUS SYSTEM IN SYMPTOMATIC OUTPATIENTS (THE PALLADIO STUDY)  
Walter Ageno*, Giuseppe Camporese, Nicoletta Riva, Angelo Ghirarduzzi, Eugenio Bucherini, Marc Righini, Pieter Kamphuisen, Peter Verhamme, James Douketis, Chiara Tonello, Paolo Prandoni (Italy) |

**Von Willebrand disease – clinical**  
**Room 701**  
**Moderators:** Karl Desch (United States), Jeroen Eikenboom (The Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:00 – 14:15 | VON WILLEBRAND DISEASE: DOES VON WILLEBRAND FACTOR DEFICIENCY DECREASE THE RISK OF CARDIOVASCULAR DISEASE?  
Craig Seaman*, Margaret Ragni, Jonathan Yabes, Diane Comer (United States) |
| 14:15 – 14:30 | QUALITATIVE AND QUANTITATIVE MODIFICATIONS OF VON WILLEBRAND FACTOR IN ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PLATELETS AND NON-ADAMTS13-DEPENDENT PROTEOLYTIC ROCESSING  
Stefano Lancellotti*, Alfredo Dragani, Paola Ranalli, Giovanna Petrucci, Maria Basso, Raffaele Tartaglione, Bianca Rocca, Raimondo De Cristofaro (Italy) |
IMPACT OF ANNEXIN A2 SNP ON VON WILLEBRAND FACTOR LEVELS IN PATIENTS WITH MODERATE AND SEVERE VON WILLEBRAND DISEASE
Waander Van Heerde*, Jelmer van Puffelen, Iris Kloots, Johan Boender, Yvonne Sanders, Marjon Crossen, Britta Laros-van Gorkom, Karin Fijnvandraat, Selene Schoormans, Johanna van der Bom, Karina Meijer, Evelien Mauser-Bunschoten, Jeroen Eikenboom, Lambertus Kiemeneij, Frank Leebeek (The Netherlands)

VARIABILITY IN VON WILLEBRAND FACTOR ANTIGEN (VWF:AG) LEVELS IN PROSPECTIVE STUDIES OF THE ZIMMERMAN PROGRAM FOR THE MOLECULAR AND CLINICAL BIOLOGY OF VON WILLEBRAND DISEASE (ZPMB8-VWD) SUBJECTS
Kenneth D. Friedman*, Pamela Christopherson, Veronica Flood, Joan Gill, Sandra Haberichter, Robert Montgomery (United States)

CHARACTERIZATION OF A NEW GENETICALLY-ENGINEERED VON WILLEBRAND DISEASE TYPE 2B MOUSE MODEL.
Frédéric Adam*, Caterina Casari, Alexandre Kauskot, Cécile Loubière, Paulette Legendre, Christelle Reperant, Dominique Baruch, Jean-Philippe Rosa, Marijke Bryckaert, Olivier Christophe, Peter Lenting, Cécile Denis (France)

SINGLE CELL TRACKING REVEALS AUTONOMOUS LOCOMOTION AS A PLATELET FUNCTION FACILITATING THROMBUS REORGANIZATION
Florian Gaertner* (Germany)

MORE THAN JUST RED CELLS: HOW DO HEMOSTATIC THROMBI PREVENT THE LOSS OF PLASMA-BORNE MOLECULES?
John D. Welsh*, Ryan Muthard, Timothy Stalker, Joshua Taliaferro, Lawrence Brass (United States)

DICER, THE KEY ENZYME OF RNA INTERFERENCE, IS REGULATED BY THROMBIN STIMULATION IN HUMAN PLATELETS.
Giorgia Manni*, Loredana Bury, Elisa Piselli, Paolo Gresele (Italy)

REPLICATION OF PLATELET REACTIVITY GENOME-WIDE ASSOCIATION SINGLE NUCLEOTIDE POLYMORPHISMS IN THE CAERPHILLY PROSPECTIVE STUDY
John D. Eicher*, Luoting Xue, Yoav Ben-Shlomo, Andrew Beswick, Andrew Johnson (United States)

VPS33B REGULATES VWF POSITIVE VESICLES TRANSPORTATION TO PROPLATELET
Jing Dai*, Yeling Lu, Conghui Wang, Xue Chen, Panlai Shi, Xuemei Fan, Xiaolin Wu, Kemin Wang, Xueli Qing, Junliang Liu (China)

PERSONALIZATION OF TREATMENT REGIMENS FOR ACTIVE PATIENTS: A COMPARISON OF FACTOR VIII AND EXTENDED HALF-LIFE TREATMENT REGIMENS
Elizabeth Schwartz*, Yen Xiong, Josh Epstein, Bruce Ewenstein, Leonard Valintino (United States)

CLINICAL EVALUATION OF NOVEL RECOMBINANT GLYCOPEGLYLATED FVIII (TUROCTOCOG ALFA PEGOL, N8-GP): EFFICACY AND SAFETY IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A – RESULTS OF PATHFINDER™2 INTERNATIONAL TRIAL
Paul Giangrande*, Pratima Chowdary, Silke Ehrenforth, Hideji Hanabusa, Frank Leebeek, Steven Lentz, Laszlo Nemes, Lone Poulsen, Elena Santagostino, Chur You, Wan Hui Clausen, Johannes Oldenburg (United Kingdom)

A SUBCUTANEOUSLY ADMINISTERED INVESTIGATIONAL RNA THERAPEUTIC (ALN-AT3) TARGETING ANTITHROMBIN FOR TREATMENT OF HEMOPHILIA: INTERIM PHASE 1 STUDY RESULTS IN PATIENTS WITH HEMOPHILIA A OR B

BAY 81-8973 PROPHYLAXIS EFFICACY IN PATIENTS WITH SEVERE HEMOPHILIA A: ANALYSES OF ANNUALIZED BLEEDING RATE OUTCOMES IN THE LEOPOLD I TRIAL
Maria Elisa Mancuso*, Horst Beckmann, Monika Maas Enriquez (Germany)

FACTORs INFLUENCING THE PHARMACOKINETICS OF PEGYLATED RECOMBINANT FACTOR VIII (BAX 855) ADMINISTERED FOR PROPHYLAXIS IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A
Oleksandra Stasyshyn, Werner Engl, Brigitte A. Bublitz*, Victoria Empson, Bruce Ewenstein (Australia)

COMPARATIVE ANALYSIS OF VON WILLEBRAND FACTOR PROFILES IN LEFT VENTRICULAR ASSIST DEVICE AND TOTAL ARTIFICIAL HEART RECIPIENTS
Heidi Reich, Francisco Arabia, Lawrence Czer, Jaime Morici, Danny Ramzy, Fardad Esmaeili, Lee Lam, Julie Dunhill, Oxana Tcherniatchouk* (United States)

RELAPSE PATTERN AND LONG TERM OUTCOMES IN 111 SUBJECTS WITH ACQUIRED HEMOPHILIA A
Terry Mizrahi*, Karine Doyon, Arnaud Donnely, Margaret Warner, Christine Demers, Stéphanie Cloutier, Jean-François Castilloux, Georges-Etienne Rivard, Jean St-Louis (Canada)
### Scientific Program

#### Cancer and thrombosis – clinical – II

**Moderators:** Huyen Tran (Australia), Rupert Bauersachs (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 14:15</td>
<td>Long-term cancer risk after venous thromboembolism</td>
<td>Lisbeth Eischer*, Paul Kyrlle, Michael Kammer, Sabine Eichinger (Australia)</td>
</tr>
<tr>
<td>14:45 – 15:00</td>
<td>Thrombin generation and venous thromboembolism among multiple myeloma patients receiving lenalidomide and prednisolone maintenance following autologous stem cell transplantation</td>
<td>Huyen Tran*, James McFadyen, Anna Kalf, Andrew Spencer (Australia)</td>
</tr>
<tr>
<td>15:00 – 15:15</td>
<td>Incidental venous thromboembolism at thoracoabdominal staging CT in colorectal cancer</td>
<td>Andreas Nordholm-Carstensen, Morten S. Rasmussen*, Hanne Hansen, Henrik Harling, Lars Jorgensen (Denmark)</td>
</tr>
</tbody>
</table>

---

### Megakaryocytes and thrombopoiesis II

**Moderators:** Li Guo (Canada), A. Kaneti Rao (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 14:15</td>
<td>Syndromes with gray platelets: NBEAL2 expression is regulated by transcription factor GATA1</td>
<td>Anouck Wijgaerts*, Marie-Christin Wittevrongel, Timothy Devos, Marloes Tijsen, Kathleen Peerlinck, Chris Van Geet, Kathleen Freson (Belgium)</td>
</tr>
<tr>
<td>14:30 – 14:45</td>
<td>84galactosyltransferase 1 (84GALT1) is a key regulator of hematopoietic stem cell function and thrombopoiesis</td>
<td>Silvia Gianmatti*, Max Adelman, Antonija Jurak Begonja, Karin Hoffmeister (United States)</td>
</tr>
<tr>
<td>14:45 – 15:00</td>
<td>Type 2B von willebrand disease (VWD) is characterized by a cytосkeletal desorganization in megakaryocytes leading to macrothrombocytopenia</td>
<td>Alexandre Kauskot*, Sonia Poirault-Chassac, Caterina Casari, Frédéric Adam, Audrey Pietrzyk-Nivau, Eliane Berrou, Marijke Bryckaert, Jean-Philippe Rosa, Olivier D. Christophé, Peter J. Lenting, Cécile V. Denis, Dominique Baruch (France)</td>
</tr>
</tbody>
</table>
SCIENTIFIC PROGRAM

15:00 – 15:15  RECEPTOR-MEDIATED ENDOCYTOSIS IS REQUIRED FOR NORMAL MEGAKARYOCYTE DEMARCATION MEMBRANE SYSTEM FORMATION AND PLATELET PRODUCTION

Silvia Giannini, Fred Pluthero, Hilary Christensen, Richard Leung, Richard Lo, Jan Kor-mann, Markus Plomann, Walter Kahr, Karin Hoffmeister, Hervé Falet* (United States)

Tissue factor and factor VII – II  Room 705

Moderators: Nima Vaezzadeh (Canada), Bjarne Østerud (Norway)

14:00 – 14:15  GENOME-WIDE SERINE PROTEASE KNOCKDOWNS IN ZEBRAFISH: IDENTIFICATION OF PROSTASIN IN FACTOR VII ACTIVATION PATHWAY

Pudur Jagadeeswaran*, Gauri Khandekar (United States)

14:15 – 14:30  TISSUE-FACTOR INDUCED ALLOSTERIC ENHANCEMENT OF FACTOR VIA ACTIVITY BY STABILIZATION OF SEGMENT 215-219 AND TAMING OF W215 FLEXIBILITY

Anders Sorensen, Jesper Madsen, Anders Svensson, Henning Stennicke, Henrik Øster-gaard, Michael Overgaard, Ole Olsen, Prafull S. Gandhi* (Denmark)

14:30 – 14:45  RELATIONSHIPS OF CIRCULATING COAGULATION FACTOR VIIA (FVIIA) WITH COMMON SINGLE NUCLEOTIDE POLYMORPHISMS AND RISK OF INCIDENT ISCHEMIC STROKE: THE CARDIOVASCULAR HEALTH STUDY

Nels C. Olson*, Leslie Lange, Alex Reiner, Russell Tracy (United States)

14:45 – 15:00  EPIDERMAL TISSUE FACTOR IN WOUND HEALING

Elizabeth Chappell*, Dougald Monroe, Maureane Hoffman, Nigel Mackman (United States)

Platelets – signal transduction II  Room 707

Moderators: Katsue Suzuki-Inoue (Japan), Kristina Modjeski (United States)

14:00 – 14:15  GLUTAMATE RECEPTOR INTERACTING PROTEIN 1 MEDIATES PLATELET ADHESION AND THROMBOSIS FORMATION

Kristina Modjeski*, Sara Ture, David Field, Scott Cameron, Craig Morrell (United States)

14:15 – 14:30  UNEXPECTED ROLE OF PLATELETS IN LUNG DEVELOPMENT DEPENDING ON A PLATELET ACTIVATION RECEPTOR, CLEC-2

Nagaharu Tsukiji*, Osamu Inoue, Shogo Tamura, Toshiaki Shirai, Tomoyuki Sasaki, Kaneo Satoh, Katsue Suzuki-Inoue, Yukio Ozaki (Japan)

14:30 – 14:45  NON-GENOMIC ACTIVITIES OF RETINOIC ACID RECEPTOR ALPHA CONTROL ACTIN CYTOSKELETAL EVENTS IN HUMAN PLATELETS

Hansjorg Schwerz*, Martin Freitag, Jesse Rowley, Larry Kraiss, Zechariah Franks, Guy Zimmermann, Andrew Weyrich, Matthew Rondina (Germany, United States)

14:45 – 15:00  LEUKEMIA-ASSOCIATED RHOGF (LARG) PLAYS A MINOR ROLE IN RH OA ACTIVATION, YET IT IS CRITICAL FOR PLATELET ACTIVATION IN MICE

Christopher M. Williams*, Matthew Harper, Robert Goggs, Tony Walsh, Stefan Offer-man, Alastair Poole (United Kingdom)

Coagulation factors V, X, and XIII  Room 709

Moderators: Cathy Hayward (Canada), Sriram Krishnaswamy (United States)

14:00 – 14:15  MACROPHAGE-SPECIFIC RECEPTOR SR-AL PLAYS A CRUCIAL PROTECTIVE ROLE IN THE REGULATION OF COAGULATION FACTOR X PLASMA LEVELS

Vincent Muczynski*, Amine Bazaaz, Amélie Harel, Cécile Loubière, Ghislaine Cherel, Peter Lenting, Cécile Denis, Olivier Christophe (France)

14:15 – 14:30  CB-FXA: AN IMPROVED SECOND GENERATION FXA VARIANT

Edwin Madison*, Christopher Thanos, Mark Fox, Keryn McCluskie, Jodi Gureasko, Tony Byun, David Sloane (United States)

14:30 – 14:45  CHARACTERIZATION OF A NOVEL FV MUTATION (A512V, FV BONN) ASSOCIATED WITH DEEP VEIN THROMBOSIS AND APC RESISTANCE

Behnaz Pezeshkpoor*, Elisabetta Castoldi, Nasim Hamedani, Arjilt Biswas, Johannes Oldenburg, Anna Pavlova (Germany)

14:45 – 15:00  PLATELET-DERIVED FACTOR V REGULATES ARTERIAL THROMBOSIS

Jianbo Wu*, Meiping Ren, Yongjie Li, Ningbo Pang, Ni Chen, Xin Deng, Yan Yang, Namei Xiao, Hongmin Sun (China)

15:00 – 15:15  DEVELOPMENT OF A NOVEL ASSAY METHOD OF COAGULATION FACTOR XIII ACTIVITY FOR THE DETECTION OF ITS INHIBITOR IN PLASMA

Masayoshi Souri*, Tsukasa Osaki, Akita Ichinose (Japan)

Arterial vascular disease  Room 711

Moderators: John Eikelboom (Canada), Michiel Coppens (The Netherlands)

14:00 – 14:15  THE EFFECT OF INTRACORONARY STEM CELL INJECTION ON MARKERS OF LEUKOCYTE ACTIVATION IN ACUTE MYOCARDIAL INFARCTION

Ragnhild Helseth*, Ingrid Opsvat, Svein Solheim, Ketil Lunde, Arild Arnesen, Ingeb-jørg Scjeflot (Norway)

14:15 – 14:30  PLATELET NEUTROPHIL COMPLEX FORMATION AND INFILTRATION IS REGULATED BY PERIPHERAL SEROTONIN IN A MOUSE MODEL OF MYOCARDIAL INFARCTION

Maximilian Mauler*, Thilo Wiltsch, Ludwig Dorner, Kelly Blanz, Christoph Koenstges, Daniela Stallmann, Christoph Bode, Heiko Bugger, Daniel Duerschmied (Germany)

14:30 – 14:45  POST-PCI THROMBIN GENERATION AND CARDIOVASCULAR MORTALITY IN ACUTE CORONARY SYNDROME PATIENTS

Monica Attanasio, Rossella Marcucci, Annamaria Gori*, Rita Panciccia, Raffaella Priora, Serafina Valente, Daniela Balzi, Alessandro Barchielli, Rosanna Abbate, Gian Franco Gensini (Italy)
14:45 – 15:00 REPEATED MEASURES OF MODIFIABLE AtherosCLerotic RISK FACTORS OVER TIME AND RISK OF MYOCARDIAL INFARCTION AND VENOUS THROMBOSIS
Birgit Småbækkek*, Ludvig Rinde, Erin Hald, Anders Vik, Tom Wilsgaard, Inger Njølstad, Elliv Mathiesen, Sigrid Brekken, John-Bjarne Hansen (Norway)

15:00 – 15:15 RECURRENCE AND MORTALITY IN YOUNG WOMEN WITH MYOCARDIAL INFARCTION OR ISCHEMIC STROKE: 19-YEAR FOLLOW-UP OF THE RISK OF ARTERIAL THROMBOSIS IN RELATION TO ORAL CONTRACEPTIVES (RATIO) STUDY.
Alberto Maino*, Bob Siegerink, Ale Algra, Flora Peyvandi, Frits Rosendaal (Italy)

Coffee break time in the exhibition (Level 800)
From 15:15 to 15:45

Tuesday, June 23, 2015
PLENARY SESSION 15:45-16:30

Maureen Andrew Plenary Lecture
Hall F&G

Moderator: Patti Massicotte (Canada)

15:45-16:30 Why do we miss the mark on preventing cardiovascular disease? Is it too little, too late or just futile?
Brian McCrindle (Canada)

Why do we miss the mark on preventing cardiovascular disease? Is it too little, too late or just futile?

Tuesday, June 23, 2015
ABSTRACT SYMPOSIA 16:45-18:00

Von Willebrand factor
Room 801

Moderators: Laura Swystun (Canada), Jorge di Paola (United States)

16:45-17:05 THE MULTIPLE ROLES OF VON WILLEBRAND FACTOR: REGULATION OF ANGIogensis
Anna Randi (United Kingdom)

17:05 - 17:19 VON Willebrand factor is indispensable for Venous Hemostasis in a Novel Murine Bleeding Model
Amine Bazaa*, Vincent Muczynski, Amélie Harel, Tom Knudsen, Cécile V. Denis, Olivier D. Christophe, Peter J. Lenting (France)

17:19-17:33 THE INTRODUCTION OF A MUCIN INSERT AT THE N-TERMINUS OF VWF-A1, BUT NOT THE C-TERMINUS, ENHANCES PLATELET GPIbα BINDING TO VWF
Anju Kelkar, Changjie Zhang*, Daniel Swartz, Sriman Neelamegham (United States)

17:33 - 17:47 HIGH RESOLUTION MICROSCOPIC CHARACTERISATION OF VWF BIOSYNTHESIS, STORAGE AND SECRETION IN TYPE 1 VWD PATIENTS WITH LARGE IN-Frame VWF Deletions
Simon J. Webster*, Ashley Cartwright, Daniel Hampshire, Ian Peake, Anne Goodeve (United Kingdom)

17:47 - 18.00 THE RECOGNITION OF COLLAGEN BY THE VWF A DOMAINS
Samir W. Hamaia*, Kirsty Ferguson, Emma Hunter, Dominique Bihan, Richard Fardale (United Kingdom)

Platelet signaling
Room 717

Moderators: Attila Braun (Germany), Wolfgang Bergmeier (United States)

16:45-17:05 TYROSINE PHOSPHATASES IN PLATELET SIGNAL TRANSDUCTION
Yotis Senis (United Kingdom)

17:05 - 17:19 RUNX1 REGulates MEGAKaryocytic/PLATELET RAS-related Small GTPase RAB18: POTENTIAL ROLE IN PLATELET DYSFUNCTION WITH RUNX1 HapLODEFICIENCY.
Gauthami S. Jalagadugula*, A. Koneti Rao (United States)

17:19 - 17:33 TRPm7 KINase REGulates ITAM-SIGNALING AND PLAYS A CRITICAL ROLE IN THROMBOSIS AND ISCHEMIC STROKE
Attila Braun*, Wenchun Chen, Carsten Schmitz, Rene Zahedi, Sanjeev Gotru, Peter Kraft, Karen Wolf, Simon Stritt, Heike Hermanns, Masayuki Matsushita, Susanna Zierler, Vladimir Chubanov, Thomas Gudermann, Guido Stolf, Bernhard Nieswandt (Germany)
TYROSINE PHOSPHORYLATION OF THE ITIM-CONTAINING RECEPTOR G6B-B IS ESSENTIAL FOR PLATELET HOMEOSTASIS
Mitchell Geer*, Silke Heising, Louise Tee, Ralph Gareus, Steve Watson, Alexandra Mazharian, Yotis Senis (United Kingdom)

RAS3 IS A CRITICAL INHIBITOR OF PLATELET ACTIVATION AND THE MISSING LINK IN THE P2Y12/RAP1 SIGNALING PATHWAY.
Lucia Stefanini*, David Paul, Raymond Robledo, Todd Getz, Caterina Casari, Raymond Piatt, Yacine Boulaftali, Luanne Peters, Wolfgang Bergmeier (United Kingdom)

Mitchell Geer*, Silke Heising, Louise Tee, Ralph Gareus, Steve Watson, Alexandra Mazharian, Yotis Senis (United Kingdom)

RASA3 IS A CRITICAL INHIBITOR OF PLATELET ACTIVATION AND THE MISSING LINK IN THE P2Y12/RAP1 SIGNALING PATHWAY.
Lucia Stefanini*, David Paul, Raymond Robledo, Todd Getz, Caterina Casari, Raymond Piatt, Yacine Boulaftali, Luanne Peters, Wolfgang Bergmeier (United Kingdom)

Mechanisms of ITP Room 705
Moderators: Rick Kapour (Canada), Barbara Konkle (United States)

THE ROLE OF T CELLS IN THE PATHOGENESIS OF IMMUNE THROMBOCYTOPENIA
John Semple (Canada)

ALTERED PLASMA MICRorna LEVELS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA
Yang He*, Bin Zuo, Yunxiao Zhao, Qingyu Wu (China)

CD40L AND ITS DNA METHYLATION IN PRIMARY IMMUNE THROMBOCYTOPENIA
Huiyuan Li*, Donglei Zhang, Renchi Yang (China)

CYCLOSPORINE ENHANCES IMMUNOSUPPRESSIVE FUNCTIONS OF MYELOID-DERIVED SUPPRESSOR CELLS IN IMMUNE THROMBOCYTOPENIA
Yu Hou*, Miao Xu, Qi Feng, Yingyi Yu, Xuena Liu, Ming Hou, Jun Peng (China)

ELEVATED SEMASA IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
Lyu Mingren*, Li yang, Hao Tating, Sun Tiantian, Liu wenjie, Iyu Cuicui, Li Huiyuan, Xue Feng, Liu Xiaofan, Zhang Lei, Yang Rench (China)

Tools for evaluation of bleeding Room 716
Moderators: Flora Peyvandi (Italy), Samantha Gouw (The Netherlands)

THE CLINICAL UTILITY OF BLEEDING SCORES
Paula James (Canada)

ACCURACY OF THREE CLINICAL PREDICTION TOOLS FOR MAJOR BLEEDING IN PATIENTS ON EXTENDED ORAL ANTICOAGULANT FOR VENOUS THROMBOEMBOLISM
Phil Wells*, ParvanehFallah, Michael Kovacs, David Anderson, Susan Kahn, Vinay Shah, Scott Rataf, Clive Kearon, Susan Solymoss, David Keeling, Russell Zide, Sam Schulerman, Isabelle Chagnon, Rosendo Rodriguez, Daniel Corsi, Marc Rodger (Canada)

ENDOTHELIAL PROGENITORS CELLS: FROM PATHOPHYSIOLOGY TO EMERGENT THERAPY OF VASCULAR DISORDERS
Françoise Dignat-George (France)

CD34+ HEMATOPOIETIC STEM CELL COUNT IS PREDICTIVE FOR VASCULAR EVENT OCCURRENCE IN SICKLE CELL DISEASE CHILDREN
Manoelle Kossorotoff, Marianne de Montalembert, Dominique Lasne, Valentine Brousse, Emmanuel Curis, David Smadja, Romaric Lacoix, Sebastien Bertli, Isabelle Desguerre, Damien Bonnet, Pascale Gaussem* (France)

TREPROSTINIL INDIRECTLY REGULATES ENDOTHELIAL COLONY FORMING CELL ANGIOGENIC PROPERTIES BY INCREASING VEGF-A PRODUCED BY MESENCHYMAL STEM CELLS
David Smadja*, Marlène Levy, Lan Huang, Elisa Rossi, Dominique Israel-Biet, Pascale Gaussem, Joyce Bischoff (France)

INDUCED PLURIPOTENT STEM CELL (IPSC) BASED STRATEGY TO CORRECT THE BLEEDING PHENOTYPE IN HEMOPHILIA A
Maria Talmon*, Cristina Olgasi, Simone Merlin, Gabriella Ranaldo, Angelo Lombardo, Donato Colangelo, Giovanni Berta, Luigi Naldini, Angel Raya, Federica Valeri, Piercarla Schinco, Maria Messina, Antonia Follenzi (Italy)

Vessel wall in health and disease, annexins Room 714
Moderators: Colin Kretz (Canada), Robert Flaumenhaft (United States)

ANNEXIN A2 IN HEALTH AND DISEASE
Katherine Hajjar (United States)

THE ENDOTHELIAL CELL TRANSCRIPTOME IS HIGHLY HETEROGENEOUS ACROSS DIFFERENT VASCULAR BEDS
Audrey Cleuren*, Hi, Jiang, Kristina Hunker, Andrew Yee, Santith Ganesh, David Ginsburg (United States)
SCIENTIFIC PROGRAM

17:30 – 17:45
AS091
A CLASS OF BIASED PAR1 AGONISTS THAT STIMULATE CYTOPROTECTIVE SIGNALING IN ENDOTHELIAL CELLS
Omozuanvbo R. Aisiku*, Christian Peters, Karen De Ceuynck, Jennifer Fitch-Tewfik, James Dilkis, Susanna Fustulo-Gunnink, Christopher Dockendorff, Robert Fläumenhaft (United States)

17:45 – 18:00
AS092
PODOPLANIN AND CLEC-2 DRIVE CEREBROVASCULAR PATTERNING AND INTEGRITY DURING DEVELOPMENT
Kate Lowe*, Brenda Finney, René Hägerling, Carsten Deppermann, Jon Frampton, Bernhard Nieswandt, Christopher Buckley, Friedemann Kiefer, Steve Watson (United Kingdom)

Cancer and thrombosis – basic

Plenary Hall F&G

Moderators: Esterina d’Asti (Canada), Gary Lyman (United States)

16:45-17:15
AS093
THROMBOSIS, INFLAMMATION AND CANCER
Tatiana V. Byzova (United States)

17:15 – 17:30
AS094
GPV IS A CENTRAL REGULATOR OF HEMOSTASIS, THROMBOSIS AND THROMBO-INFLAMMATORY BRAIN INFARCTION IN MICE
Sarah Schielli*, David Stegner, Ina Hagedorn, Peter Kraft, Ina Thielmann, Guido Stoll, Bernhard Nieswandt (Germany)

17:30 – 17:45
AS095
PLATELET INTEGRIN ALPHA 6 BETA 1 PROMOTES METASTATIC DISSEMINATION
Elmina Mammadova-Bach*, Monique Freund, Dominique Bagnard, Christian Gachet, Pierre Mangin (France)

17:45 – 18:00
AS096
PEPTIDES INHIBITING HEPARANASE PROCOAGULANT ACTIVITY SIGNIFICANTLY REDUCE TUMOR GROWTH AND VASCULARIZATION IN A MOUSE MODEL
Yonatan Crispel, Elena Axelman, Mifleh Tatour, Inna Kogan, Yona Nadir* (Israel)

Non-vitamin K antagonist oral anticoagulants

Room 718

Moderators: Mark Crowther (Canada), Paul Harper (New Zealand)

16:45-17:05
AS097
NOACs IN VENOUS THROMBOEMBOLISM: STRENGTHS AND CAVEATS
Sam Schulman (Canada)

17:05 - 17:19
AS098
REAL LIFE EFFICACY AND SAFETY OF APIXABAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION – RESULTS OF THE PROSPECTIVE NOAC REGISTRY (NCT01588119)
Jan Beyer-Westendorf*, Sebastian Werth, Luise Tittl, Franziska Michalski, Sandra Marten, Norbert Weiss (Germany)

17:19 - 17:33
AS099
FIXED-DOSE RIVAROXABAN IS NOT ASSOCIATED WITH INCREASED RECURRENT VENOUS THROMBOEMBOLISM OR MAJOR BLEEDING IN PATIENTS WITH A HIGH OR LOW BODY WEIGHT

SCIENTIFIC PROGRAM

17:33 - 17:47
AS100
DABIGATRAN PERSISTENCE AND ADHERENCE IN NEW ZEALAND
Paul L. Harper*, Su Chen Fong, Laura Chen (New Zealand)

17:47 - 18:00
AS101
INCREASED RISK OF THROMBOTIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION SHORTLY AFTER DABIGATRAN OR RIVAROXABAN DISCONTINUATION
Nina Vene, Alenka Mavri, Mirjam Gubenske, Gregor Tratar, Tjasa Vizinčin Cuderman, Maja Pohar Perme, Ales Blinc* (Slovenia)

Developmental hemostasis

Room 709

Moderators: Paul Monagle (Australia), Aisha Bruce (Canada)

16:45-17:15
AS102
DEVELOPMENTAL HEMOSTASIS: CONSEQUENCES FOR CLINICAL PRACTICE
Heleen van Ommen (The Netherlands)

17:15 – 17:30
AS103
REDUCED DOSING OF ENOXAPARIN TO TREAT DEEP VEIN THROMBOSIS (DVT) OR PULMONARY EMBOLI (PE) IN OVERWEIGHT AND OBESE PEDIATRIC PATIENTS
Stephanie Hoffman, Chi L. Braunreiter* (United States)

17:30 – 17:45
AS104
DEVELOPMENT OF A RIVAROXABAN DOSING REGIMEN FOR TREATMENT OF VTE IN CHILDREN AGED 12 TO 18 YEARS
Guy Young*, Dagmar Kubitz, Anthony Chan, Gili Kenet, Christoph Male, Patti Massicotte, Angelo Claudio Molinari, Paul Monagle, Ulrike Nowak-Goettl, Rolf Burghaus, Jan Stampfuss, Anthonie Lensing (United States)

17:45 – 18:00
AS105
DEVELOPMENTAL DIFFERENCES IN FIBRIN CLOT FORMATION UNDER VENOUS AND ARTERIAL LAMINAR FLOW
Hilde Keijchtermans*, Leonie Peikmans, Paul Monagle, Bas deLaat, Vera Ignjatovic (Australia)

Alloimmune and autoimmune platelet disorders

Room 715

Moderators: Ted Warkepin (Canada), Cindy Neunert (United States)

16:45-17:05
AS106
UPDATE ON CURRENT ATTEMPTS TO PREVENT NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
Tamam Bakchoul (Germany)

17:05 - 17:19
AS107
IMPACT OF PLATELET ACTIVATION DETECTED BY THE WASHED PLATELET ACTIVATION ASSAY ON THROMBOTIC OUTCOMES IN PATIENTS CLINICALLY SUSPECTED OF HAVING HEPARIN-INDUCED THROMBOCYTOPENIA.
Takuma Maeda*, Yoshiaki Kanaumi, Shiori Kawamura, Shu Seguchi, Mayumi Kodama, Takeshi Kawai, Toshimitsu Hamasaki, Hitoshi Okazaki, Shigeki Miyata (Japan)

17:19 - 17:33
AS108
DEVELOPMENT AND CHARACTERIZATION OF 5B9, A POTENTIAL INTERNATIONAL STANDARD FOR THE DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA
Jérôme Rollin*, Claire Pouplard, Claire Kizlik-Masson, Gaël Champion, Steven McKenzie, Yves Gruel (France)
### SCIENTIFIC PROGRAM

#### Hemostasis and infection

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>MAPPING ENDOTHELIAL CELL ACTIVATION IN THE CARDIOVASCULAR TARGET ORGANS USING ULTRA-SENSITIVE MOLECULAR MAGNETIC RESONANCE IMAGING</td>
<td>Maxime Gauberti*, Julie Bellière, Sara Martinez de Lizarrondo, Denis Vivien (France)</td>
</tr>
<tr>
<td>17:45</td>
<td>REGULATION OF STIMULATED AND BASAL RELEASE OF WEIBEL-PALADE BODIES BY SYNTAXIN-3 CONTAINING SNAP-COMPLEXES.</td>
<td>Maaike Schilleman*, Dorothee van Breevoort, Maryam Wahedi, Stephan Huveneers, Martja van den Biggelaar, Jan Voorberg, Ruben Bierings (The Netherlands)</td>
</tr>
</tbody>
</table>

#### Inhibitors - basic

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>THE IMMUNOGENICITY OF FACTOR VIII</td>
<td>Shannon Meeks (United States)</td>
</tr>
<tr>
<td>17:45</td>
<td>FACTOR VIII TOLERANCE INDUCTION IN HAEMOPHILIA A MICE VIA TRANSPLACENTAL TRANSFER OF RECOMBINANT FACTOR VIII FC</td>
<td>Maria Georgescu*, Tongyao Liu, Kate Sponagle, Kassandra Hebert, Douglas Drager, Susannah Patarroyo-White, Christine Hough, Haiyan Jiang, David Liflitramp (Canada)</td>
</tr>
</tbody>
</table>

#### Poster with refreshments

From 18:00 – 19:30 in the Exhibition on Level 800

---

**Moderators:**

- Maxime Gauberti (France), Bill Aird (United States)
- Steven Pipe (United States), Paul Monahan (United States)
- Ed Pryzdial (Canada), Travis Gould (Canada)
- Maxime Gauberti (Canada), Julie Bellière (Canada)
- Steven Pipe (United States), Paul Monahan (United States)
- Maxime Gauberti (Canada), Julie Bellière (Canada)
- Ed Pryzdial (Canada), Travis Gould (Canada)
- Maxime Gauberti (Canada), Julie Bellière (Canada)
- Steven Pipe (United States), Paul Monahan (United States)
Tuesday, June 23, 2015

POSTER SESSION  17:15-18:15

Posters will be presented on different days during the Congress and are accessible at the same times as the exhibition opening hours. The official poster sessions with refreshments will take place as follows:

Monday, June 22, 2015, from 17.15-18.30
Tuesday, June 23, 2015, from 18.00-19.30
Wednesday, June 24, 2015, from 17.15-18.30

The Poster Area is located inside the Exhibition on Level 800.

Poster setup times are as follows:

Monday, June 22, 2015, from 07.30 - 09.15
Tuesday, June 23, 2015, from 07.30 - 09.15
Wednesday, June 24, 2015, from 07.30 - 09.15

Poster dismantling times are as follows:

Monday, June 22, 2015, from 18.30 - 19.00
Tuesday, June 23, 2015, from 19.30 - 20.00
Wednesday, June 24, 2015, from 18.30 - 19.00

Posters not taken down after the dismantling time will be discarded.

If you have sent your poster to the poster printing service, kindly note that you will be able to pick it up at the Poster Booth located in the Swing Space on Level 800.

Poster Booth opening times are:

Monday, June 22, 2015, from 07.30 - 19.00
Tuesday, June 23, 2015, from 19.30 - 20.00
Wednesday, June 24, 2015, from 18.30 - 19.00

Pins are provided on the poster boards directly

Animal models II

PO001-TUE  POLYPHOSPHATE AS A NOVEL THERAPEUTIC FOR AGE-RELATED MACULAR DEGENERATION
Linnette M. Ocariza*, Alice O’Byrne, Stephanie Smith, James Morrissey, Jing Cui, Joanne Matsubara, Edward Conway (Canada)

PO002-TUE  ANTI-OXIDANT TREATMENT IMPROVES CARDIAC DYSFUNCTION IN BMAL1 DEFICIENT MICE
Blanca Hemmeryckx*, Philipp Hohensinner, Melissa Swinnen, Ward Heggermont, Johann Wolja, Henri Lijnen (Belgium)

PO003-TUE  NOVEL MOUSE HEMOSTASIS MODEL FOR REAL-TIME DETERMINATION OF BLEEDING TIME AND HEMOSTATIC PLUG COMPOSITION.
Raymond Piatt*, Todd Getz, Wolfgang Bergmeier (United States)

PO004-TUE  TARGETING EXTRACELLULAR CYCLOPHILIN A-MEDIATED NEUROVASCULAR DYSFUNCTION
Georgette Suidan*, Marissa Ilardi, Andrew Cameron, Natasha Kablaoui, Karl Fonseca, Robert Bell (United States)

SCIENTIFIC PROGRAM

TUESDAY

PO005-TUE  MODIFICATION OF THE BDNF GENE THAT INDUCES DEPRESSION-LIKE STATES IS ASSOCIATED TO PRO-INFLAMMATORY AND PRO-THROMBOTIC PHENOTYPE IN MICE.
Silvia S. Barbieri*, Patrizia Amadio, Sara Gianellini, Eva Tarantino, Alessandro Ieraci, Maura Brizioschi, Cristina Banfi, Francis Lee, Elena Tremoli (Italy)

PO006-TUE  FAMILIAL FELINE HYPERTROPHIC CARDIOMYOPATHY: A MODEL FOR EVALUATING PLATELET ACTIVATION AND CLOPIDOGREL THERAPY
Ronald Li*, Joshua Stern, Fern Tablin (United States)

PO007-TUE  PLATELET EFFECTS OF EPISODIC OZONE AND PM EXPOSURE DURING POSTNATAL DEVELOPMENT
Fern Tablin*, Monica Pombo (United States)

PO008-TUE  EVALUATION OF FACTOR XIA PHARMACOKINETICS IN MICE WITH A THROMBIN GENERATION ASSAY
Yideng Liang, Evi Struble, William Chang, Dorothy Scott, Mikhail Ovanesov* (United States)

Antiplatelets agents II

PO009-TUE  RESISTANCE TO ANTI-PLATELET AGENTS IN PATIENTS WITH ISCHEMIC STROKE
Anil Pathare*, Karima Al Falahi, Arun Gujjar, Badriya Al-Belushi, Nandagopal R, Jacob PC, Abdullah Al Asmi (Oman)

PO010-TUE  MECHANISM OF ANTIPLATELET ACTION INDUCED BY GUANOSINE VIA INCREASE IN CAMP LEVELS AND ITS ANTIARTHROMBOTIC ACTIVITY
Eduardo Fuentes*, Marcelo Alarcon, Julio Caballero, Ivan Palomo (Chile)

PO011-TUE  IMPACT OF NON-INHIBITED PLATELET SUPPLEMENTATION ON PLATELET REACTIVITY IN PATIENTS TREATED WITH PRASUGREL OR TICAGRELOR FOR AN ACUTE CORONARY SYNDROME: AN EX-VIVO STUDY
Fanny Bonhomme, Robert Bonvini, Jean-Luc Reny, Antoine Poncet, Pierre Fontana* (Switzerland)

PO012-TUE  THE EFFECTS OF TWO COMMONLY USED HERBAL PRODUCTS ON HAEMOSTATIC SYSTEM AND THEIR INTERACTIONS WITH ASPIRIN
Wan Hui Wong*, Seng Kok Ang, Foon Yin Fung, Hwee Ling Koh, Heng Lee, Xiaomei Li, Heng Joo Ng, Chuen Wen Tan, Yan Zhao, Yeh Ching Linn (Singapore)

PO013-TUE  EFFICACY OF PLATELET INHIBITION WITH PRASUGREL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION UNDERGOING THERAPEUTIC HYPOThERMIA AFTER CARDIOPULMONARY RESUSCITATION
Andreas Schäfer*, Ulrike Flierl, Johann Bauersachs (Germany)

PO014-TUE  ANTIBODY TARGETED, THROMBIN-SENSITIVE POLYMER CAPSULES FOR UROKINASE DELIVERY
Sylvia Gunawan, Kristian Kempe, Thomas Bonnard, Jiwei Cui, Karen Alt, Xiaowei Wang, Lok Law, Georgina Such, Karlheinz Peter, Frank Caruso, Christoph E. Hagemeyer* (Australia)
PO015-TUE  PLATELET TRANSFUSION MIGHT BE A POTENT ANTIDOTE FOR THIENO-PYRIDINES, BUT NOT FOR TICAGRELOR
Anne Bertling*, Kira Mergemeier, Georg Georg Geissler, Walter Sibrowski, Reinhard Kelsch, Johannes Walthenberger, Joseph Jakubowski, Beate Kehrel (Germany)

PO016-TUE  TICAGRELOR REVERSAL: IN VITRO ASSESSMENT OF VARIOUS HEMOSTATIC AGENTS
Leyla Calmette, Anne-Céline Martin, Bernard Le Bonnec, Isabelle Gouin-Thibault, Christilla Bachelot-Loza, Pascale Gaussem, Anne Godier* (France)

PO017-TUE  TWO DISINTEGRINS, TFV-1 AND TFV-3, PURIFIED FROM TRIMERESURUS FLAVOIRIDIS SNAKE VENOM, EXHIBIT DISTINCT EFFECTS ON PLATELET ACTIVATION
Tzu Yu Pan*, Chun-Chieh Hsu, Tur-Fu Huang (Taiwan)

PO018-TUE  PLATELET INHIBITION MONITORING WITH THROMBOELASTOGRAPHY (TEG) PLATELET MAPPING IN PEDIATRIC PATIENTS WITH VENTRICULAR ASSIST DEVICE
Tiphaine Belleville, Chiara Giorni, Christilla Bachelot-Loza, Philippe Pouard, Tiffany Pascreau, Vanessa Lopez, Camilla Biselli, Claudio Barbanti, Delphine Borgeil, Dominique Lasne* (France)

PO019-TUE  THE PROGNOSTICUTILITY OF PLATELET FUNCTION TESTING FOR THE DETECTION OF ‘ASPIRIN RESISTANCE’ IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE

PO020-TUE  A TIME COURSE STUDY OF HIGH ON TREATMENT PLATELET REACTIVITY IN ACS PATIENTS ON DUAL ANTIPLATELET THERAPY
Alessia Fabbri, Rosella Marcucci, Anna Maria Gori*, Betti Giusti, Rita Paniccia, Daniela Balzi, Alessandro Barchielli, Serafina Valente, Cristina Giglioli, Rosanna Abbate, Gian Franco Gensini (Italy)

PO021-TUE  INHIBITION OF PLATELET AGGREGATION BY GLS-409, AN ANTAGONIST OF BOTH P2Y1 AND P2Y12, IS DISTINCT FROM INHIBITION BY SELECTIVE P2Y1 AND P2Y12 ANTAGONISTS
Thomas Gremmel*, Ivan Yanachkov, George Wright, Alan Michelson, Andrew Frelinger (Austria, United States)

PO022-TUE  P2Y12 IS NOT INVOLVED IN THE INITIATION AND STABILIZATION OF MURAL THROMBI AFTER LASER INJURY OF AN ARTERY.
Roxane Darbouset*, Eva Caroff, Francis Hubler, Markus Riederer, Laurence Pani-cot-Dubois, Christophe Dubois (France)

PO023-TUE  SAFETY OF RIVAROXABAN: EFFECTS ON PLATELET FUNCTION
Jesus Hernandez*, Hugo Espejo, Manuel Moreno, Jose Hernandez, Irma Isordia, Abraham Majul (Mexico)

PO024-TUE  THE START-ANTIPLATELETS REGISTER: A MULTICENTER OBSERVATIONAL PROSPECTIVE STUDY TO ASSESS THE RISK-BENEFITS OF ANTI-THROMBOTIC THERAPY IN ACS PATIENTS.
Rossella Marcucci, Vittorio Pento*, Giuseppe Patti, Paol Gresele, Emilia Antonucci, Serafina Valente, Alessia Braco, Tiziana Fiero, Ilaria Cavallari, Gian Franco Gensini, Gualtiero Palareti (Italy)

PO025-TUE  ASSOCIATION OF THE MEAN PLATELET VOLUME (MPV) WITH THE DIAGNOSIS OF ACUTE CORONARY SYNDROMES (ACS) AMONG PATIENTS WHO PRESENT WITH CHEST PAIN AT THE EMERGENCY ROOM (ER)
Al-Zamzam Abubakar* (Philippines)

PO026-TUE  RESIDUAL PLATELET FUNCTION IN ACS PATIENTS TREATED WITH PRA-SUGREL IS LOWER THAN IN PATIENTS TREATED WITH CLOPIDOGREL BUT NOT IN PATIENTS WITH HYPERTENSION
Phakwan Laohathai*, Rashi Joshi, Ashwin Radhakrishnan, Jane May, Natalia Dovlatova, Stan Heptinstall, Sue Fox (Thailand, United Kingdom)

PO027-TUE  PREDICTORS OF NEW ONSET ATRIAL FIBRILLATION AFTER MYOCARDIAL INFARCTION
Serenella Conti*, Maria Cristina Vedovati, Roberta Molle, Giorgio Maragoni (Italy)

PO028-TUE  EFFECTS OF MINERALOCORTICOID RECEPTOR ANTAGONISTS ON THE RISK OF MORTALITY, THROMBOSIS AND BLEEDING IN PATIENTS WITH SECONDARY HYPERALDOSTERONISM: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Laura Elbers*, Barbara Sjouke, Victor Gerdes, Alessandro Squizzato (The Netherlands)

PO029-TUE  URINARY 11-DEHYDO-THROMBOXANE B2 IS ASSOCIATED WITH CARDIOVASCULAR EVENTS AND MORTALITY IN ATRIAL FIBRILLATION PATIENTS.
Pasquale Pignatelli*, Daniele Pastori, William Hiatt, Gregory Lip, Francesco Vioi (Italy)

PO030-TUE  ASSOCIATION BETWEEN CIRCULATING PROTEINS AND CORRESPONDING GENES EXPRESSED IN CORONARY THROMBI IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Ragnhild Helseth*, Thomas Weiss, Trine Opstad, Svein Solheim, Matthias Freynhofer, Kurt Huber, Harald Arnesen, Ingebjorg Seljeffol (Norway)

PO031-TUE  VASCULAR SMOOTH MUSCLE CELLS ARE RESPONSIBLE FOR A PRO-THROMBOTIC PHENOTYPE OF SPONTANEOUSLY HYPERTENSIVE RAT ARTERIES
Amel Mohamadi*, Karima Ait Aissa, Jérémy Lagrange, Huguette Louis, Bénédicte Houppert, Pascal Chailande, Denis Wahl, Patrick Lacolley, Véronique Reginault (France)

PO032-TUE  PLATELET ERK5 REGULATES THROMBOSIS AND MYOCARDIAL INFARCT EXTENSION VIA MATRIX METALLOPROTEINASES
Scott J. Cameron*, Sara Tunc, Kristina Modjeski, Deanne Mickelsen, Enakshi Chakrabarti, David Field, Jun-ichi Abe, Craig Morrell (United States)

PO033-TUE  ELEVATED ARTERIAL STIFFNESS AND THROMBIN GENERATION IN PATIENTS WITH END-STAGE RENAL DISEASE UNDERGOING HEMODIALYSIS
Lucie Tran, Tomas Serrato, Yvonnick Bezie, Sylvain Marchais, Patrick Lacolley, Bruno Pannier, Véronique Reginault* (France)
Atherosclerosis II

PO034-TUE  THROMBOGENIC STATE AFTER VASCULAR SURGERY AND PERIOPERATIVE CARDIOVASCULAR EVENTS
Daniela Calderaro*, Tania Rubia Rocha, Adriana Pastana, Fernanda Justo, Danielle Gualandro, Pal Yu, Mariana Matheus, Elobio D’Amico, Bruno Caramelli (Brazil)

PO035-TUE  CLINICAL FEATURES OF VASCULAR EVENTS IN PATIENTS WITH ALamyloidosis
Hyunkyung Park*, Ji-Won Kim, Youngil Koh, Jeong-Ok Lee, Ki Hwan Kim, Soo-Mee Bang, Inho Kim, Junglim Lee, Sung-Soo Yoon, Jeong-Wook Seo, Dae-Won Sohn, Seon-yang Park (Korea, Republic Of)

PO036-TUE  SIMULTANEOUS OBSERVATION OF PERIPHERAL MONONUCLEAR CELL AND PLASMA TF’S EXPRESSION FOR PREVENTION AND TREATMENT OF ISCHEMIC CARDIOCEREBROVASCULAR DISEASES
Rui Wang*, Tong Ma (China)

PO037-TUE  TOTAL CHEMICAL SYNTHESIS OF COVALENT RANTES-PF4 HETERODIMERS TO STUDY INITIATION AND PROGRESSION OF ATHEROSCLEROSIS
Stijn Agten, Dennis Suylen*, Hans Ippel, Kevin Mayo, Rory Koenen, Christian Weber, Tilman Hackeng (The Netherlands)

PO038-TUE  ENDOTHELIAL DELETION OF THIREDOXIN-INTERACTING PROTEIN PRESERVES MOUSE ARTERIES FROM AGING INDUCED BY METABOLIC DISORDERS
Tatiana Bedarida, Elise Dreano*, Françoise Vibert, Charles-Henry Cottart, Christilla Bachelot-Loza, Pascale Gaussem, Stephanie Baron, Valerie Nivet-Antoine (France)

PO039-TUE  HIGH LIPOPROTEIN(A) LEVELS ARE ASSOCIATED WITH CORONARY CALCIUM SCORE IN THE MONTIGNOSO STUDY POPULATION
Alice Sereni, Anna Maria Gori*, Rossella Marcucci, Betti Giusti, Francesco Sofi, Dante Chiappino, Daniele Della Latta, Rosanna Abbate, Gian Franco Ginsini (Italy)

PO040-TUE  ASSOCIATION OF GAMMA-GLUTAMYL TRANSFERASE TO THE PREMATURE CORONARY ARTERY DISEASE IN YOUNG ASIAN INDIANS
Madankumar Ghatge*, Ankit Sharma, Rajani kanth Vangala (India)

PO041-TUE  CORONARY ARTERY DISEASE SEVERITY IS A MARKER OF THE ANTI-INFLAMMATORY RESPONSE TO STATIN THERAPY
Rahil Rafeedheen, Kevin Bilden, Anand Singla, Martin Gesheff, Shachi Pandya, Rohit Gosain, Udaya Tantry, Paul A. Gurbel* (United States)

PO042-TUE  EFFECTS OF 12 MONTHS EXERCISE INTERVENTION ON ADIPOSE TISSUE EXPRESSION OF CHEMOKINES IN PATIENTS WITH TYPE 2 DIABETES AND STABLE CORONARY ARTERY DISEASE: A SUBSTUDY OF A RANDOMIZED CONTROLLED TRIAL (RCT).
Ida Unhammer Njørve*, Rune Byrkjeland, Harald Arnesen, Sissel Åkra, Svein Solheim, Ingebjorg Seljeflot (Norway)

PO043-TUE  ATHEROSCLEROTIC CARDIOVASCULAR MORTALITY IN GOUTY ARTHRITIS AND RHEUMATOID ARTHRITIS: IS IT ASSOCIATED WITH MEAN PLATELET VOLUME AND NEUTROPHIL/LYMPHOCYTE RATIO
Gulsum Pamuk*, Muhmmad Maden, Mehmet Uyanik, Omer Pamuk (Turkey)

Blood coagulation tests II

PO044-TUE  EVALUATION OF THE LABORATORY METHOD IN PREGNANT WOMEN WITH COMPLICATED OBSTETRIC HISTORY FOR HAEMOSTASIS MONITORING
Nadezda Vorobyeva*, Yulia Pavlovskaia (Russian Federation)

PO045-TUE  EFFECTS OF LOW AND HIGH LEVELS OF NON VKA ORAL ANTICOAGULANTS ON A COMPREHENSIVE PANEL OF ROUTINE AND SPECIALTY COAGULATION TESTS
Séverine Perroche, Nathalie Barat, François Depasse*, François Nicham, Anne Magdeleine, David Courtois, Tristan Hervé, Jérôme Beltran (France)

PO046-TUE  FVIII SENSITIVE AUTOMATED THROMBIN GENERATION TEST OF CANINE PLASMA
Daniel Elenius Madsen*, Timothy Nichols, Emily Waters, Pernille Holm, Elizabeth Merricks, Alisa Wolberg, Bo Winberg (Denmark)

PO047-TUE  DIFFERENT CENTRIFUGATION CONDITIONS DO NOT INTERFERE WITH D-DIMER RESULTS
Carlos Aguilar*, Sylvaine Savigny (Spain)

PO048-TUE  THROMBIN GENERATION IN THE NORMAL POPULATION – FLATTENED THROMBIN GENERATION CURVES ASSOCIATED WITH POOR LIPID PROFILE AND MALE SEX.
Prahlad Ho*, Carole Smith, Joseph Rigano, Geoffrey Donnan (Australia)

PO049-TUE  THE RIVAROXABAN-CALIBRATED ANTI-FXA ASSAY CAN RELIABLY IDENTIFY PRESENCE OF RIVAROXABAN IN PLASMA
Jerzy Windygą*, Beata Baran, Mirosław Lis, Edyta Odnozko, Ewa Stefanska-Windygą (Poland)

PO050-TUE  A FULLY AUTOMATED AID FOR THE IMPROVEMENT OF HIL INTERFERENCE MANAGEMENT IN THE HEMOSTASIS LABORATORY: TEST ASSAY-SPECIFIC FLAGGING OF LABORATORY RESULTS FOR HEMOLYSIS, ICTERUS AND LIPEMIA/TURBIDITY
Janos Polgar*, Hui-Feng Lin, Jack Havelick, Mary Doyle, Mark Triscott (United States)

PO051-TUE  HANDLING OF THE HEMOCLOT THROMBIN INHIBITOR ASSAY REAGENTS ON SYSMEX CS-2100I WHEN MONITORING DABIGATRAN IN ACUTE CLINICAL SITUATIONS
Louise Faaborg*, Willemin Comuth, Anna-Marie Bloch-Münster, Linda Henrikson, Steen Husted (Denmark)

PO052-TUE  TIME IN THERAPEUTIC RANGE AND COMPLICATIONS OF ANTITHROMBOTIC TREATMENT
Milena Scekic* (Serbia)
SCIENTIFIC PROGRAM

PO053-TUE
USEFULNESS OF DILUTE RUSSELL’S VIPER VENOM CLOTTING TIME (DRVVT) FOR THE ROUTINE MONITORING OF NEW ORAL ANTICOAGULANTS
Debra Hoppensteadt*, Jake Kola, Mark Brayne, Omer Iqbal, Jawed Fareed (United States)

PO054-TUE
PERFORMANCE OF HEMOSIL DIRECT THROMBIN INHIBITOR (DTI) ASSAY ON THE ACL TOP FAMILY INSTRUMENTS
Judith Hammelburger*, Zhenghua Cao, Ralph Bottenus, Mark Triscott (United States)

PO055-TUE
IN VITRO CORRECTION OF IMPAIRED BLOOD COAGULATION IN A MODEL OF SEVERE THROMBOCYTOPENIA BY FIBRINOGEN AND ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE
Boris Shenkman* (Israel)

PO056-TUE
NEW IMMUNODEPLETED PLASMA FOR DETERMINATION OF FACTOR XI ACTIVITY
Vicente Cortina*, Carmen Altisent, Anna Castro, Rafael Parra, Verónica Pons, Laura López Andreoni, Pavel Olivera, Ana Marin, Francesc Bosch, Amparo Santamaria (Spain)

PO057-TUE
ASSESSMENT OF THROMBIN GENERATION TEST BY PASSING THERAPY MONITORING IN HAEMOPHILIA PATIENT WITH INHIBITOR
Olga Sminova*, Yuriy Namestnikov, Inna Markova, Olga Golovina, Ludmila Papayan (Russian Federation)

PO058-TUE
EVALUATION OF A NEW ASSAY FOR THE MEASUREMENT OF THE DIRECT FXA INHIBITOR RIVALOXABAN (DG-CHROM ANTI-XA) ON THE Q HEMOSTASIS ANALYZER (GRIFOLS)
Kieron Hickey*, Steve Kitchen (United Kingdom)

PO059-TUE
HOW THE DIRECT ORAL ANTICOAGULANT APIXABAN AFFECTS THROMBIN GENERATION PARAMETERS
Erica Scalabrino*, Lidia Padovan, Veena Chantarangkul, Sophie Testa, Flora Peyvandi, Armando Tripodi (Italy)

PO060-TUE
THE CORRELATION OF ATYPICAL APTT CURVES WITH TYPE OF COAGULATION DEFECT
Ludek Slavik*, Jana Ulehlova, Antonin Hlusi, Jana Prochazkova, Vera Krcova (Czech Republic)

PO061-TUE
EFFICACY OF NOVEL ORAL ANTICOAGULANTS (NOACS) USING DILUTED RUSSELL’S VIPER VENOM TEST (DRVVT)
Makoto Kaneko*, Nobuko Kanno, Yutaka Yatomi (Japan)

PO062-TUE
EX-VIVO AND IN-VITRO COMPARATIVE ASSESSMENT OF MOD-5014 (FACTOR VIIA-CTP), A NOVEL LONG-ACTING COAGULATION FACTOR TO RECOMBINANT FVIIA
Gili Hart, Tami Livnat*, Boris Shenkman, Ahuva Bar-Ilan, Lior Binder, Malka Hoffman, Gili Kenet (Israel)

PO063-TUE
IMPACT OF EDOXABAN ON HAEMOSTASIS DIAGNOSIS ASSAYS: PRACTICAL RECOMMENDATIONS
Jonathan Douxfils*, Tania Del Bianco, Justine Baudar, Sarah Lessire, Bernard Chatelain, Jean-Michel Dogné, François Mullier (Belgium)

POSTERS

PO064-TUE
INTRODUCTION OF A LIQUID ANTI-XA METHOD FOR QUANTIFICATION OF CURRENT THERAPEUTIC XI INHIBITORS
Helen Lewis*, Jane Needham, Nina Harrison, Savita Rangarajan (United Kingdom)

PO065-TUE
PRELIMINARY PERFORMANCE DATA OF A NEW CHROMOGENIC DIRECT ANTI-XA ASSAY EVALUATED FOR THE QUANTIFICATION OF RIVAROXABAN
Sabine Pilgrim*, Viktoria Esch, Karin Kolbe-Scheu, Barbara Krumpholz, Matthias Schleifer, Andrea Lichte (Germany)

PO066-TUE
PRELIMINARY EVALUATION OF A NEW CHROMOGENIC ASSAY FOR THE QUANTITATIVE DETERMINATION OF DABIGATRIN IN HUMAN PLASMA
Julia Mueller*, Sabine Hallilovic, Isabell Kieper-Rupp, Dieter Koch, Juergen Kurz, Andrea Lichte (Germany)

PO067-TUE
PREDICTION OF BLEEDING TENDENCY IN HEMOPHILIA A AND B USING THROMBODYNAMICS ASSAY
Natalia M. Dashkevich*, Mikhail Panteleev, Fazol Ataullakhanov, Claude Negrier (France, Russian Federation)

PO068-TUE
DO PT AND APTT SENSITIVITIES TO FACTOR DEFICIENCIES CALCULATED BY THE H47-A2 2008 CSLI GUIDELINE REFLECT THE DEFICIENCIES FOUND IN PLASMA FROM PATIENTS?
Martina Martinuzzo*, Luis Herrera, Marcos Rodriguez, Azagary Viviana, Maria D’Adamo, Marina Lopez, Juan Otaso (Argentina)

PO069-TUE
MARKERS OF HEMOSTASIS ACTIVATION AFTER EARLY DISCONTINUATION OF FONDAPARINUX IN LOW-RISK PATIENTS HOSPITALIZED WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME
Igor S. Yavlov*, Anatoly Knayzey, Anatoly Dobrovolsky, Nikolay Gratsiansky (Russian Federation)

PO070-TUE
NEW INSIGHTS FOR FACTOR ANALYSIS WITH APTT AND PT FOR FACTORS IX, VIII, XI AND FACTOR V.
Cornelis Kluit*, Cornelis van Leuven (The Netherlands)

PO071-TUE
RELIABILITY OF A NEW POINT-OF-CARE PORTABLE COAGULOMETER FOR PT-INR TEST PERFORMED IN THE HOSPITAL ANTICOAGULATION CLINIC.
Rita Paniccia*, Raffaella Priora, Rossella Marucci, Lucia Mannini, Daniela Poli, Eleonora Tafuro, Fanny Attinasi, Laura Gori, Agatina Alessandrello Liotta, Rosanna Abbate (Italy)

PO072-TUE
STRENUEOUS EXERCISE INDUCES A PROTHROMBOTIC STATE THAT IS MORE PRONOUNCED IN MEN THAN IN WOMEN
Dana Huskens*, Mark Roest, Jasper Remijn, Saartje Bloemen, Joke Konings, Evelien Schurgers, Romy Kemers, Hilde Kelchtermans, Rinaldo van Meel, Rolf Urbanus, Marisa Ninivaggi, Bas de Laat (The Netherlands)

PO073-TUE
WHOOLE BLOOD PLATELET ACTIVITY MEASUREMENTS MULTIPLEXED WITH QUANTITATIVE FIBRINOGEN, CLOT TIME AND FIBRINOLYSIS MEASUREMENTS BY T2MR
Roger Smith*, Vyacheslav Papkov, Pierreette Andre, Oleg Yerov, Chuck Ritterhaus, Thomas Lowery (United States)
PO074-TUE  VARIABILITY IN NORMAL RANGES OF THROMBIN GENERATION BETWEEN LABORATORIES IS WIDE AND DEPENDENT ON TEST METHODOLOGY
Haritirthpal Kaur*, Chuen Wen Tan, Wan Hui Wong, Yeh Ching Linn, Heng Joo Ng (Singapore)

PO075-TUE  RESISTANCE TO THROMBOMODULIN BUT NOT TO ACTIVATED PROTEIN C IN CIRRHOTIC PATIENTS
Thomas Sinege*, Cedric Duron, Alain Marques-Verdier, Géraldine Lablin, Anne-Françoise Sapin, Armand Abergel, Aurelien Lebreton (France)

PO076-TUE  HYPERCOAGULABILITY AND HIGH RESIDUAL PLATELET REACTIVITY IN ACS PATIENTS ON DUAL ANTIPLATELET THERAPY.
Rita Paniccia*, Giacomo Zoppellaro, Gentian Denas, Manuela Miolo, Giovanni Nante, Mario Plebani, Vittorio Foppa (Italy)

PO077-TUE  EMERGENCY ASSESSMENT OF PATIENTS IN DOACS: THE ROLE OF POINT-OF-CARE TESTING.
Pao Carrao*, Halleh Afshar, Seena Padayattil Jose, Giacomo Zoppellaro, Gentian Denas, Manuela Miolo, Giovanni Nante, Mario Plebani, Vittorio Foppa (Italy)

PO078-TUE  EVALUATING DABIGATRAN AND ITS SPECIFIC REVERSAL WITH IDARUCIZUMAB USING A FULLY AUTOMATED THROMBELASTOGRAPH TEG®6S
Fowzia Zaman*, Marc Doubleday, Oliver Grottke, Joanne Van Ryn (United States)

PO079-TUE  EFFECT OF THE RESIDUAL PLATELET COUNT ON DIFFERENT COAGULATION PARAMETERS IN FREEZE-THAW PLASMA SAMPLES AT -20°C
Yolanda Adacuzck*, Sebastián de Vega, Marcela Pagano, Mabel Viola, María Lamas, Gilda Lumelsky, María Brizuela, Ana Zerdiew (Argentina)

PO080-TUE  CORRELATION TO FVIII:C IN TWO THROMBIN GENERATION ASSAYS: TGA CAT AND INNOVANCE ETP
Marcus Ljungqvist*, Maria Berndtsson, Margareta Holmström, Jovan Antovic, Erik Berntorp, Danijela Micovic, Ivo Elezovic, Eva Zetterberg (Sweden)

PO081-TUE  INFLUENCE OF VARIOUS CONCENTRATIONS OF ANTICOAGULANTS ON THE THROMBODYNAMICS ASSAY: AN IN VITRO STUDY
Gaetan Flament, Laurence Rozen, Sara Derdabi, Anne Demulder* (Belgium)

PO082-TUE  OVERALL HEMOSTATIC POTENTIAL ASSAY IS SENSITIVE TO DIFFERENT PLASMA FREEZING TECHNIQUES
Moja Bozic-Mijovski*, Blanka Ulaga (Slovenia)

PO083-TUE  DEFINING THE REFERENCE RANGE FOR BLOOD CLOT GEL POINT AND FRACTAL DIMENSION
Lindsay D'silva, Raza Alikhan*, Sophia Stanford, Ahmed Sabraa, Matthew Lawrence, Rhodri Williams, Phillip Evans (United Kingdom)

PO084-TUE  EFFECT OF HYPOThERMIA AND HEMODILUTION ON CLOTTING ACTIVATION: ROTATIONAL THROMBOELASTOMETRY ANALYSIS IN AN ARTIFICIAL ENVIRONMENT FROM HEALTHY SUBJECTS.
Sabrina Boraso*, Giuseppe Gagliardi, Alessandro Agnoli, Cinzia Bettlin, Paolo Carraro, Halleh Afshar, Gaia Lembo, Domenico Prisco, Rita Paniccia (Italy)

PO085-TUE  TEST SPECIFIC ASSESSMENT OF EFFECTS OF HAEMOLYSIS ON CITRATED BLOOD SAMPLES USING SYNEDEX CS SERIES ANALYSERS
Anita Woolley*, Yuka Tabuchi, Steve Kitchen (United Kingdom)

PO086-TUE  PROVINCE WIDE IMPLEMENTATION OF THE THROMBIN TIME FOR QUALITATIVE ASSESSMENT OF DABIGATRAN CLEARANCE
Artur Szkotak*, Gwen Clarke, Lisa Vandergouwe, Linda Stang (Canada)

PO087-TUE  EFFECTS OF RIVAROXABAN ON PT AND APTT AS DETERMINED WITH A FULL RANGE OF REAGENTS: RESULTS OF A UK NEQAS BLOOD COAGULATION EXERCISE
Stephen Kitchen*, Jan Jennings, Rob Jones, Dianne Kitchen, Tim Woods, Isobel Walker (United Kingdom)

PO088-TUE  A NOVEL PLASMA-BASED FACTOR XA GENERATION ASSAY DEFINES INTERACTION BETWEEN FVIIIA AND EACH COMPONENT OF XASE COMPLEX IN MILD HEMOPHILIA A.
Nao Kamiya*, Koji Yada, Midori Shima, Keiji Nagomi (Japan)

PO089-TUE  THE FVIII PLASMA ACTIVITY OF RVIII-SINGLE CHAIN CAN BE MEASURED IN BOTH THE ONE-STAGE AND CHROMOGENIC SUBSTRATE ASSAYS
Katie St.Ledger*, Annette Feussner, Uwe Kalina, Carsten Horn, Hubert Metzner, Anthony Stowers, Debbie Benson Kennedy (United States)

PO090-TUE  USEFULNESS OF COAGULATION SCREENING TESTS FOR DIAGNOSIS OF COAGULOPATHY
Maria Rosaria Fasulo*, Eugenia Biguzzi, Simona Siboni, Antonino Cannavò, Claudia Mistrettta, Maria Elisa Mancuso, Elena Santagostino, Flora Peyvandi (Italy)

PO091-TUE  BLEEDING SYMPTOMS OR BLEEDING DISORDER? THAT IS THE QUESTION
Maria Rosaria Fasulo*, Eugenia Biguzzi, Simona Siboni, Antonino Cannavò, Claudia Mistrettta, Maria Elisa Mancuso, Elena Santagostino, Flora Peyvandi (Italy)

PO092-TUE  EVALUATION OF AN AUTOMATED COAGULOMETER IN A NEW HEMOPHILIA CARE CENTER
Mirta Arias, Emanuel Sueldo, Beatriz Erramouspe, Rodrigo Porsella, Gabriela Guerrero, Patricia Do Nascimento*, Alejandra Baques (Argentina)

PO093-TUE  FACTOR VIII INHIBITORS QUANTIFIED USING CLOT WAVEFORM ANALYSIS
Thomas Siegemund*, Rosemarie Schobess, Ute Scholz, Annelie Siegemund (Germany)

Cancer and thrombosis/hemostasis II

PO094-TUE  TISSUE FACTOR DOWNREGULATION BY THE PUTATIVE ONCOGENIC MICRORNA, MIR-520G, IN EMBRYONAL BRAIN TUMOUR CELLS
Esterina D’Asti*, Annie Huang, Marcel Kool, Andrey Korshunov, Stefan Pfister, Janusz Rak (Canada)

PO095-TUE  VTE RECURRENCE AND BLEEDING IN PATIENTS WITH CANCER. RESULTS OF THE OPTIMEV STUDY
Marie Sevestre*, Celine Gerity, Carole Rolland, Gilles Pernod, Jean-Luc Bosson (France)
<table>
<thead>
<tr>
<th>POSTERS</th>
<th>SCIENTIFIC PROGRAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO096-TUE</td>
<td>COLLABORATIVE EFFORTS OF THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE AND THE NATIONAL CANCER INSTITUTE IN CANCER AND THROMBOSIS</td>
</tr>
<tr>
<td>Michelle A. Berny-Lang*, Andrei Kindzelski, Traci Mondoro, Emily Greenspan (United States)</td>
<td></td>
</tr>
<tr>
<td>PO097-TUE</td>
<td>PATIENTS EXPERIENCES OF LIVING WITH CANCER ASSOCIATED THROMBOSIS: THE PELICAN STUDY</td>
</tr>
<tr>
<td>Simon Noble*, Hayley Proust, Annmarie Nelson (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>PO098-TUE</td>
<td>CANCER ASSOCIATED THROMBOSIS: DEVELOPING CONSENSUS GUIDANCE TO IMPROVE PATIENT CARE AND OUTCOMES</td>
</tr>
<tr>
<td>Simon Gwynn, Roopen Arya*, John McPhelim, Toby Talbot, John Pasi, Gail Fortes-Mayer, Nitil Ledia, Stefan Kokiet, Malgosia King (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>PO099-TUE</td>
<td>REDUCING CLOT RISK IN POST-OPERATIVE CANCER PATIENTS: WHAT IS THE COMMON GROUND AMONG INTERNATIONAL VTE PREVENTION GUIDELINES?</td>
</tr>
<tr>
<td>Carol Jackson* (United States)</td>
<td></td>
</tr>
<tr>
<td>PO100-TUE</td>
<td>AGE-ADJUSTED D-DIMER CUT-OFF LEVEL INCREASES THE NUMBER OF CANCER PATIENTS IN WHOM PULMONARY EMBOLISM CAN BE SAFELY EXCLUDED WITHOUT CTPA IMAGING: THE ADJUST-PE CANCER SUB-STUDY</td>
</tr>
<tr>
<td>Dorothea Wilts*, Grégoire Le Gal, Paul den Exter, Josien van Es, Marc Carrier, Benjamin Planquett, Harry Bülker, Marc Righini, Menno Huisman, Pieter Kamphuisen (The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>PO101-TUE</td>
<td>RATES OF VENOUS THROMBOEMBOLISM DESPITE THROMBOPROPHYLAXIS IN MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE OR POMALIDOMIDE: A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
</tr>
<tr>
<td>Miriam Kimpston*, Marc Carrier, Jason Tay, Alexandra Davis, Gregoire Le Gal (Canada)</td>
<td></td>
</tr>
<tr>
<td>PO102-TUE</td>
<td>PROSPECTIVE EVALUATION OF RISK ASSESSMENT MODELS AND BIOLOGICAL MARKERS OF HYPERCOAGULABILITY FOR THE IDENTIFICATION OF HIGH VTE RISK PATIENTS WITH LUNG ADENOCARCINOMA: THE ROADMAP STUDY</td>
</tr>
<tr>
<td>Iliaas Emounlidis, Boua Parasev, Aurélie Rousseau, Ariadni Charpidou, Patrick Van Dreden, Giannos Giouzos, Konstantinos Syrigos, Anastasia Spanoudaki, Matthieu Grusse, Ismail Elalamy, Grigoris Gerotziafas* (France)</td>
<td></td>
</tr>
<tr>
<td>PO103-TUE</td>
<td>UNSUSPECTED PULMONARY EMBOLISM IN CANCER PATIENTS: AN INTERNATIONAL, ONGOING, PROSPECTIVE, OBSERVATIONAL STUDY</td>
</tr>
<tr>
<td>Suzanne M. Bleker*, Nick van Es, Ankie Kindzelski, Hilde Jensvoll, Torbjørn Kristensen, Jan Beyer Westendorf, Joel Constans, Francis Coutaudra, Anna Falanga, Diana Iosub, Isabelle Mahé, Guy Meyer, Andrés Munoz Martín, Ettore Porreca, Silvia Planquette, Harry Bülker, Marc Righini, Menno Huisman, Pieter Kamphuisen (The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>PO104-TUE</td>
<td>RISK OF SUBSEQUENT CANCER AFTER A VENOUS THROMBOEMBOLISM - THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) STUDY</td>
</tr>
<tr>
<td>Hilde Jensvoll*, Marianne Severinsen, Jens Hammerstrøm, Sigrid Brækkan, Søren Kristensen, Suzanne Caneaegieter, Kristine Blix, Anne Tjønneland, Frits Rosendaal, Olga Dziwieckou, Kim Overvad, Inger Anne Næss, John-Bjarne Hansen (Norway)</td>
<td></td>
</tr>
<tr>
<td>PO105-TUE</td>
<td>MANAGEMENT OF CANCER ASSOCIATED THROMBOSIS IN FRANCE: A NATIONAL SURVEY IN VASCULAR DISEASE AND SUPPORTIVE CARE SPECIALISTS</td>
</tr>
<tr>
<td>Isabelle Mahé*, Jean-Baptiste Rey, Ismail Elalamy, Anne Lamblin, Didier Mayeur, Gilles Pernod (France)</td>
<td></td>
</tr>
<tr>
<td>PO106-TUE</td>
<td>VENOUS THROMBOEMBOLISM AFTER SURGICAL TREATMENT OF SKEL-ETAL METASTASES – AN UNDERDIAGNOSED COMPLICATION</td>
</tr>
<tr>
<td>Riitta Lasilwa*, Maire Ratasvuori, Minna Laitinen (Finland)</td>
<td></td>
</tr>
<tr>
<td>PO107-TUE</td>
<td>MAJOR AND NON-MAJOR CLINICALLY RELEVANT BLEEDING IN PATIENTS HOSPITALIZED IN PALLIATIVE CARE UNITS: RESULTS OF A FRENCH MULTICENTRE OBSERVATIONAL STUDY</td>
</tr>
<tr>
<td>Bernard Tardy*, Célène Chapelle, Stéphane Picard, Didier De Broucker, Marie Delerue, Thomas Celarier, Pascale Vassal, Jean-François Ciais, Sébastien Salas, Elise Perceau, Marilène Filbet, Frédéric Guiraud, Jean-Marie Gomas, Christine Decher, Laurent Bertoletti, Aline Guillot, Jean-Baptiste Gauthier, Madjid Akrou, Florence Rancon, Adel Merah, Silvy Laporte (France)</td>
<td></td>
</tr>
<tr>
<td>PO108-TUE</td>
<td>HEALTHCARE RELATED COST OF THROMBOTIC EVENTS IN ELDERLY PATIENTS: A RETROSPECTIVE DATABASE ANALYSIS</td>
</tr>
<tr>
<td>Abiola Oladapo*, Yan Xiong, Aaron Novack, Joshua Epstein (United States)</td>
<td></td>
</tr>
<tr>
<td>PO109-TUE</td>
<td>THE UTILITY OF PEMB-QOL AND VEINES-QOL/SYM QUESTIONNAIRES IN EVALUATING QUALITY OF LIFE IN THE CANCER ASSOCIATED THROMBOSIS PATIENT.</td>
</tr>
<tr>
<td>Hayley Proust, Annmarie Nelson, Simon Noble* (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>PO110-TUE</td>
<td>PATIENTS’ PREFERENCES FOR THE TREATMENT OF CANCER ASSOCIATED THROMBOSIS</td>
</tr>
<tr>
<td>Simon Noble, Anthony Maraveyas, Axel Matzdorff, Majbrit Vindt Holm, Giovanni Pisa (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>PO111-TUE</td>
<td>AGE SHOULD NOT BE CONSIDERED A RISK FACTOR FOR CANCER-RELATED VENOUS THROMBOEMBOLISM: RESULTS FROM THE SCANDINAVIAN THROMBOSIS AND CANCER STUDY</td>
</tr>
<tr>
<td>Kristine Blix*, Marianne Severinsen, Sigrid Brækkan, Hilde Jensvoll, Olga Dziwiecka, Søren Kristensen, Kim Overvad, Anne Tjønneland, Inger Anne Næss, Jens Hammerstrøm, Frits Rosendaal, Suzanne Caneaegieter, John-Bjarne Hansen (Norway)</td>
<td></td>
</tr>
<tr>
<td>PO112-TUE</td>
<td>CANCER-RELATED VENOUS THROMBOEMBOLISM IN THE GENERAL POPULATION: RESULTS FROM THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) STUDY</td>
</tr>
<tr>
<td>Kristine Blix*, Marianne Severinsen, Sigrid Brækkan, Hilde Jensvoll, Olga Dziwiecka, Søren Kristensen, Kim Overvad, Anne Tjønneland, Inger Anne Næss, Jens Hammerstrøm, Frits Rosendaal, Suzanne Caneaegieter, John-Bjarne Hansen (Norway)</td>
<td></td>
</tr>
<tr>
<td>PO113-TUE</td>
<td>INCIDENCE, RISK FACTORS, AND OUTCOME OF EARLY HEMOSTATIC COMPLICATIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY OF 551 PATIENTS</td>
</tr>
<tr>
<td>HAN Yue*, Wu Depei, HAN Wei, Wang Jie, WANG Zhaoyue, RUAN Changgeng (China)</td>
<td></td>
</tr>
</tbody>
</table>
PO114-TUE  DETECTION OF HYPERCOAGULABILITY IN HEPATOCELLULAR CARCINOMA (HCC).
Luca Spiezia*, Kryssia Rodriguez-Castro, Elena Campello, Alberto Zanetto, Sabrina Gavasso, Barry Woodhams, Marco Senzolo, Patrizia Burra, Paolo Simioni (Italy)

PO115-TUE  ROLE OF ARTERIAL CARDIOVASCULAR RISK FACTORS IN THE PATHOGENESIS OF CANCER RELATED VTE.
Francesco Dentali*, Graziella Pinotti, Mara Mantiero, Alessia Pastore, Walter Ageno (Italy)

PO116-TUE  FACTORS INFLUENCING THE USE OF THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS IN THE REAL WORLD CLINICAL PRACTICE
Elena Panizo, Ana Alfonso, Alberto García-Mouriz, José López-Picazo, Ignacio Gil-Bazo, José Hermida, José Páramo, Ramón Lecumberri* (Spain)

PO117-TUE  RESIDUAL VEIN THROMBOSIS TO ASSESS THE DURATION OF LOW MOLECULAR WEIGHT HEPARIN (THE EXTENDED CANCER-DACUS)
Mariasanta Napolitano*, Giorgia Sacco, Simona Raso, Salvatrice Mancuso, Alessandra Casuccio, Sergio Siragusa (Italy)

PO118-TUE  BETWEEN A ROCK AND A HARD PLACE: CONUNDRUMS IN THE MANAGEMENT OF CEREBRAL SINOVENOUS THROMBOSIS (CSVT) IN CHILDREN WITH ACUTE LYMPHOBlastic LEUKEMIA
Uma Athale*, Jeremy Robertson, Martha Rolland, Mahendranath Moharir, Suzan Williams, Anthony Chan, Leonardo Brando (Canada)

PO119-TUE  A PROSPECTIVE STUDY ON THE INCIDENCE OF POSTOPERATIVE VENOUS THROMBOEMBOLISM IN KOREAN COLORECTAL CANCER PATIENTS
Eunyoung Lee*, Sung-Bum Kang, Sang Il Choi, Eun-Ju Chun, Soo-Mee Bang, Duck-Woo Kim, Heung-Kwon Oh, Jeong-Kyeong Lee, Jong Won Kim, Kyung-Hyun Kim, Jong Seek Lee, Jeung-Woo Lee (Korea, Republic Of)

PO120-TUE  THROMBOEMBOLIC EVENTS IN CHILDREN WITH CANCER IN SINGAPORE HOSPITAL
Patcharee Komvilaisak*, Arunee Jetsrisuparb, Surapon Wiangnon, Paiporn Sripraya (Thailand)

PO121-TUE  THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH LYMPHOMA
Darko Antic*, Srdjan Nikolovski, Natasa Milic, Vladislava Djurasinovic, Vojin Vukovic, Biljana Mihaljevic (Serbia)

PO122-TUE  SELECTION OF ANTICOAGULATION THERAPY IN CANCER PATIENTS
Alexander Vorobev*, Alexander Makatsaria (Russian Federation)

PO123-TUE  DIC AND THROMBOPHILIA DURING CHEMOTHERAPY AND ITS PREVENTION APPROACHES IN OVARIAN CANCER PATIENTS
Alexander Vorobev* (Russian Federation)

PO124-TUE  MORTALITY FOLLOWING VENOUS THROMBOEMBOLISM: A POPULATION-BASED COHORT STUDY IN PATIENTS WITH ACTIVE CANCER
Carlos Martinez*, Anja Katholing, Stephan Rietbrock, Alexander Cohen (Germany)

PO125-TUE  EVALUATION OF MEAN PLATELET VOLUME AS A PREDICTIVE MARKER FOR VENOUS THROMBOEMBOLISM AND MORTALITY IN PATIENTS TREATED FOR DIFFUSE LARGE B-CELL LYMPHOMA
Joanna Rupa-Matyssek*, Lidia Gil, Mieczysław Komarnicki (Poland)

PO126-TUE  A NEW GENERIC RISK SCORE FOR PREDICTING VENOUS THROMBOEMBOLIC EVENTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY
Andres Muñoz*, Andrey Ziyatdinov, Juan Carlos Souto, Jose Manuel Soria (Spain)

PO127-TUE  THROMBOPROPHYLAXIS OF AMBULANT PANCREATIC CANCER PATIENTS: SINGLE CENTRE EXPERIENCE UTILIZING THE LESSONS FROM FRAGEM AND CONKO-04.
Iqtedar Ahmed Muazzam*, Anthony Maraveyas (United Kingdom)

PO128-TUE  TREATMENT OF CANCER ASSOCIATED THROMBOSIS AFTER THE INITIAL 6 MONTH PERIOD.
Petr Kessler*, Hynek Poul, Michaela Harudova (Czech Republic)

PO129-TUE  DEFINING THE DIFFERENTIAL EFFECTS OF NOVEL ANTICOAGULANTS: FXA VERSUS FIIA INHIBITION ON COAGULATION AND INFLAMMATION
Khurrum Shahzad*, Fabian Bock, Dong Wei, Wang Hongjie, Ina Thielmann, Bernhard Nieswandt, Madhusudhan Thati, Berend Isermann (Pakistan, Germany)

PO130-TUE  RIVAROXABAN ASSOCIATES WITH FACTOR XA FASTER THAN APIXABAN: A POTENTIAL EXPLANATION FOR THEIR DIFFERENT EFFECTS ON TESTS OF COAGULATION
Calvin Yeh*, Brian Dale, Beverly Leslie, Paul Kim, James Fredenburgh, Jack Hirsh, John Elkisboom, Jeffrey Weitz (Canada)

PO131-TUE  GENERATION OF A RECOMBINANT TRUNCATED ACTIVATED FACTOR X AS ANTI-HEMOPHILIC AGENT
Toufik Abache, Anne-Sophie Dezetter, Alain Longue, Dominique Grenier, Celine Bourdon, Marie-Claire Dagher, Raphael Marlu, Alexandre Fontayne, Benoît Polack, Jean-Luc Plantier* (France)

PO132-TUE  PHENOTYPIC AND GENOTYPIC CHARACTERIZATION OF SEVERE FACTOR VII DEFICIENCY PATIENTS IN CENTRAL CHINA
Hui Liu*, Huafang Wang, Liang Tang, Zhipeng Cheng, Qingyun Wang, Bei Hu, Yu Hu, Wei Zeng, Yingying Wu (China)

PO133-TUE  FRAGMENT-2 INHIBITION OF PROTHROMBINASE REVEALS A UNIQUE ENZYME-SUBSTRATE INTERFACE FOR THE PLATELET-BOUND ENZYME
Francis Ayombil*, Laura Haynes, Paula Tracy (United States)

PO134-TUE  NOVEL F10: P. CYSS57ARG MUTATION IN A PAKISTANI SEVERE FX-DEFICIENT PROBAND
Munira Borhany*, Olivier Guilhot, Florence Rousseau, Christelle Delbes, Naveena Fatima, Tahir Shamsh, Muriel Giansily-Giansily-Blaizot (Pakistan)
SCIENTIFIC PROGRAM

PO135-TUE  THE IL-10 POLARIZED CYTOKINE PATTERN IN INNATE AND ADAPTIVE IMMUNITY CELLS CONTRIBUTE TO THE DEVELOPMENT OF FVIII INHIBITORS
Daniel Chaves*, Amanda Silveira, Márcio Santana, Olindo Martins-Filho (Brazil)

PO136-TUE  EVALUATION OF N8-GP LONG TERM SAFETY IN IMMUNE DEFICIENT RATS
Hanne Offenberg*, Anne Rentz, Zaneta Balantac, Christina Hoxer (Canada)

PO137-TUE  ASSOCIATION OF ARTERIAL AND VENOUS THROMBOSIS WITH CLOTTING FACTOR USED IN PATIENTS WITH HEMOPHILIA
Jiaan-Der Wang* (Taiwan)

PO138-TUE  ASSESSING THE INDICATION AND SUCCESS OF TREATMENT FOR HEMOPHILIA PATIENTS: RESULTS FROM A DELPHI PANEL
Alfonso Iorio*, Anne Rentz, Zaneta Balantac, Christina Hoxer (Canada)

PO139-TUE  ASSESSING THE BURDEN OF DISEASE IN HEMOPHILIA PATIENTS: A QUALITATIVE STUDY
Ulla Slothuus*, Michelle Field, Christina Hoxer (Denmark)

PO140-TUE  COMPARISON OF RECOMBINANT FACTOR VIII PRODUCTS WITH RESPECT TO HMWP CONTENT AND GENERAL HETEROGENEITY
Per Nielsen*, Anders Nielsen (Denmark)

PO141-TUE  DEVELOPMENT OF AN ELISA FOR THE DETECTION OF BINDING ANTIBODIES AGAINST HUMAN COAGULATION FACTOR VIII IN RAT PLASMA
Karim M. Lövgren*, Karin Weldingh, Kristina Larsson, Mads Kjelgaard-Hansen, Bo Wiinberg (Denmark)

PO142-TUE  THE TYPE OF REAGENTS DETERMINES THE ACCURACY OF CALIBRATION WITH A PRODUCT SPECIFIC STANDARD FOR THE MEASUREMENT OF THE B-DOMAIN DELETED RFVIII MOROCOCOG ALFA-AF ACTIVITY.
Marc Jacquemin*, Alexandra Vodolazkaia, Evelien Heylen, Jelle Toelen, Joke Schoeters, Kathelijne Peerlinck (Belgium)

PO143-TUE  HEALTH-RELATED QUALITY OF LIFE IN CHILDREN WITH HEMOPHILIA FROM TURKEY
Yasemin Isik Balci*, Onder Ozturk, Burge Kabukcu Basay, Omer Basay, Aziz Polat, Elif Kazanci, Omer Faruk Tuncbilek, Funda Akpinar (Turkey)

PO144-TUE  STRUCTURAL CHARACTERISATION OF RECOMBINANT FACTOR IX FUSION PROTEIN LINKED WITH HUMAN ALBUMIN
Andreas Meister*, Nicholas Grammel, Matthias Pelzing (Australia)

PO145-TUE  TISSUE FACTOR EXERTS FACTOR XA-CATALYZED FACTOR VIII ACTIVATION IN THE PRESENCE OF VON WILLEBRAND FACTOR IN A FACTOR VIIA-INDEPENDENT MECHANISM
Shoko Furukawa*, Keiji Nogami, Kenichi Ogiwara, Midori Shima (Japan)

PO146-TUE  PHYSICOCHEMICAL CHARACTERIZATION OF RECOMBINANT SINGLE-CHAIN FACTOR VIII (RFVIII-SINGLECHAIN)
Stefan Schmidbauer*, Lars Robbel, Petra Sebastian, Reinhold Witzel, Nicolas Grammel, Hubert Metzner, Stefan Schulte (Germany)

PO147-TUE  FVIII ACTIVITY OF LONG-ACTING TURCOCOCOG ALFA PEGOL (N8-GP) CAN BE ACCURATELY AND PRECISELY MEASURED BY DIFFERENT COMMERCIAL CHROMOGENIC ASSAYS
William Pickering*, Martin Hansen, Mirella Ezban, Marianne Kjälke (Denmark)

PO148-TUE  MOLECULAR GENOTYPING OF HEMOPHILIA A IN SAUDI ARABIAN POPULATION: REPORT OF NOVEL MUTATIONS.
Faisal A. Al-Allaf*, Mohiuddin Taher, Zainulabdeen Abduljaleel, Mohammed Athar, Faisal Ba-hammam, Munir Abdulla, Abdellatif Bouazzouzi, Halah Abalkhail, Tarek Owaidah (Saudi Arabia)

PO149-TUE  DIFFERENT STRATEGIES FOR TREATMENT ON HEMOPHILIA PATIENTS WITH INHIBITOR, COSTS VERSUS BENEFITS
Mohammad Reza Baghaipour* (Iran, Islamic Republic Of)

PO150-TUE  A PLASMA- AND CELL-BASED THROMBIN GENERATION ASSAY TO ASSESS THE ANTICOAGULANT EFFECT OF TISSUE FACTOR PATHWAY INHIBITOR ON ENDOTHELIAL CELLS
Gabriele Gerstenbauer, Sabrine Knappo, Erwin Panholzer, Katerina Prohaska, Fabian Knofl, Nadja Ullrich, Robert Pachlinger, Friedrich Scheifflinger, Michael Dockal* (Austria)

PO151-TUE  LETHALITY OF MOUSE TISSUE FACTOR PATHWAY INHIBITOR GENE DISRUPTION IS RESCUED BY TRANSGENIC HUMAN TISSUE FACTOR PATHWAY INHIBITOR KNOCK IN
Robert Pachlinger, Rudolf Hartmann, Andrea Kolm, Erwin Panholzer, Nadja Ullrich, Fabian Knofl, Maria Schuster, Werner Hoellriegl, Friedrich Scheifflinger, Michael Dockal* (Austria)

PO152-TUE  LONGITUDINAL MONITORING OF TFPI LEVELS AND THEIR CORRELATION WITH COAGULATION PARAMETERS IN HEALTHY SUBJECTS: A ONE-YEAR OBSERVATION
Rudolf Hartmann, Jadranka Koehn, Erwin Panholzer, Bianca Marchula, Elisabeth Schoenegger, Birgit Reiper, Friedrich Scheifflinger, Michael Dockal* (Austria)

PO153-TUE  COMPARATIVE STUDY OF FULL-LENGTH AND B-DOMAIN MODIFIED RFVIII PRODUCTS SHOWS NO RELATION BETWEEN B-DOMAIN MODIFICATION AND THE CONTENT OF SUBVISIBLE PARTICLES
Dorrit Baunsgaard*, Anette Henriksen, Heidi Bagger, Mirella Ezban (Denmark)

PO154-TUE  THROMBIN GENERATION IN HUMAN HEMOPHILIA PLASMA AT REDUCED ANTIITHROMBIN LEVELS AND CONCOMITANT FACTOR OR BYPASS AGENT ADDITION
Akin Akin*, Alifca Sehgal, Kun Qian, Harsha Prabhala, Ole Larsen, Benny Sorensen (United States)

PO155-TUE  RATE-LIMITING ROLES OF TENASE COMPLEX OF FACTORS VII AND IX IN PLATELET PROCOAGULANT ACTIVITY AND FORMATION OF PLATELET-FIBRIN THROMBI UNDER FLOW
Frauke Swieringa, Marijke Kuipers, Moniek Lamers, Paola van der Meijden, Johan W. Heemskerk* (The Netherlands)
PO156-TUE  TREATMENT OF SEVERE BLEEDING AND PROPHYLAXIS WITH RFVIIA IN A CHILD WITH FVIII INHIBITOR
Adalet Meral Gunes*, Melike Sezgin Evim, Birol Baytan (Turkey)

PO157-TUE  MISFOLDED PROTEINS IN PLASMA-DERIVED FVIII CONCENTRATES ACTIVATE PLATELETS AND INHIBIT HEME OXYGENASE-1 UPREGULATION IN MACROPHAGES BY SECRETED PLATELET FACTOR 4 (CXCL4)
Anne Bertling*, Martin Brodde, Mayken Visser, Lisa Smits, Janina Treffon, Michelle Fennen, Beate Kehrel (Germany)

PO158-TUE  CIRCUMCISION IN TURKISH PATIENTS WITH BLEEDING DISORDERS: A SOCIOCULTURAL PERSPECTIVE
Yasemin Isik Balci*, Önder Öztürk, Burke Kabukcu Basay, Omer Basay, Mehmet Akin, Funda Olguzerl Akpinar, Nazli Kapubagli, Aziz Polat (Turkey)

PO159-TUE  INTRA-LABORATORY VARIATION IN FVIII:C INHIBITOR ASSAY: RESULTS OF A STUDY IN THREE FRENCH CENTERS
Christophe Nougier*, Camille Seignovert, Carine Crampe, Raphaël Marlu (France)

PO160-TUE  STABILITY OF FVIII PRODUCTS - FORMATION OF SUBVISIBLE PARTICLES UPON PHYSICAL STRESS
Mantas Malsiauskas*, Christian Lubich, Thomas Preunninger, Friedrich Schellinger, Birgit Reipert (Austria)

PO161-TUE  COMPARISON OF FVIII ACTIVITY OF SELECT NOVEL RECOMBINANT FVIII REPLACEMENT PRODUCTS IN COMMONLY USED FDA APPROVED ONE-STAGE CLOT ASSAY SYSTEMS
Stefan Tiefenbacher*, Mary Robinson, Erika Ross, Patrick Williams, Caroline Cogswell, Tyrelle Wham, Geoff Chow, Dorothy Adcock (United States)

PO162-TUE  FACTOR XI DEFICIENCY: INHIBITION OR ABNORMAL CONTACT?
Ana Azevedo*, Isabel Freire, Teresa Gago (Portugal)

PO163-TUE  IN VITRO FACTOR VIII ACTIVITY AFTER RECONSTITUTION WITH DILUENT FLUID FOR CONTINUOUS INFUSION
Kun Soo Lee*, Ji Yoon Kim, Jin Kyung Seo, Uk Hyun Kim, Ji Hye Lee, Ye-Jee Shim, Hwi-Joong Yoon, Shin Young Hyun, Sae Yun Baik (Korea, Republic Of)

PO164-TUE  APPLICATION OF CLOT WAVEFORM ANALYSIS ON HEMOSTATIC MONITORING FOR FACTOR (F)VIII MIMICKING ANTI-FIXA/FX BISPECIFIC ANTIBODY (ACE910)
Tomoko Matsumoto*, Keiji Nogami, Koji Yada, Takehisa Kitazawa, Kunihiro Hattori, Midori Shima (Japan)

PO165-TUE  LOCALIZATION OF FACTOR XI IN PLATELETS IS NOT RESTRICTED TO ALPHA GRANULES.
Michal Zucker*, Uri Seligsohn, Hagit Hauschner, Nirit Rosenberg (Israel)

PO166-TUE  THE 2,5-DICHLOROPHENYL FRAGMENT AS STARTING POINT IN THE DESIGN OF NEW FXIIA INHIBITORS
Charlotte Bouckaert*, Silvia Serra, Jean-Michel Dogné, Raphaël Frédérick, Lionel Pochet (Belgium)

PO167-TUE  MOST OF LUPUS ANTICOAGULANT IN RECURRENT PREGNANCY LOSS PATIENTS RECOGNIZE HIGH MOLECULAR WEIGHT KININOGEN AND/OR FACTOR XII.
Yoshihiro Sato*, Toshitaka Sugii, Rie Sakai (Japan)

PO168-TUE  FACTOR XIA, FACTOR IXA AND TISSUE FACTOR ACTIVITY IN BLUNT TRAUMA PATIENTS
Saulius Butenas*, Chelsea Manning, Kalev Freeman (United States)

PO169-TUE  COAGULATION MONITORING OF VENTRICULAR ASSIST DEVICE RECIPIENTS REVEALS NEW INSIGHTS IN DISTURBED HAEMOSTASIS
Thomas Siegemund*, Stefan Feder, Andreas Oberbach, Annelie Siegemund, Friedrich Mohr (Germany)

PO170-TUE  HISTIDINE-RICH GLYCOPROTEIN BINDS DNA AND RNA AND ATTENUATES THEIR CAPACITY TO ACTIVATE THE INTRINSIC PATHWAY OF COAGULATION
Trang T. Vu*, Beverly Leslie, Alan Stafford, Ji Zhou, James Fenodrun, Jeffrey Weitz (Canada)

PO171-TUE  EVALUATION OF THE EFFECTS OF A NOVEL CONTACT PATHWAY INHIBITOR, IR-CPI, ON IN VITRO PLATELET FUNCTION AND COAGULATION
Lisa Jennings*, Jayaprakash Kotha*, Juan Cardenas, Michael Herr, Vinay Bhal, Mason Dixon, Melanie White, Sophie Combe, Edmond Godfrid (United States)

PO172-TUE  CONTACT PATHWAY
Christina Lorentz*, Suzanne Schwarzmaier, Ciaran de Chaumont, Matilde Balbi, Nicole Terpolilli, Erik Tucker, Owen McCarty, Christoph Kleinschnitz, Andras Gruber, Nikolaus Plesniala (United States)
SCIENTIFIC PROGRAM

PO178-TUE  ACTIVATION OF FACTOR XII BY PLASMIN LEADS TO BRADYKININ FORMATION IN HEREDITARY ANGIOEDEMA
Steven De Maat*, Jenny Björkqvist, Chiera Suffritti, Philip de Groot, Marco Cicardi, Thomas Renné, Coen Maas (The Netherlands)

PO179-TUE  UNEXPECTED HEPATOMYOCYTE GROWTH FACTOR ACTIVATOR (HGFA) ACTIVITY ALLOWS A POSSIBLE CROSSTALK BETWEEN ACTIVATED FACTOR XII AND THE HGFA/MET PATHWAY IN HUMAN PLASMA
Benedetto Prezoto*, Guacyara Motta, Mariana Viana, Catarina Teixeira, Priscila Araujo, Douglas Mariano, Daniel Pimenta (Brazil)

PO180-TUE  FXI AND FXII ACTIVITY LEVELS IN YOUNG PATIENTS WITH CRYPTOGENIC ISCHEMIC STROKE
Cristina Duboscq*, Jose Ceresetto, German Stemmelin, Claudia Shanley, Oscar Rabinovich, Silvina Palmer, Eduardo Bullorsky (Argentina)

PO181-TUE  ANTITHROMBOTIC EFFECTS OF IR-CPI IN AN ARTERIO-VENOUS SHUNT MODEL IN THE RABBIT
Michel Guyaux*, Pierre Guevet, Francois Becher, Jean Amiral, Stephanie Simon, Edmond Godfroid (Belgium)

PO182-TUE  SURFACE PLASMON RESONANCE: SENSIQ PIONEER AS A MEANS TO SCREEN DRUG DISCOVERY FRAGMENTS FOR HITS
Clare Wishart*, Lewis Hardy, Amy Cilia La Corte, Emma Hethershaw, Charlotte Revill, Colin Fishwick, Richard Foster, Robert Ariens, Helen Philippou (United Kingdom)

PO183-TUE  MODELLING OF SURFACE-DEPENDENT ACTIVATION OF CONTACT ACTIVATION FACTOR XII IN A BUFFER SOLUTION
Vladislava Terenteva*, Mikhail Panteleev (Russian Federation)

PO184-TUE  EFFECT OF A PLANT INHIBITOR OF THE CONTACT SYSTEM ON A MOUSE THROMBOSIS MODEL
Maria Luiza Oliva*, Marlon Brito, Bruno Sahu, José Walber Cruz, Alexander Wlodawer, Francisco Maffei (Brazil)

Endothelium and vessel wall II

PO185-TUE  ENDOTHELIAL CELL INCREASES ITS RIGIDITY DURING INFLAMMATION THROUGH MODIFICATION OF THE GAP JUNCTION
Takayuki Okamoto*, Eiji Kawamoto, Nobuyuki Akita, Tatsuya Hayashi, Koji Suzuki, Motomu Shimoka (Japan)

PO186-TUE  ANALYSIS OF THE EXPRESSION AND LOCALIZATION OF RNASE AND RNASE INHIBITOR IN BLOOD CELLS AND VASCULAR ENDOTHELIAL CELLS INVOLVED IN HOMEOSTASIS IN THE VASCULAR SYSTEM
Ayaka Ohashi*, Yuichiro Cho, Shizuko Ichinose, Osamu Hoshi, Takatoshi Koyama (Japan)

PO187-TUE  CHANGES IN THE ENDOTHELIAL EXPRESSION OF GENES RELATED TO INFLAMMATION ANDATHEROTHROMBOSIS IN RESPONSE TO UREMIA
Susana Martín-Rodriguez, Manel Vera, Enrique Mir, Marcelina Párrizas, Aleix Cases, Josep Cruzado, Ginés Escolar, Maribel Díaz-Ricart* (Spain)

SCIENTIFIC PROGRAM

PO188-TUE  UPREGULATION OF MATRIX METALLOPROTEINASE-2 EXPRESSION BY ACTIVATED PROTEIN C IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS REQUIRES ENDOTHELIAL PROTEIN C RECEPTOR AND ACTIVATION OF PROTEASE-ACTIVATED RECEPTORS-1 AND -3
Helena Liang*, MeiLiang Xue, Chris Jackson (Australia)

PO189-TUE  BIOMARKERS OF ENDOTHELIAL DAMAGE AND INFLAMMATORY PROCESS IN PATIENTS WITH ALZHEIMER DISEASE OR WITH MILD COGNITIVE IMPAIRMENT.
Melina B. Pinheiro, Marcos Vinicius Silva, Gisele Gonçalves, Mayara Faria, Edgar Moraes, Maria Aparecida Bicalho, Luci Maria Dusse, Maria das Graças Carvalho* (Brazil)

PO190-TUE  ACTIVATION OF THE ENDOTHELUM MAY BE INVOLVED IN THE HEMOSTATIC ALTERATIONS INDUCED BY MICRURUS TENER VENOM IN C57BL/6 MICE
Emelyn Salazar*, Ana Salazar, Karin Perez, Izauskun Uranbide, Alexis Rodriguez-Acosta, Peter Taylor, Betsy Guererro (Venezuela, Bolivarian Republic Of)

PO191-TUE  INCREASED ENDOCAN LEVELS AND ITS ASSOCIATION WITH SEVERITY IN STEVENS JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROSIS.
Daneyal Syed*, Omer Iqbal, Charles Bouchard, Michael Mosier, Debra Hoppensteadt, Jawed Fareed (United States)

Fibrinogen/fibrin/D-dimer I

PO192-TUE  ENDOTHELIAL PATHOGENESIS RESULTS IN THE GENERATION OF A PROTEOGLYCAN ENDOCAN IN VARIOUS DISEASES
Debra Hoppensteadt*, Amanda Walborn, Omer Iqbal, Daneyal Syed, Vinod Bansal, Michael Mosier, Charles Bouchard, Nil Guier, Jawed Fareed (United States)

PO193-TUE  UPREGULATION OF CHEMOKINE EXPRESSION BY STREPTOCOCCUS MUTANS BEARING COLLAGEN-BINDING PROTEIN IN CULTURED BRAIN ENDOTHELIAL CELLS
Yuji Matsumoto*, Kazuya Hokamura, Kazuo Umemura (Japan)

PO194-TUE  TWO NOVEL DIFFERENT SUBSTITUTIONS OF FIBRINOGEN AALPHA 98
Roman Kotlín*, Zuzana Reicheltova-Riedelova, Erika Ceznerová, Janá Štikarová, Ondrej Pastva, Jirí Suttnar, Peter Salaj, Jan Dyr (Czech Republic)

PO195-TUE  CLINICAL FEATURES AND MOLECULAR BASIS OF 102 CHINESE PATIENTS WITH CONGENITAL DYSFIBRINOGENEMIA
Jingyi Zhou*, Qiulan Ding, Yaoyang Chen, Ouyang, Linlin Jiang, Jing Dai, Yeling Lu, Xi Wu, Qian Liang, Hongli Wang, Xuefeng Wang (China)

PO196-TUE  COEXISTENCE OF CONGENITAL FIBRINOGEN DEFICIENCY AND HEREDITARY PROTEIN C DEFICIENCY IN AN INFANT PRESENTING WITH PURPURA FULMINANS
Özcan Bör*, Zeynep Özdemin, Ayse Turhan (Turkey)

PO197-TUE  INTERNATIONAL STUDY TO ASSESS THE PERFORMANCES OF A NEW LIQUID ASSAY FOR DETERMINATION OF FIBRINOGEN
Neil Harris*, Jacqueline Valadier, Sophie Testa (United States)
PO198-TUE  PHARMACOKINETIC (PK) COMPARISON OF TWO FIBRINOGEN CONCENTRATES FOR THE TREATMENT OF CONGENITAL FIBRINOGEN DEFICIENCY
Bruce Schwartz*, Savita Rangarajan, Mehran Karimi, Sigurd knaub, Flora Peyvandi
(United States)

PO199-TUE  FIBRINOGEN AND FACTOR XIII ARE MODIFIED BY N-HOMOCYSTEINYLATION REACTIONS
Valeria Genoud, Ana Maria Lauricella, Lucia Kordich, Irene Quintana* (Argentina)

PO200-TUE  A CASE OF THROMBOSIS IN CONGENITAL AFIBRINOGENEMIA PATIENT: A PHYSIOPATHOLOGIC AND MANAGEMENT DILEMMA
Cristina Santoro*, Fulvio Massaro, Vera Capria, Salvatore Venosi, Erminia Baldacci, Roberta Abbruzzese, Francesco Barone, Raffaele Bochicchio, Federico De Angelis, Paola Volpicelli, Maria Gabriella Mazzucchelli (Italy)

PO201-TUE  CTEPH-ASSOCIATED DYSFIBRINOGENEMIA WITH ENHANCED ACCESSIBILITY ON FIBRIN OF LIGANDS FOR VE-CADHERIN
Benjamin Planquette*, Peter Chiles, James Marsh, Olivier Sanchez, Guy Meyer, Timothy Morris (France, United States)

PO202-TUE  NON-ENZYMATIC FIBRINOGEN SELF-ASSEMBLY UNVEILED
Dennis Galanakis*, Liu Zhang, Miriam Rafailovich, Brendan Case (United States)

PO203-TUE  ASSESSMENT OF A TEST FOR FUNCTIONAL FIBRINOGEN IN WHOLE BLOOD USING ULTRASOUND TECHNOLOGY COMPARED TO CLAUS FIBRINOGEN IN PLASMA
Kiev Blasier*, Elisa Ferrante, Jennifer Terrasi, Timothy Fischer, Francesco Viola (United States)

PO204-TUE  HAEMOPHILIA PRESENTATIONS...LET ME COUNT THE WAYS.
Vaughan Williams*, Samantha Reardon (Australia)

PO205-TUE  INTRACRANIAL HEMORRHAGE IN EARLY NEONATES WITH HEMOPHILIA IN JAPAN
Masashi Taki*, Midori Shima (Japan)

PO206-TUE  A PHASE III, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE PHARMACOKINETICS OF A PLASMA-DERIVED WILLEBRAND FACTOR/FACTOR VIII (VWF/FVIII) CONCENTRATE IN PEDIATRIC SUBJECTS WITH HEMOPHILIA A (SWIFTLY-HA STUDY).
Maria Teresa Pompa, Genadi Iosava, Claudia Khayat, Irina Romashevskaya, Olga Aleinikova, Oleksandra Stasyshyn, Liudmyla Vashchenko, Marta Julia Lopez, Wilfried Seifert* (Germany)

PO207-TUE  NATIONAL INHIBITOR SURVEY IN HAEMOPHILIA PATIENTS (NISH) FROM INDIA
Shrimati Shetty*, Patricia Pinto, Tejasree Shelor, Vidhya Nawadkar, Darshana Mirgal, Alifya Mukaddam, Kanjaksia Ghosh (India)

PO208-TUE  IMMUNOGENICITY ASSESSMENT OF THE FIRST EXTENDED HALF-LIFE FACTOR VIII PRODUCT, RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIICF), IN HUMANS
Darshana Jani, Jason Pennucci, Jaya Goyal, Jenny Dumont, Geoffrey Allen, Glenn Pierce, Jurg M. Sommer* (United States)

PO209-TUE  A STUDY OF DEPRESSION IN FAMILY MEMBERS OF HEMOPHILIC PATIENTS
Mi Kyung Kim*, Jiwon Park, Tae Hyeong Kim, Sunah Lee (Korea, Republic Of)

PO210-TUE  HAEMTRACK: UK PATIENT HOME THERAPY REPORTING SYSTEM
Rob Hollingsworth*, Hua Xiang, Gerry Dolan, Charles Hay* (United Kingdom)

PO211-TUE  JOINT LAVAGE FOLLOWED BY VISCOSUPPLEMENTATION AND TRIAMCINOLONE IN PATIENTS WITH SEVERE HEMOPHILIC ARTHROPATHY. OBJECTIVE FUNCTIONAL RESULTS.
Thiago Pasqualini*, Marcia Rezende, Felix Andrusalis, Gustavo Campos, Renato Frucchi, Alexandre Palito, Erica Okazaki, Paula Villaça (Brazil)

PO212-TUE  ENDOVASCULAR ABDOMINAL AORTIC ANEURYSM REPAIR IN A PATIENT WITH MILD HEMOPHILIA A ON DABIGATRAN FOR ATRIAL FIBRILLATION
Beatriz Delgado*, Manuela Carvalho, Luciana Goncalves, Susana Fernandes, Carla Monteiro, Joel Sousa, Dalila Rolim, Sergio Sampaio, Fernando Araújo (Portugal)

PO213-TUE  ANALYSIS OF MODERATE PHENOTYPE OF HEMOPHILIA A WITH NOVEL MISSENSE MUTATION, W2229R IN C2 DOMAIN, OF WHICH FVIII HAS NO RESPONSIVENESS WITH DDAVP.
Takashi Suzuki*, Keiko Shinozawa, Hiroshi Inaba, Ikuo Saita, Takashi Muramatsu, Kagehiro Amano, Katsuyuki Fukutake (Japan)

PO214-TUE  RUSSIAN NATIONAL REGISTRY OF INHIBITOR HEMOPHILIA PATIENTS: FIRST CUT-OFF ANALYSIS
Nadeszda Zozulya*, Tatiana Andreeva, Vladimir Vdovin, Farida Perina, Elena Parovichnicova (Russian Federation)

PO215-TUE  SEPTIC ARTHRITIS IN HEMOPHILIC TARGET JOINTS – A NOT UNCOMMON COMPLICATION – AWARENESS IS THE MAIN DIAGNOSTIC FEATURE
Peter Staritz*, Rainer Zimmermann, Angela Huth-Kuehne (Germany)

PO216-TUE  MANAGING MODERN MAJOR ORTHOPAEDIC SURGERY WITH PLASMA DERIVED FY VIII CONCENTRATE (FANHDI®) IN SEVERE HAEMOPHILIA A PATIENTS WITH ADVANCED ARTHROPATHY
Pu-Lin Luo*, Steve Austin, Ruth Pink, Savita Rangarajan (United Kingdom)

PO217-TUE  THROMBOELASTOGRAM FOR INTRA-OPERATIVE MONITORING OF HEMOPHILIA PATIENTS DURING CORONARY ARTERY BYPASS GRAFT SURGERY
Mudi Misgav*, Gili Kenet, Tal Mandelbaum, Yigal Kassif, Ilia Tamarin (Israel)

PO218-TUE  FACTORS INFLUENCING RISK OF BLEEDING AFTER DENTAL EXTRACTION IN HEMOPHILIA PATIENTS
Predrag Miljic*, Jelena Bodrožić, Ivo Elezović, Milan Jurišić, Božidar Brkovic, Darko Antic, Danijela Leković, Mirjana Milutović (Serbia)
PO240-TUE  DDAVP-INDUCED RISE IN PRE-INFUSION VON WILLEBRAND FACTOR LEVELS MAY SLIGHTLY AFFECT THE PHARMACOKINETICS OF PLASMA-DERIVED FACTOR VIII CONCENTRATE IN SEVERE HEMOPHILIA A PATIENTS
Eva Stokhuijzen*, Janneke Loomans, Marjolein Peters, Karin Fijnvandraat (The Netherlands)

PO241-TUE  POPULATION PHARMACOKINETIC MODEL OF RECOMBINANT SINGLE-CHAIN FACTOR VIII (RVIII SINGLECHAIN) IN PATIENTS WITH HEMOPHILIA A
Ying Zhang*, Tharin Limsakun, Debra Bensen-Kennedy, Alex Veldman, Jagdev Sidhu (United States)

PO242-TUE  DISCREPANCY BETWEEN THE FACTOR VIII LEVELS AND SEVERITY OF HEMOPHILIA A IN TWO MATERNAL COUSINS’ PATIENTS
Hadjira Ahmidatou*, Meriem Bensadok, Karima Chennoukh, Amar Aour, Nadia Zidani, Mohamed Ramaoun, Meriem Belhani, Salim Nekkal (Algeria)

PO243-TUE  THE AHEAD STUDY: EFFECTIVENESS INTERIM RESULTS AFTER ONE YEAR OF OBSERVATION, AN ANALYSIS OF THE EUROPEAN PATIENTS COHORT
Johannes Oldenburg*, Dimitrios Tsakiris, Cedric Hermans, Ri Liesner, Maria Mazzucconi, Rafael Parra, Katharina Steinitz, Lydia Abad-Franch, Alexandra Loew-Baselli (Germany)

PO244-TUE  THE AHEAD STUDY: SAFETY REAL WORLD DATA AFTER 1 YEAR OF OBSERVATION, AN ANALYSIS OF THE EUROPEAN COHORT OF PATIENTS
Johannes Oldenburg*, Dimitrios Tsakiris, Cedric Hermans, Ri Liesner, Maria Mazzucconi, Rafael Parra, Katharina Steinitz, Alexandra Loew-Baselli, Lydia Abad-Franch (Germany)

PO245-TUE  A CORE SET OF OUTCOME MEASUREMENT TOOLS IN PATIENTS WITH HEMOPHILIA: A SYSTEMATIC REVIEW OF THE MEASUREMENT PROPERTIES
Victor Blanchette, Alok Srivastava, Samantha Gouw*, Brian Feldman, Pamela Hilliard, Audrey Abad, Andrea Doria, Kathelijn Fischer (The Netherlands)

PO246-TUE  CLINICAL SIGNIFICANCE OF TYPE 1, TYPE 2 T CELLS, TH17 AND TREG IN THE DEVELOPMENT OF FVIII INHIBITOR IN PEDIATRIC HEMOPHILIA A PATIENTS.
Zhenping Chen, Runhui Wu*, Qiwei Wei, Gang Li, Ling Tang, Yingzi Zhen, Xinyi Wu (China)

PO247-TUE  EVALUATE THE QUALITY OF LIFE IN THE ELDERLY WITH HAEMOPHILIA
Mohammad Reza Shaverdi Niasar*, Gholamreza Tooghe, Samin Roostaei, Jayran Zebarzad, Elham Ale booye, Shadi Shaverdi, Alireza Rahimi, Hossein Eftekhar Ardebili, Fariba Zarrabi (Iran, Islamic Republic Of)

PO248-TUE  RESULTS OF ANKLE PROSTHESIS IN PATIENTS WITH SEVERE HAEMOPHILIC ARTHROPATHY – FOLLOW UP
Manuela Krause, Daniele Pillitteri*, Markus Preis, Carl Kirchmaier, Ute Scholz, Roger Scholz (Germany)

PO249-TUE  IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A AND B WITH INHIBITOR. SINGLE CENTRE EXPERIENCE.
Angelika Batorova*, Eva Bubanska, Denisa Jankovickova, Anna Morongova, Tatiana Prigancova, Erika Balazova (Slovakia)

PO250-TUE  PUPS WITH SEVERE HAEMOPHILIA A - A GCP STUDY EVALUATING THE IMMUNOGENICITY, EFFICACY AND SAFETY OF HUMAN-CL RHFXVIII
Raina Liesner, Martina Jansen*, Natalya Kavardakova, Marina Abashidze, Sigurd Knaub (Austria)

PO251-TUE  POPULATION PHARMACOKINETICS IN HEMOPHILIA A: TOWARDS INDIVIDUALIZATION OF PERIOPERATIVE REPLACEMENT THERAPY
Hendrika C. Hazendonk*, Karin Fijnvandraat, Mariëtje Driessens, Felix van der Meer, Karina Meijer, Marieke Kruip, Britta Lars-van Gorkom, Marjolein Peters, Saskia de Wildt, Frank Leebek, Marjou Crossen, Ron Mathôt (The Netherlands)

PO252-TUE  PRENATAL DIAGNOSIS FOR HAEMOPHILIA: UMBILICAL CORD BLOOD SAMPLE USED
Jing Zhu*, Jing Dai, Xuefeng Wang (China)

PO253-TUE  BLEEDING AFFECTS HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PEOPLE WITH HAEMOPHILIA PATIENTS (PWH) – EVEN A SINGLE BLEED MATTERS
Sylvia von Mackensen*, Hermann Eichler, Katharina Holstein, Kate Haier, Wolfgang Schramm (Georgia)

PO254-TUE  INTRACRANIAL HEMORRHAGE AND MANAGEMENT IN HEREDITARY BLEEDING DISORDERS: THE EXPERIENCE OF CUKUROVA UNIVERSITY, ADANA, TURKEY
Ilgen Sasmaz*, Bulent Antmen, Barbaros Karagun, Dervis Yilmaz, Gokdel Leblebisat, Yurdanur Kilinc (Turkey)

PO255-TUE  EXPLORING COST EFFECTIVENESS OF VARIOUS PROPHYLACTIC TREATMENT STRATEGIES FOR SEVERE HAEMOPHILIA USING A COMPUTER SIMULATION MODEL
Kathelijn Fischer*, Mart Janssen (The Netherlands)

PO256-TUE  ULTRASOUND EVALUATION OF HAEMOPHILIC JOINTS BY HAEMOPHILIA PHYSICIANS: A RELIABILITY STUDY
Kathelijn Fischer*, Johannes Oldenburg, Jan Astermark, Gerald Dolan, Massimo Morfini, Natasa Marquardt, Carla Martinoli (The Netherlands)

PO257-TUE  DOSING OF RVIII-FP IN CLINICAL STUDIES IN HEMOPHILIA WITH INHIBITORS AND FACTOR VII DEFICIENCY
Britta Lars-van Gorkom*, Pat Holme, Waander van Heerde, Johnny Mahlangu, Faraazah Dato, Abd Karim, Pratima Chowdary, Debbie Bensen Kennedy, Alex Veldman, Regina Clementi, Claudia Negrier (The Netherlands)

PO258-TUE  EFFICACY AND SAFETY OF RVIII-SINGLECHAIN IN SURGICAL PROPHYLAXIS
Claudia Djambas Khayat*, Johnny Mahlangu, Cindy Leisinger, Stephanie P’ng, Elena Santostigino, Fernanda Lopez Fernandez, Debbie Bensen Kennedy, Alex Veldman, Clementi Regin, Ingrid Pablinger (Lebanon)
PO269-TUE  HEPARIN-INDUCED THROMBOCYTOPENIA AND CALIBRATED THROMBIN GENERATION ASSAY.
Valentine Minet, Charlotte Bouckaert\*, Jean-Michel Dogné, François Mullier (Belgium)

Immune thrombocytopenia (ITP) II

PO270-TUE  THE ROLE OF CELLULAR IMMUNITY IN CHILDREN WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA.
Erol Erduran\*, Fulya Celikturk, Gokce Pinar Reis, Ayşenur Bahadır (Turkey)

PO271-TUE  DIAGNOSIS OF VENOUS THROMBOEMBOLISM DURING ELTROMBOPAG THERAPY FOR IMMUNE THROMBOCYTOPENIA AND SUCCESSFUL REPLACEMENT WITH ROMIPILOSTIM.
Odelia Amit\*, Ilya Kingner, Irl Avivi (Israel)

PO272-TUE  RE-EVALUATION OF NEED FOR BONE MARROW EXAMINATION IN PATIENTS WITH ISOLATED THROMBOCYTOPENIA TREATED WITH STEROIDS AS FIRST LINE THERAPY.
Mukul Aggarwal\*, Abhishek Purohit, Pravas Mishra, Tulika Seth, Seema Tyagi, Manoranjan Mahapatra, Hara Pati, Renu Saxena (India)

PO273-TUE  GLYCOPROTEIN IBA CLUSTERING INDUCES MACROPHAGE-MEDIATED PLATELET CLEARANCE IN THE LIVER.
Rong Yan, Mengxing Chen, Kesheng Dai\* (China)

PO274-TUE  EXTENDED PLATELET PARAMETERS AS A MEANS TO DIFFERENTIATE IMMUNE THROMBOCYTOPENIA FROM HYPOPROLIFERATIVE THROMBOCYTOPENIAS.
Hvoje Melinscak\*, Tahir Mirzoyev, Mala Varma (United States)

PO275-TUE  TREATMENT OF ATRAUMATIC SPLENIC RUPTURE IN AN ADOLESCENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND AUTOIMMUNE CYTOPENIAS: A CASE REPORT.
Rungrote Natesirinilkul\*, Pimlak Charoenkwan, Wattana Chartapisak, Sanit Ruangrongrat, Sawai Kalapratiruk, Trichak Sandhu, Prapan Jutavijittum (Thailand)

PO276-TUE  CD70 MOLECULE INVOLVED IN THE DENDRITIC CELLS DYSFUNCTION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA.
Zhang Xian\*, Zhou Zeping, Hao Yating, Zhang Donglei, Li Huiyuan, Yang Renchi (China)

PO277-TUE  MEGAKARYOCYTES AND MACROPHAGE-LYMPHOCYTE INTERACTIONS IN VITRO IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA.
Tamar Saralidze\*, Tinatin Shvelidze, Bela Metreveli, Tinatin Saralidze (Georgia)

PO278-TUE  THE INVOLVEMENT OF NEUROPLIN-1 IN PRIMARY IMMUNE THROMBOCYTOPENIA.
Hu Zhou\*, Jingyi Yang, Yongping Song (China)

PO279-TUE  SUCCESSFUL TREATMENT OF REFRACTORY ITP WITH CYCLOSPORINE A, TWO CASE REPORTS.
Antonin Hlusi\*, Tomas Sztokowski (Czech Republic)
PO280-TUE  EFFICACY AND PROGNOSIS OF SHORT TERM AND VERY LOW-DOSE IVIG THERAPY (200 MG/KG/D) FOR NEWLY DIAGNOSED ACUTE IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDREN
Kun Soo Lee*, Jung Eun Kim, Uk Hyun Kim, Ye-Jee Shim, Ji Yoon Kim (Korea, Republic Of)

Inflammation II

PO281-TUE  A SYNTHETIC PEPTIDE, CORRESPONDING TO THE NONCANONICAL PAR1- TETHERED LIGAND, MIMICS THE APC-INDUCED STIMULATION OF WOUND HEALING IN VITRO
Ekaterina Kisitseva*, Lyubov Gorbacheva, Svetlana Strukova, Maria Sidorova (Russian Federation)

PO282-TUE  DIFFERENTIAL IN VIVO ACTIVATION OF MONOCYTE SUBSETS DURING EXPERIMENTAL ENDOTOXEMIA IN HUMANS
Barbara Thaler*, Philipp Hohensinner, Konstantin Krychtik, Lorenz Koller, Mira Brekalo, Gerald Maurer, Bernd Jilma, Johanna Wojta, Walter Speidl (Austria)

PO283-TUE  REGULATION OF IL-10 AND HIGH MOBILITY GROUP BOX 1 (HMGB1) EXPRESSION IN HUMAN MONOCYTES BY PLATELETS AND NEUTROPHILS
Bjørn Østerud*, Jan Ole Olsen (Norway)

PO284-TUE  EFFECT OF LIPOPOLYSACCHARIDE AND VARIOUS CYTOKINES ON PROTEIN C INHIBITOR PRODUCTION BY HEPG2 CELLS
Tatsuya Hayashi*, Nobuyuki Akita, Takayuki Okamoto, Junji Nishioka, Koji Suzuki (Japan)

PO285-TUE  DOES THE COAGULATION CASCADE PLAY A ROLE IN RETINAL PATHOLOGIES?
Tami Livnat*, Alon Zahawi, Ruth Axer-Siegel, Ayelet Dreznik, Elinor Megiddo, Mor Dachbash, Yael Nisgav, Gili Kenet, Dov Weinberger, Rita Ehrlich (Israel)

PO286-TUE  CLINICAL PRESENTATION OF THROMBOEMBOLIC EVENTS IN INFLAMMATORY BOWEL DISEASE
Lize Bollen*, Niels Vande Casteele, Vera Ballet, Séverine Vermeire, Ann Gils (Belgium)

PO287-TUE  LOSS OF PAR-4 RECEPTOR AFFECTS RENAL ISCHEMIA REPERFUSION IN MICE
Marcel P. B. Jansen*, Sandrine Florquin, Joris Roelofs (The Netherlands)

PO288-TUE  TIPE2 IS INDUCED BY SIMULATED MICROGRAVITY IN MONOCYTES
Shilong Xiong*, Zhi Wei Wang, Xiao Yan Li (China)

PO289-TUE  MOUSE MACROPHAGES UPREGULATE PODOPOLAIN UNDER INFLAMMATORY AND APOPTOTIC CONDITIONS
Julie Rayes*, Samantha Montague, Stephanie Watson, Steve Watson (United Kingdom)

PO290-TUE  ANTI-INFLAMMATORY EFFECT OF NON-CANONICAL PEPTIDE-AGONIST OF PAR-1 ON RAT MAST CELLS RESEMBLES ACTIVATED PROTEIN C ACTION
Irina Babkina*, Maria Sidorova, Lyubov Gorbacheva, Svetlana Strukova (Russian Federation)

PO291-TUE  HIGH-FAT DIET IS ASSOCIATED WITH INCREASED VON WILLEBRAND FACTOR-RELATED PROCOAGULANT ACTIVITY IN HUMAN AND MURINE MODELS
Alison Michels*, Laura Swystun, Silvia Albanez, Jeffrey Mewburn, Kate Sponagle, David Lillicrap (Canada)

PO292-TUE  INFLAMMATORY AND ENDOTHelial MARKERS AND THEIR RELATIONS TO THE HAEMOSTATIC POTENTIAL DURING THE MENSTRUAL CYCLE.
Roza Chaireti*, Tomas Lindahl, Katarina Bremme, Anders Larsson (Sweden)

PO293-TUE  CIGARETTE SMOKING SIGNIFICANTLY REDUCES GEN- AND PROTEIN EXPRESSION OF THE PRO-INFLAMMATORY CYTOKINE IL-12
Trine Baur Opstad*, Harald Arnesen, Alf-Åge Pettersen, Ingebjørg Seljeflot (Norway)

PO294-TUE  THE INTERACTION BETWEEN EXPRESSION OF COX5AC-ADENOVIRUS RECEPTOR ON THE SURFACE OF PLATELETS AND CARDIOMYOCYTES, INFLAMMATION AND VIRUS PERSISTENCE INSIDE CELLS
Elena Gupal*, Liudmila Buryakhovskaya, Petr Chunachenko, Natalia Mironova (Russian Federation)

PO295-TUE  THE ROLE OF INFLAMMATION IN PREGNANCY-RELATED VENOUS THROMBOSIS
Hilde Skuterud Wik*, Anne Jacobsen, Per Sandset (Norway)

PO296-TUE  THE EXTRACELLULAR FIBRINOGEN-BINDING PROTEIN (EFB) SECRETED BY STAPHYLOCOCCUS AUREUS BINDS P-SELECTIN AND COMPETITIVE INHIBITS ITS INTERACTION WITH P-SELECTIN GLYCOPROTEIN LIGAND-1 (PSGL-1)
Giordano Pula*, Stefan Bagby, Mareike Posner, Abhishek Upadhyay (United Kingdom)

Innate and acquired Immunity

PO297-TUE  CRITICAL BEHAVIOR OF SUBCELLULAR DENSITY ORGANIZATION DURING NEUTROPHIL ACTIVATION AND MIGRATION
Sandra Baker-Groberg*, Kevin Phillips, Laura Healy, Asako Itakura, Juliana Porter, Paul Newton, Owen McCarty (United States)

PO298-TUE  NATURALLY OCCURRING ANTIBODIES TO OXIDATION-SPECIFIC EpITOPES IN PATIENTS WITH VENOUS THROMBOEMBOLISM
Sabine Eichinger*, Paul Kyre, Michael Kammer, Maria Ozsvar Kezma, Lisbeth Eischer, Christoph Binder (Austria)

PO299-TUE  C. CANIMORSUS AFFECTS COAGULATION BY PROTEOLYTIC CLEAVAGE OF FACTOR X
Katrin Hack*, Jonathan Douflifs, Jean-Michel Dogné, Guy Cornelis (Belgium)

PO300-TUE  POLYPHOSPHATE ACTS AS A COFACTOR FOR C1-INHIBITOR-MEDIATED REGULATION OF THE CLASSICAL PATHWAY OF COMPLEMENT
Emilie Lameignere*, Lakshmi Wijeyewickrema, Alice O’Byrne, Linnette Ocariza, Toshi-kazu Shiba, Stephanie Smith, James Morrissey, Robert Pike, Edward Conway (Canada)
PO301-TUE  HUMAN MONOCYTE SUBSETS DIFFERENTLY EXPRESS TISSUE FACTOR
Konstantin Krychtik*, Barbara Thaler, Philipp Hohensinner, Max Lenz, Kurt Huber,
Gerald Maurer, Johann Wojta, Gottfried Heinz, Walter Speidl (Austria)

PO302-TUE  MHC CLASS I ANTIGEN PRESENTATION BY MEGAKARYOCYTES.
Anne Zufferey*, Edwin Speck, Li Guo, Rukhsana Aslam, Rick Kapur, John Semple
(Canada)

PO303-TUE  PROTHROMBIN MUTANTS REVEAL A NEW MECHANISM OF MASP-1
MEDIATED CLOTTING
Lorenz Jenny, Jösef Dobó, Péter GáI, Verena Schroeder* (Switzerland)

PO304-TUE  COMPLEMENT AND TISSUE-FACTOR-INDUCED THROMBIN GENERATION
IN THE PATHOGENESIS OF VENOUS THROMBOEMBOLISM
Ina Isabella Høiland*, Robin Liang, Erin Hald, Nadezhda Latsyshova, Cathrine Ramberg,
Vladimir Tichelaar, Tom Eirik Moliness, John-Bjarne Hansen (Norway)

PO305-TUE  UNIQUE GENETIC VARIATION IN AN INVASIVE SEROTYPE M23ND STRAIN
OF STREPTOCOCCUS PYOGENES INFLUENCES BACTERIUM–HOST CELL
INTERACTIONS AND COMPLEMENT-MEDIATED OPSIONIZATION
Garima Agrahari*, Zhong Liang, Dustin Higashi, Shaun Lee, Victoria Ploplis, Francis
Castellino (United States)

PO306-TUE  CD44 ANTIBODIES CAN DIRECTLY INHIBIT MURINE MACROPHAGE
FC-GAMMA RECEPTOR AND COMPLEMENT RECEPTOR 3 – MEDIATED
PHAGOCYTOSIS
Alaa Amash*, Yawen Wang, Lin Wang, Alan Lazarus (Canada)

PO307-TUE  EXOGENOUS AND ENDOGENOUS TOLL-LIKE RECEPTOR LIGANDS
INDUCE THE FORMATION OF PLATELET-NEUTROPHIL AND PLATELET-MONOCYTE
COMPLEXES IN HUMAN WHOLE BLOOD
Julia Seyfert*, Christoph Bode, Daniel Duerschmied, Ingo Ahrens (Germany)

PO308-TUE  COMPLEMENT ACTIVATION AND THROMBIN GENERATION IN HEALTHY
INDIVIDUALS SUBJECTED TO MILD ISOBARIC HYPOXIA AND VENOUS
STASIS
Ina Isabella Høiland*, Robin Liang, Erin Hald, Trond Børvik, Nadezhda Latsyshova,
Cathrine Ramberg, Tom Moliness, John Bjarne Hansen (Norway)

Management of bleeding I

PO309-TUE  RETROSPECTIVE EVALUATION OF THE USE OF RECOMBINANT FAC-
TOR VIIia BEFORE AND AFTER THE IMPLEMENTATION OF A PHARMA-
CIST-LED FACTOR STEWARDSHIP PROGRAM
Taylor White*, Lindsey Amerine, Sheh Li Chen (United States)

PO310-TUE  USE OF A 4 FACTOR PROTHROMBIN COMPLEX CONCENTRATE IN A
UNITED STATES COMMUNITY HOSPITAL SYSTEM
Linda R. Kelly*, Bente Garcia (United States)
SCIENTIFIC PROGRAM

Microparticles II

PO322-TUE
SYNTHESIS AND IN VITRO STUDIES OF NANOXIDES AS HEMOSTATIC AGENTS FOR THE BLOOD COAGULATION ACCELERATION
Juliana Bergamasco*, Gabriel Zaneri, Tânia Da Rocha, Elbio D’Amico, Moacir De Godoy, José Geraldo Nery (Brazil)

PO323-TUE
COMPOSITION-DEPENDENT EFFECTS OF NANOPARTICLES ON COAGULATION
Kamran Bakhtiari*, Joost Meijers, Sophie Laurent, Svetlana Mintova, Eng-Poh Ng, Hussein Awala, Somayyeh Mirsadeghi, Morteza Mahmoudi, Farhad Rezaee (The Netherlands)

PO324-TUE
PLATELET ACTIVATION RELEASES MATURE MIR-494 IN MICROPARTICLES
Jasmine Tay*, Jessica Jorritsma, Quintin Hughes, Ross Baker (Australia)

PO325-TUE
CHARACTERISTICS AND ROLE OF EXTRACELLULAR VESICLES IN THE PATHOPHYSIOLOGY OF TRANSFUSION DEPENDENT B-TALASSEMA
Carina Levin*, Annie Sabbah, Benjamin Brenner, Anat Aharon (Israel)

PO326-TUE
MICROPARTICLES : WHAT’S PLASMA MADE OF ?
Alain R. Brisson*, Nicolas Arraud, Celine Gounou, Romain Linares, Sisareuth Tan (France)

PO327-TUE
COAGULATION ACTIVITY OF MICROPARTICLES FROM DIFFERENT CEL- LULAR SOURCES. INVOLVEMENT OF ACTIVE TISSUE FACTOR.
Alexey Mazurov*, Svetlana Khaspokova, Olga Antonova, Olga Shustova, Nina Golubeva, Vladimir Yakushkin, Anatoly Dobrovolsky (Russian Federation)

PO328-TUE
IMPACT OF VARIOUS ANTICOAGULANTS AND STORAGE TIME ON PLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES

PO329-TUE
PLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES IN HEALTHY INDIVIDUALS SUBJECT TO MILD ISOBAR HYPOXIA AND VENOUS STASIS
Trond Børvik*, Ina Høiland, Erin Mathiesen Hald, Cathrine Ramberg, Nadezhda Latysheva, John-Bjarne Hansen (Norway)

PO330-TUE
NEW TECHNIQUE TO STUDY CELL-DERIVED MICROPARTICLES
Åsa Thulin*, Junhong Yang, Masood Kamali-Moghaddam, Agneta Siegbahn (Sweden)

PO331-TUE
MICROPARTICLE LEVEL AND ORIGIN DURING PROGRESSION OF NORMAL PREGNANCY: A LONGITUDINAL STUDY IN HEALTHY WOMEN.
Elena Campello*, Claudia Radu, Luca Spiezia, Sonia Dhima, Silvia Visetin, Sabrina Gavasso, Barry Woodhams, Erich Cosmi, Paolo Simioni (Italy)

PO332-TUE
CIRCULATING MICROPARTICLES IN CORD BLOOD OF NORMAL PREGNANCY AND OF PREGNANCY WITH PREECLAMPSIA (PET).
Elena Campello*, Luca Spiezia, Claudia Radu, Sonia Dhima, Silvia Visetin, Sabrina Gavasso, Barry Woodhams, Erich Cosmi, Paolo Simioni (Italy)

Natural anticoagulants

PO333-TUE
A GAIN-OF-FUNCTION VARIANT OF PROTEIN C MANIFESTS ITSELF AS TYPE II PROTEIN C DEFICIENCY IN A HEALTHY SUBJECT
Qiulan Ding*, Lixiu Yang, Peyman Dinarvand, Xuefeng Wang, Alizea Rezaei (China)

PO334-TUE
EVALUATION OF PROTEIN C LEVELS IN SICKLE CELL DISEASE SUBJECTS SEEN AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY, NIGERIA.
Obinna Nwachukwu*, Benedict Nwogoh (Nigeria)

PO335-TUE
POSSIBLE MECHANISM OF ACTIVATED PROTEIN C-INDUCED INHIBITION OF OSTEOCLAST DIFFERENTIATION
Nobuyuki Akita*, Rakunoshin Yoshida, Takayuki Okamoto, Kunihiro Asanuma, Junji Nishioka, Koji Suzuki, Tatsuya Hayashi (Japan)

PO336-TUE
PHARMACOKINETIC STUDY OF THE NOVEL ANTICOAGULANT PEPTIDE VARIEGIN USING LC-MS/MS, CHROMOGENIC SUBSTRATE AND MODI- FIED THROMBIN TIME ASSAYS
Norrapat Shih*, R. Manjunatha Kini (Singapore)

PO337-TUE
THROMBOMODULIN INHIBITS TISSUE FACTOR MEDIATED THROMBIN GENERATION IN BLOOD AND PROTHROMBIN COMPLEX CONCENTRATES
Jawed Paneed*, Debra Hoppensteadt, Daneyal Syed, Daniel Kahn, Michael Mosier, Inder Kauf (United States)

PO338-TUE
HEPARANASE ACTIVATES ANTITHROMBIN THROUGH THE BINDING TO ITS HEPARIN BINDING SITE
Nataliya Bohdan, Salvador Espin, Sonia Águila, Raúl Teruel-Montoya, Javier Corral, Vicente Vicente, Irene Martínez-Martínez* (Spain)

PO339-TUE
ANTITHROMBIN BINDS TO AND ENHANCES THE BARRIER FUNCTION OF HUVECS INDEPENDENTLY OF CELL-SURFACE HEPARAN SULFATE PROTEOGLYCANS
François Saller*, Stéphane Pautus, Yasmine Bouri, Allan De Carvalho, Toufik Abache, Elsa Blanchini, Jean-Luc Plantier, Delphine Borge (France)

PO340-TUE
TETRAMETHYLPYRAZINE DECREASES RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) VIA SUPPRESSION OF FOXA2 AND INDUCTION OF NOS IN HEPG2 CELLS
Junling Li*, Wenhu Zi, Ping Zhu (China)

PO341-TUE
QUANTITATIVE TRANSCRIPTOME AND PROTEOME ANALYSIS OF DERMATOPHAGOIDES PTERONYSSINUS SALIVARY GLANDS FOR THE IDENTIFICATION OF NOVEL ANTICOAGULANTS AND IMMUNOMODULATORY PROTEINS
Janaki Iyer*, Mirko Slovok, Ivo Francischetti, Jose Ribeiro, Manjunatha Kini (Singapore)

PO342-TUE
SIMILAR RESPONSES OF PHOSPHATIDYLSEINE AND PHOSPHATIDYL- LETHANOLAMINE TOWARDS COFACTOR ACTIVITY OF HUMAN PROTEIN Z, A NATURAL ANTICOAGULANT
Tanusree Sengupta*, N Manoj (India)
SCIENTIFIC PROGRAM

PO343-TUE  THE EFFECT OF AGE ON GLYCAN MICROHETEROGENEITY OF HUMAN ALPHA-2-MACROGLOBULIN
Laura S. Calvert*, Helen Atkinson, Leslie Berry, Anthony Chan (Canada)

PO344-TUE  QUANTITATIVE IMMUNOASSAY FOR THE MEASUREMENT OF ACTIVATED PROTEIN C COMPLEXES WITH ALFA-2-MACROGLOBULIN (APC:ACM)
Francisco España*, Silvia Navarro, Laura Martos, Luis Ramón, Elena Bonet, Pilar Medina (Spain)

PO345-TUE  IDENTIFICATION OF A NOVEL MUTATION PK234EF5*24 IN THE PROC GENE AND A PHENOTYPE-GENOTYPE CHARACTERISTICS OF THAI PATIENTS DIAGNOSED WITH HEREDITARY PROTEIN C DEFICIENCY AND SYMPTOMATIC THROMBOEMBOLISM
Bundarika Suwanawiboon*, Wanna Thongnoppakhun, Chanin Limwongse (Thailand)

PO346-TUE  THE PDI INHIBITOR ISOQUERCETIN REDUCES THROMBIN GENERATION IN HEALTHY ADULTS AND IN PATIENTS WITH ELEVATED ANTIPHOSPHOLIPID ANTIBODIES
Jack D. Stopa*, Bruce Furie, Robert Flaumenhaft, Jeffrey Zwicker (United States)

PO347-TUE  INVESTIGATION OF PROTEIN S DEFICIENCY INDUCED PURPURA FULMINANS
Raja Prince*, Sara Calzavarini, François Saller, Luca Bologna, Federica Bisignani, Anne Angelillo-Sherrer (Switzerland)

PO348-TUE  QUANTITATIVE PLATELET TFPI-ALPHA RELEASE IS NOT INFLUENCED BY SEX AND ORAL CONTRACEPTIVE USE.
Kristien Winckers, Stella Thomassen, Hugo ten Cate, Tilman Hackeng* (The Netherlands)

PO349-TUE  ROLE OF TISSUE FACTOR PATHWAY INHIBITOR-ALPHA IN PLATELET-DEPENDENT FIBRIN FORMATION UNDER FLOW
Stella Thomassen*, Tom Mastenbroek, Kristen Winckers, Marion Feijge, Judith Coemans, Tilman Hackeng, Johan Heemskerk (The Netherlands)

PO350-TUE  ASSOCIATION RATE CONSTANTS RATIONALIZE THE SENSITIVITY OF PROTHROMBIN TIME AND THROMBIN GENERATION ASSAY TO APIXABAN AND RIVAROXABAN
Georges Jourdi*, Virginie Siguret, Anne-Céline Martin, Jean-Louis Golmard, Anne Godier, Charles-Marc Samama, Pascale Gaussem, Isabelle Gouin-Thibault, Bernard Le Bonnicc (France)

PO351-TUE  INTERACTION OF ANDEXANET ALFA, A UNIVERSAL ANTIDOTE TO FXA INHIBITORS, WITH TISSUE FACTOR PATHWAY INHIBITOR ENHANCES REVERSAL OF FXA INHIBITOR-INDUCED ANTICOAGULATION
Gemmin Lu*, Joyce Lin, Gregory Coffey, John Curnutte, Pamela Conley (United States)

PO352-TUE  DIRECT ORAL ANTICOAGULANTS: OUR EXPERIENCE
Rita Santoro*, Roberto Minici, Piergiorgio Iannaccaro, Sergio Morgione (Italy)

PO353-TUE  CLINICAL PRESENTATION, IMPACT AND COURSE OF MAJOR BLEEDING EVENTS WITH APIXABAN AND WARFARIN
Suzanne M. Bleker*, Alexander Cohen, Harry Büller, Giancarlo Agnelli, Alexander Gallus, Gary Raskob, Jeffrey Weitz, Madelyn Curto, Melanie Sisson, Saskia Middeldorp (The Netherlands)

PO354-TUE  DABIGATRAN PREVENTS THROMBOSIS WITH ENHANCEMENT OF SECONDARY FIBRINOLYSIS IN A MOUSE VENOUS THROMBOSIS MODEL
Asuka Sakata*, Tsukasa Ohmori, Kinya Seo, Satoshi Nishimura (Japan)

PO355-TUE  DABIGATRAN AND RIVAROXABAN ADHERENCE STUDY: REAL WORLD EXPERIENCE IN DIFFERENT CLINICS AND EXTENDED FOLLOW UP (DARIVA STUDY)
Deepa Suryanarayan*, Faris Al-Khalili, Ammar Majeed, Sam Schulman (Canada)

PO356-TUE  A QUALITATIVE POINT OF CARE TEST TO ASSESS ANTICOAGULANT ACTIVITY IN URINE SAMPLES OF PATIENTS TREATED WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS – A GERMAN CONSENSUS
Job Harenberg*, Ingo Ahrens, Rupert BauerSachs, Sylvia Haas, Jürgen Koscielny, Roland Krämer, Edelgard Lindhoff-Last, Jürgen Prochaska, Sebastian Schellong, Michael Spangnall, Philipp Wild, Jan Beyer-Westendorf (Germany)

PO357-TUE  PARADOXICAL ENHANCEMENT OF THE INTRINSIC PATHWAY-INDUCED THROMBIN GENERATION IN HUMAN PLASMA BY MELAGATRAN, A DIRECT THROMBIN INHIBITOR, BUT NOT EDOXABAN, A DIRECT FACTOR XA INHIBITOR
Taketoshi Furugohri*, Yoshiyuki Morishima (Japan)

PO358-TUE  EVALUATION OF ANTICOAGULATION WITH RIVAROXABAN BY ANTI-XA ACTIVITY, THROMBIN GENERATION AND COMPLEX THROMBIN ANTI-THROMBIN LEVELS IN PATIENTS WITH NEW ONSET NON VALVULAR ATRIAL FIBRILLATION.
Victor M. Neira Vidal*, Ramón Corbalan Herreros, Jaime Pereira Garcés, Olga Panes Becerra, Bernardita Garayar Pulgar, Andrés Alzamán Sierra, Silvania Llaneras Madariaga, Luis Villarroel del Pino (Chile)

PO359-TUE  LOW DOSE RIVAROXABAN FOR SECONDARY PROPHYLAXIS AFTER FULL ANTICOAGULATION IN PATIENTS WITH VENOUS THROMBOEMBOLISM
Alan Zhou*, Anthony Chan, Keith Lau, Howard Chan (Canada)

PO360-TUE  INTRA-INDIVIDUAL VARIABILITY IN TROUGH AND PEAK DABIGATRAN LEVELS IN “REAL-LIFE” ATRIAL FIBRILLATION PATIENTS
Nina Vene*, Petra Šinigoj, Rickard Malmström, Yoko Rönquist-Nii, Mojca Božič-Mijovški, Anton Pohanka, Jovan Antović, Alenka Mavri (Slovenia)

PO361-TUE  DIRECT-ACTING ORAL ANTICOAGULANTS IN THE REAL WORLD: INSIGHTS INTO HEALTH CARE PROVIDERS’ UNDERSTANDING OF MEDICATION DOSING AND USE
Menaka Pai*, Mary Salib, Jennifer Delaney, Mohamed Panju, Sam Schulman (Canada)

PO362-TUE  DIRECT ORAL ANTICOAGULANTS IN CLINICAL PRACTICE - REAL WORLD AUDIT DATA
Sarah Bond*, Sue Rhodes (United Kingdom)
PO363-TUE  NUANCES OF NOAC'S IN A DEVELOPING COUNTRY - A SINGLE CENTER EXPERIENCE
Shamanna Iyengar*, Roopa Ravibabu, Sumithra Lakshman, Anand Shenoy, Sridhar G, Mukul Fulmali, Subash Chandra V (India)

PO364-TUE  RIVAROXABAN PHARMACOKINETICS BEFORE AND AFTER BARIATRIC SURGERY: A CASE AND DISCUSSION
George Dresser*, Markus Guillet, Richard Kim (Canada)

PO365-TUE  RENAL FUNCTION COURSE IN PATIENTS TREATED WITH NEW ORAL ANTICOAGULANTS.
Elisa Grifoni, Rossella Marcucci, Daniela Poli, Raffaëlia Priora, Maddalena Pazzi, Alessia Fabbrini, Cinzia Fatini, Lucia Mannini, Anna Maria Gori*, Rosanna Abbate, Gian Franco Gensini (Italy)

PO366-TUE  THE EFFECTS OF DIRECT ORAL ANTICOAGULANTS APIXABAN AND RIVAROXABAN ON HAEMOSTASIS TESTS: RESULTS FROM A COMPREHENSIVE CROSS-LABORATORY EXERCISE.
Roslyn A. Bonar*, Emmanuel Favaloro, Katherine Marsden, John Sioufi (Australia)

PO367-TUE  EFFECT OF NEW ORAL ANTICOAGULANTS ON PROTEIN C SYSTEM.
Irina Geltcer*, Olga Golovina, Olga Smirnova, Olesya Matvienko, Ludmila Papayan (Russian Federation)

PO368-TUE  A STUDY OF DOAC AWARENESS INDICATING INADEQUATE RECOGNITION WITH POTENTIAL FOR PATIENT HARM
Henry Watson*, Adetomilola Olaiya, Katherine Marsden, John Sioufi (Australia)

PO369-TUE  CIRCULATING CONCENTRATION OF RIVAROXABAN OR DABIGATRAN ANTICOAGULANTS IN CLINICALLY SELECTED PATIENTS
Jane Needham*, Helen Lewis, Amanda McMullen, Tamara Everington, Savita Rangaranjan, Sarah Mangles (United Kingdom)

PO370-TUE  COMPARING REVERSAL EFFECT OF FACTOR X CONCENTRATE AND BY-PASSING AGENTS ON RIVAROXABAN IN AN EX VIVO SPIKING STUDY WITH ROTEM
Anja Drebes*, Anne Riddell (United Kingdom)

PO371-TUE  MANAGEMENT OF BLEEDING AND EMERGENCY SITUATIONS FOR PATIENTS TREATED WITH DABIGATRAN- SINGLE CENTRE EXPERIENCE.
Tatiana Prigancova*, Angelika Batorova, Denisa Jankovicova (Slovakia)

PO372-TUE  BLEEDING AND TREATMENT FAILURE IN PATIENTS TAKING DIRECT ORAL ANTICOAGULANTS REFERRED TO EMERGENCY DEPARTMENT: A COHORT MANAGEMENT STUDY
Caterina Compostella, Foscarina Della Rocca, Seena Padayatti Jose, Giacomo Zoppelaro, Gentian Denas, Alessia Bracco, Gianna Vettore, Vittorio Pego* (Italy)

PO373-TUE  PERFORMANCES OF A NEW COMMERCIAL CHROMOGENIC ASSAY FOR THE MEASUREMENT OF APIXABAN CONCENTRATION IN PLASMA
Jean-Marc Minon*, Myriam Vastien, Thierry Gougard, Hélène Appeltans, Philippe Borgoens (Belgium)

PO374-TUE  TREATMENT OPTIONS FOR MAJOR HAEMORRHAGE AND URGENT INTERVENTION IN PATIENTS ON A NOAC - INTERIM RESULTS FROM THE ANTICOAGULATION REVERSAL AND EVENTS STUDY (ARES) COLLABORATIVE
Ross Baker*, Alex Gallus, Timothy Brighton, Paul Harper, Laura Young, Joanna Joseph, Amanda Hugman, Krys Hiscock, Scott McGregor, Jennifer Curnow (Australia)

PO375-TUE  PROTHROMBINASE INDUCED CLOTTING TIME (PICT®) FOR MEASURING THE ACTIVITY OF DIRECT FACTOR XA INHIBITORS IN CLINICAL SETTING.
Pavel E. Olivera*, Vicente Cortina, Verónica Pons, Broyan Merchán, Laura López-Anderoni, Gonzalo Artaza, Eva Menino, Ana Marín, Francesc Bosch, Amparo Santamaria (Spain)

PO376-TUE  AN OPEN-LABEL STUDY OF DABIGATRAN PHARMACOKINETICS AND PHARMACODYNAMICS IN PATIENTS WITH MODERATE RENAL IMPAIRMENT UNDERGOING PRIMARY UNILATERAL ELECTIVE TOTAL KNEE OR HIP REPLACEMENT SURGERY
Bengt Eriksson*, Zsolt Mikuszka, Martin Feuring, Jean Amiral, Sebastian Haertter, Joachim Stangier, Gerhard Neumiz, Maximilian Lobmeyer, Jeffery Weitz (Sweden)

PO377-TUE  QUALITATIVE FOLLOW UP OF EMERGENCY DEPARTMENT (ED) PATIENTS DISCHARGED ON RIVAROXABAN FOR LOW RISK VENOUS THROMBOEMBOLISM
Kristen E. Nordenholz*, Elaina Thompson, Toby Trujillo, Gregory Misky (United States)

PO378-TUE  NET CLINICAL BENEFIT OF DABIGATRAN VERSUS WARFARIN IN PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM: A POOLED ANALYSIS OF RE-COVER AND RE-COVER II
Sam Schulman*, Henry Eriksson, Ajay Kakkar, Clive Keen, Sebastian Schellong, Martin Feuring, Stefan Hantel, Joerg Kreutzer, Samuel Goldhaber (Canada)

PO379-TUE  IDENTIFICATION OF POSSIBLE DRUG RELATED PROBLEMS IN PATIENTS ON ORAL ANTICOAGULANTS. A SYSTEMATIC REVIEW OF MEDICATION CHARTS BY PHARMACIST.
Anne Fjørkenstad*, Eva-Marie Jacobsen, Liv Mathiesen, Espen Molden (Norway)

PO380-TUE  INFLUENCE OF DOACS ON THROMBIN GENERATION ASSAY
Kazu Kawasugi*, Tadashi Yamamoto, Naoki Shirafuji (Japan)

Platelet activation/adhesion/aggregation II

PO381-TUE  NEW FACTOR OF PLATELET HAEMOSTASIS PATHOLOGY RISK MARKER IN POPULATION OF NENETS AUTONOMOUS DISTRICT
Nadezda Vorobyeva*, Natalia Belova (Russian Federation)

PO382-TUE  THE EFFECT OF IGG OF ISCHEMIC STROKE PATIENTS ON PLATELET PROTEINS SECRETION
Tatiana B. Katrii*, Olexiy Savchuk, Ludmila Ostapchenko (Ukraine)
<table>
<thead>
<tr>
<th>POSTERS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SCIENTIFIC PROGRAM</strong></td>
</tr>
</tbody>
</table>
| PO383-TUE | MEAL-INDUCED PLATELET ACTIVATION DIFFERS BETWEEN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES AND IS RELATED TO INSULIN SECRETION  
Galia Spectre*, Ragnhild Stålesen, Claes-Göran Östenson, Paul Hjemdahl (Israel, Sweden) |
| PO384-TUE | INFLUENCE OF PLATELET COUNT IN PLATELET RICH PLASMA FOR ADENOSINE TRIPHOSPHATE RELEASE ASSAY  
Sylvie Mulliez*, Katrien Devreese (Belgium) |
| PO385-TUE | ACTIVATION OF HUMAN PLATELETS BY STAPHYLOCOCCUS AUREUS SECRETED PROTEASE STAPHOPAIN A  
Amie K. Waller*, Katie Birch, Pratik Vikhe, Graeme Cottrell, Jon Gibbins, Simon Clarke (United Kingdom) |
| PO386-TUE | LOW PLATELET REACTIVITY IS ASSOCIATED WITH MORE SEVERE ATEROSCLEROSIS AND INCREASED REVASCULARIZATION DURING FOLLOW UP.  
Tesse Leunissen*, Crystel Gijsberts, Peter Paul Wisman, Folkert Asselbergs, Imo Hoefer, Gerard Pasterkamp, Gert Jan de Borst, Frans Moll, Mark Roest (The Netherlands) |
| PO387-TUE | EVALUATION OF MULTIPLET® WHOLE BLOOD IMPEDANCE AGGREGOMETRY IN ROUTINE INVESTIGATION OF BLEEDING DISORDERS  
Joanne E. Joseph*, Joyce Low, Susan Jarvis (Australia) |
| PO388-TUE | ANALYSIS OF PROCOAGULANT PS-EXPOSING PLATELETS BY IMAGING FLOW CYTOMETRY  
Emily C. Reddy*, Hong Wang, Hilary Christensen, Sara Israels, Annie Bang, Margaret Rand (Canada) |
| PO389-TUE | THE POTENTIAL OF THE NEW PLATELET ACTIVATION IN UNPROCESSED BLOOD (PACT-UB)- TEST  
Tesse Leunissen*, Peter Paul Wisman, Thija Van Holten, Philip de Groot, Jasper Remijn, Frans Moll, Gert Jan de Borst, Martin Teraa, Marianne Verhaar, Rolf Urbanus, Mark Roest (The Netherlands) |
| PO390-TUE | DETERMINATION OF THRESHOLD AGONIST CONCENTRATIONS FOR WHOLE BLOOD AGGREGATION USING THE MULTIPLET® ANALYZER  
Sara J. Israels*, Eileen McMillan-Ward, Hong Wang, Victor Blanchette, Margaret Rand (Canada) |
| PO391-TUE | ASSESSMENT OF TIME-RELATED PREAMALYTICAL INFLUENCES ON PLATELET FUNCTION: COMPARISON OF THE MULTIPLET, THE PFA-100 AND THE VERIFY NOW  
Petra Jilma*, Franz Ratzinger, Christian Schöggenhofer, Bernd Jilma, Peter Quehenberger (Austria) |
| PO392-TUE | DYNAMICS OF CALCIUM SPIKING, MITOCHONDRIAL COLLAPSE AND PHOSPHATIDYLSERINE EXPOSURE IN SINGLE PLATELETS DURING ACTIVATION  
Sergei I. Obydennyi*, Anastasia Sveshnikova, Fazoil Ataulakhanov, Mikhail Pantaleev (Russian Federation) |
| PO393-TUE | GPVI AND THE CLEC-2/PODOPLANIN AXIS AS POTENTIAL BIOMARKERS OF PLATELET ACTIVATION IN INFLAMMATORY CONDITIONS  
Samantha J. Montague*, Robert Dinsdale, Eelo Gitz, Elizabeth Gardiner, Robert Andrews, Peter Hampson, Christopher Wearm, Christopher Buckley, Gerard Nash, Naiem Moiemen, Paul Harrison, Steve Watson (United Kingdom) |
| PO394-TUE | NOVEL WHOLE BLOOD MODEL OF THROMBOCYTOPENIA WITH PRE-SERVED PLATELET FUNCTION  
Mette T. Skipper*, Peter Rubak, Ole Larsen, Anne-Mette Hvas (Denmark) |
| PO395-TUE | LOCAL ANAESTHETICS INHIBIT ACTIVATION OF PROTEIN DISULFIDE ISOMERASE (PDI).  
Christopher Stavermann, Anne Bertling, Mayken Visser, Martin Brodde, Wiebke Gogarten, Beate E. Kehrel* (Germany) |
| PO396-TUE | PROSPECTIVE ANALYSIS OF PLATELET ACTIVATION MARKERS TO PREDICT SEVERE INFECTION AND MORTALITY IN INVASIVE CARE UNITS.  
Celine Delemerieux*, Nathalie Layios, Alexandre Hego, Justine Huard, Arnaud Joly, Pierre Geurts, Pierre Damas, Christelle Lecut, André Gothot, Cécile Gury (Belgium) |
| PO397-TUE | STAPHYLOCOCCUS AUREUS LIPOPROTEINS INHIBIT PLATELET ACTIVATION.  
Pratik Vikhe*, Amie Waller, Jonathan Gibbins, Simon Clarke (United Kingdom) |
| PO398-TUE | COMPARATIVE IMPACTS OF ANTIRETROVIRAL HIV THERAPIES ON PLATELET FUNCTION  
Erica Smyth*, Mark Nelson, Michael Emerson (United Kingdom) |
| PO399-TUE | ANALYZING IN VITRO PLATELET THROMBUS FORMATION OF PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA UNDER BLOOD FLOW CONDITIONS  
Takashi Ito*, Tomoka Nagasato, Takahiko Nakashima, Hitomi Yamashita, Hideki Matsou, Kazuya Hosokawa, Ikuko Maruyama (Japan) |
| PO400-TUE | GENERATION OF PROCOAGULANT COAT PLATELETS IN STORED PLATELET-CONCENTRATE UNITS DERIVED FROM BUFFY-COAT PREPARATIONS  
Debora Bertaggia Calderara*, David Crettaz, Stefano Barelli, Jean-Daniel Tissot, Niels Lion, Michel Prudent, Lorenzo Alberio (Switzerland) |
| PO401-TUE | OPIATES MAY ATTENUATE PLATELET ACTIVATION  
Salumeh Bastami, Nahreen Tynngard, Ankit S. Macwan*, Tomas Lindahl, Srinivas Uppugunduri (Sweden) |
| PO402-TUE | IN VIVO AND PROTEASE-ACTIVATED RECEPTOR 1-MEDIATED PLATELET ACTIVATION IN PATIENTS PRESENTING FOR CARDIAC CATHETERIZATION  
Thomas Gremmel*, Alan Michelson, Andrew Frelinger (Austria, United States) |
| PO403-TUE | PLATELET FACTOR-3 (PF-3) AVAILABILITY AND PLATELET COUNT OF PREGNANT WOMEN IN IRRUA, EDO STATE.  
Rose A. Anyanwu*, Bridget Omaivboje, Edeangbe Adesuwu (Nigeria) |
SCIENTIFIC PROGRAM

PO404-TUE  FLOW CYTOMETRY BASED EVALUATION OF PLATELET-NEUTROPHIL COMPLEX FORMATION IN HUMAN AND MURINE WHOLE BLOOD: A DETAILED ANALYSIS OF EX VIVO SAMPLE PREPARATION, CYTOMETER SETTINGS AND MOLECULAR BASICS
Maximilian Mauler*, Julia Seyfert, David Haenel, Hannah Seeba, Janine Guenther, Christoph Bode, Ingo Ahrens, Daniel Duerschmied (Germany)

PO405-TUE  T2MR PLATELET ANALYSIS CORRELATES WITH LTA AND REVEALS UNIQUE DETAILS OF ADP-MEDIATED PLATELET ACTIVATION IN WHOLE BLOOD
Adam Cuker, Tatiana Lebedeva, Holleh Husseinzadeh, Walt Massesfki, Joseph Marutana, Thomas Lowery*, Charles Abrams, Doug Cines (United States)

PO406-TUE  NEW APPROACH FOR EVALUATION OF PLATELET FUNCTION IN THROMBOCYTOPENIA USING IMPEDANCE AGGREGOMETRY
Mette T. Skipper*, Peter Rubak, Jesper Stentoft, Anne-Mette Hvas, Ole Larsen (Denmark)

PO407-TUE  DEVELOPMENT AND VALIDATION OF A FLOW CYTOMETRY ASSAY FOR ASSESSING CYCLOOXYGENASE-1 AND 2 IN PLATELETS
Peter Rubak*, Steen Kristensen, Anne-Mette Hvas (Denmark)

PO408-TUE  PLATELET AGGREGATION AND BIOLOGICAL RESPONSE MODIFIERS RELEASE BY COMBINATIONS OF STREPTOCOCCUS SANGUINIS AND PORPHYROMONAS GINGIVALIS
Archie McNicol*, Sara Israel, Hind Hamzeh-Cognasse, Fabrice Cognasse (Canada)

PO409-TUE  INCREASE IN IONIC STRENGTH INHIBITS PLATELET AGGREGATION IRRESPECTIVE OF SOLUTE TYPE IN VITRO
Gordon Ogweno* (Kenya)

PO410-TUE  A NEW APPROACH TO MEASURING PLATELET AGGREGATION AND PLATELET-LEUCOCYTE CONJUGATE FORMATION IN A SMALL VOLUME OF FIXED WHOLE BLOOD
Mohammad Algahtani*, Natalia Dovlatova, Jane May, Stan Heptinstall, Sue Fox (United Kingdom)

PO411-TUE  THE AUTOMATION OF ROUTINE LIGHT TRANSMISSION PLATELET AGGREGATION ON SYSMEX CS-2000i
Katsushi Kobayashi, Pierre Gueret, Maxime Sansot, Fabienne Nedelec Gac, Jean Amiral (France)

PO412-TUE  EFFECTS OF PH AND CONCENTRATION OF SODIUM CITRATE ANTICOAGULANT ON PLATELET AGGREGATION MEASURED BY LIGHT TRANSMISSION AGGREGOMETRY INDUCED BY ADENOSINE DIPHOSPHATE
Ksenia Germanovich, Eti A. Femia, Chun Yan Cheng*, Natalia Dovlatova, Marco Cattaneo (Italy)

PO413-TUE  ANTI-PROTAMINE/HEPARIN ANTIBODIES INDUCED PLATELET ACTIVATION IN THE PRESENCE OF NPH-INSULIN IN HEPARIN DEPENDENT MANNER
Tamam Bakchoul*, Heike Zöllner, Rabil Jouni, Lars Janzen, Jan Wesche, Jessica Fuhrmann, Andreas Greinacher (Germany)

PO414-TUE  CHARACTERISING CELL-TYPE INTERACTIONS FOLLOWING PLATELET ACTIVATION IN A NOVEL LOW VOLUME WHOLE BLOOD ASSAY
Paul C. Armstrong*, Timothy Warner (United Kingdom)

PO415-TUE  CHARACTERISATION OF PROCOAGULANT PLATELETS IN WHOLE BLOOD USING A NOVEL CELL DEATH MARKER
Leonardo Pasalic*, Heather Campbell, Philip Hogg, Vivien Chen (Australia)

Platelet disorders II

PO416-TUE  NATURAL HISTORY OF ACQUIRED GLANZMANN THROMBASTHENIA : A CASE REPORT
Marie Tuffigo, Chloé James, Estibaliz Lazaro, Jean-François Viallard, Mathieu Fiore* (France)

PO417-TUE  HOT-WATER EXTRACTS OF THE MUSHROOM, AGARICUS BRASILIENSIS, INHIBITS PLATELET ACTIVATION VIA P2Y1 RECEPTOR.
Kaneo Satoh*, Katsuyuki Akahane, Masato Ohta, Yukio Ozaki (Japan)

PO418-TUE  A REDUCED RESPONSE TO TRAP-6 IN PLATELET AGGREGATION STUDIES IS NOT USUALLY DUE TO A PAR-1 RECEPTOR DEFECT.
Michael Mitchell*, Aine McCormick, James Maloney, Gary Moore, Steve Austin (United Kingdom)

PO419-TUE  DIFFERENTIAL REGULATION OF THE PLATELET PROTEOME IN GLANZMANN THROMBASTHENIA TYPE I
Kerstin Jurk*, Stefan Loroch, Cora Reiss, Kathrin Schwierczek, Wolfgang Behnisch, Barbara Zieger, Rene Zahedi, Ulrich Walter (Germany)

PO420-TUE  GRANULES SECRETION IN PATIENTS WITH GLANZMANN’S THROMBASTHENIA
Ann-Kathrin Pilgrimm-Thorp, Manuela Krause, Daniele Pillitteri*, Tanja Behrendt, Carl Kirchmaier (Germany)

PO421-TUE  THE GFI1B C.503G>T MUTATION IN THE FIRST ZINC FINGER DOMAIN PREDICTS A Milder BLEEDING PHENOTYPE THAN THE GFI1B C.880-881INS mutation
David Rabbolini*, Marie-Christine Morel-Kopp, Qiang Chen, Sara Gabrielli, Lindsay Dunlop, Christopher Ward, William Stevenson (Australia)

PO422-TUE  ABNORMAL PROPLATELET FORMATION AND EMPERIPOLESIS IN CULTURED MEGAKARYOCYTES FORM GRAY PLATELET SYNDROME PATIENTS
Erica De Candia*, Christian Di Buduo, Maria Adele Alberelli, Ana Glembocky, Gianmarco Podda, Marco Cattaneo, Raffaele Landolfi, Paula Heller, Alessandra Balduini (Italy)

PO423-TUE  MULTIPLEX PHOSPHOSPECIFIC FLOW CYTOMETRY FOR THE SCREENING OF PLATELET SIGNALING DISORDERS
Marie Levade*, Cédric Garcia, Sarah Cadot, Jennifer Series, Pierre Sié, Bernard Payrastre (France)
**PO424-TUE**  THIOREDOXIN REDUCTASE PROTECTS PLATELETS FROM CELL DEATH
Matthew T. Harper* (United Kingdom)

**PO425-TUE**  A NOVEL MUTATION IN NBEAL2 GENE CAUSING GRAY PLATELET SYNDROME
Lijuan Cao*, Zhaoyue Wang, Xia Bai, Jiaming Li, Lijun Xia, Changgeng Ruan (China)

**PO426-TUE**  VALIDATION OF THE SELF-PBQ (SELF-ADMINISTERED PEDIATRIC BLEEDING QUESTIONNAIRE) AS A SCREENING TOOL FOR A NEW DIAGNOSIS OF VON WILLEBRAND DISEASE (VWD)
Angie Tuttle*, Julie Grabell, Steven Bae, Paul Moorehead, Victor Blanchette, John Wu, MacGregor Steele, Robert Klaassen, Mariana Silva, Margaret Rand, Paula James (Canada)

**PO427-TUE**  FAMILY HISTORY OF VENOUS THROMBOEMBOLISM IN THE PEDIATRIC POPULATION: THE NEED FOR A STANDARDIZED DEFINITION
Anna Hau, Eric Wegener*, Paul Monagle, Shoshana Revel-Vilk, Vera Ignjatovic (Australia)

**PO428-TUE**  INITIAL DOSE OF ENOXAPARIN IN NEONATES WITH THROMBOSIS
Mirta Hepner*, Gabriela Sciuccati, Carolina Cervio, Graciela Pieroni, Silvina Annetta, Diana Farinha, Juan Frontroth, Lilian Diaz, Aurora Felu Torres, Mariana Bonduel (Argentina)

**PO429-TUE**  SKIN NECROSIS AND PURPURA FULMINANS IN CHILDREN WITH AND WITHOUT THROMBOPHILIA - A TERTIARY CENTER’S EXPERIENCE
Yariv Fruchtman*, Tzipora Strauss, Marina Rubinstein, Miriam Ben Harosh, Shoshana Revel-Vilk, Joseph Kapelushnik, Gideon Pare, Gil Kenet (Israel)

**PO430-TUE**  DETERMINING THE USABILITY OF THE PEDIATRIC THROMBOSIS EDUCATIONAL TOOL (P-TET) IN CHILDREN RECEIVING ANTICOAGULATION THERAPY
Madeline I. Montoya*, Leonardo Brandao, Frederica Cassis, Jennifer Stinson, Jorge Carneiro (Canada)

**PO431-TUE**  RARE LABORATORY PRESENTATION OF TYPE IIB VON WILLEBRAND’S DISEASE IN A 6 YEAR OLD BOY.
Irene E. Regan*, Marie Lyons, Michelle O’Rourke, Brian Philbin, Vince Jenkins, Beatrice Nolan (Ireland)

**PO432-TUE**  SYNERGISTIC EFFECT OF ELEVATED LIPOPROTEIN (A) LEVELS WITH INHERITED THROMBOPHILIA RISK FACTORS IN CHILDREN WITH ARTERIAL ISCHEMIC STROKE
Desiree Coen Henak*, Jasna Lenicek Krlcea, Renata Zinski Topic, Margareta Radonic, Ivana Horvat, Marija Milos, Vlasta Djuranovic, Renata Zadrio (Croatia)

**PO433-TUE**  THE ROLE OF FVR2 POLYMORPHISM IN CHILDREN CARRIERS OF FVL-LEIDEN
Zoey Kapsimali*, Helen Pergantou, Anna Komitopoulou, Helen Platokouki (Greece)

**PO434-TUE**  WHOLE BLOOD THROMBOELASTOMETRY (ROTEM®) PROFILES IN CHILDREN WITH CYANOTIC CONGENITAL HEART DISEASES UNDERGOING CARDIAC SURGERY
Luca Spezia*, Vladimir Vida, Giacomo Bortolussi, Marta Marchetti, Elena Campello, Demetrio Pittarello, Guido Di Gregorio, Giovanni Stellini, Paolo Simion (Italy)

**PO435-TUE**  INCIDENCE RATE AND RISK FACTORS OF VENOUS THROMBOEMBOLISM IN CHILDREN WITH UNDEFINED BLEEDING DISORDERS
MacGregor Steele*, Sheri VanGunst, Leah Odlaman, Man-Chiu Poon, Shannon Jackson (Canada)

**PO436-TUE**  BENIGN JOINT HYPERMOBILITY SYNDROME IS PREVALENT IN CHILDREN WITH UNDEFINED BLEEDING DISORDERS
MacGregor Steele*, Sheri VanGunst, Leah Odlaman, Man-Chiu Poon, Shannon Jackson (Canada)

**PO437-TUE**  THE IMPACT OF SERUM BILE ACID LEVELS ON THE MRNA EXPRESSION OF PRO- AND ANTICOAGULANT PROTEINS IN LIVER TISSUE.
Maria Magnusson*, Cecilia Gälman, Björn Fischler, Eva Beijer, Henrik Arnell, Antal Németh, Gösta Eggertsen (Sweden)

---

**POSTERS**

**TUESDAY**

**PO424-TUE**  THIOREDOXIN REDUCTASE PROTECTS PLATELETS FROM CELL DEATH
Matthew T. Harper* (United Kingdom)

**PO425-TUE**  A NOVEL MUTATION IN NBEAL2 GENE CAUSING GRAY PLATELET SYNDROME
Lijuan Cao*, Zhaoyue Wang, Xia Bai, Jiaming Li, Lijun Xia, Changgeng Ruan (China)

**PO426-TUE**  VALIDATION OF THE SELF-PBQ (SELF-ADMINISTERED PEDIATRIC BLEEDING QUESTIONNAIRE) AS A SCREENING TOOL FOR A NEW DIAGNOSIS OF VON WILLEBRAND DISEASE (VWD)
Angie Tuttle*, Julie Grabell, Steven Bae, Paul Moorehead, Victor Blanchette, John Wu, MacGregor Steele, Robert Klaassen, Mariana Silva, Margaret Rand, Paula James (Canada)

**PO427-TUE**  FAMILY HISTORY OF VENOUS THROMBOEMBOLISM IN THE PEDIATRIC POPULATION: THE NEED FOR A STANDARDIZED DEFINITION
Anna Hau, Eric Wegener*, Paul Monagle, Shoshana Revel-Vilk, Vera Ignjatovic (Australia)

**PO428-TUE**  INITIAL DOSE OF ENOXAPARIN IN NEONATES WITH THROMBOSIS
Mirta Hepner*, Gabriela Sciuccati, Carolina Cervio, Graciela Pieroni, Silvina Annetta, Diana Farinha, Juan Frontroth, Lilian Diaz, Aurora Felu Torres, Mariana Bonduel (Argentina)

**PO429-TUE**  SKIN NECROSIS AND PURPURA FULMINANS IN CHILDREN WITH AND WITHOUT THROMBOPHILIA - A TERTIARY CENTER’S EXPERIENCE
Yariv Fruchtman*, Tzipora Strauss, Marina Rubinstein, Miriam Ben Harosh, Shoshana Revel-Vilk, Joseph Kapelushnik, Gideon Pare, Gil Kenet (Israel)

**PO430-TUE**  INCIDENCE RATE AND RISK FACTORS OF VENOUS THROMBOEMBOLISM IN ASIAN PEDIATRIC ONCOLOGY PATIENTS.
Wai Ming Mendy Ong*, Koon Mian Foo, Joyce Ching Mei Lam, Mei Yi Loke (Singapore)

**PO431-TUE**  THE INCIDENCE OF DEEP VEIN THROMBOSIS IN CHILDREN WITH CYANOTIC CONGENITAL HEART DISEASES UNDERGOING CARDIAC SURGERY
Luca Spezia*, Vladimir Vida, Giacomo Bortolussi, Marta Marchetti, Elena Campello, Demetrio Pittarello, Guido Di Gregorio, Giovanni Stellini, Paolo Simion (Italy)

**PO432-TUE**  THE INFECTION OF SERUM BILE ACID LEVELS ON THE MRNA EXPRESSION OF PRO- AND ANTICOAGULANT PROTEINS IN LIVER TISSUE.
Maria Magnusson*, Cecilia Gälman, Björn Fischler, Eva Beijer, Henrik Arnell, Antal Németh, Gösta Eggertsen (Sweden)
SCIENTIFIC PROGRAM

PO444-TUE THROMBOMODULIN GENE ANALYSIS IN A CASE OF ATYPICAL HEMOLYTIC-UREMIC SYNDROME
Vilalta Noelia*, Tirado Isabel, Mateo Jose, Coll Immaculada, Cuevas Biel, López-Pardo Jordi, Fraga Gloria, Brío Sonia, Souto Juan Carlos, Martinez-Sánchez Elisabet, Fontcuberta Jordi (Spain)

PO445-TUE CLINICAL CHARACTERIZATION OF VENOUS THROMBOEMBOLISM IN CHILDHOOD AT A TERTIARY LEVEL HOSPITAL
Laura L. Andreoni*, Verónica Pons, Pavel Olivera, Carlos Chavez, Vicente Cortina, Ana Marin, Francesc Bosch, Amparo Santamaría (Spain)

PO446-TUE LET'S CUT TO THE BONE: RISK FACTORS OF VENOUS THROMBOEMBOLISM IN CHILDREN WITH MUSCULOSKELETAL INFECTIONS
Rungrote Natesrinilkul*, Suzan Williams, Upton Allen, Leonardo Brandao (Canada)

PO447-TUE FEASIBILITY AND SAFETY OF ENOXAPARIN WHOLE MILLIGRAM DOSING IN PREMATURE AND TERM NEONATES
Rebecca Goldsmith*, Anthony Chan, Mihir Bhatt (Canada)

Platelets and cancer

PO448-TUE IMMUNOPHENOTYPIC EXPRESSON OF PLATELETS IN MYELODYSPLASTIC SYNDROME
Yi-Feng Wu*, Chao-Zong Liu (Taiwan)

PO449-TUE RECURSIVE PARTITIONING WITH AMALGAMATION ANALYSIS OF CANCER SPECIFIC BIOMARKERS IN THE PREDICTION OF CANCER ASSOCIATED THROMBOSIS.
Alfonso Tafur*, George Dale, Aaron Mansfield, Mohamad Cherry, Philip Comp, Suman Rathbun, Julie Stoner (United States)

PO450-TUE CANCER CELLS INDUCE THE RELEASE OF MICROPARTICLES FROM HUMAN PLATELETS
Gianni F. Guidetti*, Ilaria Canobbio, Daria Manganaro, Marta Zarà, Caterina Visconte, Mauro Torli (Italy)

PO451-TUE THE EFFECTS OF INTERFERON-α-2B ON THE DEFECTIVE BONE MARROW MESENCHYMAL STEM CELLS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
Tiantian Sun*, Cuicui Lv, Donglei Zhang, Xian Zhang, Rongfeng Fu, Mingen Lv, Wenjie Liu, Yating Hao, Huiyuan Li, Renchi Yang, Lei Zhang (China)

Regulation of coagulation and fibrinolysis

PO452-TUE SUNITINIB IS TAKEN UP BY PLATELETS AND INHIBITS PLATELET ACTIVATION AND THROMBUS FORMATION IN CANCER PATIENTS
Siamack Sabrkhany, Sharo Pineda, Linda Sanders, Maureen Aarts, Johan Heemskerk, Arjan Griffioen, Mirjam ode Egbrink, Marijke J. Kuijpers* (The Netherlands)

PO453-TUE ALLELIC VARIANTS WITHIN ANX5 DIFFERENTIALLY IMPACT ON THE CONTROL OF GENE EXPRESSION
Giovanni Tiscia*, Per Morten Sandset, Elisabeth Drørum, Christiane Myklebust, Elvira Grandone, Grethe Skretting (Italy)

PO454-TUE IMPROVEMENT IN THROMBIN GENERATION BY THE ANTI-TFPI ANTIBODY, CONCIZUMAB, IN PLASMA FROM INDIVIDUALS WITH HAEMOPHILIA A WITH OR WITHOUT INHIBITORS OR HAEMOPHILIA B, IS NOT AFFECTED BY THE PRESENCE OF CORN TRYPsin INHIBITOR
Emily K. Waters*, Ida Hilden, Supreet Dhillon, Catherine Rea, Brit Sørensen (Denmark)

PO455-TUE CHARACTERIZATION OF PRO-COAGULANT ANTIBODIES BINDING TO KUNITZ DOMAIN-1 OF TFPI

PO456-TUE THE EFFECT OF ULTRA HIGH LEVELS OF C-REACTIVE PROTEIN (CRP) ON THE COAGULATION SYSTEM
Ramin Artag*, Daniel Anderson, Jørn Dalsgaard Nielsen (United States)

PO457-TUE ASSESSMENT OF THE EFFECT OF INTER-ALPHA TRYPSIN INHIBITOR BY THROMBIN GENERATION ASSAY
Jean-Luc Plantier*, Véronique Devos, Sami Chhourou, Sylvie Jorieux (France)

PO458-TUE PROLONGATION OF CLOT LYSIS TIME BY A DIRECT THROMBIN INHIBITOR: INVOLVEMENT OF THROMBIN GENERATION ENHANCEMENT AND THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR
Yoshiyuki Morishita*, Chikako Kamisato (Japan)

PO459-TUE ORAL FACTOR XA ANTICOAGULANTS, RIVAROXABAN AND APIXABAN, ENHANCE CLOT DISSOLUTION IN PLASMA
Rolinda L. Carter*, Kimberly Talbot, Tyler Smith, Agnes Lee, Edward Prydzial (Canada)

PO460-TUE ULTRASONIC MONITORING OF FIBRIN CLOT FORMATION AND FIBRINOLYSIS IN FLOWING BLOOD
Konstantin G. Gvishua*, Shakhla Dzhuamaeva, Dmitriy Ivlev, Svetlana Uzlova, Georgy Gvishua (Russia)

PO461-TUE A NOVEL APPROACH FOR HEMOPHILIA THERAPY THROUGH ANTIBODY TARGETED TFPI
Sumin Lee*, Kim Su, Sook Lim, Heechun Kwak, Migunlee Lee, Jae Chan Park, Young Seoub Park, Young-Kwon Lim, SungHo Hwang (South Korea)

PO462-TUE FUNCTIONAL COMPONENTS OF JAPANESE TRADITIONAL SOYBEAN FOOD “NATTO” – NATTOKINASE, VITAMIN K2 AND POLYAMIN
Hiroyuki Sumi*, Tadanori Ohsugi, Sawa Naito, Chieko Yatagai (Japan)

PO463-TUE FIBRINOLYTIC ACTIVITY PRODUCED BY FERMENTED SWEET CORN WITH BACILLUS SUBTILIS NATTO
Hiroyuki Sumi*, Sawa Naito, Chieko Yatagai (Japan)

PO464-TUE INHIBITION OF FIBRINOLYSIS BY HEPARIN, LOW MOLECULAR WEIGHT HEPARIN AND A NOVEL ANTICOAGULANT, ANTI-TFPI-PDGRF COVALENT COMPLEX (ATH)
Gabriela Chang*, Helen Atkinson, Leslie Berry, Anthony Chan (Canada)

PO465-TUE COMPLEMENT C3 AND HYPOFIBRINOLYSIS: A POTENTIAL ROLE FOR PROTEIN GLYCACTION
Katharina Schuett, Rhodi King*, Fladia Phoenix, Kerrie Smith, Sebastian Maxine, Katharina Lysaja, Vera Jankowski, Nikolaus Marx, Ramzi Ajjan (Germany)
THE ARTERIOVENOUS DIFFERENCE OF HEMOSTASIS PARAMETERS IN CRITICALLY ILL PATIENTS WITH DIFFERENT TYPE OF HYPOERGOSIS
Sergei Sinkov*, Igor Zabolotskikh, Denis Velichko, Sergei Grigoriev (Russian Federation)

EFFECTS OF AN ACIDIC ENVIRONMENT ON COAGULATION DYNAMICS
Matthew Gissel*, Thomas Orfeo, Saulius Butenas, Anthony Pusateri, Kathleen Brummet-Ziedins, Kenneth Mann (United States)

EXERCISE-INDUCED CORE BODY TEMPERATURE ELEVATIONS SHIFT HEMOSTASIS TO A PROTHROMBOTIC STATE
Waander Van Heerde*, Matthijs Veltmeijer, Wiedeke Barteling, Kitty Verbeek-Knobbe, Thijs Eijsoygelis, Maria Hopman (The Netherlands)

IN VITRO INTERACTIONS OF SUGAMMADEX WITH VARIOUS ANTICOAGULANTS
Annelieke C. Kruithof*, Cornelis Kluit, Pieter-Jan de Kam, Ria Laterveer, Matthijs Moerland, Jacobus Burggraaf (The Netherlands)

COAGULOPATHY AND OSMOLAR GAP IN CRITICALLY ILL PATIENTS: AN INTIMATE RELATIONSHIP
Vladimir Sukhanov*, Olga Petrova, Alexander Levit (Russian Federation)

NET AND NEUTROPHIL INDUCED THROMBIN GENERATION
Jaewoo Song*, Eun-Young Lee, Rojin Park, Ye-Jin Song, Yun A Jo, Jongha Yoo (Korea, Republic of)

MATERNAL DEATH AND VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS ADMITTED IN A MATERNITY OF HIGH RISK: RESULTS PRE AND POST APPLICATION OF A RISK SCORE.
Roberta Santos*, Venina Barros, Ana Igai, Rossana Francisco, Marcelo Zugaib (Brazil)

A COMMON GENETIC BACKGROUND SHARED BY WOMEN WITH HISTORY OF ADVERSE PREGNANCY OUTCOMES AND CARDIOVASCULAR DISEASE: A WINDOW TO FUTURE CARDIOVASCULAR RISK.
Ilaria Romagnuolo*, Elena Sticchi, Elisa Grifoni, Maddalena Pazzi, Agatina Alessandrello Liotta, Raffaella Priora, Monica Attanasio, Rosanna Abbate, Cinzia Fatini (Italy)

POLYMORPHISMS IN TUMOR NECROSIS FACTOR-ALPHA (-863C>A, -857C>T AND +488G>A) ARE ASSOCIATED WITH IDIOPATHIC RECURRENT PREGNANCY LOSS IN KOREAN WOMEN
Hui Jeong An*, Jung O Kim, Hye Geun Jang, Gun Ho Choi, Kim Han Ho, Ji Hyang Kim, Nam Keun Kim (Korea, Republic of)

THE IMPACT OF MODE OF DELIVERY AND POSTPARTUM THROMBOPHYLAXIS ON ROTATIONAL THROMBOELASTOMETRY (ROTEM) IN PREGNANT WOMEN WITH A HIGH RISK OF POSTPARTUM VENOUS THROMBOEMBOLISM.
Boriana Guimicheva*, Lara Roberts, Jignesh Patel, Devi Subramanaian, Roopen Arya (United Kingdom)

RETROSPECTIVE STUDY OF PATIENTS WHO WERE TREATED WITH FONDAPARINUX PRE-, PERI- AND/OR POSTPARTUM FOR PROPHYLAXIS OR TREATMENT OF VENOUS THROMBOEMBOLISM (FONDAPP).
Carl-Erik Dempfle*, Juergen Koscielny, Edelgard Lindhoff-Last, Johannes Oldenburg, Hartmut Pollmann, Guenther Kappert, Ute Scholz, Stefan Kroppf, Sonja Eberle, Andreas Heinken (Germany)

ROTATIONAL THROMBOELASTOMETRY IN PREGNANCY AND ITS ROLE IN ASSESSMENT OF HAEMOSTASIS IN WOMEN WITH FACTOR XI DEFICIENCY.
Joanna Davies*, Rezan Kadir (United Kingdom)

THROMBIN GENERATION IN WOMEN UNDERGOING IVF TREATMENT IS PROLONGED, BUT NOT ENHANCED COMPARED TO CONTROLS.
Roza Chaireti*, Katarina Bromme (Sweden)

LOW-MOLECULAR –WEIGHT HEPARIN IN PREGNANCIES AFTER ART -A RANDOMIZED STUDY.
Corrado Lodigiani*, Paola Ferrazzi, Luca Libè, Elena Banfi, Luca Cafaro, Manuela Morenghi, Monica Demarco, Ilaria Quaglia, Paolo Levi-Setti (Italy)

EFFECTS OF SILDENAFIL CITRATE ON COAGULATION PROCESS DURING PREGNANCY: A PROMISING THERAPEUTIC APPROACH IN COMBINATION WITH LOW MOLECULAR WEIGHT HEPARIN FOR RECURRENT PREGNANCY LOSS.
Rayana Luna*, Christina Peixoto, Anne Croy, Maha Othman (Brazil, Canada)
PO485-TUE  A RISK SCORE FOR PREDICTION OF RECURRENT IN PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM (DAMOVES)
Ana Isabel Franco Moreno*, María José García Navarro, Judith Ortiz Sánchez, Rosa María Martín Díaz, Elena Madroñal Cerezo, Cristina Lucía de Ancos Aracil, Victoria Martínez Díaz, Alejandra Gimeno García, Carmen Montero Hernández, Sari Arponen, Noemi Cabello Clotet, José Manuel Ruiz Giardín (Spain)

PO486-TUE  ANALYSIS OF PROTHROMBIN MUTANTS IN Na+ BINDING DOMAIN AS A POTENTIAL CANDIDATE CONVEYING ANTITHROMBIN RESISTANCE
Moe Murata*, Naoki Mizutani, Yuki Takagi, Ryo Hasebe, Toshihiro Kozuka, Yukiko Nakata, Akira Takagi, Tetsuhiro Kojima (Japan)

PO487-TUE  ORAL ANTICOAGULANT THERAPY FOR THE PREVENTION OF RECURRENT THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA

PO488-TUE  ACSF2 EXPRESSION AND RISK OF RECURRENT AFTER A FIRST UNPROVOKED DEEP VENOUS THROMBOSIS EVENT. RESULTS FROM THE RETRO STUDY
Ramón Lecumberri*, Ramón Montes, Elisabeth Guruceaga, José González-Porras, Joan Reverter, Pascual Marco, Elena Pina, Javier Trujillo, Ángel Bernardo, Pilar Llamas, Alicia Lorenzo, Carmen Fernández-Capitán, David Jiménez, Ana Alfonso, José Páramo, José Hermida (Spain)

PO489-TUE  PROSPECTIVE OBSERVATIONAL STUDY ON INCIDENCE OF VENOUS THROMBOEMBOLISM IN MEDICALLY-ILL HOSPITALIZED ELDERLY PATIENTS
Jeong-Ok Lee*, Jin Won Kim, Se Hyun Kim, Jung Joon Kim, Hee Hyun Kim, Hwi-Joong Yoon, Soo-Mee Bang (Korea, Republic Of)

PO490-TUE  INHERITED PROTHROMBOTIC RISK FACTORS IN CHILDREN WITH INTRACRANIAL VENOUS THROMBOSIS: SINGLE CENTER EXPERIENCE IN TURKEY
Turkan Paticoglu*, Gonca Koc, Mehmet Canpolat, Ekrem Unal, Selim Doganay, Musa Karakulcu, Mehmet Ozdemir (Turkey)

PO491-TUE  THROMBOPROPHYLAXIS SKIPPED DOSES IN HOSPITALIZED PATIENTS. CAN WE RECOGNIZE WHICH ARE THE CAUSES OR FACTORS?
Alicia Beatriz Vilaseca*, Rubén Barbera, Jimena Bonadeo, Nadia Kujla, Adriana Lopez (Argentina)

PO492-TUE  IDENTIFICATION OF A NOVEL HOMOZYGOUS MUTATION RESPONSIBLE FOR TYPE II (R.S169F) ANTITHROMBIN DEFICIENCY
Ying Y. Wu*, Liang Tang, Wei Zeng, Yu Hu (China)

PO493-TUE  IMPACT OF INHERITED RISK FACTORS OF VENOUS THROMBOEMBOLISM (VTE) ON THE ASSOCIATIONS BETWEEN RED CELL DISTRIBUTION WIDTH AND RISK OF VTE.
Trygve Ellingsen*, Jostein Lappegård, Erinn Smith, Tom Wilsgaaard, Sigrid Brakkenn, Terry Solomon, Kelly Frazer, John-Bjarne Hansen (Norway)

PO494-TUE  IMPACT OF INHERITED RISK FACTORS OF VENOUS THROMBOSIS ON RISK OF STROKE AND VTE IN ATRIAL FIBRILLATION
Ina Rye-Holmboe*, Erinn Smith, Erinn Haid, Anders Vik, Ellen Brodin, Sigrid Brakkenn, Terry Solomon, Tom Wilsgaaard, Frits Rosendaal, Kelly Frazer, John Bjarne Hansen (Norway)

PO495-TUE  IMPACT OF THE FIBRINOGEN GAMMA GENE RS206685 VARIANT ON THE RISK OF VENOUS THROMBOSIS IN CANCER PATIENTS
Olga Dziewiecka*, Erinn Smith, Sigrid Brakkenn, Hilde Jensvoll, Kristine Blix, Terry Solomon, Tom Wilsgaaard, Frits Rosendaal, Kelly Frazer, John Bjarne Hansen (Norway)

PO496-TUE  CHARACTERISTICS OF HOSPITAL-ASSOCIATED THROMBOSIS ATTRIBUTED TO THROMBOPROPHYLAXIS FAILURE
Lara Roberts, Emma Gee*, Gayle Mulla, Cara Doyle, Melanie Ferreira, Jig Patel, Raj Patel, Roopen Arya (United Kingdom)

PO497-TUE  ANTI-VIMENTIN ANTIBodies INCREASE THROMBUS FORMATION AT VENOUS SHEAR RATES IN VITRO AND IN VIVO: IMPLICATION FOR VENOUS THROMBOEMBOLISM IN AUTOIMMUNE DISEASES
Qi Da, Rolando Rumbaut, Miguel Cruz* (United States)

PO498-TUE  SWITCHING TYPE OF ORAL CONTRACEPTIVE AND RISK OF VENOUS THROMBOEMBOLISM: A CASE-CROSSOVER STUDY
Luuk Scheres*, Willem Lifering, Astrid van Hylckama Vlieg, Saskia Middeldorp, Suzanne Caneegieter (The Netherlands)

PO499-TUE  "FORGOTTEN NO MORE" – A CASE OF A 54 YEAR OLD FEMALE WITH LEMIERRE’S SYNDROME
Edward Gacrama* (Philippines)

PO500-TUE  PREAVELANCE OF RISK FACTORS PREDISPOSING TO THROMBOSIS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION
Jerzy Dropinski*, Agnieszka Kubicka-Trzaska, Teresa Domagala, Marek Sanak, Teresa Iwancie, Jacek Musial (Poland)

PO501-TUE  NO DIFFERENCES IN THROMBIN GENERATION BETWEEN PATIENTS WITH AND WITHOUT PORTAL VEIN THROMBOSIS IN END-STAGE LIVER DISEASE
Dana R. Tomescu*, Mihai Popescu, Carmen Orban, Lavinia Jipa, Irinel Popescu (Romania)

PO502-TUE  ENDOGENOUS SEX HORMONE LEVELS IN MEN WITH UNPROVOKED DEEP VEIN THROMBOSIS
Nicola Mumoli*, Marco Cei, Barbara Brondi, Matteo Giorgi Pierfranceschi, José Vitale, Francesco Dentali (Italy)
**SCIENTIFIC PROGRAM**

**PO503-TUE**  
**A-FIBRINOGEN THR312ALA POLYMORPHISM IS AN INDEPENDENT GENETIC RISK FACTOR FOR VENOUS THROMBOEMBOLISM IN THE POPULATION OF NORTH-WESTERN RUSSIA**  
Sergey Kapustin*, Anna Demyanenko, Veronika Shmeleva, Vitaly Soldatenkov, Pavel Chechulov, Viktor Kargin, Lyudmila Papayan (Russian Federation)

**PO504-TUE**  
**VENOUS THROMBOEMBOLISM (VTE) IN HOSPITALISED NON-SURGICAL CANCER PATIENTS AND ITS BURDEN ON HEALTHCARE IN AN ASIAN TERTIARY HOSPITAL**  
Lai Heng Lee*, Arul Earnest, Jeffrey Hui, Yong Yang (Singapore)

**PO505-TUE**  
**A NOVEL MICROFLUIDIC DEVICE DEVELOPMENT FOR VENOUS THROMBUS UNDERSTANDING**  
Naoko Sugita*, Hiroyuki Himeura, Kyo Inoue, Kaoru Koike, Toshiya Murai (Japan)

**PO506-TUE**  
**ANTICOAGULANTS FOR PREVENTION OF THROMBOTIC COMPLICATIONS IN PATIENTS ON PARENTERAL NUTRITION: A SYSTEMATIC REVIEW.**  
Stefano L. Barco*, Jasper Atema, Michiel Coppens, Mireille Serlie, Saskia Middeldorp (The Netherlands)

**PO507-TUE**  
**LONG-TERM PARENTERAL NUTRITION-ASSOCIATED THROMBOEMBOLIC AND HEMORRHAGIC COMPLICATIONS IN 236 SINGLE-CENTER OUTPATIENTS.**  
Stefano L. Barco*, Michiel Coppens, Caroline Heuschen, Bram Salman, Marjolein Brekelmans, Mireille Serlie, Saskia Middeldorp (The Netherlands)

**PO508-TUE**  
**ROLE OF BODY COMPOSITION MEASUREMENTS IN PREDICTING CANCER ASSOCIATED THROMBOSIS**  
Omer Itifikh, Federico Silva, Aaron Mansfield, Mohammad Cherry, Alfonso Taur* (United States)

**PO508.1-TUE**  
**A NOVEL RS2232710 SINGLE NUCLEOTIDE VARIANT IN THE PROTEIN Z-DEPENDENT PROTEASE INHIBITOR (ZPI, SERPINA10) GENE AND A RISK OF DEEP VEIN THROMBOSIS**  
Marcin M. Gorski*, Luca A. Lotta, Hugoline de Haan, Astrid van Hylckama Vlieg, Serena Passamonti, Paolo Bucciarelli, Emanuela Pappalardo, Marco Boscarino, Richard A. Gibbs, Ida Martinelli, Flora Peyvandi (Italy)

**PO509-TUE**  
**UROKINASE PLASMINOGEN ACTIVATOR PROTECTS CARDIAC MYOCYTES FROM OXIDATIVE DAMAGE AND APOPTOSIS VIA OGG1**  
Philipp Hohensinner*, Nikol Taaks, Christoph Kaun, Stefan Pfaffenberger, Konstantin Krychtiuk, Arezu Aliabadi, Andreas Zuckermann, Gerald Maurer, Kurt Huber, Johann Wolja (Austria)

**PO510-TUE**  
**FACTOR VII ACTIVATING PROTEASE (FSAP) EXPRESSION IS NEGATIVELY REGULATED BY TRANSFORMING GROWTH FACTOR-BETA (TGF-ß) IN THE LIVER.**  
Sebastian Seidl*, Silke Leiting, Lars Muhl, Sandip Kanse (Norway)

**PO511-TUE**  
**PHOSPHATIDYLINOSITOL-3,4,5-TRISPHOSPHATE STIMULATES CA2+ ELEVATION AND AKT PHOSPHORYLATION TO CONSTITUTE A MAJOR MECHANISM OF THROMBOXANE A2 FORMATION IN HUMAN PLATELETS.**  
Kalwant S. Auth*, Nick Kassouf, Archana Ambily, Stephanie Watson, Sheila Hassock, Harmeet Auth, Steve Watson (United Kingdom)

**PO512-TUE**  
**A SYSTEMS BIOLOGY MODEL FOR THE COAGULATION NETWORK DESCRIBES BIOMARKER CHANGES OBSERVED IN A CLINICAL STUDY WITH FVIIA VARIANT**  
Dooyoung Lee, Satoshi Nakayama, Steven Arkin, Steven Martin, Anne Heatherington, Paolo Vicini, Fei Hua* (United States)

**PO513-TUE**  
**IMPORTANCE OF TRANSFORMING GROWTH FACTOR BETA-INDUCED SIGNALING FOR CHRONIC POSTTHROMBOTIC VASCULAR REMODELING PROCESSES**  
Katrin Schäfer, Magdalena L. Bochenek*, Nico Rosinus, Eva Schütz, Mareike Lankel, Markus Bosmann, Eckard Mayer, Thomas Münzel, Stavros Konstantinides (Germany)

**PO514-TUE**  
**ROLE OF P110ALPHA ISOFORM OF CLASS I PI3-KINASES IN PLATELET ACTIVATION AND FUNCTIONS**  
Pierre-Alexandre Laurent, Sonia Séverin, Béatrice Hechler, Gaëtan Chicanne, Anne-Dominique Terrisse, Gchet Christian, Bart Vanhaesebroeck, Bernard Payrastre, Marie-Pierre Gratacap* (France)

**Stroke**

**PO515-TUE**  
**EVALUATION OF THE THERAPEUTIC EFFECT OF NOVEL STROKE DRUG SMTP-7 ON EMBOLIC STROKE IN MONKEYS**  
Eriko Suzuki*, Yudai Kunikyo, Naoki Matsumoto, Hironobu Sawada, Naoko Nishimura, Keiko Hasegawa, Keiji Hasumi (Japan)

**PO516-TUE**  
**THE ASSOCIATION OF FACTOR VIII AND VON WILLEBRAND FACTOR LEVELS AND THE OUTCOME OF THROMBOLYSIS IN ISCHEMIC STROKE PATIENTS**  
Noemi Klara Toth*, Edina Székely, Katalin Kovács, László Csiba, László Muszbek, Zsuzsa Bagoly (Hungary)

**PO517-TUE**  
**ADAMTS13 DESTABILIZES THROMBI IN A MOUSE MODEL OF THROMBOTIC FOCAL CEREBRAL ISCHEMIA**  
Frederik Denorme*, Friederike Langhauser, Hanspeter Rottensteiner, Barbara Plaimauer, Friedrich Scheiffinger, Christoph Kleinschnitz, Karen Vanhoorelbeke, Simon De Meyer (Belgium)

**PO518-TUE**  
**REMOTE PLATELET FUNCTION TESTING USING MEASUREMENTS OF P-SELECTIN IN PATIENTS WITH ACUTE STROKE OR TIA ALREADY RECEIVING TREATMENT WITH ANTIPLATELET AGENTS**  
Stan Heptinstall*, Natalia Dovlatova, Jane May, Katie Robson, Philip Bath (United Kingdom)

**PO519-TUE**  
**INHIBITION OF TAFI AND PAI-1 IS PROTECTIVE IN A MOUSE MODEL OF CEREBRAL ISCHEMIA/REPERFUSION INJURY**  
Frederik Denorme*, Tine Wyseure, Miet Peeters, Ann Gilis, Paul Declerck, Simon De Meyer (Belgium)
PO520-TUE  A FACTOR XA VARIANT IMPROVES HEMOSTASIS MODELS OF INTRACRANIAL HEMORRHAGE  
Reema Jasuja, Rodney Camire, Steven Arkin, Debra Pittman* (United States)

PO521-TUE  GENETIC ABLATION OF EXTRA DOMAIN A OF CELLULAR FIBRONECTIN PROTECTS HYPERCHOLESTEROLEMIC MICE FROM ACUTE STROKE BY REDUCING THROMBO-INFLAMMATION  
Nirav Dhanesha, Ajmal Ahmad, Prem Prakash, Prakash Doppapattar, Steven Lentz, Anil Chauhan* (United States)

PO522-TUE  EFFECTS OF THE MAIN ACTIVE COMPONENT COMBINATION BETWEEN ASTRAGALUS AND PANAX NOTOGINSENG ON INFLAMMATION AND APOPTOSIS OF NERVE CELL AFTER CEREBRAL ISCHEMIA-REPERFUSION  
Chang-Qing Deng*, Xiao-Ping Huang, Huang Ding, Jin-Dong Lu, Ying-Hong Tang, Bing-Xiang Deng (China)

PO523-TUE  THE ANGIOTENSIN-CONVERTING ENZYME GENE INSERTION/DELETION POLYMORPHISM IS ASSOCIATED WITH INCREASED RISK FOR ISCHEMIC STROKE BUT NOT FOR MYOCARDIAL INFARCTION IN YOUNG MEXICAN POPULATION  
Iurma Isordia-Salas*, Rosa Maria Jiménez-Alvarado, Lorena Mendoza-Valdés, José Antonio Alvarado-Moreno, David Santiago-Germán, María Valades-Mejía, Jesús Hernández-Juárez, Abraham Majluf-Cruz (Mexico)

PO524-TUE  THROMBOELASTOMETRY (ROTEM®) PROFILES IN PATIENTS UNDERGOING THROMBOLYTIC THERAPY FOR ACUTE ISCHEMIC STROKE  
Elena Campello*, Filippo Farina, Luca Spiezia, Anna Palmieri, Sara Marracci, Letizia Banzato, Fabio Dalla Valle, Claudio Baracchini, Paolo Simioni (Italy)

PO525-TUE  SEVERE OBESITY IS A RISK FACTOR FOR CEREBRAL VENOUS THROMBOSIS: A CASE-CONTROL STUDY  
Jonathan M. Coutinho*, Susanna Zuurbier, Anne Broeg-Morvay, Mirjam Heldner, Frits Rosendaal, Saskia Middeldorp, Suzanne Canneugieter (The Netherlands)

PO526-TUE  LIGHT-SHEET FLUORESCENCE MICROSCOPY OF THE ACUTELY ISCHEMIC BRAIN REVEALS DRAMATICALLY REDUCED THROMBOTIC ACTIVITY IN T-CELL DEFICIENT MICE  
David Stegner*, Mari Gureishivi, Judith van Eeuwijk, Oguzhan Angay, Jürgen Pinnemeier, Michael Schuhmann, Mike Friedrich, Guido Stoll, Katrin Heinze, Bernhard Nieswandt (Germany)

PO527-TUE  THE ALTERATION OF IRON TRANSMEMBRANE PROTEINS EXPRESSION IN THE RAT HIPPOCAMPUS FOLLOWING FOCAL CEREBRAL ISCHEMIA  
Jun Liao*, Shaowu Cheng, Jinwen Ge (China)

PO528-TUE  NONCLINICAL AND CLINICAL DEVELOPMENT OF TMS-007, A MEMBER OF THE ANTI-INFLAMMATORY SMALL-MOLECULE THROMBOLYTIC SMTPS  
Keiji Hasumi*, Naoko Nishimura, Keiko Hasegawa, Hironobu Sawada, Eriko Suzuki (Japan)

PO529-TUE  ANTITHROMBIN LEVELS IN ADULT STROKE PATIENTS AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL  
Omolade A. Awodu*, Oluomachi Nnachi (Nigeria)

PO530-TUE  CLOPIDOGREL RESISTANCE AFTER MINOR ISCHEMIC STROKE OR TIA IS ASSOCIATED TO PRE-DIABETES, HYPERTENSION AND CEREBRAL MICROANGIOPATHY  
Annika Lundström*, Ann Charlotte Laska, Bruna Gigante, Magnus von Arbin, Gun Jönnestad, Evalds Laurencikas, Karin Hög Dembrower, Håkan Wallén (Sweden)

PO531-TUE  ASSOCIATION BETWEEN POLYMORPHISMS IN MICRORNA MACHINERY GENES (Dicer1, Drosha, Ran, and Xpo5) AND ISCHEMIC STROKE  
Hui Jeong An*, Jung O Kim, Hye Gyun Bang, Gun Ho Choi, Ki Han Ko, Ok Joon Kim, Nam Reum Kim (Korea, Republic of)

PO532-TUE  THROMBOLYSIS USING N-ACETYLCYSTEINE IN ACUTE ISCHEMIC STROKE  
Maxime Gauberti*, Sara Martínez de Lizarrondo, Clément Gakuba, Denis Vivien (France)

PO533-TUE  MULTIPLE MENINGIOMAS DOES NOT INCREASE THE RISK OF INTRACRANIAL HEMORRHAGE AFTER INTRAVENOUS THROMBOLYSIS FOR ACUTE ISCHEMIC STROKE  
Navdeep Lail*, Aashtan Mworia, Karanbir Singh, Sandhya Mehta, Peyman Shiri (United States)

PO534-TUE  PATENT FORAMEN OVALE IN PATIENTS WITH PREVIOUS CEREBRAL ISCHEMIC EVENTS: ECHOCARDIOGRAPHIC FEATURES AND RELATIONSHIPS WITH TRANSCRANIAL DOPPLER  
Paola Ierano, Antonella Tufano*, Roberta Esposito, Ciro Santoro, Francesco De Stefano, Anna Maria Cerbone, Giovanni Di Minno, Giovanni de Simone, Maurizio Galderisi (Italy)

PO535-TUE  HEMORHEOLOGY AND HEMOSTASIS IN ISCHEMIC STROKE PATIENTS TREATED WITH I.V. THROMBOLYSIS  
Marina Gafarov*, Maxim Domashenko, Marina Maximova, Mark Loskutnikov, Daria Korobkova, Alla Shabalin, Marina Kostyrev, Rodion Konovalov (Russian Federation)

PO536-TUE  ALTERED FIBRIN CLOT STRUCTURE/FUNCTION IN PATIENTS WITH CEREBRAL SINUS VENOUS THROMBOSIS AND THE RISK OF RECURRENCE  
Jakub Siudut*, Michał Zabczyk, Anetta Undas (Poland)

PO537-TUE  THE NOVEL BIASED AGONIST FOR PAR-1 PROTECTS BRAIN CELLS FROM TOXICITY SIMILAR TO ACTIVATED PROTEIN C  
Liubov Gorbacheva*, Irina Savinkova, Svetlana Strukova (Russian Federation)

PO538-TUE  ROLE OF GENETIC POLYMORPHISMS OF HAEMOSTASIS’S SYSTEM IN CASE OF HABITUAL MISCARRIAGE  
Nadezda Vorobyeva, Diana Gamirkina (Russian Federation)
PO539-TUE  INDIVIDUAL ABSOLUTE AND RELATIVE RISK (RR) OF PULMONARY EMBOLISM (PE) IN PREGNANCY AND PUERPERIUM IN PRESENCE OF HEREDITARY THROMBOPHILIC RISK FACTORS
Rainer B. Zott*, Ruediger Scharf, Andrea Gerhardt (Germany)

PO540-TUE  R147W IN PROC GENE AND THE RISK OF THROMBOEMBOLISM IN THAI CHILDREN
Nongnuch Sirachainan*, Ampaiwan Chusummit, Werasak Sasanakul, Lalita Mahakian, Jarin Vaewpanich, Pilimak Chareonkwан, Somjai Kanjanapongkul, Pakawan Wongwaraewanakoon, Pimpun Kiphoca (Thailand)

PO541-TUE  ACUTE SUPERIOR MESENTERIC VEIN THROMBOSIS IN A NON-CIRRHOTIC PATIENT WITH HETEROZYGOUS G20210A PROTHROMBIN GENE MUTATION: A CASE REPORT
Sagger Mawri*, David Paje (United States)

PO542-TUE  THROMBIN GENERATION TEST AT R2 POLYMORPHISM OF FACTOR V
Jana Prochazkova*, Ludek Slavik, Martin Prochazka, Jana Ulehlova (Czech Republic)

PO543-TUE  FACTOR V LEIDEN IN THE ABSENCE OF APC RESISTANCE IN A PATIENT AFTER LIVER TRANSPLANTATION
Edyta Odnozczo, Ksenia Bykowska, Beata Baran, Jerzy Windyga* (Poland)

PO544-TUE  VENOUS THROMBOEMBOLISM ASSOCIATED WITH FIRST PREGNANCY IN 80 WOMEN WITH HEREDITARY ANTITHROMBIN DEFICIENCY.
Marie Helene Horellou*, Narymène Benmiloud, Jacqueline Conard, Claire Flaujac, Jacques Lepercq, Martine Alhenc-Gelas, Geneviève Plu-Bureau (France)

PO545-TUE  MOLECULAR MODELING OF A NOVEL MUTATION IN THE SERPINC1 GENE ASSOCIATED WITH TYPE 1 ANTITHROMBIN DEFICIENCY
Tzu-Fei Wang*, Jennifer Dawson, Julie Forman-Kay, Walter Kahr, Suzan Williams, Anthony Chan, Riten Kumar (United States)

PO546-TUE  ANTIPHOSPHOLIPID ANTIBODIES AS EMBOLIC RISK MARKER OF INFEKTIVE ENDOCARDITIS.
Jean Devignes*, Charles-Henry Maigrait, François Goehringer, Carine Thivillier, Jacques Lepercq, Martine Alhenc-Gelas, Geneviève Plu-Bureau (France)

PO547-TUE  HEREDITARY AND ACQUIRED THROMBOPHILIAS AND WOMEN
Ivo Elezovic*, Darko Antic, Mirjana Mitrovic (Serbia)

PO548-TUE  CHARACTERIZATION OF A NEW HEREDITARY PROTHROMBIN VARIANT ASSOCIATED WITH INCREASED RISK OF VENOUS THROMBOEMBOLISM
Cristiana Bulato*, Claudia Radu, Elena Campello, Sabrina Gavasso, Daniela Tormene, Paolo Simioni (Italy)

Tissue factor and factor VII - II

PO549-TUE  ARTERIOVENOUS THROMBOSIS IN END STAGE RENAL DISEASE PATIENTS
Munira Borhany*, Naveena Fatima, Asif Hussain, Tahir Shamsi (Pakistan)

PO550-TUE  EFFECT OF A CARBOXY-TERMINAL PEPTIDE ON FACTOR VIIA ACTIVITY
Dougald M. Monroe*, Lior Binder, Malika Hoffman, Gill Hart, Maureen Hunt (United States)

PO551-TUE  A 28-YEARS-OLD WOMAN WITH FACTOR VII DEFICIENCY REVEALED AFTER TWO SEVERE POSTOPERATIVE BLEEDING EPISODES
Evangelia Papapetrou*, Muriel Giansily-Blairot, Haralambos Harissis, Georgios Vartholomatos, Nikolaos Kolaftis, Jean François Schved (Greece)

PO552-TUE  TISSUE FACTOR / FVIIA TRANSACTIVATES THE IGF-1R IN PROSTATE CANCER CELLS VIA INHIBITION OF CAVEOLIN-1
Mikael Åberg*, Agneta Siegbahn (Sweden)

PO553-TUE  THE LRP1 RECEPTOR PROMOTES THE IN VIVO CLEARANCE OF ACTIVATED FACTOR VII (FVII) IN COMPLEX WITH ANTITHROMBIN
Judicael F. Gazzana*, Nikolett Wohner, Olivier Christophe, Cécile Denis, Peter Lenting (France)

PO554-TUE  HIGH PLASMA CONCENTRATION OF ACTIVATED FACTOR VII-ANTITHROMBIN COMPLEX IS ASSOCIATED WITH AN ENHANCED THROMBIN GENERATION
Marcello Baroni*, Alessio Branchini, Patrizia Guarini, Federica Tosi, Filippo Sartori, Matteo Campioni, Francesco Puzzo, Barry Woodhams, Domenico Girelli, Oliviero Olivieri, Francesco Bernardi, Nicola Martinelli (Italy)

PO555-TUE  TISSUE FACTOR AND FACTOR VII GENE POLYMORPHISMS INFLUENCING FVIIA-AT PLASMA CONCENTRATION ARE NOT UNIFORMLY ASSOCIATED WITH MORTALITY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE.
Filippo Sartori*, Federica Tosi, Barbara Luangi, Patrizia Guarini, Marcello Baroni, Alessio Branchini, Barry Woodhams, Domenico Girelli, Oliviero Olivieri, Francesco Bernardi, Nicola Martinelli (Italy)

PO556-TUE  THE ROLE OF FACTOR VII MUTATIONS IN ENDOPLASMIC RETICULUM STRESS
Elisabeth Dørum*, Maria Eugenia Chollet, Mirko Pinotti, Francesco Bernardi, Per Morten Sandset, Grethe Stretting (Norway)

PO557-TUE  FVII DEFICIENCY: UNVEILING THE CELLULAR AND MOLECULAR MECHANISMS UNDERLYING THREE MODEL ALTERATIONS (MISSENSE, DELETION, EXTENSION) OF THE FVII CATALYTIC DOMAIN
Maria Eugenia Chollet Dugarte*, Elisabeth Dørum, Ellen Skarpen, Christian Koehler, Bernd Thiede, Jens Preben Morth, Christiane F. Myklebust, Mirko Pinotti, Francesco Bernardi, Per Morten Sandset, Grethe Stretting (Norway)

PO558-TUE  MICORNAS MODULATE HUMAN TISSUE FACTOR PATHWAY INHIBITOR-A (TFPI-A) EXPRESSION IN RESPONSE TO ANDROGENS IN ENDOTHELIAL CELLS
Ana Belén Arroyo Rodríguez*, Salam Salloum-Asfar, Carlos Pérez-Sánchez, Raul Teruel-Montoya, Nuria García-Barberá, Gines Luengo-Gil, Silvia Navarro, Pilar Medina, Chary López-Pedrera, Vicente Vicente, Constantino Martínez, Rocío Gonzalez-Conejero (Spain)

PO559-TUE  SINGLE CENTRE EXPERIENCE OF FACTOR VII DEFICIENCY
Bella Madan*, Gulnaz Shah, Theodora Vatopoulou, Mike Mitchell, Jacqueline Cutler (United Kingdom)
THROMBIN GENERATION IN PATIENTS WITH MILD FACTOR VII DEFICIENCY MEASURED IN THE PRESENCE OF THROMBOPLASTINS OF DIFFERENT ORIGIN
Roza Chaireti, Kerstin Arbring, Egon Persson, Tomas Lindahl* (Sweden)

MUTATIONS IN THE F7 GENE IN SWEDISH PATIENTS WITH DISCREPANT FACTOR VII ACTIVITY IN THE PRESENCE OF THROMBOPLASTINS OF DIFFERENT ORIGIN
Roza Chaireti, Kerstin Arbring*, Ole Olsen, Egon Persson, Tomas Lindahl (Sweden)

FVII DEFICIENCY AND THROMBOSIS, COINCIDENCE OR NEW MECHANISM OF THROMBOPHILIA
Yacine Larfi*, I Bachiri, W Zazoua, N Fenni, M Ganci-ly-claizot, Jean-François Schwed (Algeria)

USE OF A PLASMA DERIVED FVIII PRODUCT FOR PRIMARY PROPHYLACTIC THERAPY IN AN INFANT WITH CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA
MacGregor Steele*, Sheri VanGunst, Michael Leaker (Canada)

ANTI-IDIOPTYPIC DARPIANS RESTORE ADAMTS13 ACTIVITY IN BABOONS CHALLENGED WITH HUMAN MONOCLONAL ANTIBODIES: FIRST STEP TOWARDS AN ANIMAL MODEL FOR HUMAN ACQUIRED TTP
Monica Schaller*, Magdalena Skowronska, Monique Vogel, Deborah Stearns-Kurosawa, Shinichiro Kurosawa, Johanna Kremer Hovinga (Switzerland)

THE LABORATORY PROFILE THAT PREDICTS FAVORABLE OUTCOME AFTER ECULIZUMAB THERAPY IN PATIENTS WITH CLINICAL FEATURES COMPATIBLE WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME
Hira Mian*, Anthony Chan, Keith Lau, Howard Chan (Canada)

THE CLINICAL ANALYSIS OF 58 THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS
Lv Cui, Sun Tianfian, Ju Mankai, Fu Rongfeng, Li Huiyuan, Zhang Donglei, Zhang Xian, Li Yating, Zhang Lei, Yang Renchi (China)

RITUXIMAB THERAPY AS PROPHYLAXIS AGAINST THROMBOTIC THROMBOCYTOPENIC PURPURA: COMPARISON OF STANDARD AND REDUCED DOSE REGIMENS
John-Paul Westwood*, Debra Ellis, Siobhan Mc Guckin, Marie Scully (United Kingdom)

CLINICAL AND BIOCHEMICAL STUDIES OF A PATIENT WITH ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA (TPP) TREATED WITH N-Acetylcysteine (NAC)
Junmei Chen*, Tahsin Ozpolat, Colette Norby, Jennie Le, Minhua Ling, Shelby Cate, Dominic Chung, Xiaoyun Fu, Barbara Konkle, José López (United States)

AUTOANTIBODY INDUCED THROMBOTIC THROMBOCYTOPENIC PURPURA (TPP) IN A YOUNG PATIENT WITH METASTASIZING CANCER OF UNKNOWN PRIMARY (CUP) SYNDROME
Charis Von Auer*, Heidi Rossmann, Bernhard Lämmle (Germany)

SEVERE MATERNAL MORBIDITY AND FETAL DEATH IN A PREGNANT WOMAN WITH RECURRENT ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TPP)
Charis Von Auer*, Tanja Falter, Heidi Rossmann, Antje Lebrecht, Dana Maranducci, Inge Scharrer, Bernhard Lämmle (Germany)

OBESITY AS A RISK FACTOR FOR THE DEVELOPMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA IN ADAMTS13 DEFICIENT MICE
Lotte Geys, Eilen Roose*, Ilse Scroyen, Claudia Tersteeg, Hanspeter Rottensteiner, Simon De Meyer, H Roger Lijnen, Karen Vanhoorelbeke (Belgium)

A MULTICENTER, RANDOMIZED STUDY OF CYCLOSPORINE OR COR-TICOSTEROIDS AS AN ADJUNCT TO PLASMA EXCHANGE IN INITIAL THERAPY OF THROMBOTIC THROMBOCYTOPENIC PURPURA
Spero R. Cataland*, Shangbin Yang, Susan Geyer, Hai-feng Wu (United States)

COMPARING PERFORMANCES OF COMPLEMENT ACTIVATION BIOMARKERS BETWEEN RESPONDERS AND NON-RESPONDERS TO ECULIZUMAB THERAPY
Spero R. Cataland*, Shangbin Yang, Hai-wa Wu, Hai-feng Wu (United States)

EVALUATION OF LONG TERM NEUROLOGICAL SEQUELAE AFTER A FIRST EPISODE OF THROMBOTIC THROMBOCYTOPENIC PURPURA:
Barbara Ferrari, Alberto Maino, Andrea Antoni, Silvia Riva, Lucia Scirpa, Paola Santalucia*, Gabriella Pravettoni, Antonella Costa, Flora Peyvandi (Italy)

INCORPORATION OF RIGHT VENTRICULAR DYSFUNCTION INTO THE SIMPLIFIED PULMONARY EMBOLISM SEVERITY INDEX AS A PREDICTOR OF COMPLICATED CLINICAL COURSE IN LOW-RISK PATIENTS PRESENTING WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM
David Jimenez*, Jose Luis Lobo, Ana Portillo, Covadonga Fernandez-Golfin, Remedios Otero, Roger Yusen (Spain)

RADIATION AND BREAST CANCER RISK IN WOMEN DIAGNOSED WITH PULMONARY EMBOLISM: CT PULMONARY ANGIOGRAPHY VERSUS VENTILATION-PERFUSION SCANNING
Vicky Tagalakis*, Mark Tulchinsky, Alejandro Lazo-Langner, Samy Suissa, Gregore Le Gal (Canada)

RISK-ASSESSMENT MODEL OF RECURRANCE WITHIN 3 MONTHS AFTER A FIRST EPISODE OF ACUTE VENOUS THROMBOEMBOLISM:
Worcester venous thromboembolism study
Wei Huang*, Robert Goldberg, Frederick Anderson, Frederick Spencer (United States)
PO579-TUE  PERFORMANCE OF PULMONARY EMBOLISM RULE-OUT CRITERIA (PERC) COMBINED WITH LOW GESTALT CLINICAL PROBABILITY IN EUROPEAN CHEST PAIN POPULATION
Emilie Friou*, Vanessa Richard-Jourjon, Thomas Mounneh, Betty Mazet, Jacques Choukroun, Thiibault Schotte, Andrea Penalozza, Pierre-Marie Roy (France)

PO580-TUE  AN ELECTRONIC TOOL AND RECORD FOR DEEP VEIN THROMBOSIS (DVT) ASSESSMENT, DIAGNOSIS, TREATMENT AND FOLLOW UP.
Jane Strong, Victoria Frimpong, Jo Eggleston*, Deborah Thornton, Helen Briggs, Tamyka Stewart, Rachel Clarke-Druy, Karen Coultas, Alistair Steward, George Kitching, Syd Steward (United Kingdom)

PO581-TUE  VALIDATION OF THE USE OF AGE ADJUSTED D DIMER CUT OFF VALUES TO REDUCE THE COMPRESSION VENOUS ULTRASOUND RATES IN AN ACUTE AMBULATORY DVT SERVICE
Jane Strong*, Jo Eggleston, Victoria Frimpong, Deborah Thornton, Helen Briggs, Tamyka Stewart, Rachel Clarke-Druy, Karen Coultas (United Kingdom)

PO582-TUE  THE USE OF AN AGE-ADJUSTED CUT-OFF FOR D-DIMER IN SCREENING PATIENTS FOR SUSPECTED DVT IN THE COMMUNITY CAN SAFELY DECREASE THE NEED FOR COMPRESSION ULTRASONOGRAPHY.
Andrew S. Hughes*, Benjamin Hall, Kate Jennings, Victoria Webb, Georgia Page, Christine Smith, Florence Charova (United Kingdom)

PO583-TUE  DIAGNOSTIC PREDICTION MODEL VERSUS GESTALT IN THE DIAGNOSIS OF PULMONARY EMBOLISM IN PRIMARY CARE
Janneke Hendriksen*, Geert-Jan Geersing, Wim Lucassen, Petra Erkens, Ruud Oudega, Karel Moons (The Netherlands)

PO584-TUE  CLINICAL PREDICTION RULES PLUS D-DIMER TESTING DO NOT ENABLE A SAFE EXCLUSION OF DEEP VEIN THROMBOSIS OR PULMONARY EMBOLISM IN ELDERLY PATIENTS RESIDING IN NURSING HOMES OR HOMES FOR THE ELDERLY.
Geert-Jan Geersing*, Henriek Schouten, Ruud Oudega, Hans van Delden, Karel Moons, Dineke Koek (The Netherlands)

PO585-TUE  COMBINED ASSESSMENT OF THROMBOTIC AND HAEAMORRHAGIC RISK IN ACUTE MEDICAL PATIENTS
Micaela La Regina, Francesco Orlandini, francesca Marchini, Antonio Marinaro, Rosanna Bonacci, Paola Bonanni, Francesca Corsini, Francesco Dentall (Italy)

PO586-TUE  PREDICTION OF SEPSIS DEVELOPMENT IN PUERPERAS WITH SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
Sergei Sinkov*, Igor Zabolotskikh, Caroline Lind, Inger Njølstad, Ellivish Mathiesen, Erin Hald, Sigrid Braekkan, John-Bjarne Hansen (Norway)

PO587-TUE  PROSPECTIVE VALIDATION OF THE SIMPLIFIED REVISED GENEVA SCORE
Gregoire Le Gal*, Khaled Mostaguir, Marcel Hovens, Meissa Kale, Arnaud Perrier, Franck Verschuren, Philippe Girard, Menno Huisman, Hélia Robert-Etadi, Farès Moustafa, Pieter Kamphuisen, Harry Buller, Marc Righini (France, Canada)

PO588-TUE  REVIEW OF EMERGENCY DEPARTMENT INVESTIGATED DVT
Gary Benson, Rosemary Lavery*, Hilary Speers, Mark Worthington (United Kingdom)

PO589-TUE  PREVALENCE OF VENOUS THROMBOEMBOLISM & RELATED MORBIDITY AND MORTALITY AMONG HOSPITALIZED PATIENTS IN SAUDI ARABIA (SAVTE STUDY)
Essam Aboelnazar* (Saudi Arabia)

PO590-TUE  BELOW KNEE DEEP VEIN THROMBOSIS (BKDVT): A BENIGN ENTITY OR NOT?
Prahlad Ho*, Hui Yin Lim, Chyn Chua, Matthew Sleeman, Lachlan Hayes (Australia)

PO591-TUE  ETIOLOGY OF PORTAL VENOUS THROMBOSIS AND BUDD-CHIARI SYNDROME IN ADULTS
Anil Tombak*, Gizem Isguzar, Enver Ucbilek, Serkan Yaras, Aydan Akdeniz, Mehmet Ucar, Emel Gurkan, Eyup Tiftik, Mehmet Sungur (Turkey)

PO592-TUE  INCIDENCE OF CATHETER-RELATED VENOUS THROMBOEMBOLISM EVENTS IN ACUTE LEUKEMIA PATIENTS; A RETROSPECTIVE STUDY OF THE SAFETY OF PERIPHERALLY-INSERTED CENTRAL CATHETER.
Mohammad Refaee*, Bruna Fernandes, Yosef Brandwein, Cynthia Wu (Canada)

PO593-TUE  EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM IN THE FRAMINGHAM HEART STUDY
Marja K. Puurunen*, Philimon Gona, Joanne Murabito, Jared Magnani, Christopher O’Donnell (United States)

PO594-TUE  IMPACT OF INCIDENT STROKE ON FUTURE RISK OF VENOUS THROMBOEMBOLISM
Ludwig B. Rinde*, Birgit Småbrekke, Caroline Lind, Inger Njølstad, Ellivish Mathiesen, Erin Hald, Sigrid Braekkan, John-Bjarne Hansen (Norway)

PO595-TUE  EVALUATING THE ACCURACY OF INTERNATIONAL CLASSIFICATION OF DISEASES 10TH REVISION CODES FOR VENOUS THROMBOEMBOLISM (VTE) AND MAJOR BLEEDING (MB) IN EMERGENCY ROOM (ER) DISCHARGES
Fatimah Al-Ani*, Salimah Shariff, Jenecio Siqueira, Alejandro Lazo-Langner (Canada)

PO596-TUE  ASYMPTOMATIC CENTRAL VENOUS LINE-RELATED THROMBOSIS IN CHILDREN: FEASIBILITY OF CONDUCTING A CLINICAL STUDY
Sophie E. Jones*, Fiona Newall, Warwick Butt, Paul Monagle (Australia)

PO597-TUE  CEREBRAL VENOUS THROMBOSIS: A LONGITUDINAL FOLLOW UP
Maria Teresa Desancho*, Mohini Aras (United States)

PO598-TUE  PULMONARY EMBOLISM: DOES THE SEASONAL EFFECT DEPEND ON AGE? A 10 YEARS NATIONWIDE ANALYSIS OF HOSPITALIZATION AND MORTALITY
Valerie Olie*, Christophe Bonaldi (France)

PO599-TUE  IMPLICATIONS OF CYTOGENETICS FOR VENOUS THROMBOEMBOLISM IN ACUTE MYELOID LEUKEMIA
Yun-Gyoo Lee*, Inho Kim, Ji-Hyun Kwon, Sung Soo Yoon, Seongyang Park, Jae-Ho Yoon, Seung-Hwan Shin, Woo-Sung Min, Hee-Je Kim (Korea, Republic Of)
PO600-TUE  LONG-TERM HEALTH-RELATED QUALITY OF LIFE AFTER DEEP VEIN THROMBOSIS IS IMPAIRED COMPARED TO CONTROLS.
Kristin Utne*, Waleed Ghanima, Per Sandset, Hilde Wik, Lars-Petter Jelsness-Jørgensen (Norway)

PO601-TUE  LONG-HAUL TRAVEL AND THE RISK OF RECURRENT VENOUS THROMBOSIS
Jasmijn Timp*, Saskia le Cessie, Astrid van Hylckama Vlieg, Frits Rosendaal, Suzanne Cnneegieter (The Netherlands)

PO602-TUE  RECENT DISCHARGE CONFIERS RISK FOR VENOUS THROMBOEMBOLISM
Hiren Shah*, Nicholas Christensen (United States)

Venous thromboembolism - therapy II

PO603-TUE  A DRUG-DRUG INTERACTION STUDY OF DS-1040 AND ASPIRIN IN HEALTHY SUBJECTS
James Dow, Adeep Puri, Penny McPhillips, Yasurori Orihashi, Victor Dishy, Jin Zhou* (United States)

PO604-TUE  FEASIBILITY OF COMPARING INTERMITTENT PNEUMATIC COMPRESSION VS. A NOVEL DEVICE FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN TRAUMA PATIENTS WITH CONTRAINDICTION TO ANTICOAGULATION
Vinai Bhagirath*, Nayef Al Onazi, Sam Schulman, Mark Crowther (Canada)

PO605-TUE  PREDICTION OF THE BLEEDING RISK DURING ANTICOAGULATION TREATMENT FOR PULMONARY THROMBOEMBOLISM
Zhenguo Zhai*, Zhu Zhang, Yuanhua Yang, Chen Wang (China)

PO606-TUE  RECURRENTS AFTER STOPPING ANTICOAGULANT THERAPY IN THAI PATIENTS WITH NON CANCER-RELATED VENOUS THROMBOEMBOLISM
Pritiphong Krijattanakul*, Paphatsaphan Thippayanuruksakul, Benjaporn Akkawat, Ponipat Rojruckarin (Thailand)

PO607-TUE  XALIA, A NON-INTERVENTIONAL STUDY COMPARING RIVAROXABAN WITH STANDARD ANTICOAGULATION FOR INITIAL AND LONG-TERM THERAPY IN DEEP VEIN THROMBOSIS: BASELINE DEMOGRAPHICS AND HOSPITALIZATION RATES
Alexander G. Turpie*, Lorenzo Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje, Jonas Schneider, Walter Ageno (Canada)

PO608-TUE  APIXABAN FOR TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS FROM STUDY CENTRES IN ASIA; A SUBGROUP ANALYSIS OF THE AMPLIFY TRIAL
Alexander S. Gallus*, Giancarlo Agnelli, Harry Buller, Alexander Cohen, Theodore Lee, Raphael Pak, Gary Raskob, Harry Shi, Jeffrey Weitz (Australia)

PO609-TUE  SHOULD WE USE VENOUS THROMBOEMBOLISM PROPHYLAXIS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES RECEIVING CHEMOTHERAPY?
Adam Wiszniowski*, Piotr Szopinski, Krzysztof Warzocha (Poland)
SCIENTIFIC PROGRAM

PO620-TUE  THE QUA-VKA STUDY TO IDENTIFY NEW RISK FACTORS FOR BLEEDING DURING TREATMENT WITH VITAMIN K ANTAGONISTS: OBJECTIVES AND DESIGN
Nienke Van Rein*, Mettine Bos, Willem Lijfering, Felix van der Meer, Pieter Reitsma (The Netherlands)

PO621-TUE  ASSESSMENT OF THE TIME IN THERAPEUTIC RANGE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN K ANTAGONISTS BY SPECIALISTS IN HAEMOSTASIS IN ARGENTINA. THE TERRA REGISTRY.
Jose Manuel Ceresetto*, Federico Bottaro, Marcelo Casey, Alejandra Marti, Carlos Tajer (Argentina)

PO622-TUE  RESULTS FROM THE PROSPECTIVE “FARMAMICO” STUDY: INR VARIATIONS IN WARFARIN-TREATED PATIENTS UNDERGOING ANALGESIC AND ANTI-INFLAMMATORY THERAPIES
Anna Falanga*, Viola Milesi, Giuliana Martini, Daria Bettoni, Laura Russo, Federica Gualandris, Federica Brognoli (Italy)

PO623-TUE  USE OF PROTON PUMP INHIBITORS AMONG ANTICOAGULATED PATIENTS: THE MICHIGAN ANTICOAGULATION QUALITY IMPROVEMENT INITIATIVE (MAQI2) EXPERIENCE
Geoffrey D. Barnes*, Jacob Kurlander, Xiaokui Gu, Keely Haymart, Eva Kline-Rogers, Steve Almany, Jay Kozlowski, Gregory Krol, Scott Kaatz, Sameer Saini, James Froehlich (United States)

PO624-TUE  WHAT BLEEDINGS PREDICT HAS-BLED AND HEMORRHAGES SCALES IN PATIENTS ON LONG-TERM WARFARIN THERAPY?
Olga Moreva*, Ekaterina Kropacheva, Oksana Zemlyanskaya, Elena Titaeva, Anatoliy Dobrovolsky, Elizaveta Panchenko (Russian Federation)

PO625-TUE  VITAMIN K ANTAGONISTS FAVORABLY MODULATE FIBRIN CLOT PROPERTIES IN PATIENTS WITH ATRIAL FIBRILLATION AS EARLY AS AFTER 3 DAYS OF TREATMENT: RELATION TO COAGULATION FACTORS AND THROMBIN GENERATION
Michał Zabczyk*, Jacek Majewski, Grzegorz Karkowski, Anetta Undas (Poland)

PO626-TUE  PREVALENCE OF ANEMIA IN PATIENTS UNDER TREATMENT WITH VITAMIN K ANTAGONISTS
Marco Sampaio, Maria Faria*, Lurdes Moreira, Ana Spinola, Fernanda Leite, Eugenia Cruz, Manuel Campos (Portugal)

Von Willebrand disease II

PO627-TUE  GENETIC VARIATIONS IN EXON 28 OF VON WILLEBRAND FACTOR VIII CONCENTRATE TO ASSESS THE PHARMACOKINETICS, EFFICACY, AND SAFETY IN PEDIATRIC SUBJECTS WITH VON WILLEBRAND DISEASE (SWIFTLY-VWD STUDY)
Guenter Auerswald, Claudia Khayat, Olexandra Stasyshyn, Genadi Isosova, Irina Rasheuskaia, Marta Julia Lopez Ruano, Wilfried Seifert* (Germany)

PO628-TUE  VON WILLEBRAND DISEASE AND MENORRHAGIA: MULTIPLE TREATMENT OPTIONS FOR DIFFERENT PATIENTS
Kaan Kavakili*, Can Balkan, Deniz Karapinar (Turkey)

PO630-TUE  VON WILLEBRAND DISEASE AND MENORRHAGIA: MULTIPLE TREATMENT OPTIONS FOR DIFFERENT PATIENTS
Kaan Kavakli*, Can Balkan, Deniz Karapinar (Turkey)

PO631-TUE  UNEXPECTED FINDING OF LOW VON WILLEBRAND FACTOR LEVELS OR VON WILLEBRAND DISEASE IN PEDIATRIC PATIENTS WITH SCOLIOSIS
Brian Castillo*, S. Kate Hartman, Michael Gorena, Jamie Wingate, Shiu-Ki Hui, Jun Teruya (United States)

PO632-TUE  PERCENTAGE OF PLATELET AGGREGATES AND MACROPLATELETS: A POTENTIAL USEFUL LABORATORY PARAMETER FOR PREDICTING BLEEDING IN VON WILLEBRAND DISEASE TYPE 2B (VWD2B) WITH THE PVALL361MET MUTATION
Hugo Guglielmone*, Salvador Minoldo, Gustavo Jarchum, Tara Adams, Jorge DiPaola (Argentina)

PO633-TUE  DEVELOPMENT OF APLASTIC ANEMIA IN A PATIENT WITH ACQUIRED VON WILLEBRAND’S SYNDROME AND AUTOIMMUNE PREPONDERANCE
Arief Gunawan*, Gary Moore, Bella Madan (United Kingdom)

PO634-TUE  RELATIONSHIP BETWEEN BLEEDING TENDENCY AND THE AFFECTED DOMAIN WITH MUTATIONS RESPONSIBLE OF VWD2M PHENOTYPE
Adriana I. Woods*, Ana Kemper, Juvenal Paiva, Alicia Blanco, Roberto Chuit, Maria Casinelli, Analia Sanchez-Luceros, Maria Lazzari (Argentina)

PO635-TUE  CHARACTERIZATION OF VON WILLEBRAND DISEASE SUBTYPES IN 303 PATIENTS – A SINGLE CENTRE STUDY OVER THE PAST 10 YEARS
Anil Pathare*, Karima Al Falahi, Badiya Al-Belushi, Shoaib Al Zadjali, Salam Alkindi (Oman)

PO636-TUE  VWD2B PHENOTYPE: ITS PREVALENCE WITHIN FAMILIES AND BLEEDING TENDENCY IN AFFECTED MEMBERS
Adriana I. Woods*, Ana Kemper, Juvenal Paiva, Emite Bermejo, Alicia Blanco, Roberto Chuit, Analia Sanchez-Luceros, Maria Lazzari (Argentina)

PO637-TUE  VON WILLEBRAND DISEASE (VWD), EXPERIENCE OF ALGERIA IN BENI MESSOUS CENTER IN ALGIERS
Meriem Bensadok*, Karima Chennoukh, Chahyra Aboura, Mylad Aribi, Nadia Zidani, Meriem Belhani, Mohamed Salim Nekkal (Algeria)

PO638-TUE  TWO UNUSUAL CASES OF TYPE 2N VON WILLEBRAND DISEASE.
Patricia Bignell*, Nicola Curry, Pamela Wright, James Beavis, Shirley Henderson, Anna Schuh (United Kingdom)
PO639-TUE  HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND HEALTH-ECONOMIC ASSESSMENT IN PATIENTS WITH VON WILLEBRAND DISEASE IN FRANCE: THE WISH-QOL STUDY
Annie Borel-Derlon*, Jenny Goudemand, Catherine Boyer-Neumann, Edith Fressinaud, Catherine Temisien, Marc Trossaert, Agnès Veyradier, WISH-Qol Study Group, Caroline Martinez, Catherine Chatelanaz, Sylvia Von Mackensen (France)

PO640-TUE  POOR RESPONSE TO 1-DESAMINO-8-D ARGININE VASOPRESSIN (DDAVP) TEST IN A PATIENT WITH VON WILLEBRAND DISEASE TYPE 2M (VWD2M) WITH P.GLU1549LYS MUTATION
Hugo Guglielmone*, Juan Frontroh, Salvador Minoldo, Mirta Hepner, Marcela Sabagh, Gustavo Jarchum (Argentina)

PO641-TUE  ALLELE-SPECIFIC SILENCING OF THE VON WILLEBRAND FACTOR GENE TO AMELIORATE THE VON WILLEBRAND DISEASE PHENOTYPE
Annika de Jong*, Richard Dirven, Jeroen Elkenboom (The Netherlands)

PO642-TUE  EVALUATION OF A NEW AUTOMATED RISTOCETIN COFACTOR ASSAY ON THE STA-R EVOLUTION ANALYZER
Heleen Eising*, Lisan te Roller, Michelle Visser-Koldenhof, Bertil Wildeboer, Jasper Remijn (The Netherlands)

PO643-TUE  HOW WELL CAN LABORATORIES DIAGNOSE TYPE 2N VWD? DATA FROM A UK NEQAS (BLOOD COAGULATION) EXERCISE.
Ian Jennings*, Steve Kitchen, Dianne Kitchen, Timothy Woods, Mike Makris, Isobel Walker (United Kingdom)

PO644-TUE  POSTOPERATIVE BLEEDING AND OTHER OUTCOMES IN CHILDREN WITH VON WILLEBRAND DISEASE LOW VON WILLEBRAND FACTOR UNDERGOING ADENOTONSILLECTOMY
Rosa Diaz*, Donald Mahoney JR, MaryFrances Musso, Donald Yee (United States)

PO645-TUE  WILLEBRAND DISEASE MOLECULAR DIAGNOSIS BY HIGH THROUGHPUT SEQUENCING: WHAT’S ABOUT THE HIGHLY HOMOLOGOUS PSEUDogene?
Mathilde Giraud*, Solenne Dumont, Pierre Boisseau, Patricia Talarmain, Marie Annick Gourlaouen, Jessy Hary, Catherine Temisien, Edith Fressinaud, Jenny Goudemand, Agnès Veyradier, Stéphane Beziewski (France)

PO646-TUE  CLINICAL AND LABORATORY DETECTION OF TRANSIENT NEUTRALIZING ANTIBODIES IN SEVERE VON WILLEBRAND DISEASE ON LONG TERM PROPHYLAXIS
Ana Na-Sánchez-Luceros*, Maria Alberto, Ana Kempfer, Adriana Woods, Alicia Blanco, Silvia Grosso, Maria Romero, Maria Lazzari, Emilise Bermejo, Susana Meschengieser (Argentina)

PO647-TUE  VON WILLEBRAND DISEASE: THE PHENOTYPIC CHARACTERIZATION IN THAILAND
Theera Chuchatrakool*, Bundarika Suwanawiboon, Yupa Nakkinkun, Pimlak Charoenkwan, Weerasak Nawarawong, Weerasak Sasananuk, Ampawan Chonsmsri (Thailand)

PO648-TUE  ACQUIRED VON WILLEBRAND SYNDROME IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
Ksenia Bykowska, Ewa Mendek-Czajkowska, Beata Sokotowska, Adam Wiszniewski*, Beata Baran, Jerzy Windyga (Poland)

PO649-TUE  IDENTIFICATION OF NOVEL VWF GENE MUTATIONS IN THE TURKISH TYPE 2 VWD PATIENT POPULATION
Ergul Berber*, Yesim Oymak, Oguzhan Baltaci, Reyhan Diz-Kucukkaya, Bulent Zutifikar, Kaan Kavakli (Turkey)

PO650-TUE  CANCERS IN PATIENTS WITH VON WILLEBRAND DISEASE: A SURVEY FROM THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTRES
Anarita Tagliaferri, Giancarlo Castaman*, Caterina Di Perna, Cristina Santoro, Simona Maria Siboni, Ezio Zanon, Silvia Linari, Paolo Gresele, Samantha Pasca, Antonio Coppola, Rita Santoro, Ranalli Paola, Mariasanta Napoliatano, Massimo Franchini (Italy)

PO651-TUE  MODIFICATIONS OF HEMOSTATIC THERAPY FOR PATIENTS WITH VON WILLEBRAND DISEASE BASED ON COMORBIDITY
Nadezhda Zozulya*, Elena Likhacheva, Olga Yastrubinetskaya (Russian Federation)

PO652-TUE  ACQUIRED VON WILLEBRAND SYNDROME (AWS) WITH A TYPE 2B PHENOTYPE SECONDARY TO AN IGA AUTOANTIBODY WITH ANTI-VON WILLEBRAND FACTOR ACTIVITY.
Maria Alberto, Emilise Bermejo, Susana Meschengieser, Maria Romero, Adriana Woods, Ana Kempfer, Juvenal Paiva, Marcos Pizzolato, Maria Lazzari, Ana Sanchez-Luceros* (Argentina)

PO653-TUE  ACQUIRED VON WILLEBRAND SYNDROME IN PATIENTS TREATED WITH LEFT VENTRICULAR ASSIST DEVICES
Kenki Saito*, Ko Sakatsume, Ryutaro Shirakawa, Tomohiro Kimura, Masatoshi Akiyama, Yoshihito Saiki, Hisanori Horouchi (Japan)

PO654-TUE  DENTAL INVASIVE PROCEDURES IN VON WILLEBRAND DISEASE (VWD) OUTPATIENTS TREATED WITH HIGH PURITY WVF/F VIII COMPLEX CONCENTRATE: EXPERIENCE OF A SINGLE CENTER.
Valeria De Padua*, Cristina Santoro, Domenico Gaglioti, Francesco Riva, Erminia Baldacci, Caterina Mercanti, Maria Gabriella Mazzucconi (Italy)

PO655-TUE  RECOGNITION AND CORRELATION OF A RANDOM PATIENT-SPECIFIC ERROR OF THE AUTOMATED VON WILLEBRAND FACTOR ACTIVITY LATEX IMMUNOASSAY
Julie I. Tange*, Rachel Leger, Diane Grill, Rajiv Pruthi, Dong Chen (United States)

Von Willebrand factor II

PO656-TUE  LONG TERM EXERCISE SIGNIFICANTLY DECREASES VON WILLEBRAND FACTOR ANTIGEN LEVELS IN ABDOMINALLY OBESE ADULTS
Cynthia Pruss*, Robert Ross, Michael Adams (Canada)

PO657-TUE  DEVELOPMENT OF A VWF PROPEPTIDE ASSAY
Muriel Meiring* (South Africa)

PO658-TUE  CROSS-SPECIES INHIBITION OF HUMAN AND MURINE VON WILLEBRAND FACTOR BY A SINGLE DOMAIN VHH-ANTIBODY
Ibrahim Habib*, Paulette Legendre, Amine Bazzaz, Cécile Denis, Peter Lenting, Valérie Proulle, Olivier Christophe (France)
TUESDAY

PO659-TUE  HIGH ACTIVITY OF VON WILLEBRAND FACTOR AND LEVELS OF VWF-CLEAVING PROTEASE (ADAMTS-13) IN TERM AND PRETERM NEONATES
Tzipora Strauss*, Naama Elisha, Bruria Ravid, Ariela Zivelin, Ahron Lubetsky, Iris Morag, Gili Kenet (Israel)

PO660-TUE  ANGIogenetic CHARACTERISTICS OF BLOOD OUTGROWTH ENDOTHELIAL CELLS FROM PATIENTS WITH VON WILLEBRAND DISEASE
Dafna Groeneveld*, Tamara van Bekkum, Richard Dirven, Jiongwei Wang, Jan Voorberg, Pieter Reitsma, Jeroen Eikenboom (The Netherlands)

PO661-TUE  REGULATION OF VWF-GPIIb INTERACTION WITH MODIFIED RECOMBINANT BOTTROP CETIN
Taei Matsui*, Arisa Hori, Jiharu Hamako, Fumio Matsushita, Namiho Takagishi, Kazunao Kondo, Taiki Kano, Masao Hayakawa, Masanori Matsumoto, Yoshihiro Fujimura (Japan)

PO662-TUE  VON WILLEBRAND FACTOR TO MONITOR PERCUTANEOUS AORTIC VALVE INTERVENTIONS
Antoine Rauch*, Eric Van Belle, André Vincentelli, Emmanuelle Jeanpierre, Paulette Legendre, Francis Juthier, Natacha Rousse, Carlo Banfi, Anne Godier, Claudine Caron, Dupont Annabelle, Christophe Zawadski, Delphine Corseaux, Frederic Mouquet, Cédric Delhaye, Bart Staelens, Jenny Goudemand, Brigitte Jude, Peter Lenting, Sophie Susen (France)

PO663-TUE  PLATELET AND ENDOTHELIAL FUNCTION EVALUATION IN PEDIATRIC CHRONIC KIDNEY DISEASE
Luci M. S. Dusse*, Rivia Silva, Leticia Sousa, Fernanda Nunes, Rejane Diniz, Marcos Silva, Cristina Loures, Maria Carvalho, Ana Silva (Brazil)

PO664-TUE  FUNCTIONAL STUDY OF TWO NEW MUTATIONS IN THE C4 DOMAIN OF VON WILLEBRAND FACTOR
Paulette Legendre*, Pauline Delrieu, Pierre Boisseau, Catherine Ternisien, Edith Fresinaud, Agnès Veyradier, Cecile Denis, Peter Lenting, Olivier Christophe (France)

PO665-TUE  POSTOPERATIVE CHANGES IN VON WILLEBRAND FACTOR (VWF) AFTER ORTHOPAEDIC SURGERY IN HAEMOSTATICALLY HEALTHY PATIENTS
Mario von Depka*, Carsten Detering, Cornelia Wertes, Birgit Naawroth, Emilie von Depka, Mahnaz Ekhlasi-Hundrieser (Germany)

PO666-TUE  GENERATION OF REFERENCE INTERVALS FOR TWO AUTOMATED, NEW-GENERATION VON WILLEBRAND FACTOR ACTIVITY ASSAYS ON A LARGE DONOR POPULATION.
Katarzyna Mayer*, Gary Moore, Jan Jacques Michiels, Inge VanGennechten, Alain Gadisseur (United Kingdom)

PO667-TUE  EXPOSURE OF VON WILLEBRAND FACTOR (VWF) TO VORTEX SHEAR SIGNIFICANTLY ENHANCES ITS PROTEOlySIS BY PLASMIN
Teresa M. Brophy*, James O'Donnell (Ireland)

PO668-TUE  BELGIAN MULTICENTER STUDY INTO VON WILLEBRAND DISEASE (B-WILL STUDY): FIRST RESULTS
Inge VanGennechten*, Kristin Joehmans, Katrien Devreeze, Serge Motte, Alain Gadisseur (Belgium)

SCIENTIFIC PROGRAM

PO669-TUE  THE VON WILLEBRAND FACTOR A2 DOMAIN DISULFIDE BOND EXISTS IN OXIDIZED AND REDUCED STATES IN THE CIRCULATION AND REGULATES FUNCTION
Philip Hogg*, Diego Butera, Robert Andrews, Elizabeth Gardiner, Amanda Davis, Deirdre Murphy, Ross Baker, Jim Thom, Vivien Chen, Brenda Luken, Jason Wong, Camilo Aponte-Santamaria, Agnieszka Bronowska, Carsten Baldauf, Frauke Graeter (Australia)

PO670-TUE  MODIFICATION OF ABO(H) BLOOD GROUP ANTIGENS ON HUMAN VWF WITH PLASMA GLYCOSYLTRANSFERASE
Taiki Kano*, Fumio Matsushita, Jiharu Hamako, Yoshihiro Fujimura, Kazunao Kondo, Taei Matsuji (Japan)

PO671-TUE  REFERENCE VALUE OF VON WILLEBRAND FACTOR ACTIVITY BY IMMUNO-TURBIDIMETRY METHOD
Rahajuningsih Dharma*, Yona Mimanda (Indonesia)

PO672-TUE  ANALYSIS OF PLASMA VON WILLEBRAND FACTOR AND COMPLEMENT FACTOR H POLYMORPHISMS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
Mariko Yamashita*, Masanori Matsumoto, Ayami Isonishi, Yoko Yoshida, Masaki Hayakawa, Yoshihiro Fujimura, Nahoko Ogata (Japan)

PO673-TUE  IMPROVED RESOLUTION OF HIGH MOLECULAR WEIGHT MULTIMERS OF VON WILLEBRAND FACTOR–ALBUMIN FUSION PRODUCT BY AGAROSE ELECTROPHORESIS/WESTERN BLOTTING
Jeffrey Hey*, Thomas Barnes, Matthias Zimmermann, Bianca Varwood, Christophe Pical, Holger Lind (Australia)

PO674-TUE  ANALYSIS OF OXALIPLATIN-BASED CHEMOTHERAPY INDUCED LIVER INJURY IN PATIENTS WITH ADVANCED COLORECTAL CANCER WITH SPECIAL REFERENCES TO VON WILLEBRAND FACTOR
Naoto Nishigori*, Masanori Matsumoto, Fumikazu Koyama, Masaki Hayakawa, Kinta Hatakeyama, Yoshihiro Fujimura, Yoshiyuki Nakajima (Japan)

PO675-TUE  DESMPRESSIN TREATMENT IMPROVES PLATELET FUNCTION UNDER FLOW IN PATIENTS WITH POSTOPERATIVE BLEEDING
Frauke Swieringa, Marcus Lance, Birte Fuchs, Marion Felge, Barbara Solecka, Lieke Verheijen, Kevin Hughes, Hans Deckmyn, Christoph Kannicht, Johan Heemskerk, Paola Van Der Meijden* (The Netherlands)

PO676-TUE  O TO AVOID MYOCARDIAL INFARCTION.
Eimear Dunne*, James O'Donnell, Dermot Kenny (Ireland)

PO677-TUE  VON WILLEBRAND FACTOR’S SHEAR-AND-TIME DEPENDENT DEGRADATION IN THE PHASE 3 A-LONG STUDY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) IN SUBJECTS WITH HEMOPHILIA A DEMONSTRATES DIFFERENT MAGNITUDES OF TEMPORAL VARIABILITY
David Lillcrap*, Roshni Kulkarni, Shuanglian Li, Elisa Tsao, Alisson Long, Glenn Pierce, Jennifer Dumont (Canada)

PO678-TUE  MODIFICATION OF ABO(H) BLOOD GROUP ANTIGENS ON HUMAN VWF WITH PLASMA GLYCOSYLTRANSFERASE
Taiki Kano*, Fumio Matsushita, Jiharu Hamako, Yoshihiro Fujimura, Kazunao Kondo, Taei Matsuji (Japan)
PO679-TUE  EVALUATION OF AGE AND GLYCAN-RELATED CHANGES ON VON WILLEBRAND FACTOR (VWF) CLEARANCE IN A VWF DEFICIENT MOUSE MODEL  
Silvia Albánez*, Laura Swystun, Kate Sponagle, Julie Grabell, Christine Brown, Paula James, David Lillicrap (Canada)

PO680-TUE  ANNEXIN A2 SNP REGULATES PLASMA VON WILLEBRAND FACTOR LEVELS AND IS ENRICHED IN PATIENTS WITH VON WILLEBRAND DISEASE  
Waander Van Heerde*, Iris Kloots, Jelmer van Puffelen, Clint van Duren, Selene Schoormans, Paul Brons, Britta Laros-van Gorkom, Lambertus Klemeyn (The Netherlands)

Scientific Program

Wednesday, June 24

Trainee Tracks (oral sessions only):

- Platelets track
- Basic thrombosis and hemostasis track
- Clinical bleeding track
- Clinical thrombosis track
- Pediatric thrombosis and hemostasis track
- Cardiovascular and arterial diseases track

An asterisk (*) after a name denotes the presenting author
Wednesday, June 24, 2015

**ORAL COMMUNICATIONS** 5  08:00-09:15

**Venous thromboembolism – therapy – I**  Room 718

*Moderators: Sabine Eichinger (Austria), Dimitrios Scarvelis (Canada)*

08:00 – 08:15  **RESIDUAL VEIN THROMBOSIS AND THE INCIDENCE OF SUBSEQUENT SERIOUS COMPLICATIONS IN PATIENTS TREATED WITH CONVENTIONAL ANTICOAGULATION**

Paolo Prandoni*, Anthonie Lensing, Martin Prins, Sabina Villalta, Franco Noventa (Italy)

08:15 – 08:30  **EFFICACY AND SAFETY OF OUTPATIENT TREATMENT BASED ON THE HESTIA CLINICAL DECISION RULE WITH OR WITHOUT NT-PROBNP TESTING IN PATIENTS WITH ACUTE PULMONARY EMBOLISM: A RANDOMIZED TRIAL**

Paul L. den Exter*, Wendy Zondag, Frederikus Klok, Rolf Brouwer, Anneke Dolsma, Michiel Eijsovogel, Laura Faber, Marco Grootenboers, Roxane Heller-Baan, Marcel Hovens, Ge Jonkers, Klaas van Kralingen, Ronne Mairuhu, Christian Melissant, Henny Peltenburg, Judith Post, Tom Vasveld, Marielle de Vreede, Menno Huisman (The Netherlands)

08:30 – 08:45  **COMPARISON OF ULTRASOUND ASSISTED CATHETER-DIRECTED THROMBOLYSIS (CDT) AND CDT ALONE FOR TREATMENT OF PROXIMAL DEEP VEIN THROMBOSIS**

Vladimir Tichelaar*, Ellen Brodin, Anders Vik, Trond Isaksen, Finn-Egil Skjeldestad, Kulbir Singh, John-Bjarne Hansen (Norway)

08:45 – 09:00  **LONG-TERM ANTICOAGULATION WITH RIVAROXABAN FOR THE PREVENTION OF RECURRENT DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM: A BENEFIT–RISK ANALYSIS ON THE EINSTEIN EXTENSION TRIAL**

Philip S. Wells*, Martin Prins, Bennett Levitan, Zhong Yuan, Eva Katz, Jan Beyer-Westendorf, Timothy Brighton, Henri Bounaumeaux, Alexander Cohen, Bruce Davidson, Gary Raskob, Anthonie Lensing (Canada)

09:00 – 09:15  **A NETWORK META-ANALYSIS COMPARING THE EFFICACY AND SAFETY OF ANTICOAGULANTS FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS**

Florian Posch*, Oliver Koenigsbruegge, Christoph Zilienski, Ingrid Pabinger, Cihan Ay (Austria)

**ITP – Clinical**  Room 701

*Moderators: Donald Arnold (Canada), John Freedman (Canada)*

08:00 – 08:15  **ALL-TRANS RETINOIC ACID (ATRA) CORRECTS THE IMBALANCE OF MACROPHAGE POLARIZATION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**

Qi Feng*, Miao Xu, Yu Hou, Yingyi Yu, Xin Li, Yuanxin Sun, Jun Peng (China)

---

**SCIENTIFIC PROGRAM**

**ORALS**

**WEDNESDAY**

08:15 – 08:30  **RETROSPETIVE ANALYSIS OF RITUXIMAB THERAPY IN CHILDHOOD CHRONIC AND REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA**

Yilmaz Ay*, Tuba Hilikay Karapinar, Yesim Oymak, Ersin Torek, Bengu Demirag, Dilek Ince, Esin Ozcan, Nergial Moueminglo,l, Sultan Aydin Koker, Canan Vergin (Turkey)

08:30 – 08:45  **OCCURRENCE OF METHEMOGLOBINEMIA IN IMMUNE THROMBOCYTOPENIA PATIENTS TREATED WITH DAPSONE**

Marina P. Colella*, Fernanda Orsi, Joyce Annichino-Bizzacchi, Erich de Paula (Brazil)

08:45 – 09:00  **EFFECT OF CD72 ON B CELLS IN CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA**

Hao Yating*, Lyu Mingen, Li Yang, Fu Rongfeng, Liu Wenjie, Zhang Donglei, Zhang Xian, Iyu Cuicui, Sun Tianlant, Li Huiyuan, Yang Renchi (China)

09:00 – 09:15  **THE EFFECT OF DANAZOL AND A NEW TREATMENT STRATEGY IN PRIMARY IMMUNE THROMBOCYTOPENIA – AN ANALYSIS OF 412 CASES FROM A SINGLE CENTER IN CHINA**

Wenjie Liu*, Xuping Gu, Yang Li, Mingen Lv, Tianlant Sun, Cuicui Lv, Renchi Yang (China)

**Risk factors for venous thrombosis – II**  Room 801

*Moderators: William Geerts (Canada), Scott Kaatz (United States)*

08:00 – 08:15  **META-ANALYSIS OF 65,734 INDIVIDUALS IDENTIFIES TSPAN15 AND SLC44A2 AS TWO NEW SUSCEPTIBILITY LOCI FOR VENOUS THROMBOEMBOLISM**

Pierre-Emmanuel Morange*, Marine Germain, Weihong Tang, Christopher Kabrhel, Pieter Reitsma, John Heft, Daniel Chasman, David Tregouet, Frits Rosendaal, Nicholas Smith (France)

08:15 – 08:30  **ASSOCIATIONS BETWEEN ATRIAL FIBRILLATION AND CAUSE-SPECIFIC RISKS OF PULMONARY EMBOLISM AND STROKE**

Ina Rye-Holmbøe*, Ern Hald, Anders Vik, Elisiv Mathiesen, Inger Njølstad, Maja-Lisa Lachen, Sigrid Braskkan, John Bjarne Hansen (Norway)

08:30 – 08:45  **GLUCOCORTICOID RECEPTOR GENE AND RISK OF VENOUS THROMBOEMBOLISM**

Laura Elbers*, Bregje van Zaane, Victor Gerdes, Olaf Dekkers, Astrid van Hylckama Vlieg, Suzanne Cannegieter (The Netherlands)

08:45 – 09:00  **F11 IS ASSOCIATED WITH RECURRENT EVENT OF VTE IN WOMEN: A PROSPECTIVE COHORT STUDY**

Maria Bruzelius*, Maria Ljungqvist, Matteo Bottai, Annica Bergendal, Rona Strawbridge, Angela Silveira, Helle Kieler, Anders Hamsten, Gerd Lärfars, Jacob Odeberg (Sweden)

09:00 – 09:15  **ROLE OF APOLIPOPROTEIN(A) KRINGLE-IV TYPE 2 COPY NUMBER VARIATION IN VENOUS THROMBOEMBOLISM**

Elena Sticchi*, Bettli Giusti, Alberto Magi, Pia Kamstrup, Domenico Prisco, Ida Martinelli, Pier Mannucci, Rosanna Abbate (Italy)
SCIENTIFIC PROGRAM

Platelets – II Room 713

Moderators: Christian Gachet (France), Heyu Ni (Canada)

08:00 – 08:15
OR271
THE DIRECT DENIQUE VIRUS-PLATELET INTERACTION: GENERATION OF INFECTIOUS PROGENY
Michael R. Sutherland*, Ayo Simon, Edward Pryzdzial (Canada)

08:15 – 08:30
OR272
THE PH-DOMAIN ADAPTOR BAM32/DAPP1 RESTRAINS GPVI-MEDIATED PLATELET ACTIVATION AND THROMBUS FORMATION
James L. Hutchinson*, Tom Durrant, Samantha Moore, Ingeborg Hers (United Kingdom)

08:30 – 08:45
OR273
IMPAIRED PLATELET ACTIVATION BUT INTACT HEMOSTASIS IN MICE EXPRESSING LOW LEVELS OF THE RAP-GEF, CALDAG-GEFI
Raymond Piatt*, Brian Cooley, Dale Cowley, Wolfgang Bergmeier (United States)

08:45 – 09:00
OR274
THE CALCIUM-BINDING PROTEIN S100A1 NEGATIVELY REGULATES COLLAGEN-DEPENDENT PLATELET ACTIVATION AND THROMBOSIS IN MICE
Yacine Boulaftali*, David Paul, Raymond Piatt, Dengmin Feng, Brian Cooley, Patrick Most, Wolfgang Bergmeier (France, United States)

09:00 – 09:15
OR275
DISSECTING ROLES FOR THE SNARE-ASSOCIATED PROTEIN, SNAP29, IN MOUSE PLATELETS
Christopher Williams*, Joshua Savage, Matthew Harper, Samantha Moore, Ingeborg Hers, Alastair Poole (United Kingdom)

Platelets – kinases – II Room 716

Moderators: Joel Bennett (United States), Alexandra Mazharian (United Kingdom)

08:00 – 08:15
OR276
A COMPARISON OF BTK/TEC KINASES IN PLATELETS USING IBRUTINIB AND KNOCKOUT MICE
Craig E. Hughes*, Monique Laudat, Michael Tomlinson, Wilfried Ellmeier, Steve Watson (United Kingdom)

08:15 – 08:30
OR277
PP1C ALPHA NEGATIVELY REGULATES PLATELET THROMBUS FORMATION VIA MAPK P38
Subhashree Pradhan, Qi Da, Tanvir Khatliani, K. Vinod Vijayan* (United States)

08:30 – 08:45
OR278
DUSP3 PHOSPHATASE DEFICIENCY OR INHIBITION LIMIT PLATELET ACTIVATION AND ARTERIAL THROMBOSIS
Souad Rahmouni*, Lucia Musumeci, Marijke Kuijpers, Karen Gilio, Hego Alexandre, Emilie Théâtre, Yotis Senis, Johan Heemskerk, Charles-Marc Samama, Marc Thiry, Lutz Tautz, Cécile Oury (Belgium)

08:45 – 09:00
OR279
CLASS III PI3K POSITIVELY REGULATES PLATELET ACTIVATION AND THROMBUS FORMATION VIA PTDINS3P DIRECTED FUNCTION OF THE NADPH OXIDASE
Hu Hu*, Dongjiao Luo, Yang Yang, Ming Yue, Mengjiao Hu, Shuai Wang, Qian Huang, Zhongzhou Yang (China)

SCIENTIFIC PROGRAM

ORALS

09:00 – 09:15
OR280
AADACL1 REGULATION OF PKC-DEPENDENT SECRETION IN HUMAN PLATELETS
Stephen Holly*, Putianqi Wang, Rinku Majumder, Davia Blake, Leslie Parise (United States)

08:00 – 08:15
OR281
IMPACT OF ORAL ANTICOAGULATION ON TIME TO PROCEDURE IN PATIENTS ADMITTED FOR HIP FRACTURE.
Thomas Tran*, Carine de Wil, Aurelien Deliuc, William Petricchi, Gregoire Le Gal, Marc Carrier (Canada)

08:15 – 08:30
OR282
PERIOPERATIVE MANAGEMENT OF DABIGATRAN: A PROSPECTIVE COHORT STUDY
Sam Schulman*, Marc Carrier, Agnes Lee, Sudeep Shivakumar, Mark Blomstein, Frederick Spencer, Susan Solymoss, Rebecca Barty, Grace Wang, Nancy Heddle, James Douketis (Canada)

08:30 – 08:45
OR283
AN OBSERVATIONAL COHORT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DABIGATRAN ETEXILATE IN PATIENTS WITH MODERATE RENAL IMPAIRMENT UNDERGOING ELECTIVE TOTAL HIP OR KNEE REPLACEMENT SURGERY
Simon P. Frostick*, Nadia Rosencher, Eva Kleine, Martin Feuring, Martina Brueckmann, Andreas Clemens, Jenny Gullberg, Charles-Marc Samama (United Kingdom)

08:45 – 09:00
OR284
EFFECTIVENESS OF RIVAROXABAN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER KNEE ARTHROSCOPY: A RANDOMIZED DOUBLE-BLIND TRIAL (ERIKA STUDY)
Giuseppe Camporese*, Enrico Bernardi, Franco Noventa (Italy)

09:00 – 09:15
OR285
ASSAYS TO MEASURE DIRECT ORAL ANTICOAGULANTS (DOAC) : DATA FROM UK NEQAS MULTICENTRE STUDIES.
Ian Jennings*, Steve Kitchen, Dianne Kitchen, Shafina Munroe-Pearl, Robert Jones, Anna Lowe, Timothy Woods, Isobel Walker (United Kingdom)

Contact system I Room 715

Moderators: Ronit Mor-Cohen (Israel), David Gailani (United States)

08:00 – 08:15
OR286
ARTERIAL THROMBOSIS IS ACCELERATED IN HISTIDINE-RICH GLYCOPROTEIN DEFICIENT MICE
Trang T. Vu*, Ji Zhou, Beverly Leslie, Alan Stafford, James Frederburgh, Ran Ni, Shengjun Qiao, Nima Vaezzadeh, Willi Jahnen-Dechent, Brett Monia, Peter Gross, Jeffrey Weitz (Canada)

08:15 – 08:30
OR287
PHOSPHATE POLYMERS AND FACTOR XI ACTIVATION.
Anton Matafonov*, Ivan Ivanov, Maofu Sun, Vladimir Serebrow, David Gailani (Russian Federation, United States)

08:30 – 08:45
OR288
FACTOR XII ACTIVATION BY ACTIVATED FACTOR XI
Ivan Ivanov*, Anton Matafonov, Maofu Sun, Dave Gailani (United States)
**SCIENTIFIC PROGRAM**

**ORALS**

**WEDNESDAY**

**08:45 – 09:00**

**OR289**

AN ALLOSTERIC DISULFIDE BOND IS INVOLVED IN ENHANCED ACTIVATION OF FACTOR XI BY PROTEIN DISULFIDE ISOMERASE
Ronit Mor-Cohen*, Adva Yeheskel, Uri Seligsohn, Michal Zucker (Israel)

**09:00 – 09:15**

**OR290**

DNA AND RNA ACTIVATE THE CONTACT PATHWAY OF COAGULATION BY PROMOTING RECIPROCAL ACTIVATION OF FACTOR XII AND PREKALLIKREIN
Jagmanpreet S. Dang*, Trang Vu, Beverly Leslie, Alan Stafford, James Fenadghen, Jeffrey Weitz (Canada)

**08:15 – 08:30**

**OR297**

SUPPRESSION OF “LEAKY” NONSENSE MUTATIONS BY RIBOSOME READTHROUGH ACCOUNTS FOR RESIDUAL FACTOR IX LEVELS IN HAEMOPHILIA B PATIENTS
Alessio Branchini*, Mattia Ferrarese, Marcello Baroni, Matteo Campioni, Francesco Burini, Federica Nicolosi, Giancarlo Castaman, Paolo Radossi, Francesco Bernardi, Mirko Pinotti (Italy)

**08:30 – 08:45**

**OR298**

F8 AND F9 GENE VARIANTS, CADD SCORES, AND HEMOPHILIA SEVERITY IN THE MY LIFE, OUR FUTURE GENOTYPING PROJECT
Jill Johnson*, Shelley Fletcher, Haley Huston, Martin Kircher, Diane Aschman, Val Bias, Sally McAllister, Jay Shendure, Barbara Konkle (United States)

**08:45 – 09:00**

**OR299**

CB-FIX: AN IMPROVED SECOND GENERATION FIX DRUG CANDIDATE
Edwin Madison*, Christopher Thanos, Grant Boisse, Mark Fox, Russell Overbeck, Hoa Ly, Kerryn McCluskie, David Sloane (United States)

**09:00 – 09:15**

**OR300**

CORRECTION OF ABERRANT SPLICING CAUSING HAEMOPHILIA B THROUGH THE COMBINATION OF COMPENSATORY U1SNRNAS AND ANTISENSE OLIGONUCLEOTIDES
Daniela Scala*, Dario Balestra, Elena Barbon, Nicola Cavallari, Daniella Perrone, Francesco Bernardi, Mirko Pinotti (Italy)

**Factor VIII and IX**

**Room 705**

**08:00 – 08:15**

**OR296**

A UNIQUE EXON SPECIFIC U1SNRNA RESCUES DIFFERENT HAEMOPHILIA B -CAUSING SPlicing-DEFECTIVE FACTOR IX VARIANTS IN MICE.
Dario Balestra*, Daniela Scala, Franco Pagani, Francesco Bernardi, Mirko Pinotti (Italy)

**08:15 – 08:30**

**OR301**

SIMULTANEOUS MEASUREMENT OF THROMBIN GENERATION AND FIBRIN FORMATION IN WHOLE BLOOD APPLYING CONTINUOUS FLOW IS INDICATIVE FOR THE AMOUNT OF BLOOD LOSS DURING/AFTER CARDIOTHORACIC SURGERY

**08:30 – 08:45**

**OR302**

A NOVEL SUBSTRATE FOR USE IN A POINT OF CARE THROMBIN GENERATION ASSAY
Shengjun Qiao, Paul Kim, Ran Ni, Jeffrey Weitz, Peter Gross* (Canada)

**08:45 – 09:00**

**OR303**

FACTOR XIA AND TISSUE FACTOR ACTIVITY IN TRAUMA PATIENTS
Saulius Butenas, Matthew Gissel, Myung Park (United States)

**09:00 – 09:15**

**OR304**

DRVVT AS SIMPLE METHOD FOR MONITORING PATIENTS WITH FXA INHIBITORS
Annelie Siegemund*, Ute Scholz, Thomas Siegemund (Germany)

**Blood coagulation tests – I**

**Room 707**

**08:00 – 08:15**

**OR291**

THROMBOTIC BURDEN AND THE RISK OF SUBSEQUENT MANIFEST CANCER
Paolo Prandoni*, Sabina Villalta, Anthonie Lensing, Martin Prins, Franco Noventa, Andrea Piccioli (Italy)

**08:15 – 08:30**

**OR292**

RECURRENT VENOUS THROMBOEMBOLISM AND MORTALITY IN CANCER PATIENTS WITH UPPER EXTREMITY DEEP VEIN THROMBOSIS
Suzanne Bleker*, Nick van Es, Ankie Kleinjan, Harry Bülter, Pieter Kamphuisen, Anita Aggarwal, Jan Beyer-Westendorf, Giuseppe Camporese, Benilde Cosmi, Thomas Gary, Angelo Ghirarduzzi, Karin Kaasjager, Teresa Lerede, Peter Marschang, Karina Meijer, Hans-Martin Otten, Ettore Porreca, Marc Righini, Peter Verhamme, Sanne van Wissen, Marcello Di Nisio (The Netherlands)

**08:30 – 08:45**

**OR293**

INTERRELATION BETWEEN CANCER AND MYOCARDIAL INFARCTION IN THE GENERAL POPULATION

**08:45 – 09:00**

**OR294**

EPIEIDOLOGIE OF FIRST VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER
Alexandre Cohen*, Anja Katholing, Stephon Rietbrock, Carlos Martinez (United Kingdom)

**09:00 – 09:15**

**OR295**

THE RISKS AND BENEFITS OF THROMBOPROPHYLAXIS (TP) AMONG HOSPITALIZED MEDICALLY ILL CANCER PATIENTS.
Marc Carrier*, Cynthia Wu, Erica Peterson, Carine de Wit, Mabel Ma, Julia Tien, Gina Polley, Agnes Lee (Canada)

**Moderators:** Marc Carrier (Canada), Alok Khorana (United States)

---

**Moderators: Jill Johnsen (United States), Rebecca Kruse-James (United States)**
SCIENTIFIC PROGRAM

Heparin and heparinoids

Moderators: Andreas Greinacher (Germany), Thomas Lindahl (Sweden)

Room 709

08:00 – 08:15

IN VIVO CHARACTERIZATION OF ANTI-THROMBOTIC AND
ANTI-INFLAMMATORY PROPERTIES OF NEW SYNTHETIC,
PROTAMINE-REVERSIBLE LOW MOLECULAR WEIGHT HEPARIN

Kasemsiri Chandarajoti, Erica Sparkenbaugh*, Nigel Key, Yongmei Xu, Brian Cooley, Jian Liu, Rafał Pawlinski (United States)

08:15 – 08:30

PARTIALLY DESULFATED HEPARIN MODULATES THE INTERACTIONS
BETWEEN ANTI-PROTAMINE/HEPARIN ANTIBODIES AND PLATELETS

Rabie Joumi*, Heike Zöllner, Ahmad Khadour, Jan Wesche, Jessica Fuhrmann, Anne Grotevendt, Krystin Krauel, Andreas Greinacher, Tamam Bakchoul (Germany)

08:30 – 08:45

THERMAL STABILITY OF PLATELET FACTOR 4 AND ITS COMPLEXES
WITH HEPARINS STUDIED BY DIFFERENTIAL SCANNING CALORIMETRY

Mihaela Delcea*, Martin Kreimann, Andreas Greinacher (Germany)

08:45 – 09:00

COMPARISON OF BLEEDING COMPLICATIONS BETWEEN ANTI-XA AND
APTT MONITORING IN PATIENTS RECEIVING UNFRACTIONATED HEPARIN

Kathy W. Belk*, Michael Laposata, Christopher Craver (United States)

Microparticles – II

Moderators: Patrick Provost (Canada), Romaric Lacroix (France)

Room 711

08:00 – 08:15

LEUCOCYTES MPS PROMOTE CLOT DISSOLUTION IN A UPA/UPAR
DEPENDENT MANNER

Sylvie Cointe*, Romaric Lacroix, Stephane Robert, Coralie Judicone, Laurence Pani-coit-Dubois, Christophe Dubois, François Dignat-George (France)

08:15 – 08:30

THE Change of the AMOUNT OF CIRCULATING MICROPARTICLES AND
THEIR ASSOCIATION TO THE GENERAL ATHEROSCLEROTIC BURDEN
AFTER ACUTE CORONARY SYNDROME.

Christina Christersson, Birgitta Jonelid, Åsa Thulin*, Agneta Siegbahn (Sweden)

08:30 – 08:45

DECREASED MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY IN
MORBID OBESE PATIENTS AFTER BARIATRIC SURGERY

Johannes Thaler*, Leyla Ay, Johanna Brix, Gerit Schernthaner, Cihan Ay, Guntram Schernthaner, Ingrid Pabinger (Austria)

08:45 – 09:00

PROTEOLYTIC ACTIVITY OF CIRCULATING MICROPARTICLES FROM
ISCHEMIC STROKE PATIENTS REVEALED BY SINGLE PARTICLE LASER
SCANNING CONFOCAL MICROSCOPY

Sara Martinez De Lizarrondo*, Aurélien Briens, Jérôme Parcq, Joan Montaner, Denis Vivien, Maxime Gauberti (France)
Coffee break time in the exhibition (Level 800)  
From 09:15 to 09:45

**PLENARY SESSION 09:45-10:30**

Michael E. Nesheim Plenary Lecture  
**Hall F&G**

Moderator: Nigel Key (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45 - 10:30</td>
<td>Genetics of thrombosis: from mice to humans</td>
<td>David Ginsburg</td>
<td>United States</td>
</tr>
</tbody>
</table>

**Wednesday, June 24, 2015**

### Small thrombosis – a big deal?  
**Room 701**

Moderators: Philip S. Wells (Canada); Gary E. Raskob (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 11:15</td>
<td>Superficial vein thrombosis</td>
<td>Hervé Decousus</td>
<td>France</td>
</tr>
<tr>
<td>11:15 - 11:45</td>
<td>Cerebral vein thrombosis</td>
<td>Jonathan M. Coutinho</td>
<td>The Netherlands</td>
</tr>
</tbody>
</table>

### Controversies in antiplatelet therapy for patients with coronary artery disease  
**Room 801**

Moderator: Andrew Frelinger (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 11:05</td>
<td>Antiplatelet drugs: what are the best targets for which treatments?</td>
<td>Christian Gachet</td>
<td>France</td>
</tr>
<tr>
<td>11:05 - 11:25</td>
<td>Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects</td>
<td>Desmond Fitzgerald</td>
<td>Ireland</td>
</tr>
<tr>
<td>11:25 - 11:45</td>
<td>Triple therapy for PCI in atrial fibrillation: standard of care, or a nightmare soon to end?</td>
<td>Freek Verheugt</td>
<td>The Netherlands</td>
</tr>
</tbody>
</table>

### Platelets and Inflammation  
**Room 714**

Moderator: Peter M. Newman (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 11:05</td>
<td>The role of platelets in tissue regeneration following acute coronary syndrome and stroke</td>
<td>David Varon</td>
<td>Israel</td>
</tr>
<tr>
<td>11:05 - 11:25</td>
<td>Reincarnation of ancient links between coagulation and complement</td>
<td>Ed Conway</td>
<td>Canada</td>
</tr>
<tr>
<td>11:25 - 11:45</td>
<td>The role of circulating platelet transcripts</td>
<td>Jane G. Freedman</td>
<td>United States</td>
</tr>
</tbody>
</table>

### Innovations and technology  
**Room 716**

Moderators: Bjorn Dahlbäck (Sweden); Pieter H. Reitsma (The Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 11:05</td>
<td>Global assays for assessing coagulation: enough data for clinical utility?</td>
<td>Claude Négrier</td>
<td>France</td>
</tr>
<tr>
<td>11:05 - 11:25</td>
<td>Use of genetic data to guide therapy in arterial disease</td>
<td>Guillaume Paré</td>
<td>Canada</td>
</tr>
<tr>
<td>11:25 - 11:45</td>
<td>Warfarin pharmacogenomics – current best evidence</td>
<td>Steve Kimmel</td>
<td>United States</td>
</tr>
</tbody>
</table>
SCIENTIFIC PROGRAM

Treatment of anticoagulant-associated bleeding
Plenary Hall F&G

Moderators: Saskia Middeldorp (The Netherlands); Alex C. Spyropoulos (United States)

10:45 - 11:15  New strategies to treat bleeding in patients on anticoagulants: More effective treatment
Ravi Sarode (United States)

11:15 - 11:45  Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal
Sunny Dzik (United States)

Transplantation medicine in childhood
Room 713

Moderators: Suzan Williams (Canada); Christophe Male (Austria)

10:45 - 11:15  Preventing thrombosis
Jeremy Robertson (Australia)

11:15 - 11:45  Managing bleeds
Leslie Raffini (United States)

Lunch in the exhibition (Level 800)
From 11:45 to 12:15

Lunch Symposia
From 12:15 to 13:45

Lunch Symposia Programs are available in the Show Guide. Please consult the different options to attend the symposium of your choice.

Wednesday, June 24, 2015

ORAL COMMUNICATIONS 6  14:00-15:15

Non-vitamin K oral anticoagulants and reversal
Plenary Hall F&G

Moderators: Dougald Monroe (United States), Alexander Graham Turpie (Canada)

14:00 – 14:15  THROMBOTIC SAFETY OF A FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE (BERIPLEX P/N) FOR EDOXABAN REVERSAL IN A RABBIT MODEL
Eva Herzog*, Franz Kaspereit, Wilfried Krege, Baerbel Doerr, Yoshiyuki Morishima, Gerhard Dickneite (Germany)

14:15 – 14:30  REVERSING THE EFFECT OF RIVAROXABAN -AN IN-VITRO STUDY
Nina Schultz*, Hoa Thi Tuyet Tran, Carola Henriksson, Marissa LeBlanc, Stine Bjøm- sen, Per Morten Sandset, Pål Andre Holme (Norway)

14:30 – 14:45  ANDEXANET ALFA BUT NOT FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE REVERSES RIVAROXABAN-INDUCED ANTICOAGULATION AS MEASURED BY REDUCTION IN BLOOD LOSS IN A RABBIT LACERATION MODEL
Polly Pine*, Stanley Hollenbach, Francis DeGuzman, Siuste Tan, John Malinowsky, Pratiksha Pratikhiya, Genmin Lu, John Cummute, Pamela Conley (United States)

14:45 – 15:00  REVERSAL OF TARGETED ANTICOAGULANTS BY COMPLEXES OF ALPHA-2-MACROGLOBULIN WITH THROMBIN AND FACTOR XA.
Dougald M. Monraye*, Jen-Yea Chang (United States)

15:00 – 15:15  IDARUCIZUMAB DOES NOT HAVE PROTHROMBOTIC EFFECTS: ASSESSMENT OF COAGULATION MARKERS IN HEALTHY VOLUNTEERS
Joachim Stangier*, Michael Schmohl, Stephan Glund, Akiko Harada, Susumu Imazu, Marina De Smet, Viktoria Moschetti, Steven Ramael, Ipe Ikushima, Fredrick Gruen- enfelder, Paul Reilly (Germany)

Venous thromboembolism – epidemiology III
Room 718

Moderators: Paul Kyrie (Austria), John-Bjarme Hansen (Norway)

14:00 – 14:15  PROGNOSTIC SIGNIFICANCE OF ASYMPTOMATIC DEEP VEIN THROMBOSIS IN PATIENTS PRESENTING WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM
David Jimenez*, Borja Castejon, Jose Luis Lobo, Ana Portillo, Rosa Nieto, Roger Yusen (Spain)

14:15 – 14:30  THE INCREASED RISK OF ARTERIAL CARDIOVASCULAR DISEASE IN PATIENTS WITH PRIOR VENOUS THROMBOSIS IS NOT EXPLAINED THROUGH ELEVATED LEVELS OF PROCOAGULANT FACTORS.
Eng Soo Yap*, Jasmijn Timp, Astrid van Hylckama Vlieg, Frits Rosendaal, Suzanne Cannegieter, Willem Lijfering (Singapore)

14:30 – 14:45  INCIDENCE OF VENOUS THROMBOEMBOLISM IN WESTERN FRANCE: COMPARISON BETWEEN 1998 AND 2013
Aurelien Delfuc*, Cécile Tromeur, Emmanuelle Le Moigne, Vincent Coutauda, Grégoire Le Gal, Luc Bressollette, Maelouion Guillonou, Karine Lacut, Dominique Motier (France)

14:45 – 15:00  RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN WOMEN UNDER COMBINED ORAL CONTRACEPTIVE: THE PILL GENETIC RISK MONITORING (PILGRIM) STUDY
Pierre Suchon*, Fadi Al Frouh, Agahe Henneuse, Manal Ibrahim, Dominique Brunet, Marie-Christine Barthe, Marie-Françoise Aillaud, Marie-Christine Alessi, David Tregouët, Pierre-Emmanuel Morange (France)

15:00 – 15:15  SPLENECTOMY AND RISK OF VENOUS THROMBOSIS IN PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)
Ted Wun*, Ann Brunson, Aaron Rosenberg, Richard White (United States)
### SCIENTIFIC PROGRAM

#### Post-thrombotic syndrome, thrombophilia

<table>
<thead>
<tr>
<th>Time</th>
<th>ORAL</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 14:15</td>
<td>OR326</td>
<td>POST THROMBOTIC SYNDROME IN PATIENTS TREATED WITH RIVAROXABAN OR ENOXAPARIN/VITAMIN K ANTAGONISTS FOR ACUTE DEEP VEIN THROMBOSIS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Whitney Cheung*, Saskia Middeldorp, Martin Prins, Akos Pap, Anthonie Lensing, Arina Hoek-tin Cate, Marta Milan, Paolo Prandoni (The Netherlands)</td>
</tr>
<tr>
<td>14:15 – 14:30</td>
<td>OR327</td>
<td>IMPACT OF PRIMARY VENOUS INSUFFICIENCY ON THE PREVALENCE AND RISK OF POST-THROMBOTIC SYNDROME</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jean-Philippe Galanaut*, Thierry Ducruet, Susan Kahn (France)</td>
</tr>
<tr>
<td>14:30 – 14:45</td>
<td>OR328</td>
<td>A SIMPLE PEDIATRIC POST-THROMBOTIC SYNDROME CLASSIFICATION ALGORITHM FOR THE GENERAL PRACTITIONER</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Laura Avila*, Leonardo Brandao, Suzan Williams, Alex Kiss, Jennifer Stinson, Madeline Montoya, Brian Feldman (Canada)</td>
</tr>
</tbody>
</table>

#### Platelet disorders – bleeding

<table>
<thead>
<tr>
<th>Time</th>
<th>ORAL</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 14:15</td>
<td>OR336</td>
<td>DEFECTIVE ALPHAIIBETATHETA ACTIVATION CAUSES PLATELET DYSFUNCTION IN VON WILLEBRAND DISEASE PLATELET-TYPE (PT-VWD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Loredana Bury*, Emanuela Falcinelli, Anna Maria Mezzasoma, Paolo Gresele (Italy)</td>
</tr>
<tr>
<td>14:15 – 14:30</td>
<td>OR337</td>
<td>COMPREHENSIVE EVALUATION OF MECHANISMS ASSOCIATED WITH HYPER-RESPONSIVE PLATELET GPIBA AND THE ROLE OF PROTEIN INHIBITION IN SECURING HEMOSTASIS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Harmanpreet Kaur*, KathrynCorscadden, Maha Othman (Canada)</td>
</tr>
<tr>
<td>14:30 – 14:45</td>
<td>OR338</td>
<td>OXIDATIVE STRESS ACCELERATES PLATELET RECEPTOR GLYCOPROTEIN GPIBA AND GPVI SHEDDING DURING NON-SURGICAL BLEEDING IN HEART FAILURE PATIENTS SUPPORTED BY CONTINUOUS-FLOW LEFT VENTRICULAR ASSIST DEVICE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nandan Mondal*, Erik Sorensen, Mark Slaughter, Si Pham, Bartley Griffith, Zhongjun Wu (United States)</td>
</tr>
<tr>
<td>14:45 – 15:00</td>
<td>OR339</td>
<td>METHODS FOR IDENTIFYING RARE GENETIC VARIANTS AFFECTING THE FORMATION AND FUNCTION OF PLATELETS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ernest Turro*, Daniel Greene (United Kingdom)</td>
</tr>
<tr>
<td>15:00 – 15:15</td>
<td>OR340</td>
<td>SEVERE BLEEDING TENDENCY AND IMPAIRED PLATELET FUNCTION IN A PATIENT WITH CALDAG-GEFI DEFICIENCY.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hisashi Kato*, Yozo Nakazawa, Hirokazu Kashiwagi, Seiji Tadokoro, Yoichiro Morikawa, Daisuke Morita, Yumi Kurokawa, Yuzuru Kanakura, Yoshiaki Tomiyama (Japan)</td>
</tr>
</tbody>
</table>

### SCIENTIFIC PROGRAM

#### Platelets and cancer

<table>
<thead>
<tr>
<th>Time</th>
<th>ORAL</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 14:15</td>
<td>OR341</td>
<td>15(S)-HETE IS A PRO-ANGIOGENIC FACTOR PRODUCED BY PLATELETS THROUGH COX-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Francesca Rauzi*, Nicholas Kirkby, Matthew Edin, Darryl Zeldin, James Whiteford, JaneMitchell, Timothy Warner (United Kingdom)</td>
</tr>
<tr>
<td>14:15 – 14:30</td>
<td>OR342</td>
<td>PLATELETS ENGINEERED TO STORE INTERLEUKIN-24 INHIBITED MELANOMA GROWTH IN MICE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Juan Fang, Ming Yao, Weiqing Jing, Beichung Sun, Bryon Johnson, David A. Wilcox* (United States)</td>
</tr>
</tbody>
</table>

---

**SCIENTIFIC PROGRAM**

**Post-thrombotic syndrome, thrombophilia**

Moderators: Marc Rodger (Canada), Paolo Prandoni (Italy)

- **POST THROMBOTIC SYNDROME IN PATIENTS TREATED WITH RIVAROXABAN OR ENOXAPARIN/VITAMIN K ANTAGONISTS FOR ACUTE DEEP VEIN THROMBOSIS**
  - Whitney Cheung*, Saskia Middeldorp, Martin Prins, Akos Pap, Anthonie Lensing, Arina Hoek-tin Cate, Marta Milan, Paolo Prandoni (The Netherlands)

- **IMPACT OF PRIMARY VENOUS INSUFFICIENCY ON THE PREVALENCE AND RISK OF POST-THROMBOTIC SYNDROME**
  - Jean-Philippe Galanaut*, Thierry Ducruet, Susan Kahn (France)

- **A SIMPLE PEDIATRIC POST-THROMBOTIC SYNDROME CLASSIFICATION ALGORITHM FOR THE GENERAL PRACTITIONER**
  - Laura Avila*, Leonardo Brandao, Suzan Williams, Alex Kiss, Jennifer Stinson, Madeline Montoya, Brian Feldman (Canada)

**Platelet disorders – bleeding**

Moderators: Sara Israels (Canada), Paolo Gresele (Italy)

- **DEFECTIVE ALPHAIIBETATHETA ACTIVATION CAUSES PLATELET DYSFUNCTION IN VON WILLEBRAND DISEASE PLATELET-TYPE (PT-VWD)**
  - Loredana Bury*, Emanuela Falcinelli, Anna Maria Mezzasoma, Paolo Gresele (Italy)

- **COMPREHENSIVE EVALUATION OF MECHANISMS ASSOCIATED WITH HYPER-RESPONSIVE PLATELET GPIBA AND THE ROLE OF PROTEIN INHIBITION IN SECURING HEMOSTASIS**
  - Harmanpreet Kaur*, Kathryn Corscadden, Maha Othman (Canada)

- **OXIDATIVE STRESS ACCELERATES PLATELET RECEPTOR GLYCOPROTEIN GPIBA AND GPVI SHEDDING DURING NON-SURGICAL BLEEDING IN HEART FAILURE PATIENTS SUPPORTED BY CONTINUOUS-FLOW LEFT VENTRICULAR ASSIST DEVICE**
  - Nandan Mondal*, Erik Sorensen, Mark Slaughter, Si Pham, Bartley Griffith, Zhongjun Wu (United States)

- **METHODS FOR IDENTIFYING RARE GENETIC VARIANTS AFFECTING THE FORMATION AND FUNCTION OF PLATELETS**
  - Ernest Turro*, Daniel Greene (United Kingdom)

- **SEVERE BLEEDING TENDENCY AND IMPAIRED PLATELET FUNCTION IN A PATIENT WITH CALDAG-GEFI DEFICIENCY.**
  - Hisashi Kato*, Yozo Nakazawa, Hirokazu Kashiwagi, Seiji Tadokoro, Yoichiro Morikawa, Daisuke Morita, Yumi Kurokawa, Yuzuru Kanakura, Yoshiaki Tomiyama (Japan)

**Platelets and cancer**

Moderators: Issaka Yougbare (Canada), Maha Othman (Canada)

- **15(S)-HETE IS A PRO-ANGIOGENIC FACTOR PRODUCED BY PLATELETS THROUGH COX-1**
  - Francesca Rauzi*, Nicholas Kirkby, Matthew Edin, Darryl Zeldin, James Whiteford, Jane Mitchell, Timothy Warner (United Kingdom)

- **PLATELETS ENGINEERED TO STORE INTERLEUKIN-24 INHIBITED MELANOMA GROWTH IN MICE**
  - Juan Fang, Ming Yao, Weiqing Jing, Beichung Sun, Bryon Johnson, David A. Wilcox* (United States)
**Scientific Program**

**14:30 – 14:45**

**OR343**

**CLEC-2 FACILITATES HEMATOGENOUS TUMOR METASTASIS AND IN VITRO TUMOR GROWTH, BUT NOT IN VIVO TUMOR GROWTH**

Toshiaki Shirai*, Osamu Inoue, Kazuyoshi Hirayama, Hiroshi Endo, Hitomi Sato-Utida, Hideki Fujii, Katsue Suzuki-Inoue, Yukio Ozaki (Japan)

---

**14:45 – 15:00**

**OR344**

**IDENTIFICATION OF A NOVEL C-TYPE LECTIN-LIKE RECEPTOR 2 INHIBITOR THAT SUPPRESSES PODOPLANIN-INDUCED PLATELET AGGREGATION AND CANCER METASTASIS**

Yao-Wen Chang*, Pei-Wen Hsieh, Ju-Chien Cheng, Ching-Ping Tseng (Taiwan)

---

**15:00 – 15:15**

**OR345**

**SURVIVAL AFTER CANCER-ASSOCIATED VENOUS THROMBOSIS: RESULTS FROM THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) STUDY**

Monique Crobach, Hilde Jensvoll, Marianne Severinsen, Jens Hammerstrom, Sigrid Brekke, Katarina Blom, Soren Kristensen, Sigmund Hegg, Anne Tjonneland, Frits Rosendaal, Kim Overvad, John-Bjarte Meltzer, Inger Naess, Suzanne Cannegieter (The Netherlands)

---

**14:00 – 14:15**

**EFFICACY, PHARMACOKINETICS (PK) AND SAFETY RESULTS OF A PHASE 3 CLINICAL STUDY OF RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR IX WITH ALBUMIN (RIX-FP) IN PREVIOUSLY TREATED CHILDREN WITH HEMOPHILIA B**

Gili Kenet*, Herve Chambost, Christoph Male, Thierry Lambert, Maria Álvarez-Román, Susan Halimeh, Anthony Chan, Chris Barnes, Tatiana Chernova, Jan Blatty, Maria Elisa Mancuso, Sandrine Meunier, Vladimir Komrska, Hans-Juergen Laws, Massimo Morfini, Julie Curtain, Bohumir Blazek, Christine Voigt, Iris Jacobs, Elena Santagostino (Israel)

---

**14:15 – 14:30**

**EFFICACY AND SAFETY RESULTS OF A PHASE 3 PILOT CLINICAL STUDY OF RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR IX WITH ALBUMIN (RIX-FP) IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA B**

Elena Santagostino*, Uri Martinowitz, Toshio Limsakun, Jagdev Sidhu, Debra Bensen-Kennedy, Annette Feussner, Christine Voigt, Iris Jacobs, Elena Santagostino, Massimo Morfini (United States)

---

**14:30 – 14:45**

**PERIOPERATIVE HEMOSTATIC MANAGEMENT OF MAJOR SURGERY IN HEMOPHILIA B WITH LONG-ACTING RECOMBINANT GLYCOPLEGATED FACTOR IX: RESULTS FROM THE PARADIGM™3 CLINICAL TRIAL**

Miguel Escobar*, Torben Colberg, Farazah Karim, Umar Caliskan, Pratima Chowdary, Paul Giangrande, Adam Giller, Maria Mancuso, Margit Serban, Woei Tsay, Marek Zak, Johnny Mahlangu (United States)

---

**14:45 – 15:00**

**IMPROVED HEALTH-RELATED QUALITY OF LIFE (QOL) OF HEMOPHILIA B PATIENTS TREATED WITH A WEEKLY 40 IU/KG DOSE OF A NEW LONG-ACTING RECOMBINANT FACTOR IX (FIX) PRODUCT, NONACOG BETA PEGOL**

Pratima Chowdary*, Susan Kearney, Donald Yee, Juliette Meunier, Ulla Slothuus, Christina Hoxer (United Kingdom)

---

**15:00 – 15:15**

**ROLE OF FXIIA, FXIA, AND PLATELET-DERIVED POLYPHOSPHATE IN THROMBIN GENERATION USING HUMAN BLOOD PERFUSED OVER A COLLAGEN/TISSUE FACTOR SURFACE**

Shu Zhu*, Richard Travers, James Morrissey, Scott Diamond (United States)

---

**14:00 – 14:15**

**ANTITHROMBOTIC EFFECT OF ONO-8610539, A NEW, POTENT AND SELECTIVE SMALL MOLECULE FACTOR XIA INHIBITOR, IN A MONKEY MODEL OF ARTERIOVENOUS SHUNT**

Masaru Sakai*, Tetsuya Hagio, Sho Koyama, Masashi Gohda, Keizo Suzuki, Takehiro Ono, Takashi Kondo, Taihei Nishiyama, Kenji Tanaka, Hidekazu Matsu, Akira Imaga- wa, Yasushi Hirot, Kazuhiro Kawabata (Japan)

---

**14:15 – 15:00**

**PLATELET POLYPHOSPHATE ACCELERATES THE INHIBITION OF TFPI BY FACTOR XIA**

Cristina Puy*, Erik Tucker, Andras Gruber, David Gailani, Stephanie Smith, Sharon Choe, James Morrissey, Owen McCarty (United States)

---

**14:30 – 14:45**

**PLATELET POLYPHOSPHATE ACCELERATES THE INHIBITION OF TFPI BY FACTOR XIA**

Cristina Puy*, Erik Tucker, Andras Gruber, David Gailani, Stephanie Smith, Sharon Choe, James Morrissey, Owen McCarty (United States)

---

**14:00 – 14:15**

**SYNERGISTIC ANTI-TUMOR EFFECTS WITH DABIGATRAN ETIXILATE AND CISPLATIN IN A MURINE OVARIAN CANCER MODEL**

Eric Alexander, Candace Hayes, Allyson Minton, Khushboo Jain, Ashley Goss, Joanne Van Ryn, Susan Gilmour* (United States)

---

**14:15 – 15:00**

**COAGULATION FACTOR XII BINDING TO APOPTOTIC CELLS INITIATES THROMBIN GENERATION**

Aizhen Yang*, Robert Colman, Yi Wu (China)

---

**14:30 – 15:15**

**POPULATION PHARMACOKINETICS (PK) OF RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR IX WITH RECOMBINANT ALBUMIN (RIX-FP) IN ADULT AND PEDIATRIC PATIENTS WITH SEVERE HEMOPHILIA B**

Tharin Limsakun, Ying Zhang, Jagdev Sidhu, Debra Bensen-Kennedy*, Annette Feussner, Christine Voigt, Iris Jacobs, Elena Santagostino, Massimo Morfini (United States)
SCIENTIFIC PROGRAM

14:30 – 14:45
OR358
THE GENE ENCODING VITAMINE K-DEPENDENT ANTICOAGULANT PROTEIN S: A POSITIVE REGULATOR OF LUNG CANCER CELL MIGRATION AND INVASION.
Lutfi Suleiman* (France)

14:45 – 15:00
OR359
ANTI-TUMOR ROLE OF ANTITHROMBIN BY INHIBITION OF ENTEROPEPITIDASE THROUGH A NOVEL MECHANISM
Sonia Águila, Ginés Luengo-Gil, Estefan Martín-Villar, Nataliya Bohdan, Miguel Quintanilla, Ana I. Antón, Salvador Espín, Francisco Ayala, Vicente Vicente, Javier Corral, Irene Martínez-Martínez* (Spain)

15:00 – 15:15
OR360
EXPRESSION OF COAGULATION PROTEASES FROM THE APC PATHWAY IN TUMOURS FROM GYNAECOLOGICAL CANCER PATIENTS WITH AND WITHOUT VENOUS THROMBOSIS
Fiona Martin, Sharon O’Toole, Jessica Long, John O’Leary, Noreen Gleeson, Feras Abu Saadeh, Lucy Norris* (Ireland)

ADVANCED THERAPY

14:15 – 14:30
OR361
EXOSITE INTERACTIONS UNCOVER A BROAD SUBSTRATE RECOGNITION PROFILE FOR ADAMTS13
Colin A. Kretz*, Kärt Tomberg, Andrew Yee, David Ginsburg (United States)

14:30 – 14:45
OR362
THE PREDICTIVE VALUE OF ADAMTS13 ACTIVITY FOR TREATMENT OF PATIENTS WITH ACQUIRED TTP: DATA FROM THE PHASE II TITAN TRIAL WITH CAPLACIZUMAB
Filip Callewaert*, Hans Ulrichs, Johanna A. Kremer Hovinga, Katelijne De Swert, Dominique Verspoor (Belgium)

14:45 – 15:00
OR363
LOW ADAMTS13 ACTIVITY AND THE RISK OF CORONARY HEART DISEASE: A PROSPECTIVE COHORT STUDY – THE ROTTERDAM STUDY
Michelle A. Molteni, Maryam Kavousi, Mohammed Ikram, Fritz Scheiflinger, Albert Hofman, Frank Leebeek, Oscar Franco, Moniek de Maat (The Netherlands)

15:00 – 15:15
OR364
EVOLUTIONARY VARIATION IN THE ALLOSTERIC PROPERTIES OF ADAMTS13
Joshua Muia*, Jian Zhu, Garima Gupta, Lisa A. Westfield, Suellen Greco, Louis D’orcho, Karen Vanhoooverbeke, J. Evan Sadler (United States)

SCIENTIFIC PROGRAM

14:15 – 14:30
OR367
AVATHRIN: A NOVEL FAST AND TIGHT BINDING COMPETITIVE INHIBITOR OF THROMBIN FROM AMBLYOMMA VARIEGATUM
Janaki Iyer*, Maria Kazimirova, Jobichen Chako, Patricia Nuttall, Swaminathan Kunchithapadam, Manjusha Kini (Singapore)

14:30 – 14:45
OR368
INCREASED HALF-LIFE AND SELECTIVE FUNCTION OF A GLYCOENGINEERED ANTITHROMBIN VARIANT
Sonia Aguila*, Irene Martinez-Martinez, Nataliya Bohdan, Nuria Garcia-Barbera, Vicente Vicente, Jose Rivera, Javier Corral (Spain)

14:45 – 15:00
OR369
AMINO ACID RESIDUES IN THE LAMININ G DOMAINS OF PROTEIN S INVOLVED IN TISSUE FACTOR PATHWAY INHIBITOR INTERACTION
Sofia Somajo, Josefin Ahrnström*, Magdalena Gierula, Juan Fernandez-Recio, Bruno Villoutreix, Björn Dahlbäck (United Kingdom)

15:00 – 15:15
OR370
SPRING MUSIONS ON ANTITHROMBIN DEFICIENCY. DIAGNOSTIC RELEVANCE AND UNEXPECTED CONSEQUENCES.
Maria Eugenia De La Morena-Barrio*, Irene Martinez-Martinez, Susana Asenjo, Teresa Sevivas, José Padilla, Antonia Miñano, Mara Toderici, Raquel López-Gálvez, José Navarro-Fernández, Vicente Vicente, Javier Corral (Spain)

FIBRINOGEN AND FIBRIN I

14:00 – 14:15
OR365
INTERACTION OF FIBRIN WITH THE VLDL RECEPTOR ON ENDOTHELIAL CELLS: LOCALIZATION OF THE FIBRIN-BINDING SITE AND IDENTIFICATION OF ITS INHIBITORS
Leonid Medved*, Sergiy Yakovlev (United States)

14:15 – 14:30
OR371
CHARACTERIZING REACTIVE GLUTAMINES IN FIBRINOGEN ALPHA C (233-425) AND PROBING FACTOR XIII SUBSTRATE SPECIFICITY
Kelly Njine Mouapi*, Jacob Bell, Kerrie Smith, Robert Ariëns, Helen Philippou, Muriel Maurer (United States)

14:30 – 14:45
OR372
DEVELOPMENT AND VALIDATION OF A JAVA-BASED COMPUTER PROGRAM FOR IMAGE ANALYSIS OF FIBRIN ULTRASTRUCTURE
Francis Chan*, Jorell Gantioqui, Ivan Stevic, Celia Kwan, Keith Lau, Anthony Chan, Howard Chan (Canada)

14:45 – 15:00
OR373
EFFECT OF FIBRINOGEN GAMMA’ PEPTIDE ON FACTOR XI ACTIVATION BY THROMBIN
Farida Omarova*, Shirley Uitte de Willige, Robert Ariëns, Rogier Bertina, Jan Rosing, Elisabetta Castoldi (The Netherlands)

15:00 – 15:15
OR374
FIBRINOGEN(EGEN) ENGAGEMENT OF INTEGRIN MAC-1 (ALPHA-M BETA-2) LIMITS CHRONIC LIVER FIBROSIS INDUCED BY A BILE DUCT TOXICANT IN MICE
Nikita Joshi*, Anna Kopec, Holly Fedewa, Matthew Flick, James Luyendyk (United States)

Fibrinogen and fibrin I

14:00 – 14:15
OR366
DEVELOPMENT OF A NOVEL PROTEIN S-BASED ANTITHROMBOTIC AGENT
Rinku Majumder*, Anze Testen, Howard Fried, Paulo Simioni (United States)

Moderators: Paolo Simioni (Italy), Janaki Iyer (Singapore)
**Fibrinolytic system – I**

**Moderators:** Nicola Mutch (United Kingdom), Roger Lijnen (Belgium)

14:00 – 14:15 **NANOPARTICLE-BASED, MOLECULAR CONTROL OF THE PLASMIN ACTIVE SITE TO ACHIEVE DIRECT FIBRINOLYSIS IN A NOVEL IN-VITRO SYSTEM OF PULMONARY EMBOLISM**

Jeffrey A. Kline*, Nathan Alves, Aditya Shah, Daren Beam (United States)

14:15 – 14:30 **EFFECT OF QUEBEC PLATELET DISORDER ON LEUKOCYTE UROKINASE PLASMINOGEN ACTIVATOR (UPA) LEVELS.**

Subia Tasneem*, Asim Soomro, Georges-Étienne Rivard, John Waye, Catherine Hayward (Canada)

14:30 – 14:45 **ASSESSMENT OF FIBRINOLYTIC PARAMETERS IN PATIENTS WITH HEMOPHILIA A**

Marija Milos*, Desiree Coen Herak, Silva Zupancic-Salek, Renata Zdro (Croatia)

14:45 – 15:00 **DEFIBROTIDE IMPROVES FIBRINOLYSIS EFFICIENCY IN TPA-RESISTANT ARTERIAL THROMBOSIS**

Sara Martínez De Lizarondo*, Sophie Guettier, Marina Rubio, Clement Gakuba, Emmanuel Touzé, Denis Vivien, Maxime Gauberti (France)

Coffee break time in the exhibition (Level 800)
From 15:15 to 15:45

**Wednesday, June 24, 2015**

**ABSTRACT SYMPOSIA 15:45-17:15**

**Platelet activation**

**Moderators:** Alaistair Poole (United Kingdom), Vincenzo Leo (United Kingdom)

15:45-16:15 **REGULATION OF PLATELET MEMBRANE TRAFFICKING**

Sidney “Wally” Whiteheart (United States)

16:15 – 16:35 **IMPAIRED NUCLEAR ACCUMULATION AND DNA BINDING OF TWO FLI1 VARIANTS RESULTS IN ABNORMALLY LARGE PLATELET ALPHA GRANULES AND A REDUCTION IN PLATELET DENSE GRANULE NUMBER**

Vincenzo C. Leo*, Bart Wagner, Lucinda Nicholson-Goult, Michael Makris, Steve Watson, Martina Daly (United Kingdom)

16:35 – 16:55 **DYSREGULATION OF PLDN (PALLIDIN) AS A MECHANISM FOR PLATELET DENSE GRANULE DEFICIENCY IN RUNX1 HAPLODEFICIENCY**

Guangfen Mao, Chengxiang Fan, Gauthami Jalagadugula, Robert Freishtat, A. Koneti Rao* (United States)

16:55 – 17:15 **GRANUPHILIN (SYNAPTOTAGMIN-LIKE PROTEIN 4, SLP4) REGULATES PLATELET DENSE GRANULE SECRETION AND AGGREGATION**

Ewelina M. Golebiewska*, Christopher Williams, Tetsuro Izumi, Alastair Poole (Japan)

**Platelet function testing assays**

**Moderators:** Paul Harrison (United Kingdom), Owen McCarty (United States)

15:45-16:15 **CAN PLATELET FUNCTION TESTING TELL WHETHER YOUR PATIENT WILL BLEED OR THROMBOSE?**

Marie Lordkipanidze (Canada)

16:15 – 16:35 **UNCOVERING GENETIC NETWORKS UNDERLYING PLATELET RESPONSE TO THIENOPYRIDINES BY EXOME SEQUENCING OF CLOPIDOGREL-TREATED PATIENTS EXHIBITING EXTREME PLATELET REACTIVITY**

Jean-Luc Reny*, Brian Stevenson, Mark Iberson, Youssef Daali, Mylène Docquier, Ioannis Xenarios, Pierre Fontana (Switzerland)
SCIENTIFIC PROGRAM

16:35 – 16:55
AS129

DEVELOPMENT OF A SMALL VOLUME, WHOLE BLOOD, PLATELET FUNCTION ASSAY TO ASSESS NEONATAL PLATELET ADHESION, ACTIVATION, AND AGGREGATION
Sandra Baker-Groberg*, Kristina Haley, Natalia Dovlatova, Michael Recht, Owen McCarty (United States)

16:55 – 17:15
AS130

PLATELET AGGREGATION ASSAYS DO NOT RELIABLY DIAGNOSE PLATELET STORAGE POOL DEFICIENCY
Lorene Yoxtheimer*, Mary Smith, William Gunning (United States)

SCIENTIFIC PROGRAM

16:45 – 17:00
AS138

STATIN USE AND RISK OF RECURRENT VENOUS THROMBOSIS: RESULTS FROM THE MEGA FOLLOW-UP STUDY
Willem Lijfering*, Sigrid Braekkan, Camilla Caram-Deeelder, Bob Siegerink, Astrid van Hylckama Vlieg, Saskia le Cessie, Frits Rosendaal, Suzanne Cannegieter (The Netherlands)

17:00 – 17:15
AS139

LONG-TERM FOLLOW-UP OF A PROSPECTIVE COHORT OF UNPROVOKED VENOUS THROMBOEMBOLISM (VTE) PATIENTS OFF ANTICOAGULANTS- RISK STRATIFICATION EVALUATION (REVERSE)
Marc A. Rodger*, Michael Koscius, Gregoire Le Gal, Dimitri Scarvelis, Susan Kahn, David Anderson (Canada)

Therapeutic management of venous thrombosis
Plenary Hall F&G

Moderators: Susan Kahn (Canada), Ammar Majeed (Sweden)

15:45-16:15
AS135

IWC FILTERS: CLEAR AND NOT SO CLEAR INDICATIONS
Patrick Mismetti (France)

16:15 – 16:30
AS136

ADDITIONAL CATHETER-DIRECTED THROMBOLYSIS FOR HIGH PROXIMAL DEEP VEIN THROMBOSIS: 5 YEAR RESULTS OF A RANDOMIZED CONTROLLED TRIAL (THE CAVEN STUDY)
Yvha Haig*, Tone Enden, Ole Grotta, Nils-Einar Kleveland, Carl Erik Slagsvold, Waleed Ghanima, Pål Andre Holme, Per Morten Sandset (Norway)

16:30 – 16:45
AS137

ANTICOAGULANT THERAPY FOR SYMPTOMATIC DISTAL DEEP VEIN THROMBOSIS: THE CACTUS RANDOMIZED PLACEBO-CONTROLLED TRIAL
Marc Righini*, Jean-Philippe Galante, Hervé Guennegue, Dominique Brisot, Antoine Diard, Pascale Faisse, Marie-Thérèse Barrelier, Claudine Hamel Desnos, Christine Juras, Olivier Pichot, Myriam Martin, LUCIA Mazzoli, Clarisse Chaqueut, Sandrine Accassat, Marc Carrier, Grégory Le Gal, Bernardette Memmild, Jean-Pierre Laroche, Henri Bounameaux, Amaud Perrier, Susan Kahn, Isabelle Quéré (Switzerland)

Membrane scrambling
Room 711

Moderators: Ejaife Agbani (United Kingdom), Julia Anderson (Scotland)

15:45-16:15
AS140

SCRAMBLING THE MEMBRANE: A REGULATORY MECHANISM FOR PLATELET FUNCTION
Johan Heemskerk (The Netherlands)

16:15 – 16:35
AS141

PLATELETS MAXIMISE MEMBRANE SURFACE AREA THROUGH COORDINATED BALLOONING AND PROCOAGULANT SPREADING TO AMPLIFY LOCALISED THROMBIN GENERATION
Ejaife Agbani*, Ed Brown, Marion Van Den Bosch, Christopher Williams, Nadine Matthey, Judith Cosemans, Peter Collin, Johan Heemskerk, Ingeborg Hors, Alastair Poole (United Kingdom)

16:35 – 16:55
AS142

HYSTERESIS-LIKE BINDING OF COAGULATION FACTOR X/XA TO LIPIDS PROTECTS FROM BLOOD FLOW
Nadezhda Podoplelova, Anastasia Sveshnikova, James Kurasa, Andrey Sarafanov, Fazly Ataullakhanov, Mikhail Pantleev* (Russian Federation)

16:55 – 17:15
AS143

NOVEL PEPTIDE AND PEPTIDOMIMETIC INHIBITORS OF PROTHROMBINASE ASSEMBLY ON PHOSPHATIDYLSERINE INHIBIT THROMBIN GENERATION AND FIBRIN FORMATION
Noah Kastelowitz*, Abimbola Jarvis, Ormacinda White, Peter Brown, Gary Brosky, Ryo Tamura, Jorge Di Paola, Hang Yin (United States)

Modulators of fibrinolytic activity
Room 705

Moderators: Jim Fredenburg (Canada), Jonathan Foley (United Kingdom)

15:45-16:15
AS144

NOVEL APPROACHES TO MODULATING FIBRINOLYTIC ACTIVITY
Paul Declerck (Belgium)

16:15 – 16:35
AS145

EFFECT OF DS-1040 ON ENDOGENOUS FIBRINOLYSIS AND IMPACT ON BLEEDING TIME IN RATS
Kengo Noguchi*, Naoko Edo, Yusuke Ito, Kyoji Yamaguchi (Japan)

16:35 – 16:55
AS146

A NOVEL METHOD TO DEVELOP PLASMINOGEN ACTIVATOR INHIBITOR-1 ANTAGONIST AS THROMBOLYTIC AGENT
Lihu Gong, Valerie Proulle, Zebin Hong, Zhonghui Lin, Min Liu, Cai Yuan, Lin Lin, Barbara Furie, Robert Flumeinstein, Peter Andreasen, Bruce Furie, Mingdong Huang* (China, United States)
INHIBITION OF PAI-1 ACCELERATES VENOUS THROMBOSIS RESOLUTION IN TYPE II DIABETIC MICE.
Rong Li*, Xin Deng, Meiping Ren, Ni Chen, Mao Luo, Kai Yan, Min Zeng, Jianbo Wu (China)

Factor V and regulation

Moderators: Alan Mast (United States), Josefín Ahnström (United Kingdom)

15:45-16:15
AS148

FACTOR V AND TISSUE FACTOR PATHWAY INHIBITOR (TFPI) INTERACTIONS
Rodney Camire (United States)

16:15 – 16:35
AS149

FV ENHANCES PROTEIN S COFACTOR FUNCTION FOR TFPI IN THE INHIBITION OF FXA
Natalia Reglinska-Matveyev, James Crawley, Rodney Camire, David Lane, Josefín Ahnström* (United Kingdom)

16:35 – 16:55
AS150

EAST TEXAS FV-SHORT/TFPI INTERACTION IN INHIBITION OF FXA- AND TF-INITIATED THROMBIN GENERATION
Ruzica Livaja-Koshiar*, Rodney Camire, Michelle Ho, Björn Dahlbäck (Sweden)

16:55 – 17:15
AS151

DEVELOPMENT AND CHARACTERIZATION OF AN RNA APTAMER TARGETING FV/FVA
Erin Soule*, Srimat Krishnaswamy, Bruce Sullenger (United States)

Determinants of thrombus structure and susceptibility to lysis

Moderators: Robert Ariëns (United Kingdom), Marie-Christine Alessi (France)

15:45-16:15
AS152

CELLULAR AND MECHANICAL MODULATORS OF FIBRIN STRUCTURE
Krasimir Kolev (Hungary)

16:15 – 16:30
AS153

FACTOR XIIIA CROSSLINKING OF FIBRIN A-CHAINS MEDIATES RED BLOOD CELL RETENTION IN CLOTS
James R. Byrnes*, Cédric Duval, Yiming Wang, Micah Mooberry, Susan Lord, Joost Meijers, Heyu Ni, Robert Ariëns, Alisa Wolberg (United States)

16:30 – 16:45
AS154

ZN2+ ACCELERATES CLOT FORMATION, MODIFIES CLOT STRUCTURE, AND PROMOTES CLOT STABILITY
Sara J. Henderson*, Jing Xia, Alan Stafford, Beverly Leslie, James Fredenburgh, David Weitz, Jeffrey Weitz (Canada)

16:45 – 17:00
AS155

THROMBIN AND FIBRINOGEN GAMMA' REGULATE PROTOFIBRIL PACKING WITHIN THE FIBRIN FIBER LEADING TO CHANGES IN CLOT STRUCTURE AND STRENGTH
Marco Domingues*, Cedric Duval, Helen McPherson, Ramzi Ajjan, Victoria Ridger, Simon Connell, Helen Philippou, Robert Ariens (United Kingdom)

17:00 – 17:15
AS156

THE ROLE OF BLOOD MICROPARTICLES IN THE FORMATION, STRUCTURE, AND PROPERTIES OF FIBRIN CLOTS
Rustem I. Litvinov*, Rosa Nabigullina, Ilshat Mustafin, John Weisel, Laila Zubairova (Russian Federation, United States)
SCIENTIFIC PROGRAM

Platelet structure and function

Room 714

Moderators: Bernard Nieswandt (Germany), Emily Catherine Reddy (Canada)

15:45-16:15

THE ROLE OF GAP JUNCTIONS IN PLATELET ACTIVATION

Jonathan Gibbins (United Kingdom)

16:15 – 16:30

INTEGRIN PSI DOMAIN HAS ENDOGENOUS THIOL ISOMERASE FUNCTION AND IS A NOVEL TARGET FOR ANTI-THROMBOTIC THERAPY

Naadiya Carrim*, Guangsheng Zhu, Emily Reddy, Miao Xu, Xiaohong Xu, Yiming Wang, Yan Hou, Li Ma, Christopher Lavalie, Yan Li, Min Rui, Tania Petruzzello, Xi Lei, Adili Reheman, Pingguo Chen, John Wilkins, Richard Hynes, John Freedman, Heyu Ni (Canada)

16:30 – 16:45

THE WAVE COMPLEX MEMBER HEM1 IS A CRITICAL REGULATOR OF PLATELET SIZE AND FUNCTION IN MICE

Sebastian Dütting*, Simon Stritt, Sarah Schießl, Georg Krohne, Theresia Stradal, Bernhard Nieswandt (Germany)

16:45 – 17:00

VAMP-7 LINKS GRANULE EXOCYTOSIS TO PLATELET SPREADING

Secil Koseoglu, Jennifer Fitch-Tewfik, Christian Peters, Omozuanvbo Aisiku, Lydia Danglot, Thierry Galli, Robert Flamenhaft* (United States)

17:00 – 17:15

SHEAR-INDUCED GP1B-IX SIGNALING VIA UNFOLDING OF ITS JUXTAMEMBRANE MECHANOSENSORY DOMAIN

Wei Deng*, Anum Syed, Xin Liang, François Lanza, Renhao Li (United States)

Poster with refreshments

From 17:15 – 18:30 in the Exhibition on Level 800

Wednesday, June 24, 2015

POSTER SESSION 17:15-18:30

Posters will be presented on different days during the Congress and are accessible at the same times as the exhibition opening hours. The official poster sessions with refreshments will take place as follows:

Monday, June 22, 2015, from 17.15-18.30

Tuesday, June 23, 2015, from 18.00-19.30

Wednesday, June 24, 2015, from 17.15-18.30

The Poster Area is located inside the Exhibition on Level 800.

Poster setup times are as follows:

Monday, June 22, 2015, from 07.30 - 09.15

Tuesday, June 23, 2015, from 07.30 - 09.15

Wednesday, June 24, 2015, from 07.30 - 09.15

Poster dismantling times are as follows:

Monday, June 22, 2015, from 18.30 - 19.00

Tuesday, June 23, 2015, from 19.30 - 20.00

Wednesday, June 24, 2015, from 18.30 - 19.00

Posters not taken down after the dismantling time will be discarded.

If you have sent your poster to the poster printing service, kindly note that you will be able to pick it up at the Poster Booth located in the Swing Space on Level 800.

Poster Booth opening times are:

Monday, June 22, 2015, from 07.30 - 19.00

Tuesday, June 23, 2015, from 19.30 - 20.00

Wednesday, June 24, 2015, from 18.30 - 19.00

Pins are provided on the poster boards directly

Vascular remodeling

Room 717

Moderators: Stefania Momi (Italy), Giannoula Klement (United States)

15:45-16:15

CONTROL OF VASCULAR PATTERNING

Anne Eichmann (United States)

16:15 – 16:30

EXTRACELLULAR HISTONES EXERT A DIFFERENTIAL CYTOTOXIC AND ANTIANGIOGENIC EFFECT IN PROGENITOR AND MATURE ENDOTHELIAL CELLS

Hebe A. Mena*, Agostina Carestia, Mirta Schattner, Soledad Negrotto (Argentina)

16:30 – 16:45

BLOOD CELLS-DERIVED MATRIX METALLOPROTEINASE (MMP)-2 CONTRIBUTES TO ABDOMINAL AORTIC ANEURYSM (AAA) DEVELOPMENT IN A MOUSE MODEL OF HYPERTENSION/HYPERCHOLESTEROLEMIA

Stefania Momi*, Emanuela Falcinelli, Paolo Gresele (Italy)

16:45 – 17:00

MECHANISM OF REGULATION OF VEGF-A BY JUNCTIONAL ADHESION MOLECULE-A, AN ENDOGENOUS SUPPRESSOR OF ANGIOGENESIS

Mehgna Naik*, Ulhas Naik (United States)

17:00 – 17:15

PLATELET ENDOTHELIAL AGGREGATION RECEPTOR -1: A NOVEL MODIFIER OF NEOANGIOGENESIS

Christophe Vandenbriele*, Alexandre Kauskot, Ine Vandersmissen, Maarten Criet, Sander Craps, Aernout Luttun, Stefan Janssens, Peter Verhamme, Marc Hoyaert (Belgium)

Acquired coagulation disorders/inhibitors

PO001-WED

ACQUIRED HAEMOSTATIC DISORDERS BY ORTHOTOPIC LIVER TRANSPLANTATION

Dorit Blickstein*, Marius Braun, Eytan Cohen, Eytan Mor (Israel)

PO002-WED

CORRELATION BETWEEN ACTIVATED PROTEIN C (APC) RESISTANCE AND STNFR2 IN ALZHEIMER DISEASE PATIENTS CARRYING ‘EPSILON’4 ALLELE OF THE APOLIPOPROTEIN E

Priscila Moreira*, Maria das Gracas Carvalho, Gisele Goncalves, Danyelle Rios, Edgar Moraes, Maria Aparecida Bicalho, Luci Maria Dusse, Mayara Faria, Marcos Vinícius Silva, Ana Paula Fernandes, Maria Christella Thomassen, Tilman Hackeng (Brazil)

PO003-WED

PERSISTENT INTERNATIONAL NORMALIZED RATIO (INR) ELEVATION ASSOCIATED WITH OLMESARTAN-INDUCED ENTEROPATHY IN A PATIENT RECEIVING WARFARIN

Alexandra McGrath, Jennifer Lowerison*, Elizabeth MacKay (Canada)
SCIENTIFIC PROGRAM

PO004-WED  DIFFERENTIATION BETWEEN PRO- AND ANTICOAGULANT ACTIVITY DEMONSTRATES REBALANCED THROMBIN GENERATION IN LIVER CIRRHOSIS
Romy Kremers*, Marie-Claire Kleinegris, Hugo ten Cate, Rob Wagenoord, Coenraad Hemker (The Netherlands)

PO005-WED  HEMOSTATIC EFFECTS OF REGENERATIVE THERAPY IN PATIENTS WITH ALCOHOLIC CIRRHOSIS - A DEVELOPING COUNTRY EXPERIENCE.
Priyanka Saxena*, Chhagan Bihari, Pratibha Dhiman, Archana Rastogi, S.K. Sarin (India)

PO006-WED  TWO JAPANESE CASES OF ACQUIRED FACTOR V INHIBITOR WHICH WERE INITIALLY DIAGNOSED WITH CONGENITAL FACTOR V DEFICIENCY
Masato Bingo*, Keiko Shinozawa, Takeshi Hagiwara, Hiroshi Inaba, Takashi Suzuki, Kagehiro Amano, Katsuyuki Fukutake (Japan)

PO007-WED  TREATMENT OF ACQUIRED FACTOR V INHIBITORS RESULTING IN DISSEMINATED INTRAVASCULAR COAGULATION
Julie Tanant*, Christopher Hughes, Laura Malins, Martin Howard, Elizabeth Horn (United Kingdom)

PO008-WED  LUPUS ANTICOAGULANT - HYPOPROTHROMBINEMIA SYNDROME IN A 7-YEAR OLD GIRL: A CASE REPORT
Turkan Patiroglu*, Ebru Yilmaz, Ekrem Unal, Musa Karakukcu, Mehmet Ozdemir (Turkey)

PO009-WED  ACHIEVING HAEMOSTATIC CONTROL IN ACQUIRED HAEMOPHILIA A WITH PLASMA DERIVED FVIII INFUSIONS
Pu-Lin Luo*, Steve Austin, Sangeeta Atwal, Sarah Mangles, Karon Ranagarajan, Savita Ranagarajan (United Kingdom)

PO011-WED  ACQUIRED HAEMOPHILIA A IN POLAND – A REPORT FROM AHA-POL REGISTRY
Jerzy Windyga*, Joanna Zdziarska, Krzysztof Chojnowski, Magdalena Letowska, Krystyna Zawilska (Poland)

PO012-WED  SUCCESSFUL THERAPY WITH BORTEZOMIB FOR ERADICATION OF INHIBITOR IN A PATIENT WITH MULTIPLE MYELOMA AND ACQUIRED HAEMOPHILIA A
Susana Nobre Fernandes, Manuela Carvalho*, Manuela Lopes, Ricardo Pinto, Rui Bergantim, José Eduardo Guimarães, Fernando Araújo (Portugal)

PO013-WED  CRITICAL INSIGHTS INTO ACQUIRED HAEMOPHILIA A AND RISK-BENEFIT ASPECTS WITH REGARD TO CLINICAL COMPLICATIONS - A CASE REPORT
Bernhard Stephan, H. Lauer, J. Groß, Andreas Link, Joachim F. Schenk* (Germany)

PO014-WED  CLINICAL UTILITY OF HEAT INACTIVATED NIJMEGEN MODIFIED BETHESDA ASSAYS IN FVIII DEFICIENCY – A 4 YEAR SINGLE CENTRE EXPERIENCE
Tejas Gandhi*, Pura Lawler, Pratima Chowdary, Anja Drebes, Anne Riddell (United Kingdom)

SCIENTIFIC PROGRAM

PO015-WED  COMPARISON OF DIFFERENT COAGULATION ASSAYS FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA
Miguel Escobar*, Elizabeth Donnachie (United States)

PO016-WED  FVIII/VWF:AG RATIO IS A POWERFUL TOOL TO EARLY PREDICT RELAPSE IN ACQUIRED HAEMOPHILIA A
Maxime Halliez, Sophie Voisin, Marc Trossaert*, Marianne Sigaud, Marc Fouassier, Catherine Ternisien, Antoine Neel, Mohamed Hamidou, Julie Graveleau (France)

PO017-WED  ASSESSMENT OF PROTHROMBIN TIME PROLONGATION BY THROMBOELASTOMETRY AND THROMBELASTOGRAPHY DURING LIVER TRANSPLANTATION
Shu Lu, Tetsumo Sakai, Ezeldeen Abuelkasem, Raymond Planinsic, Kenichi Tanaka* (United States)

PO018-WED  A NOVEL DIAGNOSTIC SYSTEM OF ACQUIRED COAGULATION FACTOR INHIBITORS USING COMPREHENSIVE COAGULATION ASSAYS
Tomoko Matsumoto*, Keiji Nogami, Midori Shima (Japan)

PO019-WED  INHIBITOR OF FACTOR VIII IN THE NEWBORN. CASE REPORT.
Pavel Svirin*, Ekaterina Shiller, Vladimir Vdovin, Viktor Petrov, Artiom Bullih, Igor Donin, Liubov Larina (Russian Federation)

PO020-WED  USEFULNESS OF VARIOUS SCORING METHODS WITH CROSS-MIXING TEST FOR DETECTION OF LUPUS ANTICOAGULANT
Sumiyoshi Naibo*, Masahiro Ieko, Osamu Kumano, Mika Yoshida, Nobuhiko Takahashi, Takeshi Suzuki, Akihide Ito, Nobutaka Wakamiya (Japan)

PO021-WED  DEFINING COAGULATION DYSFUNCTION IN PATIENTS WITH LEPTOSPIROSIS
Lalliindr Gooneratne*, Rasa Threeswaran, Shiroma Handunetti, Senaka Rajapakse, Roopen Arga (Sri Lanka)

PO022-WED  ACQUIRED VON WILLEBRAND SYNDROME – DIAGNOSIS AND MANAGEMENT.
Angelika Batorova*, Tatiana Priganova, Denisia Jankovicova, Anna Morongova, Erika Balazova (Slovakia)

PO023-WED  ACQUIRED ACTIVATED PROTEIN C RESISTANCE IN ELDERLY PEOPLE WITH AND WITHOUT COGNITIVE IMPAIRMENT
Maria Das Graças Carvalho*, Giselle Gonçalves, Danyelle Rios, Edgar Moraes, Maria Aparecida Bicalho, Marcos Bastos, Luci Maria Dusse, Elisabetta Castoldi, Jan Rosing, Maria Christella Thomassen, Tilman Hackeng (Brazil)

PO024-WED  SINGLE-CENTER EXPERIENCE WITH RITUXIMAB IN THE TREATMENT OF INHIBITOR-ASSOCIATED HEMOSTATIC DISORDERS
Danielle Hammond*, Eliana Sakedown, Alan Timmouth (Canada)

PO025-WED  LUPUS ANTICOAGULANT (LA) TESTING OF A PREGNANT PATIENT REVEALING AN ACQUIRED FACTOR XI AUTOANTIBODY
Geoffrey D. Wool*, Tammy Utset, Jonathan Miller (United States)
PO026-WED  ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN PATIENT WITH HETEROZYGOUS MTHFR C677T MUTATION AND HYPER-HOMOCYSTEINEMIA - A CASE REPORT  
Bernadeta Ceglarek, Ksenia Bykowska, Adam Wiszniewski*, Jerzy Windyga (Poland)

PO027-WED  ACQUIRED INHIBITORS TO FACTOR VIII AND IX, A CASE REPORT  
Saša Anžej Doma, Irena Zupan*, Tadej Pajic, Dušan Andoljšek, Peter Cernelc (Slovenia)

PO028-WED  ANTITROMBIN FUNCTION IN INFECTION DEVELOPMENT IN PATIENTS WITH SEVERE BURNS  
Marina Presnyakova*, Viktoria Kuznetsova, Artem Borisevich, Irina Strelkova (Russian Federation)

PO029-WED  Efficacy of FVIII in the Treatment of Patients with Acquired HAEMOPHILIA A AND VASCULAR DISEASES  
Samantha Pasca, Claudia Battello, Giovanni Barillari* (Italy)

PO030-WED  NEUTRALIZING AUTOANTIBODY AGAINST FACTOR XIII A SUBUNIT WITH MULTIPLE INHIBITORY EFFECT ON FACTOR XIII ACTIVATION/ACTIVITY RESULTED IN SEVERE BLEEDING WITH FATAL OUTCOME  
Krisztina Pénzes*, Anna Selmeczi, Éva Katona, Zsuzsanna Bereczky, Adrienne Kerényi, Éva Molnár, Hajnalka Gulyás, Adrienne Schlammadinger, Zoltán Boda, László Muszbek (Hungary)

PO031-WED  THE ACQUIRED DEFICIENCY OF FACTORS II, VII, IX, X IN THE COURSE OF THE INTOXICATION OF SECOND GENERATION ANTICOAGULANT RO- DENTICIDES IN FEMALE PATIENT SUFFERING WITH SEVERE DIATHE-SIS HAEMORRHAGICA - A CASE REPORT  
Bernadeta Ceglarek, Ksenia Bykowska, Anna Sikorska, Beata Baran, Adam Wiszniewski*, Jerzy Windyga (Poland)

PO032-WED  ADAMTS13 II  
Kieron South*, Isabelle Salles-Crawley, James Crawley, David Lane (United Kingdom)

PO033-WED  CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH UP-SHAW-SCHULMAN SYNDROME RECEIVING MAINTENANCE HEMODIALYSIS DUE TO CHRONIC RENAL FAILURE  
Masanori Matsumoto*, Ayami Isonishi, Koichi Kokame, Masaki Hayakawa, Hideo Yagi, Toshiyuki Miyata, Yoshihiro Fujimura (Japan)

PO034-WED  THE COURSE OF ADAMTS13-PROPERTIES DURING PREGNANCY INDUCED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)  
Rita Dittmer* (Germany)

PO035-WED  PROSPECTIVE VALIDATION OF CLINICAL BIOPHYSICAL PARAMETERS INCLUDING INITIAL HEMOSTASIS, WHICH IMPROVE THE PREDICTION OF DEATH AT 1 MONTH AMONG PATIENTS WITH SEPTIC SHOCK: SEPSICO-AG STUDY  
Geraldine Lavigne-Lissalde*, Jean-Yves Lefrant, Samir Jaber, Christel Castelli, Jean-michel Constantin, Jacques Albannes, Marc Leone, Jean-Christophe Forban, Jérôme Morel, Gilles Seni, Loubna Elotmani, Jean-Christophe Gris (France)

PO036-WED  THE IMPORTANCE OF CONFORMATIONAL ACTIVATION OF ADAMTS13 FOR CONTROL OF PLATELET DEPOSITION UNDER FLOW  
Gerhardus J. A. J. M. Kuiper, Monique Mullens, Paul Verhezen, Karly Hamulyak, Maarten Christiaans, Hugo ten Cate, Yvonne Henskens* (The Netherlands)

PO037-WED  THE IMPACT OF TIMELY ADAMTS13 RESULTS ON CLINICAL DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH SUSPECTED THROMBOTIC MICROANGIOPATHY (TMA): MAYO CLINIC’S EXPERIENCE  
Mohamed Al-Sammak, Tahir Mehmood*, Michelle Taylor, Rajiv Pruthi, Jeffrey Winters, Dong Chen (United States)

PO038-WED  ADAMTS13: VON WILLEBRAND FACTOR CLEAVING PROTEASE GROWTH FACTOR?  
Justin M. Keener*, Courtney Hoyt, George Rodgers (United States)

PO039-WED  DETECTION OF ADAMTS13 ACTIVITY USING THE NATIVE VWF91 PEP-TIDE  
Xia Bai*, Jian Su, Li-juan Cao, Ziqiang Yu, Zhaoyue Wang, Changgeng Ruan (China)

PO040-WED  CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH UP-SHAW-SCHULMAN SYNDROME RECEIVING MAINTENANCE HEMODIALYSIS DUE TO CHRONIC RENAL FAILURE  
Masanori Matsumoto*, Ayami Isonishi, Koichi Kokame, Masaki Hayakawa, Hideo Yagi, Toshiyuki Miyata, Yoshihiro Fujimura (Japan)

PO041-WED  THE IMPORTANCE OF CONFORMATIONAL ACTIVATION OF ADAMTS13 FOR CONTROL OF PLATELET DEPOSITION UNDER FLOW  
Gerhardus J. A. J. M. Kuiper, Monique Mullens, Paul Verhezen, Karly Hamulyak, Maarten Christiaans, Hugo ten Cate, Yvonne Henskens* (The Netherlands)

PO042-WED  ANTI-ADAMTS13 ANTIBODY FEATURES (IG ISOTYPE TITERS, FUNCTIONAL ADAMTS13 INHIBITOR AND CIRCULATING IMMUNE COMPLEXES (CIC)) IN PATIENTS WITH ACQUIRED THROMBOSIS THROMBOCYTOPENIC PURPURA (ATTP) AT FIRST CONSULTATION IN OUR INSTITUTION.  
Ana Kempfer, Juvenal Paiva*, Analía Sanchez-Luceros, Fabiana Alberto, Adriana Woods, Maria Casinelli, Maria Lazzari (Argentina)

PO043-WED  ADAMTS13 GENE EXPRESSION IS INCREASED IN KIDNEY AND LIVER IN TYPE 1 DIABETES MELLITUS ANIMAL MODEL  
Michelle T. Alve*, Guilherme Reis, Adriana Bosco, Bárbara Quirino, Caroline Domingueti, Ana Fernandes, Karina Gomes (Brazil)

PO044-WED  AN ACTIVITY-BASED APPROACH TO ANTI-ADAMTS 13 ANTIBODIES  
Annelie Siegemund*, Ute Scholz, Thomas Siegemund (Germany)
SCIENTIFIC PROGRAM

PO045-WED DETECTION OF PLASMA ADAMTS13 ACTIVITY USING E. COLI DERIVED VWF-A2 SUBSTRATES AND MICROSPHERE-CYTOMETRY ASSAYS Sriram Neelamegham*, Shobhit Gogia, Chi Lo (United States)

PO046-WED THE EFFECT OF PEPTIDE-NOOTROPICS ON PLATELET AGGREGATION INDUCED BY EPINEPHRINE Maria Golubeva* (Russian Federation)

PO047-WED EVALUATION OF THE BLEEDING TENDENCY IN MURINE MODELS OF HEMOPHILIA AND HEPARIN THERAPY USING THE THROMBODYNAMICS ASSAY Vladimir Kolyadko*, Stepan Surov, Semen Buvaly, Vladislav Kuznetcov, Tatiana Vuimo, Fazoi Ataullahkhanov, Mikhail Panteleev (Russian Federation)

PO048-WED ASSESSMENT OF MOD-5014, A LONG ACTING FVIIa, PHARMACOKINETIC, PHARMACODYNAMICS AND CORRECTION OF HEMOPHILIC COAGULOPATHY IN DOGS WITH HEMOPHILIA A AS PART OF THE PREPARATION FOR FIRST IN HUMAN STUDY Gili Hart*, Elizabeth Merricks, Natalie Rigsbee, Robin Raymer, Ahuva Bar-Ilan, Lior Binder, Michal Jaron-Mendelson, Malka Hoffman, Timothy Nichols (Israel)

PO049-WED SAFETY EVALUATION OF CHRONIC ANTITHROMBIN SILENCING IN NON-HUMAN PRIMATE AND EXPANDED THERAPEUTIC INDEX IN A HEMOPHILIA A MOUSE MODEL Scott Barros*, Kun Qian, June Qin, Brian Bettencourt, Alifica Sehgal, Akin Akin (United States)

PO050-WED AN ANTIBODY PRETREATMENT STRATEGY FOR IMPROVING CELL-BASED THERAPY IN A MOUSE MODEL OF HEMOPHILIA B Yu-Chen Hsu*, Meng-Ni Fan, Yu-Jen Huang, Shu-Jhu Yang, I-Shing Yu, Yao-Ming Wu, Shu-Wha Lin (Taiwan)

PO051-WED EFFECTS OF ANKAFERD BLOOD STOPPER ON CUTANEOUS WOUND HEALING: EXPERIMENTAL STUDY Duzgun Ozatli*, Osman Kelahmetoglu, Ayhan Bozkurt, Volkkan Tayfur, Sirri Bozkurt, Piltan Buyukkaya, Levent Yildiz, Tunc Fisgin (Turkey)

PO052-WED ASSESSMENT OF KNEE JOINT BLEEDING IN HEMOPHILIA B MICE BY FLUORESCENCE MOLECULAR TOMOGRAPHY Elizabeth Chappell*, Junjiang Sun, Paul Monahan, Rupa Appa, Bo Winberg, Maureane Hoffman, Dougald Monroe (United States)

PO053-WED SERUM ENDOCAN LEVELS AS A POTENTIAL NON-INVASIVE BIOMARKER FOR DIAGNOSING DIFFERENT HEPATIC DISEASES Rachel Palumbo*, Susan Uprichard, Scott Cotler, Thomas Layden, Jawed Fareed, Debra Hopensteadt (United States)

PO054-WED EFFECT OF A RECOMBINANT PLANT ELASTASE INHIBITOR WITH ANTI-INFLAMMATORY ACTION - RBBCI (BAUHINIA BAUHINIOIDES CRUZAIN/ CRUZIPAIN INHIBITOR) ON A RAT MODEL OF VENOUS THROMBOSIS Maria Luiza Oliva, Cleide Oliveira, Mayara Valois, Tatiana Ottaliano, Marcelo Lima, Antonio Miranda, Misako Sampaio, Francisco H. Maffei* (Brazil)

SCIENTIFIC PROGRAM

Animal models III

Antiphospholipid syndrome II

PO055-WED EVALUATION OF THE IMPORTANCE OF MIXING PATIENT PLASMA WITH A POOL OF NORMAL PLASMAS WHEN DIAGNOSING LUPUS ANTICOAGULANT Ana Maria Lena*, Datevig Attarian, Nora Mota, Sebastian De Los Santos, Gabriela Dominguez, Ana Otero (Uruguay)

PO056-WED THE TAIPAN SNAKE VENOM TIME COULD BE A RELIABLE ASSAY FOR THE DETECTION OF LUPUS ANTICOAGULANT IN PATIENT RECEIVING RIVAROXABAN. Clément Berthomet, Bénédicte Delahousse, Yves Gruel*, Claire Poupillard (France)

PO057-WED NEW MIXING TEST INDEX TO DISCRIMINATE BETWEEN LUPUS ANTICOAGULANT AND COAGULATION INHIBITOR Osamu Kumanono*, Masahiro Ito, Sumiyoshi Naito, Mika Yoshida, Nobuhiko Takahashi, Takeshi Suzuki, Takashi Aoki (Japan)

PO058-WED PREDICTIVE MARKERS FOR THROMBOSIS EVENTS IN AUTOIMMUNE DISEASES: COMPARISON OF ANTIPHOSPHOLIPID SCORE (APL-S) AND GLOBAL ANTI-PHOSPHOLIPID SYNDROME SCORE (GAPSS) Kenji Oku*, Olga Amengual, Ryo Hisada, Kazumasa Oomura, Ikuma Nakagawa, Toshiyuki Watanabe, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda, Tatsuya Atsumi (Japan)

PO059-WED DETECTION OF ANTIPHOSPHOLIPID ANTIBODIES IN NORMAL PREGNANT WOMEN AND IN PREGNANT WOMEN AT THE TIME OF PRE-ECLAMPSIA ONSET Beatriz Grand*, Andrea Avigliano, Monica Gonzalez Alcantara, Liliana Voto (Argentina)

PO060-WED HIGH AVIDITY AUTO-ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR ARE FREQUENTLY OBSERVED IN THROMBOTIC ANTIPHOSPHOLIPID SYNDROME PATIENTS Maria Ethymiou, Andrew Lawrie, Deepa Jayakody Arachchillage, Samuel Machin, Hannah Cohen, Ian Mackie* (United Kingdom)

PO061-WED PREGNANCY IN WOMEN WITH ANTIPHOSPHOLIPID SYNDROME. Denisa Jankovicova*, Angelika Batorova, Tatiana Pitrgancova, Miroslav Korbel (Slovakia)

PO062-WED ANTIPHOSPHOLIPID ANTIBODIES IN CEREBRAL VASCULAR EVENTS Héla Baccouche, Sonia Mahjoub, Montaha Ben Jemaa, Samia Ben Sassi, Meriam Sellami*, Neila Ben Romdhane (Tunisia)

PO064-WED  ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) CORE LABORATORY VALIDATION EXERCISE: AN INTERNATIONAL PERFORMANCE ASSESSMENT OF LUPUS ANTICOAGULANT (LA) TESTS USING STANDARDISED METHODS AND REAGENTS
Ian J. Mackie*, Vittorio Pengo, Elaine Gray, Danieli Andrade, Steven Krilis, Rohan Willis, Doruk Erkan, Hannah Cohen (United Kingdom)

PO065-WED  BENEFICIAL EFFECT OF PRAVASTATIN IN FOUR PREGNANT WOMEN WITH ANTIPHOSPHOLIPID SYNDROME AND ISCHAEMIC PLACENTAL DISEASE
Eleftheria Lefkou*, Apostolos Mamopoulos, Themistoklis Dagkis, Christos Vosnakis, Gerorgios Mavromatidis, Efthimios Nounopolos, David Rousseau, Guillermina Girardi (Greece)

PO066-WED  INCREASED LEVELS OF TISSUE FACTOR IN ANTIPHOSPHOLIPID SYNDROME ARE ASSOCIATED WITH THE DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOUS AND MAY HAVE NO IMPACT ON DISEASE PROGNOSIS
Bruna Mazzeto, Kiara Zapponi, Isadora Custódio, Sabrina Saraiva, Marina Collela, Erich de Paula, Simone Appenzeller, Joyce Annichino-Bizzacchi, Fernanda Orsi* (Brazil)

PO067-WED  DISTINCT RISK FACTORS FOR ARTERIAL AND VENOUS THROMBOSIS IN ANTIPHOSPHOLIPID SYNDROME
Isadora Custódio, Bruna Mazzeto, Sabrina Saraiva, Marina Collela, Erich de Paula, Simone Appenzeller, Joyce Annichino-Bizzacchi, Fernanda Orsi* (Brazil)

PO068-WED  CLINICAL RELEVANCE OF THE GLOBAL ANTIPHOSPHOLIPID SYNDROME SCORE (GAPSS) IN DIFFERENTIATING BETWEEN TRANSIENT ISCHEMIC ATTACK AND STROKE IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES.
Savino Sciascia*, Giovanni Sanna, Veronica Murr, Dario Roccatello, Munther Khamashta, Maria Bertolaccini (United Kingdom)

PO069-WED  EVALUATION OF 82-GLYCOPROTEIN I LEVELS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME.
Teresa Iwaniec*, Magdalena Celinska-Löwenhoff, Marcik Kaczor, Jack Musial (Poland)

PO070-WED  THE ASSOCIATION OF 3 STAT4 SINGLE NUCLEOTIDE POLYMORPHISMS AND ANTIPHOSPHOLIPID SYNDROME
Magdalena M. Celinska-Löwenhoff*, Teresa Iwaniec, Sylwia Dziedzina, Marcik Kaczor, Marek Sanak, Jack Musial (Poland)

PO071-WED  LABORATORY INTERPRETATION OF LA TEST RESULTS IN THE ERA OF TARGET SPECIFIC ORAL ANTICOAGULANTS
Bo Hyun Kim*, Seongsoo Jang, Mi Hyun Bae, Young-Uk Cho, Chan-Jeoung Park (Korea, Republic Of)

PO072-WED  PRODUCTION AND PURIFICATION OF VERSATILE ENZYMES FOR POTENTIAL ANTIPLATELET APPLICATIONS
Bat-Erdene Jugder*, Altantsetseg Buyanbat, Tseren Purev (Mongolia)

PO073-WED  ANTIPLATELET EFFECTS OF GLYPROLINE PEPTIDES BY EXPERIMENTAL METABOLIC SYNDROM
Marina Grigorjeva*, Ludmila Lyapina (Russian Federation)

PO074-WED  PLATELET TRANSFUSION REVERSES BLEEDING EVOKED BY TRIPLE ANTI-PLATELET THERAPY INCLUDING VORAPAXAR, A NOVEL PLATELET THROMBIN RECEPTOR ANTAGONIST
Tian-Quan Cai*, Alexandra Wickham, Gary Sitko, Maria Michener, Richard Raubertas, Larry Handt, Madhu Chintala, Dietmar Seiffert, Michael Forrest (United States)

PO075-WED  THE ANTIPSYCHOTIC CLOzapine IS A POTENT ANTIPLATELET AGENT
Karl Egan*, Jigin Thakore, Ana Lopez Alonso, Eimear Dunne, Niamh Cooke, Nicolas Ramperti, Dermot Kenny (Ireland)

PO076-WED  AN IN VITRO TRANSFUSION MODEL FOR THE ASSESSMENT OF PLATELET FUNCTION RECOVERY FOLLOWING EXPOSURE TO TRIPLE ANTI-PLATELET AGENTS
Lisa K. Jennings*, Vinay Bhal, Michael Herr, Mason Dixon, Steven Akins, Edward Hord, Dietmar Seiffert, Jayaprakash Kohta (United States)

PO077-WED  EFFECTS OF SINGLE COMPARED TO DUAL ANTI-PLATELET THERAPY ON HEMOSTATIC SYSTEM ACTIVATION – A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN HEALTHY VOLUNTEERS
Ludwig Traby*, Alexandra Kaidar, Marietta Kollars, Sabine Eichinger, Michael Wolzt, Paul Kyrle (Austria)

PO078-WED  DEVELOPMENT OF A RECEPTOR OCCUPANCY ASSAY FOR ANFIBATIDE, A NOVEL GPIB ANTAGONIST
Alysia Cox*, Dermot Cox, Marian Brennan (Ireland)

PO079-WED  PEGYLATED DISINTEGRIN EXHIBITS MORE POTENT ANTITHROMBOTIC ACTIVITY IN VIVO
Chun-Chieh Hsu*, Woei-Jer Chuang, Tur-Fu Huang (Taiwan)

PO080-WED  RESISTANCE TO ASPIRIN IN MYELOPROLIFERATIVE NEOPLASMS. IS IT A REALITY?
Nadine Ajzenberg*, Dorothee Faille, Marie-Geneviève Huisse, Anh Cong, Lamia Lamrani, Nicolas Dumontier, Martine Jandrot-Perrus, Bruno Cassinat, Christine Chomienne, Christine Dosquet (France)

PO081-WED  PHARMACOKINETICS AND PHARMACODYNAMICS OF APAC, A DUAL NOVEL ANTICOAGULANT AND ANTIPLATELET HEPARIN COMPLEX
Annukka Jouppila*, Marie-Claude Benoit, Charles-E. Laurent, Dany Salvail, Riitta Lasilla (Finland)

PO082-WED  INHIBITION OF THROMBIN GENERATION BY APIXABAN OR RIVAROXABAN, IN A CELL-BASED MODEL OF COAGULATION PRIMED BY PLATELETS
Irene Lopez-Vilchez*, Lluis Pujadas-Mestres, Nerea Rincon-Tome, Eduardo Arellano-Rodrigo, Ana Galan, Maribel Diaz-Ricart, Gines Escolar (Spain)
PO083-WED  HOW SHOULD WE MEASURE THE EFFECT OF PERSANTINE USING THROMBOELASTOGRAPHY? CORRELATION AND AGREEMENT BETWEEN PERCENT ADP INHIBITION AND ADP NET G
Patti Massicotte, Jennifer Conway, Lindsay May, Holger Buchholz, Clara Lo, Aisha Bruce, Tiffany Tesoro, David Rosenthal, Christopher Almond (Canada)

PO084-WED  NSAIDS IN VIVO TREATMENT AND MRP4 EXPRESSION IN HUMAN PLATELETS
Flavia Temperilli*, Isabella Massimi, Maria Luisa Guarino, Laura Alemanno, Maria Paola Guzzo, Cristina Iannuccelli, Manuela Di Franco, Fabio M. Pulcinelli** (Italy)

PO085-WED  THE EFFECTIVENESS OF P2Y12 RECEPTOR BLOCKADE IS STRONGLY DETERMINED BY THE PRESENCE OF ENDOTHELIAL MEDIATORS PROSCYTACLIN AND NITRIC OXIDE
Rebecca B. Knowles*, Melissa Chan, Paul Armstrong, Chih-Chin Shih, Melissa Hayman, Ivana Vojnovic, Arthur Tucker, Adam Timmis, Timothy Warner (United Kingdom)

PO086-WED  COMPARISON OF THE BIOCYTEX AND THE VASPFIX ASSAYS OF VASP PHOSPHORYLATION IN CORONARY-ARTERY DISEASE PATIENTS TREATED WITH CLOPIDOGREL PLUS ASPIRIN
Ksenia Germanovich, Eti A. Femia, Mariangela Scavone, Vera Caroppo, Marco Cattaneo* (Italy)

Arterial vascular disorders - clinical III

PO087-WED  LOCAL PARAMETERS OF HEMOSTASIS ACTIVATION IN THE FIBRILLATING ATRIUM
Noemi Klara Toth*, Zsuzsa Bagoly, Zoltán Csanádi, Alexandra Kiss, Edina Nagy-Baló, Kitti Kovács, László Muszbek, Zsuzsanna Bereczky, László Csiba (Hungary)

PO088-WED  THE ASSESSMENT OF ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION UNDER FIBRINOLYTIC THERAPY OR PRIMARY PERCUTANEOUS CORONARY INTERVENTION
Mehmet Sonmez*, Ada Khalfi, Meltem Tutak, Ali Bilgen, Ebru Cibik, Taner Turan, Section Gümüşbey (Turkey)

PO089-WED  rHADAMTS13 TREATMENT AMELIORATES CARDIAC LONG-TERM REMODELING AFTER ISCHEMIA-REPERFUSION INJURY
Thilo Witsch*, Kimberly Martinod, Katlynn Gwilt, Denisa Wagner (United States)

PO090-WED  RISK FACTORS FOR CORONARY ARTERY DISEASE IN YOUNG IRANIAN: RESULTS FROM THE MILANO-IRAN (MIRAN) STUDY
Laísa De Paula*, Devanira Costa, Aline Urban, Joyce Annichino-Bizzacchi (Brazil)

PO091-WED  BLOCKING HOMEROMIZATION OF PLATELET CHEMOKINES CCL5 AND CXCL4 REDUCES INFLAMMATION AND PRESERVES HEART FUNCTION AFTER MYOCARDIAL INFARCTION
Rory Roenen, Isabella Werner, Tanja Vajen* Delia Projahm, Mareike Staudt, Adelina Curaj, Tahm Sönmez, Sakine Sinsekyllimaz, Tilman Hackeng, Philipp von Hundelshausen, Christian Weber, Elisa Liehm (The Netherlands)

Atherosclerosis III

PO092-WED  INCREASED CLOT FORMATION IN THE ABSENCE OF INCREASED THROMBIN GENERATION IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE
Marie-Claire Kleinigres, Joke Konings, Jan-Willem Daemen, Yvonne Henskens, Bas de Laat, Henri Spork, Arina ten Cate - Hoek, Hugo ten Cate* (The Netherlands)

PO094-WED  MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING CORONARY ANGIOPLASTY: ROLE OF NADPH OXIDASE P22PHOX GENE POLYMORPHISMS
Betti Giusti*, Claudia Saracini, Silvia Galora, Rossella Marcucci, Anna Maria Gori, Renato Valenti, Guido Parodi, Gian Franco Gensini, David Antonucci, Francesco Violi, Rosanna Abbate (Italy)

PO095-WED  THROMBOGENICITY ACCORDING TO THE VASCULAR SITE OF ATHEROSCLEROSIS DISEASE
Daniela Calderaro*, Adriana Pastana, Tania Rubia Rocha, Fernanda Justo, Danielle Gualandro, Pal Yu, Mariana Matheus, Elbio D’Amico, Bruno Caramelli (Brazil)

PO096-WED  THE ROLES OF TRANSGLUTAMINASE 2 AND FXIII-A IN ABDOMINAL AORTIC ANEURYSM DEVELOPMENT
Kathryn Griffin, Kingsley R. Simpson*, Nadira Yuldasheva, Robert Graham, Peter Grant, Julian Scott, Chris Jackson, Richard Pease (United Kingdom)

PO097-WED  FACTOR XII AND THROMBIN GENERATION ARE ELEVATED IN ACUTE CORONARY SYNDROME AND ARE PREDICTORS OF RECURRENT CARDIOVASCULAR EVENTS.
Rinske Loeffen*, Rene van Oerle, Mathie Leers, Harry Crijns, Henri Spork, Hugo ten Cate (The Netherlands)

PO098-WED  TWO PEPTIDE EPITOPES DERIVED FROM HUMAN AND MYCOBACTERIUM, RESPECTIVELY, REDUCE ATHEROSCLEROTIC LESION IN B6;129S-LDLR(TM1HER)APOB(TM2SGY)/J MICE
Min Xia, Daxin Chen, Valeria Endres, Ilidiko Lantos, Andrea Szabo, Lakshmi Mundkur, Vijay Kakkar, Xinjie Lu* (United Kingdom)

PO099-WED  THE GUT MICROBIOTA IMPACTS PLASMATIC COAGULATION FACTORS AND AUGMENTS ARTERIAL THROMBUS FORMATION.
Avinash Khandagale*, Eivor Wilms, Sven Jäckel, Karl Lackner, Ulrich Walter, Christoph Reinhardt (Germany)

PO100-WED  THE ROLE OF CLOTTING FACTOR IX IN THE DEVELOPMENT OF ATHEROSCLEROSIS
Lais De Paula*, Devanira Costa, Aline Urban, Joyce Annichino-Bizzacchi (Brazil)

PO101-WED  PHOSPHORYLATION OF PLATELET ACETYL-COA COBXYLASE IS INCREASED IN HUMAN AND MICE ATHEROSCLEROSIS AND COULD BE AN INDICATOR OF PERSISTENT THROMBIN GENERATION.
Sophie Lepropre*, Shakeel Kautbally, Marie-Blanche Onselaer, David Vancraeynest, Nicolas Barrile, Luc Bertrand, Jean-Louis Vanoverschelde, Christophe Beauloye, Sandrine Horman (Belgium)
SCIENTIFIC PROGRAM

PO102-WED  DIFFERENTIAL EFFECTS OF LEPTIN SIGNALING IN ENDOTHELIAL OR SMOOTH MUSCLE CELLS ON NEOINTIMA FORMATION FOLLOWING VASCULAR INJURY IN MICE
Katrin Schäfer, Astrid Hubert*, Magdalena Bochenek, Marco Schroeter, Thomas Münzel (Germany)

PO103-WED  BINDING OF COAGULATION FACTOR XIII TO ACTIVATED PLATELET SUB-POPULATIONS
Yana Kotova*, Nadezhda Podoplelova, Alexandra Demyanova, Herve Chambost, Marie Christine Alessi, Mikhail Panteleev (Russian Federation)

PO104-WED  EFFECT OF DABIGATRAN ETEXILATE AND WARFARIN ON Atherosclerotic Plaque Calcification in Apoe-/- MICE.
Leon J. Schungers*, Rick van Gorp, Brecht Willems, Henri Spronk, Chris Reutelsperger (The Netherlands)

PO105-WED  HYPERGLYCAEMIC APOLIPOPROTEIN-E DEFICIENT MICE HAVE ACCELERATED Atherosclerosis AND ABERRANT VASA VASORUM NEOVASCULARIZATION
Heidi Stoute*, Daniel Venegas-Pino, Kaley Veerman, Peter Shi, Geoff Werstuck (Canada)

Blood coagulation tests III

PO106-WED  THE EFFECT OF HOMOCYSTEINE ON THE RESULTS OF THROMBOBODYNAMICS TEST
Nadezda Vorobyeva*, Yulia Pavlovskaia (Russian Federation)

PO107-WED  EVALUATION OF A NEW HOMOGENEOUS IMMUNOASSAY FOR QUANTIFICATION OF PROTHROMBIN FRAGMENT 1+2 (F1+2) IN HUMAN PLASMA SAMPLES*
Matthias Ehnh*, Doris Kraul, Achim Stangl, Martina Pfeiff, Lisa Feddersen, Verena Smith, Christina Duwe, Uwe Kuhn, Olivia Pohlack-March, Petra Vesper, Elfriede Boucesin-Mueller, Norbert Zander (Germany)

PO108-WED  IDENTIFYING FACTOR DEFICIENCIES BY USING THE SECOND DERIVATIVE CURVE OF APTT ON AN ACL-STOP COAGULATION ANALYZER
Tokunaga Naoki*, Inoue Chihiro, Sakata Toshiyuki, Kagawa Kumiko, Abe Masahiro, Nakao Takayuki, Takamatsu Norimichi, D. Toshio (Japan)

PO109-WED  A RARE COMBINATION: CONGENITAL FACTOR VII DEFICIENCY WITH CHIARI MALFORMATION
Ali Bay, Elif Aktekin, Ibrahim Erkutlu (Turkey)

PO110-WED  CAN COMPARING THE VALUE OF THE PROTHROMBIN TIME RATIO AND THE ACTIVATED PARTIAL THROMBOPLASTIN TIME RATIO HELP DIAGNOSE THE CAUSE OF COAGULOPATHY?
Yingyong Chinthammitr*, Phasakorn Putchakarn (Thailand)

PO111-WED  THROMBIN GENERATION TEST FOR MONITORING OF CONVENTIONAL HEMOPHILIA TREATMENT
Olga Smirnova*, Vera Kobilyanskaya, Vitaliy Soldatenkov, Vyacheslav Burakov, Ludmila Papayan (Russian Federation)

SCIENTIFIC PROGRAM

PO112-WED  EFFECT OF RECOMBINANT LUBRICIN ON COAGULATION PARAMETERS IN HUMAN BLOOD
Jawed Fareed*, Debra Hoppensteadt, Omer Iqbal, Schuharazad Abro, Patrick Sweigert, Ed Truitt, Gregory Jay, William Hopkinson (United States)

PO113-WED  CHARACTERISTICS OF COAGULATION DYNAMICS IN ACUTE PHASE OF KAWASAKI DISEASE
Hiroyouki Yoshizawa*, Keiji Nomugi, Tatsuko Matsumoto, Tamaki Hayashi, Midori Shima (Japan)

PO114-WED  ABILITY OF THROMBOELASTOGRAPHY TO DISTINGUISH THE SEVERITY OF PHENOTYPE IN PATIENTS WITH SEVERE HEMOPHILIA
Maria Elisa Mancuso*, Veena Chantarangkul, Marigrazia Clerici, Maria Fasulo, Lidia Padovan, Erica Scalaibrino, Flora Peyrandi, Armand Tripodi, Elena Santagostino (Italy)

PO115-WED  WHOLE BLOOD COAGULATION ANALYSES ARE DEPENDENT ON THE TEMPERATURE THEY ARE PERFORMED AT
Anni N. Jeppesen*, Hans Kirkegaard, Susanne Ilkjaer, Anne-Mette Hvas (Denmark)

PO116-WED  CORRELATION OF PEAK THROMBIN CONCENTRATIONS WITH ONE-STAGE ACTIVITY ASSAY LEVELS INDICATES THAT THROMBIN GENERATION ASSAYS CORRELATE WITH FACTOR VIII ACTIVITY IN CLINICAL HEMOPHILIA A PLASMA SAMPLES.
Sunita Patel-Hett*, Julie Lee, Sayani Rakhe, Steve Arkin, Francois Huard, Debra Pittman, John Murphy, Fei Hua (United States)

PO117-WED  HEPARIN INTERFERENCE IN ANTI-XA ASSAYS FOR RIVAROXABAN AND APIXABAN
Gwen A. Cutsforth*, Kathleen Finnegan (United States)

PO118-WED  USE OF LYOPHILIZED PHOSPHOLIPID VESICLES IN THROMBOBODYNAMICS ASSAY
Natalia Korotina*, Lubov Sokolova, Elena Ponomareva, Natalia Dashkevich, Fazoil Ataullakhanov (Russian Federation)

PO119-WED  DOES ANTITHROMBOTIC THERAPY INFLUENCE RESULTS OBTAINED BY THROMBOELASTOMETRY?
Mia Hammer Holck*, Thomas Decker Christensen, Anne-Mette Hvas (Denmark)

PO120-WED  SCREENING METHOD USING TWO DIFFERENT ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) REAGENTS FOR SPECIMENS WITH PROLONGED APTT
Enni Takeo*, Etsuji Suehisa, Masayuki Toku, Tomio Kawasaki, You Hidaka (Japan)

PO121-WED  TROMBIDDEN GENERATION: ESTABLISHMENT OF A REFERENCE INTERVAL AND THE EFFECT OF ASPRIN
Vivi Bo Mogensen*, Mal Therkelsen, Søs Nedergaard-Petersen, Ivy Modrau, Anne-Mette Hvas (Denmark)

PO122-WED  A NEW ASSAY FOR MEASUREMENT OF THE IN-VIVO THROMBIN ACTIVITY IN COMPARISON TO THE IN-VITRO THROMBIN GENERATION POTENTIAL IN PATIENTS WITH HYPER- AND HYPOCOAGULABLE STATE
Silvia M. Koder*, Oliver Koenigsbruegge, Julia Riedl, Simon Panzer, Ingrid Pabinger, Cihan Ay (Austria)
PO123-WED  INFLUENCE OF PRE-ANALYTICAL HEPARIN ON T-PA INDUCED FIBRINOLYSIS DETERMINED BY THROMBOELASTOGRAPHY DESPITE THE USE OF DISCARD TUBES
Floor Moenen*, Inge Verheijen, Ron Straat, Rick Wetzel, Erik Beckers, Yvonne Henskens (The Netherlands)

PO124-WED  EFFECT OF FRESH FROZEN PLASMA IN CRITICALLY ILL PATIENTS
Emil Vibe*, Christine Hvas, Else Toennesen, Anne-Mette Hvas (Denmark)

PO125-WED  A DRVVT-BASED ASSAY TO ESTIMATE THE INTENSITY OF ANTICOAGULATION IN PATIENTS TREATED WITH NOACS
Anne-Laure Sennesael*, Jonathan Douffils, Tom Exner, Bernard Chatelain, Anne-Sophie Larock, Jean-Michel Dogné, Anne Spinewine, François Mullier (Belgium)

PO126-WED  PRE-ANALYTICAL SAMPLE CHECK IN HEMOSTASIS: EVALUATION OF THE NEW COAGULOMETER ACL TOP 750 CTS SYSTEM
Chiara Novelli*, Benedetto Morelli, Maria Gabriella Cozzi, Maria Luisa Duca, Elisa Garghetti, Franca Rampinini (Italy)

PO127-WED  THROMBIN GENERATION IN PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY
Luca Spiezia*, Francesco Vasques, Astrid Behr, Fabio Dalla Valle, Barry Woodhams, Sabrina Gavasso, Paolo Simioni (Italy)

PO128-WED  EVALUATION OF THE AUTOMATED COAGULATION ANALYSER SYMEX® CS-5100 (SIEMENS)
Isabelle Martin Toutain*, Karim Maloum, Lionel Jobic, Tessy Mancic, Alexandre Brissard, Annick Ankri (France)

PO129-WED  IMPACT OF ASSAY, PRODUCT, AND PATIENT VARIABILITY ON PRECISION DOSING FOR FACTOR VIII PROPHYLAXIS
Leonard A. Valentino*, Peter Turecek, Kenneth Mann (United States)

PO130-WED  DETERMINATION OF INSUFFICIENT ANTICOAGULANT EFFECT IN PATIENTS WITH ATRIAL FIBRILLATION USING THROMBODYNAMICS ASSAY
Nikolay N. Topalov*, Irina Zotova, Dmitriy Zateyshchikov, Fazoil Ataullakhanov, Ilya Serebriyskiy (Russian Federation)

PO131-WED  FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE SHOWS ANTI-COAGULANT EFFECT WHEN USED FOR IN VITRO EXPERIMENTS
Emilie Sandgaard Pedersen*, Christine Lodberg Hvas, Signe Voigt Lauridsen, Anne-Mette Hvas (Denmark)

PO132-WED  SILICA CLOTTING TIME (SCT) VS DILUTE VENOM RUSSELL VIPER (DVRV) AND ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) IN THE DIAGNOSIS OF ANTIPHOSPHOLIPID ANTIBODIES SYNDROME.
Evelyn Cortina de la Rosa*, Mara Nuñez Toscano, Omar Coronel Ayala, Alejandra Navarrete Villarruel, Raúl Izaguirre Avila (Mexico)

PO133-WED  DISCORDANCE BETWEEN ACTIVATED PARTIAL THROMBOPLASTIN TIME AND HEPARIN LEVEL MEASURED WITH ANTI-XA ASSAY IN ANTI-TROMBIN-DEFICIENT PLASMA
Alice Kun Yi*, Ivan Stevic, Jorell Gantioqui, Keith Lau, Robin Roberts, Anthony Chan, Howard Chan (Canada)

PO134-WED  EVALUATION OF THE NEW QSMART FROM GRIFOLS IN COMPARISON TO THE QHEMOSTASIS ANALYZER
Anita Woolley*, Stephen Kitchen (United Kingdom)

PO135-WED  HEMOCOMPATIBILITY OF HOSTETROL AND ESTRADIOL COUPLED TO CYCLODEXTRINES
Julie Laloy*, Claudio Palazzo, Luftfaye Alpan, Jean-Michel Foidart, Geraldine Piel, Jean-Michel Dogné (Belgium)

PO136-WED  EVALUATION OF PROLONGED PT / APTT TESTS IN PRESURGICAL PLASMA SAMPLES
Zühre Kaya*, Turkiz Gursel (Turkey)

PO137-WED  VALIDATION OF NEW AUTOMATED LATEX-IMMUNOTURBIDIMETRIC ASSAY FOR MEASURING VWF ACTIVITY
Vladimira Rimac, Sanela Simic Vojak, Desiree Coen Herak*, Renata Zadro (Croatia)

PO138-WED  LABORATORY EVALUATION OF PATIENTS WITH UNDIAGNOSED BLEEDING DISORDERS
Fernanda D. S. Bassora*, Graziela Alves, Susan Quaino, Silmara Montalvão, Erich de Paula, Fernanda Orsi, Joyce Annichino-Bizzacchi (Brazil)
SCIENTIFIC PROGRAM

PO146-WED COMPARISON OF METHODS OF MEASUREMENT OF FACTOR VIII INHIBITORS IN A NEW HAEMOPHILIA CARE CENTER
Mirta Arias, Emanuel Sueldo, Marcela Aválos, Patricia Do Nascimento*, Gabriela Guerrero, Alejandra Baques (Argentina)

PO147-WED THE NORMAL RANGE OF THE THROMBODYNAMICS VALUES FOR APPARENTLY HEALTHY PREGNANT WOMEN
Tatiana A. Vuimo*, Olga Baskova, Olga Gerasimova, Ruzanna Osvepyan, Stepan Surov, Anastasia Mogilevets, Oleg Brusov, Ekaterina Voroshilina (Russian Federation)

PO148-WED FACTOR VIII INHIBITOR TESTING, INTERPRETATION AND STANDARDIZATION – IT’S COMPLICATED
Thomas Siegemund*, Annele Siegemund, Ute Scholz, Zaverio Ruggeri (Germany)

PO149-WED CAN THE OVERALL HAEMOSTATIC POTENTIAL ASSAY PREDICT BLEEDING AND THROMBOSIS RISK IN WARFARINISED PATIENTS?
Caroline J. Reddel*, Kate Burbury, Ray Dauer, Sue Wilson, David Westerman, Bernhard Riedel, Jennifer Curnow (Australia)

PO150-WED DETECTION OF HYPERCOAGULATION IN HIP ARTHROPLASTY PATIENTS.
Leonid A. Parunov*, Irina Taranenko, Andrey Momot, Fazoil Ataullakhanov, Ilya Serebrjisky (Russian Federation)

PO151-WED HEPARIN AND PROTAMINE CONFOUND FACTOR ACTIVITY AND INHIBITOR TESTING WHILE ON CARDIOPULMONARY BYPASS
Michelle Sholzberg*, Chai Phua, Hubert Tsui, Hilde Vandenberghe, Georges Rivard, Hina Chaudhry, Jerome Teitel (Canada)

PO152-WED HEMOSTASIS ALTERATIONS ASSOCIATED TO COMPLICATIONS IN SICKLE CELL SYNDROME
Diego Higuera*, Martha Bravo, Guerrero Belsy, Emelyn Salazar, Karin Perez (Venezuela, Bolivarian Republic Of)

PO153-WED ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) CLOT WAVEFORM ANALYSIS (CWA) ON SYMEX CS 2000 HELPS DIFFERENTIATE MINDER FROM SEVERE PHENOTYPE IN PATIENTS WITH SEVERE HEMOPHILIA A.
Sukesh C. Nair*, Ramya Vijay, Helen Margaret, Aby Abraham, Auro Vishwabandya, Abraham Sundarsingh, Kavitha ML, Arai Nobuo, Parag Tavkar, Kurono Hiroshi, Alok Srivastava (India)

PO154-WED BLOOD COAGULATION TESTS: REVIEW OF VALIDATION REQUIREMENTS FOR FDA CLEARANCE
Iwona Fijalkowska*, Claudia Dollins (United States)

PO156-WED FRACTAL DIMENSION (DF) AS A MARKER OF HYPERCOAGULABILITY, CLOT STRUCTURE AND 12 MONTH SURVIVAL IN LUNG CANCER
Nia Davies, Nicholas Harrison, Simon Noble*, Matthew Lawrence, Vanessa Evans, Roger Morris, Karl Hawkins, Philipil Williams, Philip Evans (United Kingdom)

PO157-WED PREDICTION OF CANCER ASSOCIATED THROMBOSIS. PROSPECTIVE BIOMARKER STUDY
Alfonso Tafur*, Aaron Mansfield, Mohammad Cherry, Philip Comp, Suman Rathbun, Julie Stoner (United States)

PO159-WED FACTOR V LEIDEN MUTATION AND HIGH FVIII ARE ASSOCIATED WITH AN INCREASED RISK OF VTE IN WOMEN WITH BREAST CANCER DURING ADJUVANT TAMOXIFEN - RESULTS FROM A PROSPECTIVE, SINGLE CENTER, CASE CONTROL STUDY
Mirjana Kovac*, Zorica Tomasevic, Slavko Vucicevic, Valentina Djordjevic, Iva Pruner, Dragica Radojkovic (Serbia)

PO161-WED INCREASING PLATELETS AND OTHER MEASURES ENHANCING HEMOSTASIS ARE BOTH IMPORTANT TO PREVENT BLEEDING EPISODES WHEN THROMBOCYTOPENIC PATIENTS REQUIRING ANTIHITHROMBOTIC THERAPY – A REVIEW OF THE MEDICAL LITERATURE
Linda Chow*, Mohammed Almakadi, Keith Lau, Anthony Chan, Howard Chan (Canada)

PO162-WED PANCREATIC CANCER PATIENTS EXPRESS ELEVATED FVIII LEVELS AND METASTASIS-ASSOCIATED FIBRIN TURNOVER PRIOR TO THEIR DIAGNOSIS
Nora Varkila*, Caj Haglund, Hanna Seppänen, Riitta Lassila (Finland)

PO163-WED VARIATIONS OF PLASMA LEVELS OF TFPI AND ACTIVATED FVII-ANTI-TROMBIN COMPLEX IN CANCER PATIENTS: THE INCREASE OF TFPI AS A MAJOR DETERMINANT OF THROMBIN GENERATION.
Patrick Van Dreden, Hélène Doubre, Dominique François, Mariette Adam, Matthieu Grusse, Marc Vasse* (France)

PO164-WED PROTEIN C LEVELS ARE ASSOCIATED WITH MORTALITY IN PATIENTS WITH ADVANCED CANCER
Dorienke Wilts*, Barbara Hulton, Joost Meijers, C. Arnold Spek, Harry Büller, Pieter Willem Kamphuisen (The Netherlands)

PO165-WED L-ASPARAGINASE LOWERS PLASMA ANTITHROMBIN AND MANNAN-BINDING-LECTIN LEVELS: IMPACT ON THROMBOTIC AND INFECTIOUS EVENTS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
Cléence Merlen, Arnaud Bonnefoy*, Eric Wagner, Anik Cornier, Laurence Dedeken, Jean-Marie Leclerc, Caroline Lavender, Georges-Etienne Rivard (Canada)

PO166-WED MICROVESICLES ARE A POTENTIAL BIOMARKER FOR THROMBOSIS AND DIC IN LEUKEMIC PATIENTS: A CROSS-SECTIONAL STUDY
Damien Sheldof*, Jean-Michel Dogné, Carlos Graux, Fabienne George, Anne Sonet, Bernard Chatelain, François Mullier, Christian Chatelain (Belgium)

Cancer and thrombosis/hemostasis III

PO155-WED SP-SELECTIN AS A MARKER OF PLATELET ACTIVATION IN AFRICANS WITH PROSTATE CANCER.
Hannah Omunakwe*, Onyeannunam Ekeke, Christopher Obiorah, Oseikhuemen Ejele (Nigeria)
SCIENTIFIC PROGRAM

PO168-WED  GENETIC VARIANTS IN 3'UTR OF METHYLMETHYleneTRHYDROFOLATE REDUCTASE (MTHFR) PREDICT COLORECTAL CANCER SUSCEPTIBILITY IN KOREANS
Jung O Kim*, Hyo Geun Jang, Gun Ho Choi, Ki Han Ko, Hui Jeong An, Young Joo Jeon, Doyeon Oh, Hwi Joong Yoon, Nam Keun Kim (Korea, Republic Of)

PO169-WED  SIGNIFICANCE OF HAEMOSTATIC PARAMETERS IN PATIENTS WITH URINARY CANCER
Aristeidis Alevizopoulos, Paraskevi Kotsi*, Sofia Gkotsi, Maria Gavalaki, Olga Katsarou (Greece)

PO170-WED  EVALUATION OF THROMBOELASTOMETRY PARAMETERS AS PREDICTIVE MARKERS FOR SINESOUDAL OBSTRUCTION SYNDROME IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA
Joanna Rupa-Matysek*, Lidia Gil, Ewelina Wojtasinska, Zuzanna Kandula, Mieczyslaw Komarnicki (Poland)

PO171-WED  CANCER INDUCING NETOSIS PROMOTES WIDESPREAD ARTERIAL THROMBOSIS PRESENTING AS ISCHEMIC STROKE WITH TROPONIN ELEVATION
Charlotte Thålin*, Melanie Demers, Bo Blomgren, Ann Charlotte Laska, Magnus von Arbin, Håkan Wallén, Denis Wagner, Sara Aspegren (Sweden)

PO172-WED  RELEVANCE OF D-DIMER AND IL-6 LEVELS AMONG PATIENTS WITH CANCER AND INCIDENTAL PULMONARY EMBOLISM
Casey Oconnell*, Patricia McQuillan, Carsten Bokemeyer, Susanne Lezius, Andre Stucker (Switzerland)

PO173-WED  DIAGNOSTIC APPROACH TO RARE LOCALISATION TROMBOSIS IN CANCER PATIENTS
Alexander Vorobev, Alexander Makatsaria* (Russian Federation)

PO174-WED  CLINICAL SIGNIFICANCE OF CIRCULATING TISSUE FACTOR (TF) IN WOMEN WITH SUSPECTED OVARIAN CANCER
Carola Clausen, Alma Rausch, Brigitte Spath, Susanne Lezuis, Ali Amirkhosravi, Monica Davila, John Francis, Carsten Bokemeyer, Fritz Jänicke, Sven Mahner, Florian Langer* (Germany)

PO175-WED  RIVAROXABAN IN PATIENTS WITH VTE AND CANCER: A SINGLE CENTER EXPERIENCE
Samantha Pasca, Ugo Venturelli, Giovanni Barillari* (Italy)

PO176-WED  D-DIMER PLASMA LEVELS AS A MARKER OF PULMONARY EMBOLISM IN PATIENTS UNDERGOING SURGERY FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM
Andrea Artioni*, Paolo Bucciarelli, Serena Passamonti, Giorgio Carrabba, Valeria Conte, Massimo Castellani, Erica Scalaambrino, Ida Martinelli (Italy)

PO177-WED  TISSUE FACTOR PATHWAY INHIBITOR (TFPI) IS A MARKER OF TUMOR PROGRESSION AND PROGNOSIS IN BREAST CANCER
Mari Tinholt*, Hans Kristian Vollen, Kristine Sahlberg, Rolf Kåresen, Torill Sauer, Vessela Kristensen, Anne-Lise Børresen-Dale, Per Sandset, Nina Iversen (Norway)

PO178-WED  INCREASED ACTIVATED PROTEIN C RESISTANCE AND D-DIMER IN BREAST CANCER: PHENOTYPIC AND GENOTYPIC DETERMINANTS AND ASSOCIATION WITH TUMOR CHARACTERISTICS
Mari Tinholt*, Hans Kristian Vollen, Øystein Garred, Marie-Christine Mowinckel, Kristine Sahlberg, Marit Sletten, Anne-Lise Børresen-Dale, Vessela Kristensen, Rolf Kåresen, Ellen Schlichting, Grethe Skretting, Per Sandset, Nina Iversen (Norway)

PO179-WED  THROMBIN GENERATION (TG) IS DOWNREGULATED BY LOW MOLECULAR WEIGHT HEPARIN (LMWH) IN CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM (VTE)
Anna Falanga*, Carmen Tartari, Marina Marchetti, Laura Russo, Kim Lambregts, Davide Resta, Andrea D’Alessio (Italy)

PO180-WED  HYPERCOAGULABILITY: AN ADDED SIDE EFFECT FOR ANDROGEN DEPRIVATION THERAPY IN PROSTATE CANCER PATIENTS
Harmanpreet Kaur*, Spencer Barr, Angela Black, Sylvia Robb, Robert Siemens, Maha Othman (Canada)

Coagulation factor V, X, II, XIII - III

SCIENTIFIC PROGRAM

PO178-WED  IDENTIFICATION OF TWO NOVEL MISSENSE MUTATIONS CAUSING SEVERE FACTOR XIII DEFICIENCY
Munira Borhan*, Helena Handrkova, Verena Schroeder Schroeder, Naveena Fatima, Asif Hussain, Tahir Shamsi, Hans Peter Kohler (Pakistan)

PO182-WED  FIRST GROUNDING FOR COMPLETE STRUCTURAL CHARACTERIZATION OF FXIII HETEROHETRAMER: SUCCESSFUL DISULFIDES!
Sneha Gupta*, Christoph Reinhart, Christoph Krettler, Mohammad Akhter, Vytautas Ivaskievicius, Hartmut Micheal, Johannes Oldenburg, Arijit Biswas (Germany)

PO183-WED  REVISITING THE MECHANISM OF COAGULATION FACTOR XIII ACTIVATION IN PLASMA
Sneha Gupta*, Christoph Reinhart, Christoph Krettler, Mohammad Akhter, Johannes Dott, Hartmut Micheal, Johannes Oldenburg, Arijit Biswas (Germany)

PO184-WED  MUTATING CORE STRUCTURAL DISULFIDES OF THE FXIII B SUBUNIT AS A MEANS TO UNCOVER THE FUNCTIONAL ROLES OF INDIVIDUAL FXIII B SUBUNIT SUSHI DOMAINS
Mohammad S. Akhter*, Sneha Gupta, Hamideh Yadegari, Vytautas Ivaskievicius, Johannes Dott, Johannes Oldenburg, Arijit Biswas (Germany)

PO185-WED  THE ACTIVATION PEPTIDE OF COAGULATION FACTOR XIII IS VITAL FOR ITS EXPRESSION AND STABILITY
Helena Handrkova, Verena Schroeder*, Hans Kohler (Switzerland)

PO186-WED  THE B-SUBUNIT OF COAGULATION FACTOR XIII DOES NOT SPECIFICALLY INTERACT WITH COMPLEMENT FACTORS
Lorenz Jenny, Zhuoer Lin, Daniel Ricklin, Hans Kohler, Verena Schroeder* (Switzerland)
SCIENTIFIC PROGRAM

PO187-WED  THE EFFECT OF FACTOR XIII B SUBUNIT POLYMORPHISMS ON FACTOR XIII LEVELS AND ON THE RISK OF CORONARY ARTERY DISEASE; INTERACTION WITH FIBRINOGEN LEVEL AND FACTOR XIII A SUBUNIT P.VALL34LEU POLYMORPHISM
  László Muszbek*, Zoltán Mezei, Zsuzsanna Bereczky, Éva Katona, Réka Gindele, Szilvia Fialat, László Balogh, István Czuriga, Róza Ádány, István Édes (Hungary)

PO188-WED  FXIII-A V34L AFFECTS THROMBUS CROSS-LINKING, BUT NOT SIZE, IN A MURINE THROMBOSIS MODEL
  Cedric Duval*, Majid Ali, Waleed Chaudhry, Victoria Ridger, Helen Philippou, Robert Ariens (United Kingdom)

PO189-WED  PLATELET FACTOR XIII-A TRANSLOCATES FROM THE ACTIVATED PLATELET SURFACE ONTO ADJACENT FIBRIN FIBRES
  Joanne L. Mitchell*, Nicola Mutch (United Kingdom)

PO190-WED  RESIDENT TISSUE MACROPHAGES ARE THE PROBABLE SOURCE OF PLASMA CLOTTING FACTOR XIII-A
  Kingsley R. Simpson*, Cora Beckers, Kathryn Griffin, Jane Brown, Paul Cordell, Kerrie Smith, Esther Cooke, Mark Kearney, Jean Vacher, Warren Alexander, Richard Pease, Peter Grant (United Kingdom)

PO191-WED  EFFECT OF STABLE GABARAP KNOCKOUT ON THE FVIII SECRETION
  Heike Singer*, Behnaz Pezeshkpoor, Nicole Nuesgen, Ursula Schreck, Judith Junen, Johannes Oldenburg, Osman El-Maarri (Germany)

PO192-WED  DIMERIC ORGANIZATION OF MEMBRANE-BOUND FACTOR VIII ON LIPID NANOTUBES
  Svetla Stoilova-Mcphie*, Daniela Dalm, Jesus Galaz-Montoya, Kirill Grushin, Jaimy Miller (United States)

PO193-WED  IMPACT OF INHIBITORS TO EPITOPES OF FACTOR VIII ON THROMBIN GENERATION
  Amina Rafique*, Candise Enockson, Mindy Simpson (United States)

PO194-WED  MOLAR SPECIFIC ACTIVITY OF FACTOR VIII CONCENTRATES
  Carsten Horn, Stephanie Steede, Stefan Schmitzbauer, Hubert J. Metzner* (Germany)

PO195-WED  HIGH-PURITY, PLASMA-DERIVED, PASTEURISED FACTOR VIII CONCENTRATE IN THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A: UPDATE OF A LONG-TERM OBSERVATIONAL STUDY
  Robert Klammth*, Claudia Niekers, Susanne Holzhauer, Ronald Fischer, Christine Heller, Patrick Sommerer, Karin Kurnik (Germany)

PO196-WED  EXPRESSION, PURIFICATION AND CHARACTERIZATION OF CODON OPTIMIZED COAGULATION FACTOR VIII
  Svetlana Shestopal, James Kurassawa, Elena Karnaukhova, John McVey, Timothy Lee, Andrey G. Sarafanov* (United States)

PO197-WED  WHOLE-EXOME SEQUENCING APPROACH TO STUDY INHIBITOR DEVELOPMENT IN ITALIAN SEVERE HEMOPHILIA A PATIENTS.
  Marcin M. Gorski*, Kevin Blighe, Isabella Garagiola, Sabrina Seregni, Maria Elisa Mancuso, Elena Santagostino, Luca A. Lotta, Flora Peyvandi (Italy)

PO198-WED  MININGENE APPROACH TO CHARACTERIZE A NOVEL SPLICE SITE MUTATION IN HUMAN F8 GENE CAUSING SEVERE HAEMOPHILIA A
  Yohann Jourdy, Christophe Nougier*, Dominique Bozon, Mathilde Fretigny, Claude Nègrier, Christine Vinciguerra (France)

PO199-WED  CLEARANCE RECEPTOR INTERACTION AND HALF-LIFE PROLONGATION OF PEGYLATED RECOMBINANT FULL-LENGTH FACTOR VIII IN MICE
  Gerald Schrenk, Alexandra Schütz, Sabine Knappe, Alexander Bauer, Herbert Gritsch, Manfred Billwein, Schaedler Michaela, Peter Turecek, Michael Dockal*, Marietta Putz, Werner Hoellriegl, Friedrich Scheifflinger (Austria)

PO200-WED  SAFETY OF PEG, PEG CONJUGATES AND PEGYLATED RECOMBINANT HUMAN FULL-LENGTH COAGULATION FACTOR VIII (BAX 855)
  Reinhard Stidl, Sabine Fuchs, Mary Bossard, Juergen Siefmann, Marietta Putz*, Peter Turecek (Austria)

PO201-WED  FUNCTIONAL CHARACTERIZATION OF DIFFERENT FACTOR VIII MOLECULES WITH FOCUS ON PHOSPHOLIPID AND PLATELET BINDING
  Susanne Till, Sylvia Tipp, Michael Palige, Ernst Boehm, Gerald Schrenk, Jadranka Koehn, Herbert Gritsch, Sabine Knappe, Rudolf Hartmann, Friedrich Scheifflinger, Michael Dockal* (Austria)

PO202-WED  MOLECULAR SIGNATURE OF LSECs: A F8 SECRETING ENDOTHELIAL CELLS
  Osman El-Maarri*, Ahmer Jamil, Nicole Nuesgen, Amit Sharma, Behnaz Pezeshkpoor, Andrea Hofmann, Per Hoffmann, Stefanie Heilemann, Markus Noethen, Holger Froehlich, Johannes Oldenburg (Germany)

PO203-WED  ANCESTRAL RECONSTRUCTION OF COAGULATION FACTOR VIII
  Philip M. Zakas*, Kristopher Knight, H. Trent Spencer, Eric Gaucher, Christopher Doering (United States)

PO204-WED  A SYNONYMOUS MUTATION IN THE F8 GENE, C.120C>A; P.(L40=), MAY CAUSE MILD HEMOPHILIA A
  Hiroshi Inaba*, Keiko Shinozawa, Kazehiro Amano, Katsuyuki Fukutake (Japan)

PO205-WED  LONG-TERM PHENOTYPIC CORRECTION OF HEMOPHILIA A MICE BY NON-VIRAL PIGGYBAC TRANSPSON VECTOR
  Hideto Matsu*, Masahi Noda, Midori Shima, Akitsu Hotta, Mitsuhiro Sugimoto (Japan)

PO206-WED  DISCORDANT IN VITRO AND IN VIVO ACTIVITY OF FACTOR VIII MUTANTS
  Amine Bazza*, Vincent Muczynski, Cécile Ioubière, Amélie Harel, Tom Knudsen, Olivier D. Christophe, Cécile V. Denis, Peter J. Lenting (France)

PO207-WED  BENEFICIAL EFFECT OF VWF IN FVIII RECOVERY OF DIFFERENT FVIII CONCENTRATES IN A MOUSE MODEL OF SEVERE HEMOPHILIA WITH HIGH INHIBITOR TITERS
  Maria Isabel Bravo*, Montserrat Costa, Salvador Grancha, Juan Ignacio Jorquera (Spain)
PO208-WED  VARIATION IN FACTOR VIII MEASUREMENT AND CLASSIFICATION OF HAEMOPHILIA A SEVERITY IN THE ECAT EXTERNAL QUALITY ASSESSMENT PROGRAMME
Iris van Moort*, Piet Meijer, Bert Verbruggen, Marjon H. Cnossen, Moniek P.M. de Maat (The Netherlands)

PO209-WED  PRO-HEMOSTATIC ACTIVITY OF TFP1 INHIBITION IN HEMOPHILIA IS WELL REGULATED BY TISSUE FACTOR AND FACTOR VIII
Rudolf Hartmann, Erwin Panholzer, Willibald Kammlander, Friedrich Schellfinger, Michael Dockal* (Austria)

PO210-WED  RARE ALTERNATE PRESENTATIONS OF THE F8 INTRON 22 INVERSION MUTATION COMPLICATE DETECTION AND MAY LEAD TO MISDIAGNOSIS.
Jacky Cutler*, Gillian McGaffin, Anne White, Mike Mitchell (United Kingdom)

PO211-WED  CHARACTERIZATION OF IGA TYPE FVIII INHIBITOR IN AN ADULT PATIENT WITH CONGENITAL MODERATE HEMOPHILIA A SHOWING ABNORMALLY LARGE SUBCUTANEOUS HEMATOMA SIMILAR TO BLEEDING IN PATIENTS WITH ACQUIRED HEMOPHILIA
Atsuki Yamashita*, Chiai Nagae, Mika Mori, Tomoko Ashikaga, Mieko Akita, Noriko Suzuki, Satoshi Yamazaki, Shiginobu Takayama, Masashi Taki (Japan)

PO212-WED  RECOMBINANT FACTOR VIII INCREASES HEMOPHILIA A CLOT STRENGTH THROUGH ALTERATIONS IN CLOT STRUCTURE AND COMPOSITION
Lilley Leong*, Irina Chernysh, Yifan Xu, Derek Sim, Chandrasekaran Nagaswami, Zelda de Lange, Sofia Kosolapova, Adam Cuker, Katalin Kauser, John Weisel (United States)

PO213-WED  ADDING MULTIPLE POLYETHYLENE GLYCOL (PEG) MOIETIES FURTHER REDUCES PEG-FACTOR VIII CONJUGATE (PEG-FVIII) CLEARANCE BY HEPATOCYTES IN VITRO, BUT MINIMALLY IMPACTS PEG-FVIII CLEARANCE OR HALF-LIFE IN VIVO.
Eric Blasko*, Elena Ho, James Wu, Derek Sim, Liang Tang, Lilley Leong, Katalin Kauser, Babu Subramanyam (United States)

PO214-WED  DISTRIBUTION OF 14C-Labeled PEG (60 KDA) IN RATS
Andreas Baumann*, Thomas Schwarz, Dietrich Seidel, Wolfram Steinke, Klaus Buehner (Germany)

PO215-WED  SINGLE CENTER EXPERIENCE EVALUATING ACTIVITY OF N8-GP WITH ONE-STAGE CLOTTING ASSAY
Brigitte Cornelia Brand-Staufer*, Karin Koch, Stefan Balabanov, Wan Hui Ong Clausen, Hendrik Rahbek-Nielsen, Marianne Kjaile, Paul DeAngelis, F. Michael Haller, Jesper Haaning* (Denmark)

PO216-WED  INTERNATIONAL STUDY TO ASSESS THE PERFORMANCE OF IMMUNODEPLETED PLASMAS FOR DETERMINATION OF FACTORS VIII AND IX ACTIVITY
Chris Watson, Siegmund Gehrisch, Stefan Tiefenbacher, Alberto Tosetto*, Maria Di Paolo, Dorothy Adcock (United Kingdom)

PO217-WED  GENETIC DETERMINANTS FOR FACTOR VIII LEVELS: GENOME-WIDE LINKAGE AND ASSOCIATION ANALYSES FROM THE GAIT PROJECT
Sonia López*, Andrey Ziyatdinov, Noelia Vilalta, Jordi Fontcuberta, Juan Carlos Souto, Jose Manuel Soria (Spain)

PO218-WED  QUANTITATION OF MISFOLDED PROTEINS AND QUANTITATION AND VISUALISATION OF NANOSIZE PROTEIN AGgregATES IN RFVIII AND PDVIII CONCENTRATES
Martin Brodde*, Martin Wiemann, Mayken Visser, Lisa Smits, Anja Müller, Beate Kehrel (Germany)

PO219-WED  HEPAROSAN GLYCO-CONJUGATES OF FVIII AND FIX SHOWS PRO-LONGED CIRCULATING HALF-LIFE IN HAEMOPHILIA MOUSE MODELS
Carsten Behrens, Jens Buchardt, Mie Broberg, Ditte Karpf, Mette Lofthag, Mette Jensen, Heidi Bagger, Matthias Thörlöfsson, Maria Damiak, Johan Karlsson, Ernst Hansen, Janus Krapup, Henrik Rahbek-Nielsen, Marianne Kjaile, Paul DeAngelis, F. Michael Haller, Jesper Haaning* (Denmark)

PO220-WED  SUPPRESSION OF INHIBITOR FORMATION IN HEMOPHILIA BY LAP+ TREG INDUCED BY PLANT-BASED ORAL TOLERANCE
Xiaomei Wang*, Jin Su, Alexandra Sherman, Henry Daniell, Roland Herzog (United States)

PO221-WED  LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1 EXPRESSION IN LIVER IS ASSOCIATED WITH PLASMA FACTOR VIII LEVELS
Luis F. Bittar*, Adriana Duarte, Erich De Paula, Joyce Annichino-Bizzacchi (Brazil)

PO222-WED  THE IMMUNOGENICITY OF PLATELETS CONTAINING FVIII IN HEMOPHILIA A MICE WITH OR WITHOUT PRE-EXISTING ANTI-FVIII IMMUNITY
Yingyu Chen, Jocelyn Schroder, Xiaofeng Luo, Juan Chen, Christina Baumgartner, Robert Montgomery, Jinda Hu, Qizhen Shi* (United States)

PO223-WED  ELEVATED FACTOR VIII LEVELS AND ALL-CAUSE MORTALITY: RESULTS FROM THE MEGA FOLLOW-UP STUDY
Eng Soo Yap*, Jasmijn Timp, Linda Flintemans, Astrid van Hylckama Vlieg, Frits Rosendaal, Suzanne Cannegieter, Willem Liéfreig (Singapore)

PO224-WED  NOVEL MUTATIONS ASSOCIATED WITH A DISCREPANCY BETWEEN ONE-STAGE AND CHROMOGENIC FVIII ACTIVITY ASSAY
Dana Provaznikova*, Katerina Houskova, Alena Radosva, Ingrid Hrachovinova (Czech Republic)

PO225-WED  HEMOPHILIA A CAUSED BY RETROTRANSPOSITION OF LONG INTERSPERSED ELEMENT-1 (LINE-1) INTO THE FVIII GENE
Rima Dardik*, Ariella Zivelin, Yariv Fruchtman, Tami Livnat, Einat Avishai, Shirley Azar-Avivi, Gili Kenet, Nirit Rosenberg (Israel)

PO226-WED  COMPLEMENT MODULATES THE IMMUNE RESPONSE AGAINST THERAPEUTIC FACTOR VIII IN HEMOPHILIA A MICE WITH OR WITHOUT PRE-EXISTING ANTI-FVIII IMMUNITY
Julie Rayès, Mathieu Ing*, Ivan Peyron, Jordan Dimitrov, Sandrine Delignat, David Fritzinger, Carl-Wilhelm Vogel, Véronique Fremeaux-Bacchi, Srinivas Kaveri, Lubka Roumenina, Sébastien Lacroix-Desmazes (France)

PO227-WED  SURFACE BOUND VON WILLEBRAND FACTOR MODULATES FACTOR VIII PEPTIDE PRESENTATION BY DENDRITIC CELLS
Robin B. Hartholt*, Nicoletta Sorvillo, Magdalena Sede, Anja ten Brinke, Carmen van der Zwaan, Floris van Alphen, Alexander Meijer, Jan Voorberg (The Netherlands)
PO228-WED  ROLE OF MEMBRANE-INTERACTING RESIDUES WITHIN FACTOR VIII C2 DOMAIN IN IMMUNOGENICITY OF THERAPEUTIC FACTOR VIII.
Bagirath Gangadharan*, Mathieu Ing, Sandrine Delignaut, Ivan Peyron, Olivier Christophe, Srinivas Kaveri, Sebastien Lacroix-Desmazes (France)

PO229-WED  FVIII ACTIVITY ASSAY VARIABILITY OF THE PEGYLATED FORM OF RFVIII ADVATE (BAX 855) IN CLINICAL HEMOSTASIS LABORATORIES: INTERIM RESULTS FROM A WORLD-WIDE FIELD STUDY.
Peter L. Turecek*, Herbert Gritsch, Claudia Apostol, Stefan Romeder-Finger, Alexander Bauer, Divan Burger, Andrea Hunt (Austria)

PO230-WED  SIGNIFICANCE OF ENDOGENOUS VON WILLEBRAND FACTOR IN DEVELOPMENT OF FACTOR VIII IMMUNE RESPONSES IN SEVERE EXPERIMENTAL HEMOPHILIA A
Bagirath Gangadharan*, Mathieu Ing, Sandrine Delignaut, Olivier Christophe, Srinivas Kaveri, Sebastien Lacroix-Desmazes (France)

PO231-WED  COMPARISON OF METHODS FOR THE DOSAGE OF FVIII IN A NEW HEMOPHILIA CENTER CARE
Emanuel Sueldo, Mirta Arias, Beatriz Erramouspe, Rodrigo Porsella, Patricia Do Nascimento, Gabriela Guerrero, Alejandra Baques* (Argentina)

PO232-WED  CRITICAL QUALITY ATTRIBUTES OF RECOMBINANT FVIII PRODUCTS – PROTEIN AGGREGATES AND SUBVISIBLE PARTICLES
Mantas Malisauskas*, Christian Lubich, Thomas Pennringer, Peter Matthiessen, Peter Turecek, Friedrich Schefflinger, Birgit Reipert (Austria)

PO233-WED  FVIII OS/CS RATIOS FOR SELECT NOVEL RECOMBINANT FVIII REPLACEMENT PRODUCTS MEASURED IN FOUR FDA APPROVED FVIII ONE-STEP CLOT ASSAY SYSTEMS AND ONE CHROMOGENIC ASSAY
Stefan Tiefenbacher*, Mary Robinson, Erika Ross, Patrick Williams, Caroline Cogswell, Tyrelle Wham, Geoff Chow, Dorothy Adcock (United States)

PO234-WED  PLASMA DERIVED FVIII (PDFVIII) CONCENTRATES ENHANCE SYNVOIAL CELL PROLIFERATION AND MIGRATION BY BINDING OF MISFOLDED PROTEINS TO ADAM15
Martin Brodde*, Martin Wiemann, Robert Klamroth, Mayken Visser, Lisa Smits, Beate Kehrel (Germany)

PO235-WED  ARE DIFFERENT PLASMA DERIVED FVIII CONCENTRATES EQUALLY EFFICIENT IN TERTIARY PROPHYLAXIS?
Jelena Bodrozic*, Ivo Elezovic, Darko Antic, Predrag Miljic (Serbia)

PO236-WED  CHANGES OF COAGULATION PARAMETERS DURING HIGH ALTITUDE EXPEDITION.
Susana Der Parsehian*, Miriam Pereiro, Alvaro Ortiz Nareto, Sebastian Donato, Cristina Arltana (Argentina)

PO237-WED  RELATIONSHIP BETWEEN OXIDATIVE STRESS AND BLOOD COAGULATION IN PAEDIATRIC CHRONIC KIDNEY DISEASE (CKD)
Luci M. S. Dusse*, Leticia Sousa, Rivia Silvia, Maria Carvalho, Rita Duarte, Cristina Loures, Marcos Silva, Rejane Diniz, Sergio Pinheiro, Ana Silva (Brazil)

PO238-WED  INFLUENCE OF OXIDATIVE STRESS ONTO FIBRIN NET FORMATION, ARCHITECTURE AND LYSIS
Jana Stikarova*, Roman Kotlin, Jiri Suttnar, Tomas Riedel, Pavel Sacha, Pavel Majek, Leona Chrostinova, Alzbeta Hlavackova, Jan Dyr (Czech Republic)

PO239-WED  CD44 LOCATED IN THE SURFACE OF SICKLE RED BLOOD CELL (SRBC) CORRELATES WITH REDUCED BLOOD HBF LEVELS AND INCREASED SRBC ADHESION TO FIBRIN
Luciana W. Serrão*, Maria Clara Silva, Andrea Soares, Daniela Beghini, Russolina Zingali (Brazil)

PO240-WED  FREE FATTY ACIDS MODULATE THROMBIN ACTIVITY ON FIBRINOGEN AND DESTABILISE FIBRIN CLOTS
Anna Tanko-Salamon*, Erzsébet Komorowicz, László Szabó, Raymund Machovich, Kraszimir Kolev (Hungary)

PO241-WED  TEMPORAL EVOLUTION OF FIBRIN NANOSTRUCTURE DURING CLOTTING AND FIBRINOLYSIS
Carhel Dassi*, Emmanuelle Bigo, Landry Seye, Raphael Marlu, Benoit Polack, Francois Caton, Genevieve Contant (France)

PO242-WED  UNDERSTANDING FIBRIN PROTOFIBRILS AT THE MOLECULAR LEVEL: FORMATION AND FLEXIBILITY THROUGH A NEW COARSE-GRAINED PROTEIN MODELLING APPROACH
Albert Solernou*, Sarah Harris, Oliver Harlen, Daniel Read, Kerrie Smith, Stephen Muench (United Kingdom)

PO244-WED  IMPACT OF MATERNAL D-DIMER LEVELS IN NEWBORN OF PREECLAMPTIC MOTHERS
Melina Pinheiro, Sandra Armond, Maria das Graças Carvalho, Lara Godel, Patricia Alpoim, Karina Borges, Luci Dusse* (Brazil)

PO245-WED  FIBRIN CLOT STRUCTURE IS AFFECTED BY LEVELS OF PARTICULATE AIR POLLUTION EXPOSURE IN PATIENTS WITH VENOUS THROMBOSIS
Xiaoxi Pan*, Yunyun Gong, Ida Martinelli, Pier Mannucci, Michael Routledge, Robert Arlens (United Kingdom)

PO246-WED  INCREASED PLASMA CLOT PERMEABILITY AND SUSCEPTIBILITY TO LYSIS ARE ASSOCIATED WITH HEAVY MENSTRUAL BLEEDING OF UNKNOWING CAUSE
Piotr Szczepaniak, Michal Zabczyk, Anetta Undas* (Poland)
PO247-WED  SEVERE THROMBOSIS IN PREGNANCY IN PATIENT WITH CONGENITAL DYSFIBRINOGENEMIA
Vera Geierova*, Ingrid Hrachovinova, Roman Kotlin, Peter Salaj (Czech Republic)

PO248-WED  ARTERIOVENOUS FISTULAS FOR REPLACEMENT THERAPY IN ADULTS WITH HEMOPHILIA
Jerry Teitel*, Michelle Scholzberg, Vernon Campbell, Rachel He, Georgina Flores (Canada)

PO249-WED  A PHASE III, OPEN-LABEL, MULTICENTRE STUDY TO EVALUATE EFFICACY AND SAFETY OF A PLASMA-DERIVED VON WILLEBRAND FACTOR/FAC- TOREIII CONCENTRATE IN PEDIATRIC SUBJECTS WITH HEMOPHILIA A (SWIFTLY-HA STUDY)
Maria Teresa Pompa, Genadi Iosava, Claudia Khayat, Irina Rosashevskaya, Olga Aleinikova, Oleksandra Slasyshny, Liudmila Vashchenko, Marta Julia Lope, Wilfried Seifert* (Germany)

PO250-WED  JOINT LAVAGE FOLLOWED BY VISCOSUPPLEMENTATION AND TRIAN- CINOLONE IN PATIENTS WITH SEVERE HEMOPHILIC ARTHROPATHY. SUBJECTIVE PAIN, FUNCTION AND QUALITY OF LIFE RESULTS.
Thiago Pasqualin*, Marcia Rezende, Gustavo Campos, Thiago Rosa, Renato Frucchi, Alexandre Pailo, Erica Okazaki, Paula Villaça (Brazil)

PO251-WED  INTERIM RESULTS FROM A LARGE MULTINATIONAL EXTENSION TRIAL (GUARDIAN TM2) USING TUROCKETOCOC ALFA FOR PROPHYLAXIS AND TREATMENT OF BLEEDING IN PATIENTS WITH SEVERE HEMOPHILIA A
Steven Lentz*, Christine Kempton, Dragana Janic, Aleksandar Savic, Monica Cerqueira, Margareth Ozel, Michael Recht, Johannes Oldenburg, Andreas Tiede, Takashi Suzuki, Irina Matysina, Niels Zeuthen, Elena Santagostino (United States)

PO252-WED  VALIDATION OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS BLEEDING ASSESSMENT TOOL (ISTH-BAT) IN HEMOPHILIA CARRIERS
Paula James*, Christoph Bidlingmaier, Maria Eva Mingot-Castellano, Meera Chitlur, Patrick Fogarty, Julie Grabell, Prasad Mathew, Johnny Mahlangu (Canada)

PO253-WED  EFFICACY AND SAFETY OF RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR IX WITH ALBUMIN (RIF-FP) IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA B UNDERGOING A SURGICAL PROCEDURE
Claude Négrier*, Lynda Mae Lepatan, Aaron Lubetsky, Farazbod Ab Karim, Brigitte Pan-Petsch, Annamita Tagliaferri, Carmen Altisent, Julie Curtin, Christoph Male, Anne Liehrhart, Denise Wilko, Christine Voigt, Iris Jacobs, Elena Santagostino (France)

PO254-WED  COMPARISON OF ANNUAL BLEEDING RATES IN SUBJECTS WITH SEVERE HEMOPHILIA A RECEIVING PROPHYLAXIS TREATMENT WITH RECOMBINANT FACTOR VIII OR PEGYLATED RECOMBINANT FACTOR VIII (BAX 855).
Werner Engl, Birgitt Abbuehl*, Martin Wolfsegger, Borislava Pavlova, Bruce Ewenstein (Austria)

PO255-WED  LOW ANNUALIZED BLEEDING RATES (ABRS) WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFFVIIFC) ACROSS DEMOGRAPHIC SUBGROUPS OF PREVIOUSLY TREATED PEDIATRIC SUBJECTS WITH SEVERE HEMOPHILIA A
Guy Young*, Roshini Kulkarni, Margaret Ragni, Simon Brown, Irena Wozniaka-Kaczmarz, John Puetz, Rienk Tamminga, Giulia Gambino, Glenn Pierce, Geoffrey Allen (United States)

PO256-WED  CHILDREN WITH HEMOPHILIA IN THE US – THE HEMOPHILIA ASSOCIATED CAREGIVER BURDEN SCALE (HEMOCABTM)
Sylvia von Mackensen*, Tami Wisniewski, John Urgo, Lisa Boggio (Germany)

PO257-WED  DEVELOPING A MEASURE OF HEMOPHILIA CAREGIVER IMPACT
Carolyn Schwartz*, Adi Eldar-Lissai (United States)

PO258-WED  VENEPUNCTURE VERSUS LABORATORY SAMPLE TIMING DISCREPANCIES: IMPLICATIONS FOR PHARMACOKINETIC PREDICTION OF PROPHY- LAXIS DOSING IN SEVERE HEMOPHILIA A: UK-PK PILOT STUDY
Paul Batty*, Mike Spencer Chapman, Sean Platten, Daniel Hart (United Kingdom)

PO259-WED  A NOVEL MISSENSE MUTATION, P.PHE360CYS, IN F9 GENE RESULTS IN HEMOPHILIA B IN FEMALE PATIENT
Ziqiang Yu*, Chunchen Yang, Wei Zhang, Lijuan Cao, Xia Bai, Changgeng Ruan (China)

PO260-WED  INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH SE- VERE HEMOPHILIA A: A FOLLOW-UP COHORT STUDY.
Maria Elisa Mancuso*, H. Marijke van den Berg (Italy)

PO261-WED  SATISFACTION PATIENT SURVEY: A KEY TOOL TO IMPROVE PATIENT DELIVERY OF CARE AT A PORTUGUESE COMPREHENSIVE HEMOPHILIA CENTRE
Manuela Carvalho*, João Martins, Beatriz Delgado, Susana Fernandes, Manuela Reis, Fernando Araújo (Portugal)

PO262-WED  NUMERICAL MODELS OF THROMBIN GENERATION APPLICABLE TO HEMOPHILIA
Pierre Chelle, Michel Cournil, Michèle Piot, Aurélie Montmartin, Emilie Presles, Claire Morin, Stéphane Avril, Patrick Mismetti, Bernard Tardy, Brigitte Tardy* (France)

PO263-WED  THE EFFECT OF NORDIC WALKING ON JOINT STATUS, QUALITY OF LIFE, PHYSICAL ABILITY, EXERCISE CAPACITY AND PAIN IN OLDER MEN WITH HEMOPHILIA
Maryem Salim*, Yvonne Spãs-Abrahamsson, Erik Berntorp, Elisabeth Broduin, Eva Zetterberg (Sweden)

PO264-WED  PERIOPERATIVE MANAGEMENT AND OUTCOME OF URGENT APPENDIC- TOMY IN A PATIENT WITH SEVERE HEMOPHILIA
Murat Söker, Hikmet Zeytun, Sevda Söker, Cahit Sahin (Turkey)

PO265-WED  PREVALENCE, SEVERITY AND CORRELATION FACTORS OF HEMOPHILIC ARTHROPATHY AMONG TAIWANESE HEMOPHILIACS
Chia-Yau Chang*, Tsung-Ying Li, Shin-Nan Cheng, Ru-Yu Pan, Hung-Jung Wang, Shi-Yi Lin, You-Chin Chen (Taiwan)
PO266-WED  SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-05280602 (RECOMBINANT FVIIA VARIANT): PRELIMINARY RESULTS FROM A SINGLE ASCENDING DOSE PHASE I STUDY IN HEMOPHILIA A AND B SUBJECTS
Ralph Gruppo,* Daniel Malan, Judit Kapocsi, Charles Hay, Lisa Boggio, Pratima Chowdhary, Giuseppe Tagariello, Annette von Drygalski, Fei Hua, Matthew Scaramozzo, Harry Shi, Steven Arkin (United States)

PO267-WED  SEVERE HEMOPHILIA A PATIENTS WHO DON’T BLEED WHILE ON PROPHYLAXIS: INVESTIGATION INTO POSSIBLE FACTORS INFLUENCING THE OUTCOME
Johannes Oldenburg*, Elena Santagostino, Steven Lentz, Iriana Matlytsinsa, Niels Kettlen (Germany)

PO268-WED  QUALITY OF LIFE AMONG HAEMOPHILIA IN THAILAND
Yingyong Chinthammitr*, Ploy Pengchata, Bundarika Suwannawiboon, Bunchoo Pongtanakul, Yupa Nakkinkun, Shannon Jackson (Canada)

PO269-WED  IMPACT OF TRANSITION ON CLINICAL OUTCOMES IN HEMOPHILIA: 10 YEARS OF EXPERIENCE AT A MAJOR CANADIAN TREATMENT CENTER
Celina Woo*, Erica Crilly, Deborah Gue, Kam McIntosh, Lawren De Marchi, Sandra Squire, Alexandra Silva, Ming Yang, Jennifer Doralt, Peter Turecek* (Austria)

PO270-WED  PERSONALIZED PROPHYLAXIS WITH HUMAN-CL RHFVIII IN HEMOPHILIA A PATIENTS
Robert Klamroth*, Toscho Lissitchkov, L Rusen, Olaf Walter, Sigurd Knaub, Johann Bichler, John Pasi, Andreas Tiede (Germany)

PO271-WED  THROMBOPROPHYLAXIS FOR MAJOR ORTHOPEDIC SURGERY IN HEMOPHILIA: OUTCOMES OF AN EXPERT OPINION SURVEY ON CLINICAL PRACTICE AND APPLICABILITY OF ACCP GUIDELINES BY THE ADVANCE WORKING GROUP
Cédric Hermans*, Ingrid Pabinger, Maria Elisa Mancuso, Claude Négrier, Pål André Holme (Belgium)

PO272-WED  COMPARATIVE STUDY OF THE PREVALENCE OF CLOTTING FACTOR DEFICIENCY IN CARRIERS OF HEMOPHILIA A AND B
Ana Boban*, Nathalie Lannoy, Catherine Lambert, Cedric Hermans (Belgium)

PO273-WED  PREVALENCE AND RISK FACTORS ASSOCIATED WITH HYPERTENSION IN HEMOPHILIA
Craig D. Seaman*, Mariya Apostolova, Diane Comer, Jonathan Yabes, Margaret Ragni (United States)

PO274-WED  A CASE OF ACUTE CEREBRAL INFARCTION IN A PATIENT WITH HEMOPHILIA B
Sunah Lee*, Mi-Kyung Kim (Korea, Republic Of)

PO275-WED  MOLECULAR GENETICS AND INHIBITOR DEVELOPMENT IN PATIENTS WITH HEMOPHILIA B
Ampaiwan Chuansumrit*, Werasak Sasanalak, Nongnuch Sirachainan, Praguywan Kadegasem, Pakawan Wongerawattanakoon (Thailand)

PO276-WED  HAEMOPHILIA WITH INHIBITORS, UPDATE FROM ALGIERS EXPERIENCE, ABOUT ONE CENTER
Meriem Bensadok*, Wafia Karima Chennoukh, Chahira Aboura, Mylade Arbi, Nadia Zidani, Samira Boutiba, Meriem Madella Belhadi, Salim Nekkal (Algeria)

PO277-WED  PREVALENCE AND RISK FACTORS ASSOCIATED WITH HYPERTENSION IN HEMOPHILIA
Craig D. Seaman*, Mariya Apostolova, Diane Comer, Jonathan Yabes, Margaret Ragni (United States)

PO278-WED  A CASE OF ACUTE CEREBRAL INFARCTION IN A PATIENT WITH HEMOPHILIA B
Sunah Lee*, Mi-Kyung Kim (Korea, Republic Of)

PO279-WED  THE USE OF SECONDARY PROPHYLAXIS IN THE HAEMOPHILIA A PATIENTS
Gonul Aydogan*, Hulya Sen, Zafer Salcioglu, Ferhan Akici, Deniz Tugcu, Ali Ayicik, Muge Golce, Cengiz Bayram, Genc Keskindermeciri, Nura Ayaz (Turkey)

PO280-WED  COMPARATIVE STUDY OF THE PREVALENCE OF CLOTTING FACTOR DEFICIENCY IN CARRIERS OF HEMOPHILIA A AND B
Ana Boban*, Nathalie Lannoy, Catherine Lambert, Cedric Hermans (Belgium)

PO281-WED  PREVALENCE AND INCIDENCE OF HEMOPHILIA IN THE NORTH OF TUNISIA
Melliti Mariem*, El Mahmoudi Hajer, Zahra Kaoutcher, Meddeb Balkis, Gouider Emna (Tunisia)

PO282-WED  EFFECTS OF MODERATE-INTENSITY PHYSICAL EXERCISE ON PHARMACOKINETICS OF FACTOR VIII AND VON WILLEBRAND FACTOR IN YOUNG ADULTS WITH SEVERE HAEMOPHILIA A.
Nichan Zourkian*, Clémence Merlen, Arnaud Bonnefoy, Jean St-Louis, Georges-Etienne Rivard (Canada)

PO283-WED  PROSPECTIVE STUDY ON THE RISK, INCIDENCE AND MANAGEMENT OF CARDIOVASCULAR DISEASE IN OLDER PATIENTS WITH HAEMOPHILIA: THE ADVANCE STUDY
Robert Campbell Tait*, Pål André Holme, Christophe Combescure, Philippe de Mérilose, Erik Berntop, Roger Schutgens, Robert Klamroth, Cedric Hermans, Stephan Rauchensteiner, Gerard Dolan (United Kingdom)

PO284-WED  LONGEVITY OF NON-PATHOGENIC ANTIBODIES AGAINST HUMAN RECOMBINANT PROTEINS IN HEALTHY INDIVIDUALS
Frank Horling*, Christoph Hofbauer, Peter Allacher, Susanne Till, Brigitt Abbeuhl, Friedrich Scheifflinger, Birgit Reipert (Austria)
SCIENTIFIC PROGRAM

PO285-WED  PLASMA PROTEIN ABUNDANCES OF PROTEINS INVOLVED IN COAGULATION AND BONE/CARTILAGE TURNOVER ARE ALTERED AFTER HAEMOPHILIC JOINT BLEED
Ileana Rodriguez León*, Mari Enoksson, Lise Nikolik Nielsen, Kirstine Roepstorff, Mads Kjeldgaard-Hansen, Eva Norling Olsen, Brian Vandahl (Denmark)

PO286-WED  IMMUNE TOLERANCE INDUCTION EXPERIENCE WITH ADVATE: FINAL RESULTS OF AN INTERNATIONAL PROSPECTIVE ITI REGISTRY (PAIR)
Amy Shapiro*, Kate Khair, Jerry Teitell, Iliana Leony-Lasso, Katharina Steinitz, Alessandro Gringeri, Gerald Spotts (United States)

PO287-WED  FREQUENCY OF BLEEDING EVENTS IN PATIENTS WITH HEMOPHILIA ON PROPHYLAXIS BASED ON A COMMERCIAL INSURANCE CLAIMS DATABASE
Katharine Batt*, Anshu Shrestha, Adi Eldan-Lissai, Yanyu Wu, Sangeeta Krishnan, Darius Lakdawalla (United States)

PO288-WED  IMPROVEMENT OF THE QUALITY OF HEALTH CARE FOR CHILDREN WITH SEVERE HAEMOPHILIA A USING PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES WITH RECOMBINANT FACTOR VIII
Sofijanka Glamocanin*, Zorica Trajkova-Antevska, Biljana Coneska (Macedonia, The Former Yugoslav Republic Of)

PO289-WED  INHIBITOR DEVELOPMENT AS SWITCHING FULL-LENGTH RECOMBINANT FVIII TO B-DOMAIN DELETED RECOMBINANT FVIII IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA A: TAIWAN’S EXPERIENCE
Chia-Yau Chang*, Shu-Huey Chen, Geng-Chang Yeh, Chen-Hua Tsai, Jia-Ruey Tsai, Yen-Lin Liu (Taiwan)

PO290-WED  ULTRASONOGRAPHY OF JOINTS AND CORRELATION WITH FUNCTION IN HAEMOPHILIC ARTHROPATHY - RESULTS OF A CLINICAL PILOT TRIAL (HáMARTHROSONOPILOT) AND POTENTIAL IMPORTANCE OF JOINT-ULTRASOUND FOR AN INDIVIDUALIZED PROPHYLAXIS
Michael Sigl-Kraetzig*, Axel Seuser (Germany)

PO291-WED  COMPARING CARDIOVASCULAR DISEASE IN PATIENTS WITH HEMOPHILIA WITH DATA IN THE GENERAL POPULATION: METHODOLOGICAL CONSIDERATIONS
Karín Berger, Gordon Lowe, Dorothee Schoepohl, Campbell Tait, Pål-Andre Holme, Stephan Rauchensteiner, Robert Klamroth* (Germany)

PO292-WED  BLEEDING EVENTS IN CHINESE CHILDREN WITH SEVERE HEMOPHILIA A RECEIVING STANDARD PROPHYLAXIS VS ON-DEMAND TREATMENT WITH BAYER’S SUFCROSE-FORMULATED RECOMBINANT FACTOR VIII
Yongqiang Zhao, Juan Xiao, Renchi Yang, Runhui Wu, Yu Hu, Horst Beckmann, Junde Wu, Denny Hou, Jing Sun* (China)

PO293-WED  PROPHYLACTIC EFFICACY OF TWICE-WEEKLY VERSUS 3-TIMES-WEEKLY BAY 81-8973 IN SEVERE HEMOPHILIA A: RESULTS OF THE LEOPOLD I AND II CLINICAL TRIALS
Johnny N. Mahlangu*, Kaan Kavakli, L. Hvitfeldt Poulsen, Despina Tseneklidou-Stoetter, Horst Beckmann, Monika Maas Enriquez, Luminita Rusen (South Africa)

PO294-WED  EXPANDING COMMUNICATIONS ON HEMOPHILIA A OUTCOMES (ECHO) STUDY: A LONGITUDINAL, OBSERVATIONAL DISEASE REGISTRY OF PATIENT-REPORTED AND CLINICAL OUTCOMES IN PATIENTS WITH HEMOPHILIA A
Charles R. M. Hay*, Nikki Church, Shurjeel Choudhri, Craig Kessler (United Kingdom)

PO295-WED  EFFECTIVE RADYOACTIVE SYNOVECTOMY IN HEMOPHILIA WITH INHIBITORS
Bulent Zulfikar*, Cuneyt Turkmen, Onder Kilicoglu, Basak Koc, Ata Can Atalar, Fikret Bezgal, Hanimxz Ozcan (Turkey, Turkey)

PO296-WED  IMPROVING HEMOPHILIA CARE IN BRAZIL: AVAILABILITY OF FACTOR CONCENTRATES AND BEYOND – RESULTS OF LEVANTH SURVEY
Samuel S. Medin*, Andrea Sambo, Margareth Ozelo (Brazil)

PO297-WED  FREQUENCY OF BLEEDING EVENTS IN PATIENTS ON HEMOPHILIA A WITH INHIBITORS FROM MAJOR AND MINOR SURGERIES IN SEVERE HEMOPHILIA PATIENTS
Bulent Antmen*, Ilgen Sasmaz, Barbaros Karagun, Goksel Leblebisat, Yurdanur Kilinc, Atilla Aridogan, Iffet Yazioglu, Cenk Ozkan (Turkey, Turkey)

PO298-WED  IMPACT OF PAIN AND FUNCTIONAL IMPAIRMENT IN US ADULT PEOPLE WITH HEMOPHILIA (PWH): RESULTS FROM RETEST POPULATION IN THE PAIN FUNCTIONAL IMPAIRMENT AND QUALITY OF LIFE (P-FIQ) STUDY
Tyler Buckner*, Michelle Witkop, Michael Wang, Michael Recht, Katharine Batt, David Cooper, Christine Kempton (United States)

PO299-WED  IMPROVEMENT OF THE QUALITY OF HEALTH CARE FOR CHILDREN WITH SEVERE HAEMOPHILIA A USING PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES WITH RECOMBINANT FACTOR VIII
Sofijanka Glamocanin*, Zorica Trajkova-Antevska, Biljana Coneska (Macedonia, The Former Yugoslav Republic Of)

PO300-WED  IMMUNE TOLERANCE INDUCTION IN PATIENTS WITH SEVERE HEMOPHILIA A AND B IN THE UNITED KINGDOM
Charles Hay, Gerry Dolan, Erik Berntorp, Christopher Ludlam, Karl-Johan Myrén, Lisa Osterling Koskinen, Stefan Lethagen* (Sweden, Denmark)

PO301-WED  THE USE OF RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) DURING MAJOR AND MINOR SURGERIES IN SEVERE HEMOPHILIA PATIENTS WITH INHIBITOR
Bulent A. Antmen*, Ilgen Sasmaz, Barbaros Karagun, Goksel Leblebisat, Yurdanur Kilinc, Atilla Aridogan, Iffet Yazioglu, Cenk Ozkan (Turkey)

PO302-WED  INTRACRANIAL HEMORRHAGE AND MANAGEMENT IN HEREDITARY BLEEDING DISORDERS: THE EXPERIENCE OF CUKUROVA UNIVERSITY, ADANA, TURKEY
Ilgen Sasmaz*, Bulent Antmen, Barbaros Karagun, Goksel Leblebisat, Derbis Yilmaz, Yurdanur Kilinc (Turkey)

PO303-WED  A PROSPECTIVE ITALIAN SURVEY ON INTRACRANIAL HEMORRHAGE IN HEMOPHILIA PATIENTS: CHANGES OVER TIME
Ezio Zanon*, Marta Milan, Chiara Biasoli, Isabella Cantori, Giancarlo Castaman, Antonio Coppola, Matteo Luciani, Claudio Molinari, Piercarla Schirino, Gianluca Sottolitta, Annarita Tagliaferri, Antonino Cannavò, Elena Santagostino (Italy)
SCIENTIFIC PROGRAM

PO304-WED
COMBINATION OF BIOMARKERS FOR ASSESSMENT OF HEMOPHILIC ARTHROPATHY
Cheng Shih-Nan, Luke Yang, Tsung-Yi Li, Pan Ru-Yu, Hu Shu-Hsia, You-Chin Chen*
(Taiwan)

PO305-WED
HOW HAEMOPHILIA PATIENTS IN GERMANY PERCEIVE THEIR ACTUAL TREATMENT AND WHAT THEY EXPECT FOR FUTURE TREATMENT WITH NEW LONG-LASTING PRODUCTS
Sylvia Von Mackensen*, Heinrich Struck, Werner Kalmins (Georgia)

PO306-WED
CHALLENGES IN THE DIAGNOSIS AND MANAGEMENT OF HAEMOPHILIA
Sitalakshmi Subramanian, Cecil Ross, Shanthala Devi, Vanamala Alwar (India)

PO307-WED
FACTOR XI DEFICIENCY AND BLEEDING RISK ON ANTICOAGULATION
John Chapin*, Kelsey Kistle, Paul Christos, Maria DeSancho (United States)

PO308-WED
THE EFFECT OF ADVANCING AGE ON THE RESPONSE TO DDAVP IN RE-EXPOSED NONSEVERE HEMOPHILIA A PATIENTS
Janneke I. Loomans*, Alice Van Velzen, Marjolein Peters, Christoph Köngs, Anne Mäkipernaa, Helena Patlopouki, Evelien Mauser-Bunschoten, Christoph Male, Britta Laros-van Gorkom, Saturnino Haya, Marjon Cnossen, Johanna Van der Bom, Karin Fijnvandraat (The Netherlands)

PO309-WED
FOLLOW UP OF FACTOR VIII INHIBITOR KINETICS IN HEMOPHILIA PATIENTS
Jaewoo Song*, Ji Houn Yoon, Jung Woo Han, Rojin Park, Yun A Jo, Jongha Yoo, Moon-hee Oh (Korea, Republic Of)

PO310-WED
THE POTENTIAL CORRELATION BETWEEN PATIENT-REPORTED SYMPTOMS AND THE NEED FOR ADDITIONAL HEMOSTATIC MEDICATION; A POST HOC EXPLORATORY ANALYSIS BASED ON RPVIIA DATA FROM THE ADEPT TM2 TRIAL
Steven Lentz*, Savita Rangarajan, Faraizah Karim, Philip Andersen, Per Arkhammar, Gabriela Rosu, Johnny Mahlangu (United States)

PO311-WED
EFFICACY ASSESSMENT OF FONDAPARINUX TREATMENT OF PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
Franciszek Grzegorczyk*, Paweł Kuca, Małgorzata Dybowski, Janusz Burakowski, Cezary Czajka, Barbara Kazaneczka, Agnieszka Wróbel, Witold Tomkowski (Poland)

PO312-WED
SAFETY AND EFFICACY OF STARTING WARFARIN AFTER TWO CONSECUTIVE PLATELET RISES IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA
Lydia D. Chen*, William Dager, A. Josh Roberts (United States)

PO313-WED
RAPID FUNCTIONAL HEPARIN INDUCED THROMBOCYTOPENIA (HIT) ASSAY USING MULTIPLEX: COMPARISON WITH HEPARIN INDUCED PLATELET ACTIVATION (HIPA) ASSAY AND ACL ACUSTAR ANTIGEN ASSAY
Kevin Horner*, Joost Van Veen, Rhona Maclean, Steve Kitchen (United Kingdom)

PO314-WED
IMMUNOLOGICAL ASSAYS FOR DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Michael Nagler*, Lucas Bachmann, Hugo ten Cate, Arina ten Cate (Switzerland, Netherlands)

PO315-WED
IMPACT OF OVERDIAGNOSIS OF HIT IN A LARGE COMMUNITY HOSPITAL
Jacqueline King, Davide Ventura, Jason Hodge, Austin Satterthwaite, John Francis* (United States)

PO316-WED
NEW PLATELET FUNCTIONAL METHOD TO IDENTIFY PATHOGENIC ANTIBODIES IN HIT PATIENTS
Maria Luisa Guarino, Isabella Massimi, Flavia Temperilli, Alessandra Zicari, Fabio M. Pulcinielli* (Italy)

PO317-WED
LOW MOLECULAR WEIGHT HEPARIN TREATMENT FOR SUPERFICIAL VEIN THROMBOSIS AND THE RISK OF HEPARIN-INDUCED THROMBOCYTOPENIA
Michelangelo Sartori*, Ludovica Migliaccio, Elisabetta Favaretto, Cristina Legnani, Leila Valdrè, Giuliana Guazzaloca, Guattiero Palareti, Benilde Cosmi (Italy)

PO318-WED
AUDIT OF TEST RESULTS FOLLOWING THE INTRODUCTION OF A TESTING ALGORITHM FOR HEPARIN INDUCED THROMBOCYTOPENIA (HIT) IN A REFERRAL LABORATORY
Mary B. Byrne*, Fiona Holden, Caroline Gannon, Barry White, James O'Donnell, Kevin Ryan, Niamh O'Connell (Ireland)

Immune thrombocytopenia (ITP) III

PO319-WED
CLINICAL SIGNIFICANCE OF ANTINUCLEAR ANTIBODY TEST AND RISK FACTOR PREDICTORS OF CHILDHOOD CHRONIC IMMUNE THROMBOCYTOPENIA
Bunchoo Pongtanakul*, Suchawadee Horsuwan (Thailand)

PO320-WED
CLINICAL SIGNIFICANCE OF IPF% OR RP% MEASUREMENT IN DISTINGUISHING PRIMARY IMMUNE THROMBOCYTOPENIA FROM APLASTIC THROMBOCYTOPENIC DISORDERS
Mikiko Sakuragi, Satoru Hayashi, Miho Maruyama, Osamu Kabutomori, Tomoko Kiyokawa, Keisuke Nagamine, Hisashi Kato, Hirokazu Kashiwagi, Yuzuru Kanakura, Yoshiaki Tomiyama* (Japan)

PO321-WED
INTRAVENOUS IMMUNOGLOBULIN TREATMENT OF CHILDREN IMMUNE THROMBOCYTOPENIA META ANALYSIS OF EFFICACY AND SAFETY IN CHINA
Zhixu He*, Tao Li, Liping Shu (China)

PO322-WED
VARIATIONS OF MEAN PLATELET VOLUME OF IMMUNE THROMBOCYTOPENIA
Kenji Yokoyama*, Tomoki Ueda (Japan)

PO323-WED
THE POLYMORPHISMS OF TUMOR NECROSIS FACTOR-INDUCED PROTEIN 3 GENE MAY CONTRIBUTE TO THE SUSCEPTIBILITY OF CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA IN CHINESE POPULATION
Jingyi Yang*, Hu Zhou, Yongping Song, Renchi Yang (China)
PO324-WED  ANTI-PLATELET ANTIBODIES PRESENT IN BREAST MILK OF AN IMMUNE THROMBOCYTOPENIC MOTHER INCREASE AN APOPTOTIC MARKER IN NORMAL PLATELETS
Hagit Hauschner*, Uri Seligsohn, Nechama Sharon, Nirit Rosenberg (Israel)

PO325-WED  CLINICAL OBSERVATION OF 10 CASES OF NEWLY DIAGNOSED ITP PATIENTS RECEIVING LOW-DOSE RITUXIMAB COMBINED WITH HIGH-DOSE DEXAMETHASONE
Ke Feng* (China)

PO326-WED  ANTI-GP1B/ALPHA ANTIBODIES INDUCE IMMUNE THROMBOCYTOPENIA IN DISTINCT PATHWAYS: FC-DEPENDENT VS. FC-INDEPENDENT
Miao Xu*, Naadiya Carrim, Guangheng Zhu, Pingguo Chen, Heyu Ni (Canada)

PO327-WED  COMPARISON OF RELAPSE RATES OF IMMUNE THROMBOCYTOPENIA IN PATIENTS WHO RECEIVED INITIAL TREATMENT WITH STEROIDS VERSUS ANTI-RH(D) WITH OR WITHOUT STEROIDS
Mala Varma* (United States)

PO328-WED  PATHOGENESIS OF ANTI-INTEGRIN ALPHAIIIB-MEDIATED FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA: ESTABLISHMENT OF NOVEL MURINE MODELS IN ALPHAIIIB DEFICIENT AND HUMAN ALPHAIIIB TRANSGENIC MICE
Brian Vadasz, Darko Zdravic*, Pingguo Chen, Issaka Yougbare, Guangheng Zhu, Jonathan Frampton, Mortimer Poncz, John Freedman, Heyu Ni (Canada)

PO329-WED  ASSOCIATION BETWEEN A PRO-INFLAMMATORY AXIS COMPRISED BY TSP1-TGFB-CTGF WITH THREE MICRO-RNAS, MIR-19A, 122, AND 133A IN THE PATHOPHYSIOLOGY OF DIABETIC RETINOPATHY: A THERAPEUTIC NOVEL MODALITY
Raul Dela Cadena*, Melissa Lester, Alina Shevchenko, John St. Angelo III, Philippe Alvarez DeLa Cadena, Fabiola Del Carpio-Cano, William Foster (United States)

PO330-WED  FIBRINOGEN IN SEPSIS: CROSSTALK BETWEEN COAGULATION AND INFLAMMATION
Mirjam Bachler*, Dietmar Fries, Christian Niederwanger, Caroline Linhart, Bettina Schenk (Austria)

PO331-WED  INCREASED BIOMARKERS OF METABOLIC SYNDROME IN TOTAL JOINT ARTHROPLASTY PATIENTS
Andrew Banos*, William Hopkinson, Harold Rees, Daneyal Syed, Schuhrarazad Abro, Debra Hoppensteadt, Omer Iqbal (United States)

PO332-WED  END-STAGE RENAL DISEASE ASSOCIATED WITH METABOLIC SYNDROME: A STUDY OF BIOMARKERS RELEVANT TO CARDIOVASCULAR RISK
Vinod Bansal*, Jennifer Saluk, Debra Hoppensteadt, Daneyal Syed, Schuhrarazad Abro, Nil Guler, Rakesh Wahl, Jawed Fareed (United States)

PO333-WED  BARETTIN: A NATURAL MARINE COMPOUND WITH POTENT ANTICOAGULANT AND ANTI-INFLAMMATORY PROPERTIES
Karianne F Lind, Jan Ole Olsen, Bjarne Østerud* (Norway)

PO334-WED  PROTECTION EFFECTS OF 4AAQB ISOLATED FROM ANTRODIA CINNAMOMEA ON LPS-INDUCED SEPSIS MODEL.
Chi-en-Hsin Chang, Ching-Hu Chung* (Taiwan)

PO335-WED  ANTI-POLYPHOSPHATE ANTIBODIES AS ANTI-INFLAMMATORY/ANTICOAGULANT THERAPEUTICS
Richard J. Travers*, Catherine Baker, Rachel Breitenfeld, Michael Drake, Xiaomei Zhang, Naomi Esmon, Charles Esmom, James Morrissey (United States)

PO336-WED  EARLY MEASUREMENT OF THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) AND ACTIVATED TAFI (TAFIA) PREDICT OUTCOME IN PATIENTS WITH SEVERE SEPSIS OR SEPTIC SHOCK
Fabrizio Semeraro*, Serge Masson, Pietro Caironi, Concetta Ammollo, Nicola Semeraro, Mauro Panigada, Caterina Fanizza, Gianni Tognoni, Luciano Gattinoni, Roberto Latini, Marco Colucci (Italy)

PO337-WED  INFLAMMATORY CYTOKINE UP REGULATION MAY BE AN early MARKER OF THROMBOSIS IN PATIENTS WITH IMPLANTED LVADS
Walter Jeske*, Daneyal Syed, Erin Coglanisef, Jeffrey Schwartz, Mamdouh Bakhos, Jeanine Walenga (United States)

PO338-WED  COMBINED HIGH LEVELS OF IL-18 AND IL-12 ARE ASSOCIATED WITH NEW CLINICAL EVENTS IN CAD PATIENTS.
Trine Baur Opstad*, Harald Arnesen, Alf-Åge Pettersen, Ingebjørg Selje Selje (Norway)
SCIENTIFIC PROGRAM

PO344-WED  CYTOKINE-MEDIATED TRIGGERING OF THROMBIN GENERATION AND INFLAMMATION IN PATIENTS WITH STEVENS-JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS.
Omer Iqbal*, Daneyal Syed, Debra Hoppensteadt, Michael Mosier, Fareed Jawed, Charles Bouchard (United States)

Management of bleeding II

PO345-WED  NONCLINICAL EVALUATION OF CATIONICALLY MODIFIED POLYSACCHARIDE ANTIDOTES FOR UNFRACTIONATED HEPARIN
Bartłomiej Kalaska*, Kamil Kaminski, Emilia Sokolowska, Monika Kujdowicz, Krzysztof Szczubiłka, Dariusz Pawlak, Maria Nowakowska, Andrzej Mogielnicki (Poland)

PO346-WED  SCREENING TOOL FOR BLEEDING DISORDERS IN WOMEN WITH HEAVY MENSTRUAL BLEEDING
Sophie Wiewel-Verschueren*, H. Marieke Knol, Y.I.G. Vladimir Tichelaar, André Mulder, Ellen Klinkert, Hanneke Klui-Nellemans, Até G. van der Zee, Karina Meijer (The Netherlands)

PO347-WED  THE IMPACT OF RED BLOOD CELLS ON HEMOSTASIS UNDER WHOLE BLOOD FLOW CONDITIONS
Hiroaki Yaoi*, Yasuaki Shida, Keiji Nogami, Tomoko Matsumoto, Kenich Ogiwara, Kazuya Hosokawa, Midori Shima (Japan)

PO348-WED  REVERSAL OF DABIGATRAN COULD BE ACHIEVED BY HEMODIALYSIS WITH OR WITHOUT OTHER HEMOSTATIC AGENTS
Rachelle Li*, Francis Chan, Keith Lau, Anthony Chan, Howard Chan (Canada)

PO349-WED  INCREASED COAGULATION AND FIBRINOLYTIC POTENTIAL OF SOLVENT-DETERGENT PLASMA: AN OBSERVATIONAL STUDY BETWEEN SD-TREATED POOLED PLASMA AND FRESH FROZEN QUARANTINE PLASMA
Joyce van Beers, Lieve van Egmond, Rick Wetzel, Paul Verhezen, Erik Beckers, Rene van Oerle, Henri Spronk, Ron Straat, Yvonne Henskens* (The Netherlands)

PO350-WED  PROSPECTIVE HEMOSTASIS REGISTRY OF PATIENTS IN CARDIAC SURGERY (HEROES-CS): EVALUATION OF THE INTRODUCTION OF A THROMBOELASTOGRAPHY BASED TRANSFUSION PROTOCOL IN CARDIAC SURGERY.
Yvonne Henskens*, Lieve van Egmond, Rick Wetzel, Maurice Theunissen, Wouter van Willigem, Geert-Jan Kuiper, Marcus Lancé (The Netherlands)

PO351-WED  SIDE EFFECTS OF AND RESPONSE TO DDAVP DO NOT CORRELATE WITH OVERWEIGHT IN PATIENTS WITH HEMOPHILIA A OR VON WILLEBRAND DISEASE
Lisette M. Schutte*, Sara C.M. Stoof, Marjon Cnossen, Frank W.G. Leebeek, Marieke J.H.A. Kruip (The Netherlands)

SCIENTIFIC PROGRAM

PO352-WED  THROMBO(ELASTO)GRAPHIC EVALUATION OF THE INFLUENCE OF ANTICOAGULANT CONSTITUENTS ON THE PROHEMOSTATIC POTENTIAL OF PROTHROMBIN COMPLEX CONCENTRATE AND FACTOR IX CONCENTRATE
Herm Jan M. Brinkman*, Sanne Patiwaal, Shrijana Tripathi, Alexander Meijer, Joost Meijers (The Netherlands)

PO353-WED  PROTHROMBIN COMPLEX CONCENTRATE CAN INCREASE THROMBIN GENERATION IN THE PRESENCE OF LOW PLATELET NUMBER
Colleen Hamid*, John McVey, Anne Riddell, Keith Gomez, David Slatter, Pratima Chowdary (United Kingdom)

PO354-WED  EVALUATION OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE USE AND ITS ROLE IN THE REVERSAL OF NOVEL ORAL ANTICOAGULANTS
Sarah Sienko*, Michael Vasovski, Mona Ali (United States)

PO355-WED  THE COST-EFFECTIVENESS OF PD-APCC VERSUS RFVIIA IN PEDIATRIC PATIENTS WITH HAEMOPHILIA A AND INHIBITORS WITH MILD TO MODERATE JOINT BLEEDING IN MEXICO.
Janet Soto*, Lourdes Gonzalez, Amalia Bravo, Adolfini Bergés, Teresa Pompia, Maricarmen Rodriguez, Silva Salvador, Rogelio Paredes, Mark Lamotte (Mexico)

PO356-WED  PLATELET ADP REACTIVITY AND BLEEDING RISK IN LONG-TERM DOUBLE ANTIPLATELET THERAPY PATIENTS WITH CORONARY ARTERY DISEASE
Ekaterina Guskova*, Andrey Komarov, Anatoly Dobrovolsky, Alexander Deev, Anatoly Samko, Elizaveta Panchenko (Russian Federation)

PO357-WED  THROMBIN ACTIVATED FIBRINOLYSIS INHIBITOR IS A SIGNIFICANT RISK FACTOR OF RECURRENT BLEEDINGS IN PATIENTS ON LONG-TERM WARFARIN THERAPY.
Olga Moreva*, Ekaterina Kropacheva, Oksana Zemlyanskaya, Elena Titaeva, Anatoliy Dobrovolskiy, Elizaveta Panchenko (Russian Federation)

PO358-WED  LOW DOSE FEIBA AND HEMODIALYSIS FOR MANAGING MAJOR BLEEDING ON DABIGATRAN
William E. Dager*, Aaron Roberts, Robert Gosselin, Richard White (United States)

PO359-WED  EFFECTIVE USE OF LOW DOSE ACTIVATED PROTHROMBIN COMPLEX CONCENTRATES IN MANAGING MAJOR GI BLEEDING ON RIVAROXABAN
William E. Dager*, Aaron Roberts, Robert Gosselin, Richard White (United States)

Management of bleeding III

PO360-WED  THE COST-EFFECTIVENESS OF PD-APCC VERSUS RFVIIA IN PEDIATRIC PATIENTS WITH HAEMOPHILIA TYPE A AND INHIBITORS WITH MILD TO MODERATE JOINT BLEEDING IN COLOMBIA
Carlos A. Portilla*, Andres Felipe Gonzalez, Javier Mauricio Cortés, Angel Castro, Sandra Patricia Sterling, Mafalda Ramos (Colombia)
PO361-WED  IMPROVING EDUCATION AND ADVOCACY FOR YOUNG WOMEN WITH MENORRHAGIA THROUGH USE OF INNOVATIVE TECHNOLOGY
Lakshmi Srivaths (United States)

PO362-WED  REDUCED HEMOSTATIC CAPACITY AFTER CARDIOPULMONARY BYPASS
Lakshmi Srivaths*, Shu He, Margareta Blommbäck, Anders Jeppsson, Stefan Gräss* (Sweden)

PO363-WED  A FIXED DOSE PROTOCOL FOR PROTHROMBIN COMPLEX CONCENTRATE DOES NOT LEAD TO QUICKER AND RELIABLE INR REDUCTION IN VITAMIN K ANTAGONIST RELATED INTRACRANIAL HEMORRHAGE
Rahat Abdoellakhan*, Ishita Miah, Naklsa Khorsand, Korné Jellema, Karina Meijer (The Netherlands)

PO364-WED  RISKS AND PREDICTORS OF ISCHEMIC/BLEEDING COMPLICATIONS IN CARDIAC PATIENTS UNDERGOING ELECTIVE NON-CARDIAC SURGERY – AN ANALYSIS OF THE PRAGUE-14 STUDY
Zuzana Motovska*, Ladislav Dusek, Martina Ondrakova, Jiri Knot, Lukas Havluj, Robert Gurlich, Radek Bartoska, Valer Dzupa, Lukas Blittner, Petr Widimsky (Czech Republic)

PO365-WED  THE PHARMACOKINETICS AND IMMUNE RESPONSE OF NEW CATIONIC DEXTRAN ANTIDOTES OF HEPARIN
Bartłomiej Kalaska*, Kamil Kaminski, Dominik Czaplicki, Agnieszka Blazejczyk, Emilia Sokolowska, Monika Kujdowicz, Krystyna Stalinska, Krzysztof Szczubialka, Joanna Wietrzyk, Joanna Bereta, Dariusz Pawlak, Maria Nowakowska, Andrzej Mogielnicki (Poland)

PO366-WED  GENDER AND BLEEDING IN ATRIAL FIBRILLATION: A REAL-WORLD PROSPECTIVE COHORT STUDY
Jeroen Jaspers Focks*, Jaap Seelig, Stijn van Vugt, Alexander Serné, Lucie Bloem-de Vries, Marjo Albers-Akkers, Freek Verheugt, Marc Brouwer (The Netherlands)

PO367-WED  LOW-DOSE 4-FACTOR PCC FOR URGENT WARFARIN REVERSAL
Wesley Zemrak*, Kathryn Smith, Stephen Rolfe, Timothy Hayes, Robert Trowbridge, David Seder (United States)

PO368-WED  DEVELOPMENT AND VALIDATION OF AN ASSAY FOR INTRA-SURGICAL (OR PERI-OPERATIVE) MANAGEMENT OF BLEEDING
Elisa A. Ferrante*, Kiev Blasier, Timothy Fischer, Francesco Viola (United States)

PO369-WED  APTT SCREENING TEST IN THE COHORT OF ADULT PATIENTS UNDERGOING SURGICAL PROCEDURES: INSIGHTS FOR CLINICAL DAILY PRACTICE
Paolo Radossi, Lorena Zardo, Roberta Salviato, Silvia Chiappin, Federica Pierobon, Antonino Floridia, Gianpaolo Plaseric, Giuseppe Tagariello* (Italy)

PO370-WED  INTRAVENTRICULAR FIBRINOLYSIS RESTORES LYMPHATIC CIRCULATION AFTER SUBARACHNOID HEMORRHAGE.
Maxime Bauberti*, Thomas Gaberel, Clément Gabuka, Sara Martinez de Lizarrondo, Denis Vivien (France)

PO371-WED  EVALUATING THE INTER-OBSERVER RELIABILITY OF POTENTIAL PREDICTOR VARIABLES TO DEVELOP A MORE ACCURATE PREDICTION TOOL FOR BLEEDING FOR PATIENTS ON ORAL ANTICOAGULANT
Parvaneh Fallah*, Philip S. Wells, Melissa A Forgie (Canada)

PO372-WED  EFFECTS OF HEMOSTATIC GAUZE WITH SELF-PROPELLING THROMBIN PARTICLES ON SURVIVAL AND BLOOD LOSS IN A SWINE MODEL OF LETHAL ARTERIAL HEMORRHAGE
Alex St. John*, James Baylis, Xu Wang, Esther Lim, Diana Chien, Susan Stern, Christian Kastrup, Nathan White (United States)

PO373-WED  CLINICAL MANAGEMENT AND OUTCOME OF MAJOR BLEEDING IN PATIENTS ON TREATMENT WITH VITAMIN K ANTAGONISTS: RESULTS FROM THE CLIMBING STUDY.
Laura Franco*, Cecilia Becattini, Luca Masotti, Cinzia Nitti, Sergio Cattinelli, Roberto Cappelli, Giorgia Manina, Raffaele Sbrojavacca, Fulvio Pomero, Giancarlo Agnelli (Italy)

PO374-WED  COMPARATIVE STUDIES ON A BRANDED RECOMBINANT FACTOR VIA AND ITS GENERIC VERSION TO DEMONSTRATE EQUIVALENC.
Nasir Sadeghi, Paul O’Malley*, Massimo Iacobelli, Behrouz Vaziri, Daneyal Syed, Daniel Kahn, Debra Hoppenstead, Nil Guler, Jawed Fareed (United States)

PO375-WED  SELF-PROPELLING PARTICLES THAT TRANSPORT THROMBIN TO MANAGE HEMORRHAGE
James Baylis*, Yu Hun Yeon, Max Thomson, Amir Kazerooni, Xu Wang, Alex St. John, Esther Lim, Diana Chien, Anna Lee, Jesse Zhang, James Piret, Lindsay Machan, Thomas Burke, Nathan White, Christian Kastrup (Canada)

PO376-WED  A MICROFLUIDIC CHAMBER FOR ELONGATING MEGAKARYOCYTES AND PRODUCING FUNCTIONAL PLATELETS
Antoine Blin, Anne Le Goff, Sonia Poirault-Chassac, Geraldine Sicot, Bruno Teste, Aurelie Magniez, Mathilde Reysset, Dominique Baruch* (France)

PO377-WED  NOVEL ROLES OF THE DUAL-SPECIFIC PHOSPHATASES 1 AND 6 IN MEGAKARYOPOIESIS AND PROPLATELET FORMATION
Alexandra Mazharian*, Yotis Senis (United Kingdom)

PO378-WED  FUNCTIONALLY ACTIVE TISSUE FACTOR IS EXPRESSED DURING MEGAKARYOCYTE MATURATION AND IS TRANSFERRED TO A SUBSET OF PLATELETS
Marta Brambilla, Laura Facchinetti, Paola Canzano, Laura Rossetti, Nicola Ferr, Alessandra Balsulini, Vittorio Abbonante, Daniela Boselli, Luigi De Marco, Matteo Di Minno, Vincenzo Toschi, Alberto Corsini, Elena Tremoli, Marina Camera* (Italy)

PO379-WED  FUNCTIONAL ANALYSIS OF NBEAL2 IN HUMAN MEGAKARYOCYTES VIA COLOCALIZATION WITH SUBCELLULAR COMPARTMENTS
Richard W. Lo*, Fred Pluthero, Ling Li, Walter Kahr (Canada)

PO380-WED  CC5 RELEASED FROM PLATELETS DRIVES INCREASED MEGAKARYOCYTE MATURATION AND PROPLATELET FORMATION
Kellie R. Machlus*, Philip S. Wells, Melissa A Forgie (Canada)
PO381-WED  ANTI-GPIIB ANTIBODY INHIBITS PLATELET PRODUCTION FROM MEGAKARYOCYTES, BUT NOT MEGAKARYOCYTE MATURATION, ANALYZED IN A MURINE MODEL OF IMMUNE THROMBOCYTOPENIA. Yukinori Kozuma*, Hiroshi kojima, Haruhiko Ninomiya (Japan)

PO382-WED  PLANT FOOD CYANIDIN-3-O-ß-GLUCOSIDE PROMOTED MEGAKARYOPOIESIS BY REGULATION OF THE APOPTOTIC PATHWAY IN DAMI AND MEG-01 CELL LINES IN VITRO Yan Yang*, Jing Ren, Fulli Ya, Xiujuan Deng, Yanyan Wang, Wenhua Ling (China)

PO383-WED  MEGAKARYOCYTES AND PLATELETS EXPRESS NICOTINIC ACETYLCHOLINE RECEPTORS BUT NICOTINE DOES NOT AFFECT MEGAKARYOPOIESIS OR PLATELET FUNCTION Peter Bugert*, Angelika Schedel, Kerstin Kaiser, Stefanie Uhlig, Florian Lorenz, Anip Sarin, Julian Starigk, Dennis Hassmann, Karen Bieback (Germany)

PO384-WED  NOVEL REGULATORS OF MEGAKARYOPOIESIS BY RIBOSOME-PROTECTED RNA SEQUENCING Sjoert B. G. Jansen*, Romina Petersen, Myrto Kostadima, Maria Colzani, Mattia Frontini, Daniel Greene, Henia Semeoni, Ernest Turro, Jose Guerrero, Willem Ouwehand (United Kingdom)

PO385-WED  GENE EXPRESSION PROFILE IN MEGAKARYOCYTES FROM TYPE 2 DIABETIC MICE EMPHASIZES INCREASE IN STEFINA EXPRESSION LEVELS Anna Mezzapesa, Marjorie Poggi, Véronique Baccini, Patricia Ancel, Delphine Bastelica, Dorsaf Ghalloussi, Jean-François Landrier, Matthias Canault*, Marie-Christine Alessi (France)

PO386-WED  EFFECT OF ACETYLSALICYLIC ACID ON THE CONCENTRATION OF MONOCYTE MICROPARTICLES COEXPRESSING TISSUE FACTOR IN PATIENTS WITH DIABETES MELLITUS TYPE 2 Marcelo Luide Goncalves*, Lilian Goncalves, Fernanda Nunes, William Pedrosa, Maria Carvalho, Silvana Santos (Brazil)

PO387-WED  ALTERATIONS IN THE EXTRACELLULAR VESICLES PROPERTIES INDICATE HYPERCOAGULABLE STATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA Inna Tzoran-Rosenthal*, Annie Rebibo-Sabbah, Benjamin Brenner, Anat Aharon (Israel)

PO388-WED  RAC1 REGULATES PLATELET MICROPARTICLES FORMATION AND RHEUMATOID ARTHRITIS DETERIORATION Xue Chen*, Kemin Wang, Xiaoping Du, Junling Liu (China)

PO389-WED  PLATELET FACTOR XIII: THE RESCUE IN THE FACTOR FXIII DEFICIENCY. Claudia Maria Radu*, Cristiana Bulato, Elena Campello, Francesca Sartorello, Sabrina Gavasso, Mariangela Fadin, Paolo Simioni (Italy)

PO390-WED  PERFORMANCE OF THREE FUNCTIONAL ASSAYS FOR THE MEASUREMENT OF DABIGATRAN PLASMA CONCENTRATIONS Geneviève Freyburger*, David Girard, Anne-Laure Vervaeke, Marine Rousset, Sylvie Labrouche (France)

PO391-WED  EFFECT OF ACETYLSALICYLIC ACID ON THE CONCENTRATION OF MONOCYTE MICROPARTICLES COEXPRESSING TISSUE FACTOR IN PATIENTS WITH DIABETES MELLITUS Marcelo Luide Goncalves*, Lilian Goncalves, Fernanda Nunes, William Pedrosa, Maria Carvalho, Silvana Santos (Brazil)

PO392-WED  LOW MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY IN PATIENTS WITH PERSISTENT LUPUS ANTICOAGULANT AND A HISTORY OF THROMBOSIS Lena Heil*, Chian Ay, Florian Posch, Silvia Koder, Johanna Gebhart, Ingrid Pabinger, Johannes Thaler (Austria)

PO393-WED  LOW MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY IN PATIENTS WITH PERSISTENT LUPUS ANTICOAGULANT AND A HISTORY OF THROMBOSIS Lena Heil*, Chian Ay, Florian Posch, Silvia Koder, Johanna Gebhart, Ingrid Pabinger, Johannes Thaler (Austria)

PO394-WED  MEAL INTAKE INCREASES CIRCULATING PROCOAGULANT MICROPARTICLES IN PATIENTS WITH DIABETES MELLITUS Galia Spectre*, Fariborz Mobarrez, Ragnhild Stålesen, Håkan Wallén, Claes-Göran Östenson, Paul Hjemdahl (Israel, Sweden)

PO395-WED  MEAL INTAKE INCREASES CIRCULATING PROCOAGULANT MICROPARTICLES IN PATIENTS WITH DIABETES MELLITUS Galia Spectre*, Fariborz Mobarrez, Ragnhild Stålesen, Håkan Wallén, Claes-Göran Östenson, Paul Hjemdahl (Israel, Sweden)

PO396-WED  ATRA MODULATES THE EMISSION OF EXTRACELLULAR VESICLES – IMPLICATIONS FOR INTERCELLULAR COMMUNICATION BETWEEN ACUTE PROMYELOCYTIC LEUKEMIA AND ENDOTHELIAL CELLS Yi Fang*, Delphine Garnier, Tae Hoon Lee, Esterina D’Asti, Laura Montermini, Brian Meehan, Janusz Rak (Canada, China)

PO397-WED  ATRA MODULATES THE EMISSION OF EXTRACELLULAR VESICLES – IMPLICATIONS FOR INTERCELLULAR COMMUNICATION BETWEEN ACUTE PROMYELOCYTIC LEUKEMIA AND ENDOTHELIAL CELLS Yi Fang*, Delphine Garnier, Tae Hoon Lee, Esterina D’Asti, Laura Montermini, Brian Meehan, Janusz Rak (Canada, China)

PO398-WED  IMPACT OF A FAT-TOLERANCE TEST ON PLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES ASSESSED BY NANOPIECE TRACKING ANALYSIS Cathrine Ramberg*, Simin Jamaly, Nadezhda Latysheva, Erin Mathiesen Hald, Vladi- mir Tichelaar, John-Bjarne Hansen (The Netherlands)

PO399-WED  IMPACT OF A FAT-TOLERANCE TEST ON PLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES ASSESSED BY NANOPIECE TRACKING ANALYSIS Cathrine Ramberg*, Simin Jamaly, Nadezhda Latysheva, Erin Mathiesen Hald, Vladi- mir Tichelaar, John-Bjarne Hansen (The Netherlands)
PO399-WED  DIRECT ORAL ANTICOAGULANTS (DOAS) PLASMA LEVELS IN PATIENTS FOLLOWED BY A SINGLE CENTER
Rita Santoro*, Roberto Minici, Piergiorgio Iannaccaro, Sergio Morgione (Italy)

PO400-WED  DIRECT ORAL ANTICOAGULANTS AND SURGERY: OUR EXPERIENCE
Rita Santoro*, Roberto Minici, Piergiorgio Iannaccaro, Sergio Morgione (Italy)

PO401-WED  DILUTE RUSSELL VIPER VENOM TIME, A PARTIAL SOLUTION FOR SCREENING AND CONCENTRATION DETERMINATION OF DIRECT ORAL ANTICOAGULANTS
An K. Stroobants*, Erik-Jan van den Dool, Marion Heckman, Michiel Coppens, Auguste Sturk (The Netherlands)

PO402-WED  DRUG INTERACTIONS OF NEWER ORAL ANTICOAGULANTS DABIGATRAN, RIVAROXABAN, AND APIXABAN WITH ROUTINELY USED NONVITAMIN K ORAL ANTICOAGULANT/ANTIPLATELET DRUGS
Shermin Sayani*, Omer Iqbal, Debra Hoppensteadt, Jawed Fareed (United States)

PO403-WED  UNEXPECTEDLY STABLE DABIGATRAN LEVELS IN ANTICOAGULATION CLINIC PATIENTS
David L. Mcglasson*, George Fritsma (United States)

PO404-WED  SUCCESSFUL USE OF HEMODIALYSIS IN A DABIGATRAN OVERDOSE
Ana Freixo, Alcina Ferreira, Luciana Gonçalves, Lurdes Santos, Manuela Carvalho, Antonio Sarmento, Fernando Araujo* (Portugal)

PO405-WED  CLINICAL IMPACT OF BLEEDING COMPLICATIONS WITH DIRECT ORAL ANTICOAGULANTS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ORTHOPAEDIC SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Eleonora Tamborini Permunian*, Walter Ageno, Francesco Dentali, Nicoletta Riva (Italy)

PO406-WED  ROLE OF ANTICOAGULANT CLINICS IN THE MANAGEMENT OF PATIENTS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS (NOACS) AT CORK UNIVERSITY HOSPITAL (CUH)
Catriona O’leary*, George Fritsma (United States)

PO407-WED  ARE NON-VKA ORAL ANTICOAGULANTS (NOACS) PLASMA CONCENTRATIONS ASSOCIATED WITH THE RISK OF POSTOPERATIVE BLEEDING? PRELIMINARY RESULTS FROM THE REAL LIFE COHORT.
Pável E. Olivera*, Verónica Pons, Vicente Cortina, Laura López-Andreoni, Gonzalo Aralta, Ana Marin, Francesc Bosch, Amparo Santamaría (Spain)

PO408-WED  A NOVEL APPROACH TO EVALUATING ORAL ANTICOAGULANTS
Jeremy B. Chang*, Ronald Realubit, Charles Karan, Jacob Rand, Nicholas Tatonetti (United States)

PO409-WED  CLINICAL PRESENTATION AND EXTENT OF CLINICAL CARE OF CLINICALLY RELEVANT NON-MAJOR BLEEDING EVENTS WITH APIXABAN AND WARFARIN
Suzanne M. Bleker*, Alexander Cohen, Harry Büller, Giancarlo Agnelli, Alexander Gallus, Gary Raskob, Jeffrey Weitz, Madelyn Curto, Melanie Sisson, Saskia Middeldorp (The Netherlands)
SCIENTIFIC PROGRAM

PO419-WED
STABILITY OF RENAL FUNCTION IN PATIENTS WITH ATRIAL FIBRILLATION SWITCHED FROM WARFARIN TO TARGET-SPECIFIC ORAL ANTICOAGULANTS
Anum Minhas*, Qingmei Jiang, Xiaokui Gu, Keely Haymart, Eva Klíne-Rogers, Steve Almany, Jay Kozlowski, Gregory Krol, Scott Kaatz, James Froehlich, Geoffrey Barnes (United States)

PO420-WED
BLEEDING ON NOVEL ORAL ANTICOAGULATION - OUR EXPERIENCE IN THE NORTHERN REGION, UNITED KINGDOM: PRESENTING FEATURES AND MANAGEMENT OF BLEEDING IN INDIVIDUALS TREATED WITH A NOVEL ORAL ANTICOAGULANT (NOAC): RESULTS OF AN OBSERVATIONAL STUDY
Shikha Chattee*, Adil Iqbal, Janice Robertson, Andrew McGregor, Tina Biss (United Kingdom)

PO421-WED
DRUG USE EVALUATION OF RIVAROXABAN IN TAN TOCK SENG HOSPITAL: A REVIEW OF UTILIZATION TRENDS AMONG ASIAN POPULATION
Lee Hwei Khien*, Choo Theresa (Singapore)

PO422-WED
IN VITRO ASSESSMENT OF DIRECT ORAL ANTICOAGULANT’S HEMORRHAGIC OR THROMBOTIC RISK BY FIBRIN CLOT STRUCTURE PROFILES
Carmel Dassì*, Olivier Mathieu, Emmanuelle Bigo, Landry Seyeve, Raphaëlle Marlu, Benoit Polack, Francois Caton, Genevieve Contant (France)

PO423-WED
USE OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR NON-VALVULAR ATRIAL FIBRILLATION IN REAL-LIFE: COMPARISON WITH PHASE III TRIALS
Maria Cristina Vedovati*, Michela Giustozzi, Cecilia Becattini, Serenella Conti, Paolo Verdechcia, Federica Cianella, Melina Verde, Esmeralda Filipucci, Giancarlo Agnelli (Italy)

PO424-WED
COMPARISON IN ASSESSMENT OF THE KINETICS OF NOACS (DABIGATRAN, RIVAROXABAN, APIXABAN) BETWEEN TARGET SPECIFIC ASSAYS AND COMMON COAGULATION TESTS ASSAYS
Ramin Artag*, Jorn Dalsgaard Nielsen, Claire Dunois, Cedric Amirah, Jean Amiral (United States)

PO425-WED
ANTICOAGULATION PHARMACOKINETICS DURING DABIGATRAN THERAPY
Thomas Orfeo*, Matthew Gissel, Kenneth Mann (United States)

PO426-WED
EFFECT OF HOMOCYSTEINE AND FOLIC ACID IN CALCITONIN AND ROS PRODUCTION IN PLATELETS FROM BILE-DUCT LIGATION RATS.
Paola Romecin*, Noemí Marín, David Iyu, Jose Millán, Faustino García, Clara Ortíz, Joaquín García-Estañ (Spain)

PO427-WED
TARGET SPECIFIC ORAL ANTICOAGULANTS CAN CAUSE FALSE-POSITIVITY OF CONFIRMATORY LUPUS ANTICOAGULANT TESTING, ESPECIALLY IN DRVVT TESTING
Bo Hyun Kim*, Seongsoo Jang, Mi Hyun Bae, Young-Uk Cho, Chan-Jeoung Park (Korea, Republic Of)

PO428-WED
INTRAVITAL THREE-DIMENSIONAL VISUALIZATION AND QUANTIFICATION OF THROMBUS FORMATION BASED ON NON-LINEAR MICROSCOPE
Satoshi Nishihara*, Asuka Sakata, Kinya Seo, Tsukasa Ohmori, Koji Eto (Japan)

PO429-WED
C-CBL REGULATES GPVI-INDUCED THROMBOXANE A2 GENERATION INDEPENDENTLY OF THE SYK-PLC GAMMA 2 PATHWAY THROUGH Y737 PHOSPHORYLATION
Carol Dangelmaier*, Soochung Kim, Bhanu Kanth Manne, Jianuo Jin, Mauro Torti, Wallace Langdon, Steven McKenzie, Archana Sanjay, James Daniel, Sathy Kunapalli (United States)

PO430-WED
THROMBIN-STIMULATED PHOSPHORYLATION OF DISABLED-2 REGULATES ITS INTERACTION WITH CIN85 DURING HUMAN PLATELET ACTIVATION
Hui-Ju Tsai*, Hung-Pin Chiu, Chien-Sheng Chou, Man-Leng Kao, Yao-Wen Chang, Ju-Chien Cheng, Ching-Ping Tseng (Taiwan)

PO431-WED
DROSPIRENONE ENHANCES GP IbX-IX-V MEDIATED PLATELET ACTIVATION
Xuemei Fan, Xue Chen, Conghui Wang, Jing Dai, Yeling Lu, Yizhu Chen, Kemin Wang, Junling Liu, Junfeng Zhang, Xiaolin Wu* (China)

PO432-WED
A PARADOXICAL HAEMORRHAGIC STATE CAUSED BY DELETION OF THE SRC KINASE INHIBITOR CSK IS PARTIALLY RESCUED BY DELETION OF CD148

PO433-WED
COMPUTATIONAL MODEL OF MICROVASCULAR THROMBUS FORMATION: THE IMPACT OF DAMAGED AREA SIZE ON THROMBUS DYNAMICS
Dmitry Nechipurenko*, Mikhail Pantaleev, Fazoli Ataullakhanov (Russian Federation)
SCIENTIFIC PROGRAM

PO437-WED  SPHINGOSINE KINASE DEFICIENCY MODULATES PLATELET ACTIVATION
Benoit Decouture*, Boubacar Mariko, Salomé Gazit, Patrice Théron, Ludovic Couty, Blandine Dizier, Jessica Ransinian, Pascale Gaussem, Christilla Bachelot-Loza, Eric Cramer (France)

PO438-WED  MOLECULAR CHARACTERIZATION OF GAP JUNCTION MEDIATED INTERCELLULAR COMMUNICATION IN PLATELETS
Sakhthivel Vaiyapuri, Alexander Bye, Michael Benn, Yamiko Sakurai, Wilbur Lam, Jonathan M. Gibbins* (United Kingdom)

PO439-WED  IMPAIRED PLATELET RESPONSES TO THROMBOXANE A2 AND THROMBIN IN MICE LACKING RECEPTOR-INTERACTING PROTEIN KINASE 3
Yiwen Zhang, Jian Zhang, Kesheng Dai* (China)

PO440-WED  LYSINE ACETYLTRANSFER SUPPORTS PLATELET FUNCTION
Joseph E. Aslan*, Rachel Rigg, Sandra Baker, Jiaqing Pang, Larry David, Owen McCarty (United States)

PO441-WED  GLYCOPROTEIN VI (GPVI) IS INTERNALIZED IN PLATELETS ACTIVATED BY SOLUBLE GPVI-SPECIFIC AGONISTS
Stephanie M. Jung*, Elizabeth Gardiner, Robert Andrews, Hiroyuki Shimizu, Kenji Soejima, Tomohiro Nakagaki, Dominique Bihan, Richard Farnsdale, Masaaki Moroi (United Kingdom)

PO442-WED  RELEASE OF EXTRA CELLULAR DNA CONTRIBUTES TO RENAL ISCHEMIA REPERFUSION INJURY THROUGH PLATELET ACTIVATION AND FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS
Marcel P. B. Jansen*, Diba Emal, Gwen Teske, Sandrine Florquin, Joris Roelofs (The Netherlands)

PO443-WED  TRACTOPODS: NOVEL INTEGRIN ALPHA(IIB) BETA(3) DEPENDENT PLATELET MEMBRANE ANCHORS PROMOTING PLATELET-ENDOTHELIAL INTERACTIONS AND THROMBO-INFLAMMATION
James Mcfadyen*, Warwick Nesbitt, Imala Alwis, Zane Kaplan, Simone Schoenwaelder, Yuting Yuan, Shaun Jackson (Australia)

PO444-WED  SPECIFIC REGULATION OF MOUSE PLATELET ADP SECRETION BY SARCO-ENDOPLOSMIC RETICULUM CALCIUM ATPASE TYPE 3
Zihe Elaib*, Frédéric Adam, Elane Berrou, Régis Bobe, Marijke Bryckaert, Jean-Philippe Rosa (France)

PO445-WED  CD32 ANTIBODIES PROTECT FCGR2A MICE FROM IGG MEDIATED HYPERSENSITIVITY REACTIONS AND THROMBOSIS
Ali Amirhosravi*, Todd Meyer, Liza Robles-Carrillo, Monica Davila, Meghan Brodie, Hina Desai, Mildred Rivera-Amaya, John Francis (United States)

PO446-WED  CONVERGING ROLES OF PLATELETS AND CD32A IN IGG-MEDIATED HYPERSENSITIVITY REACTIONS
Ali Amirhosravi*, Todd Meyer, Monica Davila, Liza Robles-Carrillo, John Francis (United States)

PO447-WED  PLANT FOOD CYANIDIN-3-GLUCOSIDE INDUCES HUMAN ACTIVATED PLATELET APOPTOSIS VIA BCL-2/BCL-XL INTRINSIC PATHWAY
Yan Yang*, Jinja Tian, Liyi Chen, Like Zhang, Wenhua Ling (China)
SCIENTIFIC PROGRAM

PO458-WED  PLATELET DENSE GRANULE SECRETION DEFECTS MAY OBSCURE OUR UNDERSTANDING OF A-GRANULE SECRETION MECHANISMS: EVIDENCE FROM MUNC13-4-DEFICIENT PLATELETS
Matthew T. Harper*, Marion van den Bosch, Ingeborg Hers, Alastair Poole (United Kingdom)

PO459-WED  THE INOSITOL(1,4,5)TRISPHOSPHATE RECEPTOR TYPE 2 IS IMPORTANT IN THROMBIN INDUCED PLATELET ACTIVATION AND IS REQUIRED FOR THROMBUS FORMATION IN VIVO.
Kalwant S. Authi*, Harmeet Authi, Claire Sand, Fulye Argunhan, Manasi Nandi (United Kingdom)

PO460-WED  TRANSCRIPTION OF EXOGENOUS RNA IN HUMAN PLATELETS
Vivienne Wai Tung Chan*, Stefanie Novakowski, Simon Law, Christian Kastrup (Canada)

PO461-WED  THE PI(3,4,5)P3-BINDING PROTEIN RASA3 NEGATIVELY REGULATES RAP1B AND INTEGRIN AIIB3-MEDIATED SPREADING
Anthony M. Battram*, Tom Durrant, Ejaife Agbani, Samantha Moore, Alastair Poole, Ingeborg Hers (United Kingdom)

PO462-WED  DEXTRAN SULFATE TRIGGERS PLATELET AGGREGATION VIA PEAR1, INDEPENDENT FROM SYK
Christophe Vandenbriele*, Yi Sun, Maarten Criel, Benedetta Izzi, Peter Verhamme, Marc Hoylaerts (Belgium)

SCIENTIFIC PROGRAM

PO469-WED  EFFECT OF CARDIOPULMONARY BYPASS PUMP ON THE PLATELET FUNCTION USING PLATELET FUNCTION ANALYZER (PFA-100) PRE AND POSTOPERATIVE CARDIAC SURGERY OPERATION
Rashed B. Albakr* (Saudi Arabia)

PO470-WED  DECREASED PLATELET REACTIVITY IN WOMEN WITH HEAVY MENSTRUAL BLEEDING: A NOVEL APPROACH IN THE GYNAECOLOGY CLINIC TO DIAGNOSE THROMBOPATHY USING A NOVEL PLATELET FUNCTION TEST.
Heleen Eising*, Mark Roest, Philip de Groot, Jasper Remijn (The Netherlands)

PO471-WED  DIAGNOSTIC ACCURACY OF FLOW CYTOMETRY ANALYSIS OF PLATELET LEUKOCYTE AGGREGATES IN ACUTE CORONARY SYNDROME PATIENTS VERSUS NORMAL VOLUNTEERS
Najio Dally*, Elizabeth Estel, Tatjana Levinas, Inna Rozenfeld, Adi Sharabi-Nov, Yifat Zivony, Majdi Halabi (Israel)

PO472-WED  A STEP FORWARD IN THE EVALUATION OF PLATELET FUNCTION TESTING: ROUTINE, SIMULTANEOUS MEASUREMENT OF PLATELET AGGREGATION, SEROTONIN (5-HT) CONTENT AND SECRETION BY HPLC-ELECTROCHEMICAL DETECTION IN HEMOSTASIS LABORATORIES.
Eduardo Aranda, Pablo Riquelme, Viviana Romero, Jaime Pereira, Teresa Quiroga, Oslando Padilla, Olga Panes, Diego Mezzano* (Chile)

PO473-WED  OUTCOMES OF 65 PREGNANCIES IN 34 WOMEN WITH 5 DIFFERENT FORMS OF INHERITED PLATELET FUNCTION DISORDERS ENROLLED IN A RETROSPECTIVE AND MULTICENTRIC STUDY, ON BEHALF OF EHA-SWG ON THROMBOCYTOPENIAS AND PLATELET FUNCTION DISORDERS
Patrizia Noris*, Elisa Civaschi, Catherine Klersy, Federica Melazzini, Nuria Pu-jol-Moix, Cristina Santoro, Marco Cattaneo, Cécile Lavenu-Bombed, Loredana Bury, Pietro Minuz, Paquita Norden, Ana Rosa Cid-Haro, Adam Cuker, Véronique Latger-Cannard, Remi Favier, Ilaria Nichele, Carlo Balduini (Italy)

PO474-WED  THE VALUE OF IMPEDANCE AGGREGOMETRY IN ACUTE LEUKEMIA PATIENTS
Andra Costache*, Silvana Angelescus, Doina Barbu, Delia Mut, Anca Lupu (Romania)

PO475-WED  A NATIONAL REGISTRY OF PATIENTS WITH INHERITED PLATELET DISORDERS: BLEEDING SCORE IS ASSOCIATED WITH TIME OF FOLLOW-UP
Shoshana Revel-Vilk*, Tal Ben Ami, Chana Richter, Joanne Yacobovich, Shraga Aviner, Ayelet Ben-Barak, Amir Kuperman, Shira Ben-Barak, Chaim Kaplinsky, Hannah Tamary, Gili Kenet (Israel)

PO476-WED  PLASMA MARKERS OF FIBRINOLYSIS, THROMBIN GENERATION AND PLATELET ACTIVITY IN MYELOPROLIFERATIVE NEOPLASMS
Hung Chang*, Po-Nan Wang, Po Dunn, Alan Michelson, Andrew Frelinger (Taiwan)

PO477-WED  COMPARISON OF A NOVEL AUTOMATED MICROCHIP FLOW-CHAMBER SYSTEM AND CONVENTIONAL PLATELET FUNCTION TESTS IN PATIENTS WITH ISCHEMIC CEREBROVASCULAR DISEASES
Masako Yamazaki*, Tomoko Ohnishi, Kazuya Hosokawa, Kouji Yamaguchi, Taku Yoneyama, Akitsugu Kawashima, Yoshikazu Okada, Kazuo Kitagawa, Shinichiro Uchiyama (Japan)
SCIENTIFIC PROGRAM

PO478-WED  GENETIC AND NON-GENETIC DETERMINANTS OF MPV DIFFER IN MALES AND FEMALES – RESULTS FROM THE GUTENBERG HEALTH STUDY
Marina Panova-Noeva*, Vera Grossmann, Iris Hermanns, Andreas Schulz, Johanna Mazur, Stefan Blankenberg, Tanja Zeller, Thomas Münnzel, Karl Lackner, Hugo ten Cate, Philipp Wild (Germany)

PO479-WED  EVALUATION OF PLATELETS COUNT AND ACTIVATION DURING MENSTRUAL CYCLE IN YOUNG WOMEN IN ORAL CONTRACEPTIVE USE
Luci M. S. Dusse*, Letícia Freitas, Cristina Loures, Marcos Silva, Fernanda Nunes, Maria Carvalho (Brazil)

PO480-WED  REVISITING THE HEMOSTATIC DISORDER OF UREMIA: PATIENTS ON PERITONEAL DIALYSIS (CRF-PD) HAVE NORMAL PLATELET AGGREGATION AND SECRETION BUT INCREASED PLATELET TISSUE FACTOR ACTIVITY (TF-PCA), PROBABLY THE CAUSE OF INTRAVASCULAR CLOTTING ACTIVATION.
Olga Panes*, César González, M. Macarena Ruiz, Camila Sandoval, Marcela Cayuele, Alejandro Rojas, Mariana Soto, Melan Peralta, Jaime Pereira, Mireya Ortiz, Diego Mezzano (Chile)

PO481-WED  TREATMENT OF INHERITED PLATELET FUNCTION DISORDERS IN CHILDREN AND ADOLESCENTS – INTERDISCIPLINARY GUIDELINE OF THE GERMAN SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH (GTH).
Ralf Knöfler*, Wolfgang Eberl, Werner Streif (Germany)

PO482-WED  CHANGES IN THE EXPRESSION OF PLASMA AND PLATELET MICRORNAS IN TYPE 2 DIABETES MELLITUS AND OBESITY
Zsolt Fejes*, Szilárd Poliska, Andráss Penyige, Miklós Káplár, Ildikó Debreceni, János Kappelmayer, Béla Nagy Jr (Hungary)

PO483-WED  NICOTINIC ACETYLCOLINE RECEPTOR FUNCTION IN PLATELETS FROM ALZHEIMER DISEASE PATIENTS
Peter Bugert*, Angelika Schedel, Lucrezia Hausner, Isabella Wiest, Tim Wiemers, Anip Sarin, Dennis Hassmann, Sabrina Besenfelder, Lutz Frölich (Germany)

PO484-WED  HEMODIAFILTRATION ELICITS AN ATTENUATED DEGREE OF PLATELET ACTIVATION COMPARED TO HEMODIALYSIS
János Kappelmayer*, Gergely Becs, Renáta Hudák, Ildikó Debreceni, Harjit Bhattoa, József Balla (Hungary)

PO485-WED  TWICE-DAILY DOSING OF ASA OVERCOMES REDUCED PLATELET RESPONSE TO ONCE-DAILY ASA AFTER CORONARY ARTERY BYPASS GRAFT SURGERY: A RANDOMIZED CONTROLLED TRIAL
Jeremy S. Paikin*, Jack Hirsh, Jeff Ginsberg, Jeff Weitz, Noel Chan, Richard Whitlock, Guillaume Pare, John Elkelooboom (Canada)

PO486-WED  INCREASED MITOCHONDRIAL ELECTRON TRANSPORT ASSOCIATED WITH APOPTOSIS IN HYPER-REACTIVE PLATELETS OF PATIENTS WITH ACUTE PULMONARY EMBOLISM
Samin Rezania*, Michael Puskarih, Scott Mercer, Jeffrey Kline (United States)

POSTERS

PO487-WED  ANTENATAL GENETIC ANALYSIS OF A JAPANESE TYPE 1 CD36-DEFICIENT WOMAN IN THE PREGNANCY
Naomi Sanda*, Hiroko Endo, Chiaki Kato, Shigeo Nakamura, Tadashi Matsushita (Japan)

PO488-WED  A RELIABLE AND SIMPLE DIAGNOSTIC APPROACH TO DETECT PLATELET SECRETION DEFECTS IN SUBJECTS WITH MUCOCUTANEOUS BLEEDING
Natalia Dovlatova*, Marie Lordkipanidzé, Gillian Lowe, Ban Dawood, Jane May, Stan Hepinstall, Steve Watson, Sue Fox (United Kingdom)

PO489-WED  PLATELET CD40L CONTROLS BLEEDING DURING P2Y12 BLOCKERS TREATMENT
Charlotte Goscidier, Pierre Deharo, Denis Bernot, Pierre Morange, Kelly Daryl Blanz, Daniel Duerschmied, Dennis Wolf, Jacques Quilici, Jean-Louis Bonnet, Thomas Cuisset, Matthias Canault*, Marie-Christine Alessi (France)

PO490-WED  CLINICAL AND GENETIC PREDICTORS OF POOR PLATELET RESPONSE TO CLOPIDOGREL IN PATIENTS WHO UNDERWENT PERCUTANEOUS CORONARY INTERVENTION
Ayse A. Timur*, Gurunathan Murugesan, John Barnard, Sanjay Gandhi, Deepak Bhatt, Kandice Kottke-Marchant (United States)

PO491-WED  NO INCREASE IN PLATELET AGGREGATION IN HEALTHY WOMEN STARTING COMBINED ORAL CONTRACEPTIVES
Julie Brogaard Larsen*, Mustafa Vakur Bor, Anne-Mette Hvas (Denmark)

PO492-WED  THE PLATELETS CHARACTERISTICS IN TYPE 2 DIABETES MELLITUS (T2DM)
Liudmila I. Buryachkovskaya*, Irina Uchitel, Alexander Sumarokov, Ula Docenko (Russian Federation)
PO497-WED
STUDY OF PLATELET FUNCTION IN HEMOPHILIA A IN THE REGION OF MURCIA
Antonia Melero-Amor*, Faustino Garcia-Candel, Noemi Marín Atucha, Paola Romecin, David García Bernal, David Iyu, José Eduardo Millán, José María Moralesa (Spain)

PO498-WED
REDUCED PLATELET ACTIVITY UNDER INDUCED OXIDATIVE STRESS CONDITIONS IN GILBERT’S SYNDROME
Avinash Reddy Kundur*, Abishek Santhakumar, Andrew Bulmer, Indu Singh (Australia)

PO499-WED
CEREBRAL VEIN THROMBOSIS OCCURRING DURING OXYMETHOLEONE THERAPY IN A PATIENT WITH FANCONI APAF-thLON ANEMIA
Gokce Pinar Reis, Ayseun Bahadır, Erol Erduran* (Turkey)

PO500-WED
MANAGEMENT OF ORAL ANTICOAGULANT THERAPY INTERRUPTION IN CHILDREN
Fiona Newall*, Varun Kommidi, Paul Monagle (Australia)

PO501-WED
THROMBOSIS IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: ENDOGENOUS AND EXOGENOUS RISK FACTORS
O.N. Shipilova*, N.S. Podchernyaeva, Y.G. Kostina, M.K. Osminina, E.U. Afnina (Russian Federation)

PO502-WED
EVALUATION OF AGE-DEPENDENT DOSING RECOMMENDATIONS FOR THE ADMINISTRATION OF Tinzaparin in the Treatment of Paediatric Thrombosis
Kat Webber, Paul Murphy, Kate Talks, John Hanley, Tina Biss* (United Kingdom)

PO503-WED
USING A FUNCTIONAL PLATELET ACTIVITY ANALYSIS IN CHILDREN WITH UNEXPLAINED BLEEDING. FIRST RESULTS FROM RUSSIA
Pavel A. Zharkov*, Irina Demina, Aleksey Pshonkin, Galina Novichkova, Mikhail Panetelev, Aleksey Maschan (Russian Federation)

PO504-WED
FOUR YOUNG CHILDREN WITH THROMBOSIS COMPLICATIONS AS A RESULT OF ANTITHROMBIN HEPARIN-BINDING DEFECTS.
Michael Mitchell*, Jacky Cutler, Ruth Wheeler, Janyahlam Alamelu (United Kingdom)

PO505-WED
RISK OF THROMBOSIS IN A COHORT OF PEDIATRIC ACUTE LYMPHOBlastic LEUKEMIA PATIENTS
Sule Unal*, Fatma Gumruk, Turan Bayhan, Selin Aytaç, Betul Tatlı, Barış Kuskonmaz, Mualla Cetin (Turkey)

PO506-WED
COMPARISON OF THE IMPACT OF SERPINC1, PROC AND PROS1 MUTATIONS ON THROMBOTIC PHENOTYPES IN CHILDREN AND ADULTS: AN OBSERVATIONAL MULTICENTER COHORT STUDY
Verena Limperger*, Gill Kenet, Christine Heller, Melchior Lauten, Karin Kurnik, Ulrich Klostermeier, Rolf Mesters, Neil Goldenberg, Guy Young, Ulrike Nowak-Göttli (Germany)

PO507-WED
ACQUIRED VON WILLEBRAND DISEASE IN A PATIENT WITH UNDERLYING BECKWITH-WIEDEMANN SYNDROME
Fatma Gumruk*, Sule Unal, Turan Bayhan, Mualla Cetin (Turkey)

PO508-WED
NOVEL HOMOZYGOUS MUTATION IN MCFD2 AND HETEROZYGOUS SMALL DELETION IN LMAN1 GENES CAUSING COMBINED FACTOR V AND VIII DEFICIENCY
Mualla Cetin*, Sule Unal, Turan Bayhan, Johannes Oldenburg, Fatma Gumruk (Turkey)

PO509-WED
TREATMENT OF PEDIATRIC THROMBOSIS WITH DALTEPARIN SODIUM.
Pavel Svinin*, Libov Larina, Alena Kazankova, Viktor Petrov, Artiom Bulilü (Russian Federation)

PO510-WED
NEONATAL AND ADULT PLATELETS REVEAL A DISTINCT PROTEIN EXPRESSION PROFILE?
Eva Stokhuijzen*, Floris van Alphen, Martje van den Biggelaar, Annemarie Koornneef, Carmen van der Zwaan, Carlijn Kuijk, Koen Mertens, Karin Fijnvandraat, Alexander Meijer (The Netherlands)

PO511-WED
THE INFLUENCE OF CHILDHOOD IMMUNIZATIONS ON WARFARIN EFFECT
Mary Bauman, Patti Massicotte, Suzanne Siddons, Aisha Bruce* (Canada)

PO512-WED
NIACIN HAS LIMITED EFFECTIVENESS IN REDUCTION OF ELEVATED LIPOPROTEIN(A) IN CHILDREN WITH OR AT RISK OF THROMBOSIS OR STROKE
Kavita Patel*, Rachel Swerdlin, Robert Sidonio (United States)

PO513-WED
HEMOSTASIS PROFILE IN CALVES RECEIVING THE CARMAT BIOPROSTHETIC ARTIFICIAL HEART
David Smadja*, Sophie Susen, Antoine Rauch, Bernard Cholley, Christian Latremouille, Daniel Duveau, Luca Zilberstein, Eric Vanbelle, Antoine Capel, Pascale Gaussem, Piet Jansen, Alain Carpentier (France)

PO514-WED
PEDIATRIC STROKE OCCURRENCE IN ONE CHILDREN HOSPITAL IN CORDOBA, ARGENTINA
Maria Morelli*, Elizabeth Hiramatsu, Roberto Navarro (Argentina)

PO515-WED
DOSE REQUIREMENTS OF ACENOCOUMAROL IN PEDIATRIC PATIENTS – INITIATION OF THERAPY
Evelina Doncheva*, Ivanka Paskaleva (Bulgaria)

PO516-WED
DIRECT THROMBIN INHIBITOR FOR ANTICOAGULATION: ROLE OF ARGATROBAN IN PEDIATRIC POST LIVER TRANSPLANT PATIENTS WITH HEPATIC ARTERY THROMBOSIS
Mukt Sharma*, Richard Hendrickson, Ryan Fischer, James Daniel, Rachel Cisemos, Megan Davis, Walter Andrews, Brian Wicklund (United States)

Rare bleeding disorders II

PO517-WED
CHARACTERIZATION OF SIX ALTERATIONS IN ITGA2B AND ITGB3 ASSOCIATED WITH GLANZMANN’S THROMBASTHENIA
Essa Sabi*, Vincenzo Leo, Areej Al-Musabih, Asmaa Al-Marwani, Michael Makris, Martina Daly (United Kingdom)
SCIENTIFIC PROGRAM

PO518-WED  TWO FAMILIES FROM ARGENTINA WITH FX DEFICIENCY DUE TO TWO DIFFERENT MUTATIONS (P.CYS241GLY AND P.GLN138ARG).
Hugo Guglielmone*, Luisa Sambado, Maria Molina, Salvador Minoldo, Laura Lopez Galetti, Antonio Girolami (Argentina)

PO519-WED  PLATELET TYPE - VON WILLEBRAND DISEASE (PT-VWD): A DIAGNOSTIC AND THERAPEUTIC DILEMMA IN CHILDREN
Shilpa Shukla*, Harmanpreet Kaur, Maha Othman, Suchitra Acharya (United States)

PO520-WED  RARE BLEEDING DISORDERS: 17 YEARS OF DIAGNOSIS IN THE HEMOSTASIS LABORATORY OF THE HEMATOLOGY DEPARTMENT OF THE UNIVERSITY HOSPITAL OF BENI MESSOUS, ALGIERS, ALGERIA
Karima W. Chennoukh*, Meriem Bensadok, Mylade Aribi, Nadia Zidani, Mohamed Ramaoun, Meriem Belhani, Salim Nekkal (Algeria)

PO521-WED  FACTOR XIII DEFICIENCY: PRELIMINARY RESULTS OF THE PRO-RBDD PROJECT
Flora Peyvandi*, Roberta Palla, Marzia Menegatti, Simona Siboni, Marco Boscarino, Britta Lachmann, Susan Halimeh, Naveena Fatima, Munira Borhani, Nihal Ozdemir, Marko Saracevic, Daniela Mikovic, Andrew Harvey, Andrew Mumford, Fraustina Hsu, John Chapin, Helen Pergantou, Helen Platokouki, Ay Yilmaz, Adrianna Williamson, Amy Shapiro, Alessandro Casini, Philippe de Moerloose, John Chapin, Helen Platokouki, Ay Yilmaz, Adrianna Williamson, Amy Shapiro, Alessandro Casini, Philippe de Moerloose, Jeanette Payne, Laszlo Muszbek (Italy)

PO522-WED  EFFECTS OF FACTOR XIII DEFICIENCY ON THROMBOELASTOGRAPHY, BASAL THROMBOELASTOGRAPHY AND LYSIS BY ADDITION OF STREPTOKINASE ARE MORE AFFECTED THAN SOLUBILITY TESTS
Marta Martinuzzo*, Luis Barrera, Diana Altuna, Maria Tisi Baña, Quillen Amigo, María D`Adamo, Marina López, Juan Otaso (Argentina)

PO523-WED  HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY: A REPORT OF ELEVEN VENEZUELAN CASES
Marión Echenagucia*, Aldo Salas Boadas, Tibsaiy Jiménez, María Hernández, Carlos Acosta, María Dos Santos, Arlette Ruiz-Sáiz (Venezuela, Bolivarian Republic Of)

PO524-WED  DIAGNOSIS OF FXIII DEFICIENCY: DATA FROM MULTICENTRE STUDIES AMONGST UK NEQAS AND PRO-RBDD PROJECT LABORATORIES.
Ian Jennings*, Flora Peyvandi, Steve Kitchin, Marzia Menegatti, Roberta Palla, Isobel Walker, Mike Makris (United Kingdom)

PO525-WED  THE CLINICAL FINDINGS OF CHILDREN WITH FACTOR X DEFICIENCY AT A SINGLE CENTER IN THE MIDDLE EAST OF TURKEY
Gulen Tuysuz, Funda Tayfun*, Nihal Ozdemir (Turkey)

PO526-WED  LUPUS ANTICOAGULANT - HYPOPROTHROMBINEMIA SYNDROME IN PATIENT - A CASE REPORT.
Bernadeta Ceglarek, Ksenia Bykowska, Anna Sikorska, Beata Baran, Edyta Odnoczko, Adam Wisniewski*, Jerzy Windyga (Poland)

PO527-WED  INHERITED FXI DEFICIENCY IS NOT A RARE DISEASE IN THE NORTHERN REGION OF TURKEY
Davut Albayrak*, Canan Albayrak (Turkey)

SCIENTIFIC PROGRAM

PO528-WED  CHARACTERIZATION OF PATIENTS WITH A MILD TO MODERATE BLEEDING PHENOTYPE: RESULTS OF THE VIENNA BLEEDING BIOPANK (VIBB)
Stefanie Hofer*, Johanna Gebhart, Sylvia Kepa, Cihan Ay, Paul Knöbl, Sabine Eichinger, Paul Kyler, Peter Quehenberger, Simon Panzer, Ingrid Pabinger (Austria)

PO529-WED  CLINICOHematological PROFILE OF RARE INHERITED COAGULATION DISORDERS.
Somasundaram Venkatesan*, Mukul Aggarwal, Ankur Ahuja, Manoranjan Mahapatra, Renu Saxena (India)

PO530-WED  CLINICAL PRESENTATION AND MANAGEMENT OF RARE FACTOR DEFICIENCIES: CASE STUDY
Bulent A. Antmen*, Ilgen Sasmaz, Barbaros Karagüzin, Goksel Leblebizatan, Yurdanur Kilinc (Turkey)

PO531-WED  SPECTRUM OF RARE BLEEDING DISORDERS
Sitalakshmi Subramanian*, Cecil Ross, Fulton D’Souza, Anand Prakash, Parimala Puttaiah, Latha Shaju (India)

PO532-WED  CONGENITAL FXI DEFICIENCY: A REPORT OF NINE FAMILIES FROM GERMANY AND LITHUANIA
Vytautas Ivaskevicius*, Georg Goldmann, Lina Kyziauskaitė, Giedrius Rutkauskiene, Silvia Horneff, Natascha Marquardt, Anna Pavlova, Johannes Oldenburg (Germany)

PO533-WED  TWO FEMALE CASES OF A1-ANTITRYPSIN PITTSBURGH
Lijuan Cao*, Zhaoyue Wang, Ziqiang Yu, Jian Su, Wei Zhang, Changpeng Ruan (China)

PO534-WED  CONGENITAL FXI DEFICIENCY: PRELIMINARY RESULTS OF PHENOTYPIC (CLINICAL AND LABORATORY) AND GENOTYPIC CHARACTERIZATION OF A CASE SERIES FROM A SINGLE CENTER.
Cristina Santoro*, Roberto Di Mauro, Maria Patrizia Bicocchi, Maura Acquila, Erminia Baldacci, Roberta Abbruzzese, Maria Basso, Francesco Barone, Raffaele Bochicchio, Grazia Ferrara, Paola Volpicelli, Maria Gabriella Mazzucconi (Italy)

PO535-WED  FACTOR VII DEFICIENCY AND PROPHYLAXIS DUE TO INTERVENTIONS
Violeta Dejanova-Ilijevska*, Emilija Velkova, Violeta Neceva, Slobodan Drakulevs (Macedonia, The Former Yugoslav Republic Of)

PO536-WED  COURSE OF PREGNANCY, LABOUR AND PERIOPERATIVE MANAGEMENT OF TWO PATIENTS WITH BERNARD-SOULIER SYNDROME - CASE REPORTS AND LITERATURE REVIEW
Anna Sikorska*, Justyna M Teliga-Czajkowska, Ksenia Bykowska, Bernadeta Ceglarek, Wiesław Schubert, Ewa Dmoch-Gajzlerska, Krzysztof Czajkowski, Jerzy Windyga (Poland)

PO537-WED  INHERITED FXIII DEFICIENCY IN THE NORTHERN REGION OF TURKEY
Davut Albayrak*, Canan Albayrak (Turkey)

PO538-WED  VON WILLEBRAND DISEASE: BE OR NOT TO BE, THAT IS THE QUESTION
Ana Azevedo*, Isabel Freire, Teresa Fidalgo, Teresa Gago (Portugal)
PO539-WED  IDENTIFICATION OF COAGULATION GENE 3’UTR VARIANTS THAT ARE POTENTIALLY REGULATED BY MiRNAs
Astrid van Hylckama Vlieg*, Constantino Martínez, Carla Vossen, Salam Salloum-Asfar, Hugoline de Haan, Raúl Teruel-Montoya, Javier Corral, Pieter Reitsma, Frits Rosendaal (The Netherlands)

PO540-WED  IDENTIFICATION OF OESTROGEN RESPONSIVE MiRNAS ASSOCIATED WITH THE REGULATION OF COAGULATION AND THE INCREASED THROMBOTIC RISK IN PREGNANT WOMEN
Jasmine Tay*, Ian James, Quintin Hughes, Ross Baker (Australia)

PO541-WED  STRUCTURAL AND FUNCTIONAL STUDIES OF MONOCLONAL HIGH AFFINITY ANTIBODIES (MABS) AGAINST THE HUMAN TFPI KUNITZ-TYPE PROTEASE INHIBITOR DOMAIN 1
Anders Svensson*, Birgitte Kjar, Jes Clausen, Berit Krogh, Peder Nørby, Jens Brinholt, Helle Petersen (Denmark)

PO542-WED  ORM1: A NOVEL REGULATOR OF THROMBIN GENERATION AND POTENTIAL CARDIOVASCULAR RISK FACTOR
Mohammed A. Alsahli*, Matthew Denniff, Unni Krishnan, Ravi Singh, Joy Wright, Nilesh Samani, Alison Goodall (Saudi Arabia, United Kingdom)

PO543-WED  ROLE OF COAGULATION FACTOR XI IN PROMOTING DISTAL PLATELET-aggregation AND THROMBUS FORMATION IN WHOLE BLOOD UNDER FLOW
Jegenia Zilberman-Rudenko*, Asako Itakura, Erik Tucker, David Gallani, Stephanie Smith, Sharon Choi, James Morrissey, András Gruber, Owen McCarty (United States)

PO544-WED  NUCLEIC ACIDS AND POLYPHOSPHATE AS MODULATORS OF COAGULATION
Joshua M. Gajsiewicz*, Richard Travers, Stephanie Smith, James Morrissey (United States)

PO545-WED  SELECTIVE NEUTRALIZATION OF THE SERPIN PROTEASE NEXIN-1 BY A SPECIFIC MONOCLONAL ANTIBODY
Marie-Christine Bouton*, Déborah François, Laurence Venisse, Els Brouwers, Véronique Arocas, Paul Declerck (France)

PO546-WED  IN SILICO PREDICTION OF MICRONA BINDING SITES IN HEMOSTATIC FACTORS
Jessica Jorritsma, Jasmine Tay*, Quintin Hughes, Ross Baker (Australia)

PO547-WED  ANALYSIS OF THE MECHANISM OF SPECIES DIFFERENCES REGARDING RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN ON PROTEIN C ACTIVATION IN HUMAN AND MOUSE
Takashi Arioka*, Shunsuke Tawara, Takumi Sakai (Japan)

PO548-WED  THE IMMEDIATE AND LATE EFFECTS OF THYROID HORMONE (TRIODO-TYRONINE) ON MURINE COAGULATION GENE TRANSCRIPTION
Salam Salloum-Asfar*, Anita Boelen, Pieter H. Reitsma, Bart J. M. van Vlijmen (Netherlands, Spain)

PO549-WED  INDIRECT REGULATION OF HEMOSTATIC PROTEINS BY MiR24 AND MiR34A THROUGH HEPATIC NUCLEAR FACTOR 4 ALPHA (HNF4A)
Salam Salloum-Asfar*, Ana Belen Arroyo, Nuria Garcia-Barbera, Amjad Itchoud, Erin Schuetz, Vicente Vicente, Rocío González-Conejero, Constantino Martínez (Spain)

PO550-WED  INVESTIGATION OF MODE OF ACTION OF SUGAMMADEX EFFECTS ON COAGULATION
Annelieke C. Krulthof*, Cornelis Kluft, Pieter-Jan de Kam, Ria Laterveer, Matthijs Moerland, Jacobus Burggraaf (The Netherlands)

PO551-WED  IDENTIFYING SUBSTRATES OF PROTEIN DISULFIDE ISOMERASE USING ENZYME VARIANTS WITH ALTERNED REDOX POTENTIAL
Jack D. Stopa*, Barbara Furie, Bruce Furie (United States)

PO552-WED  INHIBITORY EFFECT OF VITAMIN D INTAKE IN PLASMA FACTOR VIII ACTIVITY AND TISSUE FACTOR EXPRESSION IN MONOCYTIC CELLS
Raul Teruel-Montoya*, Jesus Lozano, Antonia Miliano, Ana Belen Arroyo, MJ Hernández, V Gómez, Salam Salloum-Asfar, Vanessa Roldán, Begoña Muñia, Javier Corral, Maria Teresa Herranz, Vicente Vicente, Rocío González-Conejero, Constantino Martínez (Spain)

PO553-WED  THE ASSOCIATION OF ENDOGENOUS STEROID HORMONE, SHBG, AND PRECURSOR STEROID LEVELS WITH HEMOSTATIC FACTOR LEVELS IN POSTMENOPAUSAL WOMEN
Laura B. Harrington*, Brett Marck, Kerri Wiggins, Barbara McKnight, Susan Heckbert, Nancy Woods, Andrea LaCroix, Marc Blondon, Bruce Psaty, Frits Rosendaal, Alvin Matsumoto, Nicholas Smith (United States)

PO554-WED  THE IMMEDIATE AND LATE EFFECTS OF THYROID HORMONE (TRIODO-TYRONINE) ON MURINE COAGULATION GENE TRANSCRIPTION
Salam Salloum-Asfar*, Anita Boelen, Pieter H. Reitsma, Bart J. M. van Vlijmen (Netherlands, Spain)

PO555-WED  THE ASSOCIATION OF ENDOGENOUS STEROID HORMONE, SHBG, AND PRECURSOR STEROID LEVELS WITH HEMOSTATIC FACTOR LEVELS IN POSTMENOPAUSAL WOMEN
Laura B. Harrington*, Brett Marck, Kerri Wiggins, Barbara McKnight, Susan Heckbert, Nancy Woods, Andrea LaCroix, Marc Blondon, Bruce Psaty, Frits Rosendaal, Alvin Matsumoto, Nicholas Smith (United States)

PO556-WED  POLYSTAT: A SYNTHETIC POLYMER HEMOSTAT FOR USE IN COMBINATION WITH FACTOR REPLACEMENT THERAPIES FOR HEMOPHILIA A
Maria Kölínberger, Axel Trabandt, Volker Laux* (Germany)

PO557-WED  THE ASSOCIATION OF ENDOGENOUS STEROID HORMONE, SHBG, AND PRECURSOR STEROID LEVELS WITH HEMOSTATIC FACTOR LEVELS IN POSTMENOPAUSAL WOMEN
Laura B. Harrington*, Brett Marck, Kerri Wiggins, Barbara McKnight, Susan Heckbert, Nancy Woods, Andrea LaCroix, Marc Blondon, Bruce Psaty, Frits Rosendaal, Alvin Matsumoto, Nicholas Smith (United States)

PO558-WED  OBSTRUCTIVE SLEEP APNEA DOES NOT ENHANCE HYPERCOAGULABILITY AS MEASURED BY THROMBIN GENERATION IN THE MORBIDLY OBSESE
Paradzai Chitongo*, Lara Roberts, Lyall Rebecca, Raj Patel, Simon Aryan, Roopen Arya (United Kingdom)
SCIENTIFIC PROGRAM

PO559-WED  VEREMA - AN AFFINITY PROTEOMICS STUDY TO IDENTIFY AND TRANS- Late PLASMA BIOMARKERS FOR VENOUS THROMBOEMBOLISM
Maria Bruzelius*, Maria Jesus Iglesias, Mun-Gwan Hong, David Tréguoët, Juan Carles Souto, Margareta Holmström, Mattias Frånberg, Rona Strawbridge, Maria Sabater-Llei- al, Bengt Sennblad, Angela Silverve, José Manuel Soria, Pierre Morange, Lynn Butler, Jochen Schwenk, Anders Hamsten, Jacob Odeberg (Sweden)

PO560-WED  ANALYSIS OF PROTHROMBIN MISSENSE MUTANTS AT 596ARG BY SINGLE NUCLEOTIDE SUBSTITUTION FOR ANTICOAGULANT SYSTEM
Yuki Takagi*, Moe Murata, Yuki Nakamura, Toshihiro Kozuka, Yukiko Nakata, Ryo Hasebe, Akira Takagi, Tetsuhiito Kojima (Japan)

PO561-WED  RED CELL DISTRIBUTION WIDTH AND FUTURE RISK OF VENOUS THROMBOSIS, MYOCARDIAL INFARCTION, STROKE AND CANCER – A CAUSE SPECIFIC ANALYSIS.
Trygve Ellingsen*, Jostein Lappegård, Tove Skjelbakken, Elisiv Mathiesen, Inger Njelst- tad, Sigrid Brekken, John-Bjarne Hansen (Norway)

PO562-WED  RISK OF VENOUS THROMBOSIS IN PERSONS WITH INCREASED BODY MASS INDEX AND INTERACTIONS WITH OTHER GENETIC AND ACQUIRED RISK FACTORS: A CASE-CONTROL STUDY
Daniel Ribeiro*, Willem Lijfering, Frits Rosendaal, Suzanne Cannegieter (Brazil, Nether- lands)

PO563-WED  DEHYDRATION AS A POSSIBLE CAUSE OF SEASONAL VARIATIONS IN THE INCIDENCE OF VENOUS THROMBOEMBOLISM
Elias Saad*, Ron Hoffman, Benjamin Brenner, Gieb Saharow, Yona Nadir (Israel)

PO564-WED  AN AFFINITY PROTEOMICS STUDY FOR PLASMA BIOMARKER CANDI- DATES OF CARDIOVASCULAR DISEASE IN VENOUS THROMBOEMBOLISM
Maria Jesus Iglesias*, Maria Bruzelius, Mun-Gwan Hong, David Tréguoët, Ljubica Perisic, Mattias Frånberg, Paolo Parini, Andrea Ganna, Erik Ingelsson, Peter Nilsson, Ulf Hedin, Mathias Uhlen, Angela Silverve, Piene Morange, Anders Hamsten, Jochen Schwenk, Jacob Odeberg (Sweden)

PO565-WED  LUNG DISORDERS IN ELDERLY PEOPLE ARE ASSOCIATED WITH PULMO- NARY EMBOLISM AND NOT WITH DEEP VEIN THROMBOSIS
Alev Karasu*, Adeleid C. Jorissen, Marissa J. Engbers, Mary Cushman, Frits R. Rosendaal, Astrid van Hylckama Vlieg (The Netherlands)

PO566-WED  ASSESSMENT OF RISK FACTORS IN ESTABLISHED CASES OF DEEP VEIN THROMBOSIS (DVT) AND GREAT SAPHENOUS VEIN THROMBOSIS (GSVT) IN INDIAN PATIENTS
Chithra Barvadheesh (India)

PO567-WED  JOINT EFFECT HOMOZYGOUS CARRIERS OF A RISK ALLELE IN THE FIBRINOGEN GAMMA CHAIN AND OVERWEIGHT ON RISK OF VENOUS THROMBOEMBOLISM.
Tine Lønneberg*, Erin Smith, Sigrid Brekken, Lars Horvel, Terry Solomon, Tom Wils- gaard, Frits Rosendaal, Kelly Frazier, John-Bjarne Hansen (Norway)

PO568-WED  IMPACT OF THE ABO RS8176719 SINGLE NUCLEOTIDE POLYMOR- PHISM ON CANCER-RELATED VENOUS THROMBOEMBOLISM
Olga Dziewiecka*, Erin Smith, Sigrid Brekken, Hilde Jensvoll, Kristine Blix, Terry Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazier, John-Bjarne Hansen (Norway)

SCIENTIFIC PROGRAM

PO569-WED  ASSOCIATION BETWEEN THROMBOMODULIN C.1418C>T AND VENOUS THROMBOSIS: A META-ANALYSIS
Bei Hu*, Liang Tang, Yu Hu (China)

PO570-WED  NEUTROPHILS AND FACTOR XII, UNLIKE PLATELETS, ARE NOT CRU- CIAL FOR DEVELOPMENT OF EXPERIMENTAL SPONTANEOUS VENOUS THROMBOSIS
Marco Heestermans*, Salam Salloum-Asfar, El Houari Laghmani, Gerry Wagenaar, Brenda Luken, Pieter Reitsma, Bart van Vlijmen (The Netherlands)

PO571-WED  ENDOGENOUS THROMBIN POTENTIAL IS DIRECTLY CORRELATED WITH PROTEINURIA SEVERITY AND HYPOALBUMINEMIA IN NEPHROTIC SYN- DROME PATIENTS
Amanda P. Waller*, Brad Rovin, Samir Parikh, William Smoyer, Marvin Nieman, Mat- thias Kretzler, Bryce Kerlin (United States)

PO572-WED  DIFFERENTIAL EXPRESSION OF MiRNAS IN PLASMA AND PERIPHERAL BLOOD MONONUCLEAR CELLS COLLECTED FROM PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM AND HEALTHY CONTROL INDIVIDUALS
Irina Stariyakova*, Simin Jamaly, Antonio Sorrentino, Thorarinr Blondal, Nadezhda Latysheva, Cathrine Ramberg, Mikhail Sovershaev, John-Bjarne Hansen (Norway)

PO573-WED  THE RISK OF RECURRENT VENOUS THROMBOSIS IN PATIENTS WITH (LOWER) LEG CAST IMMOBILISATION.
Banne Neneth*, Jasmijn Timp, Frits Rosendaal, Suzanne Cannegieter (The Nether- lands)

PO574-WED  THE PREVALENCE OF CONGENITAL TROMBOPHILIA IN CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA WITH THROMBOSIS
Anna Klukowska*, Katarzyna Smalisz-Skrzypczyk, Katarzyna Pawelec, Michał Matysiak (Poland)

PO575-WED  THE ASSESSMENT OF RISK FACTORS FOR THROMBOSIS IN CHILDREN TREATED FOR NON- HODGKIN LYMPHOMA
Anna Klukowska*, Katarzyna Smalisz-Skrzypczyk, Iwona Malinowska, Agata Sobocins- ka-Mirska, Michał Romiszewski, Michał Matysiak (Poland)

PO576-WED  GENETIC AND ACQUIRED RISK FACTORS OF VENOUS THROMBOEM- BOLISM IN YOUNG PATIENTS IN THE NORTH-WEST REGION OF RUSSIA
Anna Demyanenko*, Sergey Kapustin, Vladimir Soroka, Pavel Chechulov (Russian Federation)

PO577-WED  LIPID LEVELS AND RISK OF RECURRENT VENOUS THROMBOSIS: RE- SULTS FROM THE MEGA FOLLOW-UP STUDY
Vânia Morelli*, Willem Lijfering, Frits Rosendaal, Suzanne Cannegieter (Brazil, Nether- lands)

Thrombophilia III

PO578-WED  SECONDARY THROMBOPROPHYLAXIS WITH RIVAROXABAN IN MAJOR INHERITED THROMBOPHILIAS
Karen Schreiber*, Savino Sciacca, Alexander Cohen, Beverley Hunt (Denmark, United Kingdom)
SCIENTIFIC PROGRAM

PO579-WED  MONITORING DRUG ACTIVITY OF DABIGATRAN AND RIVAROXABAN BY THROMBIN GENERATION USING THE CALIBRATED AUTOMATED THROMBINOSCOPE.
Andrés Moret, Noelia Cabrera, Yolanda Mira, Fernando Ferrando, Saturnino Haya, Ana R Cid, Elena Mesa, Rafael Hernani, Virtudes Vila, Santiago Bonanad* (Spain)

PO580-WED  DIFFERENT PATTERNS OF THROMBOPHILIA MARKERS IN PREGNANCY COMPLICATIONS
Gabriella Gamba*, Lorenzo Gervaso, Chiara Ambaglio, Nicola Ghidelli, Federica Zane, Fausta Beneventi (Italy)

PO581-WED  BETA2-GLYCOPROTEIN I DEFICIENCY WITH VENOUS THROMBOSIS: IDENTIFICATION AND IN VITRO EXPRESSION STUDY OF A MISSENSE MUTATION PLY38GLU IN APOH GENE
Wei Zeng*, Yu Hu (China)

PO582-WED  TOWARDS IDENTIFICATION OF GENETIC RISK FACTORS IN TWO DUTCH FAMILIES WITH UNEXPLAINED HEREDITARY VENOUS THROMBOEMBOLISM
Marisa Cunha*, Pieter Reitsma, Frits Rosendaal, Joost Meijers, Saskia Middeldorp (The Netherlands)

PO583-WED  RECURRENT VENOUS THROMBOEMBOLISM DURING PREGNANCY IN WOMEN WITH QUANTITATIVE ANTITHROMBIN DEFICIENCY WITH OR WITHOUT ANTITHROMBOTIC PROPHYLAXIS
Serena Maria Passamonti*, Andrea Artoni, Paolo Bucciarelli, Francesca Gianniello, Ida Martinelli (Italy)

PO584-WED  MOLECULAR ANALYSIS OF PROTEIN S DEFICIENCY IN THAILAND
Ponlapat Rojnuckarin*, Rung Settapiboon, Benjaporn Akkawat, Noppacharn Uaprasert (Thailand)

PO585-WED  INHERITED THROMBOPHILIA AS A HIGH RISK FACTOR OF RECURRENT PREGNANCY LOSS IN GEORGIAN POPULATION
Nino Piritskhelani*, Nino Kochiashvili, Levan Makhaldiani, Nuzgar Pargalava, Ketevan Kartvelishvili, Mamuka Bokuchava (Georgia)

PO586-WED  DO ENDOTHELIUM-RELATED GENES AND INHERITED THROMBOPHILIA INTERACT IN INCREASING PREGNANCY LOSS RISK?
Ilaria Romagnuolo*, Elena Sticchi, Angela Rogolino, Agatina Alessandroli Liotto, Anna Paola Cellai, Niccolò Maggini, Rosanna Abbate, Cinzia Fatini (Italy)

PO587-WED  RIVAROXABAN IN LONG-TERM SECONDARY PREVENTION OF VTE IN PATIENTS WITH HEREDITARY OR ACQUIRED THROMBOPHILIA IS AS EFFECTIVE AND SAFE AS STANDARD TREATMENT WITH VITAMIN K ANTAGONISTS
Grigoris T. Gerolizitas*, Eleftheria Lefkou, Vassiliki Gkalea, Anastasia Spanoudaki, Hela Ketatni, Ilias Emorfidis, Ismail Elalamy (France)

PO588-WED  OBSTETRIC HISTORY, COURSE OF PREGNANCY AND LABOUR OF PATIENTS WITH MTHFR MUTATION—CASE REPORT AND LITERATURE REVIEW
Justyna M Teliga-Czajkowska*, Anna Sikorska, Ksenia Bykowska, Bernadeta Ceglarek, Ewa Dmoch-Gajzierska, Jerzy Windyga, Krzysztof Czajkowski (Poland)

PO589-WED  LMWH IN PROPHYLAXIS OF THE REPEATED PREGNANCY COMPLICATIONS IN WOMEN WITH THROMBOPHILIA AND MULTIPLE PREGNANCY AFTER IVF
Natalya Makatsaryan*, Nadezhda Stuleva, Jamila Khizroeva (Russian Federation)

PO590-WED  ANTIBODIES TO THE K2 AND K3 DOMAINS OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) DIFFER IN BIODISTRIBUTION AND EFFECT ON PLASMA TFPI CONCENTRATION
Kasper Almholt*, Brian Lauritzen, Torben Elm, Lars Holten-Andersen, Bill Vestergaard, Mette Loftager, Lene Hansen (Denmark)

PO591-WED  EXPLOITING THE BIOLOGY OF TISSUE FACTOR PATHWAY INHIBITOR: PROSPECT FOR FUTURE THERAPEUTIC TARGETS.
Samuel Abegunde (Nigeria)

PO592-WED  POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF A NEW RECOMBINANT HUMAN FACTOR VIA (LR769) TO DERIVE THE DOSE TO BE STUDIED IN PHASE 3
Johan Frielings*, Jasper Stevens, Joannes Reijers, Matthijs Meerland, Jacobus Burggraaf, Kees van Leuven, Cornelis Kluft, Jean-François Schwed (United States)

PO593-WED  PRODUCTION OF HIGHLY ACTIVE RECOMBINANT HUMAN TISSUE FACTOR PATHWAY INHIBITOR
Mathieu Castellani, Raphaël Marlu, Benoît Polack*, Marie-Claire Dagher (France)

PO594-WED  COMPREHENSIVE ASSESSMENT OF THE SAFETY AND EFFICACY OF FACTOR VIIA-CTP SUPPORTING PHASE 2A STUDY
Ahuva Bar-Ilan, Lior Binder, Malka Hoffman, Gili Hart* (Israel)

PO595-WED  FACTOR VIIA-CTP, A LONG-ACTING COAGULATION FACTOR PROPOSING A NOVEL SUBCUTANEOUS (SC) ROUTE OF ADMINISTRATION FOR PROPHYLACTIC TREATMENT – EFFICACY AND SAFETY IN PREPARATION FOR FIRST IN HUMAN STUDY.
Lior Binder, Malka Hoffman, Miri Zakar, Ahuva Bar-Ilan, Gili Hart* (Israel)

PO596-WED  THE RECOMBINANT FUSION PROTEIN LINKING ACTIVATED FACTOR VIIA TO HUMAN ALBUMIN (RVIIA-FP) PROVIDES SUPERIOR BLEEDING PROTECTION COMPARED TO RECOMBINANT FVIIA (RFVIIA) IN A NOVEL MONKEY MODEL OF ACQUIRED FACTOR VIII INHIBITORS
Eva Herzog*, Elmar Raquet, Hendrik Peil, Baerbel Doerr, Alex Veldman, Stefan Schulte, Sabine Zollner (Germany)

PO597-WED  PF-05280602, A FACTOR VIIA VARIANT WITH ENHANCED IN VITRO POTENCY COMPARED TO WILD-TYPE FACTOR VIIA IN HEMOPHILIC HEMOSTASIS ASSAYS.
Sunita Patel-Hett*, Swapnil Rakhe, Michelle Zhao, Edwin Madison, Steven Arkin, John Murphy, Debra Pittman (United States)

PO598-WED  MATHEMATICAL MODELLING OF MEMBRANE-DEPENDENT FACTOR X ACTIVATION BY EXTRINSIC TENASE
Tatiana Kovalenko (Russian Federation)
SCIENTIFIC PROGRAM

PO599-WED  IN VITRO MECHANISM OF BAY 1093884 INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR
Subramanian Yegneswaran*, Maria Köllnberger, Vincent Evans, Chandra Patel (United States)

PO600-WED  EVALUATION OF AROYSENSE SAFETY (RECOMBINANT ACTIVATED FACTOR VII) IN PATIENTS WITH BLEEDING DISORDERS (AN OBSERVATIONAL POST-MARKETING SURVEILLANCE, STUDY)
Ailezza Abdolahji, Gholarreza Toogeh, Mohamad Reza Managhchi, Mohammad Reza Shavandi*, Katayon Rahimi, Samin Roostaei, Hassan Abolghasemi, Payman Eshghi, Jayran Zebardast, Akram Sarbayani, Fatemeh Sori (Iran, Islamic Republic Of)

PO609-WED  MONITORING PLATELET TRANSFUSION IN THROMBOCYTOPENIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES MEASURED BY THROMBOELASTOMETRY: A PILOT STUDY.
Floor Moenen*, Inge Verheijen, Ron Straat, Rick Wetzes, Erick Beckers, Yvonne Henskens (The Netherlands)

PO610-WED  CHARACTERIZATION AND EVALUATION OF THE HEMOSTATIC ACTION OF CRYOPRESERVED PLATELETS
Irene Lopez-Vilchez*, Patricia Molina, Miquel Lozano, Nerea Rincon-Tome, Joan CID, Ana Galan, Maribel Diaz-Ricart, Gines Escobar (Spain)

PO611-WED  THROMBIN GENERATION POTENTIAL OF A NEW Trehalose-Stabilized Platelet-Derived Hemostatic Agent
Arthur Bode, Narenda Tandon*, Evgenia Matveeva, Michael Fitzpatrick (United States)

SCIENTIFIC PROGRAM

PO601-WED  DOSE-RELATED PULMONARY COMPLICATION RATES AFTER FRESH FROZEN PLASMA ADMINISTRATION FOR WARFARIN REVERSAL
Ariela Marshall*, Michael Levine, Melissa Howell, Yuchiao Chang, Eric Richlin, Blair Parry, Ryan Callahan, Ikenna Okechukwu, Alison Ayres, Brian Nahed, Walter Dzik, Joshua Goldstein (United States)

PO603-WED  ANALYSIS OF MEMBRANE MICROPARTICLES AND THROMBIN GENERATION ACTIVITY OF DMSO CRYOPRESERVED PLATELETS
Tsebay Tegegn, Silvia De Paoli, Martina Orecna, Oumsalama Elhelu, Samuel Woodle, Ivan Tarandovskiy, Mikhail Ovanesov, Jan Simak* (United States)

PO604-WED  PHOSPHATIDYLINOSITOL-3-KINASE IS IMPAIRED FOLLOWING AMOTOSALEN AND ULTRAVIOLET A LIGHT TREATMENT OF PLATELETS IN CONCENTRATES FOR TRANSFUSION
Hendrik B. Feys*, Britt Van Aelst, Rosalie Devloo, Philippe Vandekerckhove, Veerle Compernolle (Belgium)

PO605-WED  INACTIVATION OF EMERGING VIRUSES BY PASTEURIZATION IN PLASMA-DERIVED MEDICINAL PRODUCTS
Nathan J. Roth, Wolfram Schäfer, Thomas Nowak, Birgit Popp*, Josephine Schlösser, Martin Eiden, M Groschup, Albrecht Gröner (United States)

PO606-WED  PLATELETS ARE DISPENSABLE DURING THE INITIAL STEPS OF IMMUNOLOGICAL TRANSFUSION RELATED ACUTE LUNG INJURY (TRALI)
Beatrice Hechler*, Birgitta Schäfer, Thomas Nowak, Birgit Popp*, Josephine Schlösser, Martin Eiden, M Groschup, Albrecht Gröner (United States)

PO607-WED  VOLUME OF FLUID RESUSCITATION IN WOMEN WITH PERSISTENT POSTPARTUM HAEMORRHAGE AND TOTAL BLOOD LOSS, MATERNAL MORTALITY AND SEVERE MATERNAL MORBIDITY
Dacia D. Henriquez*, Kitty Bloemenkamp, Jaap Jan Zwaginga, Johanna van der Bom (Netherlands)

PO609-WED  MONITORING PLATELET TRANSFUSION IN THROMBOCYTOPENIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES MEASURED BY THROMBOELASTOMETRY: A PILOT STUDY.
Floor Moenen*, Inge Verheijen, Ron Straat, Rick Wetzes, Erick Beckers, Yvonne Henskens (The Netherlands)

PO610-WED  CHARACTERIZATION AND EVALUATION OF THE HEMOSTATIC ACTION OF CRYOPRESERVED PLATELETS
Irene Lopez-Vilchez*, Patricia Molina, Miquel Lozano, Nerea Rincon-Tome, Joan CID, Ana Galan, Maribel Diaz-Ricart, Gines Escobar (Spain)

PO611-WED  THROMBIN GENERATION POTENTIAL OF A NEW Trehalose-Stabilized Platelet-Derived Hemostatic Agent
Arthur Bode, Narenda Tandon*, Evgenia Matveeva, Michael Fitzpatrick (United States)

PO612-WED  ASPHYXIA BY DROWNING INDUCES MASSIVE BLEEDING DUE TO HYPERFIBRINOLYTIC DISSEMINATED INTRAVASCULAR COAGULATION

PO613-WED  THE STABILITY OF FVIII:C, VON WILLEBRAND FACTOR AND FIBRINOGEN IN FFp AND CRYOPRECIPITATE IN THAI BLOOD DONORS
Theera Ruchutarakool*, Songari Gledkruemas, Tasneem Binahma, Yupa Nakkinkun, Warapan Meesmat, Usamee Siriboonsiri, Parichart Permpikul (Thailand)

PO614-WED  INFUSION OF CRYOPRESERVED POOLED PLATELETS IN PATIENTS WITH ACUTE LEUKEMIA: PRELIMINARY RESULTS OF A CLINICAL TRIAL (NCT02032134)
Mariasanta Napolitano*, Stefania Arfò, Lucio Lococo, Giorgia Sacculli, Giovanni De Francisci, Amalia Reina, Laura Orlando, Diana Diliberto, Salvatrice Mancuso, Giuseppe Tarantino, Simona Raso, Rosalia Agliastro, Francesco Dieli, Sergio Siragusa (Italy)

PO615-WED  MASSIVE HAEMORRHAGE MANAGEMENT: FROM CHAOS TO ORDER. LEGNANO HOSPITAL’S EXPERIENCE.
Ivo Beverina, Chiara Novelli*, Matteo Lucchelli, Erika Borotto, Alessandro Aloni, Bruno Brando (Italy)

PO616-WED  INTERVENTIONS TO REDUCE BLOOD LOSS FROM LABORATORY TESTING IN CRITICALLY ILL PATIENTS AND IMPACT ON TRANSFUSION: A SYSTEMATIC REVIEW
Neal Manning*, Nancy Heddle, Donald Arnold, Mark Crowther, Deborah Siegal (Canada)

PO617-WED  COMPARISON OF THE EFFECT OF FRESH FROZEN PLASMA PRE- AND POST-TRANSFUSION IN ITU PATIENTS ON STANDARD AND GLOBAL COAGULATION ASSAYS
Emma L. Fosbury*, Jonathan Manguist, Anne Riddell, Pratima Chowdary (United Kingdom)
PO618-WED  
**SERUM ALBUMIN AND S PROTEIN ARE BETTER PREDICTORS THAN CLINICAL SCORES IN THE DIAGNOSIS OF DEEP VENOUS THROMBOSIS IN PATIENTS WITH SEVERAL COMORBIDITIES**  
Antonella Maria Cardella*, Giovanni Tripepi, Antonio D’Astoro, Giuseppe Puccia (Italy)

PO619-WED  
**DERIVATION OF A NEW SCORE TO PREDICT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION AFTER ACUTE PULMONARY EMBOLISM**  
Frederikus A. Klok*, Olga Dzikowska-Diduch, Maciej Kostrubiec, Hubert Vliegen, Piotr Pruszczyszyn, Gerd Hasenfuss, Menno Huisman, Stavros Konstantinides, Mareike Lankelt (Germany, Netherlands)

PO620-WED  
**THE PREVALENCE OF DEEP VEIN THROMBOSIS IN HOSPITALIZED PATIENTS WITH SUSPECTED PULMONARY EMBOLISM RULED OUT BY MULTISLICE CT ANGIOGRAPHY**  
Fernando Vazquez*, Maria Lourdes Posadas-Martinez, Bruno Boietti, Alejandra Romero, Fernan Gonzalez Bernaldo de Quiros, Diego Giunta, Esteban Gándara (Argentina)

PO621-WED  
**CEREBRAL AND SPLANCHNIC VEIN THROMBOSIS: WHAT MOLECULAR GENETICS RISK FACTORS?**  
Pascaline Etancelin, Aude Bagan-Triquenot, Odile Goria, Jeanne-Yvonne Borg, Christian Bastard, Véronique Lecam Duchez* (France)

PO622-WED  
**A PROSPECTIVE EVALUATION OF VENOUS THROMBOEMBOLISM IN SPINE SURGERY: INCIDENCE, COST-EFFECTIVENESS OF PROPHYLAXIS AND BLEEDING COMPLICATIONS**  
Kerry Hitos*, David Young, John Fletcher (Australia)

PO623-WED  
**THROMBOEMBOLIC DISEASE FOLLOWING PANCREATICODUODENECTOMY FOR BENIGN OR CONFIRMED MALIGNANCY: EFFICACY OF PROPHYLACTIC MEASURES AND ASSOCIATED BLEEDING COMPLICATIONS**  
Kerry Hitos*, John Fletcher, Lawrence Yuen, Emma Johnston, Tony Pang, Vincent Lam, Michael Hollands, Arthur Richardson, Henry Pleass (Australia)

PO624-WED  
**PERFORMANCE OF A DIAGNOSTIC STRATEGY USING A CLINICAL DECISION RULE AND D-DIMER TESTING TO EXCLUDE UPPER EXTREMITY DEEP VEIN THROMBOSIS IN CLINICALLY IMPORTANT SUBGROUPS**  

PO625-WED  
**PREDICTION OF VENOUS THROMBOSIS RISK AFTER ARTHROSCOPY OF THE KNEE.**  
Banne Nemeth*, Raymond van Adrichem, Saskia le Cessie, Astrid van Hylckama Vlieg, Trevor Baglin, Frits Rosendaal, Suzanne Camneugieter (The Netherlands)

PO627-WED  
**RELATIONSHIP OF PATIENT AFFECT TO CLINICIAN-DERIVED PRETEST PROBABILITY ASSESSMENT FOR PULMONARY EMBOLISM**  
Jeffrey A. Kline*, Dawn Neumann (United States)
VENOUS THROMBOEMBOLISM - TREATMENT

**PO646-WED**

**DABIGATRAN OR WARFARIN IN THE TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM IN ANTIPHOSPHOLIPID SYNDROME**

Sam Schulman*, Samuel Goldhaber, Clive Kearon, Ajay Kakkar, Sebastian Schellong, Henry Eriksson, Elke Schueller, Martin Feuring, Jörg Kreutzer (Canada)

**PO638-WED**

**CASE-FATALITY AFTER PULMONARY EMBOLISM AND STROKE IN SUBJECTS WITH ATRIAL FIBRILLATION**

Ina Rye-Holmboe*, Erin Hald, Anders Vik, Elisiv Mathiesen, Inger Njølstad, Maja-Lisa Lachen, Sigrid Braekkan, John Bjarne Hansen (Norway)

**PO639-WED**

**HOSPITAL ACQUIRED THROMBOSIS (HAT) IN AN IRISH TERTIARY REFERRAL HOSPITAL.**

Muhammad I. Khan*, Joe Eustace, Susan O’Shea (Ireland)

**PO640-WED**

**PREVALENCE AND RISK FACTORS FOR PULMONARY EMBOLISM IN PATIENTS WITH ACUTE EXACERBATION OF COPD: RESULTS OF A LARGE COLLABORATIVE STUDY.**

Francesco Dentali*, Dimitriy Arioli, Fulvio Pomero, Nicola Mumoli, José Vitale, Filippo Pieralli, Paola Gnerre, Micaela La Regina (Italy)

**PO641-WED**

**RISK OF FIRST AND RECURRENT VENOUS THROMBOSIS IN INDIVIDUALS TREATED WITH ANTIBIOTICS**

Jasmijn F. Timp*, Suzanne Cannegieter, Vladimir Tichelaar, Sigrid Braekkan, Frits Rosendaal, Saskia le Cessie, Willem Lijfering (The Netherlands)

**PO642-WED**

**INHOSPITAL MORTALITY AMONG CLINICAL AND SURGICAL INPATIENTS RECENTLY DIAGNOSED WITH VENOUS THROMBOEMBOLIC DISEASE**

Fernando Vazquez*, Maria Posadas-Martinez, Maria Grande-Ratti, Jimena Vicens, Bruno Boletti, Paloma Rojas-Saunero, Gabriel Waismann, Fernan Quiros, Diego Giultrua (Argentina)

**PO643-WED**

**LOW PREVALENCE OF SYMPTOMATIC VENOUS THROMBOEMBOLISM AFTER HIP AND KNEE ARTHROPLASTY AT SIRIRAJ HOSPITAL**

Chompunut Wongprasert*, Theera Ruchutrakool, Bundarika Suwaniwiboon, Keerati Chareanchovanchan, Pacharapol Udomkiat, Yupa Nakkinkun, Tasneem Binhama, Yingyong Chinthammitr (Thailand)

**PO644-WED**

**THE PREVALENCE AND DIAGNOSTIC CHARACTERISTICS OF PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION**

Timothy Fernandes, Timothy Morris, William Auger* (United States)

**PO645-WED**

**PREDICTORS OF VENOUS THROMBOEMBOLISM RECURRENTNESS, ADJUSTED FOR TREATMENTS AND INTERIM EXPOSURES: A POPULATION-BASED CASE-COHORT STUDY**

John Heit, Brian Lahr, Aneel A. Ashrani*, Tanya Petterson, Kent Bailey (United States)

**PO646-WED**

**VENOUS THROMBOEMBOLISM - THERAPY III**

**PO647-WED**

**NEW ORAL ANTICOAGULANTS (NOACS) IN VTE TREATMENT: WILL MONITORING DIMINISH THEIR COST-EFFECTIVENESS?**

Carla Vossen*, Katya Sion, Andreas Karabis (The Netherlands)

**PO648-WED**

**MULTICENTER PROSPECTIVE STUDY OF TREATMENT AND RISK FACTORS FOR UNUSUAL SITE THROMBOSIS: TRUSTRegistry**

Kim Ma*, Phillip Wells, Charlotte Guzman, David Anderson, Mark Bliostein, Andrew Hirsch, Michael Kovacs, Alejandro Lazo-Langner, Marc Rodger, Vicky Tagalakis, Susan Kahn (Canada)

**PO649-WED**

**THE WITHIN PATIENT EFFECT OF STATIN USE ON COAGULATION IN VITAMIN K ANTAGONIST USERS: A CROSSOVER STUDY**

Nienke Van Rein*, Joseph Biedermann, Stacey Bonafacio, Marieke Krui, Willem Lijfering, Felix van der Meer (The Netherlands)

**PO650-WED**

**WARFARIN DOSING AND TIME TO THERAPEUTIC INTERNATIONAL NORMALIZED RATIO IN PATIENTS WITH HYPERCOAGULABILITY SYNDROMES**

Pushpinderdeep S. Kahlon*, Shahzaib Nabi, Haythem Ali (United States)

**PO651-WED**

**SAFETY OF STOPPING ANTICOAGULANT TREATMENT FOR CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM AFTER REACHING COMPLETE REMISSION FROM CANCER**

Tom Van Der Hulle*, Paul den Exter, Pim van den Hoven, Jacobus van der Hoeven, Felix van der Meer, Jeroen Elkenboom, Mennoquisman, Frederikus Klok (The Netherlands)

**PO652-WED**

**PROLONGED USE OF LMWH DURING PREGNANCY AND BONE SAFETY**

Pålvi J. Galambos*, Risto Kaaja (Finland)

**PO653-WED**

**PRACTICE VARIATION IN THE MANAGEMENT OF DISTAL DVT BETWEEN GPS AND VASCULAR MEDICINE PHYSICIANS: A FRENCH SURVEY OF PHYSICIAN PRACTICES**

Jean-Philippe Galanaud*, Jennifer Almosni, Arthur Meusy, Pierre Frances, Isabelle Quere (France)

**PO654-WED**

**IMPROVING EVIDENCE-BASED DECISIONS IN VTE TREATMENT: SIMULATION IN CONTINUING EDUCATION**

Jelena Spappyolos*, Alex Spappyolou (United States)

**PO655-WED**

**RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH A FIRST EPISODE OF UNPROVOKED PULMONARY EMBOLISM: A PRE-SPECIFIED SUBGROUP ANALYSIS FROM THE PADIS PE RANDOMIZED TRIAL**


**PO656-WED**

**NEW ORAL ANTICOAGULANTS (NOACS) IN VTE TREATMENT: WILL MONITORING DIMINISH THEIR COST-EFFECTIVENESS?**

Carla Vossen*, Katya Sion, Andreas Karabis (The Netherlands)
PO657-WED  COMMUNITY HOSPITALS ARE USING NOVEL ORAL ANTICOAGULANTS AND MORE ASPIRIN AS VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS FOLLOWING TOTAL HIP AND KNEE REPLACEMENT
Darae Ko*, Alok Kapoor, Adam Rose, Amreesh Hanchate, Donald Miller, Michael Winter, Joseph Palmisano, ZhaoYang Teng, Lori Henault, Yorghos Tripodis, Anita Karcz, Elaine Hylek (United States)

PO658-WED  GLOBAL ADHERENCE TO AMERICAN COLLEGE OF CHEST PHYSICIANS GUIDELINES FOR THROMBOPROPHYLAXIS AFTER MAJOR ORTHOPEDIC SURGERY. HAVE WE IMPROVED? A SYSTEMATIC REVIEW OF THE LITERATURE
Maria P Bautista, Miguel Farfan*, Guillermo Bonilla, Adolfo Llinas (Colombia, Colombia)

PO659-WED  INCIDENCE OF THROMBOEMBOLISM IN KOREAN MULTIPLE MYELOMA PATIENTS WITH THALIDOMIDE INDUCTION CHEMOTHERAPY; COMPARISON PREVIOUS DATA IN KOREA.
Hyerim Ha*, Jeonghwan youk, Hyunkyung Park, Jeong-Ok Lee, Soo-Mee Bang, Kihwan Kim, Jin-Hyun Park, Youngil Koh, Inho Kim, Sung-Soo Yoon, Seonyang Park (Korea, Republic Of)

PO660-WED  THROMBOPROPHYLAXIS IN A PATIENT WITH MORBID OBESEITY
Saket Badle*, Simon Coppack, Peter MacCallum (United Kingdom)

PO661-WED  COAGULATION TESTS FOR DETECTION OF VKA THERAPY INSUFFICIENCY IN PATIENTS WITH ACUTE DEEP VEIN THROMBOSIS
Faina Verkholomova*, Aleksey Krylov, Aleksander Shulutko, Fazly Ataullakhanov, Ilya Serebriyskiy (Russian Federation)

PO662-WED  BIOMARKERS FOR PREDICTION OF REOCURRENCE OF VENOUS THROMBOEMBOLISM
Abimbola Jarvis*, Elizabeth Villalobos-menuey, Linda Jacobson, Julie Smith, Marilyn Manco-Johnson (United States)

Vitamin K antagonists III

PO663-WED  MEDICATION ADHERENCE OF NOVEL ORAL ANTICOAGULANT VERSUS WARFARIN
Yi Feng Lai*, Jun Kai Neo, Mcvin Hua Heng Cheen, Ming Chai Kong, Heng Joo Ng (Singapore)

PO664-WED  RISK OF MAJOR BLEEDING IN PATIENTS TREATED WITH VITAMIN K ANTAGONISTS OR ASPIRIN. A SYSTEMATIC REVIEW AND META-ANALYSIS
Fernando Vazquez*, Walter Ageno, Daniela Poli, Sophie Testa, Simona Pedrini, Lucia Marigo, Piera Sivera, Samantha Pasca, Giuseppe Malcangi, Cavalleri Giobatta, Pietro Falco, Lucia Ruocco, Carmelo Paparo, Eugenio Bucherini, Luciano Suriano, Luigi Ria, Alberto Tosetto (Italy)

PO665-WED  IMPACT OF POINT-OF-CARE INR MONITORING ON ANTICOAGULANT CONTROL DURING TREATMENT WITH VITAMIN K ANTAGONISTS IN PATIENTS MONITORED BY A SPECIALIZED ANTICOAGULATION CLINIC: A POPULATION BASED COHORT STUDY
Joseph Biedermann*, Nienke van Rein, Peter Buhre, Moniek de Maat, Felix van der Meer, Frank Leebeek, Marieke Kruip (The Netherlands)

PO666-WED  MULTI-DOSE DRUG DISPENSING AS A TOOL TO IMPROVE MEDICATION ADHERENCE: A CROSSOVER STUDY
Nienke van Rein*, Kristel de Geus, Suzanne Cannegie, Pieter Reitsma, Felix van der Meer, Willem Lijfering (The Netherlands)

PO667-WED  CYP2C9 POLYMORPHISM CONTROLS PHENPROCOUMON METABOLISM RESULTING IN SEVERE BLEEDING EVENTS
Gesa Wiegand*, Ralf Rauch, Vanya Icheva, Elke Schäffeler, Michael Hofbeck, Matthias Schwab (Germany)

PO668-WED  INCREASED RISK FOR MAJOR BLEEDERS AFTER MINOR BLEEDS IS DETERMINED BY UNKNOWN PERSISTENT COMMON RISK FACTORS
Nienke Van Rein*, Willem Lijfering, Isabelle van Vliet, Felix van der Meer, Saskia le Cessie, Suzanne Cannegie, Pieter Reitsma (The Netherlands)

PO669-WED  ACCURACY OF A WARFARIN MAINTENANCE DOSE PREDICTOR AFTER COMPLETION OF THE 10 MG INITIATION NOMOGRAM
Parvaneh Fallah*, Philip S. Wells, Melissa A Forgie, Lisa Duffett (Canada)

PO670-WED  A NATIONAL ANTICOAGULANT MANAGEMENT SERVICE PROVIDED BY COMMUNITY PHARMACIES IN NEW ZEALAND ACHIEVES A HIGH LEVEL OF ANTICOAGULANT CONTROL WHICH IS SAFE AND CONVENIENT FOR PATIENTS.
Paul L. Harper*, Ian McMichael, Dale Griffiths, Claire Hill (New Zealand)

PO671-WED  RECURRENT THROMBOTIC EVENTS AFTER DISCONTINUATION OF VITAMIN K ANTAGONIST TREATMENT FOR SPLANCHNIC VEIN THROMBOSIS: A MULTICENTER RETROSPECTIVE COHORT STUDY
Isabelle Gouin-Thibault*, Emeline Gillet, Julie Fréchaud, Alain Stépanian, Emmanuel de Maistre, Céline Narjoz, Anne-Marie Fischer, Katell Pech, Marie-Anne Loriot, Virginie Siguret (France)

PO672-WED  PATIENTS WITH VITAMIN K ANTAGONIST (VKA) RESISTANCE: DOES THE IDENTIFICATION OF VKORC1 MUTATIONS HELP PREDICTING THE MAINTENANCE DOSAGE?
Emilia Antonucci, Daniela Poli, Alberto Tosetto, Vittorio Pengo*, Armando Tripodi, Nicola Magrini, Francesco Marongiu, Guattatiero Palairet (Italy)
THE START-REGISTER (SURVEY ON ANTICOAGULATED PATIENTS REGISTER): FOCUS ON PATIENTS TREATED FOR NON-VALVULAR ATRIAL FIBRILLATION
Emilia Antonucci, Daniela Poli, Alberto Tosetto, Vittorio Pengo*, Armando Tripodi, Nicola Magrini, Francesco Marongiu, Gualtiero Palareti (Italy)

EAHAD-DB: A COMBINED COAGULATION FACTOR VARIANT DATABASES RESOURCE FOR THE CLINICAL AND SCIENTIFIC COMMUNITIES
Daniel J. Hampshire*, Andrea Cairo, Muriel Giansily-Blaizot, Keith Gomez, Anne Goodie, Geoffrey Kemball-Cook, Christopher Ludlam, John McVey, Johannes Oldenburg, Stephen Perkins, Flora Peyvandi, Pavithra Rallapalli (United Kingdom)

POLYHEDROCYTES IN WHOLE BLOOD CLOTS OF PATIENTS WITH VEinous THROMBOEMBOLISM TAKING VITAMIN K ANTAGONISTS: A ROLE OF THE QUALITY OF ANTICOAGULATION
Michał Zabczyk*, Jakub Siudut, Anetta Undas (Poland)
**SCIENTIFIC PROGRAM**

**Thursday, June 24, 2015**

**ORAL COMMUNICATIONS 7 08:00-09:15**

▲ **Venous thromboembolism – therapy II**  
Plenary Hall F&G

**Moderators:** Michael Kovacs (Canada), Carl-Erik Dempfle (Germany)

**08:00 – 08:15**

**OR381**  
**PATIENTS WITH CANCER ASSOCIATED THROMBOSIS: LONG-TERM VTE RECURRENTS AND BLEEDINGS ACCORDING TO CANCER SITE; DATA FROM THE RIETE REGISTRY**  
Isabelle Mahé*, Laurent Bertoletti, Jean Chidiac, Javier Trujillo-Santos, Fares Mostafa, Henri Bounameaux, Llorenç Font, Maria Dolores Adarraga, Pablo Javier Marchena, Manuel Monreal (France)

**08:15 – 08:30**

**OR382**  
**DURATION OF ANTICOAGULATION FOLLOWING ACUTE VENOUS THROMBOEMBOLISM IN ROUTINE CARE IN ENGLAND: AN OBSERVATIONAL STUDY USING CPRD-HES DATABASES**  
Laure Lacoin, Essra Ridha*, Cinira Lefevre, Vidya Moorthy, Mridula Vasudev, Steven Lister, Alex Bird, Ian Minns, Ameet Bakhai, Raza Ali Khan (United Kingdom)

**08:30 – 08:45**

**OR383**  
**NO BENEFICIAL EFFECT OF STATINS IN REDUCING RECURRENT DISEASE IN A META-ANALYSIS OF 21,587 PATIENTS WITH ACUTE SYMPTOMATIC VENOUS THROMBOEMBOLISM TREATED IN PHASE 3 TRIALS COMPARING DIRECT ORAL ANTICOAGULANTS WITH VITAMIN K ANTAGONISTS**  
Mandy N. Lauw*, Sam Schulman, Martin Gebeili, George Zhang, Min Lin, Michael Grosso, Harry Buller (The Netherlands)

**08:45 – 09:00**

**OR384**  
**NET CLINICAL BENEFIT OF HOSPITALIZATION VERSUS OUTPATIENT MANAGEMENT OF PATIENTS WITH ACUTE PULMONARY EMBOLISM**  
Pierre-Marie Roy*, Daniel Corsi, Antony Theogene, Carine de Wit, Carole Dennie, Grégoire Le Gal, Marc Rodger, Phillip Wells, Marc Carrier, Esteban Gandara (France)

**09:00 – 09:15**

**OR385**  
**EXTENDED DURATIONS OF ANTICOAGULATION AND MORTALITY FOLLOWING INCIDENT VENOUS THROMBOEMBOLISM IN THE Q-VTE COHORT**  
Adi Klil-Drori*, Janie Coulombe, Samy Suissa, Vicky Tagalakis (Canada)

★ ❤ **Hemophilia – joint disease and clinical**  
Room 718

**Moderators:** Jenny Goudemand (France), Marilyn Manco-Johnson (United States)

**08:00 – 08:15**

**OR386**  
**INTRACRANIAL HAEMORRHAGE IN CHILDREN WITH INHERITED BLEEDING DISORDERS IN THE UK 2003-2013.**  
Elizabeth Chalmers*, Jayanthi Alamelu, Peter Collins, Mary Mathias, Jeanette Payne, Mike Richards, Oliver Tunstall, Mike Williams, Ben Palmer, Andrew Mumford (United Kingdom)

---

**SCIENTIFIC PROGRAM**

**THURSDAY**

**ORALS**
**SCIENTIFIC PROGRAM**

**THURSDAY**

**ORALS**

08:00 – 08:15  PROOF OF PRINCIPLE FOR EFFICIENCY IN THROMBOSIS OF SHEAR-GENERATED PLATELETS FROM CULTURED MEGAKARYOCYTES

Audrey Pietrzyk-Nivau, Sonia Poirault-Chassac, Alexandre Kauskot, Cécile Denis, Dominique Baruch,* (France)

08:30 – 08:45  THE DENSE BLOOD VESSEL NETWORK IN THE MURINE BONE MARROW SPATIALLY LIMITS MEGAKARYOCYTE MIGRATION

Judith M. M. Van Eeuwijk,* David Stegner, Oğuzhan Angay, Jürgen Pinnecker, Bernhard Nieswandt, Katrin Heinze (Germany)

09:00 – 09:15  VON WILLEBRAND FACTOR DEFICIENCY CAUSES INCREASED ANGIOGENESIS FOLLOWING ISCHEMIC TISSUE DAMAGE

Richard D. Starke,* Omary Chillo, Koval Smith, Elisabeth Deindl, Anna Randi (United Kingdom)

**MEGAKARYOCYTES AND THROMBOPOIESIS III**

Moderators: Dominique Baruch (France), Pandu Jagadeeswaran (United States)

08:00 – 08:15  MICE LACKING THE INHIBITORY COLLAGEN RECEPTOR LAIR1 EXHIBIT A MILD THROMBOCYTOSIS AND HYPERACTIVE PLATELETS

Alexandra Mazhari,* Steven Thomas, Marie Lordkipanidzé, Danai Bem, Silke Heising, Linde Meyard, Yotis Senis, Steve Watson (United Kingdom)

08:15 – 08:30  IDENTIFICATION OF HOX GENES CONTROLLING THROMBOPOIESIS IN ZEBRAFISH

Pandu Jagadeeswaran,* Hemalatha Sundaramoorthi (United States)

**ORALS 1**

08:00 – 08:15  CELL-SPECIFIC FVIII EXPRESSION IN HEMOPHILIA A GENE THERAPY TO OVERCOME IMMUNOLOGICAL RESPONSES

Simone Merlin,* Elvira Cannizzo, Valentina Bruscaggin, Kevin Bellofatto, Antonia Follenzi (Italy)

08:30 – 08:45  THE SCAVENGER RECEPTOR STABILIN-2 (STAB-2) MEDIATES CLEARANCE OF HUMAN VON WILLEBRAND FACTOR AND FACTOR VIII BY LIVER SINUSOIDAL ENDOTHELIAL CELLS

Laura L. Sweeney*, Colleen Notley, Illica Georgescu, Kate Spenagle, Karl Schledzewski, Cyril Géraud, Sergij Goerd, Paula James, David Lillicrap (Canada)

09:00 – 09:15  VON WILLEBRAND FACTOR DEFICIENCY CAUSES INCREASED ANGIOGENESIS FOLLOWING ISCHEMIC TISSUE DAMAGE

Richard D. Starke,* Onyir Chillo, Koval Smith, Elisabeth Deindl, Anna Randi (United Kingdom)

**MEGAKARYOCYTES AND THROMBOPOIESIS III**

Moderators: Dominique Baruch (France), Pandu Jagadeeswaran (United States)

08:00 – 08:15  MICE LACKING THE INHIBITORY COLLAGEN RECEPTOR LAIR1 EXHIBIT A MILD THROMBOCYTOSIS AND HYPERACTIVE PLATELETS

Alexandra Mazhari,* Steven Thomas, Marie Lordkipanidzé, Danai Bem, Silke Heising, Linde Meyard, Yotis Senis, Steve Watson (United Kingdom)

08:15 – 08:30  IDENTIFICATION OF HOX GENES CONTROLLING THROMBOPOIESIS IN ZEBRAFISH

Pandu Jagadeeswaran,* Hemalatha Sundaramoorthi (United States)
INFLUENCE OF VWF-FVIII BINDING ON ARTERIAL THROMBUS FORMATION AND STABILITY IN A MURINE MODEL OF SEVERE TYPE 2N VWD
Laura L. Swystun*, Illica Georgescu, Jeff Mewburn, Kate Sponagle, Colleen Notley, David Lilliecrap (Canada)

A FVIII/VWF CHIMERIC PROTEIN WITH VWF INDEPENDENT PHARMACOKINETIC PROPERTIES
Susannah Patarroyo-White*, Douglas Drager, Tongyao Liu, Ayman Ismail, Jiayun Liu, Amy Holthaus, Ekta Chhabra, John Kulman, Volker Schellenberger, Robert Peters (United States)

FVIII/VWF INTERACTION ASSESSED BY HYDROGEN-DEUTERIUM EXCHANGE MASS SPECTROMETRY AND BINDING AFFINITY
Johan H. Faber*, Kasper Lamberth, Jens Hansen, Ole Hvilshed Olsen, Martin Heitmann, Gert Bolt, Thomas Nylandsted Krogh, Frederik Rode, Marianne Kjalke, Jesper Haaning, Lars Thim (Denmark)

IMPROVED PHARMACOKINETICS AND IN VIVO EFFICACY OF PLATELET-TARGETED FACTOR VIIA-XTEN IN HUMAN ALPHA IIB TRANSGENIC / HEMOPHILIA A MICE
Arjan Van Der Flier*, Joe Salas, Zhan Liu, Tamera Ashworth, Elena Kistanova, Sarah Smith, Kai Chen, Deana Rabinovich, David Light, Robert Peters (United States)

TARGETED DOWNREGULATION OF CLEC-2 OCCURS THROUGH SRC FAMILY KINASE DEPENDENT INTERNALIZATION IN MOUSE PLATELETS
Viola Lorenz*, David Stegner, Simon Stritt, Timo Vögtle, Friedemann Kiefer, Walter Witke, Steve Watson, Barbara Walzog, Bernhard Nieswandt (Germany)

PROTEIN DISULFIDE ISOMERASE DENITROSYLASE ACTIVITY IN PLATELET ACTIVATION
Roelof Bekendam*, Srila Gopal, Pavan BendaPudi, Kristina Cook, James Dilks, Lin Lin, Sheryl Bowley, Jack Stopa, Mingdong Huang, Kevin Croce, Bruce Furie, Phil Hogg, Robert Flament (United States)

AN ANTI-STAPHYLOCOAGULASE MONOCLONAL ANTIBODY INHIBITS PROTHROMBIN ACTIVATION AND PROLONGS SURVIVAL IN MICE FOLLOWING STAPHYLOCOCCUS AUREUS INFECTION.
Kaitlyn Begins*, William Church, Ashoka Maddur, Paul Bock (United States)

PROTEIN DISULFIDE ISOMERASE RELEASED DURING THROMBUS FORMATION CLEAVES A DISULFIDE BOND IN PLASMA VITRONECTIN AND ENABLES ITS BINDING TO ALPHAVBETA3 INTEGRIN.
Sheryl R. Bowley*, Robert Furie, Bruce Furie (United States)

IDENTIFICATION OF ALPHA-1 PROTEINASE INHIBITOR VARIANTS WITH ENHANCED SPECIFICITY FOR ACTIVATED FACTOR XI OVER THROMBIN VIA COMBINED PHAGE DISPLAY AND BACTERIAL LYSATE SCREENING
Varsha Bhakta, William Sheffield* (Canada)

GPVI INTERACTION WITH POLYMERIZED FIBRIN BOOSTS THROMBIN GENERATION AND THROMBUS GROWTH
Pierre Mangin*, Elmina Mammedova-Bach, Bénédicte Dumont, Stéphane Loyau, Christian Gachet, Véronique Ollivier, Martine Jandrot-Perrus (France)

PLASMINOGEN ACTIVATOR INHIBITOR-1 PARTIALLY PROTECTS MICE AGAINST CARDIAC FIBROSIS BY INHIBITING UROKINASE-TYPE PLASMINOGEN ACTIVATOR
Kamlesh K. Gupta*, Deborah Donahue, Mayra Sandoval-CooPer, Donna Emge, Francis Castellino, Victoria Ploplis (United States)

PROTECTIVE ROLE OF PROTEASE NEXIN-1 AGAINST LUNG FIBROSIS IN BLEOMYCIN-TREATED MICE
Déborah Francois*, Marie-Christine Bouton, Laurence Venisse, Martine Jandrot-Perrus, Véronique Arocas (France)

ANTI-STAPHYLOCOAGULASE MONOCLONAL ANTIBODY INHIBITS PROTHROMBIN ACTIVATION AND PROLONGS SURVIVAL IN MICE FOLLOWING STAPHYLOCOCCUS AUREUS INFECTION.
Kaitlyn Begins*, William Church, Ashoka Maddur, Paul Bock (United States)

PROTEIN DISULFIDE ISOMERASE RELEASED DURING THROMBUS FORMATION CLEAVES A DISULFIDE BOND IN PLASMA VITRONECTIN AND ENABLES ITS BINDING TO ALPHAVBETA3 INTEGRIN.
Sheryl R. Bowley*, Robert Furie, Bruce Furie (United States)

IDENTIFICATION OF ALPHA-1 PROTEINASE INHIBITOR VARIANTS WITH ENHANCED SPECIFICITY FOR ACTIVATED FACTOR XI OVER THROMBIN VIA COMBINED PHAGE DISPLAY AND BACTERIAL LYSATE SCREENING
Varsha Bhakta, William Sheffield* (Canada)

ANALYSIS OF FACTOR XIA, FACTOR IXA AND TISSUE FACTOR ACTIVITY IN BURN PATIENTS
Saulius Butenas*, Daniel Jo, Lauren Moffatt, Jeffrey Shupp (United States)

THE WHOLE BLOOD THROMBIN GENERATION TEST PREDICTS BLEEDING RISK IN PATIENTS TAKING VITAMIN K ANTAGONISTS
Saatje Bloemen*, Arina ten Cate-Hoek, Hugo ten Cate, Bas de Laat (The Netherlands)

COMPARATIVE IN VITRO EVALUATION OF THROMBIN GENERATION ASSAY (TGA) AFTER SPIKING FRESH FROZEN PLASMA (FFP) OR PROTHROMBIN COMPLEX CONCENTRATE (PCC) TO SAMPLES FROM PATIENTS UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION (OLT)
Mikael Perin, Laurent Ardillon, Benidicte Delahousse, Ephrem Salamé, Yves Gruel* (France)

EFFECTS OF APIXABAN ON PT AND APTT AS DETERMINED WITH A FULL RANGE OF REAGENTS: RESULTS OF A UK NEQAS EXERCISE
Stephen Kitchen, Ian Jennings*, Anna Lowe, Dianne Kitchen, Tim Woods, Isobel Walker (United Kingdom)
SCIENTIFIC PROGRAM

08:00 – 09:15 PROTHROMBOTIC MECHANISMS IN A SETTING OF PERI-OPERATIVE BRIDGING WITH LOW MOLECULAR WEIGHT HEPARINS IN PATIENTS UNDERGOING SURGERY
Pieter Eijgenraam, Hugo ten Cate, Yvonne Henskens, René van den Ham, Arina ten Cate-Hoek* (The Netherlands)

08:45 – 09:00 INHIBITION OF MICROPARTICLE INDUCED TUMOR CELL MIGRATION BY LMWH TINZAPARIN
Frank Gieseler*, Hans Gamperl, Corinna Plattfaut, Rike Theophil, Tabea Quecke (Germany)

09:00 – 09:15 NOVEL REGULATION OF TFPI EXPRESSION BY OESTROGENS IN BREAST CANCER CELLS THROUGH MICRORNAS
Huda O. Ali*, Ana Arroyo, Rocío Conejero, Benedita Stavik, Nina Iversen, Per Morten Sandset, Constantino Martinez, Grethe Skretting (Norway)

Fibrin and fibrin II Room 707

Moderators: Michael Nagler (The Netherlands), Nicola Mutch (United Kingdom)

08:00 – 08:15 SEQUENCING OF FGA, FGB AND FGG REVEALS BOTH NOVEL AND PREVIOUSLY DESCRIBED MUTATIONS IN PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCIES
Natalie Smith*, Leila Noetzli, Tara Adams, Salvador Minolodo, Hugo Guglielmone, Marilyn Manco-Johnson, Jorge Di Paola (United States)

08:15 – 08:30 HEREDITARY AFIBRINOGENEMIA – LONG-TERM OBSERVATION OF A HIGHLY THROMBOPHILIC CONDITION AND IT’S MANAGEMENT
Michael Nagler*, Johanna Kremer Hovinga, Lorenzo Alberio, Kristiina Peter-Salonen, Hendrik von Tengg-Kobligk, Daniel Lottaz, Bernhard Lämmlle (Switzerland, Netherlands)

08:30 – 08:45 ELEVATED FIBRINOGEN BUT NOT FIBRINOGEN GAMMA PRIME IN ABDOMINAL AORTIC ANEURYSMAL DISEASE
Fraser Macrae*, Tittu Thomas, Anne Johnson, Katherine Bridge, Helen Philippou, D Scott, Robert Ariens (United Kingdom)

08:45 – 09:00 ROLE OF FIBRIN(OGEN) IN HEPATOCYTE PROLIFERATION AFTER ACETAMINOPHEN OVERDOSE
Anna Kope*, Nikita Joshi, Keara Towery, Holly Cline-Fedewa, Matthew Flick, James Luyendyk (United States)

09:00 – 09:15 PROTHROMBOTIC PROPERTIES OF FIBRIN CLOTS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Wilma Potze, Mohammad Siddiqui, Sherry Boyett, Jelle Adelmeijer, Kalyani Daita, Arun Sanyal, Ton Lisman* (The Netherlands)

Cancer and thrombosis – basic – II Room 707

Moderators: Ali Al-Hashimi (Canada), Cihan Ay (Austria)

08:00 – 08:15 ANTI-TUMORIGENIC EFFECTS ARE EXERTED BY EXOSOMES DERIVED FROM HEPARIN TREATED HUMAN BREAST CANCER CELLS AND PERSIST EVEN AFTER HEPARIN TREATMENT HAS BEEN DISCONTINUED
Yunliang Chen*, Michael Scully, Christopher Goodwin, Ajay Kakkar (United Kingdom)

08:15 – 08:30 CONTRIBUTION OF ANTI-GRP78 AUTOANTIBODIES TO PROSTATE CANCER PROGRESSION THROUGH TISSUE FACTOR PROCOAGULANT ACTIVITY
Ali Al-Hashimi* (Canada)

08:30 – 08:45 CANCER CELLS BXPC3 AND MCF7 DIFFERENTIALLY REVERSE THE INHIBITION OF THROMBIN GENERATION BY APIXABAN, FONDAPARINUX AND ENOXAPARIN
Aurélie Rousseau, Patrick Van Dreden, Ismail Elalamy, Grigoris Gerotziafas* (France)

Coffee break time in the Foyers (Levels 700 and 800)
From 09:15 to 09:30
### SCIENTIFIC PROGRAM

**Thursday, June 25, 2015**

**PLENARY SESSION 09:30-10:15**

**Louis B. Jaques Plenary Lecture**

*Moderator: Geoff Werstuck (Canada)*

09:30 - 10:15

**Non-coding RNAs: novel therapeutic targets in cardiovascular disease**

Stefanie Dimmeler (Germany)

---

**Wednesday, June 24, 2015**

**ABSTRACT SYMPOSIA 10:30-11:45**

**ADAMTS13**

*Room 717*

*Moderators: Johanna Kremmer Hovinga (Switzerland), Andrew Yee (United States)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:50</td>
<td>ADAMTS13: DYNAMIC INTERACTIONS WITH VON WILLEBRAND FACTOR</td>
</tr>
<tr>
<td>AS177</td>
<td>David Lane (United Kingdom)</td>
</tr>
<tr>
<td>10:50 - 11:04</td>
<td>ADAMTS13-INDUCED UNFOLDING OF THE VON WILLEBRAND FACTOR A2 DOMAIN</td>
</tr>
<tr>
<td>AS178</td>
<td>Louis Deforche*, Hendrik Feyes, Karen De Ceunynck, Aline Vandenbulcke,</td>
</tr>
<tr>
<td></td>
<td>Nele Vandeputte, Ellen Roose, Yoshinori Fujimura, Kenji Soejima, David A.</td>
</tr>
<tr>
<td></td>
<td>Lane, Brenda Luken, J. Evan Sadler, Hans Deckmyn, Simon De Meyer, Karen</td>
</tr>
<tr>
<td></td>
<td>Vanhoorelbeke (Belgium)</td>
</tr>
<tr>
<td>11:04 - 11:18</td>
<td>N-LINKED GLYCOSYLATION IS A MODULATOR OF ADAMTS13 EXPRESSION, STRUCTURE</td>
</tr>
<tr>
<td>AS179</td>
<td>AND FUNCTION.</td>
</tr>
<tr>
<td></td>
<td>Agata A. Nowak*, Rens de Groot, Mike Laffan, Thomas McKinnon (United</td>
</tr>
<tr>
<td></td>
<td>Kingdom)</td>
</tr>
<tr>
<td>11:18 - 11:32</td>
<td>ADAMTS13 DEFICIENCY WORSENS MURINE COLITIS AND TREATMENT OF WILD TYPE</td>
</tr>
<tr>
<td>AS180</td>
<td>COLITIC MICE WITH RHADAMTS13 LEADS TO IMPROVEMENT</td>
</tr>
<tr>
<td></td>
<td>Naamah L. Zitomersky*, Melanie Demers, Kimberly Martinod, Maureen</td>
</tr>
<tr>
<td></td>
<td>Gallant, Maureen (United States)</td>
</tr>
</tbody>
</table>

---

**SCIENTIFIC PROGRAM**

**11:32 - 11:45**

**VON WILLEBRAND FACTOR, ADAMTS13 AND THE RISK OF MORTALITY: THE ROTTERDAM STUDY**

Michelle A. H. Sonneveld*, Mohammed Ikram, Maryam Kavousi, Albert Hofman, Oscar Franco, Frank Leebeek, Moniek de Maat (The Netherlands)

*Novel anti-platelet agents*  
*Plenary Hall F&G*

*Moderators: Paul Jurasz (Canada), Jean-François Schved (France)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-11:00</td>
<td>CHEMOPROTEOMIC DISCOVERY OF NOVEL ANTI-PLATELET TARGETS</td>
</tr>
<tr>
<td>AS182</td>
<td>Leslie Parise (United States)</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td>A SMALL MOLECULE INHIBITOR OF ASK1 PROTECTS MICE FROM</td>
</tr>
<tr>
<td>AS183</td>
<td>THROMBOSIS WITH MINIMAL EFFECT ON HEMOSTASIS</td>
</tr>
<tr>
<td></td>
<td>Meghna Naik*, Brendan Bachman, David Maloney, Ulhas Naik (United States)</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>SITE SPECIFIC INHIBITION OF THROMBUS FORMATION USING SHEAR SENSITIVE</td>
</tr>
<tr>
<td>AS184</td>
<td>ANTI-THROMBOTIC NANOPIERCLES</td>
</tr>
<tr>
<td></td>
<td>Erik Westen*, Christopher Molloy, Joy Yao, Karlheinz Peter (Australia)</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>MODULATING PLATELET REACTIVITY THROUGH REGULATED CONTROL OF FREE RGS18</td>
</tr>
<tr>
<td>AS185</td>
<td>LEVELS</td>
</tr>
<tr>
<td></td>
<td>Peisong Ma*, Andrew Sinnamon, Kristy Ou, Lawrence Brass (United States)</td>
</tr>
</tbody>
</table>

---

**Glycobiology**

*Room 711*

*Moderators: Gilbert White (United States), Silvia Giannini (United States)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-11:00</td>
<td>PLATELET GLYCObIOLOGY: THE POWERS OF POSTTRANSLATIONAL MODIFICATIONS</td>
</tr>
<tr>
<td>AS186</td>
<td>Karin Hoffmeister (United States)</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td>RECESSIVE AND TRANSIENT ANTITHROMBIN DEFICIENCY CAUSED BY A WIDE</td>
</tr>
<tr>
<td>AS187</td>
<td>SPECTRUM OF CONGENITAL DISORDERS OF N-GLYCOsyLATION WITH UNUSUAL</td>
</tr>
<tr>
<td></td>
<td>CLINICAL FEATURES.</td>
</tr>
<tr>
<td></td>
<td>IDENTIFICATION OF A NEW THROMbOPHILIC DISORDER</td>
</tr>
<tr>
<td></td>
<td>Maria Eugenia De La Morena-Barrio*, Irene Martinez-Martinez, Mara</td>
</tr>
<tr>
<td></td>
<td>Toderici, Carmen De Cos, Teresa Sevivas, Antonia Milito, Jose</td>
</tr>
<tr>
<td></td>
<td>Padilla, Dirk Lefeber, Jaak Jaeken, Vicente Vicente, Javier Corral</td>
</tr>
<tr>
<td></td>
<td>(Spain)</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>MECHANISM OF N-LINKED GLYCAn STABILISATION OF THE VON</td>
</tr>
<tr>
<td>AS188</td>
<td>WILLEBRAND FACTOR A2 DOMAIn</td>
</tr>
<tr>
<td></td>
<td>Christopher J. Lynch*, David Lane (United Kingdom)</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>PEPTIDE ANTAGONISTS FOR P-SELECTIN DISCRIMINATE BETWEEN</td>
</tr>
<tr>
<td>AS189</td>
<td>SULFATIDE-DEPENDENT PLATELET AGGREGATION AND PSLG-1-MEDIATED CELL</td>
</tr>
<tr>
<td></td>
<td>ADHESION</td>
</tr>
<tr>
<td></td>
<td>Suzanne J. Korporaal*, Tom Molenaar, Bianca Lutters, Illiana Meurs,</td>
</tr>
<tr>
<td></td>
<td>Sandra Verhoeft, Martin Ijseldijk, Johan Kuiper, Theo Van Berkel, Jan</td>
</tr>
<tr>
<td></td>
<td>Wille Akkerman, Erik Biessen (The Netherlands)</td>
</tr>
</tbody>
</table>

---
SCIENTIFIC PROGRAM

Unusual site venous thrombosis Room 718

**Moderators:** Alejandro Lazo-Langner (Canada), Walter Ageno (Italy)

- **10:30-11:00**
  - MANAGEMENT OF MESENTERIC VEIN THROMBOSIS
    - Geoffrey Nguyen (Canada)
  - **ANTITHROMBOTIC TREATMENT AND OUTCOMES OF CIRRHOTIC PATIENTS WITH SPLANCHNIC VEIN THROMBOSIS: A SUB-STUDY FROM THE Isth REGISTRY**
    - Nicoletta Riva*, Walter Ageno, Marco Senzolo, Sam Schulman, Jan Beyer-Westendorf, Rita Duce, Rita Santoro, Pieter Kamphuisen, Doyeun Oh, Cecilia Becattini, Kryssia Rodrigez, Giovanni Barillari, Serena Maria Passamonti, Maria Anna Guardascione, Gianpaolo Vidili, Antonella Vaccarino, Francesco Dentali, IRSVT study investigators (Italy)

- **11:00 – 11:15**
  - **NEXT-GENERATION DNA SEQUENCING APPROACH TO IDENTIFY NOVEL GENETIC RISK FACTORS UNDERLYING CEREBRAL VEIN THROMBOSIS.**
    - Marcin M. Gorski*, Hugoline de Haan, Astrid van Hylckama Vlieg, Luca A. Lotta, Paolo Bucciarelli, Serena Passamonti, Ida Martinelli, Frits Rosendaal, Flora Peyvandi (Italy)

- **11:15 - 11:30**
  - **NEXT-GENERATION DNA SEQUENCING APPROACH TO IDENTIFY NOVEL GENETIC RISK FACTORS UNDERLYING CEREBRAL VEIN THROMBOSIS.**
    - Marcin M. Gorski*, Hugoline de Haan, Astrid van Hylckama Vlieg, Luca A. Lotta, Paolo Bucciarelli, Serena Passamonti, Ida Martinelli, Frits Rosendaal, Flora Peyvandi (Italy)

**Atherosclerosis: progression and development Room 709

**Moderators:** Hugo Ten Cate (The Netherlands), Tilman Hackeng (The Netherlands)

- **10:30-10:50**
  - ENDOTHELIAL DYSFUNCTION, INFLAMMATION AND THE INITIATION OF ATHEROSCLEROSIS
    - Myron Cybulsky (Canada)
  - **PLATELET-DERIVED MATRIX METALLOPROTEINASE (MMP)-2 CONTRIBUTES TO ATHEROSCLEROSIS PROGRESSION IN HYPERCHOLESTEROLEMIC MICE**
    - Stefanie Momi*, Emanuela Falcinelli, Giorgia Manni, Paolo Gresele (Italy)

- **11:04 - 11:18**
  - **MACROPHAGE M2 DIFFERENTIATION INDUCES PAI-1 EXPRESSION VIA A STAT6 DEPENDENT PATHWAY**
    - Philipp Hohenninger*, Barbara Thaler, Christoph Kaun, Benjamin Ebenbauer, Michael Fischer, Gerald Maurer, Kurt Huber, Walter Speidl, Johann Wolff (Austria)

- **11:18 - 11:32**
  - **M1 AND M2 MACROPHAGE PROTEOLYTIC AND ANGIOPGENIC PROFILES ANALYSIS IN ATHEROSCLEROTIC PATIENTS REVEALS A DISTINCTIVE PROFILE IN TYPE 2 DIABETES**
    - Charlotte Roma, Madjid Tagzirt, Christophe Zawadzki, Rodrigo Lorenzi, André Vincen- telli, Stephan Haulon, Francis Juthier, Bart Staelens, Brigitte Jude, Eric Van Belle, Giulia Chinetti-Gbaguidi, Sophie Susen, Annabelle Dupont* (France)

**Fibrinolysis in health and disease Room 707**

**Moderators:** Francis Castellino (United States), Thijs van Mens (The Netherlands)

- **10:30-10:50**
  - ROLE OF PLASMINOGEN RECEPTOR KT (PLG-RKT) IN HEALTH AND DISEASE
    - Lindsey Miles (United States)
  - **PLASMINOGEN LOCALIZES TO DISTINCT CAPS ON PHOSPHATIDYLSERINE-EXPOSING PLATELETS AND PROMOTES THROMBUS LYSIS UNDER FLOW**
    - Claire S. Whyte, Frauke Swieringa, Tom Mastenbroek, Aura Lionikienne, Marcus Lance, Paola van der MeiJden, Johan Heemskerk, Nicola Mutch* (United Kingdom)

- **11:15 - 11:30**
  - **INHIBITION OF TAFI AFFECTS AAA FORMATION AND RUPTURE IN THE ANGIOTENSIN II MODEL OF ABDOMINAL AORTIC ANEURYSM**
    - Katherine I. Bridge*, Charlotte Revill, Marc Bailey, Nadira Yuldasheva, Stephen Wheatcroft, Roger Butlin, Richard Foster, Julian Scott, Ann Gils, Robert Ariens (United Kingdom)

- **11:30 - 11:45**
  - **ROLE OF DNA METHYLATION IN CANDIDATE GENES REGIONS ON TISSUE PLASMINOGEN ACTIVATOR LEVELS**
    - Nora Zwingerman*, Izfahan Kassam, Vinh Thuong, Dylan Alissi, Jessica Dennis, Michael Wilson, Phil Wells, Pierre-Emmanuel Morange, David-Alexandre Trégouët, France Gagnon (Canada)

**Protein C and sepsis Room 714**

**Moderators:** Laura Pepler (Canada), Kamlesh Gupta (United States)

- **10:30-11:00**
  - PROTEIN C (APC) FUNCTIONS IN INFLAMMATORY DISEASES
    - Charles “Chuck” Esmon (United States)
  - **SILENCING ANTITHROMBIN AND PROTEIN C IN APOE KNOCKOUT MICE CAUSES SEVERE COAGULOPATHY BUT NOT ATHEROTHROMBOSIS**
    - Amber B. Ouweene*, Marco Heestermans, Bart Van Vlijmen, Miranda Van Eek (The Netherlands)

- **11:15 - 11:30**
  - **E-WE THROMBIN ACTIVATES PROTEIN C ON THE PLATELET SURFACE AND RAPIDLY INTERRUPTS EXPERIMENTAL THROMBUS PROGRESSION IN PRIMATES**
    - Erik Tucker*, Michael Wallisch, Norah Verbout, Brandon Markway, Owen McCarty, András Gruber (United States)

- **11:30 - 11:45**
  - **IMPACT OF THE ENDOTHELIAL PROTEIN C RECEPTOR IN COAGULATION, INFLAMMATION AND HEMATOPOIESIS**
    - Laura Pepler*, Pei Yu, Dhruva Dwivedi, Bernardo Trigatti, Patricia Liaw (Canada)
**SCIENTIFIC PROGRAM**

**Chronic kidney disease and coagulation**  
Room 705  

**Moderators:** Joanne van Ryn (Germany), Rita Selby (Canada)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-11:00</td>
<td><strong>CHRONIC KIDNEY DISEASE AS A RISK FACTOR FOR THROMBOTIC AND BLEEDING EVENTS</strong></td>
</tr>
<tr>
<td>AS211</td>
<td>Manish Sood (Canada)</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td><strong>GRP78 INJECTION AMELIORATES HAEMOLYTIC URAEMIC SYNDROME (HUS) PHENOTYPE IN A SUBAB TOXIN INDUCED MOUSE MODEL</strong></td>
</tr>
<tr>
<td>AS212</td>
<td>Sarah Kamel*, Susanna Freddi, Carly Selin, Anushka Samudra, Anup Sharma, Peter Cowan, HarshaL Nandurkar (Australia)</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td><strong>TUMOR NECROSIS FACTOR SUPPRESSES THE GLOMERULAR ENDOTHELIAL CELL SURFACE PROTEIN CD141 (THROMBOMODULIN) AND STIMULATES EXPRESSION OF C3 AND FACTOR B: IMPLICATIONS FOR RENAL INJURY AND THROMBOSIS IN THE ATYPICAL HEMOLYTIC UREMIC SYNDROME</strong></td>
</tr>
<tr>
<td>AS213</td>
<td>Sarah Sartain*, Nancy Turner, Joel Moake (United States)</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td><strong>LONG-TERM TINZAPARIN VERSUS WARFARIN FOR TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS – ANALYSIS OF RENAL IMPAIRMENT (RI) IN THE CATCH STUDY</strong></td>
</tr>
</tbody>
</table>

**Endothelial cell-VTE models**  
Room 715  

**Moderators:** Iqbal Jaffer (Canada), Anthony Chan (Canada)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:50</td>
<td><strong>THE ROLE OF GAS6 AND INFLAMMATION IN THE PATHOPHYSIOLOGY OF VENOUS THROMBOEMBOLISM</strong></td>
</tr>
<tr>
<td>AS215</td>
<td>Mark Blostein (Canada)</td>
</tr>
<tr>
<td>10:50 - 11:04</td>
<td><strong>CORRELATION BETWEEN DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM USING AN IN VIVO MOUSE MODEL OF VENOUS THROMBOEMBOLISM: EFFECT OF THROMBIN INHIBITION</strong></td>
</tr>
<tr>
<td>AS216</td>
<td>Shana A. Shaya*, Lisa Saldanha, Nima Vaezzadeh, Ran Ni, Ji Zhou, Peter Gross (Canada)</td>
</tr>
<tr>
<td>11:04 - 11:18</td>
<td><strong>INHIBITION OF PLATELET FUNCTION WITH THE NOVEL 12-LOX INHIBITOR ML355 IMPAIRS THROMBUS GROWTH, STABILITY AND VESSEL OCCLUSION IN VIVO</strong></td>
</tr>
<tr>
<td>AS217</td>
<td>Reheman Adili*, Jennifer Yeung, Theodore Holman, Michael Holinstat* (United States)</td>
</tr>
<tr>
<td>11:18 - 11:32</td>
<td><strong>TISSUE FACTOR PATHWAY INHIBITOR (TFPI): AN ENDOGENOUS SUBSTRATE FOR FACTOR VII ACTIVATING PROTEASE (FSAP) IN VIVO</strong></td>
</tr>
<tr>
<td>AS218</td>
<td>Saravanan Subramaniyan*, Ina Thiellmann, Martina Morowski, Ingo Pragst, Per Sandset, Bernhard Niewandt, Michael Etscheid, Sandip Kanse (Germany)</td>
</tr>
<tr>
<td>11:32 - 11:45</td>
<td><strong>INTRINSIC AND EXTRINSIC COAGULATION PATHWAYS BOTH CONTRIBUTE TO LIGATION-INDUCED DEEP VEIN THROMBOSIS IN RATS</strong></td>
</tr>
<tr>
<td>AS219</td>
<td>Ji Zhou*, Peng Liao, Beverly Leslie, Trang Vu, Ran Ni, Alan Stafford, James Fredenburgh, Brett Monia, Peter Gross, Jeffrey Weitz (Canada)</td>
</tr>
</tbody>
</table>

**Inhibitors - clinical**  
Room 801  

**Moderators:** Roshni Kulkarni (United States), Amy Dunn (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:50</td>
<td><strong>FACTOR VIII INHIBITORS IN PATIENTS WITH NON-SEVERE HEMOPHILIA A</strong></td>
</tr>
<tr>
<td>AS220</td>
<td>Christine Kempton (Canada)</td>
</tr>
<tr>
<td>10:50 - 11:04</td>
<td><strong>STATE-OF-THE-ART ANALYSIS OF FVIII-BINDING ANTIBODIES REVEALS IGA AS A PROGNOSTIC BIOMARKER FOR POOR TREATMENT OUTCOMES IN ACQUIRED HEMOPHILIA A</strong></td>
</tr>
<tr>
<td>AS221</td>
<td>Christoph J. Hofbauer*, Sonja Wewlitzke, Paul Knebel, Saskia Gottlieb, Ruediger Scharf, Juergen Heinz, Juergen Gross, Katharina Holstein, Christiane Dobbelstein, Friedrich Scheiffinger, Birgit Reipert, Andreas Tiede (Austria)</td>
</tr>
<tr>
<td>11:04 - 11:18</td>
<td><strong>PREDICTORS OF SUCCESS OF IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A PATIENTS WITH HIGH-RESPONDING INHIBITORS. A PROGNOSTIC SCORE FROM THE ITALIAN PROFIT REGISTRY</strong></td>
</tr>
<tr>
<td>AS222</td>
<td>Antonio Coppola*, Maurizio Margaglione, Angela Rocino, Maria Elisa Mancuso, Annarita Tagliaferri, Ezio Zanon, Rita Santoro, Piercarla Schinco, Silvia Linari, Giancarlo Castaman, Maria Messina, Dorina Cultlera, Cristina Santoro, Chiara Biasoli, Elena Santagostino, Giovanni Di Minno (Italy)</td>
</tr>
<tr>
<td>11:18 - 11:32</td>
<td><strong>RISK FOR INHIBITOR DEVELOPMENT IN SEVERE HEMOPHILIA A PUPS IS NOT ASSOCIATED WITH CLASS OF FVIII CONCENTRATES NOR BY HIGH VON-WILLEBRAND FACTOR OR BY TYPE OF VIRAL INACTIVATION PROCEDURE</strong></td>
</tr>
<tr>
<td>AS223</td>
<td>SM Hashemi*, J Oldenburg, H Platokouki, R Liesner, HM van den Berg (The Netherlands)</td>
</tr>
<tr>
<td>11:32 - 11:45</td>
<td><strong>MUTATION ANALYSIS OF SWEDISH HEMOPHILIA B FAMILIES - HIGH FREQUENCY OF UNIQUE MUTATIONS</strong></td>
</tr>
<tr>
<td>AS224</td>
<td>Annika Mörtensson*, Anna Letelier, Rolf LJung (Sweden)</td>
</tr>
</tbody>
</table>

**Stroke**  
Room 713  

**Moderators:** Paul Ockelford (New Zealand), Pieter Kamphuisen (The Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-11:00</td>
<td><strong>WHAT IS THE OPTIMAL ANTITHROMBOTIC THERAPY FOR NON-CARDIOEMBOLIC STROKE?</strong></td>
</tr>
<tr>
<td>AS225</td>
<td>Martin O’Donnell (Ireland)</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td><strong>PRE-EVENT CHA2DS2-VASC SCORE AND SEVERITY OF ACUTE STROKE IN PATIENTS WITH ATRIAL FIBRILLATION: FINDINGS FROM THE RAF STUDY</strong></td>
</tr>
<tr>
<td>AS226</td>
<td>Maurizio Paciaroni*, Cecilia Becattini, Giancarlo Agnelli, Monica Acciarresi (Italy)</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td><strong>EARLY RECURRENT AND CEREBRAL BLEEDING IN PATIENTS WITH ACUTE ISCHEMIC STROKE AND ATRIAL FIBRILLATION: EFFECT OF ANTICOAGULATION AND ITS TIMING. THE (RAF) STUDY</strong></td>
</tr>
<tr>
<td>AS227</td>
<td>Maurizio Paciaroni*, Cecilia Becattini, Giancarlo Agnelli (Italy)</td>
</tr>
</tbody>
</table>
## SCIENTIFIC PROGRAM

### THURSDAY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:20 - 11:30</td>
<td>MAGNESIUM TRANSPORTER MAGT1 PLAYS A CRITICAL ROLE IN THROMBO-INFLAMMATORY DISEASES AND HEMOSTASIS IN MICE</td>
<td>Sanjeev Kiran Gotru*, Karen Wolf, Timo Vögtle, Peter Kraft, Simon Stritt, Guido Stoll, Bernhard Nieswandt, Attila Braun (Germany)</td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>RECEPTORS FOR PLASMINOGEN ACTIVATORS: ROLE IN INFLAMMATION, ATHEROSCLEROSIS, AND CANCER</td>
<td>Stevens Gonias (United States)</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>CM-352, A NEW MATRIX METALLOPROTEINASE INHIBITOR, IS A POTENT AND SAFE ANTIFIBRINOLYTIC AGENT FOR THE PREVENTION AND TREATMENT OF HEMORRHAGE</td>
<td>Josune Orbe*, Jose Rodriguez, Juan Sanchez, Agustina Salicio, Miriam Belzunce, Ana Ugarte, Haisul Chang, Obulba Rabal, Julen Oyarzabal, Jose Paramo (Spain)</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>INHIBITION OF COMPLEMENT C3 AND FIBRINOGEN INTERACTION: A POTENTIAL NOVEL THERAPEUTIC TARGET TO REDUCE FIBRIN-RELATED THROMBOSIS RISK</td>
<td>Rhodri King*, Christian Tiede, Katie Simmons, Colin Fishwick, Katharina Schuett, Katherine Kearney, Darren Tomlinson, Ramzi Ajan (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>MODULATION OF RECOMBINANT ANTIGENIC CONSTRUCTS CONTAINING MULTI-EPITOPE TOWARDS EFFECTIVE REDUCTION OF ATHEROSCLEROTIC LESION IN B6;129S-LDLR(TM1HER)APOB (TM2SGY/J) MICE</td>
<td>Min Xia, Valeria Endresz, Daxin Chen, Ildiko Lantos, Andrea Szabo, Lakshmi Mundkur, Vijay Kakkar, Xinjie Lu* (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>11:32 - 11:45</td>
<td>RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER</td>
<td>Alexander Cohen*, Stephan Rietbrock, Anja Katholing, Carlos Martinez (United Kingdom)</td>
<td></td>
</tr>
</tbody>
</table>

### Coversations

#### Atherosclerosis, inflammation and cancer

**Room 701**

- **Moderators:** Angela Silveira (Sweden), Jossane Orbe (Spain)

#### Cancer and thrombosis – clinical

**Room 716**

- **Moderators:** Agnes Lee (Canada), Aurelien Delluc (France)

### SYMPOSIA

- **10:30 - 10:50** CONTROVERSIES IN CANCER-ASSOCIATED THROMBOSIS
  - Marc Carrier (Canada)

- **10:50 - 11:04** TISSUE FACTOR (TF) AS PREDICTOR OF RECURRENT VENOUS THROMBOEMBOLISM (VTE): RISK FACTOR AND BIOMARKER ANALYSIS FROM THE CATCH TRIAL OF TREATMENT OF CANCER-ASSOCIATED VTE WITH Tinzaparin or Warfarin

- **11:04 - 11:18** EXTENSIVE SCREENING BASED ON 18F-FDG PET/CT FOR OCCULT MALIGNANT DISEASE IN UNPROVOKED VENOUS THROMBOEMBOLISM: A PROSPECTIVE RANDOMIZED CLINICAL TRIAL
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>3i - Intelligent Imaging Innovations</td>
<td>640</td>
</tr>
<tr>
<td>Accriva Diagnostics</td>
<td>1015</td>
</tr>
<tr>
<td>Affinity Biologicals, Inc.</td>
<td>737</td>
</tr>
<tr>
<td>Aniara Diagnostica &amp; CoaChrom Diagnostica</td>
<td>424</td>
</tr>
<tr>
<td>Answering T.T.P. (Thrombotic Thrombocytopenic Purpura) Foundation</td>
<td>1804</td>
</tr>
<tr>
<td>Aspen Pharma</td>
<td>512</td>
</tr>
<tr>
<td>Baxalta</td>
<td>1602</td>
</tr>
<tr>
<td>Bayer HealthCare</td>
<td>1722 + 702 + 502</td>
</tr>
<tr>
<td>Bio Products Laboratory USA, Inc.</td>
<td>1017</td>
</tr>
<tr>
<td>Biogen and Sobi</td>
<td>922</td>
</tr>
<tr>
<td>bioMerieux</td>
<td>741</td>
</tr>
<tr>
<td>Biotest AG</td>
<td>1739</td>
</tr>
<tr>
<td>Boehringer Ingelheim GmbH</td>
<td>1638 + 1639</td>
</tr>
<tr>
<td>Canadian Hemophilia Society (CHS)</td>
<td>1814</td>
</tr>
<tr>
<td>CEDARLANE®</td>
<td>1711</td>
</tr>
<tr>
<td>Chrono-log Corp.</td>
<td>638</td>
</tr>
<tr>
<td>Covidiën</td>
<td>1840</td>
</tr>
<tr>
<td>CSL Behring GmbH</td>
<td>1522</td>
</tr>
<tr>
<td>Daichi Sankyo, Inc.</td>
<td>422</td>
</tr>
<tr>
<td>Diapharma Group</td>
<td>1016</td>
</tr>
<tr>
<td>DSM Nutritional Products Ltd Branch Pentapharm</td>
<td>521</td>
</tr>
<tr>
<td>Enzyme Research / r2 Diagnostics</td>
<td>1616</td>
</tr>
<tr>
<td>European and Mediterranean League against Thrombotic Disorders (EMLTD)</td>
<td>1542</td>
</tr>
<tr>
<td>Ferrer inCode</td>
<td>1802</td>
</tr>
<tr>
<td>Foundation for Women &amp; Girls with Blood Disorders (FWGBD)</td>
<td>1808</td>
</tr>
<tr>
<td>George King Bio-Medical, Inc.</td>
<td>642</td>
</tr>
<tr>
<td>GRIFOLS</td>
<td>1336</td>
</tr>
<tr>
<td>Haematologic Technologies, Inc.</td>
<td>1612</td>
</tr>
<tr>
<td>Hemostasis Reference Laboratory Inc.</td>
<td>739</td>
</tr>
<tr>
<td>HYPHEN BioMed</td>
<td>1702</td>
</tr>
<tr>
<td>Immucor</td>
<td>648</td>
</tr>
<tr>
<td>Instrumentation Laboratory</td>
<td>410</td>
</tr>
<tr>
<td>International Initiative on Thrombosis and Cancer (ITAC-CME)</td>
<td>1810</td>
</tr>
<tr>
<td>International Society on Thrombosis and Haemostasis (ISTH)</td>
<td>1036</td>
</tr>
<tr>
<td>ISTH 2017 - Berlin, Germany</td>
<td>1036</td>
</tr>
<tr>
<td>ISTH SSC 2016 - Montpellier, France</td>
<td>1036</td>
</tr>
<tr>
<td>Journal of Thrombosis and Haemostasis</td>
<td>1036</td>
</tr>
<tr>
<td>Kedrion Biopharma</td>
<td>428</td>
</tr>
<tr>
<td>LABTEK Science and Development Co., Ltd.</td>
<td>1828</td>
</tr>
<tr>
<td>LFB BIOMEDIKENTS</td>
<td>1546</td>
</tr>
<tr>
<td>MediRox</td>
<td>1709</td>
</tr>
<tr>
<td>Novo Nordisk Haemophilia Foundation (NNHF)</td>
<td>1018</td>
</tr>
<tr>
<td>Novo Nordisk Health Care AG</td>
<td>1010</td>
</tr>
<tr>
<td>Octapharma AG</td>
<td>1301</td>
</tr>
<tr>
<td>Pfizer</td>
<td>736</td>
</tr>
<tr>
<td>Pfizer Canada Inc./Bristol-Myers Squibb Canada</td>
<td>522</td>
</tr>
<tr>
<td>Portola Pharmaceuticals, Inc.</td>
<td>1713</td>
</tr>
<tr>
<td>Precision BioLogic</td>
<td>1610</td>
</tr>
<tr>
<td>Roche Diagnostics International Ltd</td>
<td>1728</td>
</tr>
<tr>
<td>Schattauer Publishers</td>
<td>1822</td>
</tr>
<tr>
<td>Sekisui Diagnostics</td>
<td>1800</td>
</tr>
<tr>
<td>Siemens Healthcare</td>
<td>436</td>
</tr>
<tr>
<td>STAGO</td>
<td>1122</td>
</tr>
<tr>
<td>Sysmex Corporation</td>
<td>436</td>
</tr>
<tr>
<td>TECHNOCLONE</td>
<td>1538</td>
</tr>
<tr>
<td>Thrombosis.TV</td>
<td>1826</td>
</tr>
<tr>
<td>Wiley</td>
<td>1614</td>
</tr>
<tr>
<td>World Federation of Hemophilia</td>
<td>1812</td>
</tr>
<tr>
<td>World Thrombosis Day (WTD) - 13 October</td>
<td>1036</td>
</tr>
</tbody>
</table>
# Reversal of old and newer anticoagulants: evolving evidence from trials

**A lunchtime satellite symposium**

**Programme**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15</td>
<td>Chairs’ welcome</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Emergency reversal of warfarin: lessons from randomised controlled trials</td>
<td>Ravi Sarode (USA)</td>
</tr>
<tr>
<td></td>
<td>Reversal of apixaban anticoagulation with 4-factor prothrombin complex concentrates: a healthy volunteer study</td>
<td>Charles Frost (USA)</td>
</tr>
<tr>
<td></td>
<td>4F-PCC reverses edoxaban-associated bleeding: data from a healthy volunteer study</td>
<td>Hamim Zahir (USA)</td>
</tr>
<tr>
<td></td>
<td>The role of prothrombin complex concentrate in patients with major bleeding while using NOACs</td>
<td>Pieter Kamphuisen (The Netherlands)</td>
</tr>
<tr>
<td>13:45</td>
<td>Closing remarks</td>
<td></td>
</tr>
</tbody>
</table>

**Tuesday 23 June 2015, 12:15–13:45**

**Room 714, Metro Toronto Convention Centre (MTCC), Toronto, Canada**

CSL Behring-sponsored satellite symposium at the XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH)

The information presented in the symposium will not necessarily reflect the content of the approved Canadian product monograph.
Abstracts
The ISTH 2015 abstracts are available on USB sticks which will be distributed at the ISTH Booth (#1036). Abstracts will also be available as an online supplement (only) to JTH as an open-access publication on the Congress app and on the Congress website.

Accommodation
Participants who have booked their accommodation in advance via MCI can visit the Registration Help Desk counter located in the Registration Area for any questions related to their hotel booking. The staff at this counter will also help you to find and book rooms, if required and pending availabilities.

Badges
Participants will receive their name badges when collecting their meeting documents on site. You are required to wear your name badge during all meeting events, including the All Congress Party (if you have purchased tickets). Please note that admission to scientific sessions and the exhibition is restricted to participants wearing their badges.

Please note:
- Accompanying persons and exhibitors will not be admitted to the scientific sessions.
- Accompanying persons will not be admitted to the Exhibition Area and the Poster area except for the Welcome Reception on Sunday, June 21.

The charge for the replacement of a lost badge is CAD 105.

Automatic Teller Machines (ATM)
In the MTCC Congress venue, ATM machines are located in the North wing inside the main entrance from Front Street; in the South wing on Level 600 in the Registration Area and on Level 800 at the corner of the Plenary Hall and the Exhibition Hall.

Business Center
MTCC Toronto has its own Business Center that provides the following services:
- Printing (including posters and business cards)
- Copying
- Faxing Scanning
- Laminating
- Binding

Furthermore, the Business Center sells a wide range of office and ICT supplies. You can also ship small packages there.
The Business Center is located between the 2 Exhibition entrance doors on Level 800.

Certificates of Attendance
Certificates of attendance will be distributed to all registered participants inside the congress bags.

Charging Stations—“Stay Plugged In”
Conveniently located in the exhibition hall, 10 charging stations for mobile phones are provided for attendees to charge their mobile devices.

Cloakroom and Luggage
The cloakroom (free of charge) is located near the Registration Area, Level 600.

Saturday, June 20      07:30-18:00
Sunday, June 21      07:30-20:00
Monday, June 22      07:30-20:00
Tuesday, June 23      07:30-19:30
Wednesday, June 24   07:30-18:30
Thursday, June 25     07:30-13:00

CME
Royal College MOC credit, AMA PRA credit, ECMEC credit
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada and approved by McMaster University, Continuing Health Sciences Education Program for up to 26 MOC Section 1 hours.
Immucor is the leading provider of transfusion and transplantation diagnostic products worldwide. In addition, Immucor also delivers a unique portfolio to assist with the identification of deficiencies in clotting factors and detection of antibodies involved in thrombosis and thrombocytopenia, providing support for the diagnosis of Heparin-Induced Thrombocytopenia (HIT), Von Willebrand Disease (VWD) and Thrombotic Thrombocytopenic Purpura (TTP).

Visit us at Booth #648 to learn more about:

- PF4 Family of Products
- ATS-13® Activity Assay*
- VWF & Propeptide Assay**
- Factor VIII Antibody Screen

www.immucor.com or call 855.IMMUCOR

* For Research Use Only
** For Research Use Only
Not for use in diagnostic procedures
Not for diagnostic use in US and Canada

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring in Canada, recognized by the Royal College of Physicians and Surgeons of Canada as Accredited Group Learning Activities (Section 1) are deemed by the European Union of Medical Specialists (UEMS) eligible for ECMEC®.

Each attendee should only claim the hours they attended.

Please note that the Royal College MOC will send your certificate after the Congress. In order to receive this, please go to the designated computer stations near the Registration Area on Level 600. You will be able to update your profile to your personal e-mail. This can be done as of Monday, June 22, 14:00.

**EHA Accreditation**

The European Hematology Association (EHA) has accredited ISTH 2015 in Toronto, Canada (June 20 – 25, 2015) with 35 credit points. All participants may print a European Hematology Association CME System approved CME certificate indicating the number of EHA-CME Credit Points awarded, directly from the system on the CME section of the EHA website at www.ehaweb.org. All participants will receive the relevant information by e-mail after the meeting.

**Congress Bag**

The Congress bag including all delegate material will be distributed to registered participants at the Congress bag desk in the Registration Area. Please note that no replacements for lost bags are available.

**Computers / Cyber Café**

If you need access to a computer while at ISTH 2015, you’re in luck! A Cyber Café is located for attendees to use in the ISTH booth (1036) located in the Exhibition area on Level 800.

**Lunch Symposia**

Monday, June 22 - Wednesday, June 24
12:15 – 13:45

**Technical Sessions**

Monday, June 22
18:30 – 20:00

For more details and the program of each of these symposia and sessions, please refer to the Show Guide. For the Lunch Symposia, lunchboxes will be served near the session rooms.
Duplicating/Recording
Any form of duplication (recording, audio taping, photography and video) of sessions is prohibited without expressed written consent of the author and Congress organizer.

Exhibition Hours
The ISTH 2015 Industry Exhibition is located in Ballroom D and E on Level 800 of the Metro Toronto Convention Center (MTCC), South Building.

- Sunday, June 21
  19:30 - 22:00 (Welcome Reception in the Exhibition Hall)
- Monday, June 22
  09:00 - 18:30
- Tuesday, June 23
  09:00 - 19:30
- Wednesday, June 24
  09:00 - 18:30

Internet
WIFI is available throughout the MTCC.

exhibitor: ISTH 2015
Password: biogensobi

The Cyber Cafè, located in the ISTH booth (#1036) in the Exhibition Hall, will be for the exclusive use of meeting attendees.

Insurance and Liability
It is recommended that participants obtain adequate insurance coverage for travel, health and accidents before they depart from their countries of residence. ISTH and MCI as organizers cannot accept responsibility for personal injuries, or loss of, or damage to private property belonging to the conference participants and accompanying persons.

ISTH 2015 President’s Room
The ISTH 2015 President’s Room is located in room 401 on Level 400.

ISTH Secretariat
The ISTH secretariat is located in room 501 on Level 500.

Language
The official language of the meeting is English. There is no simultaneous translation service provided.

Lost and Found
Found articles may be brought to the lost items collected from the Registration Desk on Level 600.

Lunch and Coffee Breaks
Lunch is provided during the duration of the Congress. Lunch tickets will be provided as part of the registration package. The tickets are valid from Saturday, June 20 to Wednesday, June 24.

- From Monday, June 22 to Wednesday, June 24, lunch and coffee will be available in the Exhibition Area (Level 800).
- There will be continuous complimentary coffee stations throughout the opening times of the Exhibition during those days, too. Lunches will also be available in front of the meeting rooms of the lunch time symposia.

- On Saturday and Sunday, June 20 - 21 as well as on Thursday June 25, lunch and coffee will be available in the foyers of the session rooms.

Mobile Telephones
As a courtesy to speakers and other participants, all mobile phones and pagers must be muted when attending sessions or symposia.

Notepads and Pens
A notepad and pen are included in the Congress bag.

Nurses Program
The Nurses’ Program takes place Sunday and Monday, June 21-22, 2015, during the Congress. On the morning of the second day (Monday, June 22), there is a scientific session with oral presentation of peer-reviewed abstracts.

Official Carrier Network
Star Alliance is the official carrier network for ISTH 2015

STAR ALLIANCE

Online Disclosures
As part of the CME accreditation procedures, all speakers are obliged to provide disclosure of potential conflicts of interest. On the first slide of every presentation, these disclosures must be presented. The Speaker Ready Room can assist you with drafting this slide.

Lost and Found
Found articles may be brought to the lost items collected from the Registration Desk on Level 600.

Lunch and Coffee Breaks
Lunch is provided during the duration of the Congress. Lunch tickets will be provided as part of the registration package. The tickets are valid from Saturday, June 20 to Wednesday, June 24.

- From Monday, June 22 to Wednesday, June 24, lunch and coffee will be available in the Exhibition Area (Level 800).
- There will be continuous complimentary coffee stations throughout the opening times of the Exhibition during those days, too. Lunches will also be available in front of the meeting rooms of the lunch time symposia.

- On Saturday and Sunday, June 20 - 21 as well as on Thursday June 25, lunch and coffee will be available in the foyers of the session rooms.

Mobile Telephones
As a courtesy to speakers and other participants, all mobile phones and pagers must be muted when attending sessions or symposia.

Notepads and Pens
A notepad and pen are included in the Congress bag.

Nurses Program
The Nurses’ Program takes place Sunday and Monday, June 21-22, 2015, during the Congress. On the morning of the second day (Monday, June 22), there is a scientific session with oral presentation of peer-reviewed abstracts.

Official Carrier Network
Star Alliance is the official carrier network for ISTH 2015

STAR ALLIANCE

Online Disclosures
As part of the CME accreditation procedures, all speakers are obliged to provide disclosure of potential conflicts of interest. On the first slide of every presentation, these disclosures must be presented. The Speaker Ready Room can assist you with drafting this slide.
Pocket Program
A pocket program will be provided to participants upon registration. It is an at-a-glance reference. It contains a program-at-a-glance, venue information and map, information about Toronto and other useful tips.

Poster Printing Service & Pick Up Booth
If you have opted to take advantage of the ISTH 2015 poster printing service, kindly note that you will be able to pick up your poster(s) at the Poster Booth located in the Swing Space on Level 800.

Poster Booth opening times are:
- Sunday, June 21, 2015 from 19:30 - 22:00
- Monday, June 22, 2015 from 07:30 - 19:00
- Tuesday, June 23, 2015 from 07:30 - 20:00
- Wednesday, June 24, 2015 from 07:30 - 19:00

Poster Sessions
Posters will be presented on different days during the Congress and are accessible at the same times as the exhibition opening hours. The official poster sessions with refreshments will take place as follows:
- Monday, June 22, 2015 from 17:15-18:30
- Tuesday, June 23, 2015 from 18:00-19:30
- Wednesday, June 24, 2015 from 17:15-18:30
- The Poster Area is located inside the Exhibition on Level 800.

Program Changes
Program changes will be made public via the official ISTH 2015 mobile app and the website.

Prayer Room
An all-denomination prayer room is located in room 830 on Level 800.

Press Room
ISTH 2015 will feature both a press lounge available for journalists attending the Congress to use and ISTH 2015 exhibitors as well as a press briefing room that will hold press briefings from 8:00 through 17:00 beginning Monday, June 22 through Wednesday, June 24.

To use the press lounge, media credentials must be presented. Public relations and company representatives may enter the room to drop off materials to share with the media; however, we ask that they do not stay. All media are asked to follow the media policy in its entirety.

For a full schedule of media briefings, see the board in front of the Press Briefing Room or stop by the press lounge for the schedule. The press lounge is located near the Registration Area on Level 600.

SickKids Handbook of Pediatric Thrombosis and Hemostasis

Editors:
Victor S. Blanchette (Toronto, Ont.)
Vicky R. Breakey (Hamilton, Ont.)
Shoshana Revel-Vilk (Jerusalem)

Contents
- Pediatric Thrombosis and Hemostasis: A Historical Perspective
- Primary and Secondary Hemostasis, Regulators of Coagulation, and Fibrinolysis: Understanding the Basics
- An Approach to the Bleeding Child
- Bleeding in the Neonate
- Platelet Disorders in Children
- Managing Hemophilia in Children and Adolescents
- von Willebrand Disease in Children
- Rare Congenital Factor Deficiencies in Childhood
- Acquired Bleeding Disorders in Children
- A Diagnostic Approach to a Child with Thrombosis
- Venous Thrombosis
- Arterial Thrombosis
- Thromboembolic Events at Specific Organ Sites
- Pediatric Stroke
- Bleeding and Clotting in Children with Cardiac Disease
- Antithrombotic Therapy in Children
- Reference Ranges for Common Tests of Bleeding and Clotting
- Common Products Used to Manage Bleeding and Clotting
Ramadan - Special Considerations

The month of Ramadan will fall during the ISTH 2015 Congress in June 2015. For those of you who are observing Ramadan, we will have boxed meals available for you at the Registration Area on Level 600 to take back to your rooms in the late afternoon each day of the Congress.

Registration Hours

Registration will start Friday, June 19 in the afternoon. The Registration Area, located on Level 600 at the MTCC in Toronto will be open during the following hours:

- Friday, June 19: 15:30-20:00
- Saturday, June 20: 07:30-18:00
- Sunday, June 21: 06:30-20:00
- Monday, June 22: 06:30-20:00
- Tuesday, June 23: 06:30-19:30
- Wednesday, June 24: 06:30-18:30
- Thursday, June 25: 07:30-13:00

Show Guide

The ISTH 2015 Show Guide to Corporate Symposia and the Industry Exhibition is distributed to all participants as part of the delegate materials as well as on-site in literature racks in the registration area and the exhibition hall. It provides an overview and the detailed programs of the corporate symposia (Special Symposia, Satellite Symposia and Technical Sessions) as well as trade show floor plan, exhibitor and sponsor profiles.

Smoking

Please note that this is a non-smoking meeting. Smoking is neither permitted in or outside the meeting halls nor in the Exhibition Area.

Social Media

ISTH 2015 encourages the use of social media, such as Twitter, Facebook, LinkedIn, Instagram and other social media platforms at the conference as a way to summarize, highlight, excerpt, review or promote the presented materials, of the Congress in general, provided that:

1) Copyright law is observed; 2) verbatim information is limited to a few quotes, and; 3) the author or speaker is referenced and cited appropriately. To get the latest updates throughout the Congress, follow ISTH online via the following links:

- Congress hashtag via Facebook and Twitter: #isth2015.
- Facebook: https://www.facebook.com/internationalsocietyonthrombosisandhaemostasis
- Twitter: https://twitter.com/isth
- LinkedIn: https://www.linkedin.com/company/internationalsocietyonthrombosisandhaemostasis-isth
- Instagram: http://www.instagram.com/isthofficeteam

Speaker Ready Room

Speakers were contacted in advance to upload their presentations but should still report to the Speaker Ready Room at least two hours in advance of their presentation to ensure proper viewing. All conference rooms feature state-of-the-art technical equipment. Audiovisual material will be available for your presentation: The use of your own laptop during your presentation is prohibited.

The Speaker Ready Room is located on Level 600 near the Registration Area. The opening hours of the Speaker Ready Room are as follows:

- Friday, June 19: 15:30-20:00
- Saturday, June 20: 07:30-18:00
- Sunday, June 21: 07:30-20:00
- Monday, June 22: 07:30-20:00
- Tuesday, June 23: 07:30-19:30
- Wednesday, June 24: 07:30-18:30
- Thursday, June 25: 07:30-13:00

State-of-the-Art Book and Abstracts

The ISTH 2015 State-of-the-Art manuscripts and abstracts are available on USB sticks which will be distributed at the ISTH Booth (#1036). Both the State-of-the-Art manuscripts and abstracts will also be available as online supplements (only) to JTH as open-access publications.

Abstracts are also available via the Congress app and on the Congress website.

Toronto Information Desk

For city and restaurant information, please visit the Toronto Information Desk located near the Registration Area on Level 600.

- Saturday, June 20: 10:00 – 17:00
- Sunday, June 21: 09:30 – 18:00
- Monday, June 22: 09:00 – 16:00
- Tuesday, June 23: 09:00 – 16:00
- Wednesday, June 24: 09:00 – 16:00

Useful Telephone Numbers

- Name: ISTH Executive Office
- Location: Room 401, Level 400
- Telephone: 001 416-585-3823

- Name: Hotel Information Desk
- Location: Registration Area, Level 600
- Telephone: 001 416-585-3824

- Name: Registration Desk
- Location: Registration Area, Level 600
- Telephone: 001 416-585-3825

Transportation

No transportation is provided during the Congress since the conference venue is very centrally located and all official hotels are within walking distance. If you need additional information on public transportation, please see page 421.

Travel Grants

Travel Grant recipients can go to the specific “Travel Grant” desk at the Registration Area (Level 600) to receive their grant. Grants will be distributed between Monday, June 22, 10.00 and Thursday, June 25, 12 noon.

Water Stations

Keeping hydrated is always important, particularly during a busy day at ISTH 2015. 15 distinct water stations are located in the exhibition hall for the convenience of our attendees.

Website

Up-to-date information regarding the Congress program, including all abstracts, is available on the website www.isth2015.org.
THROMBOSIS RESEARCH

About
Thrombosis Research is an international journal with a goal of rapid dissemination of new information on thrombosis, hemostasis, and vascular biology to advance science and clinical care.

The journal publishes peer-reviewed original research, along with reviews, editorials, and opinions and critics. Both basic and clinical studies are published.

Publication of research which will lead to novel approaches in diagnosis, therapy, prognosis and prevention of thrombotic and hemorrhagic diseases is given high priority.

Your benefit of publishing in Thrombosis Research:
- Unrivalled article visibility via inclusion in Scopus, the world’s largest abstract and citation database
- Article Usage Alert service: a combination of an email and a dashboard that shows usage data of your article, downloads & article views, social media mentions and from which countries
- Online submission which is fast, efficient and provides step-by-step instructions on how to submit your article
- Advance notification of the publication of your article via ScienceDirect’s online alerting service
- The option to enrich your article with graphical abstracts, research highlights, AudioSlides and video content

VISIT THE JOURNAL HOMEPAGE FOR DETAILS:
www.thrombosisresearch.com

Editors in Chief
Per Morten Sandset
Oslo University Hospital,
Oslo, Norway

Follow us on
Facebook: www.facebook.com/ELShematology
Twitter: @ELShematology

VISIT THE JOURNAL HOMEPAGE FOR DETAILS:
www.thrombosisresearch.com

Social Program

Opening Ceremony and Welcome Reception
Sunday, June 21, 2015
Time: 18:00 – 22:00
Venue: MTCC – Metro Toronto Convention Center
Price: included in registration fee

The opening ceremony takes place in the Plenary Hall (Level 800) in the Congress Center from 18:00 – 19:30. The ISTH Grant Medal will be awarded during this ceremony. Besides official opening speeches, all participants are invited to enjoy a selection of typical Canadian entertainment and performances.

The welcome reception will take place in the adjacent exhibition hall from 19:30 – 22:00.

All Congress Party
Wednesday, June 24, 2015
Time: 19:30 – 01:00
Venue: MUZIK
Price per person: CAD 100

The All Congress Party is always the talk of the town, and you really don’t want to miss out! We have something special planned for you in Toronto – a smashing evening on the penultimate day of the Congress at the nightclub MUZIK, which has developed a reputation for style and unsurpassed service. Relaxing in a 1907 building under a 60-foot-high classical glass dome is an experience that one could describe as “a Canadian in Paris.”

The highlight of the night will be the rock band Barenaked Ladies with their performance and entertainment.

Please go to the Registration Desk if you still want to buy tickets onsite.
Buses for the All Congress Party will leave in front of the Congress Center South Entrance starting 18:30 until 19:30 at the latest.

MUZIK: 15 Saskatchewan Rd,
Toronto, ON, M6K 3C3

Notes:
None of the listed events are industry supported
Social events are only open to individuals who are registered (including accompanying persons) with a ticket.

ISTH 5K Fun Run
Tuesday, June 23, 2015
Time: 20:00 - 21:00
Venue: Budapest Park, Toronto
Ticketed event, late registration fee CAD 45
Register at http://www.isth.org/page/2015FunRun
Buses will leave in front of the Congress Center South Entrance starting 18:30 until 19:30 at the latest.
Toronto & Canada Information

Banks, Banking Services and Automatic Teller Machines (ATM)
The official currency in Canada is the Canadian Dollar (CAD) which is divided into 100 cents. For denominations under five dollars, coins are used.

Only major banks exchange foreign currency. Credit Cards and Travelers checks are accepted at most (but not all) major retailers. Traveler’s checks should be issued in Canadian dollars for maximum convenience. Banking hours are Monday to Friday 9 AM to 5 PM. Currency exchange is also available at the airport.

ATMs are widespread and found in most banks, hotels and shopping centers. In the MTCC Congress venue, ATM machines are located in the North wing inside the main entrance from Front Street; in the South wing on Level 600 in the Registration Area and on Level 800 at the corner of the Plenary Hall and the Exhibition Hall.

Climate
Toronto has a humid continental climate. Summers are usually warm and humid. The average temperature in June is 80 degrees F (27 degrees C) for a high and 65 degrees F (18 degrees C) for a low.

Electricity
110-120 volts, 60 Hz. Plugs are mainly the two, flat-pin type, although three-pin plugs are also widely used. Appliances without dual voltage capabilities will require an adapter, which can be purchased in most major airports.

Emergency Phone Numbers
Dial 911 for all emergencies (police, fire, medical). Callers will then be placed through to the appropriate emergency service. Calls are free from pay phones.

Shopping in Toronto
Shoppers delight in trendy Queen Street West, Yorkville’s designer boutiques, fabulous malls like the Toronto Eaton Center and Vaughan Mills and the PATH, which features more than 1,200 shops in over 16 miles of underground concourses.

Visit http://www.toronto.ca/ for more information.

Taxes
The Harmonized Sales Tax (HST) is a 13% tax that is applied to most purchases of taxable supplies of goods and services in the Province of Ontario. The HST consists of a 5% federal portion and an 8% retail sales tax portion.

Visitors to Canada may qualify for a refund of some of the Goods and Services Tax/Harmonized Sales Tax (GST/HST) they have paid during their visit in Canada.

Please visit the Canada Revenue Agency website for more information. http://www.cra-arc.gc.ca/tx/bsnss/tpcs/gst-tps/rbts/rtcs/FTP-eng.html

Time
Standard time zone: UTC/GMT -5 hours
Daylight Savings Time: +1 hour
Toronto is on EST (Eastern Standard Time)

Tipping Etiquette in Canada
Restaurants: It is customary to tip approximately 15% on the total bill before tax, 20% for exceptional service. Many restaurants charge an automatic gratuity of 15% or more for larger groups – typically 8 or more persons.

Hotels: It is customary to tip the valet service and the staff that brings the baggage to a guest room as well as the chambermaids.

Taxi drivers, hairdressers, manicurists, aestheticians etc.: 10% is the common minimum.

Overall, servers/wait staff are not paid well in Canada. However, when you see a “tip jar” on a counter in a bar, cafeteria etc. it is NOT necessary to tip.

Toronto City Guide App
To learn more about Toronto, download Tourism Toronto’s new See Toronto App. Available for iPhone, Android, Blackberry and Windows Phone, it provides tips on things to see and including easy-to-search event, dining, attractions and shopping listings.

Learn more about Toronto online at www.seetorontonow.com

Dining Out in Toronto and Tipping
Restaurants usually open at 18:00, with busiest time between 20:00 and 22:00. Booking is recommended, particularly on Thursday, Friday and Saturday nights.

If you’re happy with the service you receive, a 15-20% tip on the pre-tax bill is a standard expression of appreciation when dining out in the city. Note that some restaurants automatically add this gratuity when serving large groups, so be sure to check your bill. For more information and to find the right restaurant please visit www.dine.to/
Transportation in Toronto

Public Transport Ticket
The Toronto public transit system is the Toronto Transit Commission (TTC), and it includes subways, buses and streetcars.

GO Transit is Ontario’s inter-regional bus and train service. It links Toronto with outlying areas of the Greater Toronto region and beyond.

To learn more about Toronto’s parking, taxi and bike resources, visit the Tourism Toronto website.

Maps and Guides
There are many visitor guides, pedestrian maps and more available via Tourism Toronto. These cover areas such as downtown Toronto as well as the Greater Toronto region.

How to Reach the MTCC Toronto?
From the Airport
The Union Pearson (UP) Express train takes you directly from the airport to the Union Station in downtown Toronto in less than 25 minutes. Union Station is only a few blocks away from the Congress center (Metro Toronto Convention Centre) and most of the Congress hotels.

The adult regular fare is $27.50, with reduced fares for seniors, children and families. Tickets can be purchased online, in-station, or at the ticket vending machines and counters.

By Train
The MTCC is located next to the Union Station Toronto. From Union station you can proceed west on Front Street to the North Building, where you can access the Skywalk to enter the South Building. You can, in case of rainy weather, walk the entire way from Union Train Station to the MTCC indoors and through covered skywalks.

Please visit www.gotransit.com to plan your trip and find your most convenient connection.

By Subway
Yonge-University-Spadina Line: Exit at Union station and proceed west on Front Street to the North Building, where you can access the Skywalk to enter the South Building.

Scarborough RT Line: Travel west to Kennedy Station. From Kennedy Station transfer to the Bloor-Yonge Line. Continue on the Bloor-Yonge Line until you reach Union Station.

Sheppard Line: Travel west to the Sheppard-Yonge Station and transfer to the Yonge-University Spadina Line. Travel south until you reach Union Station.

By Subway
Yonge-University-Spadina Line: Exit at Union station and proceed west on Front Street to the North Building, where you can access the Skywalk to enter the South Building.

Sheppard Line: Travel west to the Sheppard-Yonge Station and transfer to the Yonge-University Spadina Line. Travel south until you reach Union Station.

By Subway
Yonge-University-Spadina Line: Exit at Union station and proceed west on Front Street to the North Building, where you can access the Skywalk to enter the South Building.

Car Parking
The MTCC Toronto has dedicated parking both for the North and the South building and can accommodate up to 1,700 vehicles.

The following rates apply: (incl. 13% tax)

<table>
<thead>
<tr>
<th>Time Period</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day (7am – 7pm)</td>
<td></td>
</tr>
<tr>
<td>1/2 hr or less</td>
<td>CAD 4.00</td>
</tr>
<tr>
<td>1/2 hr to 1 hr</td>
<td>CAD 8.00</td>
</tr>
<tr>
<td>1 hr to 1.5 hrs</td>
<td>CAD 12.00</td>
</tr>
<tr>
<td>1.5 hrs to 2 hrs</td>
<td>CAD 16.00</td>
</tr>
<tr>
<td>2 hrs to 2.5 hrs</td>
<td>CAD 20.00</td>
</tr>
<tr>
<td>Day max (&lt; 2.5 hrs)</td>
<td>CAD 23.00</td>
</tr>
<tr>
<td>Evenings (5pm – 7am)</td>
<td></td>
</tr>
<tr>
<td>1/2 hr or less</td>
<td>CAD 4.00</td>
</tr>
<tr>
<td>1/2 to 1 hr</td>
<td>CAD 8.00</td>
</tr>
<tr>
<td>1 hr to 1.5 hrs</td>
<td>CAD 12.00</td>
</tr>
<tr>
<td>1.5 hrs to 2 hrs</td>
<td>CAD 16.00</td>
</tr>
<tr>
<td>2 hrs to 2.5 hrs</td>
<td>CAD 20.00</td>
</tr>
<tr>
<td>Eve. Max (&lt; 2.5 hrs)</td>
<td>CAD 23.00</td>
</tr>
<tr>
<td>Day Max + 1/2 hr</td>
<td>CAD 27.00</td>
</tr>
<tr>
<td>Day Max + 1 hr</td>
<td>CAD 28.00</td>
</tr>
<tr>
<td>24 hr Max</td>
<td>CAD 28.00</td>
</tr>
</tbody>
</table>

There are also more than 10,000 alternate spaces within walking distance to the Metro Toronto Convention Center.
Publish your next research article in

**Thrombosis Journal**

Editors-in-Chief:
Yukio Ozaki (Japan), Hugo ten Cate (Netherlands)

---

**Reasons to publish in Thrombosis Journal**
- Internationally renowned Editorial Board
- Publishes various article types
- Supports research in the developing world
- Free color images

---

**Future ISTH Meetings and Congresses**

<table>
<thead>
<tr>
<th>Meetings and Congresses</th>
<th>President</th>
<th>Date</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>62nd Annual SSC Meeting</td>
<td>Jean-François Schved</td>
<td>May 25-28, 2016</td>
<td>Montpellier, France</td>
</tr>
<tr>
<td>XXVI ISTH Congress with 63rd Annual SSC Meeting</td>
<td>Johannes Oldenburg</td>
<td>July 8 - 13, 2017</td>
<td>Berlin, Germany</td>
</tr>
<tr>
<td>64th Annual SSC Meeting</td>
<td>to be confirmed</td>
<td>to be confirmed</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>XXVII ISTH Congress with 65th Annual SSC Meeting</td>
<td>Robert Medcalf</td>
<td>2019</td>
<td>Melbourne, Australia</td>
</tr>
</tbody>
</table>

Learn more at [www.isth.org](http://www.isth.org)
Arteriosclerosis, Thrombosis, and Vascular Biology
An American Heart Association Journal

Fast and Reliable.
Rapid publication online within 5 to 10 days of acceptance.

Impactful.
4,122 total citations and top-ranked among 65 Peripheral Vascular Disease and 68 Hematology journals.*

Influential.
More than 3.1 million articles influencing future research downloaded by 12,200 subscribers and users at 12,400 institutions with access.†

Flexible.
The ATVB iPad® app has been downloaded more than 4,662 times. †

Submit Your Manuscript
http://atvb-submit.aha-journals.org
The forum for publication of basic, translational, clinical, and population research in the area of arteriosclerosis, thrombosis, and vascular biology.

ATVB is top-ranked for total cites, Impact Factor, 5-Year Impact Factor, Article Influence Score, and Eigenfactor® Score among journals in the Peripheral Vascular Disease and Hematology subject categories.*

Join the AHA/ASA
Call: 1-800-787-8984 (United States)
+1-301-223-2307 (Rest of World)
my.americanheart.org/membership

Subscribe
Call: 1-800-638-3030 (United States)
+44 (0) 20-7981-0525 (Europe)
+1-301-223-2300 (Rest of World)
www.ahajournals.org/site/subscriptions

Life is why. Science is how.
The American Heart Association Professional Membership is where you’ll find the richest source of cardiovascular science and news.
Enhance your knowledge, experience, and networking with a membership today.
Visit my.americanheart.org/membership

Learn how ATVB impacts the caliber of scientific publishing at www.ahajournals.org/site/metrics

atvb.ahajournals.org

Notes

*2013 Journal Citation Reports® (Thomson Reuters, 2014).
†As of December 31, 2014.

Apple and iPad are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.
The Academy is the online education arm of the International Society of Thrombosis and Haemostasis (ISTH). As part of the Society’s mission to advance the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders, the ISTH Academy promotes advanced learning opportunities, networking and the opportunity to build an understanding of a desired topic without managing travel budgets or flight plans.

The ISTH Academy includes a comprehensive webinar series, educational webcasts and online course modules for scientists, physicians and allied health professionals with notable speakers and presenters on a variety of topics related to bleeding and clotting. All accessible from a computer and location of your choice, let the ISTH Academy provide you with the knowledge needed to advance science and patient care to improve the health outcomes for patients around the world.

Join Us! For more information on upcoming programming, visit academy.isth.org.

Authors Index

Visit us at Booth 1036
Authors Index

Luna R., PO484-TUE
Lundberg A., PO588-MON
Lunde B., OR567-WED
Lundin B., OR388
Lundström A., PO343-MON
Lunghi B., OR050, OR333, PO335-MON
Luo C., OR018
Luo D., OR279
Luo M., PO217-MON, PO205-MON
Luo X., PO222-WED
Lupu A., PO474-WED
Lutze E., PO485-MON
Lücher T., PO207-MON
Lusichkin S., PO496-MON
Lüth J., PO346-MON
Lutter R., PO068-MON
Luttun A., PO344-MON
Lusty D., PO248-MON
Lusher J., PO247-MON
Lushchekina S., PO496-MON
Lurie B., PO247-MON, PO216-
Luo P.-L.
Luo M., OR279
Luo D., PO333-MON
Luo C., OR333, OR388
Lundin B., OR251
Luna R.
Magniez A.
Maes P.
Maekawa K.
Maeda T.
Madroñal Cerezo E.
Madridano O.
Madan B.
Macwan A.
Macrae F.
Macmullan P.
Macrae G.
Mackin S.
Machlus K.
Machin S.
Machan L.
Machlus K.
Machin S.
Machan L.
Male C.
Malato A.
Makris M.
Mäkipernaa A.
Makhaldiani L.
Makatsaria A.
Majoor C.
Majluf A.
Majewski J.
Majeed A.
Mahjoub S.
Mahé I.
Mahapatra M.
Mahan C.
Mahaklan L.
Maloney J.
Maloney J.
Malins L.
Malfliet J.
Marcucci M.
Marcos-Contreras O. A.
Marco A.
Marck B.
Marchetti G.
Marchesini E.
Marchais S.
Marchian F. J.
Marchesi E.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Marchetti G.
Save the date for the next ISTH Scientific and Standardization Committee (SSC) meeting in Montpellier, France, from May 25 – 28, 2016.

The 62nd Annual SSC Meeting of the ISTH will be devoted to the discussion of diagnostic standards, disease nomenclature and classification, and the latest research on bleeding and thrombotic disorders. SSC 2016 will continue the tradition of offering dedicated education and plenary sessions to complement the in-depth presentations of the work in progress by the SSC subcommittees and working groups. A must-attend event in the field of thrombosis and hemostasis, you are welcome to participate and get involved!

The program will include the following topics:
- Animal, Cellular, and Molecular Models;
- Biorheology; Control of Anticoagulation;
- Disseminated Intravascular Coagulation;
- Factor VIII, Factor IX and Rare Coagulation Disorders; Factor XI and the Contact System;
- Factor XIII and Fibrinogen; Fibrinolysis;
- Genomics in Thrombosis and Hemostasis;
- Hemostasis & Malignancy; Lupus Anticoagulant/Phospholipid-Dependent Antibodies; Pediatric/Neonatal Hemostasis and Thrombosis; Plasma Coagulation Inhibitors; Platelet Immunology; Platelet Physiology; Perioperative Thrombosis and Hemostasis; Predictive and Diagnostic Variables in Thrombotic Disease; Vascular Biology; Von Willebrand Factor; and, Women’s Health Issues in Thrombosis and Hemostasis.

Mark your calendars to join us for SSC 2016!

www.ssc2016.org

May 25-28, 2016
62nd Annual SSC Meeting
Montpellier, France
Jean-François Schved, President

Please visit us at Booth 1036!
You are invited to attend the XXVIth Congress of the International Society on Thrombosis and Haemostasis (ISTH). Held in Berlin, Germany, from July 8 –13, 2017, the ISTH 2017 Congress will be the foremost meeting in thrombosis, hemostasis and vascular biology and will be attended by thousands of the world’s experts.

Join us in Transcending Scientific Boundaries at ISTH 2017!

www.isth2017.org

Visit the ISTH at Booth 1036!